0001493152-24-013118.txt : 20240404 0001493152-24-013118.hdr.sgml : 20240404 20240404083632 ACCESSION NUMBER: 0001493152-24-013118 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 100 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240404 DATE AS OF CHANGE: 20240404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Reliance Global Group, Inc. CENTRAL INDEX KEY: 0001812727 STANDARD INDUSTRIAL CLASSIFICATION: INSURANCE AGENTS BROKERS & SERVICES [6411] ORGANIZATION NAME: 02 Finance IRS NUMBER: 463390293 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40020 FILM NUMBER: 24821734 BUSINESS ADDRESS: STREET 1: 300 BOULEVARD OF THE AMERICAS, STREET 2: SUITE 105 CITY: LAKEWOOD STATE: NJ ZIP: 08701 BUSINESS PHONE: 732-780-4647 MAIL ADDRESS: STREET 1: 300 BOULEVARD OF THE AMERICAS, STREET 2: SUITE 105 CITY: LAKEWOOD STATE: NJ ZIP: 08701 10-K 1 form10-k.htm
false FY 0001812727 http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember 0001812727 2023-01-01 2023-12-31 0001812727 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2023-01-01 2023-12-31 0001812727 2023-06-30 0001812727 2024-04-04 0001812727 2023-12-31 0001812727 2022-12-31 0001812727 us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 us-gaap:NonrelatedPartyMember 2022-12-31 0001812727 us-gaap:RelatedPartyMember 2023-12-31 0001812727 us-gaap:RelatedPartyMember 2022-12-31 0001812727 2022-01-01 2022-12-31 0001812727 us-gaap:NonrelatedPartyMember 2023-01-01 2023-12-31 0001812727 us-gaap:NonrelatedPartyMember 2022-01-01 2022-12-31 0001812727 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001812727 us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001812727 us-gaap:PreferredStockMember 2022-12-31 0001812727 us-gaap:CommonStockMember 2022-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001812727 RELI:SubscriptionReceivableMember 2022-12-31 0001812727 us-gaap:RetainedEarningsMember 2022-12-31 0001812727 us-gaap:PreferredStockMember 2021-12-31 0001812727 us-gaap:CommonStockMember 2021-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001812727 RELI:SubscriptionReceivableMember 2021-12-31 0001812727 us-gaap:RetainedEarningsMember 2021-12-31 0001812727 2021-12-31 0001812727 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001812727 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001812727 RELI:SubscriptionReceivableMember 2023-01-01 2023-12-31 0001812727 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001812727 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001812727 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001812727 RELI:SubscriptionReceivableMember 2022-01-01 2022-12-31 0001812727 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001812727 us-gaap:PreferredStockMember 2023-12-31 0001812727 us-gaap:CommonStockMember 2023-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001812727 RELI:SubscriptionReceivableMember 2023-12-31 0001812727 us-gaap:RetainedEarningsMember 2023-12-31 0001812727 2023-03-01 2023-03-31 0001812727 srt:MinimumMember 2023-12-31 0001812727 srt:MaximumMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyLLCMember us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyLLCMember us-gaap:SegmentDiscontinuedOperationsMember 2023-12-31 0001812727 us-gaap:ComputerEquipmentMember 2023-12-31 0001812727 RELI:OfficeEquipmentAndFurnitureMember 2023-12-31 0001812727 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001812727 us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001812727 us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001812727 us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001812727 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001812727 us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001812727 us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001812727 us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001812727 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001812727 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001812727 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2021-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2021-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2021-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-01-01 2022-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2022-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2023-01-01 2023-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2023-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2023-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputCreditSpreadMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member RELI:NumberOfTradingDaysMember 2023-01-01 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2023-01-01 2023-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2023-01-01 2023-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2023-01-01 2023-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember 2023-01-01 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2023-01-01 2023-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2023-01-01 2023-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2023-01-01 2023-12-31 0001812727 RELI:USBenefitsAllianceLLCMember 2023-01-01 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2023-01-01 2023-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2023-01-01 2023-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2023-01-01 2023-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember 2023-01-01 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2023-01-01 2023-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2023-01-01 2023-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2023-01-01 2023-12-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember 2023-01-01 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2023-01-01 2023-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2023-01-01 2023-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2023-01-01 2023-12-31 0001812727 RELI:FortmanInsuranceServicesLLCMember 2023-01-01 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2023-01-01 2023-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2023-01-01 2023-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2023-01-01 2023-12-31 0001812727 RELI:AltruisBenefitsConsultingIncMember 2023-01-01 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:KushMember 2023-01-01 2023-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:KushMember 2023-01-01 2023-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:KushMember 2023-01-01 2023-12-31 0001812727 RELI:KushMember 2023-01-01 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:ReliExchangeMember 2023-01-01 2023-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:ReliExchangeMember 2023-01-01 2023-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:ReliExchangeMember 2023-01-01 2023-12-31 0001812727 RELI:ReliExchangeMember 2023-01-01 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:LifeMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-12-31 0001812727 RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-12-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-12-31 0001812727 RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-12-31 0001812727 RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:KushMember 2022-01-01 2022-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:KushMember 2022-01-01 2022-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:KushMember 2022-01-01 2022-12-31 0001812727 RELI:KushMember 2022-01-01 2022-12-31 0001812727 RELI:MedicalMember RELI:RegularMember RELI:ReliExchangeMember 2022-01-01 2022-12-31 0001812727 RELI:LifeMember RELI:RegularMember RELI:ReliExchangeMember 2022-01-01 2022-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:ReliExchangeMember 2022-01-01 2022-12-31 0001812727 RELI:ReliExchangeMember 2022-01-01 2022-12-31 0001812727 RELI:MedicalMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:LifeMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:NonrelatedPartyMember 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:RelatedPartyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:RelatedPartyMember 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:CarryingValuePriorToAbandonmentMember us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetAndLiabilityTransfersRetainedByTheCompanyMember us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetImpairmentsAndLiabilityWriteOffsMember us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:CarryingValuePriorToAbandonmentMember us-gaap:RelatedPartyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetAndLiabilityTransfersRetainedByTheCompanyMember us-gaap:RelatedPartyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetImpairmentsAndLiabilityWriteOffsMember us-gaap:RelatedPartyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:RelatedPartyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:CarryingValuePriorToAbandonmentMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetAndLiabilityTransfersRetainedByTheCompanyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetImpairmentsAndLiabilityWriteOffsMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2023-01-01 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2022-01-01 2022-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001812727 RELI:BarraAndAssociatesLLCMember RELI:APAMember 2022-04-26 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:APAMember RELI:PaidAtClosingMember 2022-04-26 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:APAMember RELI:PayableInNineMonthsMember 2022-04-26 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:APAMember RELI:PayableOverTwoYearsMember 2022-04-26 2022-04-26 0001812727 RELI:MeasurementInputRoyaltyRateMember us-gaap:TradeNamesMember RELI:BarraAndAssociatesLLCMember 2022-04-26 0001812727 us-gaap:MeasurementInputDiscountRateMember us-gaap:TradeNamesMember RELI:BarraAndAssociatesLLCMember 2022-04-26 0001812727 us-gaap:MeasurementInputDiscountRateMember us-gaap:CustomerRelationshipsMember RELI:BarraAndAssociatesLLCMember 2022-04-26 0001812727 RELI:MeasurementInputObsolescenceRateMember RELI:DevelopmentTechnologyMember RELI:BarraAndAssociatesLLCMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember 2022-04-26 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember 2022-04-26 2022-12-31 0001812727 RELI:BarraAndAssociatesLLCMember 2023-01-01 2023-12-31 0001812727 RELI:BarraAndAssociatesLLCMember RELI:AcquiredAccountsReceivableMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:PropertyPlantAndEquipmentMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:RightOfUseAssetMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:TradeNamesMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:CustomerRelationshipsMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:DevelopmentTechnologyMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:AgencyRelationshipMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:LeaseLiabilityMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:GoodwillMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:GoodwillMember 2022-04-26 2022-04-26 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-01-01 2022-12-31 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2020-10-07 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-10-07 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-10-07 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-10-07 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-03-31 0001812727 RELI:NSUREIncMember 2022-01-01 2022-12-31 0001812727 RELI:NSUREIncMember 2023-04-01 2023-04-30 0001812727 RELI:NSUREIncMember 2023-12-31 0001812727 RELI:ComputerEquipmentAndSoftwareMember 2023-12-31 0001812727 RELI:ComputerEquipmentAndSoftwareMember 2022-12-31 0001812727 RELI:OfficeEquipmentAndFurnitureMember 2022-12-31 0001812727 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2023-06-30 0001812727 RELI:BarraMember 2022-01-01 2022-12-31 0001812727 RELI:BarraMember 2023-01-01 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2023-01-01 2023-12-31 0001812727 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001812727 RELI:InternallyDevelopedSoftwareMember 2023-12-31 0001812727 us-gaap:CustomerRelationshipsMember 2023-12-31 0001812727 RELI:PurchasedSoftwareMember 2023-12-31 0001812727 RELI:VideoProductionAssetsMember 2023-12-31 0001812727 RELI:NoncompetitionAgreementsMember 2023-12-31 0001812727 us-gaap:TrademarksAndTradeNamesMember 2022-12-31 0001812727 RELI:InternallyDevelopedSoftwareMember 2022-12-31 0001812727 us-gaap:CustomerRelationshipsMember 2022-12-31 0001812727 RELI:PurchasedSoftwareMember 2022-12-31 0001812727 RELI:VideoProductionAssetsMember 2022-12-31 0001812727 RELI:NoncompetitionAgreementsMember 2022-12-31 0001812727 RELI:EBSandUSBAMember 2023-12-31 0001812727 RELI:EBSandUSBAMember 2022-12-31 0001812727 RELI:CCSMember 2023-12-31 0001812727 RELI:CCSMember 2022-12-31 0001812727 RELI:SWMTMember 2023-12-31 0001812727 RELI:SWMTMember 2022-12-31 0001812727 RELI:FISMember 2023-12-31 0001812727 RELI:FISMember 2022-12-31 0001812727 RELI:ABCMember 2023-12-31 0001812727 RELI:ABCMember 2022-12-31 0001812727 RELI:BarraMember 2023-12-31 0001812727 RELI:BarraMember 2022-12-31 0001812727 RELI:EBSandUSBAMember 2023-01-01 2023-12-31 0001812727 RELI:CCSMember 2023-01-01 2023-12-31 0001812727 RELI:SWMTMember 2023-01-01 2023-12-31 0001812727 RELI:FISMember 2023-01-01 2023-12-31 0001812727 RELI:ABCMember 2023-01-01 2023-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCAndUSBenefitsAllianceMember RELI:CreditAgreementMember RELI:OakStreetFundingLLCMember 2018-08-01 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember 2018-12-07 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember 2018-12-06 2018-12-07 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember us-gaap:PrimeRateMember 2018-12-07 0001812727 RELI:TermLoanMember RELI:OakStreetFundingLLCMember 2019-12-31 0001812727 RELI:TermLoanMember RELI:OakStreetFundingLLCMember 2019-01-01 2019-12-31 0001812727 RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember us-gaap:PrimeRateMember 2019-12-31 0001812727 RELI:OakStreetFundingLLCMember RELI:MasterCreditAgreementMember 2022-04-26 0001812727 RELI:OakStreetFundingLLCMember RELI:MasterCreditAgreementMember 2022-04-26 2022-04-26 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember srt:MaximumMember 2021-12-22 0001812727 RELI:SecuritiesPurchaseAgreementMember us-gaap:CommonStockMember 2021-12-22 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-21 2021-12-22 0001812727 RELI:SeriesBConvertiblePreferredStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-21 2021-12-22 0001812727 RELI:SeriesBConvertiblePreferredStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-22 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2021-12-22 0001812727 RELI:SecuritiesPurchaseAgreementMember 2021-12-21 2021-12-22 0001812727 2021-01-01 2021-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-01-04 2022-01-04 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-01-04 0001812727 RELI:NonPrivatePlacementMember RELI:SeriesBWarrantLiabilityMember 2022-12-27 0001812727 RELI:NonPrivatePlacementMember RELI:SeriesBWarrantLiabilityMember us-gaap:CommonStockMember 2022-12-27 2022-12-27 0001812727 RELI:NonPrivatePlacementMember RELI:SeriesBWarrantLiabilityMember 2023-12-31 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:SeriesBWarrantLiabilityMember 2023-12-12 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember 2023-12-12 2023-12-12 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:CustomerMember 2023-01-01 2023-12-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:PriorityHealthMember 2023-01-01 2023-12-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:PriorityHealthMember 2022-01-01 2022-12-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:BlueCrossBlueShieldMember 2023-01-01 2023-12-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:BlueCrossBlueShieldMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2022-08-31 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2022-08-01 2022-08-31 0001812727 us-gaap:PrivatePlacementMember 2022-01-01 2022-01-31 0001812727 RELI:MedigapAcquisitionMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantMember 2022-01-31 0001812727 RELI:EmployeeAgreementMember 2022-03-01 2022-03-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-05-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-06-30 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-05-31 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-06-30 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-07-31 0001812727 RELI:SeriesDPrepaidWarrantsMember us-gaap:CommonStockMember 2022-07-31 0001812727 RELI:EmployeeAgreementMember 2022-12-01 2022-12-31 0001812727 RELI:SeriesBWarrantsMember 2022-12-01 2022-12-31 0001812727 RELI:SeriesBWarrantsMember 2022-12-31 0001812727 us-gaap:CommonStockMember 2023-01-01 2023-01-31 0001812727 RELI:BoardOfDirectorsMember 2023-02-22 2023-02-23 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-01 2023-02-28 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-28 0001812727 us-gaap:PrivatePlacementMember 2023-03-01 2023-03-31 0001812727 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001812727 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001812727 RELI:SeriesBWarrantsMember 2023-07-01 2023-09-30 0001812727 RELI:SeriesEWarrantMember 2023-10-01 2023-12-31 0001812727 RELI:SeriesFWarrantMember 2023-10-01 2023-12-31 0001812727 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001812727 RELI:SeriesBWarrantsMember 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantsMember 2023-11-30 0001812727 RELI:SeriesAWarrantsMember 2023-11-01 2023-11-30 0001812727 RELI:SeriesAWarrantsMember 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2022-12-31 0001812727 RELI:SeriesAWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-01-31 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-01-31 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-01-31 0001812727 RELI:SeriesCandDWarrantsMember 2023-12-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-07-01 2022-07-31 0001812727 RELI:SecuritiesPurchaseAgreementMember 2023-03-13 2023-03-13 0001812727 RELI:SecuritiesPurchaseAgreementMember 2023-03-13 0001812727 RELI:SeriesEWarrantsMember 2023-03-13 0001812727 RELI:SeriesFWarrantsMember 2022-03-13 0001812727 RELI:PAWarrantMember 2022-03-13 0001812727 2023-03-13 2023-03-13 0001812727 RELI:SeriesFWarrantsMember 2023-03-13 0001812727 RELI:PAWarrantMember 2023-03-13 0001812727 us-gaap:PrivatePlacementMember 2023-03-16 2023-03-16 0001812727 us-gaap:PrivatePlacementMember 2023-01-01 2023-12-31 0001812727 RELI:WarrantAgreementMember 2023-12-31 0001812727 RELI:SeriesFWarrantsMember 2023-12-12 0001812727 RELI:SeriesFWarrantsMember 2023-12-11 2023-12-12 0001812727 RELI:SeriesFWarrantsMember 2023-12-31 0001812727 RELI:SeriesFWarrantsMember 2023-12-31 2023-12-31 0001812727 us-gaap:CommonStockMember 2023-12-12 0001812727 RELI:PreExchangeWarrantMember 2023-12-12 0001812727 RELI:PostExchangeWarrantMember 2023-12-12 0001812727 RELI:PreAndPostExchangeWarrantMember 2023-12-31 0001812727 2023-12-12 2023-12-12 0001812727 RELI:SeriesGWarrantsMember RELI:SeriesFInducementAgreementMember 2023-12-12 0001812727 RELI:SeriesFInducementAgreementMember 2023-12-12 0001812727 RELI:SeriesGWarrantsMember RELI:SeriesFInducementAgreementMember 2023-12-12 2023-12-12 0001812727 RELI:SeriesFInducementAgreementMember 2023-12-12 2023-12-12 0001812727 RELI:SeriesEWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesGWarrantsMember 2023-12-31 0001812727 RELI:AbeyanceSharesMember 2023-12-31 0001812727 RELI:AbeyanceSharesMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-31 0001812727 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-31 0001812727 RELI:AbeyanceSharesMember us-gaap:SubsequentEventMember 2024-03-31 0001812727 RELI:AbeyanceSharesMember us-gaap:SubsequentEventMember 2024-04-01 2024-06-30 0001812727 RELI:TwoThousandNineteenEquityIncentivePlanMember 2019-12-31 0001812727 RELI:TwoThousandNineteenEquityIncentivePlanMember 2023-12-31 0001812727 RELI:TwoThousandNineteenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001812727 RELI:TwoThousandTwentyThreeEquityIncentivePlanMember 2023-12-31 0001812727 RELI:EmployeesDirectorsAndConsultantsMember 2023-01-01 2023-12-31 0001812727 RELI:EmployeesDirectorsAndConsultantsMember 2022-01-01 2022-12-31 0001812727 RELI:ExecutivesAndEmployeesMember 2023-01-01 2023-12-31 0001812727 srt:DirectorMember 2022-01-01 2022-12-31 0001812727 RELI:ExecutiveMember RELI:AgreementInAprilTwoThousandTwentyTwoMember 2022-10-01 2022-10-31 0001812727 RELI:ExecutiveMember RELI:AgreementInAprilTwoThousandTwentyTwoMember 2023-01-01 2023-12-31 0001812727 RELI:ExecutiveMember RELI:AgreementInAprilTwoThousandTwentyTwoMember 2022-01-01 2022-12-31 0001812727 RELI:ExecutiveMember RELI:AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember 2022-12-28 0001812727 RELI:ExecutiveMember RELI:AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember 2023-01-01 2023-12-31 0001812727 RELI:ExecutiveMember RELI:AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember 2022-01-01 2022-12-31 0001812727 srt:MinimumMember 2022-12-31 0001812727 srt:MaximumMember 2022-12-31 0001812727 srt:MinimumMember 2023-01-01 2023-12-31 0001812727 srt:MaximumMember 2023-01-01 2023-12-31 0001812727 srt:MinimumMember 2022-01-01 2022-12-31 0001812727 srt:MaximumMember 2022-01-01 2022-12-31 0001812727 RELI:StockOptionsMember 2023-01-01 2023-12-31 0001812727 RELI:StockOptionsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesAWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesBWarrantsAndPlacementAgentWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesBWarrantsAndPlacementAgentWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesGWarrantsAndPlacementAgentWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesGWarrantsAndPlacementAgentWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:UnvestedStockAwardsMember 2023-01-01 2023-12-31 0001812727 RELI:UnvestedStockAwardsMember 2022-01-01 2022-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2022-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2022-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2022-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2022-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2023-01-01 2023-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2023-01-01 2023-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2023-01-01 2023-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2023-01-01 2023-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2023-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2023-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2023-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2023-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2021-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2021-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2021-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2021-12-31 0001812727 RELI:BarraMember 2021-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2022-01-01 2022-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2022-01-01 2022-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2022-01-01 2022-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2022-01-01 2022-12-31 0001812727 RELI:CARESActMember 2023-01-01 2023-12-31 0001812727 RELI:RelianceHoldingsMember 2023-12-31 0001812727 RELI:RelianceHoldingsMember 2022-12-31 0001812727 RELI:YESAmericanaGroupLLCMember RELI:EmployeeMember 2019-07-31 0001812727 RELI:YESAmericanaGroupLLCMember RELI:EmployeeMember 2019-07-01 2019-07-31 0001812727 RELI:YESAmericanaGroupLLCMember RELI:EmployeeMember 2023-12-31 0001812727 RELI:YESAmericanaGroupLLCMember RELI:EmployeeMember 2022-12-31 0001812727 RELI:YESAmericanaGroupLLCMember RELI:EmployeeMember 2023-01-01 2023-12-31 0001812727 RELI:YESAmericanaGroupLLCMember 2022-09-13 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-07 2023-02-07 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-07 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-13 2023-02-13 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-13 0001812727 RELI:YESAmericanaGroupLLCMember 2023-01-01 2023-12-31 0001812727 RELI:YESAmericanaGroupLLCMember 2022-01-01 2022-12-31 0001812727 RELI:CommonStocksMember RELI:YESAmericanaGroupLLCMember 2023-12-31 0001812727 RELI:CommonStocksMember RELI:YESAmericanaGroupLLCMember 2022-12-31 0001812727 2023-01-31 2023-01-31 0001812727 2023-01-31 0001812727 RELI:EmployeeMember RELI:PurchaseAgreementMember us-gaap:SubsequentEventMember 2024-01-11 0001812727 RELI:EmployeeMember RELI:PurchaseAgreementMember us-gaap:SubsequentEventMember 2024-01-10 2024-01-11 0001812727 us-gaap:RelatedPartyMember RELI:PurchaseAgreementMember us-gaap:SubsequentEventMember 2024-01-11 0001812727 RELI:ATMAgreementMember us-gaap:SubsequentEventMember 2024-02-14 2024-02-15 0001812727 RELI:ATMAgreementMember us-gaap:SubsequentEventMember 2024-12-14 2024-12-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission file number: 001-40020

 

RELIANCE GLOBAL GROUP, INC.

(Exact name of registrant as specified in its charter)

 

Florida   46-3390293

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

300 Blvd. of the Americas, Suite 105

Lakewood, NJ

  08701
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (732) 380-4600

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   RELI   The Nasdaq Capital Market
Series A Warrants   RELIW   Nasdaq Capital Market

 

Securities registered pursuant to section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 

Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

 

Yes ☐ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company, in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

 

Yes ☐ No

 

The aggregate market value of the common stock, $0.086 par value per share, held by non-affiliates of the registrant, based on the closing sale price of registrant’s common stock ($4.71) as quoted on the NASDAQ on June 30, 2023 (the last business day of the registrant’s most recently completed second fiscal quarter), was approximately $7.8 million.

 

At April 4, 2024, the registrant had 5,692,387 shares of common stock, par value $0.086 per share, outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE: None

 

 

 

 
 

 

TABLE OF CONTENTS

 

PART I  
Item 1. Business 1
Item 1A. Risk Factors 17
Item 1B. Unresolved Staff Comments 29
Item 1C. Cybersecurity 30
Item 2. Properties 30
Item 3. Legal Proceedings 30
Item 4. Mine Safety Disclosures 30
PART II  
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 31
Item 6. RESERVED 33
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 33
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 42
Item 8. Financial Statements and Supplementary Data 42
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures 43
Item 9A. Controls and Procedures 43
Item 9B. Other information 44
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 44
PART III  
Item 10. Directors, Executive Officers and Corporate Governance 44
Item 11. Executive Compensation 48
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 49
Item 13. Certain Relationships and Related Transactions, and Director Independence 50
Item 14. Principal Accounting Fees and Services 50
PART IV  
Item 15. Exhibits, Financial Statement Schedules 51
Item 16. 10-K Summary 51
Signatures 55

 

 
 

 

Industry and Market Data

 

Unless otherwise indicated, information contained in this Annual Report on Form 10-K concerning our industry and the markets in which we operate, including our general expectations and market opportunity and market size, is based on information from various sources, including independent industry publications. In presenting this information, we have also made assumptions based on such data and other similar sources, and on our knowledge of, and our experience to date in the relevant industries and markets. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We believe that the information from these industry publications that is included in this Annual Report on Form 10-K is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Risk Factors.” These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

 

PART I

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains forward-looking statements (within the meaning of the federal securities law) that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Annual Report on Form 10-K regarding our strategy, future operations, future financial position, future net sales, gross margin expectations, projected costs, projected expenses, prospects and plans and objectives of management are forward-looking statements. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying any of our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections, or expectations prove incorrect, our actual results, performance, or financial condition may vary materially and adversely from those anticipated, estimated, or expected. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the section entitled “Risk Factors,” that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or terminations of distribution arrangements that we may make. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

 

Unless the context requires otherwise, references to “Reliance Global Group,” the “Company,” “we,” “our,” and “us” in this Annual Report on Form 10-K refer to Reliance Global Group, Inc.

 

Item 1. BUSINESS

 

About Reliance Global Group, Inc.

 

Reliance Global Group, Inc. (formerly known as Ethos Media Network, Inc.) was incorporated in Florida on August 2, 2013. In September 2018, Reliance Global Holdings, LLC, a related party (“Reliance Holdings”), purchased a controlling interest in the Company. Ethos Media Network, Inc. was renamed Reliance Global Group, Inc. on October 18, 2018.

 

We operate as a company managing assets in the insurance markets, as well as other related sectors. Our focus is to grow the Company by pursuing an aggressive acquisition strategy, initially and primarily focused upon wholesale and retail insurance agencies. We are led and advised by a management team that offers over 100 years of combined business expertise in insurance, real estate and the financial service industry.

 

1

 

 

In the insurance sector, our management has extensive experience acquiring and managing insurance portfolios in several states, as well as developing specialized programs targeting niche markets. Our primary strategy is to identify specific risk to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows.

 

As part of our growth and acquisition strategy, we remain active in M&A markets and anticipate completing insurance agency/brokerage transactions throughout the course of 2024 and beyond. As of December 31, 2023, we have acquired nine insurance agencies. During 2022, the Company acquired Barra & Associates, LLC., an unaffiliated full-service insurance agency, which we rebranded to RELI Exchange and expanded its footprint nationally.

 

The Company also developed and launched 5MinuteInsure.com (“5MI”), a proprietary direct to consumer InsurTech platform which went live during the summer of 2021. 5MI is a business to consumer website which enables consumers to compare and purchase car and home insurance in a time efficient and effective manner. The platform is currently live in 44 states and offers coverage with more than thirty carriers.

 

Over the next 12 months, we plan to expand and grow our footprint and market share both through organic growth, and by expansion through additional acquisitions in various insurance markets.

 

Our competitive advantage includes the ability to:

 

  Scale to compete at a national level.
  Capitalize on the consumer shift to ‘online’ with the personal touch of an agent, as the only InsurTech company with this combination.
  Leverage proprietary agency software & automation to compare carrier prices, for competitive renewal pricing.
  Employ an empowered and scalable insurance agency model.
  Leverage technology that facilitates comparing carriers for the best prices.

 

The RELI Exchange Business to Business (“B2B”) InsurTech platform and partner network for insurance agents and agencies also:

 

  Boast being the only white label insurance brokerage agency – New agents can have a multimillion-dollar agency look on day one, with a full suite of back-office support (business resources, licensing, compliance, etc.).
  Combines the low barriers to entry of an agency network, with state-of-the-art tech.
  Builds on the artificial intelligence and data mining backbone of 5MinuteInsure.com
  Is designed to provide instant and competitive insurance quotes from more than thirty insurance carriers nationwide.
  Reduces back-office burden and expenses by reducing the need for paperwork and redundant tasks.
  Provides agents more time to focus on revenue driving activities, such as selling policies.

 

In addition, we have a vast mentorship program behind the scenes, to upskill our sales teams. Once people are registered, we enroll them in our mentorship program, and coach them to bring new business.

 

RELI Exchange is a complete, private label system where agents have more flexibility in how they choose to brand themselves, compared to competitor platforms that require agents to work under the platform’s brand name. In effect, agents have a greater sense of ownership on our platform, and the feeling that comes with a well-financed agency.

 

2

 

 

Insurance Market Overview

 

There are three main insurance sectors: (1) property/casualty (P/C), which consists mainly of auto, home, and commercial insurance; (2) life/health (L/H), which consists mainly of life insurance and annuity products; and (3) accident and health, which is normally written by insurers whose main business is health insurance. The insurance industry plays a huge role in the U.S. economy (Source: OECD Insurance Statistics).

 

The U.S. remained the world’s largest insurance market, with a 40% market share of global direct premiums written in 2023, with premiums of $2.8 trillion, and Swiss Re forecasts that premiums will grow by an average 9% per annum over the next decade, stronger than the 7.5% annual average of 2015–2023 (Source: beinsure, Top Ranking the World’s Largest Insurance Markets 2024).

 

Insurance Agency Industry Overview

 

Insurance agencies act as intermediaries between insurance carriers and consumers. Unlike carriers, agencies do not bear insurance risk. The market has grown steadily including a sharp increase in 2019 due to macroeconomic growth, beneficial legislation, COVID treatments, and positive trends within the insurance sector. While inflation and other factors have impacted the industry, it has continued to grow through 2021. The market flattened in 2022 (12.15% of US GDP in 2022 vs. 12.20% in 2021), with a positive outlook due to the increased use of AI. Results may be impacted by changes to federal interest rates, with the federal funds rate skyrocketing from about 0% in early 2022 to 5.33% in February 2024, the highest rate in over 20 years (Source: St. Louis Federal Reserve, Federal Funds Effective Rate).

 

An insurance agency or broker solicits, writes, and binds policies through many different insurance companies, as they are not directly employed by any insurance carrier. Thus, insurance agencies can decide which insurance carriers they would like to represent and which products they would like to sell. They are like a retail shop that sells insurance services and products created by the insurance carrier. The main difference between a broker and an agent has to do with who they represent. An agent represents one or more insurance companies, acting as an extension of the insurer. A broker represents the insurance buyer.

 

An insurance carrier, on the other hand, is a manufacturer of insurance services and products that the insurance agencies sell. They control the underwriting process, claims process, pricing, and the overall management of the insurance products. Insurance carriers do not sell their products through direct agents, but only through independent agencies. Insurance policies are created and administered by the insurance carrier.

 

A key operating difference between agencies and carriers is the risk profile. The potential financial risks to the insurance industry caused by unforeseen events such as natural disasters are the responsibility of the carriers (and their re-insurers). Agencies and brokers bear no insurance risk. Furthermore, increased damage caused by natural disasters generally boosts demand for insurance and results in possible premium increases. Since insurance brokers and agents are a central part of the distribution of these products, they normally benefit from this increase in demand and premiums despite damaged profit margins among these upstream underwriters and carriers. (Source: IBISWorld Insurance Brokers & Agencies Industry in the US, January 2023). Natural disasters are inherently difficult to forecast, but any increase in the frequency of these events has the potential to boost insurance policy volumes, particularly for property and casualty products.

 

3

 

 

This risk difference is key, especially considering volatile weather patterns and an increased rate of natural disasters. The economic costs of 2023’s natural disaster events was $380 billion, up from $313 billion in 2022 (Source: Statista, Cost of natural disaster losses worldwide from 2000 to 2023, by type of loss). Insurance only covered 42% of the total damages from 421 natural disaster events in 2022 (Source: AON, Testimony of Eric Anderson, President of Aon, before the United States Senate Committee on Budget, Wednesday, March 22, 2023).

 

Key external drivers for insurance industry performance include factors such as motor vehicle registrations, the homeowner rate, and per capita disposable income. The industry is in a hardening cycle, which leads to growth. There are still effects from the COVID-19 measures, with shifting sales trends expected to boost profitability while lowering marginal costs. Additionally, businesses rebounding from COVID-19 are reported to translate to a consistent stream of new insurance customers (Source: IBISWorld, Insurance Brokers & Agencies Industry in the US, January 2023).

 

In 2023, the global insurance brokerage & agency market had an estimated value of $436 billion, and is forecasted to grow 7.2% to $468 billion in 2024 and to $613 billion by 2028 (Source: Research and Markets, Insurance Brokers & Agents Global Market Report 2024). The insurance distribution industry continues to prove its resiliency and the growth is reflected in continued robust mergers and acquisition (M&A) activity within the sector, despite decreases as compared to recent prior years. Total deal volume in 2023 was $78 billion, 41% lower than in 2022, with a 15% drop in total deals to 1,062 M&A deals in 2023. That said, there were 22 mega-deals of over $1 billion in 2023, a 38% increase over 2022 (Source: GlobalData, Insurance M&A Deals 2023 – Top Themes – Thematic Intelligence). The drop in deal volume was due to a 40-year high in inflation, rising capital costs and tightening budgets. As rate increases have already peaked, companies may allocate more capital to acquisitions. In 2024, there is an expected influx of private equity money into insurance M&A. (Source: Deloitte, 2024 insurance M&A outlook: Climbing the leaderboard).

 

The global InsurTech market size was valued at $16.6 billion in 2023 and is expected to grow to $336.5 billion by 2032, including the highest CAGR of 41.0% between 2023 and 2032 (Market.us, Global Insurtech Market By Type (Auto, Business, Health, and Other Types), By Deployment (On-Premise, and Cloud Based), By Technology, By Services, By End-User, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032). The increasing need for digitization of insurance services is expected to propel the market growth. Insurtech is the usage of technology innovations particularly designed to make the existing insurance model more efficient. By using technologies such as AI and data analytics, InsurTech solutions allow products to be priced more competitively. Insurance companies are widely adopting these solutions to drive cheaper, better, and faster operational results. Hence, the insurance industry is witnessing increased investment in technology. The outbreak of COVID-19 had a positive impact on the market. Numerous insurance companies are reconsidering their long-term strategies and short-term needs. COVID-19 and its impacts have accelerated the implementation of online platforms and new mobile applications to meet consumer needs. (Sources: Grand View Research, Insurtech Market Size, Share & Growth Report, 2021-2028 and 2022 - 2030).

 

The Company therefore has strategically invested in its RELI Exchange and 5MinuteInsure.com online digital platforms as additional steps in expanding its national footprint which now also includes a client referral portal. As discussed above, RELI Exchange and 5MI are high-tech proprietary tools developed by the Company as business to business or business to consumer portals which enables agents/consumers to compare and purchase car home and life insurance in a time efficient and effective manner. These platforms tap into the growing number of online users and utilize advanced artificial intelligence and data mining techniques, to provide competitive insurance quotes in around 1-5 minutes, with minimal data input needed from the agent/consumer.

 

4

 

 

General Industry Outlook

 

Insurance brokers and agencies play a critical role within the insurance market by distributing policies and consulting insurance underwriters and consumers. This industry is a vital component to the larger insurance sector as industry operators act as intermediaries between insurance providers and downstream consumers. Operators generate income via commissions earned on policies sold. Given the transaction-based nature of the industry, revenue primarily depends on three factors: (1) policy (premium) pricing; (2) demand for insurance; and (3) the popularity of using agents and brokers in the distribution process.

 

As mentioned, the insurance broker and agency industry has grown steadily over the five years due to macroeconomic growth, beneficial legislation that has been passed, and positive trends in the insurance sector, achieving approximately $436 billion in revenues in 2023. As macroeconomic conditions improve over the next few years, revenue generated by industry operators is expected to increase to $613 billion in 2028 as businesses regain confidence in their financial stability, despite increased external competition from online insurance marketplace platforms.

 

Insurance carriers should not continue to depend on the positive (though uncertain) fundamental economic strength of years past to maintain positive balance sheet momentum. To succeed, carriers must address foundational challenges, which include remaining relevant despite systemic economic changes combined with expanding consumer preferences. Some of the issues that insurers must address will fall within the areas of mergers and acquisitions (M&A), technology, product development, talent, regulation, as well as tax reform, as described below.

 

  M&A. The convergence of market pressures to attain sustainable growth, a persistent wealth of capital and capacity, combined with the upturn in interest rates may demonstrate that insurers should be prepared for an uptick in M&A activity in 2024. As it stands now, fairly rich valuations could dampen activity, however, M&A could offer opportunities to scale and obtain new capabilities, primarily as it relates to technology.
     
  Proprietary Technology. Advancements in AI, mobile and digital technology are forcing insurers to innovate, which is expected to continue and intensify, where every insurance agency will need to focus on what makes their customer experiences and products unique. They will also need to integrate with technology enablers to bring to their customers a value proposition via a connected ecosystem. Furthermore, to better compete within the industry, those within the distribution system would benefit tremendously by improving the ability to share critical data and analytics between systems. Insurers are seeking to employ the cloud to power advanced analytics, improve data gathering, and grow cognitive applications. To keep pace with the industry and prepare for a cloud-enabled future, insurance carriers should prioritize migrating their existing systems to the cloud and launch new applications off-site.
     
  Product Development. Economic and technological changes create the need for new types of coverage, revamped policies, and alternative distribution platforms; adaptation of this, however, has been slow within the insurance industry. Siloed business lines, legacy processes, and regulatory considerations hinder the rapid and agile product development needed within this highly competitive landscape. Accordingly, insurers would benefit by focusing on creating hybrid policies that cover both commercial and personal risks. They could also supply on-demand coverage options, which provide greater control to customers for their policy terms and time frames. Furthermore, novel and unique micro-experiences could become the foundation for digital expansion as agencies are distinguished by the niche markets they sell to and can better service versus their peers. Digital content campaigns and user interfaces targeting specialized prospects and customer segments are expected to continue to expand. These micro-experiences could allow agencies to have access to a market that can quote, bind, and service insurance online, and where they are focused on commercial lines and specialty insurance for niche markets. In such a scenario, they may be able to offer new opportunities for agencies to expand quickly via digital building blocks that can be easily integrated into existing business and/or workflows.

 

5

 

 

  Regulation. Regulation will continue to play a significant role in the operations and development of the insurance industry, with three high-priority compliance issues (each with global and domestic implications) facing insurers:

 

  Market conduct. “Best interest” standards have been implemented and more are being considered at both the federal and state levels to protect consumers who purchase annuities and life insurance. In 2020, the NAIC required producers to put the consumer’s interests ahead of their own. Currently, the NAIC’s Suitability in Annuity Transactions Model Regulation (#275) has been adopted by 41 states. It aims to protect consumers from potentially abusive and predatory practices among life insurance and annuity producers (Source: NAIC, The NAIC Annuity Suitability “Best Interest” Model Regulation). Additionally, similar standards were adopted in New York (Source: Debevoise & Plimpton, New York’s “Best Interest” Rule for Life and Annuities Found Constitutional). Due to these standards, insurers should seek to review and adjust their compliance structures to accommodate what could turn into a patchwork oversight system. One possibility could be to integrate new technologies that would allow for continual oversight and management of the sales process.
     
  Cyber risk. With New York State’s latest cybersecurity regulations, insurers are facing compliance deadlines, which have formed the basis of a nationwide model law developed by the National Association of Insurance Commissioners. Going forward, the spotlight is likely to be on how insurers plan to manage third-party risks, given so much importance has been placed on migrating policyholder data and software systems to external hosts.
     
  Privacy oversight. Privacy is both a data-security and reputational risk issue given the European Union’s General Data Protection Regulation (GDPR) having been implemented along with similar standards set to be imposed in California. Equally as important is how data can be used moving forward, specifically when it comes to disclosure and consumer signoff. In addition to legal and IT experts, insurers should include multiple stakeholders in its compliance efforts. Over the longer term, carriers may reexamine how the vast amounts of alternative data at their disposal may be leveraged for the mutual benefit not only for the carriers but their policyholders, while simultaneously remaining compliant with domestic and global regulations.

 

  Taxes. The global trend has been to lower corporate income tax rates, with a recent report from the Organization for Economic Co-operation and Development citing significant tax reform packages enacted in Argentina, France, Latvia, and the U.S., with other countries introducing more disjointed reforms. U.S. insurers continue to focus on adapting to the changes introduced in the Tax Cuts and Jobs Act of 2017. The U.S. Department of the Treasury and the Internal Revenue Service (IRS) have issued final and proposed guidance on certain important, newly enacted provisions, such as the application of the base erosion and anti-abuse tax to reinsurance, as well as the taxation of foreign operations owned by U.S. taxpayers. Additional guidance could be imminent on many other important provisions, including how the new loss carryover rules will fit with the old rules in the context of consolidated returns.

 

Further complexity may come from several areas in 2024, including (Source: Accenture, 5 predictions for the insurance industry in 2024):

 

Monetizing AI, including generative AI such as ChatGPT.
Alternative human capital strategies which include the use of generative AI acting as “supplementary talent.”
Cost pressures driving operational model change including allocation methodologies and centralized costs.
Risk portfolio shifts and capital reallocation, including shifts into the retirement space as Millennials and GenZ become beneficiaries.
Service revenue increases alongside risk capital decreases, to raise RoE, and to expand product offerings in advice and services including tele-health, care navigation, and risk mitigation.

 

While the industry may need to address internal and external pressures, the impact from these issues will continue to fall within the individual insurer. Thus, since insurers have choice in their decision making process, potentially the most significant factor is likely to be how committed and prepared insurers are to quickly adjust to changes in the economy, society, and technology, and respond accordingly.

 

Insurance Options

 

Single-product platforms limit buyers’ choices and often lead to high costs or insufficient coverage. We’ve partnered with an extensive list of carriers and filter results for buyers according to their needs. This gets them the right coverage at a fair price. From there, they’re connected to an agent who onboards them with minimal friction.

 

Insurance Buyers

 

Insurance buyers want coverage that fits their needs at a fair price. They also want good customer service. We believe the independent insurance agents, combined with the RELI Exchange platform can serve these needs best. Our platform makes it easy to weigh the options and connect with a knowledgeable agent with the buyer’s interests in mind.

 

6

 

 

Expert Agents

 

We train our agents to evaluate coverages based on buyers’ needs, and to explain options in simple terms. Furthermore, service doesn’t stop there. People’s needs change during different life events, and we facilitate adjustments to their coverage when it matters most.

 

Agents can revolutionize their insurance businesses—or start a new one on RELI Exchange. They have the freedom to offer coverage from a variety of carriers, utilizing our cutting-edge technology, and proven sales system. This is particularly beneficial to captive insurance agents who previously found themselves limited to one carrier and pricing model. By offering more choices, agents now have more chances of closing business with interested buyers. By partnering with us, agents gain access to a variety of carriers, yet are able to streamline their workflows to focus on business development with support from our team and lower marketing costs.

 

Top Carriers

 

Insurance carriers want to maximize profits without detracting from the customer experience. The challenge is that it’s costly to distribute coverage through independent agents with varying levels of expertise. Some carriers choose the Captive Agent route to save on cost, but RELI Exchange offers a better alternative. We reduce overhead and scale distribution for carriers while maintaining good standards with our technology and back office support team.

 

The performance improvements and lower costs lead to higher customer retention and a better customer experience, which translates to a higher customer lifetime value and more profits for the carrier and the agent.

 

Leadership Team

 

Our leadership team has over 100 years of combined industry experience.

 

Ezra Beyman, Chairman & Chief Executive Officer, brings nearly three decades of entrepreneurial experience in real estate and fifteen years in insurance. His portfolio of commercial and residential properties at one point consisted of more than 40,000 residential units, as well as several insurance companies. In 1985, he founded his first mortgage brokerage, which rapidly grew into the third largest licensed mortgage brokerage in the United States of America by 2008. He also expanded to real estate acquisition, having grown his portfolio to over three billion dollars.

 

Scott Korman, Director, serves as President of Nashone, Inc., a private equity firm, which he founded in 1984. In this role, Mr. Korman is involved in financial advisory, M&A, and general management assignments. He is a founder and Managing Member and CEO of Illumina Radiopharmaceuticals LLC, CEO of Red Mountain Medical Holdings, Inc. Mr. Korman previously served as Chairman of Da-Tech Corporation, a Pennsylvania based contract electronics manufacturer and as Chairman and CEO of Best Manufacturing Group LLC, a leading manufacturer and distributor of uniforms, napery, service apparel, and hospitality and healthcare textiles. Mr. Korman also served as President and CEO of Welsh Farms Inc., a full-service dairy processor and distributor of milk, ice cream mix and ice cream products.

 

Ben Fruchtzweig, Director, brings decades of executive experience in accounting and financial services. He has served as Chief Comptroller/Financial Analyst at national financial services and investment companies. He received his NYS C.P.A. license in 1987 and has worked at Deloitte Haskins and Sells and other leading accounting firms. Currently, Mr. Fruchtzweig lectures on a variety of topics including business ethics. He also serves on a voluntary basis as a trustee of a non-profit private foundation, which serves to provide the needed financial support, services and guidance to qualifying individuals and families.

 

Sheldon Brickman, Director, brings over 25 years of M&A advisory and business development experience with more than $40 billion in deals value. He has worked for numerous multibillion-dollar insurance carriers, including assignments for such companies as AIG, Aetna and National General. Sheldon has assisted international companies (UAE, UK, Asia and Latin America), start-up operations, and regional insurance carriers. Mr. Brickman’s experience covers the property casualty and life/health markets, including working with insurance carriers, managing general agencies, wholesalers, retailers and third-party administrators.

 

Alex Blumenfrucht, Director, previously served as CFO of Reliance, and prior to that, served as an Audit & Assurance Professional at Deloitte & Touche, LLP where he successfully led audit teams on both public and privately held corporations. He brings extensive experience in internal controls, financial analysis and reporting for both private and publicly traded companies. Currently Alex serves as the CFO of a Private Equity backed company in the healthcare space. Additionally, he has served as a Board Member of an ESOP structured entity.

 

7

 

 

Joel Markovits, CPA, Chief Financial Officer, Joel joined Reliance Global Group in June 2021, bringing over 12 years of financial and accounting experience in both the public and private sectors. Prior to joining Reliance Global Group, Joel was a senior manager at KPMG LLP from April 2015 through May 2021, where he led some of the larger and more complex audit engagements, including serving as lead audit senior manager on a global $16 billion (annual revenues) enterprise reporting on both US GAAP and IFRS standards. He was also a data & analytics specialist and technology innovation leader at KPMG for its largest US Business Unit, overseeing the development and deployment of technological capabilities that enhance data analyses. Joel has been a Certified Public Accountant in the State of New Jersey since November 2013.

 

Yaakov Beyman - Executive Vice President, Insurance Division, oversees the overall insurance operations of Reliance, including strategy and developing/implementing operational tools. He holds insurance licenses in most of the continental United States, and is involved heavily in marketing, maintaining state of the art technological models, financial management and distributions, and entity creation and maintenance.

 

Grant Barra - Senior Vice President of Operations, Mr. Barra brings extensive insurance experience scaling businesses by employing innovative tactics to increase revenue and overall profitability. He founded Barra & Associates in 2008 and served as its CEO until it was acquired by Reliance in 2022 and subsequently rebranded as RELI Exchange. Concurrent with the acquisition, Mr. Barra was appointed as Reliance’s senior vice president of operations, where he’s responsible to oversee operations, innovation, and growth, amongst other senior responsibilities.

 

Moshe Fishman, Director of Insurtech and Operations, brings a unique perspective to the insurance sales process. Prior to starting his own insurance agency, Mr. Fishman was a recognized guru in the travel industry leveraging the technology in the travel sector. This tech savviness has been applied into the insurance and financial services industries with the founding of Fishman Insurance Agency as well as Tekeno Financial. Mr. Fishman is one of the driving talents of the RELI Exchange & 5MinuteInsure.com InsurTech platforms.

 

Agency Partner network and proprietary InsurTech platform at ReliExchange.com

 

Our Go-to-Market Strategy

 

Our Go-to-Market high level goals include:

 

  Brand awareness

 

  Targeted Market Segmentation and Positioning

 

  Content Marketing and Thought Leadership

 

  Best in class recruitment team

 

Target #1: Captive

 

  When an agent represents one insurance company, they have limited offerings for clients, assuming the same activity they’ll close more business, earning multiples of what they make currently due to our partnerships with many of the largest carriers in the industry.

 

  Key target for Agency Partners

 

  Eliminate many of the biggest expenses running an independent agency as an Agency Partner with RELI Exchange.

 

8

 

 

Target #2: Agency Producers/CSRs

 

  Agents that want their own agency.

 

Target #3: New Agency Startups

 

  Our platform makes it easy for those with little to no experience that want to start their own agency business. This is a significant market with manty potential participants.

 

Promotion

 

To meet our agency registration objectives, we have engaged in both inbound and outbound marketing. Outbound sales and marketing includes outreach on social media through posts and direct messages using tools on LinkedIn and other platforms, phone, email, and other methods of communication. Inbound marketing is primarily through driving traffic to our website through search engines, social media, and digital publicity campaigns. These combined tactics give us a constant influx of marketing qualified leads (MQL) and sales qualified leads (SQL) to predictably hit our target metrics each month.

 

Email Marketing

 

As we continue to build our database of customers and prospects, we will implement an effective email marketing campaign. This includes newsletters as well as content flows that drip out over time to keep people engaged. This content is pre-programmed to automatically fire at set intervals whenever someone registers for a list. Through automation, we continue to build rapport with people who eventually sign up for the service.

 

Public Relations

 

The digital marketing tactics that we use have the following benefits:

 

  Increase brand credibility
  Generate leads
  Attract investors and partners
  Make other marketing more effective
  Attract talent
  Improve reputation on Google
  Drive domain authority for SEO
  Differentiate from competitors
  Increase perceived value
  Convert leads faster

 

9

 

 

Social Media

 

As part of our content creation process, we’ve implemented a system for ongoing posts to social media channels such as LinkedIn. Tactics include:

 

  Daily social listening – eye-on competitor + industry news + influencer
  Creative design and content planning
  Daily posting schedule
  Real-time events support and live posting
  Daily monitoring comments and discussions
  A content coordinator with approving capabilities to approve/direct.
  Monitoring data, providing monthly reports
  Weekly meetings with updates on new content, industry news approval etc.…
  Daily outreach, engagement, and growth of LinkedIn profile.
  Weekly: 2 posts that demonstrate expertise, experience and thought leadership.
  Monthly: Strategic growth and visibility

 

Using platforms like LinkedIn, Facebook, and Twitter, we post regular content with the aim of growing our visibility and credibility through social media storytelling. Our goal is to maintain a consistent brand story for customers, prospects, stakeholders, and industry experts.

 

Planning, writing, creating, and posting a mixture of our available assets, plus curated topics on industry trends and influencer thought leadership to provide validation and exposure outside of our existing followers, to develop the company story.

 

Our initial focus is on LinkedIn, with expansion to other platforms as it makes sense.

 

Podcasts

 

We have appeared on several podcasts as subject matter experts, and will continue with outreach to increase exposure, visibility, brand awareness, and sales.

 

Website Search Engine Optimization

 

Our goal is to improve the website to drive more organic traffic through Google and other search engines. The two primary objectives are to create engaging content, and to improve the technical SEO of the website.

 

SEO growth opportunities include:

 

  SEO Audit and Execution to improve HTML, structured data and other technical issues
  SEO review of any future site migration and platform upgrade plans as part of the M&A process
  Information architecture & internal linking for SEO
  Content topic and structural improvements
  Keyword Tracking
  Competitive analysis

 

Product

 

Our best-in-class product offerings include the following:

 

  1) An agency partner contract
  2) An agent / pro contract

 

10

 

 

Our value proposition is that we’re giving people a complete, white label business. Agents have a fast and easy website presence, get contracts with carriers they wouldn’t normally access, and they can get paid for referrals.

 

 

Price

 

Costs are very low. Access is approximately $90/month for agents, and $190/month for agency partners. This is a singular solution that gives people an all-in-one insurance agency.

 

For comparison, people used to pay about $50,000 to build out an insurance agency. Additionally, licensing can be around $750, with $100-200 in monthly expenditures. RELI Exchange removes these costly barriers to entry through technology.

 

With the RELI Exchange platform, our vision is to remove all barriers and activate contracted agents at scale. Being cost efficient for these agencies is key to our success. Unlike the franchise model, RELI Exchange is designed with low barriers to entry and a compelling value proposition. In addition, RELI Exchange significantly enhances competitive advantages through provided agency partners.

 

People (Target Audience)

 

We have identified several highly receptive target audiences, including:

 

  Existing insurance agents & agency leadership/owners
  People looking for a career change (GenX, older Millennials)
  Experienced salespeople
  Younger “quiet quitters” and “Great Resigners” who want more purposeful, lucrative work & flexibility
  Recent college graduates with debt & unmarketable degrees with few career options
  Captive Agents who feel trapped

 

The RELI Exchange Platform

 

The RELI Exchange platform is a revolutionary way to get insurance quotes without requiring users to undergo a complicated process of manually completing lengthy forms. With basic contact information, our proprietary tool can generate accurate home auto and life insurance quotes from credible providers in under 5 minutes, for free. Then, our platform connects each user with a fully trained and knowledgeable agent who guides them through the rest of the process to deliver the best coverage at the best price.

 

11

 

 

RELI Exchange is at the forefront of the digital transformation of the insurance industry. Our platform leverages unique technology, a proprietary database, and expert methodologies from experienced insurance agents to deliver a quality experience to agents and people looking to get insured.

 

In addition to providing customers with a great experience, RELI Exchange automates many processes for agents to free up their time to sell to new customers. The result is higher profitability with less work. Most importantly, mentorship is part of the RELI Exchange model, so that agents always receive the support they need to be successful.

 

System for Agent and Agency Partner Success

 

RELI Exchange agents have a distinct advantage over their captive counterparts when it comes to serving clients. They have access to multiple carriers in their markets, to provide more choices and solutions that fit their customers’ needs. Additionally, our automations and back-office support eliminate time spent on service requests and renewals, so agents can focus on sales growth.

 

We spent years developing our proprietary sales processes, backed up by an engaging mentorship program to maximize agent success. We provide every agent with comprehensive training, product and carrier knowledge, and cutting-edge technology. Plus, our back-office support team is readily available to train and assist agents at every step.

 

We actively recruit agents who are passionate about owning their own business and have a proven track record in business development. Our revenues are tied directly to their success, creating an environment that delivers consistent results.

 

Agents benefit from low startup costs and minimal overhead—no employees or physical location is required. In contrast, captive agents are often burdened with immediate hiring requirements, storefront leases, and advertising budgets. Moreover, our software platform delivers economies of scale so that fixed and variable costs are reduced for greater profitability.

 

Online Insurance and 5MinuteInsure.com

 

In August 2021, we launched 5MinuteInsure.com, which is a licensed online insurance agency that utilizes state of the art digital technology and seek to use this platform to develop business in the online insurance business which we believe represents an underutilized opportunity.

 

While 90% of customers are open to purchasing insurance online, 75% of the people who attempt to make online purchases report problems (Source: J.D. Power, Direct-to-Consumer Auto Insurers Take Top Honors in Shopping Study as New Normal Arrives for P&C Industry, J.D. Power Finds; Invoca, 36 Insurance Marketing Statistics You Need to Know in 2023). Moreover, the current insurance purchasing processes is time consuming and lacks transparency. There are over 96 insurance companies paying thousands of affiliates to generate leads, paying as much as $120 per lead (Source: The Insurance Marketer, Best Life Insurance Affiliate Programs: How Much Can You Earn?; Lasso, The 96 Best Insurance Affiliate Programs of 2023). Consequently, most of the current online sites are simply lead generators, which result in false insurance quotes, constant spam and aggressive sales pitches. We believe consumers are looking for an online platform that will replicate the services they could obtain from a traditional brick and mortar insurance agency, thus driving business toward the online site as we all migrate to online in this post COVID world.

 

Another key benefit to online insurance is the ability to combine seamlessly with electronic capabilities in processing, such as 5MinuteInsure.com’s proprietary backend processing technology to support our traditional agency business. 5MinuteInsure.com will be used internally by all the Reliance Global Group affiliated agencies to offer more products to our existing client base. By implementing artificial intelligence, robotic process automation and automatic shopping for best rates at renewals, we believe we can dramatically reduce costs, and allow our agents to focus on selling new policies, creating a digitally empowered and scalable insurance agency model.

 

12

 

 

Specific benefits of the 5MinuteInsure.com platform include:

 

  First, a simplified application process
  Second, 5MinuteInsure.com has real-time connections with over 15 top-rated insurance companies, which allows consumers to transparently compare real live quotes from multiple insurers side-by-side.
  Third, 5MinuteInsure.com provides instant accurate coverage recommendations for home, auto and life insurance, providing consumers confidence they are not under or over-insured.
  Fourth, 5MinuteInsure.com provides in-house insurance buying and policy binding capabilities, meaning no redirection to other websites and the ability to finalize purchases on 5MinuteInsure.com in as little as five minutes.
  Fifth, coming soon is 5MinuteInsure’s free and secure account enables 24/7 access to previous quotes, policies and other documents.
  Finally, when it’s time for a policy renewal, 5MinuteInsure.com can populate the best offers in the market before their policy expires.

 

Thus, we believe in the specific benefits of the online insurance business, and we believe that 5MinuteInsure.com provides the platform to transform this segment of the industry.

 

Business Operations (OneFirm)

 

Reliance Global Group has adopted a ‘One-Firm’ approach, whereby the Reliance owned and operated agencies come together to operate as one cohesive unit which allows for efficient and effective cross-selling, cross-collaboration, and the effective deployment of the Company’s human capital. This strategy also aims to enhance the Company’s overall market presence across the U.S., with all business lines operating under the RELI Exchange brand. It’s expected to benefit agents and clients by improving relationships with carriers, leading to better commission and bonus contracts due to higher business volumes. The approach also strengthens the capability of RELI Exchange agency partners in securing diverse insurance policies and fosters increased cross-selling opportunities. This unified strategy positions the company for rapid scaling and integration of accretive acquisitions, expanding its industry reach.

 

Insurance M&A Overview

 

As noted above, M&A deal volume in the insurance agency market remains robust with $78 billion in deals during 2023, despite drops as compared prior recent years and 2024 is expected to bring more acquisition opportunities.

 

13

 

 

The COVID-19 crisis may have an impact on the insurance industry for quite some time. Some factors to consider:

 

  Strain on investment portfolios – Insurance companies rely on their investment portfolios to generate returns. Markets have been in turmoil and, as a result, insurers’ investment portfolios may be significantly impacted.
  Delayed payments – Regulators are urging insurance companies to accept late premium payments with no penalty, putting a strain on cash flow. Despite liquidity being impacted, insurance companies are still being expected to pay out claims.
  Decreased premium volume – Full or partial closing of businesses coupled with social distancing has led to decreased demand for insurance. Lower payroll levels lead to lower payroll-based premiums, such as those in workers’ compensation, and an uptick in layoffs results in fewer people buying houses, cars, and other insurable purchases. A decrease in premium volume means a decrease in income for insurers.
  Coverage disputes – Pandemics are generally excluded from insurance policy coverage and therefore policy premium has not included the necessary charges to provide such coverage. A number of states are attempting to legislate to force insurance companies to provide insurance coverage for business interruption and other losses for claims resulting from the COVID-19 pandemic. There is uncertainty regarding which party will ultimately incur the additional cost for these adjustments.

 

We cannot presently estimate the full financial impact of the unprecedented COVID-19 pandemic on our business or predict the related federal, state and local civil authority actions, which are highly dependent on the severity and duration of the pandemic; however, we see opportunities which may arise as to changes in the markets. Due to the uncertainties associated with the COVID-19 pandemic and the indeterminate length of time it will affect, we have taken proactive measures to secure our liquidity position to be able to meet our obligations for the foreseeable future.

 

Reliance Insurance Agency Brand Acquisitions:

 

  RELI Exchange
  Altruis Benefits
  J.P. Kush & Associates
  US Benefits Alliance
  Employee Benefits Solutions
  Fortman Insurance Solutions
  Southwestern Montana Insurance Center
  UIS Agency
  Commercial Coverage Solutions

 

Acquisition History

 

  In October 2018, announced first two acquisitions: Employee Benefits Solutions and U.S. Benefits Alliance; Michigan-based agencies specializing in the sale of health insurance products in the wholesale and retail industry
  In December 2018, acquired Commercial Coverage Solutions, LLC, a commercial property and casualty insurance company specializing in commercial trucking and transportation insurance

 

14

 

 

  In September 2019, two agencies transferred ownership from Reliance Global Holdings, LLC, a private company affiliated with Reliance Global Group:

 

  Ø Southwestern Montana Insurance, a group health insurance agency providing personal and commercial lines of insurance

 

  Ø Fortman Insurance Agency, LLC, an agency providing multiple lines of insurance in the property/casualty and life/health insurance sectors

 

  In September 2019, acquired Altruis Benefit Consulting; serves customers throughout the entire State of Michigan, specializing in providing individual and group health insurance

 

  In September 2020, acquired the assets of UIS Agency, LLC (UIS), a premier regional insurance agency serving the commercial transportation industry

 

  In May 2021, acquired J.P. Kush and Associates, Inc., a premier healthcare insurance agency with operations in 10 states, headquartered in Troy, Michigan

 

  In April 2022, acquired Barra & Associates, (changed to RELI Exchange following acquisition) a recognized provider of both personal and commercial insurance products, including P&C insurance, life insurance, health insurance and other insurance products.

 

Insurance Agency Acquisition Strategy

 

  Numerous acquisition targets within a highly fragmented market

 

  Ø Reliance’s access to capital supports the growth of the acquired companies

 

  Ownership and management remain engaged

 

  Focus on acquiring growing and profitable businesses, for below-market prices

 

  Ø Ability to leverage cash flow of acquiree through low-cost debt financing and provide earnouts as part of consideration

 

  Economies of scale through first class technology infrastructure and national sales/marketing platform

 

  Ø Few insurance agencies have the size and scale to compete at a national level

 

  Management expertise in acquisitions, operations, and financial management

 

Digitizing Bricks & Mortar Agencies

 

  Capitalizing on consumer shift to ‘online’

 

  Ø More and more customers search for insurance online, but consumers prefer the personal touch of an agent

 

  Proprietary backend processing technology to support Reliance’s agency business

 

  Strategy to acquire traditional ‘offline’ home, auto and life agencies, and utilize technology to more cost effectively service the acquired policies

 

  By implementing artificial intelligence, robotic process automation (RPA) and automatic shopping for best rates at renewals, Reliance can:

 

  Ø Dramatically reduce cost

 

  Ø Allow agents to focus on selling new policies,

 

  Ø Create a digitally empowered and scalable insurance agency model

 

  Ability to rapidly expand Reliance’s agency network nationwide and drive margin expansion through the combination of digital backend and continued M&A of cash flow positive and accretive acquisitions

 

Employees

 

As of December 31, 2023, we employed 67 employees across all Company subsidiaries.

 

We believe that a diverse workforce is important to our success. We will continue to focus on the hiring, retention, and advancement of underrepresented populations, and to cultivate an inclusive and diverse corporate culture. In the future, we intend to continue to evaluate our use of human capital measures or objectives in managing our business such as the factors we employ or seek to employ in the development, attraction and retention of personnel and maintenance of diversity in our workforce.

 

15

 

 

The success of our business is fundamentally connected to the well-being of our people. Accordingly, we are committed to the health, safety and wellness of our employees. We provide our employees and their families with access to a variety of innovative, flexible and convenient health and wellness programs, including benefits that provide protection and security so they can have peace of mind concerning events that may require time away from work or that impact their financial well-being; that support their physical and mental health by providing tools and resources to help them improve or maintain their health status and encourage engagement in healthy behaviors; and that offer choice where possible so they can customize their benefits to meet their needs and the needs of their families.

 

We also provide robust compensation and benefits programs to help meet the needs of our employees. We believe that we maintain a satisfactory working relationship with our employees and have not experienced any labor disputes.

 

Competition

 

The insurance brokerage business is highly competitive, and numerous firms actively compete with us for customers and insurance markets. Competition is largely based upon innovation, knowledge, terms and conditions of coverage, quality of service and price. We believe that we’re well positioned to be highly competitive and continuously gain market share. Additionally, our focus on InsurTech is a game-changer in the industry and helps us stand-out vs. the competition.

 

The Merger and Acquisition of Insurance Agencies is a highly competitive industry, as well. Competition is due to many well-established companies having extensive experience in identifying and effecting business combinations who possess great technical, human, and financial resources. Several firms and banks with substantially greater resources and market presence compete with us. While we believe that there are numerous potential target businesses that we could acquire, our ability to compete in acquiring certain sizable target businesses might be limited.

 

Government Regulation

 

The business practices and compensation arrangements of the insurance intermediary industry, including our practices and arrangements, are regulated by various governmental authorities. Certain of our offices are parties to profit-sharing contingent commission agreements with certain insurance companies, including agreements providing for potential payment of revenue-sharing commissions by insurance companies based primarily on the overall profitability of the aggregate business written with those insurance companies and/or additional factors such as retention ratios and the overall volume of business that an office or offices place with those insurance companies. The legislatures of various states may adopt new laws addressing contingent commission arrangements, including laws prohibiting such arrangements, and addressing disclosure of such arrangements to insureds.

 

We and our employees must be licensed to act as brokers, intermediaries, or third-party administrators by state regulatory authorities in the locations in which we conduct business. Regulations and licensing laws vary by individual state and are often complex. The applicable licensing laws and regulations in all states are subject to amendment or reinterpretation by regulatory authorities, and such authorities are vested in most cases with relatively broad discretion as to the granting, revocation, suspension, and renewal of licenses. We believe that we are in compliance with the applicable licensing laws and regulations of all states in which we currently operate. However, the possibility still exists that we or our employees could be excluded or temporarily suspended from carrying on some or all of our activities in, or could otherwise be subjected to penalties by, a particular jurisdiction.

 

Nearly all states have insurance laws requiring personal property and casualty insurers to file rating plans, policy or coverage forms, and other information with the state’s regulatory authority. In many cases, such rating plans, policy, or coverage forms, must be approved prior to use and the regulator has the authority to disapprove a rate filing. While we are not an insurer, and thus not required to comply with state laws and regulations regarding insurance rates, our commissions are derived from a percentage of the premium rates set by insurers in conjunction with state law.

 

16

 

 

Item 1a. RISK FACTORS

 

The following important factors, among others, could cause our actual operating results to differ materially from those indicated or suggested by forward-looking statements made in this Annual Report on Form 10-K or presented elsewhere by management from time to time. Investors should carefully consider the risks described below before making an investment decision. The risks described below are not the only ones we face. Additional risks not presently known to us or that we currently believe are not material may also significantly impair our business operations. Our business could be harmed by any of these risks. The trading price of our common stock could decline due to any of these risks, and investors may lose all or part of their investment.

 

Risks Related to Our Business

 

We may experience significant fluctuations in our quarterly and annual results.

 

Fluctuations in our quarterly and annual financial results have resulted and will continue to result from numerous factors, including:

 

  The Company having a limited operating history
  The Company has limited resources and there is significant competition for business combination opportunities. Therefore, the Company may not be able to acquire other assets or businesses
  The Company may be unable to obtain additional financing, if required, to complete an acquisition, or to complement the operations and growth of existing and target business, which could compel the Company to restructure a potential business transaction or abandon a particular business combination
We hold our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts that could be adversely affected if the financial institution holding such funds fail.
  Our inability to retain or hire qualified employees, as well as the loss of any of our executive officers, could negatively impact our ability to retain existing business and generate new business
  Our growth strategy depends, in part, on the acquisition of other insurance intermediaries, which may not be available on acceptable terms in the future or which, if consummated, may not be advantageous to us
  A cybersecurity attack, or any other interruption in information technology and/or data security and/or outsourcing relationships, could adversely affect our business, financial condition and reputation
  Rapid technological change may require additional resources and time to adequately respond to dynamics, which may adversely affect our business and operating results
  Changes in data privacy and protection laws and regulations, or any failure to comply with such laws and regulations, could adversely affect our business and financial results
  Because our insurance business is highly concentrated in Michigan, New York, Montana, New Jersey, Ohio, and Illinois adverse economic conditions, natural disasters, or regulatory changes in these regions could adversely affect our financial condition
  If we fail to comply with the covenants contained in certain of our agreements, our liquidity, results of operations and financial condition may be adversely affected
  Certain of our agreements contain various covenants that limit the discretion of our management in operating our business and could prevent us from engaging in certain potentially beneficial activities
  There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with United States Generally Accepted Accounting Principles (U.S. GAAP). Any changes in estimates, judgments and assumptions could have a material adverse effect on our financial position and results of operations and therefore our business
  Improper disclosure of confidential information could negatively impact our business
  Our business could be adversely impacted by inflation.

 

These factors, some of which are not within our control, may cause the price of our common stock to fluctuate substantially. If our operating results fail to meet or exceed the expectations of securities analysts or investors, our stock price could drop suddenly and significantly. Due to the Company’s limited operating history, we believe period to period comparisons of our financial results are not always meaningful and should not be relied upon as an indication of future performance.

 

17

 

 

The Company has limited resources and there is significant competition for business combination opportunities. Therefore, the Company may not be able to acquire other assets or businesses.

 

The Company expects to encounter intense competition from other entities having a business objective similar to ours, which are also competing for acquisitions. Many of these entities are well established and have extensive experience in identifying and effecting business combinations directly or through affiliates. Many of these competitors possess greater technical, human, financial and other resources. While the Company believes that there are numerous potential target businesses that it could acquire, the Company’s ability to compete in acquiring certain sizable target businesses might be limited if the Company’s limited financial resources are less than that of its competitors. This inherent competitive limitation gives others an advantage in pursuing the acquisition of certain target businesses.

 

The Company may be unable to obtain additional financing, if required, to complete an acquisition, or to Company the operations and growth of existing and target business, which could compel the Company to restructure a potential business transaction or abandon a particular business combination.

 

To date, much of our capital for acquiring and operating insurance agencies comes from loans from unaffiliated lenders, from direct market capital raises or funds provided by Reliance Global Holdings our affiliate. We may be required to seek additional financing. We cannot assure you that such financing would be available on acceptable terms, if at all. If additional financing proves to be unavailable, we would be compelled to restructure or existing business, or abandon a proposed acquisition or acquisitions. In addition, if we consummate additional acquisitions, we may require additional financing to complement the operations or growth of that business. The failure to secure additional financing could have a material adverse effect on the continued development or growth of our business.

 

We hold our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts that could be adversely affected if the financial institution holding such funds fail.

 

We hold our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts at one financial institution. The balance held in these accounts exceeds the Federal Deposit Insurance Corporation, or FDIC, standard deposit insurance limit of $250,000. If the financial institution in which we hold such funds fails or is subject to significant adverse conditions in the financial or credit markets, we could be subject to a risk of loss of all or a portion of such uninsured funds or be subject to a delay in accessing all or a portion of such uninsured funds. Any such loss or lack of access to these funds could adversely impact our short-term liquidity and ability to meet our operating expense obligations, including payroll obligations.

 

For example, on March 10, 2023, Silicon Valley Bank, or SVB, and Signature Bank, were closed by state regulators and the FDIC was appointed receiver for each bank. The FDIC created successor bridge banks and all deposits of SVB and Signature Bank were transferred to the bridge banks under a systemic risk exception approved by the United States Department of the Treasury, the Federal Reserve and the FDIC. If the financial institution in which we hold funds for working capital and operating expenses were to fail, we cannot provide any assurances that such governmental agencies would take action to protect our uninsured deposits or investments in a similar manner.

 

Our inability to retain or hire qualified employees, as well as the loss of any of our executive officers, could negatively impact our ability to retain existing business and generate new business.

 

Our success depends on our ability to attract and retain skilled and experienced personnel. There is significant competition from within the insurance industry and from businesses outside the industries for exceptional employees, especially in key positions. If we are not able to successfully attract, retain and motivate our employees, our business, financial results and reputation could be materially and adversely affected.

 

18

 

 

Losing employees who manage or support substantial customer relationships or possess substantial experience or expertise could adversely affect our ability to secure and complete customer engagements, which would adversely affect our results of operations. Also, if any of our key personnel were to join an existing competitor or form a competing company, some of our customers could choose to use the services of that competitor instead of our services. While our key personnel are generally prohibited by contract from soliciting our employees and customers for a two-year period following separation from employment with us, they are not prohibited from competing with us.

 

In addition, we could be adversely affected if we fail to adequately plan for the succession of our senior leaders and key executives. We cannot guarantee that the services of these executives will continue to be available to us. The loss of our senior leaders or other key personnel, or our inability to continue to identify, recruit and retain such personnel, or to do so at reasonable compensation levels, could materially and adversely affect our business, results of operations, cash flows and financial condition.

 

Our growth strategy depends, in part, on the acquisition of other insurance intermediaries, which may not be available on acceptable terms in the future or which, if consummated, may not be advantageous to us.

 

Our growth strategy partially includes the acquisition of other insurance intermediaries. Our ability to successfully identify suitable acquisition candidates, complete acquisitions, integrate acquired businesses into our operations, and expand into new markets requires us to implement and continuously improve our operations and our financial and management information systems. Integrated, acquired businesses may not achieve levels of revenues or profitability comparable to our existing operations, or otherwise perform as expected. In addition, we compete for acquisition and expansion opportunities with firms and banks that may have substantially greater resources than we do. Acquisitions also involve a number of special risks, such as diversion of management’s attention; difficulties in the integration of acquired operations and retention of personnel; increase in expenses and working capital requirements, which could reduce our return on invested capital; entry into unfamiliar markets or lines of business; unanticipated problems or legal liabilities; estimation of the acquisition earn-out payables; and tax and accounting issues, some or all of which could have a material adverse effect on our results of operations, financial condition and cash flows. Post-acquisition deterioration of operating performance could also result in lower or negative earnings contribution and/or goodwill impairment charges.

 

A cybersecurity attack, or any other interruption in information technology and/or data security and/or outsourcing relationships, could adversely affect our business, financial condition, and reputation.

 

We rely on information technology and third-party vendors to provide effective and efficient service to our customers, process claims, and timely and accurately report information to carriers and which often involves secure processing of confidential sensitive, proprietary, and other types of information. Cybersecurity breaches of any of the systems we rely on may result from circumvention of security systems, denial-of-service attacks or other cyber-attacks, hacking, “phishing” attacks, computer viruses, ransomware, malware, employee or insider error, malfeasance, social engineering, physical breaches, or other actions, any of which could expose us to data loss, monetary and reputational damages and significant increases in compliance costs. An interruption of our access to, or an inability to access, our information technology, telecommunications or other systems could significantly impair our ability to perform such functions on a timely basis. If sustained or repeated, such a business interruption, system failure or service denial could result in a deterioration of our ability to write and process new and renewal business, provide customer service, pay claims in a timely manner or perform other necessary business functions. We have from time-to-time experienced cybersecurity breaches, such as computer viruses, unauthorized parties gaining access to our information technology systems and similar incidents, which to date have not had a material impact on our business.

 

Additionally, we are an acquisitive organization and the process of integrating the information systems of the businesses we acquire is complex and exposes us to additional risk as we might not adequately identify weaknesses in the targets’ information systems, which could expose us to unexpected liabilities or make our own systems more vulnerable to attack. In the future, any material breaches of cybersecurity, or media reports of the same, even if untrue, could cause us to experience reputational harm, loss of clients and revenue, loss of proprietary data, regulatory actions and scrutiny, sanctions or other statutory penalties, litigation, liability for failure to safeguard clients’ information or financial losses. Such losses may not be insured against or not fully covered through insurance we maintain.

 

19

 

 

Rapid technological change may require additional resources and time to adequately respond to dynamics, which may adversely affect our business and operating results.

 

Frequent technological changes, new products and services and evolving industry standards are influencing the insurance businesses. The Internet, for example, is increasingly used to securely transmit benefits, property and personal information, and related information to customers and to facilitate business-to-business information exchange and transactions.

 

We are continuously taking steps to upgrade and expand our information systems capabilities. Maintaining, protecting, and enhancing these capabilities to keep pace with evolving industry and regulatory standards, and changing customer preferences, requires an ongoing commitment of significant resources. If the information we rely upon to run our businesses was found to be inaccurate or unreliable or if we fail to effectively maintain our information systems and data integrity, we could experience operational disruptions, regulatory or other legal problems, increases in operating expenses, loss of existing customers, difficulty in attracting new customers, or suffer other adverse consequences.

 

Changes in data privacy and protection laws and regulations, or any failure to comply with such laws and regulations, could adversely affect our business and financial results.

 

We are subject to a variety of continuously evolving and developing laws and regulations globally regarding privacy, data protection, and data security, including those related to the collection, storage, handling, use, disclosure, transfer, and security of personal data. Significant uncertainty exists as privacy and data protection laws may be interpreted and applied differently from country to country and may create inconsistent or conflicting requirements. These laws apply to transfers of information among our affiliates, as well as to transactions we enter into with third party vendors. These and similar initiatives around the world could increase the cost of developing, implementing, or securing our servers and require us to allocate more resources to improved technologies, adding to our information technology and compliance costs. In addition, enforcement actions and investigations by regulatory authorities related to data security incidents and privacy violations continue to increase. The enactment of more restrictive laws, rules, regulations or future enforcement actions or investigations could impact us through increased costs or restrictions on our business, and noncompliance could result in regulatory penalties and significant legal liability.

 

Because our insurance business is highly concentrated in Michigan, New York, Montana, New Jersey, Ohio, and Illinois adverse economic conditions, natural disasters, or regulatory changes in these regions could adversely affect our financial condition.

 

A significant portion of our insurance business is concentrated in Michigan, New York, Montana, New Jersey, Ohio, and Illinois. For the years ended December 31, 2023, and 2022 we derived $13,731,826 and $11,761,882 respectively or 100% of our annual revenue, respectively, from our operations located in these regions (FYE 2023 - Michigan – 55%, New York – 2%, Montana – 14% and Ohio – 16%, and Illinois – 13%. FYE 2022 - Michigan – 55%, New York – 2%, Montana – 16%, Ohio – 18%, and Illinois – 9%.). The insurance business is primarily a state-regulated industry, and therefore, state legislatures may enact laws that adversely affect the insurance industry. Because our business is concentrated in these four states, we face greater exposure to unfavorable changes in regulatory conditions in those states than insurance intermediaries whose operations are more diversified through a greater number of states. In addition, the occurrence of adverse economic conditions, natural or other disasters, or other circumstances specific to or otherwise significantly impacting these states could adversely affect our financial condition, results of operations and cash flows. We are susceptible to losses and interruptions caused by hurricanes or other weather conditions, and other possible events such as terrorist acts and other natural or man-made disasters. Our insurance coverage with respect to natural disasters is limited and is subject to deductibles and coverage limits. Such coverage may not be adequate or may not continue to be available at commercially reasonable rates and terms.

 

20

 

 

If we fail to comply with the covenants contained in certain of our agreements, our liquidity, results of operations and financial condition may be adversely affected.

 

The Oak Street credit agreements, in the aggregate principal amount of $12,417,737 and $13,468,394, as of December 31, 2023 and 2022, that govern our debt contain various covenants and other limitations with which we must comply including a debt to EBITDA ratio covenant and a covenant that at all times that the loans are outstanding: (i) Ezra Beyman, our chief executive officer, Debra Beyman, Mr. Beyman’s wife, or Yaakov Beyman, son of Mr. and Ms. Beyman, or someone else approved by Oak Street, as applicable, will be the manager of the current subsidiaries of the Company, (ii) Mr. Ezra Beyman will be President and Chairperson of the Board of the Company, and (iii) Reliance Global Holdings will continue to remain a shareholder of the Company’s equity and Ezra and Debra will be the sole owners of Reliance Global Holdings as tenants in entirety. The credit agreements also contain provisions which cause a “cross default” if we default our obligations under other material contracts to which we are parties. The credit agreements contain customary and usual events of default, including, subject to certain specified cure periods and notice requirements, the Company’s or one of its subsidiaries’ failure to comply with the covenants therein. Upon an event of default, the lender has customary and usual remedies to cure these defaults including, but not limited to, the ability to accelerate the indebtedness.

 

The credit agreements contain financial covenants including debt service coverage ratio and debt to EBIDTA (earnings before interest, taxes, depreciation, and amortization) tests. As of December 31, 2023, the Company is in compliance with all financial covenants.

 

Certain of our agreements contain various covenants that limit the discretion of our management in operating our business and could prevent us from engaging in certain potentially beneficial activities.

 

The restrictive covenants in our debt agreements may impact how we operate our business and prevent us from engaging in certain potentially beneficial activities. Among other covenants, our debt agreements require us to maintain a minimum ratio of Consolidated EBITDA, adjusted for certain transaction-related items (“Consolidated EBITDA”), to consolidated interest expense and a maximum ratio of consolidated net indebtedness to Consolidated EBITDA. Our compliance with these covenants could limit management’s discretion in operating our business and could prevent us from engaging in certain potentially beneficial activities.

 

There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with U.S. GAAP. Any changes in estimates, judgments and assumptions could have a material adverse effect on our financial position and results of operations and therefore our business.

 

The preparation of financial statements in accordance with U.S. GAAP involves making estimates, judgments and assumptions that affect reported amounts of assets (including intangible assets), liabilities and related reserves, revenues, expenses, and income. Estimates, judgments and assumptions are inherently subject to change in the future, and any such changes could result in corresponding changes to the values of assets, liabilities, revenues, expenses and income, and could have a material adverse effect on our financial position, results of operations and cash flows.

 

Improper disclosure of confidential information could negatively impact our business.

 

We are responsible for maintaining the security and privacy of our customers’ confidential and proprietary information and the personal data of their employees. We have put in place policies, procedures and technological safeguards designed to protect the security and privacy of this information; however, we cannot guarantee that this information will not be improperly disclosed or accessed. Disclosure of this information could harm our reputation and subject us to liability under our contracts and laws that protect personal data, resulting in increased costs or loss of revenues.

 

21

 

 

Our business, results of operations, financial condition and liquidity may be materially adversely affected by certain actual and potential claims, regulatory actions and proceedings.

 

We are subject to various actual and potential claims, regulatory actions and other proceedings including those relating to alleged errors and omissions in connection with the placement or servicing of insurance and/or the provision of services in the ordinary course of business, of which we cannot, and likely will not be able to, predict the outcome with certainty. Because we often assist customers with matters involving substantial amounts of money, including the placement of insurance and the handling of related claims that customers may assert, errors and omissions claims against us may arise alleging potential liability for all or part of the amounts in question. Also, the failure of an insurer with whom we place business could result in errors and omissions claims against us by our customers, which could adversely affect our results of operations and financial condition. Claimants may seek large damage awards, and these claims may involve potentially significant legal costs, including punitive damages. Such claims, lawsuits and other proceedings could, for example, include claims for damages based upon allegations that our employees or sub-agents failed to procure coverage, report claims on behalf of customers, provide insurance companies with complete and accurate information relating to the risks being insured or appropriately apply funds that we hold for our customers on a fiduciary basis. In addition, given the long-tail nature of professional liability claims, errors and omissions matters can relate to matters dating back many years. Where appropriate, we have established provisions against these potential matters that we believe to be adequate in the light of current information and legal advice, and we adjust such provisions from time to time according to developments.

 

While most of the errors and omissions claims made against us (subject to our self-insured deductibles) have been covered by our professional indemnity insurance, our business, results of operations, financial condition and liquidity may be adversely affected if, in the future, our insurance coverage proves to be inadequate or unavailable, or if there is an increase in liabilities for which we self-insure. Our ability to obtain professional indemnity insurance in the amounts and with the deductibles we desire in the future may be adversely impacted by general developments in the market for such insurance or our own claims experience. In addition, regardless of monetary costs, these matters could have a material adverse effect on our reputation and cause harm to our carrier, customer or employee relationships, or divert personnel and management resources.

 

Our business could be adversely impacted by inflation.

 

Increases in inflation may have an adverse effect on our business. Current and future inflationary effects may be driven by, among other things, supply chain disruptions and governmental stimulus or fiscal policies. Continuing increases in inflation could impact the overall demand for our products, our costs for labor, material and services, and the margins we are able to realize on our products, all of which could have an adverse impact on our business, financial position, results of operations and cash flows. Inflation may also result in higher interest rates, which in turn would result in higher interest.

 

Risks Related to the Insurance Industry

 

We may experience increased competition from insurance companies, technology companies and the financial services industry, as well as the shift away from traditional insurance markets.

 

The insurance intermediary business is highly competitive and we actively compete with numerous firms for customers, properties and insurance companies, many of which have relationships with insurance companies, or have a significant presence in niche insurance markets that may give them an advantage over us. Other competitive concerns may include the quality of our products and services, our pricing, and the ability of some of our customers to self-insure and the entrance of technology companies into the insurance intermediary business. Several insurance companies are engaged in the direct sale of insurance, primarily to individuals, and do not pay commissions to agents and brokers. In addition, and to the extent that banks, securities firms, private equity companies, and insurance companies affiliate, the financial services industry may experience further consolidation, and we therefore may experience increased competition from insurance companies and the financial services industry, as a growing number of larger financial institutions increasingly, and aggressively, offer a wider variety of financial services, including insurance intermediary services.

 

22

 

 

Worsening of Current U.S. economic conditions as a result of the COVID-19 pandemic and the Russian Federation Military Action may adversely affect our business.

 

Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position or results of its operations, the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.

 

If economic conditions were to worsen, a number of negative effects on our business could result, including declines in values of insurable exposure units, declines in insurance premium rates, the financial insolvency of insurance companies, the reduced ability of customers to pay, declines in the stock of residential housing or declines in property values. Also, if general economic conditions are poor, some of our customers may cease operations completely or be acquired by other companies, which could have an adverse effect on our results of operations and financial condition. If these customers are affected by poor economic conditions, but yet remain in existence, they may face liquidity problems or other financial difficulties that could result in delays or defaults in payments owed to us, which could have a significant adverse impact on our consolidated financial condition and results of operations. Any of these effects could decrease our net revenues and profitability.

 

Our business, and therefore our results of operations and financial condition, may be adversely affected by conditions that result in reduced insurer capacity.

 

Our results of operations depend on the continued capacity of insurance carriers to underwrite risk and provide coverage, which depends in turn on those insurance companies’ ability to procure reinsurance. Capacity could also be reduced by insurance companies failing or withdrawing from writing certain coverages that we offer to our customers. We have no control over these matters. To the extent that reinsurance becomes less widely available or significantly more expensive, we may not be able to procure the amount or types of coverage that our customers desire and the coverage we are able to procure for our customers may be more expensive or limited.

 

Quarterly and annual variations in our commissions that result from the timing of policy renewals and the net effect of new and lost business production may have unexpected effects on our results of operations.

 

Our commission income (including profit-sharing contingent commissions and override commissions) can vary quarterly or annually due to the timing of policy renewals and the net effect of new and lost business production. We do not control the factors that cause these variations. Specifically, customers’ demand for insurance products can influence the timing of renewals, new business, and lost business (which includes policies that are not renewed), and cancellations. In addition, we rely on insurance companies for the payment of certain commissions. Because these payments are processed internally by these insurance companies, we may not receive a payment that is otherwise expected from a particular insurance company in a particular quarter or year until after the end of that period, which can adversely affect our ability to forecast these revenues and therefore budget for significant future expenditures. Quarterly and annual fluctuations in revenues based upon increases and decreases associated with the timing of new business, policy renewals and payments from insurance companies may adversely affect our financial condition, results of operations and cash flows.

 

Profit-sharing contingent commissions are special revenue-sharing commissions paid by insurance companies based upon the profitability, volume and/or growth of the business placed with such companies generally during the prior year. Override commissions are paid by insurance companies based upon the volume of business that we place with them and are generally paid over the course of the year. Because profit-sharing contingent commissions and override commissions affect our revenues, any decrease in their payment to us could adversely affect our results of operations, profitability, and our financial condition.

 

23

 

 

Our business practices and compensation arrangements are subject to uncertainty due to potential changes in regulations.

 

The business practices and compensation arrangements of the insurance intermediary industry, including our practices and arrangements, are subject to uncertainty due to investigations by various governmental authorities. Certain of our offices are parties to profit-sharing contingent commission agreements with certain insurance companies, including agreements providing for potential payment of revenue-sharing commissions by insurance companies based primarily on the overall profitability of the aggregate business written with those insurance companies and/or additional factors such as retention ratios and the overall volume of business that an office or offices place with those insurance companies. Additionally, to a lesser extent, some of our offices are parties to override commission agreements with certain insurance companies, which provide for commission rates in excess of standard commission rates to be applied to specific lines of business, such as group health business, and which are based primarily on the overall volume of business that such office or offices placed with those insurance companies. The legislatures of various states may adopt new laws addressing contingent commission arrangements, including laws prohibiting such arrangements, and addressing disclosure of such arrangements to insureds. Various state departments of insurance may also adopt new regulations addressing these matters which could adversely affect our results of operations.

 

Risk of lack of knowledge in distant geographic markets

 

Although the Company intends to focus its investments in locations with which we are generally familiar, the Company runs a risk of experiencing underwriting challenges or issues associated with a lack of familiarity in some markets. Each market has nuances and idiosyncrasies that affect values, marketability, desirability, and demand for individual assets that may not be easily understood from afar. While we believe we can effectively mitigate these risks in a myriad of ways, there is no guarantee that investments in any geographic market will perform as expected.

 

Potential liability or other expenditures associated with potential environmental contamination may be costly.

 

Various federal, state, and local laws subject multifamily residential community owners or operators to liability for management, and the costs of removal or remediation, of certain potentially hazardous materials that may be present in the land or buildings of a multifamily residential community. Potentially hazardous materials may include polychlorinated biphenyls, petroleum-based fuels, lead-based paint or asbestos, among other materials. Such laws often impose liability without regard to fault or whether the owner or operator knew of, or was responsible for, the presence of such materials. The presence of, or the failure to manage or remediate properly, these materials may adversely affect occupancy at such apartment communities as well as the ability to sell or finance such apartment communities. In addition, governmental agencies may bring claims for costs associated with investigation and remediation actions, damages to natural resources and for potential fines or penalties in connection with such damage or with respect to the improper management of hazardous materials. Moreover, private plaintiffs may potentially make claims for investigation and remediation costs they incur or personal injury, disease, disability or other infirmities related to the alleged presence of hazardous materials at a multifamily residential community. In addition to potential environmental liabilities or costs associated with our current multifamily residential communities, we may also be responsible for such liabilities or costs associated with communities we acquire or manage in the future, or multifamily residential communities we no longer own or operate.

 

24

 

 

We compete in a highly regulated industry, which may result in increased expenses or restrictions on our operations.

 

We conduct business in several states of the United States of America and are subject to comprehensive regulation and supervision by government agencies in each of those states. The primary purpose of such regulation and supervision is to provide safeguards for policyholders rather than to protect the interests of our shareholders, and it is difficult to anticipate how changes in such regulation would be implemented and enforced. As a result, such regulation and supervision could reduce our profitability or growth by increasing compliance costs, technology compliance, restricting the products or services we may sell, the markets we may enter, the methods by which we may sell our products and services, or the prices we may charge for our services and the form of compensation we may accept from our customers, carriers and third parties.

 

The laws of the various state jurisdictions establish supervisory agencies with broad administrative powers with respect to, among other things, licensing of entities to transact business, licensing of agents, admittance of assets, regulating premium rates, approving policy forms, regulating unfair trade and claims practices, determining technology and data protection requirements, establishing reserve requirements and solvency standards, requiring participation in guarantee funds and shared market mechanisms, and restricting payment of dividends. Also, in response to perceived excessive cost or inadequacy of available insurance, states have from time to time created state insurance funds and assigned risk pools, which compete directly, on a subsidized basis, with private insurance providers. We act as agents and brokers for such state insurance funds and assigned risk pools in Michigan as well as certain other states. These state funds and pools could choose to reduce the sales or brokerage commissions we receive. Any such reductions, in a state in which we have substantial operations could affect the profitability of our operations in such state or cause us to change our marketing focus.

 

Further, state insurance regulators and the National Association of Insurance Commissioners continually re-examine existing laws and regulations, and such re-examination may result in the enactment of insurance-related laws and regulations, or the issuance of interpretations thereof, that adversely affect our business. Certain federal financial services modernization legislation could lead to additional federal regulation of the insurance industry in the coming years, which could result in increased expenses or restrictions on our operations.

 

Other legislative developments that could adversely affect us include: changes in our business compensation model as a result of regulatory developments (for example, the Affordable Care Act); and federal and state governments establishing programs to provide health insurance or, in certain cases, property insurance in catastrophe-prone areas or other alternative market types of coverage, that compete with, or completely replace, insurance products offered by insurance carriers. Also, as climate change issues become more prevalent, the U.S. and foreign governments are beginning to respond to these issues. This increasing governmental focus on climate change may result in new environmental regulations that may negatively affect us and our customers. This could cause us to incur additional direct costs in complying with any new environmental regulations, as well as increased indirect costs resulting from our customers incurring additional compliance costs that get passed on to us. These costs may adversely impact our results of operations and financial condition.

 

Although we believe that we are in compliance in all material respects with applicable local, state, and federal laws, rules and regulations, there can be no assurance that more restrictive laws, rules, regulations or interpretations thereof, will not be adopted in the future that could make compliance more difficult or expensive.

 

25

 

 

Risks Related to Investing in our Securities

 

We may experience volatility in our stock price that could affect your investment.

 

The market price of our common stock may be subject to significant fluctuations in response to various factors, including: quarterly fluctuations in our operating results; changes in securities analysts’ estimates of our future earnings; changes in securities analysts’ predictions regarding the short-term and long-term future of our industry; changes to the tax code; and our loss of significant customers or significant business developments relating to us or our competitors. Our common stock’s market price also may be affected by our inability to meet stock analysts’ earnings and other expectations. Any failure to meet such expectations, even if minor, could cause the market price of our common stock to decline. In addition, stock markets have generally experienced a high level of price and volume volatility, and the market prices of equity securities of many listed companies have experienced wide price fluctuations not necessarily related to the operating performance of such companies. These broad market fluctuations may adversely affect our common stock’s market price. In the past, securities class action lawsuits frequently have been instituted against companies following periods of volatility in the market price of such companies’ securities. If any such litigation is initiated against us, it could result in substantial costs and a diversion of management’s attention and resources, which could have a material adverse effect on our business, results of operations, financial condition, and cash flows.

 

Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.

 

Our shares of common stock are currently listed on Nasdaq. If we fail to satisfy the continued listing requirements of The Nasdaq Capital Market, such as the corporate governance requirements, minimum bid price requirement or the minimum stockholders’ equity requirement, Nasdaq may take steps to delist our common stock. Any delisting would likely have a negative effect on the price of our common stock and would impair stockholders’ ability to sell or purchase their common stock when they wish to do so.

 

As previously disclosed in the Current Report on Form 8-K filed on January 16, 2024 by the Company on January 12, 2024, the Company received written notice from Nasdaq’s Listing Qualifications Department notifying the Company that for the preceding 30 consecutive business days (November 29, 2023 to January 11, 2024), the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock continued to trade on Nasdaq under the symbol “RELI.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until July 10, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2).

 

Any perception that we may not comply with Nasdaq continued listing requirements or a delisting of our common stock by Nasdaq could adversely affect our ability to attract new investors, decrease the liquidity of the outstanding shares of our common stock, reduce the price at which such shares trade and increase the transaction costs inherent in trading such shares with overall negative effects for our stockholders. In addition, delisting of our common stock from Nasdaq could deter broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, and might deter certain institutions and persons from investing in our common stock.

 

The Company’s CEO has a significant common stock equity interest.

 

As of April 4, 2024, our CEO, Ezra Beyman, is the beneficial owner of approximately 8% of the common stock, consisting of 381,020 common shares. As of December 31, 2023, the are no outstanding loan balances due to affiliated entities to our CEO, Reliance Global Holdings LLC and YES Americana Group, LLC.

 

26

 

 

Under our credit agreements with Oak Street, the Company has agreed that at all times that the loans are outstanding: (i) Ezra Beyman, our chief executive officer, Debra Beyman, Mr. Beyman’s wife, or Yaakov Beyman, son of Mr. and Ms. Beyman, or someone else approved by Oak Street, as applicable, will be the manager of the current subsidiaries of the Company, (ii) Mr. Ezra Beyman will be President and Chairperson of the Board of the Company, and (iii) Reliance Global Holdings will continue to remain a shareholder of the Company’s equity and Ezra and Debra will be the sole owners of Reliance Global Holdings as tenants in entirety. The loans by Oak Street immediately mature and become due and payable if the Company fails to comply with these provisions, subject to certain notice and/or cure periods.

 

Broad discretion of management

 

Any person who invests in the Company’s common stock will do so without an opportunity to evaluate the specific merits or risks of any prospective acquisition. As a result, investors will be entirely dependent on the broad discretion and judgment of management in connection with the selection of acquisitions. There can be no assurance that determinations made by the Company’s management will permit us to achieve the Company’s business objectives.

 

Future sales or other dilution of our equity could adversely affect the market price of our common stock.

 

We grow our business organically as well as through acquisitions. One method of acquiring companies or otherwise Companying our corporate activities is through the issuance of additional equity securities. The issuance of any additional shares of common or of preferred stock or convertible securities could be substantially dilutive to holders of our common stock. Moreover, to the extent that we issue restricted stock units, performance stock units, options or warrants to purchase shares of our common stock in the future and those options or warrants are exercised or as the restricted stock units or performance stock units vest, our stockholders may experience further dilution. Holders of our common stock have no preemptive rights that entitle holders to purchase their pro rata share of any offering of shares of any class or series and, therefore, such sales or offerings could result in increased dilution to our stockholders. The market price of our common stock could decline as a result of sales of shares of our common stock or the perception that such sales could occur.

 

The price of our common stock may fluctuate significantly, and this may make it difficult to resell shares of common stock at attractive prices.

 

The trading price of our common stock may fluctuate widely as a result of a number of factors, including the risk factors described above many of which are outside our control. In addition, the stock market is subject to fluctuations in the share prices and trading volumes that affect the market prices of the shares of many companies. These broad market fluctuations have adversely affected and may continue to adversely affect the market price of our common stock. Among the factors that could affect our stock price are:

 

  General economic and political conditions such as recessions, economic downturns and acts of war or terrorism;
  Quarterly variations in our operating results;
  Seasonality of our business cycle;
  Changes in the market’s expectations about our operating results;
  Our operating results failing to meet the expectation of securities analysts or investors in a particular period;
  Changes in financial estimates and recommendations by securities analysts concerning us or the insurance brokerage or financial services industries in general;
  Operating and stock price performance of other companies that investors deem comparable to us;
  News reports relating to trends in our markets, including any expectations regarding an upcoming “hard” or “soft” market;
  Cyberattacks and other cybersecurity incidents;
  Changes in laws and regulations affecting our business;
  Material announcements by us or our competitors;
  The impact or perceived impact of developments relating to our investments, including the possible perception by securities analysts or investors that such investments divert management attention from our core operations;
  Market volatility;
  A negative market reaction to announced acquisitions;
  Competitive pressures in each of our divisions;
  General conditions in the insurance brokerage and insurance industries;
  Legal proceedings or regulatory investigations;
  Sales of substantial amounts of common shares by our directors, executive officers or significant stockholders or the perception that such sales could occur.

 

Stockholder class action lawsuits may be instituted against us following a period of volatility in our stock price. Any such litigation could result in substantial cost and a diversion of management’s attention and resources.

 

27

 

 

Possible issuance of additional securities.

 

Our Articles of Incorporation authorize the issuance of 2,000,000,000 shares of common stock, par value $0.086 per share. As of December 31, 2023 we had 4,761,974 shares issued and outstanding. We may be expected to issue additional shares in connection with our pursuit of new business opportunities and new business operations. To the extent that additional shares of common stock are issued, our shareholders would experience dilution of their respective ownership interests. If we issue shares of common stock in connection with our intent to pursue new business opportunities, a change in control of the Company may be expected to occur. The issuance of additional shares of common stock may adversely affect the market price of our common stock, in the event that an active trading market commences.

 

We could be negatively impacted by cybersecurity attacks.

 

We may use a variety of information technology systems in the ordinary course of business, which are potentially vulnerable to unauthorized access, computer viruses and cyberattacks, including cyberattacks to our information technology infrastructure and attempts by others to gain access to our propriety or sensitive information, and ranging from individual attempts to advanced persistent threats. The risk of such a security breach or disruption has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased and will likely continue to increase in the future. The procedures and controls we use to monitor these threats and mitigate our exposure may not be sufficient to prevent cyber security incidents. The results of these incidents could include disrupted operations, misstated or unreliable financial data, theft of trade secrets or other intellectual property, liability for disclosure of confidential customer, supplier or employee information, increased costs arising from the implementation of additional security protective measures, regulatory enforcement litigation and reputational damage, which could materially adversely affect our financial condition, business and results of operations. These risks require continuous and likely increasing attention and other resources from us to, among other actions, identify and quantify these risks, upgrade and expand our technologies, systems and processes to adequately address them and provide periodic training for employees to assist them in detecting phishing, malware and other schemes. Such attention diverts time and other resources from other activities and there is no assurance that our efforts will be effective. Additionally, the cost of maintaining and improving such systems and processes, procedures and internal controls may increase from its current level. Potential sources for disruption, damage or failure of our information technology systems include, without limitation, computer viruses, security breaches, human error, cyberattacks, natural disasters and defects in design. Additionally, we rely on third party service providers for certain aspects of our business. We can provide no assurance that the networks and systems that our third party vendors have established or use will be effective. Even if we are not targeted directly, cyberattacks on the U.S. and foreign governments, financial markets, financial institutions, or other businesses, including vendors, software creators, cybersecurity service providers, and other third parties with whom we do business, may occur, and such events could disrupt our normal business operations and networks in the future.

 

We are subject to a variety of federal, state, and international laws and other obligations regarding data protection.

 

We are subject to a variety of federal, state, and international laws and other obligations regarding data protection. Several jurisdictions have passed laws in this area, and other jurisdictions are considering imposing additional restrictions. These laws continue to develop and may be inconsistent from jurisdiction to jurisdiction. Complying with emerging and changing domestic and international requirements may cause us or our businesses to incur substantial costs or require us or one of our businesses to change its business practices. Any failure by us to comply with our own privacy policy, applicable association rules, or with other federal, state or international privacy-related or data protection laws and regulations could result in proceedings against us by governmental entities or others.

 

Dividends unlikely.

 

The Company does not expect to pay dividends for the foreseeable future. The payment of dividends will be contingent upon the Company’s future revenues and earnings, if any, capital requirements and overall financial conditions. The payment of any future dividends will be within the discretion of the Company’s board of directors as then constituted. It is the Company’s expectation that future management following a business combination will determine to retain any earnings for use in its business operations and accordingly, the Company does not anticipate declaring any dividends in the foreseeable future.

 

28

 

 

Speculative Nature of Warrants.

 

Warrants offered in our various equity offerings do not confer any rights of common stock ownership on their holders, such as voting rights, and could limit the rights to receive dividends, they rather merely represent the right to acquire shares of our common stock at a fixed price for a limited period of time. Moreover, following these offerings, the market value of the warrants is uncertain and there can be no assurance that the market value of the warrants will equal or exceed their public offering price. There can be no assurance that the market price of the common stock will ever equal or exceed the exercise price of the warrants, and consequently, whether it will ever be profitable for holders of the warrants to exercise the warrants.

 

State blue sky registration; potential limitations on resale of the Company’s common stock

 

The holders of the Company’s shares of common stock registered under the Securities Exchange Act of 1934, as amended (the “Securities Act”) and those persons who desire to purchase them in any trading market that may develop in the future, should be aware that there may be state blue-sky law restrictions upon the ability of investors to resell the Company’s securities. Accordingly, investors should consider the secondary market for the Company’s securities to be a limited one.

 

Changes in tax laws could materially affect our financial condition, results of operations and cash flows.

 

The tax regimes we are subject to or operate under, including income and non-income taxes, are unsettled and may be subject to significant change. For example, the Inflation Reduction Act (the “IRA”) was signed into law on August 16, 2022 and was effective beginning in fiscal 2023. The IRA imposes a 15% minimum tax for large corporations on global adjusted financial statement income for tax years beginning after December 31, 2022, and a 1% excise tax on certain share repurchases occurring after December 31, 2022. We do not currently expect that the IRA will have a material impact on our income tax liability, but will continue to monitor this change in future periods. We are unable to predict what changes to the tax laws of the U.S. and other jurisdictions may be proposed or enacted in the future or what effect such changes would have on our business. Any significant increase in our future effective tax rate could have a material adverse impact on our business, financial condition, results of operations, or cash flows.

 

Expectations of our company relating to environmental, social and governance factors may impose additional costs and expose us to new risks.

 

There is an increasing focus from certain investors, customers and other key stakeholders concerning corporate responsibility, specifically related to environmental, social and governance (“ESG”) factors. We expect that an increased focus on ESG considerations will affect some aspects of our operations, particularly as we expand into new geographic markets. There are a number of constituencies that are involved in a range of ESG issues, including investors, special interest groups, public and consumer interest groups and third-party service providers. As a result, there is an increased emphasis on corporate responsibility ratings and several third parties provide reports on companies to measure and assess corporate responsibility performance. In addition, the ESG factors by which companies’ corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. Alternatively, if we are unable to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate. We risk damage to our brand and reputation if our corporate responsibility procedures or standards do not meet the standards set by various constituencies. In the future, we may be required to make substantial investments in matters related to ESG which could require significant investment and impact our results of operations. Any failure in our decision-making or related investments in this regard could affect consumer perceptions as to our brand. Furthermore, if our competitors’ corporate responsibility performance is perceived to be greater than ours, potential or current investors may elect to invest with our competitors instead. In addition, in the event that we communicate certain initiatives and goals regarding ESG matters, we could fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could be criticized for the scope of such initiatives or goals. If we fail to satisfy the expectations of investors and other key stakeholders or our initiatives are not executed as planned, our reputation and financial results could be materially and adversely affected.

 

Item 1B. Unresolved Staff Comments

 

Not applicable.

 

29

 

 

Item 1C. Cybersecurity

 

Cybersecurity Risk Management and Strategy

 

The cybersecurity risk management program, processes, and strategy described in this section are limited to the personal and business information belonging to or maintained by the Company (collectively, “Confidential Information”), our own third-party critical systems and services supporting or used by the Company (collectively, “Critical Systems”), and service providers.

 

We will consider developing and implementing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our Confidential Information and Critical Systems. Our cybersecurity risk management program will be integrated into our overall enterprise risk management program and includes a cybersecurity incident response plan.

 

Our contemplated cybersecurity risk management program shall include:

 

  risk assessments designed to help identify material cybersecurity risks to our Confidential Information, Critical Systems and the broader enterprise IT environment;
  a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;
  cybersecurity awareness and spear-phishing resistance training of our employees, and senior management;
  a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and
  a vendor management policy for service providers.

 

We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, could have a material adverse effect on us including an adverse effect on our business, financial condition and results of operations.

 

Cybersecurity Governance

 

Our executive management team, along with our managed information technology service provider, is responsible for assessing and managing risks from cybersecurity threats to the Company, including our Confidential Information and Critical Systems. The team has primary responsibility for our overall cybersecurity risk management program. Our management team works closely with our information technology service provider.

 

Our management team may meet with our information technology service provider periodically to discuss then-current cybersecurity issues, which may include efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, including threat intelligence and other information obtained from governmental, public or private sources, and external service providers engaged by us; and alerts and reports produced by security tools deployed in the information technology environment including a spear-phishing report.

 

Our Board considers cybersecurity risk as part of its risk oversight function and oversight of cybersecurity and other information technology risks.

 

Our Board oversees management’s implementation of our cybersecurity risk management program. Our executive management team is responsible for updating the Board, as necessary, regarding significant cybersecurity incidents.

 

Our Board shall also receive period reports from management (as deemed applicable) on our cybersecurity risks and cybersecurity risk management program.

 

Item 2. Properties

 

Below is a schedule of the properties we currently occupy:

 

Entity Name  Location  Own/Lease  Description  Approx. Sq. Footage   Lease Term  Monthly
Rent in USD
 
Employee Benefits Solutions  Cadillac, Michigan  Lease  Office Building   3,024   10/2019– 9/2024  $2,600 
Southwestern Montana Insurance Center  Belgrade, Montana  Lease  Office Building   6,000   4/2019– 3/2024   $7,000 
Southwestern Montana Insurance Center  Belgrade, Montana  Lease  Office Building   6,000   4/2024– 3/2028  $7,500 
Fortman Insurance Center  Bluffton, Ohio  Lease  Office Building   990   9/2020 – 8/2024  $600 
Fortman Insurance Center  Ottawa, Ohio  Lease  Office Building   2,386   5/2019– 4/2024  $2,400 
Altruis Benefits Consultants  Bingham Farms, MI  Lease  Office Building   1,767   6/2021– 5/2024  $4,997 
Reliance Global Group, Inc.  Lakewood, NJ  Lease  Office Building   4,436   6/2021 – 3/2029  $8,737 
Reliance Global Group, Inc.  Suffern, NY  Lease  Office Building       9/2022 – 8/2024  $2,000 
Reli Exchange  Schaumburg, IL  Lease  Office Building       4/2022 – 05/2025  $3,589 

 

Item 3. Legal Proceedings

 

From time to time, we are subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows. Litigation relating to the insurance brokerage industry is not uncommon. As such the Company, from time to time have been, subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

30

 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Holders of Record

 

As of December 31, 2023, there were approximately 522 holders of record of our ordinary shares, although there is a much larger number of beneficial owners.

 

Dividends

 

The Company has never paid any cash dividends and does not expect to pay dividends for the foreseeable future. We anticipate that we will retain funds and future earnings to support operations and to finance the growth and development of our business. The payment of dividends will be contingent upon the Company’s future revenues and earnings, if any, capital requirements, overall financial condition, and other factors that our board of directors deems relevant. The payment of any future dividends will be within the discretion of the Company’s board of directors as then constituted. It is the Company’s expectation that future management following a business combination will determine to retain any earnings for use in its business operations and accordingly, the Company does not anticipate declaring any dividends in the foreseeable future.

 

Issuer Purchases of Equity Securities

 

There have been no equity securities repurchased by the Company for the years ending December 31, 2023 and 2022.

 

Market Information

 

Our common stock is listed on the NASDAQ Capital Market under the symbol “RELI”, and our warrants to purchase common stock are listed on the NASDAQ Capital Market under the symbol “RELIW.”

 

On April 03, 2024, the closing price per share of our common stock was $0.37 as reported on the NASDAQ.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

2019 Equity Incentive Plans

 

On January 29, 2019, our board of directors and stockholders adopted the 2019 Equity Incentive Plan, pursuant to which 46,667 shares of our common stock are reserved for issuance as awards to employees, directors, consultants, advisors, and other service providers. The following table gives information about the Company’s common stock that may be issued upon the exercise of options granted to employees, directors and consultants under its 2019 Equity Incentive Plans as of December 31, 2023 which had outstanding grants and remaining unissued shares, taking into account issuance of restricted stock to officers and directors, as follows:

 

Equity Compensation Plan Information

 

Plan category   Number of securities to be issued upon exercise of outstanding options, warrants and rights     Weighted-average exercise price of outstanding options, warrants and rights     Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))  
      (a)       (b)       (c)  
Equity compensation plans approved by security holders     10,928     $ 232.55       -  
Equity compensation plans not approved by security holders     -       -       -  
Total     10,928     $ 232.55       -  

 

31

 

 

2023 Equity Incentive Plans

 

On August 10, 2023, the Company adopted the Reliance Global Group, Inc. 2023 Equity Incentive Plan (the “2023 Plan”, and together with the 2019 Plan, the “Plans”). The purpose of the 2023 Plan is to provide a means through which the Company and its subsidiaries may attract and retain key personnel, and to provide a means whereby directors, officer, employees, consultants, and advisors of the Company and its subsidiaries can acquire and maintain an equity interest in the Company, or be paid incentive compensation, thereby strengthening their commitment to the welfare of the Company and its subsidiaries and aligning their interests with those of the Company’s stockholders. There were no options issued under the 2023 Equity Incentive Plan.

 

Recent Sales of Unregistered Securities

 

Date of

Transaction

  

Transaction type

(e.g. new issuance,

cancellation,

shares returned to

treasury) and all

under Section

4(a)(2) of the

Securities Act of

1933

 

Number of

Securities

Issued (or

cancelled) (1)

   Class of Securities  Value of Securities issued ($/per share) at Issuance   Were the Securities issued at a discount to market price at the time of issuance? (Yes/No) 

Individual/

Entity Securities

were issued to

(entities must have

individual

with voting /

investment

control

disclosed).

 

Reason for

Securities

issuance (e.g. for

cash or debt

conversion) OR

Nature of

Services

Provided

(if

applicable)

 

Restricted or

Unrestricted

as of this

filing?

  Exemption or Registration Type? 
                                
01/05/2023   New   92,771(1)  Common   7.50   Yes  Altruis Benefits Consulting, Inc.  Acquisition      4(a)(2) 
                                   
1/17/2023   New   16,587(1)  Common   8.85   Yes  Joshua Paul Kushnereit  Acquisition      4(a)(2) 
                                   
2/13/2023   New   66,743(1)  Common   9.664   No  YES Americana Group, LLC  Conversion      3(a)(9) 
                                   
3/16/2023   New   155,038   Common   3.55   No  Armistice Capital Master Fund, Ltd.  Cash      4(a)(2) 
                                   
3/16/2023   New   897,594   Prefunded (Series E) Warrants exercisable @ $0.001 per share   3.549   No  Armistice Capital Master Fund, Ltd.  Cash      4(a)(2) 
                                   
3/16/2023   New   2,105,264   Common (Series F) Warrants exercisable @ $3.55 per share   0.125   No  Armistice Capital Master Fund, Ltd.  Cash      4(a)(2) 
                                   
4/03/2023   New   65,000   Common   2.63   No  New To The Street  Services      4(a)(2) 
                                   
5/18/2023   New   176,130   Common   4.07   No  Jonathan Fortman  Acquisition      4(a)(2) 
                                   
5/18/2023   New   176,130   Common   4.07   No  Zachary Fortman  Acquisition      4(a)(2) 
                                   
6/06/2023   New   29,974   Common   4.41   No  Maxim Partners LLC  Services      4(a)(2) 
                                   
06/20/2023   New   440   Common   4.50   No  Chad Champion  Services      4(a)(2) 
                                   
06/20/2023   New   13,187   Common   4.50   No  Sandstone Group Corp.  Services      4(a)(2) 
                                   
06/20/2023   New   3,956   Common   4.50   No  Newbridge Securities Corporation  Services      4(a)(2) 
                                   
7/7/2023   New   400   Common   2.50   Yes  Bitbean LLC  Services      4(a)(2) 
                                   
7/14/2023   New   73,264   Common   2.50   Yes  Hudson Bay Master Fund Ltd.  Exercise of Series B warrants      3(a)(9)
                                   
10/11/2023   New   174,610   Common   2.42   No  Julie A. Blockey  Acquisition Earn-Out payment  Restricted   4(a)(2)
                                   
12/06/2023   New   65,000   Common   1.64   No  New to the Street Group, LLC  Services  Restricted   4(a)(2) 
                                   
12/08/2023   New   82,645   Common   1.21   No  Outside the Box Capital Inc.  Services  Restricted   4(a)(2) 
                                   
12/12/2023   New   4,210,528   Series G Warrants   See footnote(2)   No  Armistice Capital Master Fund, Ltd.  Inducement to exercise Series F Warrants  Restricted   4(a)(2) 
                                   
12/15/2023   New   300,000   Common   See footnote(3)   See footnote(3)  Hudson Bay Master Fund Ltd.  Inducement to exchange Series B Warrants  Restricted   3(a)(9) 

 

(1) Gives effect to a 1:15 reverse stock split effective as of February 23, 2023.
   
(2) Reflects issuance of Series G Warrants pursuant to Series F Inducement Agreement dated December 12, 2023 exercisable at an exercise price of $0.6562 per share.
   
(3) Reflects issuance of Common Stock in exchange for 300,000 Series B Warrants pursuant to Exchange Offer of Warrants to Purchase Common Stock and Amendment dated December 12, 2023.

 

32

 

 

Use of Proceeds from Registered Securities

 

Not applicable

 

Issuer Purchases of Equity Securities

 

Not applicable.

 

Item 6. Selected Financial Data

 

RESERVED

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Overview

 

Reliance Global Group, Inc. (formerly known as Ethos Media Network, Inc.) was incorporated in Florida on August 2, 2013. In September 2018, Reliance Global Holdings, LLC, a related party, purchased a controlling interest in the Company. Ethos Media Network, Inc. was renamed Reliance Global Group, Inc. on October 18, 2018.

 

We operate as a diversified company engaging in business in the insurance market, as well as other related sectors. Our focus is to grow the Company by pursuing an aggressive acquisition strategy, initially and primarily focused upon wholesale and retail insurance agencies. We are led and advised by a management team that offers over 100 years of combined business expertise in real estate, insurance, and the financial service industry.

 

In the insurance sector, our management has extensive experience acquiring and managing insurance portfolios in several states, as well as developing specialized programs targeting niche markets. Our primary strategy is to identify specific risk to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows.

 

As part of our growth and acquisition strategy, we continue to survey the current insurance market for value-add acquisition opportunities. As of December 31, 2023, we have acquired ten insurance agencies, including both affiliated and unaffiliated companies and long term, we seek to conduct all transactions and acquisitions through our direct operations.

 

Over the next 12 months, we plan to focus on the expansion and growth of our business through continued asset acquisitions in insurance markets and organic growth of our current insurance operations through geographic expansion and market share growth.

 

Further, we launched our 5MinuteInsure.com (“5MI”) Insurtech platform during 2021 which expanded our national footprint. 5MI is a high-tech proprietary tool developed by us as a business to consumer portal which enables consumers to instantly compare quotes from multiple carriers and purchase their car and home insurance in a time efficient and effective manner. 5MI taps into the growing number of online shoppers and utilizes advanced artificial intelligence and data mining techniques, to provide competitive insurance quotes in around 5 minutes with minimal data input needed from the consumer. The platform launched during the summer of 2021 and currently operates in 46 states offering coverage with more than 30 highly rated insurance carriers.

 

33

 

 

With the acquisition of Barra, we launched RELI Exchange, our business-to-business (B2B) InsurTech platform and agency partner network that builds on the artificial intelligence and data mining backbone of 5MinuteInsure.com. Through RELI Exchange we on-board agency partners and provide them an InsurTech platform white labeled, designed and branded specifically for their business. This combines the best of digital and human capabilities by providing our agency partners and their customers quotes from multiple carriers within minutes. Since its inception, RELI Exchange, has increased its agent roster by close to 130%.

 

Business Operations

 

We’ve adopted a ‘One-Firm’ strategy, whereby the Reliance owned and operated agencies come together to operate as one cohesive unit which allows for efficient and effective cross-selling, cross-collaboration, and the effective deployment of the Company’s human capital. This strategy also aims to enhance the Company’s overall market presence across the U.S., with all business lines operating under the RELI Exchange brand. It’s expected to benefit agents and clients by improving relationships with carriers, leading to better commission and bonus contracts due to higher business volumes. The approach also strengthens the capability of RELI Exchange agency partners in securing diverse insurance policies and fosters increased cross-selling opportunities. This unified strategy positions the company for rapid scaling and integration of accretive acquisitions, expanding its industry reach.

 

Business Trends and Uncertainties

 

The insurance intermediary business is highly competitive, and we actively compete with numerous firms for customers, properties and insurance companies, many of which have relationships with insurance companies, or have a significant presence in niche insurance markets that may give them an advantage over us. Other competitive concerns may include the quality of our products and services, our pricing and the ability of some of our customers to self-insure and the entrance of technology companies into the insurance intermediary business. A number of insurance companies are engaged in the direct sale of insurance, primarily to individuals, and do not pay commissions to agents and brokers.

 

Financial Instruments

 

The Company’s financial instruments as of December 31, 2023, consist of derivative warrants. These are accounted at fair value as of inception/issuance date, and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, (non-cash) gain or loss.

 

Insurance Operations

 

Our insurance operations focus on the acquisition and management of insurance agencies throughout the U.S. Our primary focus is to pinpoint undervalued wholesale and retail insurance agencies with operations in growing or underserved segments (including healthcare and Medicare, as well as personal and commercial insurance lines). We then focus on expanding their operations on a national platform and improving operational efficiencies in order to achieve asset value appreciation while generating interim cash flows. In the insurance sector, our management team has over 100 years of experiences acquiring and managing insurance portfolios in several states, as well as developing specialized programs targeting niche markets. We plan to accomplish these objectives by acquiring wholesale and retail insurance agencies it deems to represent a good buying opportunity (as opposed to insurance carriers) as insurance agencies bear no insurance risk. Once acquired, we plan to develop them on a national platform to increase revenues and profits through a synergetic structure. The Company is initially focused on segments that are underserved or growing, including healthcare and Medicare, as well as personal and commercial insurance lines.

 

Revenues

 

The Company’s revenue is primarily comprised of commission paid by health insurance carriers related to insurance plans that have been purchased by a member who used the Company’s service. The Company defines a member as an individual currently covered by an insurance plan, including individual and family, Medicare-related, small business, and ancillary plans, for which the Company is entitled to receive compensation from an insurance carrier.

 

Insurance Acquisitions and Strategic Activities

 

As of the date of this filing, we have acquired nine insurance brokerages (see table below). As we continue to execute on our acquisition strategy, our reach within the insurance industry can provide us with the ability to offer lower rates, which could boost our competitive position within the industry.

 

34

 

 

Acquired   Date   Location   Line of Business  
               
U.S. Benefits Alliance, LLC (USBA)   October 24, 2018   Michigan   Health Insurance  
               
Employee Benefit Solutions, LLC (EBS)   October 24, 2018   Michigan   Health Insurance  
               
Commercial Solutions of Insurance Agency, LLC (CCS or Commercial Solutions)   December 1, 2018   New Jersey   P&C – Trucking Industry  
               
Southwestern Montana Insurance Center, Inc. (Southwestern Montana or Montana)   April 1, 2019   Montana   Group Health Insurance  
               
Fortman Insurance Agency, LLC (Fortman or Fortman Insurance)   May 1, 2019   Ohio  

P&C and

Health Insurance

 
               
Altruis Benefits Consultants, Inc. (Altruis)   September 1, 2019   Michigan   Health Insurance  
               
UIS Agency, LLC (UIS)   August 17, 2020   New York   Health Insurance  
               
J.P. Kush and Associates, Inc. (Kush)   May 1, 2021   Michigan   Health Insurance  
               
Barra & Associates, LLC   April 26, 2022   Illinois   Health Insurance  

 

35

 

 

Barra & Associates, LLC Transaction

 

On April 26, 2022, we entered into an asset purchase agreement (the “APA”) with Barra & Associates, LLC (“Barra”) pursuant to which the Company purchased all of the assets of Barra & Associates, LLC on April 26, 2022 for a purchase price in the amount of $7,725,000 in cash, with $6,000,000 paid to Barra at closing, $1,125,000 payable in nine months from closing, and a final earnout of $600,000 payable over two years from closing based upon meeting stated milestones. The APA contains standard, commercial representations and warranties and covenants. The source of the cash payment was $6,520,000 in funds borrowed from Oak Street Lending (“Loan”), our existing lender pursuant to a Fifth Amendment to Credit Agreement and Promissory Note, of even date. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties.

 

The acquisition of Barra was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.

 

The preliminary allocation of the purchase price in connection with the acquisition of Barra was calculated as follows:

 

Description  Fair Value  

Weighted

Average Useful

Life (Years)

 
Acquired accounts receivable  $92,585      
Property, plant and equipment   8,593    7 
Right-of-use asset   122,984      
Trade names   22,000    4 
Customer relationships   550,000    10 
Developed technology   230,000    5 
Agency relationships   2,585,000    10 
Lease liability   (122,984)     
Goodwill   4,236,822    Indefinite 
   $7,725,000      

 

Goodwill of $4,236,822 arising from the acquisition of Barra consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the acquisition of Barra is currently expected to be deductible for income tax purposes. Total acquisition costs incurred through December 31, 2022 for the acquisition of Barra were 72,793 recorded as a component of General and administrative expenses.

 

36

 

 

Recent Developments

 

Private Placements

 

On March 13, 2023, the Company entered into a securities purchase agreement with one institutional buyer for the purchase and sale of, (i) an aggregate of 155,038 shares (the “Common Shares”) of the Company’s common stock, par value $0.086 per share (the “Common Stock”) along with accompanying common warrants (the “Common Units”), (ii) prefunded warrants (the “Prefunded Warrants”) that are exercisable into 897,594 shares of Common Stock (the “Prefunded Warrant Shares”) along with accompanying common warrants (the “Pre-Funded Units”), and (iii) common warrants (the “Common Warrants”) to initially acquire up to 2,105,264 shares of Common Stock (the “Common Warrant Shares”) (representing 200% of the Common Shares and Prefunded Warrant Shares) in a private placement offering (the “Private Placement”). Additionally, the Company agreed to issue a warrant to the Placement Agent (defined below), to initially acquire 52,632 shares of common stock (the “PA Warrant”). The closing of the Private Placement occurred on March 16, 2023.

 

Nasdaq Notification

 

On January 12, 2024, the Company received written notice from Nasdaq’s Listing Qualifications Department notifying the Company that for the preceding 30 consecutive business days (November 29, 2023 to January 11, 2024), the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock continued to trade on Nasdaq under the symbol “RELI.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until July 10, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2).

 

Stock Splits

 

On February 23, 2023, pursuant to authority granted by the Board of Directors of the Company, the Company implemented a 1-for-15 reverse split of the Company’s authorized and issued and outstanding common stock (the “Reverse Split-2023”). The par value remains unchanged. All share and per share information as well as common stock and additional paid-in capital have been retroactively adjusted to reflect the Reverse Split-2023 for all periods presented, unless otherwise indicated.

 

Non-GAAP Measure

 

The Company believes certain financial measures which meet the definition of non-GAAP financial measures, as defined in Regulation G of the SEC rules, provide important supplemental information. Namely our key financial performance metric Adjusted EBITDA (“AEBITDA”) is a non-GAAP financial measure that is not in accordance with, or an alternative to, measures prepared in accordance with GAAP. “AEBITDA” is defined as earnings before interest, taxes, depreciation, and amortization (EBITDA) with additional adjustments as further outlined below, to result in Adjusted EBITDA (“AEBITDA”). The Company considers AEBITDA an important financial metric because it provides a meaningful financial measure of the quality of the Company’s operational, cash impacted and recurring earnings and operating performance across reporting periods. Other companies may calculate Adjusted EBITDA differently than we do, which might limit its usefulness as a comparative measure to other companies in the industry. AEBITDA is used by management in addition to and in conjunction (and not as a substitute) with the results presented in accordance with GAAP. Management uses AEBITDA to evaluate the Company’s operational performance, including earnings across reporting periods and the merits for implementing cost-cutting measures. We have presented AEBITDA solely as supplemental disclosure because we believe it allows for a more complete analysis of results of operations and assists investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Consistent with Regulation G, a description of such information is provided below herein and tabular reconciliations of this supplemental non-GAAP financial information to our most comparable GAAP information are contained in this Annual Report on Form 10-K under “Results of Operations”.

 

We exclude the following items, and the following items define our non-GAAP financial measure AEBITDA:

 

  Interest and related party interest expense: Unrelated to core Company operations and excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
 

Depreciation and amortization: Non-cash charge, excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.

  Goodwill impairment: Non-cash charge, excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
  Equity-based compensation: Non-cash compensation provided to employees and service providers, excluded to provide more meaningful supplemental information regarding the Company’s core cash impacted operational performance.
  Change in estimated acquisition earn-out payables: An Earn-out liability is a liability to the seller upon an acquisition which is contingent on future earnings. These liabilities are valued at each reporting period and the changes are reported as either a gain or loss in the change in estimated acquisition earn-out payables account in the consolidated statements of operations. The gain or loss is non-cash, can be highly volatile and overall is not deemed relevant to ongoing operations, thus, it’s excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
  Recognition and change in fair value of warrant liabilities: This account includes changes to derivative warrant liabilities which are valued at each reporting period and could result in either a gain or loss. The period changes do not impact cash, can be highly volatile, and are unrelated to ongoing operations, and thus are excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
  Other income (expense), net: This account includes non-routine income or expenses and other individually de minimis items and is thus excluded as unrelated to core operations of the company.
  Loss from discontinued operations before tax: This account includes the net results from discontinued operations and since discontinued, are unrelated to the Company’s ongoing operations and thus excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.

 

Refer to the reconciliation of net (loss) income to AEBITDA, illustrated below in tabular format.

 

37

 

 

Results of Operations

 

Comparison of the year ended December 31, 2023 to the year ended December 31, 2022

 

The following table sets forth our revenue and expenses for each of the years presented and provides insight into the value and percentage changes:

 

RELIANCE GLOBAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS ANALYTICS

 

    Year Ended December 31, 2023     Year Ended December 31, 2022     $ Change     %
Change
    Change Description
Commission Income   $ 13,731,826     $ 11,761,882     $ 1,969,944       17 %   Commission income increase of 17% primarily driven by sustained organic growth (67%) coupled with acquisition related expansion (33%).
                                     
Commission Expense     3,732,939       3,140,725       592,214       19 %   Commission expense increase primarily directly correlates to the organic and acquisition related growth in commission income.
Salaries and wages     7,503,052       7,508,312       (5,260 )     0 %   Moderate decrease in salaries & wages indicates the ability for the Company to effectively leverage its in place talent (human capital) despite robust increase in top-line revenue.
General and administrative (“G&A”)     4,089,989       4,959,151       (869,162 )     -18 %   Decreased G&A is driven by the Company’s adoption of OneFirm, our strategy to operate leaner and streamline costs across all agencies, coupled with  lower acquisition related costs.

Marketing and advertising

(“M&A”)

    364,974       170,311       194,663       114 %   M&A increase is a result of spiked branding and marketing outreach as we continue to rigorously grow our market share.
Change in estimated acquisition earn-out payables     1,716,873       524       1,716,349       327,548 %   Estimated acquisition earn-out payables increase due to adjustments of estimated terminal payments and fair value thereof.
Depreciation and amortization     2,609,191       2,563,518       45,673       2 %   Depreciation and amortization increase  primarily relates to acquisition related additional fixed tangible and intangible assets.
Goodwill impairment     7,594,000       -       7,594,000             Goodwill impairment increase reflects the results from our annual impairment test of goodwill.
Total operating expenses     27,611,018       18,342,541                      
                                     
Loss from operations     (13,879,192 )     (6,580,659 )                    
                                     
Other income (expense)                                  
Interest expense     (1,506,186 )     (911,106 )     (595,080 )     65 %   Interest expense increase primarily due to overall increased interest rate environment and new acquisition related debt financing.
Interest related parties     (150,067 )     (6,920 )     (143,147 )     2,069 %   Interest related parties increase primarily due to a seller financing note which began accruing interest in 2023.
Other income (expense), net     6,530       (4,341 )     10,871       -250 %   Other income (expense) increase primarily due to certain non-recurring and non-significant other income sources.
Recognition and change in fair value of warrant liabilities     5,503,647       29,064,958       (23,561,311 )     -81 %   Decrease in gain due to fair value changes in derivative warrant liabilities carried at fair value.
Total other income (expense)     3,853,924       28,142,591                      
                                     
Income (loss) from continuing operations before tax     (10,025,268 )     21,561,932                      
Loss from discontinued operations before tax     (1,984,714 )     (15,095,770 )     13,111,056       -87 %   Decreased loss primarily stems from a discontinued operations goodwill impairment charge that occurred in 2022.
Net (loss) income   $ (12,009,982 )   $ 6,466,162       (18,476,144 )            
                                     
Non-GAAP Measure                                    
AEBITDA   $ (686,973 )   $ (2,766,744 )   $ 2,079,771       -75 %   AEBITDA loss improves by $2.5 million, or 75%, a result of increased revenues and decreased AEBITDA costs,  driven by OneFirm, our strategy to operate leaner and streamline costs across all agencies, coupled with  lower acquisition related costs.

 

38

 

 

Non-GAAP Reconciliation from Net (Loss) Income to AEBITDA

 

The following table provides a reconciliation from net (loss) income to AEBITDA (adjusted EBITDA) for the years ended December 31, 2023 and December 31, 2022.

 

   December 31, 2023   December 31, 2022 
Net (loss) income  $(12,009,982)  $6,466,162 
Adjustments:          
Interest and related party interest expense   1,656,253    918,026 
Depreciation and amortization   2,609,191    2,563,518 
Goodwill impairment   7,594,000    - 
Equity-based compensation employees, directors, and service providers   1,272,155    1,249,873 
Change in estimated acquisition earn-out payables   1,716,873    524 
Other (income) expense, net   (6,530)   4,341 
Recognition and change in fair value of warrant liabilities   (5,503,647)   (29,064,958)
Loss from discontinued operations before tax   1,984,714    15,095,770 
Total adjustments   11,323,009    (9,232,906)
           

AEBITDA

  $(686,973)  $(2,766,744)

  

Liquidity and capital resources

 

As of December 31, 2023, the Company had a cash balance of approximately $2,739,000, of which approximately $1,410,000 was restricted, and working capital of approximately $1,189,000 compared with a cash balance of approximately $1,910,000, of which approximately $1,404,000 was restricted and a working capital deficit of approximately ($4,576,000) as of December 31, 2022. The 2023 increase in working capital is primarily attributable to increases in current assets stemming from the 17% increase in top line revenue, an equity private placement, cash received from warrant exercises and decreases to current liabilities.

 

Inflation

 

The Company generally may be impacted by rising costs for certain inflation-sensitive operating expenses such as labor, employee benefits, and facility leases. The Company believes inflation could have a material impact to pricing and operating expenses in future periods due to the state of the economy and current inflation rates.

 

39

 

 

Off-balance sheet arrangements

 

We do not have any off-balance sheet arrangements as such term is defined in Regulation S-K.

 

Cash Flows

 

   Year Ended December 31, 
   2023   2022 
Net cash used in operating activities  $(847,970)   $(3,189,997)
Net cash provided and used in investing activities   710,189    (24,642,312)
Net cash provided by financing activities   966,923    25,121,356 
Net increase (decrease) in cash, cash equivalents, and restricted cash  $829,142   $(2,710,953)

 

Operating Activities

 

Net cash used in continuing and discontinued operating activities for the year ended December 31, 2023 was approximately $848,000, compared to approximately $3,190,000 for the year ended December 31, 2022 representing a decrease of cash used in operations of $2,342,000, or 73%. The 2023 cash used comprises an approximate net loss of $12,010,000, continuing non-cash positive adjustments of approximately $7,413,000 and non-cash positive adjustments from discontinued operations of approximately $3,749,000. Continuing non-cash adjustments stem from depreciation and amortization of approximately $2,609,000, goodwill impairment of $7,594,000, amortization of debt issuance costs of approximately $47,000, equity-based compensation for employees, directors, and service providers of approximately $1,272,000, and change in estimated acquisition earn-out payables of approximately 1,717,000, offset by non-cash lease expense of approximately $5,000 and the change in fair value of warrant liability of approximately $5,504,000, as well as changes in net working capital items in the net amount of approximately $317,000.

 

Investing Activities

 

Net cash flows provided from continuing and discontinued investing activities for the year ended December 31, 2023, was approximately $710,000 compared to net cash flows used in investing activities of approximately $24,642,000 for the year ended December 31, 2022. The 2023 net cash provided comprises $900,000 in cash proceeds from the sale of the NSURE investment, offset by approximately $190,000 of cash spend for the purchase of property, equipment and intangible assets.

 

Financing Activities.

 

Net cash provided from continuing and discontinued financing activities for the year ended December 31, 2023, was approximately $967,000 as compared to $25,121,000 for the year ended December 31, 2022. The 2023 net cash provided primarily comprises cash proceeds from an equity private placement and warrant exercises of approximately $4,475,000, offset by debt principal repayments of approximately $1,091,000, payments net of proceeds on short term financings of approximately $80,000, payments on related party loans and related party convertible debt of approximately $1,900,000, payments on earn-out liabilities of approximately $419,000 and approximately $18,000 of cash used in discontinued financing activities.

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Estimates and judgments are based on historical experience, forecasted events, and various other assumptions that we believe to be reasonable under the circumstances. Estimates and judgments may vary under different assumptions or conditions. We evaluate our estimates and judgments on an ongoing basis. Our management believes the accounting policies below are critical in the portrayal of our financial condition and results of operations and require management’s most difficult, subjective, or complex judgments.

 

40

 

 

Business acquisitions: Accounting for acquisitions requires us to estimate the fair value of consideration paid and the individual assets and liabilities acquired, which involves a number of judgments, assumptions, and estimates that could materially affect the amount and timing of costs recognized in subsequent periods. Accounting for acquisitions can also involve significant judgment to determine when control of the acquired entity is transferred. We typically obtain independent third-party valuation studies to assist in determining fair values, including assistance in determining future cash flows, discount rates, and comparable market values. Items involving significant assumptions, estimates, and judgments include the following:

 

  Debt, including discount rate and timing of payments;
  Deferred tax assets, including projections of future taxable income and tax rates;
  Fair value of consideration paid or transferred;
  Intangible assets, including valuation methodology, estimations of future revenue and costs, and discount rates;

 

Contingencies: We are subject to the possibility of losses from various contingencies. Significant judgment is necessary to estimate the probability and amount of a loss, if any, from such contingencies. An accrual is made when it is probable that a liability has been incurred or an asset has been impaired, and the amount of loss can be reasonably estimated. In accounting for the resolution of contingencies, significant judgment may be necessary to estimate amounts pertaining to periods prior to the resolution that are charged to operations in the period of resolution and amounts related to future periods.

 

Goodwill and intangible assets: We test goodwill for impairment in our fourth quarter each year, or more frequently if indicators of an impairment exist, to determine whether it is more likely than not that the fair value of the reporting unit with goodwill is less than its carrying value. For reporting units for which this assessment concludes that it is more likely than not that the fair value is more than its carrying value, goodwill is considered not impaired and we are not required to perform the goodwill impairment test. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance, and other relevant events and factors affecting the fair value of the reporting unit. For reporting units for which this assessment concludes that it is more likely than not that the fair value is below the carrying value, goodwill is tested for impairment by determining the fair value of each reporting unit and comparing it to the carrying value of the net assets assigned to the reporting unit. If the fair value of the reporting unit exceeds its carrying value, goodwill is considered not impaired. If the carrying value of the reporting unit exceeds its fair value, we would record an impairment loss up to the difference between the carrying value and implied fair value.

 

Determining when to test for impairment, the reporting units, the assets and liabilities of the reporting unit, and the fair value of the reporting unit requires significant judgment and involves the use of significant estimates and assumptions. These estimates and assumptions include revenue growth rates, and expenses and are developed as part of our long-range planning process. The same estimates are used in business planning, forecasting, and capital budgeting. We test the reasonableness of the output of our long-range planning process by calculating an implied value per share and comparing that to current stock prices, analysts’ consensus pricing, and management’s expectations. These estimates and assumptions are used to calculate projected future cash flows for the reporting unit, which are discounted using a risk-adjusted rate to estimate a fair value. The discount rate requires determination of appropriate market comparables. We base fair value estimates on assumptions we believe to be reasonable but that are unpredictable and inherently uncertain. Actual future results may differ from those estimates.

 

We test other identified intangible assets with definite useful lives when events and circumstances indicate the carrying value may not be recoverable by comparing the carrying amount to the sum of undiscounted cash flows expected to be generated by the asset. We test intangible assets with indefinite lives annually for impairment using a fair value method such as discounted cash flows. Estimating fair values involves significant assumptions, including future sales prices, sales volumes, costs, and discount rates.

 

41

 

 

Income taxes: We are required to estimate our provision for income taxes and amounts ultimately payable or recoverable in numerous tax jurisdictions around the world. These estimates involve significant judgment and interpretations of regulations and are inherently complex. Resolution of income tax treatments in individual jurisdictions may not be known for many years after completion of the applicable year. We are also required to evaluate the realizability of our deferred tax assets on an ongoing basis in accordance with U.S. GAAP, which requires the assessment of our performance and other relevant factors. Realization of deferred tax assets is dependent on our ability to generate future taxable income. In recent periods, our results of operations have benefited from increases in the amount of deferred taxes we expect to realize, primarily from the levels of capital spending and increases in the amount of taxable income we expect to realize. Our income tax provision or benefit is dependent, in part, on our ability to forecast future taxable income in these and other jurisdictions. Such forecasts are inherently difficult and involve significant judgments including, among others, projecting future average selling prices and sales volumes, manufacturing and overhead costs, levels of capital spending, and other factors that significantly impact our analyses of the amount of net deferred tax assets that are more likely than not to be realized.

 

Revenue recognition: All commission revenue is recorded net of any deductions for estimated commission adjustments due to lapses, policy cancellations, and revisions in coverage.

 

The Company earns additional revenue including contingent commissions, profit-sharing, override and bonuses based on meeting certain revenue or profit targets established periodically by the carriers (collectively the Contingent Commissions). The Contingent Commissions are earned when the Company achieves the targets established by the insurance carries. The insurance carriers notify the company when it has achieved the target. The Company only recognizes revenue to the extent that it is probable that a significant reversal of the revenue will not occur.

 

Equity-based compensation: Equity-based compensation is estimated at the grant date based on the fair value of the award and is recognized as expense using the straight-line amortization method over the requisite service period. For performance-based stock awards, the expense recognized is dependent on our assessment of the likelihood of the performance measure being achieved. We utilize forecasts of future performance to assess these probabilities and this assessment requires significant judgment.

 

Determining the appropriate fair-value model and calculating the fair value of stock-based awards at the grant date requires significant judgment, including estimating stock price volatility and expected option life. We develop these estimates based on historical data and market information which can change significantly over time. A small change in the estimates used can result in a relatively large change in the estimated valuation. We use the Black-Scholes option valuation model to value employee stock options and awards granted under our employee stock purchase plan. We estimate stock price volatility based on our historical volatility implied volatility derived from traded options on our stock.

 

Item 7A. Quantitative and Qualitative Disclosure about Market Risk

 

Not applicable.

 

Item 8. Financial Statements and Supplementary Data

 

See the financial statements filed as part of this Annual Report on Form 10-K as listed under Item 15 below.

 

42

 

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

Not Applicable.

 

Item 9A. Controls and Procedures

 

Controls and Procedure Requirements

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this annual report, is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined under Exchange Act Rules 13a-15(f) and 14d-14(f). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 

All internal control systems, no matter how well designed, have inherent limitations and may not prevent or detect misstatements. Therefore, even those systems determined to be effective can only provide reasonable assurance with respect to financial reporting reliability and financial statement preparation and presentation. In addition, projections of any evaluation of effectiveness to future periods are subject to risk that controls become inadequate because of changes in conditions and that the degree of compliance with the policies or procedures may deteriorate.

 

The Company determined it has a material weakness in its disclosure controls and procedures relating to goodwill and earnings per share (“EPS”). The Company continues the process of mitigating the deficiencies by ensuring it is appropriately consulting with experts in the respective areas. During fiscal year 2023, Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023, and concluded that they were not effective as of December 31, 2023, due to the material weakness identified.

 

Changes in Internal Control over Financial Reporting

 

During fiscal year 2022, the Company retained subject matter expert advisors to prepare the accounting and disclosures over Earnings per Share. These advisors assisted the Company in the calculations and disclosures of EPS for the year ended December 31, 2023. Aside for the foregoing, there have been no other changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter which is the subject of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

43

 

 

Item 9B. Other Information

 

None.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

Not applicable.

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

Listed below are the names of the directors and executive officers of the Company, their ages as of the date of this Form 10-K, their positions held, and all commenced service with the Company in 2023.

 

Name   Age   Position(s) Held
Ezra Beyman   69   Chief Executive Officer (CEO) and Chairman of the Board of Directors
Joel Markovits   43   Chief Financial Officer (CFO), Chief Accounting Officer (CAO), Financial Reporting Manager (FRM)
Yaakov Beyman   41   Executive Vice President, Insurance Division
Scott Korman   69   Director and Chair of the Audit Committee (Audit Committee Financial Expert), and Member of the Compensation and Nominating and Governance Committees
Ben Fruchtzweig   59   Director and Chair of the Compensation Committee and Member of the Audit and Nominating and Governance Committees
Sheldon Brickman   58   Director and Chair of the Nominating and Governance Committee and Member of the Audit and Compensation Committees
Alex Blumenfrucht   35   Director and former Chief Financial Officer

 

Ezra Beyman:

Director of Reliance Global Group, Inc.

2018 – Present: Chief Executive Officer of Reliance Global Group, Inc.

1985- Present: Chairman of Reliance Global Holdings, LLC and Affiliates

 

Ezra Beyman has served as the Chairman of our Board of Directors and our Chief Executive Officer since 2018. Mr. Beyman is the central force leading the success and growth of Reliance Global Group, Inc. Drawing on his nearly three decades of entrepreneurial experience in real estate and ten years in insurance, he has set his vision and acuity on one integrated goal: integrity and success. At one point in time Mr. Beyman’s portfolio of commercial and residential properties comprised of approximately 40,000 units, as well as several insurance agencies. In 1985, he founded a small mortgage brokerage, together with his wife, which he operated in his basement. From there, his company rapidly grew into a dynamic force on the market. By 2008, he owned the third largest licensed mortgage brokerage in the U.S., having acquired numerous mortgage companies in the interim. He also expanded to real estate acquisition, having grown his portfolio to over three billion dollars. In expanding his investments, Mr. Beyman began exploring opportunities in other markets, acquiring several insurance agencies in both Florida and New Jersey. His ventures included entering the domains of warrantee and insurance carriers. Raised in the New York metropolitan area, Mr. Beyman spent his secondary and post-secondary school years at Mesivta Tifereth Yerushalayim, where he advanced his analytic abilities while mastering various areas of Talmudic studies, earning a position as one of the closest students of the Dean. He earned his First Talmudic degree in 1975.

 

44

 

 

Joel Markovits:

2021 – Present: Chief Financial Officer of Reliance Global Group, Inc.

2015 – 2021: KPMG Audit Senior Manager

 

Joel Markovits, Chief Financial Officer, joined the Company in June 2021 as our SEC financial reporting manager, and in February 2022 was appointed Chief Accounting Officer (CAO) and subsequently appointed CFO as of January 1, 2023. Joel brings over 12 years’ financial, accounting and reporting experience in both the public and private sectors. Prior to joining Reliance Global Group, Joel was a senior manager at KPMG LLP from April 2015 through May 2021, where he led some of the larger and more complex audit engagements, including serving as lead audit senior manager on a global $16 billion (annual revenues) enterprise reporting on both US GAAP and IFRS. He was also a data & analytics specialist and technology innovation leader at KPMG for its largest US Business Unit, overseeing the development and deployment of technological capabilities that enhance data analyses. Joel is a Certified Public Accountant in the State of New Jersey since November 2013.

 

Yaakov Beyman:

2018 – Present: Executive VP of Insurance Division, Reliance Global Group, Inc.

2012 – 2018: Executive VP of Insurance Division, Empire Insurance Holdings

 

Yaakov Beyman, son of Mr. Ezra Beyman has served as the Executive Vice President of the Insurance Divisions since July 2018. Mr. Beyman oversees the insurance operations of Reliance Global Group, Inc. From December 2012 – July 2018, he was Executive VP of Insurance Division, of Empire Insurance Holdings. He works from a platform that includes both strategizing the future vision of the insurance division and developing and implementing operational tools on a more granular level to grow the various insurance businesses. In his role as a strategist, Mr. Beyman has mapped a clear future: expand the various insurance products that RELI offers both geographically and in category. On the more hands-on level, Mr. Beyman (who holds insurance licenses in most of the continental U.S.) is heavily involved in marketing, maintaining state of the art technological models, financial management and distribution, and entity creation and maintenance. Combining his roles as the idea-generator and implementer, he is well-equipped to take the lead role in growing the Company.”

 

Scott Korman:

Director – Joined Board in 2019

1984 – Present: President of Nashone, Inc

2019 – Present: CEO, Illumina Radiopharmaceuticals LLC

 

Mr. Korman has served on our board of directors since December 2019 and he currently serves as President of Nashone, Inc., a private equity firm, which he founded in 1984. In this role, Mr. Korman is involved in financial advisory, M&A, and general management assignments. He is a founder and Managing Member and CEO of Innervate Radiopharmaceuticals LLC since May 2019, CEO of Sentry Laboratories LLC since February 2020 and CFO and board member of Adenocyte LLC since 2018. Mr. Korman previously served as Chairman and CEO of Best Manufacturing Group LLC, a leading manufacturer and distributor of uniforms, napery, service apparel, and hospitality and healthcare textiles. Mr. Korman also served as President and CEO of Welsh Farms Inc., a full-service dairy processor and distributor of milk, ice cream mix and ice cream products. Mr. Korman received a B.S. degree in Economics from the University of Pennsylvania Wharton School. He has served as a member of the Board of Directors of Tofutti Brands, Inc. since December 2011. He also serves on the boards of various not-for-profit groups. The Board determined that Mr. Korman’s business experience makes him an ideal director for the Company.

 

Ben Fruchtzweig:

Joined Board in 2019

2013 – Current: Mosdos Beis Abba

 

Mr. Fruchtzweig has served on our board of directors since December 2019 and brings decades of executive experience in accounting and financial services. He currently serves on the board of Mosdos Beis Abba since June 2013. He has served as Chief Comptroller/Financial Analyst at national financial services and investment companies. He received his NYS C.P.A. license in 1987 and has worked at Deloitte Haskins and Sells and other leading accounting firms. Currently, Mr. Fruchtzweig lectures on a variety of topics including business ethics. He also serves on a voluntary basis as a trustee of a non-profit private foundation, which serves to provide the needed financial support, services and guidance to qualifying individuals and families. Mr. Fruchtzweig graduated Magna Cum Laude from Queens College/C.U.N.Y. in June 1985. The Board believes that Mr. Fruchtzweig’s strong accounting and finance background makes him a strong director.

 

45

 

 

Sheldon Brickman:

Joined Board in 2020

2013 – Present: President of Rockshore Advisors LLC

 

Mr. Brickman has served on our board of directors since August 2020 and has been President of Rockshore Advisors LLC since May, 2013. Sheldon has over 25 years of M&A advisory and business development experience, totaling more than $40 billion in deal value. Additionally, he has served as Chief Financial Officer of InfinT Acquisition Corporation since May 2021. Sheldon has worked for numerous multibillion-dollar insurance carriers, including assignments for such companies as AIG, Aetna and National General. He has assisted international companies (in the UAE, UK, Asia and Latin America), start-up operations, and regional insurance carriers. Mr. Brickman’s experience covers the property casualty and life/health markets, including working with insurance carriers, managing general agencies, wholesalers, retailers and third-party administrators. The Board determined that Mr. Brickman’s M&A and insurance industry experience makes him an ideal director for the Company.

 

Alex Blumenfrucht:

Director of Reliance Global Group, Inc.

2018 – 2022: Former CFO of Reliance Global Group, Inc.

2015 – 2018: Audit senior at Deloitte and Touché.

 

Alex Blumenfrucht has served as member of our board of directors since 2018 and formerly also served as our Chief Financial Officer (CFO) from 2018 until June 2022, at which time he resigned and accepted employment with an unaffiliated company. Prior to joining Reliance, Mr. Blumenfrucht served as an Audit & Assurance Professional at Deloitte & Touché, LLP from September 2015 until May 2018, where he successfully led audit teams on both public and privately held corporations. The Board determined that Mr. Blumenfrucht’s extensive experience in internal control, financial analysis, and reporting for both private and publicly traded companies is central to the Company’s management of finances, reporting, and controls and makes him an ideal director.

 

William Lebovics:

2022 Former CFO of Reliance Global Group, Inc.

2019 – 2021: Director of Business Development at IDT Corporation

 

William Lebovics was appointed by the Company to serve as Chief Financial Officer (CFO) effective June 1, 2022 and as of January 1, 2023 transitioned from CFO into the role of Senior Vice President of Acquisitions. Prior to joining the Company, William served as Head of Business Development at IDT Corporation (NYSE: IDT), from November 2021- May 2022, where he worked closely with Chairman Howard Jonas on two new lines of business for the company. From January 2019- November 2021, William served as Finance Manager of IDW Media Holdings (NYSE: IDW) where he was responsible for dealing with financial reporting, financing, and M&A, as well as other finance related operations. From 2016-2018, Mr. Lebovics was Partner and Product Owner of a mobile tech company overseen by T5 Capital. William has extensive corporate finance experience, including prior roles as a Portfolio Manager of Alternative Investments at Nippon Life Global Investors and as a Real Estate Consultant in PwC’s Real Assets Group. William has an MS in Accounting from Fairleigh Dickenson University, an MS in Real Estate with a concentration in Finance and Investment from NYU, and a BS in Business Management from Touro College.

 

Family Relationships

 

There are no arrangements between our directors and any other person pursuant to which our directors were nominated or elected for their positions. Except for Ezra Beyman and Yaakov Beyman (father and son), there are no family relationships between any of our directors or executive officers.

 

Committees of the Board of Directors

 

Our Board has established three standing committees: an Audit Committee, a Nominating and Governance Committee and a Compensation Committee, which are described below. Members of these committees are elected annually at a regular meeting of the Board of Directors held in conjunction with the annual stockholders’ meeting. The charter of each committee is available on our website at www.relianceglobalgroup.com, and our committee appointments are set forth above.

 

Audit Committee

 

The Audit Committee has authority to review our financial records, deal with our independent auditors, recommend to the Board policies with respect to financial reporting, and investigate all aspects of our business. All of the members of the Audit Committee currently satisfy the independence requirements and other established criteria of NASDAQ.

 

The Audit Committee has sole authority for the appointment, compensation and oversight of the work of our independent registered public accounting firm, and responsibility for reviewing and discussing with management and our independent registered public accounting firm our audited consolidated financial statements included in our Annual Report on Form 10-K, our interim financial statements and our earnings press releases. The Audit Committee also reviews the independence and quality control procedures of our independent registered public accounting firm, reviews management’s assessment of the effectiveness of internal controls, discusses with management the Company’s policies with respect to risk assessment and risk management and will review the adequacy of the Audit Committee charter on an annual basis.

 

Scott Korman, Ben Fruchtzweig and Sheldon Brickman who are all independent directors and sit on this Committee, with Scott Korman being the Chair and Audit Committee Financial Expert.

 

Nominating and Governance Committee

 

The Nominating and Corporate Governance Committee has the following responsibilities: (a) setting qualification standards for director nominees; (b) identifying, considering and nominating candidates for membership on the Board; (c) developing, recommending and evaluating corporate governance standards and a code of business conduct and ethics applicable to the Company; (d) implementing and overseeing a process for evaluating the Board, Board committees (including the Committee) and overseeing the Board’s evaluation of the Chairman and Chief Executive Officer of the Company; (e) making recommendations regarding the structure and composition of the Board and Board committees; (f) advising the Board on corporate governance matters and any related matters required by the federal securities laws; and (g) assisting the Board in identifying individuals qualified to become Board members; recommending to the Board the director nominees for the next annual meeting of shareholders; and recommending to the Board director nominees to fill vacancies on the Board.

 

46

 

 

The Nominating and Governance Committee determines the qualifications, qualities, skills, and other expertise required to be a director and to develop, and recommend to the Board for its approval, criteria to be considered in selecting nominees for director (the “Director Criteria”); identifies and screens individuals qualified to become members of the Board, consistent with the Director Criteria. The Nominating and Governance Committee considers any director candidates recommended by the Company’s shareholders pursuant to the procedures described in the Company’s proxy statement, and any nominations of director candidates validly made by shareholders in accordance with applicable laws, rules and regulations and the provisions of the Company’s charter documents. The Nominating and Governance Committee makes recommendations to the Board regarding the selection and approval of the nominees for director to be submitted to a shareholder vote at the Annual Meeting of shareholders, subject to approval by the Board. The Nominating and Governance Committee does not have a set policy or process for considering diversity in identifying nominees but strives to identity and recruit nominees with a broad diversity of experience, talents, professions, backgrounds, perspective, age, gender, ethnicity and country of citizenship, and who possess the commitment necessary to make a significant contribution to the Company. Board nominees should be committed to enhancing long-term stockholder value and should possess high standards of integrity and ethical behavior.

 

Scott Korman, Ben Fruchtzweig and Sheldon Brickman sit on this Committee with Sheldon Brickman being the Chair.

 

Compensation Committee

 

The Compensation Committee oversees our executive compensation and recommends various incentives for key employees to encourage, and reward increased corporate financial performance, productivity and innovation.

 

The Compensation Committee is responsible for: (a) assisting our Board in fulfilling its fiduciary duties with respect to the oversight of the Company’s compensation plans, policies and programs, including assessing our overall compensation structure, reviewing all executive compensation programs, incentive compensation plans and equity-based plans, and determining executive compensation; and (b) reviewing the adequacy of the Compensation Committee charter on an annual basis. The Compensation Committee, among other things, reviews and approves the Company’s goals and objectives relevant to the compensation of the Chief Executive Officer, evaluate the Chief Executive Officer’s performance with respect to such goals, and set the Chief Executive Officer’s compensation level based on such evaluation. The Compensation Committee also considers the Chief Executive Officer’s recommendations with respect to other executive officers and evaluates the Company’s performance both in terms of current achievements and significant initiatives with long-term implications. It assesses the contributions of individual executives and recommend to the Board levels of salary and incentive compensation payable to executive officers of the Company; compares compensation levels with those of other leading companies in similar or related industries; reviews financial, human resources and succession planning within the Company; recommend to the Board the establishment and administration of incentive compensation plans and programs and employee benefit plans and programs; recommends to the Board the payment of additional year-end contributions by the Company under certain of its retirement plans; grants stock incentives to key employees of the Company and administer the Company’s stock incentive plans; and reviews and recommends for Board approval compensation packages for new corporate officers and termination packages for corporate officers as requested by management.

 

Scott Korman, Ben Fruchtzweig and Sheldon Brickman sit on this Committee with Ben Fruchtzweig being the Chair.

 

Changes in Nominating Procedures

 

None.

 

Board Leadership Structure and Role in Risk Oversight

 

Although we have not adopted a formal policy on whether the Chairman and Chief Executive Officer positions should be separate or combined, we have traditionally determined that it is in the best interests of the Company and its shareholders to partially combine these roles. Due to the small size of the Company, we believe it is currently most effective to have the Chairman and Chief Executive Officer positions partially combined.

 

47

 

 

Our Board is primarily responsible for overseeing our risk management processes. The Board receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding the Company’s assessment of risks. The Board focuses on the most significant risks facing the Company and our general risk management strategy, and also ensures that risks undertaken by us are consistent with the Board’s risk parameters. While the Board oversees the Company, our management is responsible for day-to-day risk management processes. We believe this division of responsibilities is the most effective approach for addressing the risks facing the Company and that our board leadership structure supports this approach.

 

Compliance with Section 16(a) of the Exchange Act

 

Section 16(a) of Exchange Act requires our executive officers and directors and persons who beneficially own more than 10% of a registered class of our equity securities to file with the Commission initial statements of beneficial ownership, statements of changes in beneficial ownership and annual statement of changes in beneficial ownership with respect to their ownership of the Company’s securities, on Form 3, 4 and 5 respectively. Executive officers, directors and greater than 10% shareholders are required by the Securities and Exchange Commission regulations to furnish our Company with copies of all Section 16(a) reports they file.

 

The Company does not report on compliance with Section 16(a).

 

Item 11. Executive Compensation

 

Pursuant to disclosure requirements in Item 402 of Regulation S-K and paragraphs (e)(4) and (e)(5) of Item 407, the following table summarizes executive compensation for the years ended December 31, 2023 and 2022.

 

Summary Compensation Table

 

Name and principal position  Year   Salary
($)
   Bonus (2)
($)
   Stock
awards
($)
   Option
awards
(Unvested)
($)
   Non-equity
incentive plan
compensation
($)
   Change in
pension
value and
nonqualified
deferred
compensation
earnings
   All other
compensation
($)
   Total
($)
 
Ezra Beyman,   2023    338,942    -    105,840         -        -        -    -    444,782 
CEO   2022    300,000    305,963    -    -    -    -    -    605,963 
                                              
Joel Markovits,   2023    286,019    34,581    88,031    -    -    -    2,034(1)   410,665 
CFO   2022    197,499    -    130,625    -    -    -    -    328,124 
                                              
Yaakov Beyman, EVP   2023    237,135    2,000    68,670    -    -    -    9,565(2)   317,370 
Insurance   2022    219,539    30,000    -    -    -    -    -    249,539 

 

  (1) Represents other fringe benefits.
  (2) Represents employer 401(k) plan contributions.

 

48

 

 

Director Compensation

 

The table below shows the compensation paid to our non-employee directors during 2023 and 2022.

 

Name     

Fees

earned

or paid

in cash

  Stock awards ($)  

Un-

exercisable Option awards

(# of Shares)

   Non-equity incentive plan compensation ($)   Nonqualified deferred compensation earnings ($)   All other compensation ($)  

Total

($)

 
Ben Fruchtzweig    2023   $ 44,332     22,680     -          -           -    

     -

     67,012
Director                                              
Scott Korman   2023   $  45,000    22,680    -    -    -    -     67,680 
Director                                          
Sheldon Brickman   2023   $ 43,668      22,680    -    -    -    -     66,348 
Director                                          
Alex Blumenfrucht   2023    $ 43,000    22,680                         65,680 
Director                                          

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following table sets forth certain information concerning the ownership of our common stock as of December 31, 2023 with respect to:

 

  (i) each person known to us to be the beneficial owner of more than five percent of our common stock;
  (ii) all directors;
  (iii) all named executive officers; and
  (iv) all directors and executive officers as a group.

 

Beneficial ownership is determined in accordance with the rules of the SEC that deem shares to be beneficially owned by any person who has voting or investment power with respect to such shares. Shares of common stock issuable upon exercise of options or warrants as of December 31, 2023 or are exercisable within 60 days of such date are deemed to be outstanding and to be beneficially owned by the person holding such options for the purpose of calculating the percentage ownership of such person but are not treated as outstanding for the purpose of calculating the percentage ownership of any other person. Applicable percentage ownership is based on 4,761,974 shares of common stock outstanding as the date of December 31, 2023.

 

Name and Address of Beneficial Owner 

Number of

Shares

Common

  

Beneficial

Ownership

Percentage

 
Named Executive Officers and Directors          
Ezra Beyman   381,020(1)   8.0%
Joel Markovits   71,532(2)   1.5%
Yaakov Beyman   58,783    1.2%
Sheldon Brickman   36,000    * 
Scott Korman   38,177    * 
Ben Fruchtzweig   36,477    * 
Alex Blumenfrucht   44,233    * 
All directors and executive officers as a group (7 persons)   666,212(3)   14.0%
           
5% Stockholders          
Armistice Capital, LLC (4)   511,736(5)   10.07%
YES Americana Group, LLC (6)   263,021    5.5%

 

* Represents beneficial ownership of less than 1%.

 

  (1) Represents (i) 117,886 shares of common stock held by Ezra Beyman directly, (ii) 113 shares of common stock held by Reliance Global Holdings, LLC; and (iii) 263,021 shares of common stock held by YES Americana Group, LLC. Reliance Global Holdings, LLC is an entity controlled by Ezra Beyman and his spouse. YES Americana Group, LLC is an entity controlled by Ezra Beyman’s spouse.
     
  (2) Represents (i) 66,865 shares of common stock held by Mr. Markovits, and (ii) 2,667 shares of common stock that Mr. Markovits has or had the right to acquire within 60 days of the Record Date; provided, however, that certain of the shares referenced in clause (ii) have been or will be withheld for payment of payroll taxes.
     
  (3) Includes 2,667 shares of common stock the directors and named executive officers have or had the right to acquire within 60 days of the Record Date; provided, however, that certain of these shares have been or will be withheld for payment of payroll taxes.
     
  (4) Armistice Capital, LLC’s address is 510 Madison Avenue, 7th Floor, New York, NY 10022.
     
  (5) Represents (i) 149,736 shares of common stock held by Armistice Capital, LLC, and (ii) 362,000 shares that Armistice Capital, LLC has the right to acquire within 60 days of the Record Date pursuant to abeyance shares and/or exercisable warrants. Armistice Capital has the rights to 1,734,264 abeyance shares and holds warrants to purchase an aggregate of 5,077,195 shares of common stock; however, only 362,000 of these abeyance shares and/or warrants can be initially released and/or exercised within 60 days due to equity blockers and/or other limiting provisions in the abeyance shares and/or warrants.
     
  (6) YES Americana Group, LLC is an entity controlled by Ezra Beyman’s spouse and its address is 300 Blvd. of the Americas, Suite 105, Lakewood, NJ 08701.

 

The transfer agent and registrar for our common stock is VStock Transfer. The transfer agent and registrar’s address is 18 Lafayette Place, Woodmere, New York 11598. Its telephone number is (212) 828-8436.

 

49

 

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

The following is a description of transactions which we were a party in which (i) the amount involved exceeded or will exceed the lesser of (A) $120,000 or (B) one percent of our average total assets at year-end for the last two completed fiscal years and (ii) any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, any of the foregoing persons, who had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other similar arrangements, which are described under “Executive Compensation.”

 

The Company entered into a Loan Agreement with Reliance Global Holdings, LLC, a related party under common control. There is no term to the loan, and it bears no interest. The proceeds from the various loans were utilized to fund the acquisitions of USBA, EBS, CCS, SWMT Acquisition, Fortman, Altruis, and UIS. As of December 31, 2023, and the 2022 the related party loan payable was $0 and $100,724 respectively. At December 31, 2023 and 2022, Reliance Holdings owned approximately 0% and 24%, respectively, of the common stock of the Company.

 

On September 13, 2022, the Company issued a promissory note of convertible debt to YES Americana Group, LLC, (“YES Americana”) a related party entity for the principal sum of $1,500,000 (the “Note”). The Note matures on January 15, 2024, bearing interest of 0% per annum for the first six months, and 5% per annum thereafter, payable monthly. In the event the Note is not paid by the maturity date, the loan will automatically be extended for an additional year until January 15, 2025, and if necessary, extended again for one additional year through January 15, 2026. As of December 31, 2023, and 2022 the balance to YES Americana was $0 and $1,500,000 respectively. At December 31, 2023 and 2022, Yes Americana owned approximately 5.5% and 0%, respectively, of the common stock of the Company.

 

Pursuant to the first amendment to the April 26, 2022 asset purchase agreement between the Company and Barra & Associates, LLC, a related party entity beneficially owned by a senior vice president of the Company, the Company agreed to pay a deferred purchase price (the “DPP”) of $1,375,000 by January 31, 2023, and all amounts unpaid thereafter will accrue interest at a rate of 1.5% per month until paid. The Company intends to fully repay all unpaid amounts inclusive of interest over the next two years. The Company classifies amounts planned to be settled within twelve months from the balance sheet date to current liabilities. Accordingly, the Company reclassifies and presents current balances of $233,504 and $1,375,000 respectively, in the current portion of loans payables, related parties account in the condensed consolidated balance sheets as of December 31, 2023 and December 31, 2022. Non-current amounts are classified to the loans payable, related parties, less current portion account in the condensed consolidated balance sheets and amounted to $247,055 and $0 as of December 31, 2023, and December 31, 2022 respectively. Interest expense for the year ended December 31, 2023 was $145,344, recorded to interest expense, related parties in the condensed consolidated statements of operations.

 

The Company, Fortman Insurance Services, LLC, Fortman Insurance Agency, LLC, Jonathan Fortman, and Zachary Fortman (collectively, the “Parties”) entered into a purchase agreement on or around May 1, 2019 (the “Purchase Agreement”), whereby the Company purchased the business and certain assets noted within the Purchase Agreement, as well as that certain second amendment to the Purchase Agreement on or around May 18, 2023 (the “Second Amendment”). On January 11, 2024, the Parties entered into that certain third amendment to the Purchase Agreement (the “Third Amendment”), pursuant to which the Parties agreed to a total remaining earn-out balance of $423,107 owed to both Jonathan Fortman and Zachary Fortman each under the Purchase Agreement, both employees and related parties to the Company, for a combined total earn-out amount owed of $846,214 (the “Remaining Balances”). In satisfaction of such Remaining Balances, the Company agreed to pay $11,000.00 on the first business day of each month to both Jonathan Fortman and Zachary Fortman each until the Remaining Balances are paid in full. In addition, the Parties agreed under the Third Amendment that the Remaining Balances shall accrue interest at the rate of 10% per annum until the Remaining Balances are paid in full, with an effective date of January 2, 2024, for purposes of the commencement of interest accrual. Since the Remaining Balances are final and no longer subject to contingencies, as of December 31, 2023 and the period then ended, they have been reclassified from the earn-out liability account to the loan payable, related parties, less current portion account in the amount of, $650,473 and the current portion of loans payables, related parties in the amount of, $195,741 and for the same period ended no interest has accrued.

 

To the best of our knowledge, during the past two fiscal years, other than as set forth above, there were no material transactions, or series of similar transactions, or any currently proposed transactions, or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds the lesser of (A) $120,000 or (B) one percent of our average total assets at year-end for the last two completed fiscal years, and in which any director or executive officer, or any security holder who is known by us to own of record or beneficially more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, has an interest (other than compensation to our officers and directors in the ordinary course of business).

 

Messrs. Fruchtzweig, Korman and Brickman are “independent” directors based on the definition of independence in the listing standards of the NASDAQ Stock Market LLC (“NASDAQ”).

 

Policies and Procedures for Related Party Transactions

 

All future transactions between us and our officers, directors or five percent stockholders, and respective affiliates will be on terms no less favorable than could be obtained from unaffiliated third parties and will be approved by a majority of our independent directors who do not have an interest in the transactions and who had access, at our expense, to our legal counsel or independent legal counsel.

 

Item 14. Principal Accounting Fees and Services

 

Mazars USA LLP (“Mazars”) has served as our independent auditors since March 9, 2020. The appointment of Mazars as our independent public accountants was unanimously approved by the Audit Committee and our Board of Directors.

 

The following table sets forth the aggregate fees paid by the Company for the fiscal years ended December 31, 2023 and 2022 to our independent auditors:

 

Auditors  Years   Audit Fees    Tax Fees   All Other Fees 
Mazars USA LLP   2023   $368,440    $31,200   $- 
Mazars USA LLP   2022   $319,750    $11,000   $7,500 

 

50

 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

a) The following documents are filed as part of this Annual Report on Form 10-K

 

  (1) Financial Statements
     
    See Index to Financial Statements on page F-1 of this Annual Report on Form 10-K
  (2) Financial Statement Schedules
     
    Schedules not listed above have been omitted because they are not required, not applicable, or the required information is otherwise included elsewhere in Annual Report on Form 10-K.
     
  (3) Exhibits

 

Item 16. Form 10-K Summary

 

Not applicable.

 

51

 

 

Report of Independent Registered Public Accounting Firm PCAOB ID 339

 

To the Stockholders and the Board of Directors of

Reliance Global Group, Inc. and Subsidiaries

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Reliance Global Group, Inc. and Subsidiaries (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

 F-1 

 

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which they relate.

 

Impairment Evaluation of Goodwill

 

Critical Audit Matter Description

 

As described in Notes 6 to the consolidated financial statements, the Company’s consolidated goodwill balance was approximately $6.7 million as of December 31, 2023. Management tests goodwill for impairment at least annually, or more frequently should an event or a change in circumstances occur that would indicate the carrying value may be impaired. If the carrying amount of a reporting unit exceeds its fair value, an impairment is recorded equal to the amount by which the carrying value exceeds the fair value, up to the amount of goodwill associated with the reporting unit. As a result of management’s assessment, the Company recognized impairment charges of $7.6 million related to goodwill during the year ended December 31, 2023.

 

The principal considerations for our determination that the goodwill impairment assessment was a critical audit matter are that there is significant judgment in selection of the valuation methods to use, along with assumptions used to estimate the future revenues and cash flows, including revenue growth rates, operating expenses and cash outflows necessary to support the cash flows, weighted average cost of capital and future market conditions as well as the valuation methodologies applied by the Company. This in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating audit evidence related to managements inputs and selection of methods used. In addition, the audit effort involved the use of auditor employed professionals with specialized skill and knowledge to assist in performing these procedures and evaluating the audit evidence obtained.

 

How the Critical Matter Was Addressed in the Audit

 

The primary audit procedures we performed to address this critical audit matter included:

 

  - Obtaining an understanding over the Company’s process for evaluation whether an event of a change in circumstances occur that would indicate the carrying value of goodwill may be impaired.
     
  - Utilizing a firm employed valuation specialist with the skills and knowledge to assist in: (i) evaluating and challenging the reasonableness of the valuation methods selected by management to determine the fair value of the Company, (ii) evaluating management’s significant assumptions by comparing inputs to market data (iii) performing a control premium sensitivity study to determine the impact to the market participant acquisition approach, and (iv) performing recalculations of the method utilized by management.
     
  - Testing the completeness and accuracy of the underlying data utilized by management in their evaluation of goodwill impairment.

 

/s/ Mazars USA LLP

 

We have served as the Company’s auditor since 2020.

 

Fort Washington, Pennsylvania

 

April 4, 2024

 

 F-2 

 

 

Reliance Global Group, Inc. and Subsidiaries

Consolidated Balance Sheets

 

   December 31   December 31, 
   2023   2022 
Assets          
Current assets:          
Cash  $1,329,016   $505,410 
Restricted cash   1,409,895    1,404,359 
Accounts receivable   1,298,863    994,321 
Accounts receivable, related parties   6,603    18,292 
Other receivables   899    11,464 
Prepaid expense and other current assets   333,756    245,535 
Current assets - discontinued operations   -    85,998 
Total current assets   4,379,032    3,265,379 
Property and equipment, net   139,999    162,767 
Right-of-use assets   739,830    1,018,952 
Investment in NSURE, Inc.   -    900,000 
Intangibles, net   11,042,757    13,439,369 
Goodwill   6,693,099    14,287,099 
Other non-current assets   20,292    23,284 
Other assets - discontinued operations   -    5,330,879 
Total assets  $23,015,009   $38,427,729 
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable and other accrued liabilities  $835,483   $951,382 
Short term financing agreements   56,197    154,017 
Current portion of loans payables, related parties   454,953    1,422,249 
Other payables   7,414    101,113 
Current portion of long-term debt   1,390,766    1,118,721 
Current portion of leases payable   285,171    339,937 
Earn-out liability, current portion   159,867    2,153,478 
Current liabilities - discontinued operations   -    1,600,636 
Total current liabilities   3,189,851    7,841,533 
           
Loans payable, related parties, less current portion   897,529    122,266 
Convertible debt, related parties, less current portion   -    1,500,000 
Long term debt, less current portion   11,026,971    12,349,673 
Leases payable, less current portion   484,335    714,068 
Earn-out liability, less current portion   -    556,000 
Warrant liabilities   268,993    6,433,150 
Total liabilities   15,867,679    29,516,690 
Stockholders’ equity:          
Preferred stock, $0.086 par value; 750,000,000 shares authorized and 0 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively   -    - 
Common stock, $0.086 par value; 2,000,000,000 shares authorized and 4,761,974 and 1,219,573 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively   409,509    104,883 
Additional paid-in capital   45,739,786    35,798,139 
Accumulated deficit   (39,001,965)   (26,991,983)
Total stockholders’ equity   7,147,330    8,911,039 
Total liabilities and stockholders’ equity  $23,015,009   $38,427,729 

 

The accompanying notes are an integral part of these consolidated financial statements

 

 F-3 

 

 

Reliance Global Group, Inc. and Subsidiaries

Consolidated Statements of Operations

 

   Year ended   Year ended 
   December 31, 2023   December 31, 2022 
Revenue          
Commission income  $13,731,826   $11,761,882 
Total revenue   13,731,826    11,761,882 
           
Operating expenses          
Commission expense   3,732,939    3,140,725 
Salaries and wages   7,503,052    7,508,312 
General and administrative    4,089,989    4,959,151 
Marketing and advertising   364,974    170,311 
Change in estimated acquisition earn-out payables   1,716,873    524 
Depreciation and amortization   2,609,191    2,563,518 
Goodwill impairment   7,594,000    - 
Total operating expenses   27,611,018    18,342,541 
           
Loss from operations   (13,879,192)   (6,580,659)
           
Other income (expense)          
Interest expense   (1,506,186)   (911,106)
Interest expense, related parties   (150,067)   (6,920)
Other expense, net   6,530    (4,341)
Recognition and change in fair value of warrant liabilities   5,503,647    29,064,958 
Total other income (expense)   3,853,924    28,142,591 
Loss (income) from continuing operations before tax   (10,025,268)   21,561,932 
Loss from discontinued operations before tax   (1,984,714)   (15,095,770)
           
Net (loss) income  $(12,009,982)  $6,466,162 
           
Basic (loss) earnings per share          
Continuing operations  $(4.46)  $13.36 
Discontinued operations  $(0.70)  $(13.78)
Basic loss per share  $(5.16)  $(0.42)
           
Diluted (loss) earnings per share          
Continuing operations  $(4.46)  $13.36 
Discontinued operations  $ (0.70)  $(13.78)
Diluted loss per share  $(5.16)  $(0.42)
           
Weighted average number of shares outstanding – Basic   

2,820,275

    

1,094,781

 
           
Weighted average number of shares outstanding – Diluted   

2,820,275

    

1,094,989

 

 

The accompanying notes are an integral part of these consolidated financial statements

 

 F-4 

 

 

Reliance Global Group, Inc. and Subsidiaries

Consolidated Statements of Stockholders’ Equity

 

   Shares   Amount   Shares   Amount   capital    Deficit   Total 
   Preferred stock   Common stock  

Additional paid-in

   

Accumulated

    
   Shares   Amount   Shares   Amount   capital    Deficit   Total 
                              
Balance, December 31, 2022   -   $    -    1,219,573    

$

104,883   $35,798,139   - $(26,991,983)  $8,911,039 
                                     
Share based compensation             766,596    65,928    809,178     -    875,106 
                                   - 
Common shares issued for earnout liabilities             636,228    54,714    2,946,331     

-

    3,001,045 
                                   - 
Common shares issued to settle convertible debt, related parties             66,743    5,740    639,260     -    645,000 
                                   - 
Round up of shares due to reverse split             15,336    1,300    (1,300)    

-

    - 
                                   - 
Shares issued in 2023 private placement             155,038    13,333    3,433,151     -    3,446,484 
                                   - 
Common shares issued for services             260,602    22,412    567,448     

-

    589,860 
                                     
Common shares issued for Series B warrants             373,264    32,100    628,410     -    660,510 
                                   - 
Common shares issued for Series E warrants             897,594    77,193    (78,897)    -    (1,704)
                                   - 
Common shares issued for Series F warrants             371,000    31,906    998,066     

-

    1,029,972 
                                     
Net loss   -     -     -              -  (12,009,982)   

(12,009,982

)
                                     
Balance, December 31, 2023   --    --    4,761,974   $409,509  -

$

45,739,786   - $(39,001,965)  $7,147,330 

 

The accompanying notes are an integral part of these consolidated financial statements

 

 F-5 

 

 

Reliance Global Group, Inc. and Subsidiaries

Consolidated Statements of Stockholders’ Equity

 

   Shares   Amount   Shares   Amount    capital   Receivable   Deficit   Total 
   Preferred stock   Common stock   

Additional

paid-in

   Subscription   Accumulated     
   Shares   Amount   Shares   Amount    capital   Receivable   Deficit   Total 
                                  
Balance, December 31, 2021   -   $-    730,407   $62,815    $27,329,201   $(20,000,000)  $(33,458,145)  $(26,066,129)
                                          
Share based compensation   -    -    -    -     1,249,873    -    -    1,249,873 
                                          
Shares issued in private placement   9,076    781    178,060    15,313     (16,043)   20,000,000    -    20,000,051 
                                          
Shares issued pursuant to acquisition    -    -    40,402    3,475     4,759,976    -    -    4,763,451 
                                          
Series A warrants   -    -    25,000    2,150     2,472,850    -    -    2,475,000 
                                          
Issuance of Series C warrants in exchange for common shares             (218,462)   (18,788)    18,788    -    -    - 
                                          
Shares issued for vested stock awards   -    -    14,675    1,262     (1,262)   -    -    - 
                                          
Issuance of common stock for conversion of Series C warrants   -    -    218,462    18,788     (17,452)   -    -    1,336 
                                          
Issuance of common stock for conversion of Series D warrants   -    -    81,423    7,002     (6,207)   -    -    795 
                                          
Issuance of common stock for conversion of Series B warrants   -    -    1,667    143     12,357    -    -    12,500 
                                          
Warrant liability reclassified to equity upon exercise of Series B Warrants   -    -    -    -     8,000    -    -    8,000 
                                          
Shares issued due to conversion of preferred stock   (9,076)   (781)   147,939    12,723     (11,942)   -    -    - 
                                          
Net Income   -    -    -    -     -    -    6,466,162    6,466,162 
                                          
Balance, December 31, 2022   -    -    1,219,573   $104,883    $35,798,139    -   $(26,991,983)  $8,911,039 

 

The accompanying notes are an integral part of these consolidated financial statements

 

 F-6 

 

 

Reliance Global Group, Inc. and Subsidiaries and Predecessor

Consolidated Statements of Cash Flows

 

   2023   2022 
   For the year ended December 31,  
   2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net (Loss) income   (12,009,982)   6,466,162 
Adjustment to reconcile net income to net cash used in operating activities:          
Depreciation and amortization   2,609,191    2,563,518 
Goodwill impairment   7,594,000    - 
Amortization of debt issuance costs and accretion of debt discount   46,883    41,875 
Non-cash lease expense   (5,377)   21,452 
Share based compensation expense   875,106    1,249,873 
Share based payments to service providers   397,049    

-

 
Recognition and change in fair value of warrant liability   (5,503,647)   (29,064,958)
Change in estimated acquisition earn-out payables   1,716,873    524 
Change in operating assets and liabilities:          
Accounts receivable   (304,542)   123,096 
Accounts receivable, related parties   11,689    (11,161)
Other receivables   10,565    (11,464)
Prepaid expense and other current assets   104,590    2,501,023 
Other non-current assets   2,992    (6,492)
Accounts payables and other accrued liabilities   (48,266)   (1,811,237)
Other payables   (93,699)   269,613 
Net cash used in continuing operating activities   (4,596,575)   (17,668,176)
           
Net cash provided by discontinued operating activities   3,748,605    14,478,179 
           
Net cash used in continuing and discontinued operating activities   (847,970)   (3,189,997)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property and equipment   (22,864)   (61,454)
Purchase of intangible assets   (166,947)   (740,922)
Proceeds from sale of investment in NSURE   900,000    450,000 
Business acquisitions, net of cash acquired   -    (6,000,000)
Net cash provided and used in continuing investing activities   710,189    (6,352,376)
           
Net cash used in discontinued investing activities   -    (18,289,936)
           
Net cash provided and used in continuing and discontinued investing activities   710,189    (24,642,312)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Principal repayments of debt   (1,090,622)   (875,010)
Debt issuance costs   -    (214,257)
Loans acquired through acquisitions   -    6,520,000 
Issuance of common shares in exchange for Series B warrants   

-

    12,500 
Issuance of common shares in exchange for Series C warrants   -    2,131 
Proceeds from short term financing   241,975    - 
Principal repayments of short-term financings   (322,095)   (310,383)
Payments of loans payable, related parties   (1,045,164)   (184,252)
Cash payments and proceeds of convertible debt, related parties   (855,000)   1,500,000 
Cash payments on earn-out liability   (419,225)   (1,704,924)
Proceeds from exercise of warrants into common stock   1,028,270    2,475,000 
Private Placement of shares and warrants   3,446,484    17,853,351 
Net cash provided from continuing financing activities   984,623    25,074,156 
           
Net cash used and provided from discontinued financing activities   (17,700)   47,200 
           
Net cash provided from continuing and discontinued financing activities   966,923    25,121,356 
           
Net increase and decrease in cash and restricted cash   829,142    (2,710,953)
Cash and restricted cash at beginning of year   1,909,769    4,620,722 
Cash and restricted cash at end of year   2,738,911    1,909,769 
           
SUPPLEMENTAL DISCLOSURE OF CASH AND NON-CASH TRANSACTIONS:          
Cash paid during the period for:          
Interest  $

1,612,829

   $863,936 
Noncash investing and financing transactions:          
Common shares issued to settle convertible debt, related parties   

645,000

    - 
Common shares issued for earnout liabilities   3,001,045    - 
Common shares issued for Series B warrants   

660,510

    

8,000

 
Common shares issued for Series D Warrants   

-

    

36,761

 
Common shares issued for preferred stock   

-

    

190,069

 
Common stock issued for pre-paid assets   

192,811

    

-

 
Issuance of Series D Warrants   -    6,930,335 
Issuance of placement agent warrants   -    1,525,923 
Acquisition of business deferred purchase price liability        1,125,000 
Lease assets acquired in exchange for lease liabilities   

156,542

    310,146 
Noncash investing and financing transactions, discontinued operations        

5,081,309

 

 

The accompanying notes are an integral part of these consolidated financial statements

 

 F-7 

 

 

Reliance Global Group, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

 

NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Reliance Global Group, Inc. (formerly known as Ethos Media Network, Inc.) (“RELI”, “Reliance”, or the “Company”) was incorporated in Florida on August 2, 2013.

 

On April 26, 2022, the Company acquired the assets of Barra & Associates, LLC., an unaffiliated full-service insurance agency headquartered in Illinois (see Note 3).

 

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated financial statements included herein have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounting of Reliance Global Group, Inc., and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

 

Liquidity

 

As of December 31, 2023, the Company’s reported cash and restricted cash aggregated balance was approximately $2,739,000, current assets were approximately $4,379,000, while current liabilities were approximately 3,190,000. As of December 31, 2023, the Company had working capital of approximately $1,189,000 and stockholders’ equity of approximately $7,147,000. For the year ended December 31, 2023, the Company reported a loss from operations of approximately $13,879,000, of which $7,594,000 was related to goodwill impairment. The Company also reported a non-cash, non-operating gain on the recognition and change in fair value of warrant liabilities of approximately $5,504,000, other expense, primarily interest expense of approximately $1,650,000, which resulted in a loss from continuing operations of $10,025,000. Additionally, the Company reported a loss from discontinued operations of approximately $1,985,000. The total net loss of the company was approximately $12,010,000. The Company completed a capital offering in March 2023, raising net proceeds of approximately $3,446,000.

 

Although there can be no assurance that debt or equity financing will be available on acceptable terms, the Company believes its financial position and its ability to raise capital to be reasonable and sufficient. Based on our assessment, we do not believe there are conditions or events that, in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one year of filing these financial statements with the Securities and Exchange Commission (“SEC”).

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

 

 F-8 

 

 

Cash and Restricted Cash

 

Cash consists of checking accounts. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Restricted cash includes cash pledged as collateral to secure obligations and/or all cash whose use is otherwise limited by contractual provisions.

 

At times, some cash balances held in banks may exceed the Federal Deposit Insurance Corporation, or FDIC, standard deposit insurance limit of $250,000.

 

The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows:

 

 

  

December 31,

2023

  

December 31,

2022

 
Cash  $1,329,016   $505,410 
Restricted cash   1,409,895    1,404,359 
Total cash and restricted cash  $2,738,911   $1,909,769 

 

Property and Equipment

 

Property and equipment is stated at cost, less accumulated depreciation. Depreciation is recognized over an asset’s estimated useful life using the straight-line method beginning on the date an asset is placed in service. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Certain capitalized software has been reclassified in the consolidated balance sheet from property and equipment, net to intangibles, net and comparative periods have been adjusted accordingly. Maintenance and repairs are charged to expense as incurred. Estimated useful lives of the Company’s Property and Equipment are as follows:

 

   Useful Life (in years) 
Computer equipment   5 
Office equipment and furniture   7 
Leasehold improvements   Shorter of the useful life or the lease term 

 

Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance includes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels of the fair value hierarchy are as follows:

 

Level 1 — Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities;

 

Level 2 — Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and

 

Level 3 — Unobservable inputs for the asset or liability, which include management’s own assumption about the assumptions market participants would use in pricing the asset or liability, including assumptions about risk.

 

As of December 31, 2023, and 2022 respectively, the Company’s balance sheet includes certain financial instruments, including cash, notes receivables, accounts payable, and short and long-term debt. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amounts of long-term debt approximate their fair value as the variable interest rates are based on a market index.

 

 F-9 

 

 

Warrant Liabilities: The Company’s warrant liabilities (see Note 9, Warrant Liabilities) represent liability-classified derivative financial instruments recorded at fair value on a recurring basis. The fair value of the Warrant Liabilities includes significant inputs unobservable in the market and thus are considered Level 3. The Company measured the fair value of the warrant liabilities at the issuance date, December 12, 2023, and subsequently at the balance sheet date, using a binomial option pricing model. The following summarizes the significant unobservable inputs:

 

  

  

December 31,

2023

  

December 31,

2022

 
Stock price  $0.54   $8.55 
Volatility   110.0%   105.0%
Time to Expiry   4.99    4.01 
Dividend yield   0%   0%
Risk free rate   3.8%   4.1%

 

The following reconciles the warrant liabilities for the years ended December 31, 2023 and 2022:

 

  

                     
   Years ended December 31, 2023 and 2022 
   Series B Warrant Commitment   Series B warrant liabilities   Placement agent warrants   Total 
Beginning balance, December 31, 2021   37,652,808    -    -    37,652,808 
Initial recognition   -    55,061,119    1,525,924    56,587,043 
Unrealized (gain) loss   17,408,311    (48,668,869)   (1,477,024)   (32,737,582)1
Warrants exercised or transferred   (55,061,119)   (8,000)   -    (55,069,119)
Ending balance, December 31, 2022  $-   $6,384,250   $48,900   $6,433,150 
Unrealized (gain) loss        (5,534,931)   (48,575)   (5,583,506)2
Warrants exercised or exchanged   -    (580,651)   -    (580,651)
Ending balance, December 31, 2023   -   $268,668   $325   $268,993 

 

1 Recognition and change in fair value of warrant liabilities per income statement is $29,064,958. The difference of $3,672,624 is made up of the Warrant issuance costs.
2 Recognition and change in fair value of warrant liabilities per income statement is $5,503,647. The difference of $79,859 was due to a loss on a warrant exchange.

 

Earn-out liabilities: The Company generally values its Level 3 earn-out liabilities using the income valuation approach. Key valuation inputs include contingent payment arrangement terms, projected revenues and cash flows, rate of return, and probability assessments. The following table summarizes the significant unobservable inputs used in the fair value measurements:

 

   

    December 31, 2023   December 31, 2022
Valuation technique   Discounted cash flow   Discounted cash flow
Significant unobservable input   Projected revenue and probability of achievement   Projected revenue and probability of achievement

 

 F-10 

 

 

The Company values its Level 3 earn-out liability related to the Southwestern Montana Insurance Center acquisition using a Monte Carlo simulation in a risk-neutral framework (a special case of the Income Approach). The following summarizes the significant unobservable inputs:

 

 

  

December 31,

2023

 
Volatility   110%
Credit Spread   7.73%
Number of trading days   252 
Risk free rate   5.34

%

Remaining term (years)   0.2 
Stock Price  $0.54 
Dividend Yield   0%
Number of Iterations   100,000 

 

Undiscounted remaining earn out cash payments were approximately $165,000 as of December 31, 2023. The following table reconciles fair value of earn-out liabilities for the years ending December 31, 2023 and 2022:

  

 

   December 31,
2023
   December 31,
2022
 
Beginning balance – January 1  $2,709,478   $3,813,878 
           
Acquisitions and Settlements   (3,260,403)   (1,104,924)
           
Period adjustments:          
Fair value and estimate changes*   1,716,873    524 
Earn-out payable in common shares   (159,867)   - 
Earn-out transferred to loans payable, related parties   (846,214)   

-

 
           
Ending balance  $159,867   $2,709,478 
Less: Current portion   (159,867)   (2,153,478)
Ending balance, less current portion  $-   $556,000 

 

* Recorded as change in estimated acquisition earn-out payables on the consolidated statements of operations.

 

Deferred Financing Costs

 

The Company has recorded deferred financing costs because of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized to interest expense using the straight-line method which approximates the interest rate method over the term of the related debt. As of December 31, 2023, and 2022, unamortized deferred financing costs were $273,864, and $313,829, respectively and are netted against the related debt.

 

Business Combinations

 

The Company accounts for its business combinations using the acquisition method of accounting. Under the acquisition method, assets acquired, liabilities assumed, and consideration transferred are recorded at the date of acquisition at their respective fair values. Definite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

 

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration such as earn-outs, the Company records the contingent consideration at fair value at the acquisition date. The Company remeasures fair value as of each reporting date and changes resulting from events after the acquisition date, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings.

 

 F-11 

 

 

Identifiable Intangible Assets, net

 

Finite-lived intangible assets such as customer relationships assets, trademarks and tradenames are amortized over their estimated useful lives, generally on a straight-line basis for periods ranging from 3 to 20 years. Finite-lived intangible assets are reviewed for impairment or obsolescence whenever events or circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of intangible assets is measured by a comparison of the carrying amount of the asset to the future undiscounted net cash flows expected to be generated by that asset. If the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the estimated fair value. No impairment was recognized during the periods presented.

 

Goodwill and other indefinite-lived intangibles

 

The Company records goodwill when the purchase price of a business acquisition exceeds the estimated fair value of net identified tangible and intangible assets acquired. Goodwill is assigned on the acquisition date and tested for impairment at least annually, or more frequently when events or changes in circumstances indicate that the fair value of a reporting unit has more likely than not declined below its carrying value. Similarly, indefinite-lived intangible assets (if any) other than goodwill are tested annually or more frequently if indicated, for impairment. If impaired, intangible assets are written down to fair value based on the expected discounted cash flows.

 

Financial Instruments

 

The Company evaluates issued financial instruments for classification as either equity or liability based on an assessment of the financial instrument’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”) as well as in accordance with ASU 2020-06. The assessment considers whether the financial instruments issued are freestanding pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and, if applicable whether the financial instruments meet all of the requirements for equity classification under ASC 815, including whether the financial instruments are indexed to the Company’s own Common Stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance and as of each subsequent reporting period end date while the financial instruments are outstanding. Financial instruments that are determined to be liabilities under ASC 480 or ASC 815 are held at their initial fair value and remeasured to fair value at each subsequent reporting date, with changes in fair value recorded as a non-operating, non-cash loss or gain, as applicable.

 

The Company’s financial instruments consist of derivatives related to the warrants issued with the securities purchase agreement as discussed in Note 9, Warrant Liabilities. The accounting treatment of derivative financial instruments requires that we record the derivatives at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense at each balance sheet date. Upon the determination that an instrument is no longer subject to derivative accounting, the fair value of the derivative instrument at the date of such determination will be reclassified to paid in capital.

 

The adoption of Topic 326 did not significantly change our approach to the valuation of trade receivables. The Company determines whether there is an expected loss on our accounts receivable by reviewing all available data, including our customers' latest available financial statements, their credit standing, our historical collection experience, and current and future market and economic conditions. As of December 31, 2023, and December 31, 2022, it was not deemed necessary to recognize any allowance for credit losses on our trade receivables.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606 Revenue from Contracts with Customers which at its core, recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services.

 

The Company’s revenue is primarily comprised of agency commissions earned from insurance carriers (the “Customer” or “Carrier”) related to insurance plans produced through brokering, producing, and servicing agreements between insurance carriers and members. The Company defines a “Member” as an individual, family or entity currently covered or seeking insurance coverage.

 

 F-12 

 

 

The Company focuses primarily on agency services for insurance products in the “Healthcare” and property and casualty, which includes auto (collectively “P&C”) space, with nominal activity in the life insurance and bond sectors. Healthcare includes plans for individuals and families, Medicare supplements, ancillary and small businesses. The Company also earns revenue in the “Insurance Marketing” space as discussed further below.

 

Consideration for all agency services typically is based on commissions calculated by applying contractual commission rates to policy premiums. For P&C, commission rates are applied to premiums due, whereas for healthcare, commission rates, including override commissions, are applied to monthly premiums received by the Carrier.

 

The Company has two forms of billing practices, “Direct Bill” and “Agency Bill”. With Direct Bill, Carriers bill and collect policy premium payments directly from Members without any involvement from the Company. Commissions are paid to the Company by the Carrier in the following month. With Agency Bill, the Company bills Members premiums due and remits them to Carriers net of commission earned.

 

The following outlines the core principles of ASC 606:

 

Identification of the contract, or contracts, with a customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

 

Identification of the performance obligations in the contract. Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract.

 

Determination of the transaction price. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.

 

Allocation of the transaction price to the performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.

 

Recognition of revenue when, or as, the Company satisfies a performance obligation. The Company satisfies performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.

 

Healthcare revenue recognition:

 

The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.

 

There typically is one performance obligation in contracts with Carriers, to perform agency services that culminate in monthly premium cash collections by the Carrier. The performance obligation is satisfied through a combination of agency services including, marketing carrier’s insurance plans, soliciting Member applications, binding, executing and servicing insurance policies on a continuous basis throughout a policy’s life cycle which includes and culminates with the Customer’s collection of monthly premiums. No commission is earned if cash is not received by Carrier. Thus, commission revenue is earned only after a month’s cash receipts from Members’ dues is received by the Customer. Each month’s Carrier cash collections is considered a separate unit sold and transferred to the Customer i.e., the satisfaction of that month’s performance obligation.

 

 F-13 

 

 

Transaction price is typically stated in a contract and usually based on a commission rate applied to Member premiums paid and received by Carrier. The Company generally continues to receive commission payments from Carriers until a Member’s plan is cancelled or the Company terminates its agency agreement with the Carrier. Upon termination, the Company normally will no longer receive any commissions from Carriers even on business still in place. In some instances, trailing commissions could occur which would be recognized similar to other Healthcare revenue. With one performance obligation, allocation of transaction price is normally not necessary.

 

Healthcare typically utilizes the Direct Bill method.

 

The Company recognizes revenue at a point in time when it satisfies its monthly performance obligation and control of the service transfers to the Customer. Transfer occurs when Member insurance premium cash payments are received by the Customer. The Customer’s receipt of cash is the culmination and complete satisfaction of the Company’s performance obligation, and the earnings process is complete.

 

With Direct Bill, since the amount of monthly Customer cash receipts is unknown to the Company until the following month when notice is provided by Customer to Company, the Company accrues revenue at each period end. Any estimated revenue accrued and recognized at a period-end is trued up for financial reporting per actual revenue earned as provided by the Customer during the following month.

 

P&C revenue recognition:

 

The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.

 

There typically is one performance obligation in contracts with Customers, to perform agency services to solicit, receive proposals and bind insurance policies culminating with policy placement. Commission revenue is earned at the time of policy placement.

 

Transaction price is typically stated in a contract and usually based on commission rates applied to Member premiums due. With one performance obligation, allocation of transaction price is normally not necessary.

 

P&C utilizes both the Agency Bill and Direct Bill methods, depending on the Carrier.

 

The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of the service transfers to the Customer. Transfer occurs when the policy placement process is complete.

 

With both Direct Bill and Agency Bill, the Company accrues commission revenue in the period policies are placed. With Agency Bill, payment is typically received from Members in the month earned, however with Direct Bill, payment is typically received from Carriers in the month subsequent to the commissions being earned.

 

Other revenue policies: Insurance commissions earned from Carriers for life insurance products are recorded gross of amounts due to agents, with a corresponding commission expense for downstream agent commissions being recorded as commission expense within the condensed consolidated statements of operations.

 

When applicable, commission revenue is recognized net of any deductions for estimated commission adjustments due to lapses, policy cancellations, and revisions in coverage.

 

The Company could earn additional revenue from contingent commissions, profit-sharing, override and bonuses based on meeting certain revenue or profit targets established periodically by the Carriers (collectively, “Contingent Commissions”). Contingent Commissions are earned when the Company achieves targets established by Carriers. The Carriers notify the Company when it has achieved the target. The Company recognizes revenue for any Contingent Commissions at the time it is reasonably assured that a significant revenue reversal is not probable, which is generally when a Carrier notifies the Company that it is on track or has earned a Contingent Commission.

 

 F-14 

 

 

The following table disaggregates the Company’s revenue by line of business, showing commissions earned:

 

 

Year ended

December 31, 2023

  Medical   Life   Property and Casualty   Total 
                 
EBS  $883,327   $22,114   $-   $905,441 
USBA   43,193    3184    -    46,377 
CCS/UIS   -    -    289,486    289,486 
Montana   1,863,455    12,488    -    1,875,943 
Fortman   1,161,506    5,487    1,044,592    2,211,585 
Altruis   5,454,654    -    -    5,454,654 
Kush   1,209,854    -    -    1,209,854 
Reli Exchange   209,615    127,486    1,401,385    1,738,486 
Total  $10,825,064   $170,759   $2,735,463   $13,731,826 

 

Year ended

December 31, 2022

  Medical     Life     Property and Casualty     Total  
                                 
EBS   $ 781,570     $ 16,843     $ -     $ 798,413  
USBA     51,006       1462       -       52,468  
CCS/UIS     -       -              254,325       254,325  
Montana     1,860,475       7,661       -       1,868,136  
Fortman     1,267,945       6705       842,961       2,117,611  
Altruis     4,041,495       2954       -       4,044,449  
Kush     1,535,416       1040       -       1,536,456  
Reli Exchange     152,094       106,052       831,878       1,090,024  
Total   $ 9,690,001     $ 142,717     $ 1,929,164     $ 11,761,882  

 

General and Administrative

 

General and administrative expenses primarily consist of personnel costs for the Company’s administrative functions, professional service fees, office rent, all employee travel expenses, and other general costs.

 

Marketing and Advertising

 

The Company’s direct channel expenses primarily consist of costs for e-mail marketing and newspaper advertisements. The Company’s online advertising channel expense primarily consist of social media ads. Advertising costs for both direct and online channels are expensed as incurred.

 

Equity-Based Compensation

 

Equity-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, based on the terms of the awards. The fair value of the stock-based payments to nonemployees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. To the extent possible, the Company will estimate and recognize expected forfeitures.

 

 F-15 

 

 

Leases

 

The Company recognizes leases in accordance with Accounting Standards Codification Topic 842, “Leases” (“ASC 842” or “ASU 2016-12”). This standard provides enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases are recognized as a single lease expense, generally on a straight-line basis.

 

The Company is the lessee in a contract when the Company obtains the right to use an asset. We currently lease real estate and office space under non-cancelable operating lease agreements. When applicable, consideration in a contract is allocated between lease and non-lease components. Lease payments are discounted using the implicit discount rate in the lease. If the implicit discount rate for the lease cannot be readily determined, the Company uses an estimate of its incremental borrowing rate. The Company did not have any contracts accounted for as finance leases as of December 31, 2023, or 2022. Operating leases are included in the line items right-of-use assets, current portion of leases payable, and leases payable, less current portion in the consolidated balance sheets. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations. The Company determines a lease’s term by agreement with lessor and includes lease extension options and variable lease payments when option and/or variable payments are reasonably certain of being exercised or paid.

 

Income Taxes

 

The Company recognizes deferred tax assets and liabilities using enacted tax rates for the effect of temporary differences between the book and tax basis of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. In evaluating its ability to recover deferred tax assets within the jurisdiction in which they arise, the Company considers all available positive and negative evidence, including the expected reversals of taxable temporary differences, projected future taxable income, taxable income available via carryback to prior years, tax planning strategies, and results of recent operations. The Company assesses the realizability of its deferred tax assets, including scheduling the reversal of its deferred tax assets and liabilities, to determine the amount of valuation allowance needed. Scheduling the reversal of deferred tax asset and liability balances requires judgment and estimation. The Company believes the deferred tax liabilities relied upon as future taxable income in its assessment will reverse in the same period and jurisdiction and are of the same character as the temporary differences giving rise to the deferred tax assets that will be realized.

 

Discontinued Operations

 

The Company’s board of directors approved the discontinuation and abandonment of Medigap Healthcare Insurance Company, LLC (“Medigap”), a subsidiary of the Company, effective April 17, 2023, due to Medigap’s sustained recurring losses stemming from amongst other factors, greater than anticipated revenue chargebacks. The Company was unable to divest its interest in Medigap for value, and accordingly, operations were wound down in an orderly manner. In doing so, the Company transferred to its operating entity, Medigap’s customer relationships and internally developed and purchased software intangible assets, with net of amortization combined value of approximately $4,300,000, as well as, its short-term financing arrangement of $29,500, and each are respectively classified at their adjusted book values in the intangible assets and short term financing agreements accounts in the condensed consolidated balance sheets for the periods ended December 31, 2023 and December 31, 2022. These assets have continued value to the Company and have not been impaired as the fair value exceeds carrying cost. Medigap’s remaining assets were considered to have no remaining asset value and were fully impaired. Certain liabilities and estimated liabilities as outlined in the tables herein, were discharged and/or written-off in conjunction with the Settlement Agreement (as defined below) because of them having a net zero dollar estimated liability value. Accordingly, the Company recognized a net of estimated liability adjustments gain/loss of approximately $0, and an impairment loss of approximately $4,400,000, presented in income (loss) from discontinued operations in the consolidated statements of operations for the year ended December 31, 2023. As part of the abandonment, the Company cancelled third party contracts, settled outstanding vendor and other third-party obligations, ceased to enter new customer contracts via Medigap, and no further customer performance obligations existed. The Company does not expect further continuing involvement with Medigap, and in accordance with ASC 205-20-45-9, no corporate overhead has been allocated to discontinued operations.

  

Settlement Agreement

 

On June 30, 2023, the Company entered into a confidential settlement agreement and mutual release (the “Settlement Agreement”) with certain Medigap affiliated entities and persons, and the former owners of Medigap, whereby the Company would receive a settlement payment, net of costs, of $2,761,190 and was released from all past and future Medigap obligations and liabilities. The settlement payment was received in full by the Company in July 2023 and is recorded as income from discontinued operations in the condensed consolidated statements of operations for the year ended December 31, 2023.

 

The following tables present the major components of assets and liabilities included in discontinued operations on the condensed consolidated balance sheets.

 

 

   December 31, 2023   December 31, 2022 
Accounts receivable  $     -   $          73,223 
Accounts receivable, related parties   -    3,595 
Other receivables   -    5,388 
Prepaid expense and other current assets   -    3,792 
Current Assets - Discontinued Operations  $-   $85,998 
           
Condensed consolidated balance sheets - Current Assets - Discontinued Operations  $-   $85,998 
           
Property and equipment, net   -   $24,116 
Right-of-use assets   -    163,129 
Intangibles, net   -    318,000 
Goodwill   -    4,825,634 
Other Assets - Discontinued Operations  $-   $5,330,879 
           
Condensed consolidated balance sheets - Other Assets - Discontinued Operations  $-   $5,330,877 
           
Accounts payable and other accrued liabilities   -   $506,585 
Chargeback reserve   -    915,934 
Current portion of leases payable   -    178,117 
Current Liabilities - Discontinued Operations  $-   $1,600,636 
           
Condensed consolidated balance sheets - Current Liabilities - Discontinued Operations  $-   $1,600,636 

 

 F-16 

 

 

The following table rolls forward Medigap’s assets and liabilities from their carrying values pre-abandonment to their values post abandonment, and presents the impact of reclassifications, impairments, and write-offs:

 

Medigap Related Assets  Carrying Value Prior To Abandonment   Asset and Liability Transfers Retained by the Company   Asset Impairments and Liability Write-Offs   Carrying Value as of December 31, 2023 
                 
Accounts receivable  $56,398   $-   $(56,398)  $       - 
Accounts receivable, related party   3,595    -    (3,595)   - 
Other receivables   5,388    -    (5,388)   - 
Current assets – Medigap  $65,381   $-   $(65,381)  $- 
                     
Property and equipment, net  $22,378   $-   $(22,378)  $- 
Right-of-use assets   119,594    -    (119,594)   - 
Intangibles, net   4,570,536    (4,258,214 )1    (312,322)   - 
Goodwill   4,825,634    -    (4,825,634)   - 
Other assets - Medigap  $9,538,142   $(4,258,214)  $(5,279,928)  $- 
                     
Total assets - Medigap  $9,603,523   $(4,258,214)  $(5,345,309)  $- 
                     
Accounts payable and other accrued liabilities  $4,157   $-   $(4,157)  $- 
Short term financing agreements   29,500    (29,500)   -    - 
Chargeback reserve   831,725    -    (831,725 )2    - 
Current portion of leases payable   134,517    -    (134,517 )3    - 
Other liabilities   9,842    -    (9,842 )3    - 
Current liabilities - Medigap  $1,009,741   $(29,500)  $(980,241)  $- 
                     
Total liabilities - Medigap  $1,009,741   $(29,500)  $(980,241)  $- 
                     
Net assets and liabilities - Medigap  $8,593,782   $(4,228,714)  $(4,365,068)  $- 

 

  1 Includes customer relationships and internally developed and purchased software intangible assets that have continued value to the Company and have not been impaired as the fair value exceeds carrying cost.
  2 Estimated liability write-off per net zero dollar estimated liability value.
  3 Liability discharge pursuant to the Settlement Agreement.

 

The following tables disaggregate the major classes of pretax gain and loss as presented in discontinued operations in the condensed consolidated statements of operations.

 

  

Year Ended

December 31, 2023

  

Year Ended

December 31, 2022

 
Income          
Commission income  $744,030   $4,994,002 
           
Expenses          
Commission expense   110,639    604,042 
Salaries and wages   454,663    1,973,579 
General and administrative    129,363    508,342 
Marketing and advertising   426,818    2,414,583 
Depreciation and amortization   7,283    238,307 
Other expenses (income)   (3,902)   (22,454)
Total discontinued operations expenses before impairments and write-offs   1,124,864    5,716,399 
Total discontinued operations income / (loss) before impairments and write-offs  $(380,834)  $(722,397)
Gains and (losses) from recoveries and impairments / write-offs of discontinued operations assets and liabilities          
           
Settlement Recovery, net of costs  $2,761,190    - 
           
Asset impairment losses          
Accounts receivable   56,398    - 
Accounts receivable, related parties   3,595    - 
Other receivables   5,388    - 
Property and equipment, net   22,378    - 
Right-of-use assets   119,593    - 
Intangibles, net   312,322    - 
Goodwill   4,825,634    14,373,374 
Total asset impairments   5,345,308    14,373,374 
           
Liability write-off gains          
Accounts payable and other accrued liabilities   4,154    - 
Other payables   9,842    - 
Chargeback reserve   831,725    - 
Current portion of leases payable   134,517    - 
Total liability write-off gains   980,238    - 
           
Discontinued operations net asset and liability impairments / write-offs gains and (losses)   4,365,070    14,373,374 
           
Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities   (1,603,880)   (14,373,374)
           
Loss from discontinued operations before tax   (1,984,714)   (15,095,770)
           
Consolidated statement of operations - Loss from discontinued operations before tax  $(1,984,714)  $(15,095,770)

 

Seasonality

 

A greater number of the Company’s Medicare-related health insurance plans are sold in the fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage. The majority of the Company’s individual and family health insurance plans are sold in the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.

 

 F-17 

 

 

Recently Issued Accounting Pronouncements

 

In March 2024, the FASB issued ASU No. 2024-01, Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards (“ASU 2024-01”), to clarify the scope application of profits interest and similar awards by adding illustrative guidance in ASC 718, Compensation - Stock Compensation.  The ASU clarifies how to determine whether profits interest and similar awards are in the scope of ASC 718 and applies to all reporting entities that account for profits interest awards as compensation to employees or non-employees. In addition to adding the illustrative guidance, the ASU modified the language in paragraph 718-10-15-3 to improve its clarity and operability. However, this amendment does not change the intent of that guidance, nor how it should be applied. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024, including interim periods within those years. The Company is currently evaluating the effects of the adoption of ASU No. 2024-01 on its consolidated financial statements.

 

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segment’s profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures.

 

NOTE 3. STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS

 

To date, we have acquired ten insurance brokerages (see table below). As our acquisition strategy continues, our reach within the insurance arena can provide us with the ability to offer lower rates, which could boost our competitive position within the industry.

 

Acquired   Reliance 100% Controlled Entity   Date   Location   Line of Business
                 
U.S. Benefits Alliance, LLC (USBA)   US Benefits Alliance, LLC   October 24, 2018   Michigan   Health Insurance
                 
Employee Benefit Solutions, LLC (EBS)   Employee Benefits Solutions, LLC   October 24, 2018   Michigan   Health Insurance
                 
Commercial Solutions of Insurance Agency, LLC (CCS or Commercial Solutions)   Commercial Coverage Solutions LLC   December 1, 2018   New York   P&C – Trucking Industry
                 
Southwestern Montana Insurance Center, Inc. (Southwestern Montana or Montana or SWMT)   Southwestern Montana Insurance Center, LLC   April 1, 2019   Montana   Group Health Insurance
                 
Fortman Insurance Agency, LLC (Fortman or Fortman Insurance or FIS)   Fortman Insurance Solutions, LLC   May 1, 2019   Ohio  

P&C and

Health Insurance

                 
Altruis Benefits Consultants, Inc. (Altruis or ABC)   Altruis Benefits Corporation   September 1, 2019   Michigan   Health Insurance
                 
UIS Agency, LLC (UIS)   UIS Agency, LLC   August 17, 2020   New York   P&C – Trucking Industry
                 
J.P. Kush and Associates, Inc. (Kush)   Kush Benefit Solutions, LLC   May 1, 2021   Michigan   Health Insurance
                 
Barra & Associates, LLC (Barra)   RELI Exchange, LLC   April 26, 2022   Illinois  

P&C and

Health Insurance

 

 F-18 

 

 

Barra & Associates, LLC Transaction

 

On April 26, 2022, we entered into an asset purchase agreement (the “APA”) with Barra & Associates, LLC (“Barra”) pursuant to which the Company purchased all of the assets of Barra & Associates, LLC on April 26, 2022 for a purchase price in the amount of $7,725,000 in cash, with $6,000,000 paid to Barra at closing, $1,125,000 payable in nine months from closing, and a final earnout of $600,000 payable over two years from closing based upon meeting stated milestones. The APA contains standard, commercial representations and warranties and covenants. The source of the cash payment was $6,520,000 in funds borrowed from Oak Street Lending (“Loan”), our existing lender pursuant to a Fifth Amendment to Credit Agreement and Promissory Note, of even date. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties.

 

The acquisition of Barra was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.

 

The preliminary allocation of the purchase price in connection with the acquisition of Barra was calculated as follows:

 

  

Description  Fair Value  

Weighted

Average Useful

Life (Years)

 
Acquired accounts receivable  $92,585      
Property, plant, and equipment   8,593    7 
Right-of-use asset   122,984      
Trade names   22,000    4 
Customer relationships   550,000    10 
Developed technology   230,000    5 
Agency relationships   2,585,000    10 
Lease liability   (122,984)     
Goodwill   4,236,822    Indefinite 
   $7,725,000      


 

 F-19 

 

 

Trade name was measured at fair value using the relief-from-royalty method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue from the trade name, a pre-tax royalty rate of 0.5% and a discount rate of 19.5%.

 

Customer and Agency relationships were measured at fair value using the multiple-period excess earnings method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue and costs associated with existing customers, and a discount rate of 19.5%.

 

Developed technology was measured at fair value using the cost replacement method of the cost approach. Significant inputs used to measure the fair value include an estimate of cost to replace, an obsolescence rate of 28.6%.

 

Goodwill of $4,236,822 arising from the acquisition of Barra consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the acquisition of Barra is currently expected to be deductible for income tax purposes. Total acquisition costs incurred for the acquisition of Barra were $72,793 recorded as a component of General and administrative expenses.

 

The approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from April 26, 2022 to December 31, 2022 was $1,090,023 and a loss of $393,708, respectively.

 

Pro Forma Information

 

The results of operations of Barra will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental pro forma financial information approximate combined financial information assumes that the acquisition had occurred at the beginning of the nine months ended December 31, 2022:

 

  

    December 31, 
    2022 
Revenue   $12,309,504 
Net Income (Loss)   $6,700,594 
Earnings (Loss) per common share, basic   $(0.21)
Earnings (Loss) per common share, diluted   $(0.21)

 

NOTE 4. INVESTMENT IN NSURE, INC.

 

On February 19, 2020, the Company entered into a securities purchase agreement with NSURE, Inc. (“NSURE”), which was further amended on October 8, 2020, and as amended provides that the Company may invest up to an aggregate of $5,700,000 in NSURE to be funded in three tranches. In exchange, the Company will receive a total of 928,343 shares of NSURE’s Class A Common Stock.

 

During the year 2020, by October 8, 2020, the Company funded the first tranche, $1,350,000 in exchange for 394,029 shares. The second tranche allowed the Company to acquire an additional 209,075 shares at a price of $6.457 per share by no later than December 30, 2020. The third full tranche allowed the Company to purchase an additional 325,239 shares at a purchase price of $9.224 after December 20, 2020, but no later than March 31, 2021.

 

The Company did not fund tranches two and three in the required timeframes, thus, the Company relinquished its rights under the contract to any additional NSURE shares aside for the ones already acquired with tranche one.

 

During the fourth quarter of the year ended December 31, 2022, the Company sold 131,345 of its NSURE shares to unaffiliated third parties, receiving cash proceeds of $450,000. During April 2023, the Company sold its remaining 262,684 of NSURE shares to unaffiliated third parties, receiving the shares’ cost basis and cash proceeds of $900,000. The Company’s remaining NSURE share balance as of December 31, 2023, was $0.

 

 F-20 

 

 

The Company measured the NSURE shares subsequent to acquisition in accordance with ASC 321-10-35-2, at cost less impairment since no readily determinable fair value was available to the Company. The investment was reviewed for impairment at each reporting period by qualitatively assessing any indicators demonstrating fair value of the investment is less than carrying value. The Company did not observe any price changes resulting from orderly transactions for identical or similar assets for the years ended December 31, 2023, or 2022. ASC 321-10-50-4 further requires an entity to disclose unrealized gains and losses for periods that relate to equity securities held at a reporting date. To date, the Company has not recognized any unrealized gains or losses on NSURE security.

 

NOTE 5. PROPERTY AND EQUIPMENT

 

Property and equipment consists of the following:

 

  

December 31,

2023

  

December 31,

2022

 
Computer equipment  $110,350   $92,278 
Office equipment and furniture   47,652    40,693 
Leasehold Improvements   120,378    122,830 
Property and equipment   278,380    255,801  
Less: Accumulated depreciation   (138,381)   

(93,034

)
Property and equipment, net  $139,999   $162,767 

 

Depreciation expense associated with property and equipment, is included within depreciation and amortization in the Company’s consolidated statements of operations and is, $45,632 and $37,638 for the years ended December 31, 2023, and 2022, respectively.

 

NOTE 6. GOODWILL AND OTHER INTANGIBLE ASSETS

 

In accordance with ASC 350-20-35-45, all the Company’s goodwill is assigned to a single operating and reporting unit. All acquisitions made by the Company are in one general insurance agency industry and operate in a very similar economic and regulatory environment. The Company has one executive who is responsible for the operations of the insurance agencies. This executive reports directly to the Chief Executive Officer (“CEO”) on a quarterly basis. Additionally, the CEO who is responsible for the strategic direction of the Company reviews the operations of the insurance agency business collectively, as opposed to office by office.

 

For the year ended December 31, 2022, due to a declining market capitalization attributed to Medigap’s performance, the Company performed a goodwill impairment test utilizing a hybrid of the Market Approach – Traded Market Value Method and Income Approach – Discounted Cash Flow Method and Discounted Forward Market Multiple Method, concluding that the Company’s fair value and resultant net assets, implied a goodwill balance of $19,100,000 versus our goodwill balance prior to write-down of $33,400,000. Thus, the Company recognized an approximate impairment charge of $14,373,000 presented in the loss from discontinued operations before tax account in the consolidated statements of operations for the year ended December 31, 2022.

 

As of June 30, 2023, the Company recognized an additional goodwill impairment of $4,825,634 upon the abandonment of Medigap, presented in the loss from discontinued operations before tax account in the consolidated statements of operations for the year ended December 31, 2023.

 

For the year ended December 31, 2023, due to a declining market capitalization, the Company performed a quantitative goodwill impairment test utilizing the discounted cash flow method of the income approach with market participant control adjustments in consideration of market capitalization, and concluded that the Company’s carrying value of equity exceeded its fair value of equity in the approximate amount of $7,594,000 which the Company recognized as a goodwill impairment charge, presented in the goodwill impairment account on the consolidated statements of operations for the year ended December 31, 2023.

 

 F-21 

 

 

The following table rolls forward the Company’s goodwill balance for the periods ending December 31, 2023 and 2022 exclusive of discontinued operations.

  

   Goodwill 
December 31, 2021  $10,050,277 
Goodwill recognized in connection with Barra acquisition on April 26, 2022   4,236,822 
December 31, 2022   14,287,099 
Goodwill impairment recognized as of December 31, 2023   (7,594,000)
December 31, 2023  $6,693,099 

 

The following table rolls forward the Company’s goodwill balance for the periods ended December 31, 2023, and December 31, 2022 inclusive of discontinued operations.

 

   Goodwill 
December 31, 2021  $10,050,277 
Goodwill recognized in connection with Medigap acquisition   19,199,008 
Goodwill recognized in connection with Barra acquisition   4,236,822 
Goodwill impairment (Medigap) during the year-ended December 31, 2022   (14,373,374)
December 31, 2022   19,112,733 
Goodwill impairment (Medigap) during the year ended December 31, 2023   (4,825,634)
Goodwill impairment recognized as of December 31, 2023   (7,594,000)
December 31, 2023  $6,693,099 

 

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2023:

  

   Weighted Average Remaining Amortization period (Years)   Gross Carrying Amount   Accumulated Amortization  

Net

Carrying Amount

 
Trade name and trademarks   1.5   $1,807,189   $(1,320,939)  $486,250 
Internally developed software   3.2    1,798,922    (650,029)   1,148,893 
Customer relationships   8.0    11,922,290    (3,193,629)   8,728,661 
Purchased software   0.3    667,206    (618,418)   48,788 
Video Production Assets   -    50,000    (50,000)   - 
Non-competition agreements   0.9    3,504,810    (2,874,645)   630,165 
Trade name and trademarks       $19,750,417   $(8,707,660)  $11,042,757 

 

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2022:

 

   Weighted Average Remaining Amortization period (Years)   Gross Carrying Amount   Accumulated Amortization  

Net

Carrying Amount

 
Trade name and trademarks   4.4   $1,806,188   $(969,241)  $836,947 
Internally developed software   4.1    1,635,178    (287,990)   1,347,188 
Customer relationships   9.0    11,922,290    (2,076,086)   9,846,204 
Purchased software   0.4    665,137    (581,497)   83,640 
Video Production Assets   0.0    50,000    (50,000)   - 
Non-competition agreements   1.9    3,504,810    (2,179,420)   1,325,390 
        $19,583,603   $(6,144,234)  $13,439,369 

 

Amortization expense is $2,563,559 and $2,525,880 for the years ended December 31, 2023 and 2022, respectively.

 

 F-22 

 

 

The following table reflects expected amortization expense as of December 31, 2023, for each of the following five years and thereafter:

 

Years ending December 31,  Amortization Expense 
2024  $2,195,191 
2025   1,801,235 
2026   1,532,267 
2027   1,196,989 
2028   1,097,825 
Thereafter   3,218,683 
Total  $11,042,757 

 

NOTE 7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Significant components of accounts payable and accrued liabilities were as follows:

 

  

December 31,

2023

  

December 31,

2022

 
         
Accounts payable,  $635,339   $747,469 
Accrued expenses   40,540    109,502 
Accrued credit card payables   54,416    58,120 
Other accrued liabilities   105,188    36,291 
Accounts payable and other accrued liabilities  $835,483   $951,382 

 

NOTE 8. LONG-TERM DEBT

 

The composition of the long-term debt follows:

 

  

December 31,

2023

  

December 31,

2022

 
         
Oak Street Funding LLC Term Loan  $369,602   $426,883 
Oak Street Funding LLC Term Loan for the acquisition of EBS and USBA, variable interest of Prime Rate plus 2.5%, maturing August 2028, net of deferred financing costs of $10,069 and $12,388 as of December 31, 2023 and 2022, respectively  $369,602   $426,883 
Oak Street Funding LLC Senior Secured Amortizing Credit Facility for the acquisition of CCS, variable interest of Prime Rate plus 1.5%, maturing December 2028, net of deferred financing costs of $12,525 and $15,076 as of December 31, 2023 and 2022, respectively   604,830    693,682 
Oak Street Funding LLC Term Loan for the acquisition of SWMT, variable interest of Prime Rate plus 2.0%, maturing April 2029 net of deferred financing costs of $7,733 and $9,206 as of December 31, 2023 and 2022, respectively   695,758    788,596 
Oak Street Funding LLC Term Loan for the acquisition of FIS, variable interest of Prime Rate plus 2.0%, maturing May 2029, net of deferred financing costs of $31,026 and $36,843 as of December 31, 2023 and 2022, respectively   1,758,558    1,987,846 
Oak Street Funding LLC Term Loan for the acquisition of ABC, variable interest of Prime Rate plus 2.0%, maturing September 2029, net of deferred financing costs of $35,649 and $42,129 as of December 31, 2023 and 2022, respectively   2,899,409    3,249,575 
Oak Street Funding LLC Term Loan, variable interest of Prime Rate plus 2.5%, maturing May 2032, for the acquisition of Barra, net of deferred financing costs of $176,762 and $198,188 as of December 31, 2023 and December 31, 2022, respectively   6,089,580    6,321,812 
Long term debt gross   12,417,737    13,468,394 
Less: current portion   (1,390,766)   (1,118,721)
Long-term debt  $11,026,971   $12,349,673 

 

 F-23 

 

 

Oak Street Funding LLC – Term Loans and Credit Facilities

 

During the year of 2018 the Company entered into two debt agreements with Oak Street Funding LLC (“Oak Street”). On August 1, 2018, EBS and USBA entered into a Credit Agreement with Oak Street whereby EBS and USBA borrowed $750,000 from Oak Street under a Term Loan. The Term Loan is secured by certain assets of the Company. Interest accrues at 11.00% on the basis of a 360-day year, maturing 120 months from the Amortization Date (September 25, 2018). The Company incurred debt issuance costs associated with the Term Loan in the amount of $22,188. On December 7, 2018, CCS entered into a Facility with Oak Street whereby CCS borrowed $1,025,000 from Oak Street under a senior secured amortizing credit facility. The borrowing rate under the Facility is a variable rate equal to Prime +1.50% and matures 10 years from the closing date. The Company incurred debt issuance costs associated with the Facility in the amount of $25,506, which were deferred and are amortized over the length of the Facility.

 

During the year of 2019 the Company entered in a number of Credit Agreements with Oak Street whereby the Company borrowed a total amount of $7,912,000 under the Term Loans. The Term Loans are secured by certain assets of the Company. The borrowing rates under the Facility is a variable rate equal to Prime + 2.00% and matures 10 years from the closing date. The Company recorded debt issuance costs associated with the loans in total of $181,125.

 

On April 26, 2022 the Company entered into a secured promissory note (the Note) with Oak Street subject to the terms of the Master Credit Agreement, whereby the Company borrowed $6,250,000 with a maturity date of May 25, 2032. The Note is secured by certain assets of the Company and subject to certain financial covenants. Interest accrues at the Prime Rate plus an Applicable Margin of 2.500% on the basis of a 360-day year. The Company incurred debt issuance costs associated with the Note of $214,257.

 

Aggregated cumulative maturities of long-term obligations (including the Term Loan and the Facility), excluding deferred financing costs, as of December 31, 2023 are:

  

Fiscal year ending December 31, 

Maturities of

Long-Term Debt

 
2024  $1,390,766 
2025   1,552,772 
2026   1,729,160 
2027   1,925,603 
2028   2,107,128 
Thereafter   3,986,172 
Total   12,691,601 
Less debt issuance costs   (273,864)
Total  $12,417,737 

 

Short-Term Financings

 

The Company has various short-term notes payable for financed items such as insurance premiums and CRM software purchases. Total financed for the year ended December 31, 2023 and 2022 respectively was approximately $181,000 and $482,000. These are normally paid in equal installments over a period of twelve months or less and carry interest rates ranging between 12.75% and 0% per annum. As of December 31, 2023 and 2022, approximately $56,000 and $154,000 remains outstanding on short-term financings.

 

 F-24 

 

 

NOTE 9. WARRANT LIABILITIES

 

Series B Warrants

 

On December 22, 2021, the Company entered into a securities purchase agreement (SPA) with two institutional investors for the purchase and sale of (i) warrants to purchase up to an aggregate of 651,997 shares of the Company’s common stock, par value $0.086 per share at an exercise price of $61.35 per share, (ii) an aggregate of 178,060 shares of Common Stock, and (iii) 9,076 shares of the Company’s newly-designated Series B convertible preferred stock, par value $0.086 per share, with a stated value of $1,000 per share, initially convertible into an aggregate of 147,939 shares of Common Stock at a conversion price of $61.35 per share, each a freestanding financial instrument, (the “Private Placement”). The aggregate purchase price for the Common Shares, the Preferred Shares and the Warrants was approximately $20,000,000.

 

By entering into the Private Placement on December 22, 2021, the Company entered into a commitment to issue the Common Shares, Preferred Shares, and Series B Warrants on the Initial Closing Date for a fixed price and exercise price, as applicable. The commitment to issue Series B Warrants (the “Warrant Commitment”) represents a derivative financial instrument, other than an outstanding share, that, at inception, has both of the following characteristics: (i) embodies a conditional obligation indexed to the Company’s equity. The Company classified the commitment to issue the warrants as a derivative liability because it represents a written option that does not qualify for equity accounting The Company initially measured the derivative liability at its fair value and will subsequently remeasure the derivative liability, at fair value with changes in fair value recognized in earnings. An option pricing model was utilized to calculate the fair value of the Warrant Commitment. The Company initially recorded $17,408,311 of non-operating unrealized losses within the recognition and change in fair value of warrant liabilities account for the year ended December 31, 2021.

 

The Private Placement closed on January 4, 2022, at which time the Company remeasured the derivative liability for the warrants issued in the transaction, recognizing $17,408,311 of non-operating unrealized losses and a derivative liability of $55,061,119. The closing of the Private Placement settled the subscription receivable reported on the Company’s balance sheet as of December 31, 2021.

 

Pursuant to the terms of the SPA, due to a non-Private Placement related dilutive share issuance, effective December 27, 2022, the Series B Warrants outstanding increased to 1,333,333 and the exercise price reset to $7.50. On December 27, 2022, 1,667 Series B Warrants were exercised into 1,667 shares of common stock with cash proceeds to the Company of $12,500. Pursuant to a number of dilutive issuances throughout fiscal year 2023, as of December 31, 2023, the exercise price in effect was $0.63.

 

On December 12, 2023, the Company entered into an agreement with one of the SPA institutional investors, pursuant to which (i) the Company extended the expiration date of their 866,667 remaining outstanding Series B Warrants to December 28, 2028 and (ii) institutional investor waived a restriction in the SPA such that the Company will be permitted to consummate an “at-the-market offering” with a registered broker-dealer, whereby such registered broker-dealer is acting as principal or agent in the purchase of shares (the “ATM”) of the Company’s common stock from the Company after sixty (60) days following December 14, 2023. Further, on December 12, 2023, the Company entered into an exchange offer with the other SPA institutional investor, pursuant to which the investor exchanged its remaining Series B Warrants to purchase 300,000 shares of Common Stock for 300,000 shares of Common Stock.

 

For the years ended December 31, 2023 and 2022, net fair value gains recognized for the Series B Warrants were $5,534,931 and $48,668,869 respectively, presented in the recognition and change in fair value of warrant liabilities account in the consolidated statements of operations. The Series B Warrant liability outstanding as of December 31, 2023 and 2022 is $268,667 and $6,384,250 respectively, presented in the warrant liability account on the consolidated balance sheets and there remain 866,667 of Series B Warrants outstanding.

 

Placement Agent Warrants

 

In connection with the Private Placement, the Company issued 16,303 warrants to the placement agent for the Private Placement. The warrants were issued as compensation for the Placement Agent’s services. The Placement Agent Warrants (PAW) are: (i) exercisable on any day after the six (6) month anniversary of the issue date, (ii) expire five years after the closing of the Private Placement, and (iii) exercisable at $61.35 per share. The Placement Agent Warrants contain terms that may require the Company to transfer assets to settle the warrants. Therefore, the Placement Agent Warrants are classified as a derivative liability, initially measured at fair value of $1,525,923 on the date of issuance and will be remeasured each accounting period with the changes in fair value reported in earnings. The Placement Agent Warrants are considered financing expense fees paid to the Placement Agent in relation to a derivative liability measured at fair value, thus, are included along with non-operating unrealized gains and losses in the recognition and change in fair value of warrant liabilities account in the consolidated statements of operations.

 

 F-25 

 

 

For the years ended December 31, 2023 and 2022, net fair value gains recognized for the PAW were, $48,575 and $1,477,024 respectively, presented in the recognition and change in fair value of warrant liabilities account in the consolidated statements of operations. The PAW liability outstanding as of December 31, 2023 and 2022 is $325 and $48,900 respectively, presented in the warrant liability account on the consolidated balance sheets.

 

NOTE 10. SIGNIFICANT CUSTOMERS

 

Carriers representing 10% or more of total revenue are presented in the table below:

 

Insurance Carrier 

December 31,

2023

  

December 31,

2022

 
Priority Health   35%   32%
BlueCross BlueShield   15%   14%

 

No other single insurance carrier accounted for more than 10% of the Company’s commission revenues. The loss of any significant customer could have a material adverse effect on the Company.

 

NOTE 11. EQUITY

 

Preferred Stock

 

The Company has been authorized to issue 750,000,000 shares of $0.086 par value Preferred Stock. The Board of Directors is expressly vested with the authority to divide any or all of the Preferred Stock into series and to fix and determine the relative rights and preferences of the shares of each series so established, within certain guidelines established in the Articles of Incorporation.

 

In January 2022, the Company issued 9,076 shares of its newly designated Series B convertible preferred stock through the Private Placement for the purpose of raising capital. The Series B convertible preferred stock have no voting rights and initially each share may be converted into 16 shares of the Company’s common stock. The holders of the Series B convertible preferred stock are not entitled to receive any dividends other than any dividends paid on account of the common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder) to common stock which amounts shall be paid pari-passu with all holders of common stock.

 

During August 2022, all 9,076 Series B Convertible Preferred Stock were converted by third parties into 147,939 shares of common stock and as of December 31, 2023 and 2022 none remain outstanding.

 

 F-26 

 

 

Common Stock

 

The Company has been authorized to issue 2,000,000,000 shares of common stock, $0.086 par value. Each share of issued and outstanding common stock shall entitle the holder thereof to fully participate in all shareholder meetings, to cast one vote on each matter with respect to which shareholders have the right to vote, and to share ratably in all dividends and other distributions declared and paid with respect to common stock, as well as in the net assets of the corporation upon liquidation or dissolution.

 

In January 2022, the Company issued 178,060 shares of common stock through the Private Placement for the purpose of raising capital. See Note 9 - Warrant Liabilities for proceeds received by the Company.

 

In January 2022, the Company issued 40,402 shares of common stock pursuant to the Medigap Acquisition.

 

In January 2022, upon agreement with Series A warrant holders, 25,000 warrants were exercised at a price of $99.00 into 25,000 shares of the Company’s common stock.

 

In March 2022, the Company issued 400 shares of the Company’s common stock due to the vesting of 400 stock awards pursuant to an employee agreement.

 

In May and June 2022, 218,462 Series C prepaid warrants were exchanged for 218,462 shares of the Company’s common stock.

 

In July 2022, 81,423 Series D prepaid warrants were exchanged for 81,423 shares of the Company’s common stock.

 

In December 2022, the Company issued 14,275 shares of the Company’s common stock due to the vesting of 14,275 stock awards pursuant to several employee agreements.

 

 F-27 

 

 

In December 2022, upon agreement with Series B warrant holders, 1,667 warrants were exercised at a price of $7.50 into 1,667 shares of the Company’s common stock with cash proceeds to the Company of $12,500.

 

In January 2023, the Company issued 109,358 shares of the Company’s common stock to settle two earn-out liabilities.

 

On February 23, 2023, pursuant to authority granted by the Board of Directors of the Company, the Company implemented a 1-for-15 reverse split of the Company’s authorized and issued and outstanding common stock (the “Reverse Split-2023”). The par value remains unchanged. All share and per share information as well as common stock and additional paid-in capital have been retroactively adjusted to reflect the Reverse Split-2023 for all periods presented, unless otherwise indicated. The split resulted in a rounding addition of approximately 15,300 shares valued at par, totaling $1,300.

 

In February 2023, Yes Americana, a related party, converted $645,000 of its outstanding convertible debt into 66,743 shares of the Company’s common stock. The conversion considered the fair market value of the stock on the day of conversion of $9.67 for the total of 66,743 shares.

 

In March 2023, the Company issued 155,038 shares of the Company’s common stock in conjunction with the Private Placement-2023 as defined and discussed further below.

 

During the second quarter of 2023, the Company issued from its common stock, 112,557 shares in lieu of services provided, 352,260 shares to settle an earn-out liability and 22,219 shares pursuant to vested restricted stock awards earned by agents through an equity-based compensation program at one of the Company’s subsidiaries.

 

During the third quarter of 2023, the Company issued from its common stock, 174,610 shares to settle an earn-out liability, 400 shares in lieu of services provided, 3,017 shares to employees for vested stock awards, and 73,264 for Series B Warrants exercised.

 

During the fourth quarter of 2023, the Company issued from its common stock, 897,594 and 371,000 shares for Series E and Series F warrant exercises, respectively, 741,360 for share based compensation, 147,645 shares in lieu of services, and 300,000 shares for Series B Warrants exchanged.

 

As of December 31, 2023 and December 31, 2022, there were 4,761,974 and 1,219,573 shares of Common Stock outstanding, respectively.

 

Warrants

 

Series A Warrants

 

In conjunction with the Company’s initial public offering, the Company issued 2,070,000 Series A Warrants which were classified as equity warrants because of provisions, pursuant to the warrant agreement, that permit the holder obtain a fixed number of shares for a fixed monetary amount. The warrants are standalone equity securities that are transferable without the Company’s consent or knowledge. The warrants were recorded at a value per the offering of $0.15. The warrants may be exercised at any point from the effective date until the 5-year anniversary of issuance, on or around February 8, 2026, and are not subject to antidilution provisions. In January 2022, 375,000 Series A Warrants were exercised into 25,000 shares of common stock.

 

In November 2023 the Series A Warrant holders voted and approved an amendment to the Series A Warrant agreement pursuant to which the warrants were issued, and reduced the exercise price from the stated $6.60 (post-Reverse Split-2023 effective exercise price of $99.00) per share to $6.13 per share, subject to adjustment.

 

As of both December 31, 2023 and December 31, 2022, 1,695,000 Series A Warrants remain outstanding, exercisable into 113,000 shares of common stock.

 

 F-28 

 

 

Series C and D Warrants

 

In January 2022, as a result of the Private Placement and the Medigap Acquisition, the Company received a deficiency notification from Nasdaq indicating violation of Listing Rule 5365(a). As part of its remediation plan, in March 2022, the Company entered into Exchange Agreements with the holders of common stock issued in January 2022. Pursuant to the Exchange Agreements, the Company issued 218,462 Series C prepaid warrants in exchange for 218,462 shares of the Company’s common stock. Additionally, as compensation for entering into the Exchange Agreements, the Company issued 81,500 Series D prepaid warrants to the Private Placement investors for no additional consideration. The fair value of the Series D prepaid warrants was treated as a deemed dividend and accordingly treated as a reduction from income available to common stockholders in the calculation of earnings per share. Refer to Note 12, Earnings (Loss) Per Share for additional information.

 

The Series C and D Warrants are equity classified pursuant to the warrant agreement provisions that permit holders to obtain a fixed number of shares for a fixed monetary amount. The warrants are standalone equity securities that are transferable without the Company’s consent or knowledge. The warrants expire on the fifth anniversary of the respective issuance dates and are exercisable at a per share exercise price equal to $0.015.

 

In May and June 2022, the 218,462 Series C prepaid warrants were converted for 218,462 shares of the Company’s common stock for a conversion price of $0.015. Through December 31, 2022, the Company has received payments of $1,336 for these issuances.

 

In July 2022, 81,423 Series D prepaid warrants were converted into 81,472 shares of the Company’s common stock for a conversion price of $0.015 through both cash and cashless exercises. Proceeds of $795 were received in conjunction with the cash exercise.

 

Series E, F & G Warrants, and

Abeyance Shares

 

On March 13, 2023, the Company entered into a securities purchase agreement (the “SPA-2023”) with one institutional buyer for the purchase and sale of, (i) an aggregate of 155,038 shares (the “Common Shares”) of the Company’s common stock, par value $0.086 per share (the “Common Stock”) along with accompanying common warrants (the “Common Units”), (ii) prefunded warrants (the “Prefunded Warrants” or “Series E Warrants”) that are exercisable into 897,594 shares of Common Stock (the “Prefunded Warrant Shares”) along with accompanying common warrants (the “Pre-Funded Units”), and (iii) common warrants (the “Common Warrants” or “Series F Warrants”) to initially acquire up to 2,105,264 shares of Common Stock (the “Common Warrant Shares”) (representing 200% of the Common Shares and Prefunded Warrant Shares) in a private placement offering (the “Private Placement-2023”). Additionally, the Company agreed to issue a warrant to the Placement Agent (defined below), to initially acquire 52,632 shares of common stock (the “PA Warrant”) and entered into a registration rights agreement with the buyer to register for resale the common shares underlying the Series E and F Warrants.

 

The aggregate purchase price for the Common Shares, Prefunded Warrants (Series E Warrants) and the Common Warrants (Series F Warrants) to be purchased by the Buyer shall be equal to (i) $3.80 for each Common Unit purchased by such Buyer, or (ii) $3.799 for each Prefunded Unit purchased by the Buyer, which Prefunded Warrants are exercisable into Prefunded Warrant Shares at the initial Exercise Price (as defined in the Prefunded Warrant) of $0.001 per Prefunded Warrant Share in accordance with the Prefunded Warrant.

 

The Common Warrant (Series F) has an exercise price of $3.55 per share, subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the date of the Private Placement-2023. The Common Warrant will be exercisable six months following the date of issuance and will expire five and a half years from the date of issuance.

 

The PA Warrant has an exercise price of $3.91 per share, subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the date of the SPA-2023. The PA Warrant will be exercisable six months following the date of issuance and will expire five years from the date of issuance.

 

 F-29 

 

 

The closing of the Private Placement-2023 occurred on March 16, 2023. EF Hutton, a division of Benchmark Investments, LLC (the “Placement Agent”) acted as the sole placement agent and was entitled to an 8% of gross proceeds cash fee and the reimbursement of certain Placement Agent fees and customary expenses.

 

Gross and net proceeds to the Company from the Private Placement-2023 were approximately $4 million and $3.4 million respectively, to be utilized primarily for general working capital and administrative purposes. Direct financing fees approximated $553,000.

 

The Company determined the Series E Warrants, Series F Warrants, and PA Warrants are equity in nature because of provisions, pursuant to the warrant agreements, that permit the holder to obtain a fixed number of shares for a fixed monetary amount. The values offset to $0 in additional paid-in capital in the Company’s condensed consolidated statements of stockholders’ equity (deficit).

 

On December 12, 2023, the Company entered into that certain Inducement Offer to Exercise Series F Warrants to Subscribe for Common Shares with the institutional investor (the “Series F Inducement Agreement”), pursuant to which (i) the Company agreed to lower the exercise price of the Series F Warrants to $0.6562 per share (which is equal to the Nasdaq minimum price) (the “Nasdaq Minimum Price”) and (ii) the institutional buyer agreed to exercise the Series F Warrants to purchase 2,105,264 shares of Common Stock into 2,105,264 shares of Common Stock (the “Exercise Shares”) by payment of the aggregate exercise price of approximately $1,381,474, gross of $351,503 of expenses, including but not limited to EF Hutton LLC, who acted as placement agent in connection therewith, resulting in $1,029,972 in net proceeds to the Company. The closing occurred on December 14, 2023 (the “Closing Date”). The Exercise Shares were all exercised, resulting in the issuance of 371,000 shares, and 1,734,264 shares held in abeyance (the “Abeyance Shares”) due to the 9.99% beneficial ownership limitation stipulated in the Series F Inducement Agreement. The Company accounted for the exercise price decrease inducement as a modification which resulted in a deemed dividend of $302,997 recorded as an increase and decrease to the additional paid-in capital account, in the consolidated balance sheets and statements of stockholders’ equity (deficit) as of December 31, 2023. The Company valued (a) the fair value of the 2,105,264 warrants immediately before exchange in the amount of $1,103,377, (b) the fair value of the warrants immediately after the exchange in the amount of $800,380, and (c) recorded the difference as a deemed dividend in the amount of $302,997. The warrants were valued using the Black-Scholes option pricing model using the following assumptions: a) fair value of common stock of $0.6562, b) exercise prices of $3.55 pre-exchange and $0.6562 post-exchange, c) term of 4.77 years pre-exchange and post-exchange, d) dividend rate of 0%, e) volatility of 112% pre-exchange and post-exchange, and f) risk free interest rate of 4.23% pre-exchange and post-exchange.

 

Further, pursuant to the Series F Inducement Agreement, the Company issued a new unregistered Series G common share purchase warrant (the “Series G Warrant”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended to purchase 4,210,528 shares of Common Stock at an initial exercise price equal to $0.6562, but subject to a 4.99% beneficial ownership limitation. The Series G Warrant termination date is December 12, 2028. The Company’s accounting for the Series G Warrant resulted in a deemed dividend of $2,236,760 recorded as an increase and decrease to the additional paid-in capital account, in the consolidated balance sheets and statements of stockholders’ equity (deficit) as of December 31, 2023. The warrants were valued using the Black-Scholes option pricing model with the following assumptions: a) fair value of common stock of $0.6562, b) exercise price of $0.6562, c) term of 5 years, d) dividend rate of 0%, e) volatility of 112%, and f) risk free interest rate of 4.23%.

 

As of December 31, 2023:

 

Series E: There remains no Series E Warrants outstanding pursuant to exercises occurring throughout the fiscal year of 897,594 warrants exercised into 897,594 shares of the Company’s common stock for a net of $898 in cash proceeds.
Series F: There remain no Series F Warrants outstanding pursuant to the Series F Inducement Agreement.
Series G: There remain 4,210,528 Series G Warrants outstanding.
Abeyance Shares: There remain 1,734,264 unissued Abeyance Shares outstanding.

 

Subsequent to December 31, 2023, during the first quarter of 2024, upon request from the institutional investor, the Company converted 723,264 Abeyance Shares into Common Stock, thereby issuing 723,264 of Common Stock, resulting in a remaining 1,011,000 outstanding Abeyance Shares. During the second quarter of 2024, the institutional investor requested the Company convert the remaining 1,011,000 Abeyance Shares into Common Stock. The Company has yet to issue any shares in reference to this request but does intend to issue them during the remaining period of the second quarter of 2024. Upon and post issuance of these shares, there will be no remaining Abeyance Shares outstanding.

 

Equity Incentive Plans

 

2019 Equity Incentive Plan. During the year ended December 31, 2019, the Company adopted the Reliance Global Group, Inc. 2019 Equity Incentive Plan (the “2019 Plan”) under which various forms of equity awards can be granted to employees, directors, consultants, and service providers. Awards include but are not limited to, restricted stock, restricted stock units, performance shares and stock options. A total of 46,667 shares of common stock were reserved for issuance under the 2019 Plan. As of December 31, 2023, after considering 2019 Plan shares held for outstanding options, there remains no additional capacity for further awards. As of the same date, there are 10,928 options outstanding with a weighted average exercise price of $232.55 and weighted average remaining contractual life of 0.57 years. The Company issues new shares of common stock for any option exercises, from its shares available under either its 2019 Plan or 2023 Plan (as defined below).

 

 F-30 

 

 

2023 Equity Incentive Plan. On August 10, 2023, the Company adopted, the Reliance Global Group, Inc. 2023 Equity Incentive Plan (the “2023 Plan”, and together with the 2019 Plan, the “Plans”). The purpose of the 2023 Plan is to provide a means through which the Company and its subsidiaries may attract and retain key personnel, and to provide a means whereby directors, officer, employees, consultants, and advisors of the Company and its subsidiaries can acquire and maintain an equity interest in the Company, or be paid incentive compensation, thereby strengthening their commitment to the welfare of the Company and its subsidiaries and aligning their interests with those of the Company’s stockholders. The 2023 Plan provides for various stock-based incentive awards, including incentive and nonqualified stock options, stock appreciation rights (“SARs”), restricted stock and restricted stock units (“RSUs”), and other equity-based or cash-based awards. It became effective on August 10, 2023 and will terminate on August 10, 2033, unless the Compensation Committee terminates it earlier. A total of 800,000 shares of Common Stock were reserved for issuance under the 2023 Plan, and as of December 31, 2023 there were no new options granted, and there remain 47,080 shares available for issuance.

 

Administration of the Plans. The Plans are administered by the Compensation Committee of the Board. The Compensation Committee is authorized to select from among eligible employees, directors, and service providers those individuals to whom shares and options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Compensation Committee is also authorized to prescribe, amend, and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any shares and options granted hereunder is within the discretion of the Compensation Committee.

 

Stock Options: The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees, non-employee directors, consultants, and service providers are eligible to receive options which are not ISOs, i.e. “Non-Statutory Stock Options.” The options granted by the Compensation Committee in connection with its adoption of the Plans were Non-Statutory Stock Options.

 

The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option.

 

The following is a summary of the stock options granted, forfeited or expired, and exercised under the Plans for the years ended December 31, 2023 and 2022 respectively:

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years)   Aggregate Intrinsic Value 
Outstanding at December 31, 2022   10,928   $232.55    1.61   $        - 
Granted   -    -    -    - 
Forfeited or expired   -    -    -    - 
Exercised   -    -    -    - 
Outstanding at December 31, 2023   10,928   $232.55    0.61    - 

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years)   Aggregate Intrinsic Value 
Outstanding at December 31, 2021   10,928   $232.55    2.61   $                - 
Granted   -    -    -    - 
Forfeited or expired   -   $-    -    - 
Exercised   -    -    -    - 
Outstanding at December 31, 2022   10,928   $232.55    1.61    - 

 

 F-31 

 

 

The following is a summary of the Company’s non-vested stock options as of December 31, 2023 and 2022 respectively:

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years) 
Non-vested at December 31, 2022   271   $236.83    2.27 
Granted   -    -    - 
Vested   (248)   239.68    0.81 
Forfeited or expired   -    -    - 
Non-vested at December 31, 2023   23   $205.70    1.59 

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years) 
Non-vested at December 31, 2021   3,587   $227.78    0.90 
Granted   -    -    - 
Vested   (3,315)   14.89    1.71 
Forfeited or expired   -    -    - 
Non-vested at December 31, 2022   271   $236.83    2.27 

 

For the years ended December 31, 2023 and 2022, the Board did not approve any options to be issued pursuant to the Plan.

 

During the years ended December 31, 2023 and 2022, no employee terminations occurred resulting in option forfeitures of $0.

 

As of December 31, 2023, the Company determined that the options granted and outstanding had a total fair value of $2,421,960. The options will be amortized in future periods through February 2024. During the year ended December 31, 2023, the Company recognized $15,624 of compensation expense relating to the stock options granted to employees, directors, and consultants. As of December 31, 2023, unrecognized compensation expense totaled $1,542 which will be recognized on a straight-line basis over the vesting period or requisite service period through February 2024.

 

The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on December 31, 2023. The market value as of December 31, 2023 was $0.54 based on the closing bid price for December 31, 2023.

 

As of December 31, 2022, the Company determined that the options granted and outstanding had a total fair value of $2,421,960. The options will be amortized in future periods through February 2024. During the year ended December 31, 2022, the Company recognized $178,579 of compensation expense relating to the stock options granted to employees, directors, and consultants. As of December 31, 2022, unrecognized compensation expense totaled $17,166 which will be recognized on a straight-line basis over the vesting period or requisite service period through February 2024.

 

The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on December 31, 2022. The market value as of December 31, 2022 was $8.55 based on the closing bid price for December 31, 2022.

 

 F-32 

 

 

The Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes option-pricing models require the Company to make predictive assumptions regarding future stock price volatility, recipient exercise behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the expected term of the option. The expected term of the options was computed by taking the mid-point between the vesting date and expiration date. The following assumptions were used in the Black-Scholes option-pricing model, not accounting for the reverse splits:

 

   

Year Ended

December 31, 2023

   

Year Ended

December 31, 2022

 
Exercise price   $ 0.16 - $0.26     $ 0.16 - $0.26  
Expected term     3.25 to 3.75 years       3.25 to 3.75 years  
Risk-free interest rate     0.38% - 2.43 %     0.38% - 2.43 %
Estimated volatility    

293.07% - 517.13

%     293.07% - 517.13 %
Expected dividend     -       -  

 

Stock Awards

 

The Plans provide for various forms of stock awards. During the years ended December 31, 2023, and 2022, certain directors, executives and employees were granted equity awards which vested immediately. Respectively, 758,026 and 12,460 shares were awarded and issued, valued at $477,556 and $766,250, presented in the salaries and wages (for executives and employees) and general and administrative (for directors) accounts in the consolidated statements of operations.

 

Pursuant to an agreement in April 2022, further amended in October 2022 between the Company and an executive, the executive was granted 7,418 restricted shares of the Company’s common stock which vest quarterly over a three-year period. The shares granted were valued at $180,546 at the date of the grant. For the years ended December 31, 2023, and 2022 respectively, 3,908 and 667 shares have been issued under the agreement, and compensation expense was $83,464 and $32,131, presented in the salaries and wages account in the consolidated statements of operations.

 

Pursuant to a grant award agreement effective December 28, 2022 between the Company and an executive, the executive was granted an annual award of 2,667 shares of the Company’s common stock to vest monthly each year throughout the duration of employment. The grant value for the years ended December 2023 and 2022 respectively was, $22,404 and $241 and recorded as compensation expense, presented in the salaries and wages account in the consolidated statements of operations. For the years ended December 31, 2023, and 2022 respectively, 2,695 and 0 shares have been issued under the agreement.

 

Pursuant to an equity-based commission compensation program at one of the Company’s subsidiaries which provides down-line agents the ability to earn and receive restricted stock awards upon completion of agreed upon service requirements, the Company grants annual restricted stock awards which have vesting or other restrictions of up to twelve months. For the years ended December 31, 2023 and 2022 respectively, 22,221 and 0 shares were issued under the program, and commission equity award expense was, $276,400 and 249,650, presented in the commission expense account in the consolidated statements of operations.

 

Total equity-based compensation for the years ended December 31, 2023 and 2022 was approximately $875,000 and $1,250,000, respectively.

 

NOTE 12. EARNINGS (LOSS) PER SHARE

 

Basic earnings per common share (“EPS”) applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted-average number of common shares outstanding.

 

 F-33 

 

 

The following calculates basic and diluted EPS:

 

   2023   2022 
   For the Years Ended December 31, 
   2023   2022 
(Loss) income from continuing operations  $(10,025,268)  $21,561,932 
Deemed dividend   (2,539,757)   (6,930,335)
(Loss) income from continuing operations, numerator, basic   (12,565,025)   14,631,597 
(Loss) income from continuing operations, numerator, diluted  $(12,565,025)  $14,631,597 
           
Weighted average common shares, basic   2,820,275    1,094,781 
Effect of weighted average vested stock awards   -    208 
Diluted weighted average shares outstanding   2,820,275    1,094,989 
Basic (loss) income loss per common share from continuing operations:  $(4.46)  $13.36 
Diluted (loss) income per common share from continuing operations:  $(4.46)  $13.36 

 

Additionally, the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common share:

 

   2023   2022 
   For the years ended December 31, 
   2023   2022 
Shares subject to outstanding common stock options   10,928    10,928 
Shares subject to outstanding Series A warrants   113,000    113,000 
Shares subject to outstanding Series B Warrants and PAW   

882,970

    1,347,970 
Shares subject to outstanding Series G warrants and PA Warrants   

4,263,160

    - 
Shares subject to unvested stock awards   

3,709

    6,576 

 

NOTE 13. LEASES

 

Operating Leases

 

ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. The standard requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease, initially measured at the present value of the lease payments. The Company’s leases consist of operating leases on buildings and office space.

 

In accordance with ASU 2016-02, right-of-use assets are amortized over the life of the underlying leases. Lease expense for the years ended December 31, 2023 and 2022 was $534,404 and $598,422, respectively. As of December 31, 2023 and 2022, the weighted average remaining lease term and weighted average discount rates for the operating leases were 3.92 years and 6.08% and 3.82 years and 5.67% respectively.

 

Future minimum lease payment under these operating leases consisted of the following:

 

Year ending December 31, 

Operating Lease

Obligations

 
2024  $320,420 
2025   153,831 
2026   113,738 
2027   117,150 
2028   120,665 
Thereafter   30,387 
Total undiscounted operating lease payments   856,191 
Less: Imputed interest   (86,685)
Present value of operating lease liabilities  $769,506 

 

 F-34 

 

 

NOTE 14. COMMITMENTS AND CONTINGENCIES

 

Legal Contingencies

 

The Company is subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly, $0 legal contingencies are accrued as of December 31, 2023 and 2022. Litigation relating to the insurance brokerage industry is not uncommon. As such the Company, from time to time have been, subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future.

 

Earn-out liabilities

 

The Company has recognized several earn-out liabilities resulting from contingent consideration provisions included in business combination agreements. Earn-out consideration is normally earned by acquirees when they meet or exceed pre-agreed upon earnings targets.

 

The following outlines changes to the Company’s earn-out liability balances for the respective years ended December 31, 2023 and 2022:

 

    Fortman   Montana   Altruis   Kush   Barra   Total 
Ending balance December 31, 2022   $667,000   $500,001   $834,943   $147,534   $560,000   $2,709,478 
Payments    (1,433,700)   

(750,001

)   (929,168)   

(147,534

)   -    (3,260,403)

Estimate & fair value adjustments

   1,612,914    569,734    94,225    -    (560,000)   1,716,873 

Payable in Common Stock

   -     

(159,867

)   

-

    

-

    

-

    

(159,867

)

Reclass to loans payable, related parties*

   (846,214

)   -     

-

    

-

    

-

    

(846,214

)
Ending balance December 31, 2023   $-   $159,867   $-   $-   $-   $159,867 

 

   Fortman   Montana   Altruis   Kush   Barra   Total 
Ending balance December 31, 2021  $515,308   $615,969   $992,868   $1,689,733   $-   $3,813,878 
Business combinations   -    -    -    -    600,000    600,000 
Payments   (34,430)   (326,935)   (84,473)   (1,259,086)        (1,704,924)

Estimate & fair value adjustments

   186,122    210,967    (73,452)   (283,113)   (40,000)   524 
Ending balance December 31, 2022  $667,000   $500,001   $834,943   $147,534   $560,000   $2,709,478 

 

*As further described in the Note 16, Related Parties, the Company modified the Fortman contingent earn-out payable, entering into a fixed payment agreement, thus, the remaining open balance is reclassified to the loans payable, related parties account on the consolidated balance sheet as of December 31, 2023.

 

 F-35 

 

 

NOTE 15. INCOME TAXES

 

The difference between the actual income tax rate versus the tax computed at the Federal Statutory rate follows:

 

  

December 31,

2023

  

December 31,

2022

 
Federal rate   21.0%   21.0%
State net of federal   

8.9

%   -7.9%
Non-taxable change in fair value of warrant commitment   9.3%   -106.3%
Goodwill impairment   11.8%   46.7%
Rate Change   -0.2%   -4.1%
Other   0.0%   2.2%
Valuation allowance   -50.9%   48.5%
Effective income tax rate   0.0%   0.0%

 

The Company did not have any material uncertain tax positions. The Company’s policy is to recognize interest and penalties accrued related to unrecognized benefits as a component income tax expense (benefit). The Company did not recognize any interest or penalties, nor did it have any interest or penalties accrued as of December 31, 2023 and 2022.

 

Deferred income tax assets and (liabilities) consist of the following:

 

  

December 31,

2023

  

December 31,

2022

 
Deferred tax assets (liabilities)          
Net operating loss carryforward  $10,399,616   $4,938,164 
Equity-based compensation   1,462,901    1,148,836 
Goodwill   (332,159)   (771,631)
Intangibles   694,358    745,227 
Fixed assets   (151,775)   (99,002)
Right of use assets   (186,905)   (300,616)
Lease liabilities   194,403    313,342 
Other   4,027    1,525 
Total deferred tax assets   

12,084,466

    5,975,846 
Valuation allowance   (12,084,466)   (5,975,846)
Net deferred tax assets  $

-

   $- 

 

The Company has approximately $41.3 million of Federal Net Operating Loss Carry forwards, of which $1.3 million will begin to expire beginning 2031 and $40.0 million will not expire but are limited to use of 80% of current year taxable income.

 

The Company has approximately $34.8 million of state net operation loss carry forward to offset future taxable income in the states in which it currently operates. These carryforwards start expiring in 2029.

 

Internal Revenue Code Section 382 limits the ability to utilize net operating losses if a 50% change in ownership occurs over a three-year period. Such limitation of the net operating losses may have occurred, but we have not analyzed it at this time as the deferred tax asset is fully reserved.

 

During the year ended December 31, 2023 and 2022, the valuation allowance increased $6,108,620 and $3,140,780, respectively.

 

The tax periods ending December 31, 2020, 2021, and 2022 are open for examination.

 

NOTE 16. RELATED PARTY TRANSACTIONS

 

The Company entered into a Loan Agreement with Reliance Global Holdings, LLC (“Reliance Holdings”), a related party under common control. There is no term to the loan, and it bears no interest. Repayment will be made as the Company has business cash flows. The proceeds from the various loans were utilized to fund the acquisitions of USBA, EBS, CCS, SWMT Acquisition, Fortman, Altruis, and UIS. As of December 31, 2023, and the 2022 the Reliance Holdings related party loan payable balance was $0 and $100,724 respectively, and Reliance Holdings owned approximately 0% and 24% respectively, of the Company’s Common Stock.

 

 F-36 

 


 

The Company incurred a liability of $200,000 to an employee for a software purchased in July of 2019. The payable was issued with a $27,673 discount, utilizing a 7.5% discount rate. There are monthly payment terms of $4,167 through June 2024, the date of final settlement. The balance is carried at present value on the condensed consolidated balance sheets. The Company classifies amounts planned to be settled within twelve months from the balance sheet date to current liabilities. Accordingly, the Company presents current balances of $ 29,167 and $47,249 in the current portion of loans payables, related parties account in the condensed consolidated balance sheets as of December 31, 2023, and December 31, 2022. Non-current amounts are classified to the loans payable, related parties, less current portion account in the condensed consolidated balance sheets and amounted to $0 and $21,541 as of December 31, 2023, and December 31, 2022, respectively. Amortization expense to bring the payable to present value for the year ended December 31, 2023, was $6,918, and is classified to the interest expense, related parties account in the condensed consolidated statements of operations.

 

On September 13, 2022, the Company issued a promissory note to YES Americana Group, LLC (“Americana”) a related party entity beneficially owned by the Company’s Chief Executive Officer, for the principal sum of $1,500,000 (the “Note”), accruing monthly interest of 5% per annum beginning nine months after Note issuance. On February 7, 2023 , the Company and Americana entered into an amendment to the Note pursuant to which (i) the principal amount of the Note was increased to $1,845,000, (ii) the maturity date of the Note was amended to January 15, 2026, (iii) the interest rate under the Note shall not increase after the maturity date, and (iv) the Note can be converted at any time, at the option of Americana, into shares of the Company’s common stock, par value $0.086 per share at an agreed upon conversion price. On February 13, 2023, Americana effectuated a conversion of $645,000 of the Note into 66,743 shares of the Company’s common stock, $0.086 par value per share, in accordance with the terms of the Amendment. In addition, throughout the year of 2023 the Company repaid principal to Americana of $693,145. As of December 31, 2023, and December 31, 2022 respectively, the balance owed to Americana was $0 and $1,500,000, reclassified and recorded in the convertible debt, related parties, less current portion account in the condensed consolidated balance sheets. Interest expense for the year ended December 31, 2023, was $5,334, recorded to interest expense, related parties in the condensed consolidated statements of operations. Americana owned approximately 5.52% and 0.00% respectively, of the Company’s Common Stock as of December 31, 2023, and 2022 respectively.

 

Pursuant to the first amendment to the April 26, 2022 asset purchase agreement between the Company and Barra & Associates, LLC, a related party entity beneficially owned by a senior vice president of the Company, the Company agreed to pay a deferred purchase price (the “DPP”) of $1,375,000 by January 31, 2023, and all amounts unpaid thereafter will accrue interest at a rate of 1.5% per month until paid. The Company intends to fully repay all unpaid amounts inclusive of interest over the next two years. The Company classifies amounts planned to be settled within twelve months from the balance sheet date to current liabilities. Accordingly, the Company reclassifies and presents current balances of $233,504 and $1,375,000 respectively, in the current portion of loans payables, related parties account in the condensed consolidated balance sheets as of December 31, 2023 and December 31, 2022. Non-current amounts are classified to the loans payable, related parties, less current portion account in the condensed consolidated balance sheets and amounted to $247,055 and $0 as of December 31, 2023, and December 31, 2022 respectively. Interest expense for the year ended December 31, 2023 was $145,344, recorded to interest expense, related parties in the condensed consolidated statements of operations.

 

The Company, Fortman Insurance Services, LLC, Fortman Insurance Agency, LLC, Jonathan Fortman, and Zachary Fortman (collectively, the “Parties”) entered into a purchase agreement on or around May 1, 2019 (the “Purchase Agreement”), whereby the Company purchased the business and certain assets noted within the Purchase Agreement, as well as that certain second amendment to the Purchase Agreement on or around May 18, 2023 (the “Second Amendment”). On January 11, 2024, the Parties entered into that certain third amendment to the Purchase Agreement (the “Third Amendment”), pursuant to which the Parties agreed to a total remaining earn-out balance of $423,107 owed to both Jonathan Fortman and Zachary Fortman each under the Purchase Agreement, both employees and related parties to the Company, for a combined total earn-out amount owed of $846,214 (the “Remaining Balances”). In satisfaction of such Remaining Balances, the Company agreed to pay $11,000.00 on the first business day of each month to both Jonathan Fortman and Zachary Fortman each until the Remaining Balances are paid in full. In addition, the Parties agreed under the Third Amendment that the Remaining Balances shall accrue interest at the rate of 10% per annum until the Remaining Balances are paid in full, with an effective date of January 2, 2024, for purposes of the commencement of interest accrual. Since the Remaining Balances are final and no longer subject to contingencies, as of December 31, 2023 and the period then ended, they have been reclassified from the earn-out liability account to the loan payable, related parties, less current portion account in the amount of, $650,473 and the current portion of loans payables, related parties in the amount of, $195,741 and for the same period ended no interest has accrued.

 

NOTE 17. SUBSEQUENT EVENTS

 

On February 15, 2024, the Company entered into an At Market Issuance Sales Agreement (the “ATM Agreement”) with EF Hutton LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent, shares of its Common Stock (the “Shares”), having an aggregate offering price of up to $858,637. Any Shares offered and sold in the offering will be issued pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-275190), which was declared effective by the Securities and Exchange Commission on November 7, 2023, and the related prospectus supplement and accompanying base prospectus relating to the offering of the Shares. Under the Agreement, the Agent may sell Shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The offering of Shares pursuant to the Agreement will terminate upon the earlier of (i) the sale of all of the Shares subject to the Agreement, or (ii) the termination of the Agreement by the Agent or the Company, as permitted therein. The Company shall pay to the Agent in cash, upon each sale of Shares pursuant to the ATM Agreement, an amount equal to 3.5% of the gross proceeds from each sale of Shares. The Company will also reimburse the Agent for certain specified expenses in connection with entering into the Agreement. The Company has since sold 187,614 shares of Common Stock under the ATM Agreement, receiving proceeds, net of $4,634 Agent commissions, of $124,649.

 

 F-37 

 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

The following exhibits are filed or furnished with this Annual Report on Form 10-K.

 

Exhibit No.   Description
3.1   Amended and Restated Articles as filed on November 27, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 30, 2023)
     
3.2   Bylaws of Eye on Media Network, Inc. (now, Reliance Global Group, Inc.) (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on October 8, 2020 (File No. 333-249381)).
     
4.1   Form of Series C Warrant (incorporated herein by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2022 (SEC File No. 001-40020)).
     
4.2   Form of Series D Warrant (incorporated herein by reference to Exhibit 4.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2022 (SEC File No. 001-40020)).
     
4.3   Series G Common Stock Purchase Warrant dated as of December 12, 2023, by and between Reliance Global Group, Inc. and Armistice Capital Master Fund Ltd. (incorporated herein by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on December 13, 2023).
     
4.4*   Description of Capital Stock.
     
4.5   Form of Senior Indenture (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-3 (File No. 333-275190) filed on October 27, 2023).
     
4.6   Form of Subordinated Indenture (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-3 (File No. 333-275190) filed on October 27, 2023).
     
10.2   Irrevocable Assignment & Acquisition Agreement between Reliance Global Holdings, LLC and Ezra Beyman effective as of June 3, 2020 (incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on October 8, 2020 (File No. 333-249381)).
     
10.3   Lease between Coverage Consultants Unlimited, Inc. and Commercial Coverage Solutions, LLC dated August 17, 2020 (incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on Form S-1 (Amendment No. 3) filed with the Securities and Exchange Commission on January 28, 2021 (File No. 333-249381)).
     
10.4   Master Credit Agreement between Southwestern Montana Insurance Center, LLC and Oak Street Funding LLC dated April 3, 2019 (incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (Amendment No. 1) filed with the Securities and Exchange Commission on December 4, 2020 (File No. 333-249381)).

 

52

 

 

10.5†   Reliance Global Group Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form S-1 (Amendment No. 3) filed with the Securities and Exchange Commission on January 28, 2021 (File No. 333-249381)).
     
10.6   Amendment No. 1 to Securities Purchase Agreement between Nsure Inc. and Reliance Global Group, Inc. dated October 8, 2020 (incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form S-1 (Amendment No. 3) filed with the Securities and Exchange Commission on January 28, 2021 (File No. 333-249381)).
     
10.7   Form of Warrant Agent Agreement between Reliance Global Group, Inc. and VStock Transfer, LLC (incorporated by reference to Exhibit 10.7 to the Company’s Registration Statement on Form S-1 (Amendment No. 3) filed with the Securities and Exchange Commission on January 28, 2021 (File No. 333-249381)).
     
10.8   Purchase Agreement among Kush Benefit Solutions, LLC, J.P. Kush and Associates, Inc. and Joshua Kushnereit dated May 12, 2021 (incorporated herein by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 23, 2021 (SEC File No. 001-40020)).
     
10.9   Form of Securities Purchase Agreement among Reliance Global Group, Inc. and the investors identified on the signature pages thereto dated as of December 22, 2021 (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 23, 2021 (SEC File No. 001-40020)).
     
10.10   Form of Registration Rights Agreement 2021 (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 23, 2021 (SEC File No. 001-40020)).
     
10.11   Form of Series B Warrant (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 23, 2021 (SEC File No. 001-40020)).
     
10.12   Form of Certificate of Designation for Series B Convertible Preferred Stock (incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 23, 2021 (SEC File No. 001-40020)).
     
10.13   Asset Purchase Agreement between Reliance Global Group, Inc. and Medigap Healthcare Insurance Company, LLC and the sole member thereof entered into agreement as of December 21, 2021 (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2022 (SEC File No. 001-40020)).
     
10.14   Form of Investor Exchange Agreement between Reliance Global Group, Inc. and the parties signatory to the agreement dated as of March 23, 2022 (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2022 (SEC File No. 001-40020)).
     
10.15   Form of Medigap Exchange Agreement between Reliance Global Group, Inc. and the parties signatory to the agreement dated as of March 23, 2022 (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2022 (SEC File No. 001-40020)).
     
10.16   Asset Purchase Agreement between RELI Exchange, LLC and Barra & Associates, LLC dated April 26, 2022 (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 2, 2022 (File Number 001-40020)).
     
10.17   Security Agreement between Medigap Healthcare Insurance Agency, LLC and Oak Street Funding LLC dated April 26, 2022 (Incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 2, 2022 (File Number 001-40020))
     
10.18†   Employment Agreement between Reliance Global Group, Inc. and Grant Barra dated April 26, 2022 Incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 2, 2022 (File Number 001-40020))Ex. 10.3
     
10.19   Promissory Note issued by Reliance Global Group, Inc. to YES Americana Group LLC on September 13, 2022 (incorporated herein by reference to Exhibit 4.1 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022 (SEC File No. 001-40020)).
     
10.20   Amendment No. 1 to the Promissory Note between Reliance Global Group, Inc. and YES Americana Group, LLC, dated as of February 7, 2023 (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 13, 2023 (SEC File No. 001-40020)).

 

53

 

 

10.21†   Promotion Letter by and between Reliance Global Group, Inc. and Joel Markovits dated as of December 28, 2022 (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2023 (SEC File No. 001-40020)).
     
10.22#   Securities Purchase Agreement, dated March 13, 2023, between Reliance Global Group, Inc. and Investor (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 14, 2023 (SEC File No. 001-40020)).
     
10.23   Form of Warrant (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 14, 2023 (SEC File No. 001-40020)).
     
10.24   Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 14, 2023 (SEC File No. 001-40020)).
     
10.25   Form of Placement Agent Warrant (incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 14, 2023 (SEC File No. 001-40020)).
     
10.26   Form of Registration Rights Agreement (incorporated herein by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 14, 2023 (SEC File No. 001-40020)).
     
10.27   Second Amendment to the Purchase Agreement, dated as of May 18, 2023, by and between Reliance Global Group, Inc., Fortman Insurance Services, LLC, Fortman Insurance Agency, LLC, Jonathan Fortman, and Zachary Fortman (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2023).
     
10.28   Confidential Settlement and Mutual General Release Agreement, dated as of June 30, 2023, by and among the registrant, Medigap Healthcare Insurance Agency, LLC, Pagidem, LLC f/k/a Medigap Healthcare Insurance Company, LLC, Joseph J. Bilotti, III, Kyle Perrin, Zachary Lewis, T65 Health Insurance Solutions, Inc. f/k/a T65 Health Solutions, Inc., and Seniors First Life, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 7, 2023).
     
10.29   Second Amendment to the Purchase Agreement, dated as of May 18, 2023, by and between Reliance Global Group, Inc., Fortman Insurance Services, LLC, Fortman Insurance Agency, LLC, Jonathan Fortman, and Zachary Fortman (incorporated by reference to Exhibit 10.27 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (File No. 333-271110) filed on September 8, 2023).
     
10.30   Confidential Settlement and Mutual General Release Agreement, dated as of June 30, 2023, by and among the registrant, Medigap Healthcare Insurance Agency, LLC, Pagidem, LLC f/k/a Medigap Healthcare Insurance Company, LLC, Joseph J. Bilotti, III, Kyle Perrin, Zachary Lewis, T65 Health Insurance Solutions, Inc. f/k/a T65 Health Solutions, Inc., and Seniors First Life, LLC (incorporated by reference to Exhibit 10.28 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (File No. 333-271110) filed on September 8, 2023).
     
10.31   Amendment #1 to the Purchase Agreement, dated as of September 29, 2023, by and between Reliance Global Group, Inc., Southwestern Montana Insurance Center, LLC, Southwestern Montana Financial Center, Inc., and Julie A. Blockey (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 4, 2023).
     
10.32   Inducement Offer to Extend Existing Warrants, dated as of December 12, 2023, by and between Reliance Global Group, Inc. and Armistice Capital Master Fund Ltd. Blockey (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 13, 2023).
     
10.33   Inducement Offer to Exercise Series F Warrants to Subscribe for Common Shares, dated as of December 12, 2023, by and between Reliance Global Group, Inc. and Armistice Capital Master Fund Ltd. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on December 13, 2023).
     
10.34   Exchange Offer of Warrants to Purchase Common Stock and Amendment, dated as of December 12, 2023, by and between Reliance Global Group, Inc. and Hudson Bay Master Fund Ltd. (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on December 13, 2023).
     
10.35   Third Amendment to the Purchase Agreement, dated as of January 11, 2024, by and between Reliance Global Group, Inc., Fortman Insurance Services, LLC, Fortman Insurance Agency, LLC, Jonathan Fortman, and Zachary Fortman (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 11, 2024).
     
10.36†   Executive Employment Agreement, dated January 25, 2024, between the Company and Ezra Beyman (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 31, 2024).
     
10.37   At Market Issuance Sales Agreement, dated February 15, 2024, by and between the registrant and EF Hutton LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 16, 2024).
     
14.1   Code of Ethics (incorporated by reference to Exhibit 14.1 to the Company’s Form 10-K filed with the Securities and Exchange Commission on March 31, 2022).
     
21.1   List of subsidiaries (incorporated by reference to exhibits to the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2022).
     
23.1*   Consent of Mazars USA LLP.
     
24.1*   Power of Attorney (included on the signature page).
     
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002
     
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002
     
32.1**   Section 1350 Certification of the Chief Executive Officer and Chief Financial Officer
     
101.INS*   Inline XBRL Instance Document
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104*   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith
** Furnished herewith
Includes management contracts and compensation plans and arrangements
# Certain schedules and exhibits have been omitted pursuant to Item 601(A)(5) of Regulation S-K. The Company will furnish supplementally copies of omitted schedules and exhibits to the Securities and Exchange Commission or its staff upon its request.

 

54

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on April 4, 2024.

 

Reliance Global Group, Inc.  
     
By: /s/ Ezra Beyman  
  Ezra Beyman  
  Chief Executive Officer and Chairman of the Board  

 

POWER OF ATTORNEY

 

Each person whose signature appears below hereby appoints Ezra Beyman and Joel Markovits, and each of them, as attorney-in-fact with full power of substitution to execute in the name and on behalf of the registrant and each such person, individually and in each capacity stated below, one or more amendments to the annual report on Form 10-K, which amendments may make such changes in the report as the attorney-in-fact acting deems appropriate and to file any such amendment to the annual report on Form 10-K with the Securities and Exchange Commission. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Ezra Beyman   Chief Executive Officer and Executive Chairman and Director   April 4, 2024
Ezra Beyman   (Principal Executive Officer)    
         
/s/ Joel Markovits   Chief Financial Officer   April 4, 2024
Joel Markovits   (Principal Financial and Accounting Officer)    
         
/s/ Scott Korman   Director   April 4, 2024
Scott Korman        
         
/s/ Sheldon Brickman   Director   April 4, 2024
Sheldon Brickman        
         
/s/ Ben Fruchtzweig   Director   April 4, 2024
Ben Fruchtzweig        
         
/s/ Alex Blumenfrucht   Director   April 4, 2024
Alex Blumenfrucht        

 

55

 

EX-4.4 2 ex4-4.htm

 

Exhibit 4.4

 

DESCRIPTION OF CAPITAL STOCK

 

The following descriptions of common and preferred stock, together with the additional information we include in any applicable prospectus supplement, summarizes the material terms and provisions of our common stock and preferred stock, but is not intended to be complete. For the full terms of our common and preferred stock, please refer to our articles of incorporation, as amended from time to time, and our bylaws, as amended from time to time. The Florida Business Corporation Act (“FBCA”) may also affect the terms of these securities.

 

Our authorized capital stock consists of 2,750,000,000 shares of capital stock with a par value of $0.086 per share, consisting of 2,000,000,000 shares of common stock, par value of $0.086 per share, and 750,000,000 shares of preferred stock, par value of $0.086 per share, which may, at the sole discretion of the Board of Directors be issued in one or more series. The Board of Directors has designated 50,000,000 shares of preferred stock as Series A Convertible Preferred Stock and 9,077 shares of preferred stock as Series B Convertible Preferred Stock. As of the date of this filing, there were 5,692,387 shares of common stock issued and outstanding, held by approximately 519 holders of record, no shares of the Series A Convertible Preferred Stock and no shares of the Series B Convertible Preferred Stock issued and outstanding. The authorized and unissued shares of both common stock and preferred stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. Unless approval of our stockholders is so required, our board of directors will not seek stockholder approval for the issuance and sale of either our common stock or preferred stock.

 

The Board may from time to time authorize by resolution the issuance of any or all shares of the preferred stock authorized in accordance with the terms and conditions set forth in the articles of incorporation, as amended, for such purposes, in such amounts, to such persons, corporations, or entities, for such consideration and in one or more series, all as the Board in its discretion may determine and without any vote or other action by the stockholders, except as otherwise required by law.

 

Common Stock

 

Dividends. Subject to the rights of holders of any Preferred Stock having preference as to dividends and except as otherwise provided by the Articles of Incorporation from time to time, or the FBCA, as the same may be amended and supplemented, the holders of Common Stock shall be entitled to receive dividends when, as and if declared by the board of directors out of assets legally available therefor.

 

Voting Rights. Except as otherwise provided by the FBCA, the holders of the issued and outstanding shares of Common Stock shall be entitled to one vote for each share of Common Stock. No holder of shares of Common Stock shall have the right to cumulate votes.

 

Liquidation Rights. In the event of liquidation, dissolution or winding up of the affairs of the Corporation, whether voluntary or involuntary, subject to the prior rights of holders of Preferred Stock to share ratably in the Company’s assets, the Common Stock and any shares of Preferred Stock which are not entitled to any preference in liquidation shall share equally and ratably in the Company’s assets available for distribution after giving effect to any liquidation preference of any shares of Preferred Stock. A merger, conversion, exchange or consolidation of the Company with or into any other person or sale or transfer of all or any part of the assets of the Company (which shall not in fact result in the liquidation of the Company and the distribution of assets to stockholders) shall not be deemed to be a voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company.

 

No Conversion, Redemption, or Preemptive Rights. The holders of Common Stock shall not have any conversion, redemption, or preemptive rights.

 

Consideration for Shares. The Common Stock authorized by the Articles of Incorporation shall be issued for such consideration as shall be fixed, from time to time, by the board of directors.

 

Non-Assessment of Stock. The Common Stock, after the amount of the subscription price has been fully paid, are non-assessable.

 

 

 

 

Reverse Stock Split

 

On February 23, 2023, pursuant to authority granted by the Board, we implemented a 1-for-15 reverse split of our authorized and issued and outstanding common stock (the “Reverse Split-2023”). The par value remained unchanged. All share and per share information as well as common stock and additional paid-in capital have been retroactively adjusted to reflect the Reverse Split-2023 for all periods presented, unless otherwise indicated. The split resulted in a rounding addition of approximately 15,300 shares valued at par, totaling $1,300.

 

Preferred Stock

 

Our board of directors may, without further action by our stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 750,000,000 shares of Preferred Stock in one or more series and authorize their issuance. The voting powers, designations, preferences, limitations, restrictions, and relative, participating, option and other rights of the Preferred Stock and the qualifications, limitations, or restrictions relating thereto, shall be prescribed by resolution of the board of directors pursuant to the Articles of Incorporation.

 

The following summary of terms of our Preferred Stock is not complete. You should refer to the provisions of our Articles of Incorporation and Bylaws and the resolutions containing the terms of each class or series of the Preferred Stock which have been or will be filed with the SEC at or prior to the time of issuance of such class or series of Preferred Stock and described in the applicable prospectus supplement. The applicable prospectus supplement may also state that any of the terms set forth herein are inapplicable to such series of Preferred Stock, provided that the information set forth in such prospectus supplement does not constitute material changes to the information herein such that it alters the nature of the offering or the securities offered.

 

We will fix the designations, voting powers, preferences and rights of the preferred stock of each series we issue, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series.

 

Series A Convertible Preferred Stock. Each share of Series A Convertible Preferred Stock shall have ten (10) votes per share and may be converted into ten (10) shares of $0.086 par value common stock. The holders of the Series A Convertible Preferred Stock shall be entitled to receive, when, if and as declared by the Board, out of funds legally available therefore, cumulative dividends payable in cash. The annual interest rate at which cumulative preferred dividends will accrue on each share of Series A Convertible Preferred Stock is 0%. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution of assets of the Corporation shall be made to or set apart for the holders of the Common Stock and subject and subordinate to the rights of secured creditors of the Company, the holders of Series A Preferred Stock shall receive an amount per share equal to the greater of (i) one dollar ($1.00), adjusted for any recapitalization, stock combinations, stock dividends (whether paid or unpaid), stock options and the like with respect to such shares, plus any accumulated but unpaid dividends (whether or not earned or declared) on the Series A Convertible Preferred Stock, and (ii) the amount such holder would have received if such holder has converted its shares of Series A Convertible Preferred Stock to common stock, subject to but immediately prior to such liquidation. As of December 31, 2021, all Series A Convertible Preferred Stock had been converted into shares of common stock and none remain issued and outstanding.

 

Series B Convertible Preferred Stock. In January 2022, the Company issued 9,076 shares of the Series B Convertible Preferred Stock through the Private Placement for the purpose of raising capital. The Series B Convertible Preferred Stock have no voting rights and initially each share may be converted into 16 shares of the Company’s common stock. The holders of the Series B Convertible Preferred Stock are not entitled to receive any dividends other than any dividends paid on account of the common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder) to common stock which amounts shall be paid pari-passu with all holders of common stock. During August 2022, all 9,076 Series B Convertible Preferred Stock were converted by third parties into 147,939 shares of common stock. As of December 31, 2023, 2022 and 2021, all shares of Series B Convertible Preferred Stock had been converted and none remain outstanding.

 

 

 

 

Stock Options

 

During the year ended December 31, 2019, the Company adopted the Reliance Global Group, Inc. 2019 Equity Incentive Plan (the “Plan”) under which various forms of equity awards can be granted to employees, directors, consultants, and service providers. Awards include but are not limited to, restricted stock, restricted stock units, performance shares and stock options. A total of 46,667 shares of common stock were reserved for issuance under the Plan, and as of June 30, 2023 there are 10,928 options outstanding at a weighted average exercise price of $232.78 with a weighted average remaining contractual life of 1.12 years. 35,739 shares remain available for issuance pursuant to the Plan. With regards to stock options, the Company issues new shares of common stock from the shares reserved under the Plan upon exercise of stock options.

 

The Plan is administered by the Board. The Board is authorized to select from among eligible employees, directors, and service providers those individuals to whom shares and options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend, and rescind terms relating to options granted under the Plan. Generally, the interpretation and construction of any provision of the Plan or any shares and options granted hereunder is within the discretion of the Board.

 

The Plan provides that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees, non-employee directors, consultants, and service providers are eligible to receive options which are not ISOs, i.e. “Non-Statutory Stock Options.” The options granted by the Board in connection with its adoption of the Plan were Non-Statutory Stock Options.

 

The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option.

 

Effects of Authorized but Unissued Stock

 

We have shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of the Nasdaq Capital Market. We may utilize these additional shares for a variety of corporate purposes, including for future public offerings to raise additional capital, or facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could have the effect of making it more difficult for a third party to acquire or could discourage a third party from seeking to acquire, a controlling interest in our company by means of a merger, tender offer, proxy contest or otherwise. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders of common stock, and the likelihood that such holders will receive dividend payments and payments upon liquidation.

 

 

 

 

Florida Law and Certain Charter and Bylaw Provisions

 

Florida Anti-Takeover Law. As a Florida corporation, we are subject to certain anti-takeover provisions that apply to public corporations under Florida law.

 

Pursuant to Section 607.0901 of the FBCA a publicly held Florida corporation may not engage in a broad range of business combinations or other extraordinary corporate transactions with an interested shareholder without the approval of the holders of two-thirds of the voting shares of the corporation (excluding shares held by the interested shareholder), unless:

 

  The transaction is approved by a majority of disinterested directors before the shareholder becomes an interested shareholder;
     
  The interested shareholder has owned at least 80% of the corporation’s outstanding voting shares for at least five years preceding the announcement date of any such business combination;
     
  The interested shareholder is the beneficial owner of at least 90% of the outstanding voting shares of the corporation, exclusive of shares acquired directly from the corporation in a transaction not approved by a majority of the disinterested directors; or
     
  The consideration paid to the holders of the corporation’s voting stock is at least equal to certain fair price criteria.

 

An interested shareholder is defined as a person who, together with affiliates and associates, beneficially owns more than 10% of a corporation’s outstanding voting shares. We have not made an election in our Articles of Incorporation to opt out of Section 607.0901.

 

In addition, we are subject to Section 607.0902 of the FBCA which prohibits the voting of shares in a publicly held Florida corporation that are acquired in a control share acquisition unless (i) the board of directors approved such acquisition prior to its consummation or (ii) after such acquisition, in lieu of prior approval by the board of directors, the holders of a majority of the corporation’s voting shares, exclusive of shares owned by officers of the corporation, employee directors or the acquiring party, approve the granting of voting rights as to the shares acquired in the control share acquisition. A control share acquisition is defined as an acquisition that immediately thereafter entitles the acquiring party to 20% or more of the total voting power in an election of directors.

 

Articles of Incorporation, as amended and Bylaws.

 

Our Articles of Incorporation, as amended and Bylaws contain provisions that could have the effect of discouraging potential acquisition proposals or tender offers or delaying or preventing a change of control of our company. These provisions are as follows:

 

  they provide that special meetings of shareholders may be called by the board of directors, or at the request in writing by shareholders of record owning at least 10% of all the stockholders entitled to vote; and
     
  they do not include a provision for cumulative voting in the election of directors. Under cumulative voting, a minority shareholder holding a sufficient number of shares may be able to ensure the election of one or more directors. The absence of cumulative voting may have the effect of limiting the ability of minority shareholders to effect changes in the board of directors.

 

Transfer Agent

 

The transfer agent and registrar for our common stock is VStock Transfer. The transfer agent and registrar’s address is 18 Lafayette Place, Woodmere, New York 11598. Its telephone number is (212) 828-8436.

 

Listing on the Nasdaq Capital Market

 

Our Common Stock is listed on the Nasdaq Capital Market under the symbol “RELI” and our Series A Warrants are listed on the Nasdaq Capital Market under the symbol “RELIW”.

 

 

 

EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-267799 and 333-275911), Registration Statements on Form S-1 (File Nos. 333-249381, 333-252884, 333-262445, and 333-271110), and Registration Statement on Form S-3 (File No. 333-275190) of our report dated April 4, 2024 on the consolidated financial statements of Reliance Global Group, Inc as of December 31, 2023 and 2022 and for each of the two years in the two-year period ended December 31, 2023, which appears in the Annual Report on Form 10-K of Reliance Global Group, Inc. for the year ended December 31, 2023.

 

/s/ Mazars USA LLP

Mazars USA LLP

Fort Washington, Pennsylvania

April 4, 2024

 

 

 

EX-31.1 4 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, Ezra Beyman, certify that:

 

1. I have reviewed this annual report on Form 10-K for the fiscal year ended December 31, 2023 of Reliance Global Group, Inc.;

 

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this report is being prepared;
     
  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

  a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: April 4, 2024 By: /s/ Ezra Beyman
    Ezra Beyman
    Chief Executive Officer and Executive Chairman (Principal Executive Officer)

 

 

 

EX-31.2 5 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Joel Markovits, certify that:

 

1. I have reviewed this annual report on Form 10-K for the fiscal year ended December 31, 2023 of Reliance Global Group, Inc.;

 

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this report is being prepared;
     
  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

  a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: April 4, 2024 By: /s/ Joel Markovits
    Joel Markovits
    Chief Financial Officer (Principal Financial Officer)

 

 

 

EX-32.1 6 ex32-1.htm

 

Exhibit 32.1

 

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002

(Subsections (A) And (B) Of Section 1350, Chapter 63 of Title 18, United States Code)

 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Reliance Global Group, Inc. (the “Company”), does hereby certify, that:

 

The Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 4, 2024 By: /s/ Ezra Beyman
    Ezra Beyman
    Chief Executive Officer and Executive Chairman (Principal Executive Officer)
     
Date: April 4, 2024 By: /s/ Joel Markovits
    Joel Markovits
    Chief Financial Officer (Principal Financial Officer)

 

 

GRAPHIC 7 image_001.jpg begin 644 image_001.jpg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end EX-101.SCH 8 reli-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - INVESTMENT IN NSURE, INC. link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - WARRANT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SIGNIFICANT CUSTOMERS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - EARNINGS (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - LONG-TERM DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SIGNIFICANT CUSTOMERS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SCHEDULE OF WARRANT LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF DISAGGREGATION REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SCHEDULE OF ALLOCATION OF PURCHASE PRICE (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - INVESTMENT IN NSURE, INC. (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - SCHEDULE OF IMPAIRMENT OF GOODWILL (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - SCHEDULE OF LONG TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - SCHEDULE OF LONG TERM DEBT (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - LONG-TERM DEBT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - WARRANT LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - SCHEDULE OF CONCENTRATIONS OF REVENUES (Details) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - SIGNIFICANT CUSTOMERS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED (Details) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - SCHEDULE OF NON - VESTED STOCK OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL (Details) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000070 - Disclosure - SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS (Details) link:presentationLink link:calculationLink link:definitionLink 00000071 - Disclosure - SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES (Details) link:presentationLink link:calculationLink link:definitionLink 00000072 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000073 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000074 - Disclosure - SCHEDULE OF EARN-OUT LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000075 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000076 - Disclosure - SCHEDULE OF ACTUAL INCOME TAX RATE (Details) link:presentationLink link:calculationLink link:definitionLink 00000077 - Disclosure - SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000078 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000079 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000080 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 reli-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 reli-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 11 reli-20231231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Series A Warrants [Member] Related Party, Type [Axis] Nonrelated Party [Member] Related Party [Member] Equity Components [Axis] Preferred Stock [Member] Additional Paid-in Capital [Member] Subscription Receivable [Member] Retained Earnings [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Disposal Group Name [Axis] Medigap Healthcare Insurance Company, LLC [Member] Disposal Group Classification [Axis] Discontinued Operations [Member] Long-Lived Tangible Asset [Axis] Computer Equipment [Member] Office Equipment and Furniture [Member] Leasehold Improvements [Member] Measurement Input Type [Axis] Measurement Input, Share Price [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Term [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Derivative Instrument [Axis] Series B Warrant Commitment [Member] Series B Warrant Liability [Member] Placement Agent Warrants [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Measurement Input, Credit Spread [Member] Number of Trading Days [Member] Product and Service [Axis] Medical [Member] Timing of Transfer of Good or Service [Axis] Regular [Member] Consolidated Entities [Axis] Employee Benefits Solutions LLC [Member] Life [Member] Property and Casualty [Member] US Benefits Alliance LLC [Member] Commercial Coverage Solutions LLC [Member] Southwestern Montana Financial Center Inc [Member] Fortman Insurance Services LLC [Member] Altruis Benefits Consulting Inc [Member] Kush [Member] Reli Exchange [Member] Medigap Healthcare Insurance Company [Member] Scenario [Axis] Carrying Value Prior to Abandonment [Member] Revision of Prior Period [Axis] Revision of Prior Period, Reclassification, Adjustment [Member] Asset and Liability Transfers Retained by the Company [Member] Asset Impairments and liability WriteOffs [Member] Reclassification, Type [Axis] Asset Acquisition [Axis] Barra And Associates LLC [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Asset Purchase Agreement [Member] Paid At Closing [Member] Payable In Nine Months [Member] Payable Over Two Years [Member] Measurement Input Royalty Rate [Member] Finite-Lived Intangible Assets by Major Class [Axis] Trade Names [Member] Business Acquisition [Axis] Measurement Input, Discount Rate [Member] Customer Relationships [Member] Measurement Input Obsolescence Rate [Member] Development Technology [Member] Acquired Accounts Receivable [Member] Property, Plant and Equipment [Member] Right of use asset [Member] Agency Relationship [Member] Lease liability [Member] Goodwill [Member] Securities Purchase Agreement [Member] Legal Entity [Axis] NSURE, Inc. [Member] Common Class A [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Share-Based Payment Arrangement, Tranche Three [Member] Computer Equipment [Member] Barra & Associates, LLC [Member] Trademarks and Trade Names [Member] Internally Developed Software [Member] Purchased Software [Member] Video Production Assets [Member] Non-competition Agreements [Member] Credit Facility [Axis] EBS and USBA [Member] CCS [Member] SWMT [Member] FIS [Member] ABC [Member] Employee Benefits, Solutions, LLC, and US Benefits Alliance [Member] Credit Agreement [Member] Oak Street Funding LLC [Member] Debt Instrument [Axis] Senior Secured Amortizing Credit Facility [Member] Variable Rate [Axis] Prime Rate [Member] Term Loan [Member] Master Credit Agreement [Member] Series B Convertible Preferred Stock [Member] Sale of Stock [Axis] Non Private Placement [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Customer [Member] Priority Health [Member] BlueCross BlueShield [Member] Private Placement [Member] Medigap Acquisition [Member] Series A Warrant [Member] Employee Agreement [Member] Series C Prepaid Warrants [Member] Series D Prepaid Warrants [Member] Series B Warrants [Member] Title of Individual [Axis] Board of Directors [Member] YES Americana Group LLC [Member] Series E Warrant [Member] Series F Warrant [Member] Series C and D Warrants [Member] Series E Warrants [Member] Series F Warrants [Member] PA Warrant [Member] Warrant Agreement [Member] Pre Exchange Warrant [Member] Post Exchange Warrant [Member] Pre And Post Exchange Warrant [Member] Series G Warrants [Member] Series F Inducement Agreement [Member] Abeyance Shares [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Plan Name [Axis] 2019 Equity Incentive Plan [Member] 2023 Equity Incentive Plan [Member] Employees, Directors, and Consultants [Member] Executives And Employees [Member] Director [Member] Executive [Member] Agreement In April 2022 [Member] Agreement In December 28, 2022 [Member] Antidilutive Securities [Axis] Stock Options [Member] Series B Warrants And Placement Agent Warrants [Member] Series G Warrants And Placement Agent Warrants [Member] Unvested Stock Awards [Member] Fortman Insurance Agency LLC [Member] Southwestern Montana Insurance Center Inc [Member] Altruis Benefits Consultants Inc [Member] JP Kush And Associates Inc [Member] CARES Act [Member] Investment, Name [Axis] Reliance Holdings [Member] Employee [Member] Common Stock [Member] Purchase Agreement [Member] ATM Agreement [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Assets Current assets: Cash Restricted cash Accounts receivable Other receivables Prepaid expense and other current assets Current assets - discontinued operations Total current assets Property and equipment, net Right-of-use assets Investment in NSURE, Inc. Intangibles, net Goodwill Other non-current assets Other assets - discontinued operations Total assets Liabilities and stockholders’ equity Current liabilities: Accounts payable and other accrued liabilities Short term financing agreements Current portion of loans payables, related parties Other payables Current portion of long-term debt Current portion of leases payable Earn-out liability, current portion Current liabilities - discontinued operations Total current liabilities Loans payable, related parties, less current portion Convertible debt, related parties, less current portion Long term debt, less current portion Leases payable, less current portion Earn-out liability, less current portion Warrant liabilities Total liabilities Stockholders’ equity: Preferred stock, $0.086 par value; 750,000,000 shares authorized and 0 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively Common stock, $0.086 par value; 2,000,000,000 shares authorized and 4,761,974 and 1,219,573 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Statement of Financial Position [Abstract] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Revenue Commission income Total revenue Operating expenses Commission expense Salaries and wages General and administrative Marketing and advertising Change in estimated acquisition earn-out payables Depreciation and amortization Goodwill impairment Total operating expenses Loss from operations Other income (expense) Interest expense Other expense, net Recognition and change in fair value of warrant liabilities Total other income (expense) Loss (income) from continuing operations before tax Loss from discontinued operations before tax Net (loss) income Basic (loss) earnings per share Continuing operations Discontinued operations Basic loss per share Diluted (loss) earnings per share Continuing operations Discontinued operations Diluted loss per share Weighted average number of shares outstanding – Basic Weighted average number of shares outstanding – Diluted Balance Balance, shares Share based compensation Share based compensation, shares Common shares issued for earnout liabilities Common shares issued for earnout liabilities, shares Shares issued due to conversion of preferred stock Shares issued due to conversion of preferred stock, shares Round up of shares due to reverse split Round up of shares due to reverse split, shares Shares issued in private placement Shares issued in private placement, shares Common shares issued for services Common shares issued for services, shares Common shares issued for Series B warrants Common shares issued for series B warrant in shares Common shares issued for Series E warrants Common shares issued for Series E warrants, shares Common shares issued for Series F warrants Common shares issued for Series F warrants, shares Net Income (loss) Share based compensation Shares issued pursuant to acquisition Shares issued pursuant to acquisition of Medigap, shares Series A warrants Series A warrants, shares Issuance of Series C warrants in exchange for common shares Issuance of Series C warrants in exchange for common shares, shares Shares issued for vested stock awards Shares issued for vested stock awards, shares Issuance of common stock for conversion of Series C warrants Issuance of common stock for conversion of Series C warrants, shares Issuance of common stock for conversion of Series D warrants Issuance of common stock for conversion of Series D warrants, shares Issuance of common stock for conversion of Series B warrants Issuance of common stock for conversion of Series B warrants, shares Warrant liability reclassified to equity upon exercise of Series B Warrants Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net (Loss) income Adjustment to reconcile net income to net cash used in operating activities: Depreciation and amortization Amortization of debt issuance costs and accretion of debt discount Non-cash lease expense Share based compensation expense Share based payments to service providers Recognition and change in fair value of warrant liability Change in operating assets and liabilities: Accounts receivable Accounts receivable, related parties Other receivables Prepaid expense and other current assets Other non-current assets Accounts payables and other accrued liabilities Other payables Net cash used in continuing operating activities Net cash provided by discontinued operating activities Net cash used in continuing and discontinued operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Purchase of intangible assets Proceeds from sale of investment in NSURE Business acquisitions, net of cash acquired Net cash provided and used in continuing investing activities Net cash used in discontinued investing activities Net cash provided and used in continuing and discontinued investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Principal repayments of debt Debt issuance costs Loans acquired through acquisitions Issuance of common shares in exchange for Series B warrants Issuance of common shares in exchange for Series C warrants Proceeds from short term financing Principal repayments of short-term financings Payments of loans payable, related parties Cash payments and proceeds of convertible debt, related parties Cash payments on earn-out liability Proceeds from exercise of warrants into common stock Private Placement of shares and warrants Net cash provided from continuing financing activities Net cash used and provided from discontinued financing activities Net cash provided from continuing and discontinued financing activities Net increase and decrease in cash and restricted cash Cash and restricted cash at beginning of year Cash and restricted cash at end of year SUPPLEMENTAL DISCLOSURE OF CASH AND NON-CASH TRANSACTIONS: Interest Noncash investing and financing transactions: Common shares issued to settle convertible debt, related parties Common shares issued for earnout liabilities Common shares issued for Series B warrants Common shares issued for Series D Warrants Common shares issued for preferred stock Common stock issued for pre-paid assets Issuance of Series D Warrants Issuance of placement agent warrants Acquisition of business deferred purchase price liability Lease assets acquired in exchange for lease liabilities Noncash investing and financing transactions, discontinued operations Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Combination and Asset Acquisition [Abstract] STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS Investments, All Other Investments [Abstract] INVESTMENT IN NSURE, INC. Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] GOODWILL AND OTHER INTANGIBLE ASSETS Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Debt Disclosure [Abstract] LONG-TERM DEBT Warrant Liabilities WARRANT LIABILITIES Risks and Uncertainties [Abstract] SIGNIFICANT CUSTOMERS Equity [Abstract] EQUITY Earnings Per Share [Abstract] EARNINGS (LOSS) PER SHARE Leases LEASES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Income Tax Disclosure [Abstract] INCOME TAXES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation and Principles of Consolidation Liquidity Use of Estimates Cash and Restricted Cash Property and Equipment Fair Value of Financial Instruments Deferred Financing Costs Business Combinations Identifiable Intangible Assets, net Goodwill and other indefinite-lived intangibles Financial Instruments Revenue Recognition General and Administrative Marketing and Advertising Equity-Based Compensation Leases Income Taxes Discontinued Operations Seasonality Recently Issued Accounting Pronouncements SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT SCHEDULE OF WARRANT LIABILITY SCHEDULE OF RECONCILES WARRANT COMMITMENT SCHEDULE OF FAIR VALUE MEASUREMENTS SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE SCHEDULE OF DISAGGREGATION REVENUE SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] SCHEDULE OF ALLOCATION OF PURCHASE PRICE SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF IMPAIRMENT OF GOODWILL SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES SCHEDULE OF LONG TERM DEBT SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES SCHEDULE OF CONCENTRATIONS OF REVENUES SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED SCHEDULE OF NON - VESTED STOCK OPTIONS SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT SCHEDULE OF EARN-OUT LIABILITY SCHEDULE OF ACTUAL INCOME TAX RATE SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES Total cash and restricted cash Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Estimated useful life Property, Plant and Equipment, Depreciation Method [Extensible Enumeration] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrant Liabilities Time to expiry Offsetting Assets [Table] Offsetting Assets [Line Items] Beginning balance, December 31, 2022 Initial recognition Unrealized (gain) loss Warrants exercised or exchanged Ending balance, December 31, 2023 Recognition and change in fair value of warrant liability Warrant issuance cost Platform Operator, Crypto-Asset [Table] Platform Operator, Crypto-Asset [Line Items] Valuation technique Significant unobservable input Earn out liability Earn out liability Number of iterations Beginning balance – January 1 Acquisitions and Settlements Fair value and estimate changes Earn-out payable in common shares Earn-out transferred to loans payable, related parties Ending balance Less: Current portion Ending balance, less current portion Schedule of Product Information [Table] Product Information [Line Items] Total Current Assets - Discontinued Operations Current assets – Medigap Other Assets - Discontinued Operations Other assets - Medigap Chargeback reserve Current Liabilities - Discontinued Operations Current liabilities - Medigap Total assets - Medigap Short term financing agreements Other liabilities Total liabilities - Medigap Net assets and liabilities - Medigap Other expenses (income) Total discontinued operations expenses before impairments and write-offs Total discontinued operations income / (loss) before impairments and write-offs Settlement Recovery, net of costs Accounts receivable, related parties Other receivables Property and equipment, net Right-of-use assets Intangibles, net Goodwill Total asset impairments Accounts payable and other accrued liabilities Other payables Chargeback reserve Current portion of leases payable Total liability write-off gains Discontinued operations net asset and liability impairments / write-offs gains and (losses) Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities Loss from discontinued operations before tax Consolidated statement of operations - Loss from discontinued operations before tax Aggregate cash balance Current assets Current liabilities Working capital Stockholder's equity Operating income loss Goodwill impairment loss Fair value of warrant liabilities Interest expense Income loss from continuing operations Income loss from discontinued operations Net loss Raising net proceeds FDIC insured amount Earn out payments Unamortized deferred financing costs Estimated useful lives of intangible assets Net of amortization combined Net of estimated liability adjustments gain Impairment loss on discontinued operations Settlement payment Property, plant and equipment Finite lived intangible asset useful life Finite lived intangible asset useful life Revenue Net Income (Loss) Earnings (Loss) per common share, basic Earnings (Loss) per common share, diluted Asset Acquisition [Table] Asset Acquisition [Line Items] Asset Acquisition, Consideration Transferred Working capital Business combination, measurement input Acquisition costs Revenue from acquired entity Shares issued upon termination of employee Investments Number of shares of common stock, shares Share price Sale of stock, shares Cash proceeds Proceeds from sale of stock Remaining balance shares Property and equipment Less: Accumulated depreciation Property and equipment, net Depreciation expense Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Goodwill Beginning Goodwill acquired during period Goodwill impairment loss Goodwill end Goodwill Beginning Goodwill end Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Weighted Average Remaining Amortization Period Gross Carrying Amount Accumulated Amortization Net carrying amount 2024 2025 2026 2027 2028 Thereafter Total Goodwill, Written off Related to Sale of Business Unit Goodwill, Impaired, Accumulated Impairment Loss Amortization of intangible assets Accounts payable, Accrued expenses Accrued credit card payables Other accrued liabilities Accounts payable and other accrued liabilities Line of Credit Facility [Table] Line of Credit Facility [Line Items] Long term debt gross Less: current portion Long-term debt Variable interest of prime rate plus Maturity date Net of deferred financing cost 2024 2025 2026 2027 2028 Thereafter Total Less debt issuance costs Total Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Total financed Interest rate Debt issuance costs Debt description Debt instrument term Maturity date Short-term financings Issued warrant Exercisable price Shares of common Stock Conversion of Stock, Shares Converted Convertible into aggregate shares Conversion price, per share Aggregate purchase price Unrealized losses Non-operating unrealized gains Derivative Liability Outstanding warrants Number of shares issued exercised Cash proceeds Net fair value gains losses Warrant liability Warrants and rights outstanding term Derivative liability measured at fair value Concentration Risk [Table] Concentration Risk [Line Items] Concentration of risk percentage Total revenue Number of Stock Options Outstanding, Outstanding at Beginning of Period Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period Aggregate Intrinsic Value, Outstanding at Beginning of Period Number of Stock Options Outstanding, Granted Weighted Average Exercise Price Per Share, Granted Aggregate Intrinsic Value, Granted Number of Stock Options Outstanding, Forfeited or expired Weighted Average Exercise Price Per Share, Forfeited or expired Aggregate Intrinsic Value, Forfeited or expired Number of Stock Options Outstanding, Exercised Weighted Average Exercise Price Per Share, Exercised Aggregate Intrinsic Value, Exercised Number of Stock Options Outstanding, Outstanding at End of Period Weighted Average Exercise Price, Outstanding at End of Period Weighted Average Remaining Contractual Life (years), Outstanding at End of Period Aggregate Intrinsic Value, Outstanding at End of Period Number of Non-vested Stock Options Outstanding, Outstanding at Beginning of Period Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period Number of Non-vested Stock Options Outstanding, Granted Weighted Average Exercise Price Per Share, Granted Number of Non-vested Stock Options Outstanding, Vested Weighted Average Exercise Price Per Share, Vested Weighted Average Remaining Contractual Life (years), Vested Number of Non-vested Stock Options Outstanding, Forfeited or expired Weighted Average Exercise Price Per Share, Forfeited or expired Number of Stock Options Outstanding, Outstanding at End of Period Weighted Average Exercise Price, Outstanding at End of Period Weighted Average Remaining Contractual Life (years), Outstanding at End of Period Exercise price Expected term Risk-free interest rate Expected volatility Expected dividend Schedule of Stock by Class [Table] Class of Stock [Line Items] Conversion of stock shares converted Conversion of shares Stock issued during period, shares, acquisitions Exercise of warrants, shares Warrants exercise prices Vested restricted stock awards Stock issued during period, shares, acquisitions Cash proceeds Stockholders' equity, reverse stock split Round up of shares due to reverse split Round up of shares due to reverse split, value Debt conversion original debt amount Debt Conversion converted instrument shares Warrants exercise price Shares issued service Settle an earn-out liability Share based compensation, shares Number of shares converted Exercise price Exercise price reduced Class of Warrant or Right, Outstanding Proceeds from issuance Warrant conversion shares Warrants description Gross proceeds cash fee percentage Gross proceeds Net Proceeds Financing fee Additional paid in capital Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Payments for Repurchase of Warrants Stock Issued During Period, Value, New Issues [custom:IssuanceOfWarrants] [custom:PercentageOfBeneficialOwnership-0] Deemed dividend Warrants and rights outstanding before exchange Warrants and rights outstanding after exchange Shares issued price per share Warrants term Dividend rate Volatility rate Risk free interest rate Number of shares converted Net of cash proceeds Class of warrant unissued Common Stock, Capital Shares Reserved for Future Issuance Options outstanding Weighted average exercise price Weighted average remaining contractual life Available for issuance Number of shares option forfeitures Fair value Share-Based Payment Arrangement, Noncash Expense Unrecognized compensation expense Market value price per share Shares restricted Shares restricted, value Share based compensation Shares vested Shares issued commission equity award expense Value issued commission equity award expense Equity-based compensation expense (Loss) income from continuing operations Deemed dividend (Loss) income from continuing operations, numerator, basic (Loss) income from continuing operations, numerator, diluted Weighted average common shares, basic Effect of weighted average vested stock awards Diluted weighted average shares outstanding Basic (loss) income loss per common share from continuing operations: Diluted (loss) income per common share from continuing operations: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares subject to unvested stock awards Schedule Of Future Minimum Lease Payment 2024 2025 2026 2027 2028 Thereafter Total undiscounted operating lease payments Less: Imputed interest Present value of operating lease liabilities Lease expense Weighted average remaining lease term Weighted average discount rate Payments Estimate & fair value adjustments Payable in Common Stock Reclass to loans payable, related parties Business combinations Legal contingencies Federal rate State net of federal Non-taxable change in fair value of warrant commitment Goodwill impairment Rate Change Other Valuation allowance Effective income tax rate Net operating loss carryforward Equity-based compensation Goodwill Intangibles Fixed assets Right of use assets Lease liabilities Other Total deferred tax assets Valuation allowance Net deferred tax assets Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Federal net operating loss carryforwards excluding indefinite life Operating loss carryforward limitation Income tax description State net operating loss carry forwards Income tax description Change in valuation of allowance Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Loans payables, related parties Ownership percentage Due to related party Debt instrument unmortized discount Accrue interest percentage Monthly payment Current portion of loans payables, related parties Non-current portion of loans payables, related parties Interest expense, related parties Promissory note principle Accruing monthly interest percentage Debt instrument description Common stock par value Conversion of stock Conversion of stock shares Agreed to payment Repayment of related party owed Other expenses Deferred purchase price Accrue interest rate percentage Loans payables, current Loans payables, related parties Earn out balance Earn out owned amount Accrued interest Subsequent Event [Table] Subsequent Event [Line Items] Aggregate offering price Sold shares Receiving proceeds, net Agent commissions Non cash lease expense Earnout fair value and writeoff adjustments Securities Purchase Agreement [Member] NSURE, Inc. [Member] Proceeds from loan acquired through acquisition. Isusance of common shares in exchange for series C warrants. Isusance of common shares in exchange for warrants. Payments on earnout liabilities. Issuance of Series D Warrants. Issuance of placement agent warrants Cashless conversion of series d warrants into common stock. Common stock issued pursuant to acquisition Prepaid insurance acquired through short term financing. Warrant liability reclassified to equity upon exercise of series B warrants. Unpaid deferred transaction costs. Stock subscriptions. Acquisition of business deferred purchase price. Lease assets acquired in exchange for lease liabilities. Liquidity [Policy Text Block] Working capital deficiency. Short term financing agreements. Medigap Healthcare Insurance Company [Member] Barra & Associates, LLC [Member] Office Equipment and Furniture [Member] Internally Developed Software [Member] Purchased Software [Member] Video Production Assets [Member] Non-competition Agreements [Member] Schedule of Warrant Liability [Table Text Block] Warrant liabilities. Schedule of Reconciles Warrant Commitment [Table Text Block] Series B Warrant Commitment [Member] Series B Warrant Liability [Member] Placement Agent Warrants [Member] Initial recognition of warrant commitment Unrealized (gain) loss. Warrants exercised or transferred. Contracts Backlog [Member] Recognition and change in fair value of warrant liability. Valuation technique. Significant unobservable input. Number of Iterations Earn out payments. Acquisitions and settlements. Earn-out payable in common shares. Accrued credit card payables. Financial Instrument Policy Text Block. EBS and USBA [Member] CCS [Member] SWMT [Member] FIS [Member] Regular [Member] ABC [Member] Property and Casualty [Member] Commission income. Commission expense. Long term debt, net. Discontinued operation gain loss on disposal of discontinued operation net of amortization combined. Medigap Healthcare Insurance Company, LLC [Member] Chargeback reserve current. Carrying Value Prior to Abandonment [Member] Asset and Liability Transfers Retained by the Company [Member] Asset Impairments and liability WriteOffs [Member] Assets and liabilities of disposal group including discontinued operation current. Settlement recovery. Accounts receivable impairements. Accounts payable and other accrued liabilities write offs. Other payables writeoffs. Chargeback reserve write offs. Current portion of leases payable write offs. Total liability writeoffs. Discontinued operations net asset and liability umpairments writeoffs. Net recoveries and impairments writeoffs from discontinued assets and liabilities. Seasonality [Policy Text Block] Right of use asset [Member] Employee Benefits, Solutions, LLC, and US Benefits Alliance [Member] Credit Agreement [Member] Oak Street Funding LLC [Member] Lease liability [Member] JP Kush And Associates Inc [Member] Commercial Coverage Solutions LLC [Member] Senior Secured Amortizing Credit Facility [Member] Term Loan [Member] Finite-lived intangible asset, useful lives. Master Credit Agreement [Member] Measurement Input Obsolescence Rate [Member] Shares issued upon termination of employee. Common shares issued to settle loan, value. Reduction in the number of value during the period as a result of a reverse stock split. Common shares issued for series warrants, value. Common shares issued for series warrants, value. Common shares issued for series warrants, value. Deemed dividend. Subscription Receivable [Member] Shares issued for exercise of warrants, shares. Shares issued for vested stock awards, shares. Asset Purchase Agreement [Member] Shares issued for exercise of warrants. Shares issued for vested stock awards. Warrant Liabilities [Text Block] Series B Convertible Preferred Stock [Member] Fortman Insurance Agency LLC [Member] Southwestern Montana Insurance Center Inc [Member] Altruis Benefits Consultants Inc [Member] Changes due to payments. Changes due to fair value adjustments. Changes due to business combinations. Aggregate purchase price of common shares, preferred shares and warrants. Commercial Solutions Of Insurance Agency LLC [Member] Effective income tax rate reconciliation change in fair value of warrant commitment. Non Private Placement [Member] Deferred tax liabilities lease liabilities. Income tax expiration date description. CARES Act [Member] Reliance Holdings [Member] Warrant liability. YES Americana Group LLC [Member] Employee [Member] Loans payable-related parties, current. Loans payable-related parties, non-current. Accruing monthly interest percentage Repayments of related partys owed. Priority Health [Member] BlueCross BlueShield [Member] Customer [Member] Medigap Acquisition [Member] Series A Warrant [Member] Series C Prepaid Warrants [Member] Series D Prepaid Warrants [Member] Deferred purchase price. Accrue interest rate percentage Board of Directors [Member] Series A Warrants [Member] Series C and D Warrants [Member] Series E Warrants [Member] Series F Warrants [Member] PA Warrant [Member] Gross proceeds cash fee percentage. Proceeds from private placement, gross. Warrant Agreement [Member] Issuance of warrants. Percentage of beneficial ownership. Acquired Accounts Receivable [Member] Stock issued during period value issuance on series warrants in exchange for common shares. Stock issued during period shares conversion of units series D. Tabular disclosure of earn out liabilities. Changes due to amount payable in common shares. Reclass to loans payable related parties. Tabular disclosure of actual income tax rate. Purchase Agreement [Member] ATM Agreement [Member] Series G Warrants [Member] Abeyance Shares [Member] 2019 Equity Incentive Plan [Member] 2023 Equity Incentive Plan [Member] share-based compensation arrangement by share-based payment award options outstanding weighted average remaining contractual term. Share-based compensation arrangement by share-based payment award granted outstanding intrinsic value. Share-based compensation arrangement by share-based payment award forfeited or expired outstanding intrinsic value. Share-based compensation arrangement by share-based payment award exercised outstanding intrinsic value. Conversion of common stock into series c warrants. Private placement equity financing costs. Common stock issuance to settle earnout liabilities. Common stock issuance to repay related party liability. Warrant issuance cost. Number of Trading Days [Member] Medical [Member] Life [Member] Reli Exchange [Member] Change in estimated acquisition earnout payables. Barra And Associates LLC [Member] Development Technology [Member] Agency Relationship [Member] Common shares issued to settle loan yes americana in shares. Common shares issued for eries e warrant. Common shares issued for series b warrant shares. Common shares issued for series f warrant. Common Stock Issuable [Member] Paid At Closing [Member] Payable Over Two Years [Member] Working capital. Stock issued during period value conversion of units series D. Stock issued during period value conversion of units series B. Stock issued during period shares issuance of series c warrants in exchange for common shares. Stock issued during period value conversion of units series B shares. Share-based compensation arrangement by share-based payment award options outstanding weighted average remaining contractual term non-vested. Share-based compensation arrangement by share-based payment award, options, vested weighted average remaining contractual term Share-based compensation arrangement by share-based payment award options outstanding weighted average remaining contractual term non-vested. Share based compensation arrangement by share based payment award options forfeitures. Employees, Directors, and Consultants [Member] Market value of share. Three Employees [Member] Effect of weighted averagevested stock awards. Series B Warrants [Member] Loans payable non current. Weighted average common shares. Impairment loss on discontinued operations. Net of estimated liability adjustments gain. Derivative liability measured at fair value. Intangibles, net. Schedule of Estimated Useful Life of Property Plant and Equipment [Table Text Block] Earn-out liabilities measurement input. Earn-out liabilities measurement input term. Payable In Nine Months [Member] Measurement Input Royalty Rate [Member] Series B Warrants and PAW [Member] Employee Agreement [Member] Common Stock [Member] Executive [Member] Series E Warrant [Member] Series F Warrant [Member] Unvested Stock Awards [Member] Stock Options [Member] Computer Equipment [Member] Kush [Member] Altruis Benefits Consulting Inc [Member] Fortman Insurance Services LLC [Member] Southwestern Montana Financial Center Inc [Member] US Benefits Alliance LLC [Member] Employee Benefits Solutions LLC [Member] Settlement recovery net of costs. Recognition of change in fair value of warrant liabilities. Common shares issued for earnout liabilities. Common shares issued for Series B Warrants. Common shares issued for Series D Warrants. Common shares issued for preferred stock. Common stock issued for pre-paid assets. Common stock issued for discontinued operations. Lease assets acquired in exchange for lease liabilities, continuing operations. Lease assets acquired in exchange for lease liabilities, discontinued operations. Series B Warrants And Placement Agent Warrants [Member] Series G Warrants And Placement Agent Warrants [Member] Acquisition of business deferred purchase price liability. Noncash investing and financing transactions, discontinued operations. Executives And Employees [Member] Agreement In April 2022 [Member] Agreement In December 28, 2022 [Member] Shares issued commission equity award expense. Value issued commission equity award expense. Deemed dividends. Warrants and rights outstanding before exchange. Warrants and rights outstanding after exchange. Pre Exchange Warrant [Member] Post Exchange Warrant [Member] Pre And Post Exchange Warrant [Member] Series F Inducement Agreement [Member] Useful Life, Shorter of Lease Term or Asset Utility [Member] Computer Equipment [Member] [Default Label] Common Stock [Member] [Default Label] Assets [Default Label] Liabilities Liabilities and Equity Revenues Operating Expenses Operating Income (Loss) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Depreciation, Depletion and Amortization Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Receivable, Related Parties Increase (Decrease) in Other Receivables Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Other Noncurrent Assets Increase (Decrease) in Other Accounts Payable Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Intangible Assets Payments to Acquire Businesses, Net of Cash Acquired Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net Cash Provided by (Used in) Investing Activities Repayments of Debt Payments of Debt Issuance Costs Repayments of Short-Term Debt PaymentsOnEarnoutLiabilities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations CommonSharesIssuedForEarnoutLiabilities CommonSharesIssuedForSeriesBWarrants Lessee, Leases [Policy Text Block] Restricted Cash and Cash Equivalents, Current Warrants and Rights Outstanding, Measurement Input EarnOutLiabilitiesMeasurementInputTerm ShortTermFinancingAgreements AccountsReceivableImpairements Other Asset Impairment Charges Tangible Asset Impairment Charges Operating Lease, Impairment Loss IntangiblesNet Asset Impairment Charges AccountsPayableAndOtherAccruedLiabilitiesWriteOffs OtherPayablesWriteoffs ChargebackReserveWriteOffs CurrentPortionOfLeasesPayableWriteOffs Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Working capital deficiency Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Business Acquisition, Pro Forma Revenue Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Disposal Group, Including Discontinued Operation, Goodwill Accounts Payable and Accrued Liabilities, Current Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Long-Term Debt, Maturity, Year Five Long-Term Debt, Maturity, after Year Five Long-Term Debt, Gross Debt Instrument, Maturity Date Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermNonVested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermsNonVested Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture DeemedDividends Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, Year Five Lessee, Operating Lease, Liability, to be Paid, after Year Five Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent Deferred Tax Liabilities, Goodwill Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Leasing Arrangements Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Income Tax Examination, Description LoansPayableRelatedPartiesCurrent LoansPayableNonCurrent EX-101.PRE 12 reli-20231231_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
Apr. 04, 2024
Jun. 30, 2023
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 001-40020    
Entity Registrant Name RELIANCE GLOBAL GROUP, INC.    
Entity Central Index Key 0001812727    
Entity Tax Identification Number 46-3390293    
Entity Incorporation, State or Country Code FL    
Entity Address, Address Line One 300 Blvd. of the Americas    
Entity Address, Address Line Two Suite 105    
Entity Address, City or Town Lakewood    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 08701    
City Area Code (732)    
Local Phone Number 380-4600    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 7.8
Entity Common Stock, Shares Outstanding   5,692,387  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 339    
Auditor Name Mazars USA LLP    
Auditor Location Washington, Pennsylvania    
Common Stock [Member]      
Title of 12(b) Security Common Stock    
Trading Symbol RELI    
Security Exchange Name NASDAQ    
Series A Warrants [Member]      
Title of 12(b) Security Series A Warrants    
Trading Symbol RELIW    
Security Exchange Name NASDAQ    
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash $ 1,329,016 $ 505,410
Restricted cash 1,409,895 1,404,359
Other receivables 899 11,464
Prepaid expense and other current assets 333,756 245,535
Current assets - discontinued operations 85,998
Total current assets 4,379,032 3,265,379
Property and equipment, net 139,999 162,767
Right-of-use assets 739,830 1,018,952
Investment in NSURE, Inc. 900,000
Intangibles, net 11,042,757 13,439,369
Goodwill 6,693,099 14,287,099
Other non-current assets 20,292 23,284
Other assets - discontinued operations 5,330,879
Total assets 23,015,009 38,427,729
Current liabilities:    
Accounts payable and other accrued liabilities 835,483 951,382
Short term financing agreements 56,197 154,017
Other payables 7,414 101,113
Current portion of long-term debt 1,390,766 1,118,721
Current portion of leases payable 285,171 339,937
Earn-out liability, current portion 159,867 2,153,478
Current liabilities - discontinued operations 1,600,636
Total current liabilities 3,189,851 7,841,533
Long term debt, less current portion 11,026,971 12,349,673
Leases payable, less current portion 484,335 714,068
Earn-out liability, less current portion 556,000
Warrant liabilities 268,993 6,433,150
Total liabilities 15,867,679 29,516,690
Stockholders’ equity:    
Preferred stock, $0.086 par value; 750,000,000 shares authorized and 0 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
Common stock, $0.086 par value; 2,000,000,000 shares authorized and 4,761,974 and 1,219,573 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively 409,509 104,883
Additional paid-in capital 45,739,786 35,798,139
Accumulated deficit (39,001,965) (26,991,983)
Total stockholders’ equity 7,147,330 8,911,039
Total liabilities and stockholders’ equity 23,015,009 38,427,729
Nonrelated Party [Member]    
Current assets:    
Accounts receivable 1,298,863 994,321
Related Party [Member]    
Current assets:    
Accounts receivable 6,603 18,292
Current liabilities:    
Current portion of loans payables, related parties 454,953 1,422,249
Loans payable, related parties, less current portion 897,529 122,266
Convertible debt, related parties, less current portion $ 1,500,000
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.086 $ 0.086
Preferred stock, shares authorized 750,000,000 750,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.086 $ 0.086
Common stock, shares authorized 2,000,000,000 2,000,000,000
Common stock, shares issued 4,761,974 1,219,573
Common stock, shares outstanding 4,761,974 1,219,573
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue    
Commission income $ 13,731,826 $ 11,761,882
Total revenue 13,731,826 11,761,882
Operating expenses    
Commission expense 3,732,939 3,140,725
Salaries and wages 7,503,052 7,508,312
General and administrative 4,089,989 4,959,151
Marketing and advertising 364,974 170,311
Change in estimated acquisition earn-out payables 1,716,873 524
Depreciation and amortization 2,609,191 2,563,518
Goodwill impairment 7,594,000
Total operating expenses 27,611,018 18,342,541
Loss from operations (13,879,192) (6,580,659)
Other income (expense)    
Other expense, net 6,530 (4,341)
Recognition and change in fair value of warrant liabilities 5,503,647 29,064,958
Total other income (expense) 3,853,924 28,142,591
Loss (income) from continuing operations before tax (10,025,268) 21,561,932
Loss from discontinued operations before tax (1,984,714) (15,095,770)
Net (loss) income $ (12,009,982) $ 6,466,162
Basic (loss) earnings per share    
Continuing operations $ (4.46) $ 13.36
Discontinued operations (0.70) (13.78)
Basic loss per share (5.16) (0.42)
Diluted (loss) earnings per share    
Continuing operations (4.46) 13.36
Discontinued operations (0.70) (13.78)
Diluted loss per share $ (5.16) $ (0.42)
Weighted average number of shares outstanding – Basic 2,820,275 1,094,781
Weighted average number of shares outstanding – Diluted 2,820,275 1,094,989
Nonrelated Party [Member]    
Other income (expense)    
Interest expense $ (1,506,186) $ (911,106)
Related Party [Member]    
Other income (expense)    
Interest expense $ (150,067) $ (6,920)
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Stockholders' Equity - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscription Receivable [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 62,815 $ 27,329,201 $ (20,000,000) $ (33,458,145) $ (26,066,129)
Balance, shares at Dec. 31, 2021 730,407        
Shares issued due to conversion of preferred stock $ (781) $ 12,723 (11,942)
Shares issued due to conversion of preferred stock, shares (9,076) 147,939        
Shares issued in private placement $ 781 $ 15,313 (16,043) 20,000,000 20,000,051
Shares issued in private placement, shares 9,076 178,060        
Net Income (loss) 6,466,162 6,466,162
Share based compensation 1,249,873 1,249,873
Shares issued pursuant to acquisition $ 3,475 4,759,976 4,763,451
Shares issued pursuant to acquisition of Medigap, shares   40,402        
Series A warrants $ 2,150 2,472,850 2,475,000
Series A warrants, shares   25,000        
Issuance of Series C warrants in exchange for common shares   $ (18,788) 18,788
Issuance of Series C warrants in exchange for common shares, shares   (218,462)        
Shares issued for vested stock awards $ 1,262 (1,262)
Shares issued for vested stock awards, shares   14,675        
Issuance of common stock for conversion of Series C warrants $ 18,788 (17,452) 1,336
Issuance of common stock for conversion of Series C warrants, shares   218,462        
Issuance of common stock for conversion of Series D warrants $ 7,002 (6,207) 795
Issuance of common stock for conversion of Series D warrants, shares   81,423        
Issuance of common stock for conversion of Series B warrants $ 143 12,357 12,500
Issuance of common stock for conversion of Series B warrants, shares   1,667        
Warrant liability reclassified to equity upon exercise of Series B Warrants 8,000 8,000
Balance at Dec. 31, 2022 $ 104,883 35,798,139 (26,991,983) 8,911,039
Balance, shares at Dec. 31, 2022 1,219,573        
Share based compensation   $ 65,928 809,178   875,106
Share based compensation, shares   766,596        
Common shares issued for earnout liabilities   $ 54,714 2,946,331   3,001,045
Common shares issued for earnout liabilities, shares   636,228        
Shares issued due to conversion of preferred stock   $ 5,740 $ 639,260   $ 645,000
Shares issued due to conversion of preferred stock, shares   66,743        
Round up of shares due to reverse split   1,300 (1,300)  
Round up of shares due to reverse split, shares   15,336        
Shares issued in private placement   $ 13,333 $ 3,433,151   $ 3,446,484
Shares issued in private placement, shares   155,038        
Common shares issued for services   $ 22,412 567,448   589,860
Common shares issued for services, shares   260,602        
Common shares issued for Series B warrants   $ 32,100 628,410   660,510
Common shares issued for series B warrant in shares   373,264        
Common shares issued for Series E warrants   $ 77,193 (78,897)   (1,704)
Common shares issued for Series E warrants, shares   897,594        
Common shares issued for Series F warrants   $ 31,906 998,066   1,029,972
Common shares issued for Series F warrants, shares   371,000        
Net Income (loss)     (12,009,982) (12,009,982)
Balance at Dec. 31, 2023 $ 409,509 $ 45,739,786 $ (39,001,965) $ 7,147,330
Balance, shares at Dec. 31, 2023 4,761,974        
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net (Loss) income $ (12,009,982) $ 6,466,162
Adjustment to reconcile net income to net cash used in operating activities:    
Depreciation and amortization 2,609,191 2,563,518
Goodwill impairment 7,594,000
Amortization of debt issuance costs and accretion of debt discount 46,883 41,875
Non-cash lease expense (5,377) 21,452
Share based compensation expense 875,106 1,249,873
Share based payments to service providers 397,049
Recognition and change in fair value of warrant liability (5,503,647) (29,064,958)
Change in estimated acquisition earn-out payables 1,716,873 524
Change in operating assets and liabilities:    
Accounts receivable (304,542) 123,096
Accounts receivable, related parties 11,689 (11,161)
Other receivables 10,565 (11,464)
Prepaid expense and other current assets 104,590 2,501,023
Other non-current assets 2,992 (6,492)
Accounts payables and other accrued liabilities (48,266) (1,811,237)
Other payables (93,699) 269,613
Net cash used in continuing operating activities (4,596,575) (17,668,176)
Net cash provided by discontinued operating activities 3,748,605 14,478,179
Net cash used in continuing and discontinued operating activities (847,970) (3,189,997)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (22,864) (61,454)
Purchase of intangible assets (166,947) (740,922)
Proceeds from sale of investment in NSURE 900,000 450,000
Business acquisitions, net of cash acquired (6,000,000)
Net cash provided and used in continuing investing activities 710,189 (6,352,376)
Net cash used in discontinued investing activities (18,289,936)
Net cash provided and used in continuing and discontinued investing activities 710,189 (24,642,312)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Principal repayments of debt (1,090,622) (875,010)
Debt issuance costs (214,257)
Loans acquired through acquisitions 6,520,000
Issuance of common shares in exchange for Series B warrants 12,500
Issuance of common shares in exchange for Series C warrants 2,131
Proceeds from short term financing 241,975
Principal repayments of short-term financings (322,095) (310,383)
Payments of loans payable, related parties (1,045,164) (184,252)
Cash payments and proceeds of convertible debt, related parties (855,000) 1,500,000
Cash payments on earn-out liability (419,225) (1,704,924)
Proceeds from exercise of warrants into common stock 1,028,270 2,475,000
Private Placement of shares and warrants 3,446,484 17,853,351
Net cash provided from continuing financing activities 984,623 25,074,156
Net cash used and provided from discontinued financing activities (17,700) 47,200
Net cash provided from continuing and discontinued financing activities 966,923 25,121,356
Net increase and decrease in cash and restricted cash 829,142 (2,710,953)
Cash and restricted cash at beginning of year 1,909,769 4,620,722
Cash and restricted cash at end of year 2,738,911 1,909,769
SUPPLEMENTAL DISCLOSURE OF CASH AND NON-CASH TRANSACTIONS:    
Interest 1,612,829 863,936
Noncash investing and financing transactions:    
Common shares issued to settle convertible debt, related parties 645,000
Common shares issued for earnout liabilities 3,001,045
Common shares issued for Series B warrants 660,510 8,000
Common shares issued for Series D Warrants 36,761
Common shares issued for preferred stock 190,069
Common stock issued for pre-paid assets 192,811
Issuance of Series D Warrants 6,930,335
Issuance of placement agent warrants 1,525,923
Acquisition of business deferred purchase price liability   1,125,000
Lease assets acquired in exchange for lease liabilities $ 156,542 310,146
Noncash investing and financing transactions, discontinued operations   $ 5,081,309
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.1
ORGANIZATION AND DESCRIPTION OF BUSINESS
12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND DESCRIPTION OF BUSINESS

NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Reliance Global Group, Inc. (formerly known as Ethos Media Network, Inc.) (“RELI”, “Reliance”, or the “Company”) was incorporated in Florida on August 2, 2013.

 

On April 26, 2022, the Company acquired the assets of Barra & Associates, LLC., an unaffiliated full-service insurance agency headquartered in Illinois (see Note 3).

 

XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated financial statements included herein have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounting of Reliance Global Group, Inc., and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

 

Liquidity

 

As of December 31, 2023, the Company’s reported cash and restricted cash aggregated balance was approximately $2,739,000, current assets were approximately $4,379,000, while current liabilities were approximately 3,190,000. As of December 31, 2023, the Company had working capital of approximately $1,189,000 and stockholders’ equity of approximately $7,147,000. For the year ended December 31, 2023, the Company reported a loss from operations of approximately $13,879,000, of which $7,594,000 was related to goodwill impairment. The Company also reported a non-cash, non-operating gain on the recognition and change in fair value of warrant liabilities of approximately $5,504,000, other expense, primarily interest expense of approximately $1,650,000, which resulted in a loss from continuing operations of $10,025,000. Additionally, the Company reported a loss from discontinued operations of approximately $1,985,000. The total net loss of the company was approximately $12,010,000. The Company completed a capital offering in March 2023, raising net proceeds of approximately $3,446,000.

 

Although there can be no assurance that debt or equity financing will be available on acceptable terms, the Company believes its financial position and its ability to raise capital to be reasonable and sufficient. Based on our assessment, we do not believe there are conditions or events that, in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one year of filing these financial statements with the Securities and Exchange Commission (“SEC”).

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

 

 

Cash and Restricted Cash

 

Cash consists of checking accounts. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Restricted cash includes cash pledged as collateral to secure obligations and/or all cash whose use is otherwise limited by contractual provisions.

 

At times, some cash balances held in banks may exceed the Federal Deposit Insurance Corporation, or FDIC, standard deposit insurance limit of $250,000.

 

The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows:

 

 

  

December 31,

2023

  

December 31,

2022

 
Cash  $1,329,016   $505,410 
Restricted cash   1,409,895    1,404,359 
Total cash and restricted cash  $2,738,911   $1,909,769 

 

Property and Equipment

 

Property and equipment is stated at cost, less accumulated depreciation. Depreciation is recognized over an asset’s estimated useful life using the straight-line method beginning on the date an asset is placed in service. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Certain capitalized software has been reclassified in the consolidated balance sheet from property and equipment, net to intangibles, net and comparative periods have been adjusted accordingly. Maintenance and repairs are charged to expense as incurred. Estimated useful lives of the Company’s Property and Equipment are as follows:

 

   Useful Life (in years) 
Computer equipment   5 
Office equipment and furniture   7 
Leasehold improvements   Shorter of the useful life or the lease term 

 

Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance includes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels of the fair value hierarchy are as follows:

 

Level 1 — Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities;

 

Level 2 — Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and

 

Level 3 — Unobservable inputs for the asset or liability, which include management’s own assumption about the assumptions market participants would use in pricing the asset or liability, including assumptions about risk.

 

As of December 31, 2023, and 2022 respectively, the Company’s balance sheet includes certain financial instruments, including cash, notes receivables, accounts payable, and short and long-term debt. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amounts of long-term debt approximate their fair value as the variable interest rates are based on a market index.

 

 

Warrant Liabilities: The Company’s warrant liabilities (see Note 9, Warrant Liabilities) represent liability-classified derivative financial instruments recorded at fair value on a recurring basis. The fair value of the Warrant Liabilities includes significant inputs unobservable in the market and thus are considered Level 3. The Company measured the fair value of the warrant liabilities at the issuance date, December 12, 2023, and subsequently at the balance sheet date, using a binomial option pricing model. The following summarizes the significant unobservable inputs:

 

  

  

December 31,

2023

  

December 31,

2022

 
Stock price  $0.54   $8.55 
Volatility   110.0%   105.0%
Time to Expiry   4.99    4.01 
Dividend yield   0%   0%
Risk free rate   3.8%   4.1%

 

The following reconciles the warrant liabilities for the years ended December 31, 2023 and 2022:

 

  

                     
   Years ended December 31, 2023 and 2022 
   Series B Warrant Commitment   Series B warrant liabilities   Placement agent warrants   Total 
Beginning balance, December 31, 2021   37,652,808    -    -    37,652,808 
Initial recognition   -    55,061,119    1,525,924    56,587,043 
Unrealized (gain) loss   17,408,311    (48,668,869)   (1,477,024)   (32,737,582)1
Warrants exercised or transferred   (55,061,119)   (8,000)   -    (55,069,119)
Ending balance, December 31, 2022  $-   $6,384,250   $48,900   $6,433,150 
Unrealized (gain) loss        (5,534,931)   (48,575)   (5,583,506)2
Warrants exercised or exchanged   -    (580,651)   -    (580,651)
Ending balance, December 31, 2023   -   $268,668   $325   $268,993 

 

1 Recognition and change in fair value of warrant liabilities per income statement is $29,064,958. The difference of $3,672,624 is made up of the Warrant issuance costs.
2 Recognition and change in fair value of warrant liabilities per income statement is $5,503,647. The difference of $79,859 was due to a loss on a warrant exchange.

 

Earn-out liabilities: The Company generally values its Level 3 earn-out liabilities using the income valuation approach. Key valuation inputs include contingent payment arrangement terms, projected revenues and cash flows, rate of return, and probability assessments. The following table summarizes the significant unobservable inputs used in the fair value measurements:

 

   

    December 31, 2023   December 31, 2022
Valuation technique   Discounted cash flow   Discounted cash flow
Significant unobservable input   Projected revenue and probability of achievement   Projected revenue and probability of achievement

 

 

The Company values its Level 3 earn-out liability related to the Southwestern Montana Insurance Center acquisition using a Monte Carlo simulation in a risk-neutral framework (a special case of the Income Approach). The following summarizes the significant unobservable inputs:

 

 

  

December 31,

2023

 
Volatility   110%
Credit Spread   7.73%
Number of trading days   252 
Risk free rate   5.34

%

Remaining term (years)   0.2 
Stock Price  $0.54 
Dividend Yield   0%
Number of Iterations   100,000 

 

Undiscounted remaining earn out cash payments were approximately $165,000 as of December 31, 2023. The following table reconciles fair value of earn-out liabilities for the years ending December 31, 2023 and 2022:

  

 

   December 31,
2023
   December 31,
2022
 
Beginning balance – January 1  $2,709,478   $3,813,878 
           
Acquisitions and Settlements   (3,260,403)   (1,104,924)
           
Period adjustments:          
Fair value and estimate changes*   1,716,873    524 
Earn-out payable in common shares   (159,867)   - 
Earn-out transferred to loans payable, related parties   (846,214)   

-

 
           
Ending balance  $159,867   $2,709,478 
Less: Current portion   (159,867)   (2,153,478)
Ending balance, less current portion  $-   $556,000 

 

* Recorded as change in estimated acquisition earn-out payables on the consolidated statements of operations.

 

Deferred Financing Costs

 

The Company has recorded deferred financing costs because of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized to interest expense using the straight-line method which approximates the interest rate method over the term of the related debt. As of December 31, 2023, and 2022, unamortized deferred financing costs were $273,864, and $313,829, respectively and are netted against the related debt.

 

Business Combinations

 

The Company accounts for its business combinations using the acquisition method of accounting. Under the acquisition method, assets acquired, liabilities assumed, and consideration transferred are recorded at the date of acquisition at their respective fair values. Definite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

 

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration such as earn-outs, the Company records the contingent consideration at fair value at the acquisition date. The Company remeasures fair value as of each reporting date and changes resulting from events after the acquisition date, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings.

 

 

Identifiable Intangible Assets, net

 

Finite-lived intangible assets such as customer relationships assets, trademarks and tradenames are amortized over their estimated useful lives, generally on a straight-line basis for periods ranging from 3 to 20 years. Finite-lived intangible assets are reviewed for impairment or obsolescence whenever events or circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of intangible assets is measured by a comparison of the carrying amount of the asset to the future undiscounted net cash flows expected to be generated by that asset. If the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the estimated fair value. No impairment was recognized during the periods presented.

 

Goodwill and other indefinite-lived intangibles

 

The Company records goodwill when the purchase price of a business acquisition exceeds the estimated fair value of net identified tangible and intangible assets acquired. Goodwill is assigned on the acquisition date and tested for impairment at least annually, or more frequently when events or changes in circumstances indicate that the fair value of a reporting unit has more likely than not declined below its carrying value. Similarly, indefinite-lived intangible assets (if any) other than goodwill are tested annually or more frequently if indicated, for impairment. If impaired, intangible assets are written down to fair value based on the expected discounted cash flows.

 

Financial Instruments

 

The Company evaluates issued financial instruments for classification as either equity or liability based on an assessment of the financial instrument’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”) as well as in accordance with ASU 2020-06. The assessment considers whether the financial instruments issued are freestanding pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and, if applicable whether the financial instruments meet all of the requirements for equity classification under ASC 815, including whether the financial instruments are indexed to the Company’s own Common Stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance and as of each subsequent reporting period end date while the financial instruments are outstanding. Financial instruments that are determined to be liabilities under ASC 480 or ASC 815 are held at their initial fair value and remeasured to fair value at each subsequent reporting date, with changes in fair value recorded as a non-operating, non-cash loss or gain, as applicable.

 

The Company’s financial instruments consist of derivatives related to the warrants issued with the securities purchase agreement as discussed in Note 9, Warrant Liabilities. The accounting treatment of derivative financial instruments requires that we record the derivatives at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense at each balance sheet date. Upon the determination that an instrument is no longer subject to derivative accounting, the fair value of the derivative instrument at the date of such determination will be reclassified to paid in capital.

 

The adoption of Topic 326 did not significantly change our approach to the valuation of trade receivables. The Company determines whether there is an expected loss on our accounts receivable by reviewing all available data, including our customers' latest available financial statements, their credit standing, our historical collection experience, and current and future market and economic conditions. As of December 31, 2023, and December 31, 2022, it was not deemed necessary to recognize any allowance for credit losses on our trade receivables.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606 Revenue from Contracts with Customers which at its core, recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services.

 

The Company’s revenue is primarily comprised of agency commissions earned from insurance carriers (the “Customer” or “Carrier”) related to insurance plans produced through brokering, producing, and servicing agreements between insurance carriers and members. The Company defines a “Member” as an individual, family or entity currently covered or seeking insurance coverage.

 

 

The Company focuses primarily on agency services for insurance products in the “Healthcare” and property and casualty, which includes auto (collectively “P&C”) space, with nominal activity in the life insurance and bond sectors. Healthcare includes plans for individuals and families, Medicare supplements, ancillary and small businesses. The Company also earns revenue in the “Insurance Marketing” space as discussed further below.

 

Consideration for all agency services typically is based on commissions calculated by applying contractual commission rates to policy premiums. For P&C, commission rates are applied to premiums due, whereas for healthcare, commission rates, including override commissions, are applied to monthly premiums received by the Carrier.

 

The Company has two forms of billing practices, “Direct Bill” and “Agency Bill”. With Direct Bill, Carriers bill and collect policy premium payments directly from Members without any involvement from the Company. Commissions are paid to the Company by the Carrier in the following month. With Agency Bill, the Company bills Members premiums due and remits them to Carriers net of commission earned.

 

The following outlines the core principles of ASC 606:

 

Identification of the contract, or contracts, with a customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

 

Identification of the performance obligations in the contract. Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract.

 

Determination of the transaction price. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.

 

Allocation of the transaction price to the performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.

 

Recognition of revenue when, or as, the Company satisfies a performance obligation. The Company satisfies performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.

 

Healthcare revenue recognition:

 

The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.

 

There typically is one performance obligation in contracts with Carriers, to perform agency services that culminate in monthly premium cash collections by the Carrier. The performance obligation is satisfied through a combination of agency services including, marketing carrier’s insurance plans, soliciting Member applications, binding, executing and servicing insurance policies on a continuous basis throughout a policy’s life cycle which includes and culminates with the Customer’s collection of monthly premiums. No commission is earned if cash is not received by Carrier. Thus, commission revenue is earned only after a month’s cash receipts from Members’ dues is received by the Customer. Each month’s Carrier cash collections is considered a separate unit sold and transferred to the Customer i.e., the satisfaction of that month’s performance obligation.

 

 

Transaction price is typically stated in a contract and usually based on a commission rate applied to Member premiums paid and received by Carrier. The Company generally continues to receive commission payments from Carriers until a Member’s plan is cancelled or the Company terminates its agency agreement with the Carrier. Upon termination, the Company normally will no longer receive any commissions from Carriers even on business still in place. In some instances, trailing commissions could occur which would be recognized similar to other Healthcare revenue. With one performance obligation, allocation of transaction price is normally not necessary.

 

Healthcare typically utilizes the Direct Bill method.

 

The Company recognizes revenue at a point in time when it satisfies its monthly performance obligation and control of the service transfers to the Customer. Transfer occurs when Member insurance premium cash payments are received by the Customer. The Customer’s receipt of cash is the culmination and complete satisfaction of the Company’s performance obligation, and the earnings process is complete.

 

With Direct Bill, since the amount of monthly Customer cash receipts is unknown to the Company until the following month when notice is provided by Customer to Company, the Company accrues revenue at each period end. Any estimated revenue accrued and recognized at a period-end is trued up for financial reporting per actual revenue earned as provided by the Customer during the following month.

 

P&C revenue recognition:

 

The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.

 

There typically is one performance obligation in contracts with Customers, to perform agency services to solicit, receive proposals and bind insurance policies culminating with policy placement. Commission revenue is earned at the time of policy placement.

 

Transaction price is typically stated in a contract and usually based on commission rates applied to Member premiums due. With one performance obligation, allocation of transaction price is normally not necessary.

 

P&C utilizes both the Agency Bill and Direct Bill methods, depending on the Carrier.

 

The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of the service transfers to the Customer. Transfer occurs when the policy placement process is complete.

 

With both Direct Bill and Agency Bill, the Company accrues commission revenue in the period policies are placed. With Agency Bill, payment is typically received from Members in the month earned, however with Direct Bill, payment is typically received from Carriers in the month subsequent to the commissions being earned.

 

Other revenue policies: Insurance commissions earned from Carriers for life insurance products are recorded gross of amounts due to agents, with a corresponding commission expense for downstream agent commissions being recorded as commission expense within the condensed consolidated statements of operations.

 

When applicable, commission revenue is recognized net of any deductions for estimated commission adjustments due to lapses, policy cancellations, and revisions in coverage.

 

The Company could earn additional revenue from contingent commissions, profit-sharing, override and bonuses based on meeting certain revenue or profit targets established periodically by the Carriers (collectively, “Contingent Commissions”). Contingent Commissions are earned when the Company achieves targets established by Carriers. The Carriers notify the Company when it has achieved the target. The Company recognizes revenue for any Contingent Commissions at the time it is reasonably assured that a significant revenue reversal is not probable, which is generally when a Carrier notifies the Company that it is on track or has earned a Contingent Commission.

 

 

The following table disaggregates the Company’s revenue by line of business, showing commissions earned:

 

 

Year ended

December 31, 2023

  Medical   Life   Property and Casualty   Total 
                 
EBS  $883,327   $22,114   $-   $905,441 
USBA   43,193    3184    -    46,377 
CCS/UIS   -    -    289,486    289,486 
Montana   1,863,455    12,488    -    1,875,943 
Fortman   1,161,506    5,487    1,044,592    2,211,585 
Altruis   5,454,654    -    -    5,454,654 
Kush   1,209,854    -    -    1,209,854 
Reli Exchange   209,615    127,486    1,401,385    1,738,486 
Total  $10,825,064   $170,759   $2,735,463   $13,731,826 

 

Year ended

December 31, 2022

  Medical     Life     Property and Casualty     Total  
                                 
EBS   $ 781,570     $ 16,843     $ -     $ 798,413  
USBA     51,006       1462       -       52,468  
CCS/UIS     -       -              254,325       254,325  
Montana     1,860,475       7,661       -       1,868,136  
Fortman     1,267,945       6705       842,961       2,117,611  
Altruis     4,041,495       2954       -       4,044,449  
Kush     1,535,416       1040       -       1,536,456  
Reli Exchange     152,094       106,052       831,878       1,090,024  
Total   $ 9,690,001     $ 142,717     $ 1,929,164     $ 11,761,882  

 

General and Administrative

 

General and administrative expenses primarily consist of personnel costs for the Company’s administrative functions, professional service fees, office rent, all employee travel expenses, and other general costs.

 

Marketing and Advertising

 

The Company’s direct channel expenses primarily consist of costs for e-mail marketing and newspaper advertisements. The Company’s online advertising channel expense primarily consist of social media ads. Advertising costs for both direct and online channels are expensed as incurred.

 

Equity-Based Compensation

 

Equity-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, based on the terms of the awards. The fair value of the stock-based payments to nonemployees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. To the extent possible, the Company will estimate and recognize expected forfeitures.

 

 

Leases

 

The Company recognizes leases in accordance with Accounting Standards Codification Topic 842, “Leases” (“ASC 842” or “ASU 2016-12”). This standard provides enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases are recognized as a single lease expense, generally on a straight-line basis.

 

The Company is the lessee in a contract when the Company obtains the right to use an asset. We currently lease real estate and office space under non-cancelable operating lease agreements. When applicable, consideration in a contract is allocated between lease and non-lease components. Lease payments are discounted using the implicit discount rate in the lease. If the implicit discount rate for the lease cannot be readily determined, the Company uses an estimate of its incremental borrowing rate. The Company did not have any contracts accounted for as finance leases as of December 31, 2023, or 2022. Operating leases are included in the line items right-of-use assets, current portion of leases payable, and leases payable, less current portion in the consolidated balance sheets. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations. The Company determines a lease’s term by agreement with lessor and includes lease extension options and variable lease payments when option and/or variable payments are reasonably certain of being exercised or paid.

 

Income Taxes

 

The Company recognizes deferred tax assets and liabilities using enacted tax rates for the effect of temporary differences between the book and tax basis of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. In evaluating its ability to recover deferred tax assets within the jurisdiction in which they arise, the Company considers all available positive and negative evidence, including the expected reversals of taxable temporary differences, projected future taxable income, taxable income available via carryback to prior years, tax planning strategies, and results of recent operations. The Company assesses the realizability of its deferred tax assets, including scheduling the reversal of its deferred tax assets and liabilities, to determine the amount of valuation allowance needed. Scheduling the reversal of deferred tax asset and liability balances requires judgment and estimation. The Company believes the deferred tax liabilities relied upon as future taxable income in its assessment will reverse in the same period and jurisdiction and are of the same character as the temporary differences giving rise to the deferred tax assets that will be realized.

 

Discontinued Operations

 

The Company’s board of directors approved the discontinuation and abandonment of Medigap Healthcare Insurance Company, LLC (“Medigap”), a subsidiary of the Company, effective April 17, 2023, due to Medigap’s sustained recurring losses stemming from amongst other factors, greater than anticipated revenue chargebacks. The Company was unable to divest its interest in Medigap for value, and accordingly, operations were wound down in an orderly manner. In doing so, the Company transferred to its operating entity, Medigap’s customer relationships and internally developed and purchased software intangible assets, with net of amortization combined value of approximately $4,300,000, as well as, its short-term financing arrangement of $29,500, and each are respectively classified at their adjusted book values in the intangible assets and short term financing agreements accounts in the condensed consolidated balance sheets for the periods ended December 31, 2023 and December 31, 2022. These assets have continued value to the Company and have not been impaired as the fair value exceeds carrying cost. Medigap’s remaining assets were considered to have no remaining asset value and were fully impaired. Certain liabilities and estimated liabilities as outlined in the tables herein, were discharged and/or written-off in conjunction with the Settlement Agreement (as defined below) because of them having a net zero dollar estimated liability value. Accordingly, the Company recognized a net of estimated liability adjustments gain/loss of approximately $0, and an impairment loss of approximately $4,400,000, presented in income (loss) from discontinued operations in the consolidated statements of operations for the year ended December 31, 2023. As part of the abandonment, the Company cancelled third party contracts, settled outstanding vendor and other third-party obligations, ceased to enter new customer contracts via Medigap, and no further customer performance obligations existed. The Company does not expect further continuing involvement with Medigap, and in accordance with ASC 205-20-45-9, no corporate overhead has been allocated to discontinued operations.

  

Settlement Agreement

 

On June 30, 2023, the Company entered into a confidential settlement agreement and mutual release (the “Settlement Agreement”) with certain Medigap affiliated entities and persons, and the former owners of Medigap, whereby the Company would receive a settlement payment, net of costs, of $2,761,190 and was released from all past and future Medigap obligations and liabilities. The settlement payment was received in full by the Company in July 2023 and is recorded as income from discontinued operations in the condensed consolidated statements of operations for the year ended December 31, 2023.

 

The following tables present the major components of assets and liabilities included in discontinued operations on the condensed consolidated balance sheets.

 

 

   December 31, 2023   December 31, 2022 
Accounts receivable  $     -   $          73,223 
Accounts receivable, related parties   -    3,595 
Other receivables   -    5,388 
Prepaid expense and other current assets   -    3,792 
Current Assets - Discontinued Operations  $-   $85,998 
           
Condensed consolidated balance sheets - Current Assets - Discontinued Operations  $-   $85,998 
           
Property and equipment, net   -   $24,116 
Right-of-use assets   -    163,129 
Intangibles, net   -    318,000 
Goodwill   -    4,825,634 
Other Assets - Discontinued Operations  $-   $5,330,879 
           
Condensed consolidated balance sheets - Other Assets - Discontinued Operations  $-   $5,330,877 
           
Accounts payable and other accrued liabilities   -   $506,585 
Chargeback reserve   -    915,934 
Current portion of leases payable   -    178,117 
Current Liabilities - Discontinued Operations  $-   $1,600,636 
           
Condensed consolidated balance sheets - Current Liabilities - Discontinued Operations  $-   $1,600,636 

 

 

The following table rolls forward Medigap’s assets and liabilities from their carrying values pre-abandonment to their values post abandonment, and presents the impact of reclassifications, impairments, and write-offs:

 

Medigap Related Assets  Carrying Value Prior To Abandonment   Asset and Liability Transfers Retained by the Company   Asset Impairments and Liability Write-Offs   Carrying Value as of December 31, 2023 
                 
Accounts receivable  $56,398   $-   $(56,398)  $       - 
Accounts receivable, related party   3,595    -    (3,595)   - 
Other receivables   5,388    -    (5,388)   - 
Current assets – Medigap  $65,381   $-   $(65,381)  $- 
                     
Property and equipment, net  $22,378   $-   $(22,378)  $- 
Right-of-use assets   119,594    -    (119,594)   - 
Intangibles, net   4,570,536    (4,258,214 )1    (312,322)   - 
Goodwill   4,825,634    -    (4,825,634)   - 
Other assets - Medigap  $9,538,142   $(4,258,214)  $(5,279,928)  $- 
                     
Total assets - Medigap  $9,603,523   $(4,258,214)  $(5,345,309)  $- 
                     
Accounts payable and other accrued liabilities  $4,157   $-   $(4,157)  $- 
Short term financing agreements   29,500    (29,500)   -    - 
Chargeback reserve   831,725    -    (831,725 )2    - 
Current portion of leases payable   134,517    -    (134,517 )3    - 
Other liabilities   9,842    -    (9,842 )3    - 
Current liabilities - Medigap  $1,009,741   $(29,500)  $(980,241)  $- 
                     
Total liabilities - Medigap  $1,009,741   $(29,500)  $(980,241)  $- 
                     
Net assets and liabilities - Medigap  $8,593,782   $(4,228,714)  $(4,365,068)  $- 

 

  1 Includes customer relationships and internally developed and purchased software intangible assets that have continued value to the Company and have not been impaired as the fair value exceeds carrying cost.
  2 Estimated liability write-off per net zero dollar estimated liability value.
  3 Liability discharge pursuant to the Settlement Agreement.

 

The following tables disaggregate the major classes of pretax gain and loss as presented in discontinued operations in the condensed consolidated statements of operations.

 

  

Year Ended

December 31, 2023

  

Year Ended

December 31, 2022

 
Income          
Commission income  $744,030   $4,994,002 
           
Expenses          
Commission expense   110,639    604,042 
Salaries and wages   454,663    1,973,579 
General and administrative    129,363    508,342 
Marketing and advertising   426,818    2,414,583 
Depreciation and amortization   7,283    238,307 
Other expenses (income)   (3,902)   (22,454)
Total discontinued operations expenses before impairments and write-offs   1,124,864    5,716,399 
Total discontinued operations income / (loss) before impairments and write-offs  $(380,834)  $(722,397)
Gains and (losses) from recoveries and impairments / write-offs of discontinued operations assets and liabilities          
           
Settlement Recovery, net of costs  $2,761,190    - 
           
Asset impairment losses          
Accounts receivable   56,398    - 
Accounts receivable, related parties   3,595    - 
Other receivables   5,388    - 
Property and equipment, net   22,378    - 
Right-of-use assets   119,593    - 
Intangibles, net   312,322    - 
Goodwill   4,825,634    14,373,374 
Total asset impairments   5,345,308    14,373,374 
           
Liability write-off gains          
Accounts payable and other accrued liabilities   4,154    - 
Other payables   9,842    - 
Chargeback reserve   831,725    - 
Current portion of leases payable   134,517    - 
Total liability write-off gains   980,238    - 
           
Discontinued operations net asset and liability impairments / write-offs gains and (losses)   4,365,070    14,373,374 
           
Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities   (1,603,880)   (14,373,374)
           
Loss from discontinued operations before tax   (1,984,714)   (15,095,770)
           
Consolidated statement of operations - Loss from discontinued operations before tax  $(1,984,714)  $(15,095,770)

 

Seasonality

 

A greater number of the Company’s Medicare-related health insurance plans are sold in the fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage. The majority of the Company’s individual and family health insurance plans are sold in the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.

 

 

Recently Issued Accounting Pronouncements

 

In March 2024, the FASB issued ASU No. 2024-01, Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards (“ASU 2024-01”), to clarify the scope application of profits interest and similar awards by adding illustrative guidance in ASC 718, Compensation - Stock Compensation.  The ASU clarifies how to determine whether profits interest and similar awards are in the scope of ASC 718 and applies to all reporting entities that account for profits interest awards as compensation to employees or non-employees. In addition to adding the illustrative guidance, the ASU modified the language in paragraph 718-10-15-3 to improve its clarity and operability. However, this amendment does not change the intent of that guidance, nor how it should be applied. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024, including interim periods within those years. The Company is currently evaluating the effects of the adoption of ASU No. 2024-01 on its consolidated financial statements.

 

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segment’s profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures.

 

XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.1
STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS
12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS

NOTE 3. STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS

 

To date, we have acquired ten insurance brokerages (see table below). As our acquisition strategy continues, our reach within the insurance arena can provide us with the ability to offer lower rates, which could boost our competitive position within the industry.

 

Acquired   Reliance 100% Controlled Entity   Date   Location   Line of Business
                 
U.S. Benefits Alliance, LLC (USBA)   US Benefits Alliance, LLC   October 24, 2018   Michigan   Health Insurance
                 
Employee Benefit Solutions, LLC (EBS)   Employee Benefits Solutions, LLC   October 24, 2018   Michigan   Health Insurance
                 
Commercial Solutions of Insurance Agency, LLC (CCS or Commercial Solutions)   Commercial Coverage Solutions LLC   December 1, 2018   New York   P&C – Trucking Industry
                 
Southwestern Montana Insurance Center, Inc. (Southwestern Montana or Montana or SWMT)   Southwestern Montana Insurance Center, LLC   April 1, 2019   Montana   Group Health Insurance
                 
Fortman Insurance Agency, LLC (Fortman or Fortman Insurance or FIS)   Fortman Insurance Solutions, LLC   May 1, 2019   Ohio  

P&C and

Health Insurance

                 
Altruis Benefits Consultants, Inc. (Altruis or ABC)   Altruis Benefits Corporation   September 1, 2019   Michigan   Health Insurance
                 
UIS Agency, LLC (UIS)   UIS Agency, LLC   August 17, 2020   New York   P&C – Trucking Industry
                 
J.P. Kush and Associates, Inc. (Kush)   Kush Benefit Solutions, LLC   May 1, 2021   Michigan   Health Insurance
                 
Barra & Associates, LLC (Barra)   RELI Exchange, LLC   April 26, 2022   Illinois  

P&C and

Health Insurance

 

 

Barra & Associates, LLC Transaction

 

On April 26, 2022, we entered into an asset purchase agreement (the “APA”) with Barra & Associates, LLC (“Barra”) pursuant to which the Company purchased all of the assets of Barra & Associates, LLC on April 26, 2022 for a purchase price in the amount of $7,725,000 in cash, with $6,000,000 paid to Barra at closing, $1,125,000 payable in nine months from closing, and a final earnout of $600,000 payable over two years from closing based upon meeting stated milestones. The APA contains standard, commercial representations and warranties and covenants. The source of the cash payment was $6,520,000 in funds borrowed from Oak Street Lending (“Loan”), our existing lender pursuant to a Fifth Amendment to Credit Agreement and Promissory Note, of even date. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties.

 

The acquisition of Barra was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.

 

The preliminary allocation of the purchase price in connection with the acquisition of Barra was calculated as follows:

 

  

Description  Fair Value  

Weighted

Average Useful

Life (Years)

 
Acquired accounts receivable  $92,585      
Property, plant, and equipment   8,593    7 
Right-of-use asset   122,984      
Trade names   22,000    4 
Customer relationships   550,000    10 
Developed technology   230,000    5 
Agency relationships   2,585,000    10 
Lease liability   (122,984)     
Goodwill   4,236,822    Indefinite 
   $7,725,000      


 

 

Trade name was measured at fair value using the relief-from-royalty method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue from the trade name, a pre-tax royalty rate of 0.5% and a discount rate of 19.5%.

 

Customer and Agency relationships were measured at fair value using the multiple-period excess earnings method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue and costs associated with existing customers, and a discount rate of 19.5%.

 

Developed technology was measured at fair value using the cost replacement method of the cost approach. Significant inputs used to measure the fair value include an estimate of cost to replace, an obsolescence rate of 28.6%.

 

Goodwill of $4,236,822 arising from the acquisition of Barra consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the acquisition of Barra is currently expected to be deductible for income tax purposes. Total acquisition costs incurred for the acquisition of Barra were $72,793 recorded as a component of General and administrative expenses.

 

The approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from April 26, 2022 to December 31, 2022 was $1,090,023 and a loss of $393,708, respectively.

 

Pro Forma Information

 

The results of operations of Barra will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental pro forma financial information approximate combined financial information assumes that the acquisition had occurred at the beginning of the nine months ended December 31, 2022:

 

  

    December 31, 
    2022 
Revenue   $12,309,504 
Net Income (Loss)   $6,700,594 
Earnings (Loss) per common share, basic   $(0.21)
Earnings (Loss) per common share, diluted   $(0.21)

 

XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.1
INVESTMENT IN NSURE, INC.
12 Months Ended
Dec. 31, 2023
Investments, All Other Investments [Abstract]  
INVESTMENT IN NSURE, INC.

NOTE 4. INVESTMENT IN NSURE, INC.

 

On February 19, 2020, the Company entered into a securities purchase agreement with NSURE, Inc. (“NSURE”), which was further amended on October 8, 2020, and as amended provides that the Company may invest up to an aggregate of $5,700,000 in NSURE to be funded in three tranches. In exchange, the Company will receive a total of 928,343 shares of NSURE’s Class A Common Stock.

 

During the year 2020, by October 8, 2020, the Company funded the first tranche, $1,350,000 in exchange for 394,029 shares. The second tranche allowed the Company to acquire an additional 209,075 shares at a price of $6.457 per share by no later than December 30, 2020. The third full tranche allowed the Company to purchase an additional 325,239 shares at a purchase price of $9.224 after December 20, 2020, but no later than March 31, 2021.

 

The Company did not fund tranches two and three in the required timeframes, thus, the Company relinquished its rights under the contract to any additional NSURE shares aside for the ones already acquired with tranche one.

 

During the fourth quarter of the year ended December 31, 2022, the Company sold 131,345 of its NSURE shares to unaffiliated third parties, receiving cash proceeds of $450,000. During April 2023, the Company sold its remaining 262,684 of NSURE shares to unaffiliated third parties, receiving the shares’ cost basis and cash proceeds of $900,000. The Company’s remaining NSURE share balance as of December 31, 2023, was $0.

 

 

The Company measured the NSURE shares subsequent to acquisition in accordance with ASC 321-10-35-2, at cost less impairment since no readily determinable fair value was available to the Company. The investment was reviewed for impairment at each reporting period by qualitatively assessing any indicators demonstrating fair value of the investment is less than carrying value. The Company did not observe any price changes resulting from orderly transactions for identical or similar assets for the years ended December 31, 2023, or 2022. ASC 321-10-50-4 further requires an entity to disclose unrealized gains and losses for periods that relate to equity securities held at a reporting date. To date, the Company has not recognized any unrealized gains or losses on NSURE security.

 

XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.1
PROPERTY AND EQUIPMENT
12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

NOTE 5. PROPERTY AND EQUIPMENT

 

Property and equipment consists of the following:

 

  

December 31,

2023

  

December 31,

2022

 
Computer equipment  $110,350   $92,278 
Office equipment and furniture   47,652    40,693 
Leasehold Improvements   120,378    122,830 
Property and equipment   278,380    255,801  
Less: Accumulated depreciation   (138,381)   

(93,034

)
Property and equipment, net  $139,999   $162,767 

 

Depreciation expense associated with property and equipment, is included within depreciation and amortization in the Company’s consolidated statements of operations and is, $45,632 and $37,638 for the years ended December 31, 2023, and 2022, respectively.

 

XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.1
GOODWILL AND OTHER INTANGIBLE ASSETS
12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS

NOTE 6. GOODWILL AND OTHER INTANGIBLE ASSETS

 

In accordance with ASC 350-20-35-45, all the Company’s goodwill is assigned to a single operating and reporting unit. All acquisitions made by the Company are in one general insurance agency industry and operate in a very similar economic and regulatory environment. The Company has one executive who is responsible for the operations of the insurance agencies. This executive reports directly to the Chief Executive Officer (“CEO”) on a quarterly basis. Additionally, the CEO who is responsible for the strategic direction of the Company reviews the operations of the insurance agency business collectively, as opposed to office by office.

 

For the year ended December 31, 2022, due to a declining market capitalization attributed to Medigap’s performance, the Company performed a goodwill impairment test utilizing a hybrid of the Market Approach – Traded Market Value Method and Income Approach – Discounted Cash Flow Method and Discounted Forward Market Multiple Method, concluding that the Company’s fair value and resultant net assets, implied a goodwill balance of $19,100,000 versus our goodwill balance prior to write-down of $33,400,000. Thus, the Company recognized an approximate impairment charge of $14,373,000 presented in the loss from discontinued operations before tax account in the consolidated statements of operations for the year ended December 31, 2022.

 

As of June 30, 2023, the Company recognized an additional goodwill impairment of $4,825,634 upon the abandonment of Medigap, presented in the loss from discontinued operations before tax account in the consolidated statements of operations for the year ended December 31, 2023.

 

For the year ended December 31, 2023, due to a declining market capitalization, the Company performed a quantitative goodwill impairment test utilizing the discounted cash flow method of the income approach with market participant control adjustments in consideration of market capitalization, and concluded that the Company’s carrying value of equity exceeded its fair value of equity in the approximate amount of $7,594,000 which the Company recognized as a goodwill impairment charge, presented in the goodwill impairment account on the consolidated statements of operations for the year ended December 31, 2023.

 

 

The following table rolls forward the Company’s goodwill balance for the periods ending December 31, 2023 and 2022 exclusive of discontinued operations.

  

   Goodwill 
December 31, 2021  $10,050,277 
Goodwill recognized in connection with Barra acquisition on April 26, 2022   4,236,822 
December 31, 2022   14,287,099 
Goodwill impairment recognized as of December 31, 2023   (7,594,000)
December 31, 2023  $6,693,099 

 

The following table rolls forward the Company’s goodwill balance for the periods ended December 31, 2023, and December 31, 2022 inclusive of discontinued operations.

 

   Goodwill 
December 31, 2021  $10,050,277 
Goodwill recognized in connection with Medigap acquisition   19,199,008 
Goodwill recognized in connection with Barra acquisition   4,236,822 
Goodwill impairment (Medigap) during the year-ended December 31, 2022   (14,373,374)
December 31, 2022   19,112,733 
Goodwill impairment (Medigap) during the year ended December 31, 2023   (4,825,634)
Goodwill impairment recognized as of December 31, 2023   (7,594,000)
December 31, 2023  $6,693,099 

 

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2023:

  

   Weighted Average Remaining Amortization period (Years)   Gross Carrying Amount   Accumulated Amortization  

Net

Carrying Amount

 
Trade name and trademarks   1.5   $1,807,189   $(1,320,939)  $486,250 
Internally developed software   3.2    1,798,922    (650,029)   1,148,893 
Customer relationships   8.0    11,922,290    (3,193,629)   8,728,661 
Purchased software   0.3    667,206    (618,418)   48,788 
Video Production Assets   -    50,000    (50,000)   - 
Non-competition agreements   0.9    3,504,810    (2,874,645)   630,165 
Trade name and trademarks       $19,750,417   $(8,707,660)  $11,042,757 

 

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2022:

 

   Weighted Average Remaining Amortization period (Years)   Gross Carrying Amount   Accumulated Amortization  

Net

Carrying Amount

 
Trade name and trademarks   4.4   $1,806,188   $(969,241)  $836,947 
Internally developed software   4.1    1,635,178    (287,990)   1,347,188 
Customer relationships   9.0    11,922,290    (2,076,086)   9,846,204 
Purchased software   0.4    665,137    (581,497)   83,640 
Video Production Assets   0.0    50,000    (50,000)   - 
Non-competition agreements   1.9    3,504,810    (2,179,420)   1,325,390 
        $19,583,603   $(6,144,234)  $13,439,369 

 

Amortization expense is $2,563,559 and $2,525,880 for the years ended December 31, 2023 and 2022, respectively.

 

 

The following table reflects expected amortization expense as of December 31, 2023, for each of the following five years and thereafter:

 

Years ending December 31,  Amortization Expense 
2024  $2,195,191 
2025   1,801,235 
2026   1,532,267 
2027   1,196,989 
2028   1,097,825 
Thereafter   3,218,683 
Total  $11,042,757 

 

XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.1
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Significant components of accounts payable and accrued liabilities were as follows:

 

  

December 31,

2023

  

December 31,

2022

 
         
Accounts payable,  $635,339   $747,469 
Accrued expenses   40,540    109,502 
Accrued credit card payables   54,416    58,120 
Other accrued liabilities   105,188    36,291 
Accounts payable and other accrued liabilities  $835,483   $951,382 

 

XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.1
LONG-TERM DEBT
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
LONG-TERM DEBT

NOTE 8. LONG-TERM DEBT

 

The composition of the long-term debt follows:

 

  

December 31,

2023

  

December 31,

2022

 
         
Oak Street Funding LLC Term Loan  $369,602   $426,883 
Oak Street Funding LLC Term Loan for the acquisition of EBS and USBA, variable interest of Prime Rate plus 2.5%, maturing August 2028, net of deferred financing costs of $10,069 and $12,388 as of December 31, 2023 and 2022, respectively  $369,602   $426,883 
Oak Street Funding LLC Senior Secured Amortizing Credit Facility for the acquisition of CCS, variable interest of Prime Rate plus 1.5%, maturing December 2028, net of deferred financing costs of $12,525 and $15,076 as of December 31, 2023 and 2022, respectively   604,830    693,682 
Oak Street Funding LLC Term Loan for the acquisition of SWMT, variable interest of Prime Rate plus 2.0%, maturing April 2029 net of deferred financing costs of $7,733 and $9,206 as of December 31, 2023 and 2022, respectively   695,758    788,596 
Oak Street Funding LLC Term Loan for the acquisition of FIS, variable interest of Prime Rate plus 2.0%, maturing May 2029, net of deferred financing costs of $31,026 and $36,843 as of December 31, 2023 and 2022, respectively   1,758,558    1,987,846 
Oak Street Funding LLC Term Loan for the acquisition of ABC, variable interest of Prime Rate plus 2.0%, maturing September 2029, net of deferred financing costs of $35,649 and $42,129 as of December 31, 2023 and 2022, respectively   2,899,409    3,249,575 
Oak Street Funding LLC Term Loan, variable interest of Prime Rate plus 2.5%, maturing May 2032, for the acquisition of Barra, net of deferred financing costs of $176,762 and $198,188 as of December 31, 2023 and December 31, 2022, respectively   6,089,580    6,321,812 
Long term debt gross   12,417,737    13,468,394 
Less: current portion   (1,390,766)   (1,118,721)
Long-term debt  $11,026,971   $12,349,673 

 

 

Oak Street Funding LLC – Term Loans and Credit Facilities

 

During the year of 2018 the Company entered into two debt agreements with Oak Street Funding LLC (“Oak Street”). On August 1, 2018, EBS and USBA entered into a Credit Agreement with Oak Street whereby EBS and USBA borrowed $750,000 from Oak Street under a Term Loan. The Term Loan is secured by certain assets of the Company. Interest accrues at 11.00% on the basis of a 360-day year, maturing 120 months from the Amortization Date (September 25, 2018). The Company incurred debt issuance costs associated with the Term Loan in the amount of $22,188. On December 7, 2018, CCS entered into a Facility with Oak Street whereby CCS borrowed $1,025,000 from Oak Street under a senior secured amortizing credit facility. The borrowing rate under the Facility is a variable rate equal to Prime +1.50% and matures 10 years from the closing date. The Company incurred debt issuance costs associated with the Facility in the amount of $25,506, which were deferred and are amortized over the length of the Facility.

 

During the year of 2019 the Company entered in a number of Credit Agreements with Oak Street whereby the Company borrowed a total amount of $7,912,000 under the Term Loans. The Term Loans are secured by certain assets of the Company. The borrowing rates under the Facility is a variable rate equal to Prime + 2.00% and matures 10 years from the closing date. The Company recorded debt issuance costs associated with the loans in total of $181,125.

 

On April 26, 2022 the Company entered into a secured promissory note (the Note) with Oak Street subject to the terms of the Master Credit Agreement, whereby the Company borrowed $6,250,000 with a maturity date of May 25, 2032. The Note is secured by certain assets of the Company and subject to certain financial covenants. Interest accrues at the Prime Rate plus an Applicable Margin of 2.500% on the basis of a 360-day year. The Company incurred debt issuance costs associated with the Note of $214,257.

 

Aggregated cumulative maturities of long-term obligations (including the Term Loan and the Facility), excluding deferred financing costs, as of December 31, 2023 are:

  

Fiscal year ending December 31, 

Maturities of

Long-Term Debt

 
2024  $1,390,766 
2025   1,552,772 
2026   1,729,160 
2027   1,925,603 
2028   2,107,128 
Thereafter   3,986,172 
Total   12,691,601 
Less debt issuance costs   (273,864)
Total  $12,417,737 

 

Short-Term Financings

 

The Company has various short-term notes payable for financed items such as insurance premiums and CRM software purchases. Total financed for the year ended December 31, 2023 and 2022 respectively was approximately $181,000 and $482,000. These are normally paid in equal installments over a period of twelve months or less and carry interest rates ranging between 12.75% and 0% per annum. As of December 31, 2023 and 2022, approximately $56,000 and $154,000 remains outstanding on short-term financings.

 

 

XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.1
WARRANT LIABILITIES
12 Months Ended
Dec. 31, 2023
Warrant Liabilities  
WARRANT LIABILITIES

NOTE 9. WARRANT LIABILITIES

 

Series B Warrants

 

On December 22, 2021, the Company entered into a securities purchase agreement (SPA) with two institutional investors for the purchase and sale of (i) warrants to purchase up to an aggregate of 651,997 shares of the Company’s common stock, par value $0.086 per share at an exercise price of $61.35 per share, (ii) an aggregate of 178,060 shares of Common Stock, and (iii) 9,076 shares of the Company’s newly-designated Series B convertible preferred stock, par value $0.086 per share, with a stated value of $1,000 per share, initially convertible into an aggregate of 147,939 shares of Common Stock at a conversion price of $61.35 per share, each a freestanding financial instrument, (the “Private Placement”). The aggregate purchase price for the Common Shares, the Preferred Shares and the Warrants was approximately $20,000,000.

 

By entering into the Private Placement on December 22, 2021, the Company entered into a commitment to issue the Common Shares, Preferred Shares, and Series B Warrants on the Initial Closing Date for a fixed price and exercise price, as applicable. The commitment to issue Series B Warrants (the “Warrant Commitment”) represents a derivative financial instrument, other than an outstanding share, that, at inception, has both of the following characteristics: (i) embodies a conditional obligation indexed to the Company’s equity. The Company classified the commitment to issue the warrants as a derivative liability because it represents a written option that does not qualify for equity accounting The Company initially measured the derivative liability at its fair value and will subsequently remeasure the derivative liability, at fair value with changes in fair value recognized in earnings. An option pricing model was utilized to calculate the fair value of the Warrant Commitment. The Company initially recorded $17,408,311 of non-operating unrealized losses within the recognition and change in fair value of warrant liabilities account for the year ended December 31, 2021.

 

The Private Placement closed on January 4, 2022, at which time the Company remeasured the derivative liability for the warrants issued in the transaction, recognizing $17,408,311 of non-operating unrealized losses and a derivative liability of $55,061,119. The closing of the Private Placement settled the subscription receivable reported on the Company’s balance sheet as of December 31, 2021.

 

Pursuant to the terms of the SPA, due to a non-Private Placement related dilutive share issuance, effective December 27, 2022, the Series B Warrants outstanding increased to 1,333,333 and the exercise price reset to $7.50. On December 27, 2022, 1,667 Series B Warrants were exercised into 1,667 shares of common stock with cash proceeds to the Company of $12,500. Pursuant to a number of dilutive issuances throughout fiscal year 2023, as of December 31, 2023, the exercise price in effect was $0.63.

 

On December 12, 2023, the Company entered into an agreement with one of the SPA institutional investors, pursuant to which (i) the Company extended the expiration date of their 866,667 remaining outstanding Series B Warrants to December 28, 2028 and (ii) institutional investor waived a restriction in the SPA such that the Company will be permitted to consummate an “at-the-market offering” with a registered broker-dealer, whereby such registered broker-dealer is acting as principal or agent in the purchase of shares (the “ATM”) of the Company’s common stock from the Company after sixty (60) days following December 14, 2023. Further, on December 12, 2023, the Company entered into an exchange offer with the other SPA institutional investor, pursuant to which the investor exchanged its remaining Series B Warrants to purchase 300,000 shares of Common Stock for 300,000 shares of Common Stock.

 

For the years ended December 31, 2023 and 2022, net fair value gains recognized for the Series B Warrants were $5,534,931 and $48,668,869 respectively, presented in the recognition and change in fair value of warrant liabilities account in the consolidated statements of operations. The Series B Warrant liability outstanding as of December 31, 2023 and 2022 is $268,667 and $6,384,250 respectively, presented in the warrant liability account on the consolidated balance sheets and there remain 866,667 of Series B Warrants outstanding.

 

Placement Agent Warrants

 

In connection with the Private Placement, the Company issued 16,303 warrants to the placement agent for the Private Placement. The warrants were issued as compensation for the Placement Agent’s services. The Placement Agent Warrants (PAW) are: (i) exercisable on any day after the six (6) month anniversary of the issue date, (ii) expire five years after the closing of the Private Placement, and (iii) exercisable at $61.35 per share. The Placement Agent Warrants contain terms that may require the Company to transfer assets to settle the warrants. Therefore, the Placement Agent Warrants are classified as a derivative liability, initially measured at fair value of $1,525,923 on the date of issuance and will be remeasured each accounting period with the changes in fair value reported in earnings. The Placement Agent Warrants are considered financing expense fees paid to the Placement Agent in relation to a derivative liability measured at fair value, thus, are included along with non-operating unrealized gains and losses in the recognition and change in fair value of warrant liabilities account in the consolidated statements of operations.

 

 

For the years ended December 31, 2023 and 2022, net fair value gains recognized for the PAW were, $48,575 and $1,477,024 respectively, presented in the recognition and change in fair value of warrant liabilities account in the consolidated statements of operations. The PAW liability outstanding as of December 31, 2023 and 2022 is $325 and $48,900 respectively, presented in the warrant liability account on the consolidated balance sheets.

 

XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.1
SIGNIFICANT CUSTOMERS
12 Months Ended
Dec. 31, 2023
Risks and Uncertainties [Abstract]  
SIGNIFICANT CUSTOMERS

NOTE 10. SIGNIFICANT CUSTOMERS

 

Carriers representing 10% or more of total revenue are presented in the table below:

 

Insurance Carrier 

December 31,

2023

  

December 31,

2022

 
Priority Health   35%   32%
BlueCross BlueShield   15%   14%

 

No other single insurance carrier accounted for more than 10% of the Company’s commission revenues. The loss of any significant customer could have a material adverse effect on the Company.

 

XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.1
EQUITY
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
EQUITY

NOTE 11. EQUITY

 

Preferred Stock

 

The Company has been authorized to issue 750,000,000 shares of $0.086 par value Preferred Stock. The Board of Directors is expressly vested with the authority to divide any or all of the Preferred Stock into series and to fix and determine the relative rights and preferences of the shares of each series so established, within certain guidelines established in the Articles of Incorporation.

 

In January 2022, the Company issued 9,076 shares of its newly designated Series B convertible preferred stock through the Private Placement for the purpose of raising capital. The Series B convertible preferred stock have no voting rights and initially each share may be converted into 16 shares of the Company’s common stock. The holders of the Series B convertible preferred stock are not entitled to receive any dividends other than any dividends paid on account of the common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder) to common stock which amounts shall be paid pari-passu with all holders of common stock.

 

During August 2022, all 9,076 Series B Convertible Preferred Stock were converted by third parties into 147,939 shares of common stock and as of December 31, 2023 and 2022 none remain outstanding.

 

 

Common Stock

 

The Company has been authorized to issue 2,000,000,000 shares of common stock, $0.086 par value. Each share of issued and outstanding common stock shall entitle the holder thereof to fully participate in all shareholder meetings, to cast one vote on each matter with respect to which shareholders have the right to vote, and to share ratably in all dividends and other distributions declared and paid with respect to common stock, as well as in the net assets of the corporation upon liquidation or dissolution.

 

In January 2022, the Company issued 178,060 shares of common stock through the Private Placement for the purpose of raising capital. See Note 9 - Warrant Liabilities for proceeds received by the Company.

 

In January 2022, the Company issued 40,402 shares of common stock pursuant to the Medigap Acquisition.

 

In January 2022, upon agreement with Series A warrant holders, 25,000 warrants were exercised at a price of $99.00 into 25,000 shares of the Company’s common stock.

 

In March 2022, the Company issued 400 shares of the Company’s common stock due to the vesting of 400 stock awards pursuant to an employee agreement.

 

In May and June 2022, 218,462 Series C prepaid warrants were exchanged for 218,462 shares of the Company’s common stock.

 

In July 2022, 81,423 Series D prepaid warrants were exchanged for 81,423 shares of the Company’s common stock.

 

In December 2022, the Company issued 14,275 shares of the Company’s common stock due to the vesting of 14,275 stock awards pursuant to several employee agreements.

 

 

In December 2022, upon agreement with Series B warrant holders, 1,667 warrants were exercised at a price of $7.50 into 1,667 shares of the Company’s common stock with cash proceeds to the Company of $12,500.

 

In January 2023, the Company issued 109,358 shares of the Company’s common stock to settle two earn-out liabilities.

 

On February 23, 2023, pursuant to authority granted by the Board of Directors of the Company, the Company implemented a 1-for-15 reverse split of the Company’s authorized and issued and outstanding common stock (the “Reverse Split-2023”). The par value remains unchanged. All share and per share information as well as common stock and additional paid-in capital have been retroactively adjusted to reflect the Reverse Split-2023 for all periods presented, unless otherwise indicated. The split resulted in a rounding addition of approximately 15,300 shares valued at par, totaling $1,300.

 

In February 2023, Yes Americana, a related party, converted $645,000 of its outstanding convertible debt into 66,743 shares of the Company’s common stock. The conversion considered the fair market value of the stock on the day of conversion of $9.67 for the total of 66,743 shares.

 

In March 2023, the Company issued 155,038 shares of the Company’s common stock in conjunction with the Private Placement-2023 as defined and discussed further below.

 

During the second quarter of 2023, the Company issued from its common stock, 112,557 shares in lieu of services provided, 352,260 shares to settle an earn-out liability and 22,219 shares pursuant to vested restricted stock awards earned by agents through an equity-based compensation program at one of the Company’s subsidiaries.

 

During the third quarter of 2023, the Company issued from its common stock, 174,610 shares to settle an earn-out liability, 400 shares in lieu of services provided, 3,017 shares to employees for vested stock awards, and 73,264 for Series B Warrants exercised.

 

During the fourth quarter of 2023, the Company issued from its common stock, 897,594 and 371,000 shares for Series E and Series F warrant exercises, respectively, 741,360 for share based compensation, 147,645 shares in lieu of services, and 300,000 shares for Series B Warrants exchanged.

 

As of December 31, 2023 and December 31, 2022, there were 4,761,974 and 1,219,573 shares of Common Stock outstanding, respectively.

 

Warrants

 

Series A Warrants

 

In conjunction with the Company’s initial public offering, the Company issued 2,070,000 Series A Warrants which were classified as equity warrants because of provisions, pursuant to the warrant agreement, that permit the holder obtain a fixed number of shares for a fixed monetary amount. The warrants are standalone equity securities that are transferable without the Company’s consent or knowledge. The warrants were recorded at a value per the offering of $0.15. The warrants may be exercised at any point from the effective date until the 5-year anniversary of issuance, on or around February 8, 2026, and are not subject to antidilution provisions. In January 2022, 375,000 Series A Warrants were exercised into 25,000 shares of common stock.

 

In November 2023 the Series A Warrant holders voted and approved an amendment to the Series A Warrant agreement pursuant to which the warrants were issued, and reduced the exercise price from the stated $6.60 (post-Reverse Split-2023 effective exercise price of $99.00) per share to $6.13 per share, subject to adjustment.

 

As of both December 31, 2023 and December 31, 2022, 1,695,000 Series A Warrants remain outstanding, exercisable into 113,000 shares of common stock.

 

 

Series C and D Warrants

 

In January 2022, as a result of the Private Placement and the Medigap Acquisition, the Company received a deficiency notification from Nasdaq indicating violation of Listing Rule 5365(a). As part of its remediation plan, in March 2022, the Company entered into Exchange Agreements with the holders of common stock issued in January 2022. Pursuant to the Exchange Agreements, the Company issued 218,462 Series C prepaid warrants in exchange for 218,462 shares of the Company’s common stock. Additionally, as compensation for entering into the Exchange Agreements, the Company issued 81,500 Series D prepaid warrants to the Private Placement investors for no additional consideration. The fair value of the Series D prepaid warrants was treated as a deemed dividend and accordingly treated as a reduction from income available to common stockholders in the calculation of earnings per share. Refer to Note 12, Earnings (Loss) Per Share for additional information.

 

The Series C and D Warrants are equity classified pursuant to the warrant agreement provisions that permit holders to obtain a fixed number of shares for a fixed monetary amount. The warrants are standalone equity securities that are transferable without the Company’s consent or knowledge. The warrants expire on the fifth anniversary of the respective issuance dates and are exercisable at a per share exercise price equal to $0.015.

 

In May and June 2022, the 218,462 Series C prepaid warrants were converted for 218,462 shares of the Company’s common stock for a conversion price of $0.015. Through December 31, 2022, the Company has received payments of $1,336 for these issuances.

 

In July 2022, 81,423 Series D prepaid warrants were converted into 81,472 shares of the Company’s common stock for a conversion price of $0.015 through both cash and cashless exercises. Proceeds of $795 were received in conjunction with the cash exercise.

 

Series E, F & G Warrants, and

Abeyance Shares

 

On March 13, 2023, the Company entered into a securities purchase agreement (the “SPA-2023”) with one institutional buyer for the purchase and sale of, (i) an aggregate of 155,038 shares (the “Common Shares”) of the Company’s common stock, par value $0.086 per share (the “Common Stock”) along with accompanying common warrants (the “Common Units”), (ii) prefunded warrants (the “Prefunded Warrants” or “Series E Warrants”) that are exercisable into 897,594 shares of Common Stock (the “Prefunded Warrant Shares”) along with accompanying common warrants (the “Pre-Funded Units”), and (iii) common warrants (the “Common Warrants” or “Series F Warrants”) to initially acquire up to 2,105,264 shares of Common Stock (the “Common Warrant Shares”) (representing 200% of the Common Shares and Prefunded Warrant Shares) in a private placement offering (the “Private Placement-2023”). Additionally, the Company agreed to issue a warrant to the Placement Agent (defined below), to initially acquire 52,632 shares of common stock (the “PA Warrant”) and entered into a registration rights agreement with the buyer to register for resale the common shares underlying the Series E and F Warrants.

 

The aggregate purchase price for the Common Shares, Prefunded Warrants (Series E Warrants) and the Common Warrants (Series F Warrants) to be purchased by the Buyer shall be equal to (i) $3.80 for each Common Unit purchased by such Buyer, or (ii) $3.799 for each Prefunded Unit purchased by the Buyer, which Prefunded Warrants are exercisable into Prefunded Warrant Shares at the initial Exercise Price (as defined in the Prefunded Warrant) of $0.001 per Prefunded Warrant Share in accordance with the Prefunded Warrant.

 

The Common Warrant (Series F) has an exercise price of $3.55 per share, subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the date of the Private Placement-2023. The Common Warrant will be exercisable six months following the date of issuance and will expire five and a half years from the date of issuance.

 

The PA Warrant has an exercise price of $3.91 per share, subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the date of the SPA-2023. The PA Warrant will be exercisable six months following the date of issuance and will expire five years from the date of issuance.

 

 

The closing of the Private Placement-2023 occurred on March 16, 2023. EF Hutton, a division of Benchmark Investments, LLC (the “Placement Agent”) acted as the sole placement agent and was entitled to an 8% of gross proceeds cash fee and the reimbursement of certain Placement Agent fees and customary expenses.

 

Gross and net proceeds to the Company from the Private Placement-2023 were approximately $4 million and $3.4 million respectively, to be utilized primarily for general working capital and administrative purposes. Direct financing fees approximated $553,000.

 

The Company determined the Series E Warrants, Series F Warrants, and PA Warrants are equity in nature because of provisions, pursuant to the warrant agreements, that permit the holder to obtain a fixed number of shares for a fixed monetary amount. The values offset to $0 in additional paid-in capital in the Company’s condensed consolidated statements of stockholders’ equity (deficit).

 

On December 12, 2023, the Company entered into that certain Inducement Offer to Exercise Series F Warrants to Subscribe for Common Shares with the institutional investor (the “Series F Inducement Agreement”), pursuant to which (i) the Company agreed to lower the exercise price of the Series F Warrants to $0.6562 per share (which is equal to the Nasdaq minimum price) (the “Nasdaq Minimum Price”) and (ii) the institutional buyer agreed to exercise the Series F Warrants to purchase 2,105,264 shares of Common Stock into 2,105,264 shares of Common Stock (the “Exercise Shares”) by payment of the aggregate exercise price of approximately $1,381,474, gross of $351,503 of expenses, including but not limited to EF Hutton LLC, who acted as placement agent in connection therewith, resulting in $1,029,972 in net proceeds to the Company. The closing occurred on December 14, 2023 (the “Closing Date”). The Exercise Shares were all exercised, resulting in the issuance of 371,000 shares, and 1,734,264 shares held in abeyance (the “Abeyance Shares”) due to the 9.99% beneficial ownership limitation stipulated in the Series F Inducement Agreement. The Company accounted for the exercise price decrease inducement as a modification which resulted in a deemed dividend of $302,997 recorded as an increase and decrease to the additional paid-in capital account, in the consolidated balance sheets and statements of stockholders’ equity (deficit) as of December 31, 2023. The Company valued (a) the fair value of the 2,105,264 warrants immediately before exchange in the amount of $1,103,377, (b) the fair value of the warrants immediately after the exchange in the amount of $800,380, and (c) recorded the difference as a deemed dividend in the amount of $302,997. The warrants were valued using the Black-Scholes option pricing model using the following assumptions: a) fair value of common stock of $0.6562, b) exercise prices of $3.55 pre-exchange and $0.6562 post-exchange, c) term of 4.77 years pre-exchange and post-exchange, d) dividend rate of 0%, e) volatility of 112% pre-exchange and post-exchange, and f) risk free interest rate of 4.23% pre-exchange and post-exchange.

 

Further, pursuant to the Series F Inducement Agreement, the Company issued a new unregistered Series G common share purchase warrant (the “Series G Warrant”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended to purchase 4,210,528 shares of Common Stock at an initial exercise price equal to $0.6562, but subject to a 4.99% beneficial ownership limitation. The Series G Warrant termination date is December 12, 2028. The Company’s accounting for the Series G Warrant resulted in a deemed dividend of $2,236,760 recorded as an increase and decrease to the additional paid-in capital account, in the consolidated balance sheets and statements of stockholders’ equity (deficit) as of December 31, 2023. The warrants were valued using the Black-Scholes option pricing model with the following assumptions: a) fair value of common stock of $0.6562, b) exercise price of $0.6562, c) term of 5 years, d) dividend rate of 0%, e) volatility of 112%, and f) risk free interest rate of 4.23%.

 

As of December 31, 2023:

 

Series E: There remains no Series E Warrants outstanding pursuant to exercises occurring throughout the fiscal year of 897,594 warrants exercised into 897,594 shares of the Company’s common stock for a net of $898 in cash proceeds.
Series F: There remain no Series F Warrants outstanding pursuant to the Series F Inducement Agreement.
Series G: There remain 4,210,528 Series G Warrants outstanding.
Abeyance Shares: There remain 1,734,264 unissued Abeyance Shares outstanding.

 

Subsequent to December 31, 2023, during the first quarter of 2024, upon request from the institutional investor, the Company converted 723,264 Abeyance Shares into Common Stock, thereby issuing 723,264 of Common Stock, resulting in a remaining 1,011,000 outstanding Abeyance Shares. During the second quarter of 2024, the institutional investor requested the Company convert the remaining 1,011,000 Abeyance Shares into Common Stock. The Company has yet to issue any shares in reference to this request but does intend to issue them during the remaining period of the second quarter of 2024. Upon and post issuance of these shares, there will be no remaining Abeyance Shares outstanding.

 

Equity Incentive Plans

 

2019 Equity Incentive Plan. During the year ended December 31, 2019, the Company adopted the Reliance Global Group, Inc. 2019 Equity Incentive Plan (the “2019 Plan”) under which various forms of equity awards can be granted to employees, directors, consultants, and service providers. Awards include but are not limited to, restricted stock, restricted stock units, performance shares and stock options. A total of 46,667 shares of common stock were reserved for issuance under the 2019 Plan. As of December 31, 2023, after considering 2019 Plan shares held for outstanding options, there remains no additional capacity for further awards. As of the same date, there are 10,928 options outstanding with a weighted average exercise price of $232.55 and weighted average remaining contractual life of 0.57 years. The Company issues new shares of common stock for any option exercises, from its shares available under either its 2019 Plan or 2023 Plan (as defined below).

 

 

2023 Equity Incentive Plan. On August 10, 2023, the Company adopted, the Reliance Global Group, Inc. 2023 Equity Incentive Plan (the “2023 Plan”, and together with the 2019 Plan, the “Plans”). The purpose of the 2023 Plan is to provide a means through which the Company and its subsidiaries may attract and retain key personnel, and to provide a means whereby directors, officer, employees, consultants, and advisors of the Company and its subsidiaries can acquire and maintain an equity interest in the Company, or be paid incentive compensation, thereby strengthening their commitment to the welfare of the Company and its subsidiaries and aligning their interests with those of the Company’s stockholders. The 2023 Plan provides for various stock-based incentive awards, including incentive and nonqualified stock options, stock appreciation rights (“SARs”), restricted stock and restricted stock units (“RSUs”), and other equity-based or cash-based awards. It became effective on August 10, 2023 and will terminate on August 10, 2033, unless the Compensation Committee terminates it earlier. A total of 800,000 shares of Common Stock were reserved for issuance under the 2023 Plan, and as of December 31, 2023 there were no new options granted, and there remain 47,080 shares available for issuance.

 

Administration of the Plans. The Plans are administered by the Compensation Committee of the Board. The Compensation Committee is authorized to select from among eligible employees, directors, and service providers those individuals to whom shares and options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Compensation Committee is also authorized to prescribe, amend, and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any shares and options granted hereunder is within the discretion of the Compensation Committee.

 

Stock Options: The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees, non-employee directors, consultants, and service providers are eligible to receive options which are not ISOs, i.e. “Non-Statutory Stock Options.” The options granted by the Compensation Committee in connection with its adoption of the Plans were Non-Statutory Stock Options.

 

The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option.

 

The following is a summary of the stock options granted, forfeited or expired, and exercised under the Plans for the years ended December 31, 2023 and 2022 respectively:

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years)   Aggregate Intrinsic Value 
Outstanding at December 31, 2022   10,928   $232.55    1.61   $        - 
Granted   -    -    -    - 
Forfeited or expired   -    -    -    - 
Exercised   -    -    -    - 
Outstanding at December 31, 2023   10,928   $232.55    0.61    - 

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years)   Aggregate Intrinsic Value 
Outstanding at December 31, 2021   10,928   $232.55    2.61   $                - 
Granted   -    -    -    - 
Forfeited or expired   -   $-    -    - 
Exercised   -    -    -    - 
Outstanding at December 31, 2022   10,928   $232.55    1.61    - 

 

 

The following is a summary of the Company’s non-vested stock options as of December 31, 2023 and 2022 respectively:

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years) 
Non-vested at December 31, 2022   271   $236.83    2.27 
Granted   -    -    - 
Vested   (248)   239.68    0.81 
Forfeited or expired   -    -    - 
Non-vested at December 31, 2023   23   $205.70    1.59 

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years) 
Non-vested at December 31, 2021   3,587   $227.78    0.90 
Granted   -    -    - 
Vested   (3,315)   14.89    1.71 
Forfeited or expired   -    -    - 
Non-vested at December 31, 2022   271   $236.83    2.27 

 

For the years ended December 31, 2023 and 2022, the Board did not approve any options to be issued pursuant to the Plan.

 

During the years ended December 31, 2023 and 2022, no employee terminations occurred resulting in option forfeitures of $0.

 

As of December 31, 2023, the Company determined that the options granted and outstanding had a total fair value of $2,421,960. The options will be amortized in future periods through February 2024. During the year ended December 31, 2023, the Company recognized $15,624 of compensation expense relating to the stock options granted to employees, directors, and consultants. As of December 31, 2023, unrecognized compensation expense totaled $1,542 which will be recognized on a straight-line basis over the vesting period or requisite service period through February 2024.

 

The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on December 31, 2023. The market value as of December 31, 2023 was $0.54 based on the closing bid price for December 31, 2023.

 

As of December 31, 2022, the Company determined that the options granted and outstanding had a total fair value of $2,421,960. The options will be amortized in future periods through February 2024. During the year ended December 31, 2022, the Company recognized $178,579 of compensation expense relating to the stock options granted to employees, directors, and consultants. As of December 31, 2022, unrecognized compensation expense totaled $17,166 which will be recognized on a straight-line basis over the vesting period or requisite service period through February 2024.

 

The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on December 31, 2022. The market value as of December 31, 2022 was $8.55 based on the closing bid price for December 31, 2022.

 

 

The Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes option-pricing models require the Company to make predictive assumptions regarding future stock price volatility, recipient exercise behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the expected term of the option. The expected term of the options was computed by taking the mid-point between the vesting date and expiration date. The following assumptions were used in the Black-Scholes option-pricing model, not accounting for the reverse splits:

 

   

Year Ended

December 31, 2023

   

Year Ended

December 31, 2022

 
Exercise price   $ 0.16 - $0.26     $ 0.16 - $0.26  
Expected term     3.25 to 3.75 years       3.25 to 3.75 years  
Risk-free interest rate     0.38% - 2.43 %     0.38% - 2.43 %
Estimated volatility    

293.07% - 517.13

%     293.07% - 517.13 %
Expected dividend     -       -  

 

Stock Awards

 

The Plans provide for various forms of stock awards. During the years ended December 31, 2023, and 2022, certain directors, executives and employees were granted equity awards which vested immediately. Respectively, 758,026 and 12,460 shares were awarded and issued, valued at $477,556 and $766,250, presented in the salaries and wages (for executives and employees) and general and administrative (for directors) accounts in the consolidated statements of operations.

 

Pursuant to an agreement in April 2022, further amended in October 2022 between the Company and an executive, the executive was granted 7,418 restricted shares of the Company’s common stock which vest quarterly over a three-year period. The shares granted were valued at $180,546 at the date of the grant. For the years ended December 31, 2023, and 2022 respectively, 3,908 and 667 shares have been issued under the agreement, and compensation expense was $83,464 and $32,131, presented in the salaries and wages account in the consolidated statements of operations.

 

Pursuant to a grant award agreement effective December 28, 2022 between the Company and an executive, the executive was granted an annual award of 2,667 shares of the Company’s common stock to vest monthly each year throughout the duration of employment. The grant value for the years ended December 2023 and 2022 respectively was, $22,404 and $241 and recorded as compensation expense, presented in the salaries and wages account in the consolidated statements of operations. For the years ended December 31, 2023, and 2022 respectively, 2,695 and 0 shares have been issued under the agreement.

 

Pursuant to an equity-based commission compensation program at one of the Company’s subsidiaries which provides down-line agents the ability to earn and receive restricted stock awards upon completion of agreed upon service requirements, the Company grants annual restricted stock awards which have vesting or other restrictions of up to twelve months. For the years ended December 31, 2023 and 2022 respectively, 22,221 and 0 shares were issued under the program, and commission equity award expense was, $276,400 and 249,650, presented in the commission expense account in the consolidated statements of operations.

 

Total equity-based compensation for the years ended December 31, 2023 and 2022 was approximately $875,000 and $1,250,000, respectively.

 

XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.1
EARNINGS (LOSS) PER SHARE
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE

NOTE 12. EARNINGS (LOSS) PER SHARE

 

Basic earnings per common share (“EPS”) applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted-average number of common shares outstanding.

 

 

The following calculates basic and diluted EPS:

 

   2023   2022 
   For the Years Ended December 31, 
   2023   2022 
(Loss) income from continuing operations  $(10,025,268)  $21,561,932 
Deemed dividend   (2,539,757)   (6,930,335)
(Loss) income from continuing operations, numerator, basic   (12,565,025)   14,631,597 
(Loss) income from continuing operations, numerator, diluted  $(12,565,025)  $14,631,597 
           
Weighted average common shares, basic   2,820,275    1,094,781 
Effect of weighted average vested stock awards   -    208 
Diluted weighted average shares outstanding   2,820,275    1,094,989 
Basic (loss) income loss per common share from continuing operations:  $(4.46)  $13.36 
Diluted (loss) income per common share from continuing operations:  $(4.46)  $13.36 

 

Additionally, the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common share:

 

   2023   2022 
   For the years ended December 31, 
   2023   2022 
Shares subject to outstanding common stock options   10,928    10,928 
Shares subject to outstanding Series A warrants   113,000    113,000 
Shares subject to outstanding Series B Warrants and PAW   

882,970

    1,347,970 
Shares subject to outstanding Series G warrants and PA Warrants   

4,263,160

    - 
Shares subject to unvested stock awards   

3,709

    6,576 

 

XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.1
LEASES
12 Months Ended
Dec. 31, 2023
Leases  
LEASES

NOTE 13. LEASES

 

Operating Leases

 

ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. The standard requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease, initially measured at the present value of the lease payments. The Company’s leases consist of operating leases on buildings and office space.

 

In accordance with ASU 2016-02, right-of-use assets are amortized over the life of the underlying leases. Lease expense for the years ended December 31, 2023 and 2022 was $534,404 and $598,422, respectively. As of December 31, 2023 and 2022, the weighted average remaining lease term and weighted average discount rates for the operating leases were 3.92 years and 6.08% and 3.82 years and 5.67% respectively.

 

Future minimum lease payment under these operating leases consisted of the following:

 

Year ending December 31, 

Operating Lease

Obligations

 
2024  $320,420 
2025   153,831 
2026   113,738 
2027   117,150 
2028   120,665 
Thereafter   30,387 
Total undiscounted operating lease payments   856,191 
Less: Imputed interest   (86,685)
Present value of operating lease liabilities  $769,506 

 

 

XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 14. COMMITMENTS AND CONTINGENCIES

 

Legal Contingencies

 

The Company is subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly, $0 legal contingencies are accrued as of December 31, 2023 and 2022. Litigation relating to the insurance brokerage industry is not uncommon. As such the Company, from time to time have been, subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future.

 

Earn-out liabilities

 

The Company has recognized several earn-out liabilities resulting from contingent consideration provisions included in business combination agreements. Earn-out consideration is normally earned by acquirees when they meet or exceed pre-agreed upon earnings targets.

 

The following outlines changes to the Company’s earn-out liability balances for the respective years ended December 31, 2023 and 2022:

 

    Fortman   Montana   Altruis   Kush   Barra   Total 
Ending balance December 31, 2022   $667,000   $500,001   $834,943   $147,534   $560,000   $2,709,478 
Payments    (1,433,700)   

(750,001

)   (929,168)   

(147,534

)   -    (3,260,403)

Estimate & fair value adjustments

   1,612,914    569,734    94,225    -    (560,000)   1,716,873 

Payable in Common Stock

   -     

(159,867

)   

-

    

-

    

-

    

(159,867

)

Reclass to loans payable, related parties*

   (846,214

)   -     

-

    

-

    

-

    

(846,214

)
Ending balance December 31, 2023   $-   $159,867   $-   $-   $-   $159,867 

 

   Fortman   Montana   Altruis   Kush   Barra   Total 
Ending balance December 31, 2021  $515,308   $615,969   $992,868   $1,689,733   $-   $3,813,878 
Business combinations   -    -    -    -    600,000    600,000 
Payments   (34,430)   (326,935)   (84,473)   (1,259,086)        (1,704,924)

Estimate & fair value adjustments

   186,122    210,967    (73,452)   (283,113)   (40,000)   524 
Ending balance December 31, 2022  $667,000   $500,001   $834,943   $147,534   $560,000   $2,709,478 

 

*As further described in the Note 16, Related Parties, the Company modified the Fortman contingent earn-out payable, entering into a fixed payment agreement, thus, the remaining open balance is reclassified to the loans payable, related parties account on the consolidated balance sheet as of December 31, 2023.

 

 

XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.1
INCOME TAXES
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 15. INCOME TAXES

 

The difference between the actual income tax rate versus the tax computed at the Federal Statutory rate follows:

 

  

December 31,

2023

  

December 31,

2022

 
Federal rate   21.0%   21.0%
State net of federal   

8.9

%   -7.9%
Non-taxable change in fair value of warrant commitment   9.3%   -106.3%
Goodwill impairment   11.8%   46.7%
Rate Change   -0.2%   -4.1%
Other   0.0%   2.2%
Valuation allowance   -50.9%   48.5%
Effective income tax rate   0.0%   0.0%

 

The Company did not have any material uncertain tax positions. The Company’s policy is to recognize interest and penalties accrued related to unrecognized benefits as a component income tax expense (benefit). The Company did not recognize any interest or penalties, nor did it have any interest or penalties accrued as of December 31, 2023 and 2022.

 

Deferred income tax assets and (liabilities) consist of the following:

 

  

December 31,

2023

  

December 31,

2022

 
Deferred tax assets (liabilities)          
Net operating loss carryforward  $10,399,616   $4,938,164 
Equity-based compensation   1,462,901    1,148,836 
Goodwill   (332,159)   (771,631)
Intangibles   694,358    745,227 
Fixed assets   (151,775)   (99,002)
Right of use assets   (186,905)   (300,616)
Lease liabilities   194,403    313,342 
Other   4,027    1,525 
Total deferred tax assets   

12,084,466

    5,975,846 
Valuation allowance   (12,084,466)   (5,975,846)
Net deferred tax assets  $

-

   $- 

 

The Company has approximately $41.3 million of Federal Net Operating Loss Carry forwards, of which $1.3 million will begin to expire beginning 2031 and $40.0 million will not expire but are limited to use of 80% of current year taxable income.

 

The Company has approximately $34.8 million of state net operation loss carry forward to offset future taxable income in the states in which it currently operates. These carryforwards start expiring in 2029.

 

Internal Revenue Code Section 382 limits the ability to utilize net operating losses if a 50% change in ownership occurs over a three-year period. Such limitation of the net operating losses may have occurred, but we have not analyzed it at this time as the deferred tax asset is fully reserved.

 

During the year ended December 31, 2023 and 2022, the valuation allowance increased $6,108,620 and $3,140,780, respectively.

 

The tax periods ending December 31, 2020, 2021, and 2022 are open for examination.

 

XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.1
RELATED PARTY TRANSACTIONS
12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 16. RELATED PARTY TRANSACTIONS

 

The Company entered into a Loan Agreement with Reliance Global Holdings, LLC (“Reliance Holdings”), a related party under common control. There is no term to the loan, and it bears no interest. Repayment will be made as the Company has business cash flows. The proceeds from the various loans were utilized to fund the acquisitions of USBA, EBS, CCS, SWMT Acquisition, Fortman, Altruis, and UIS. As of December 31, 2023, and the 2022 the Reliance Holdings related party loan payable balance was $0 and $100,724 respectively, and Reliance Holdings owned approximately 0% and 24% respectively, of the Company’s Common Stock.

 


 

The Company incurred a liability of $200,000 to an employee for a software purchased in July of 2019. The payable was issued with a $27,673 discount, utilizing a 7.5% discount rate. There are monthly payment terms of $4,167 through June 2024, the date of final settlement. The balance is carried at present value on the condensed consolidated balance sheets. The Company classifies amounts planned to be settled within twelve months from the balance sheet date to current liabilities. Accordingly, the Company presents current balances of $ 29,167 and $47,249 in the current portion of loans payables, related parties account in the condensed consolidated balance sheets as of December 31, 2023, and December 31, 2022. Non-current amounts are classified to the loans payable, related parties, less current portion account in the condensed consolidated balance sheets and amounted to $0 and $21,541 as of December 31, 2023, and December 31, 2022, respectively. Amortization expense to bring the payable to present value for the year ended December 31, 2023, was $6,918, and is classified to the interest expense, related parties account in the condensed consolidated statements of operations.

 

On September 13, 2022, the Company issued a promissory note to YES Americana Group, LLC (“Americana”) a related party entity beneficially owned by the Company’s Chief Executive Officer, for the principal sum of $1,500,000 (the “Note”), accruing monthly interest of 5% per annum beginning nine months after Note issuance. On February 7, 2023 , the Company and Americana entered into an amendment to the Note pursuant to which (i) the principal amount of the Note was increased to $1,845,000, (ii) the maturity date of the Note was amended to January 15, 2026, (iii) the interest rate under the Note shall not increase after the maturity date, and (iv) the Note can be converted at any time, at the option of Americana, into shares of the Company’s common stock, par value $0.086 per share at an agreed upon conversion price. On February 13, 2023, Americana effectuated a conversion of $645,000 of the Note into 66,743 shares of the Company’s common stock, $0.086 par value per share, in accordance with the terms of the Amendment. In addition, throughout the year of 2023 the Company repaid principal to Americana of $693,145. As of December 31, 2023, and December 31, 2022 respectively, the balance owed to Americana was $0 and $1,500,000, reclassified and recorded in the convertible debt, related parties, less current portion account in the condensed consolidated balance sheets. Interest expense for the year ended December 31, 2023, was $5,334, recorded to interest expense, related parties in the condensed consolidated statements of operations. Americana owned approximately 5.52% and 0.00% respectively, of the Company’s Common Stock as of December 31, 2023, and 2022 respectively.

 

Pursuant to the first amendment to the April 26, 2022 asset purchase agreement between the Company and Barra & Associates, LLC, a related party entity beneficially owned by a senior vice president of the Company, the Company agreed to pay a deferred purchase price (the “DPP”) of $1,375,000 by January 31, 2023, and all amounts unpaid thereafter will accrue interest at a rate of 1.5% per month until paid. The Company intends to fully repay all unpaid amounts inclusive of interest over the next two years. The Company classifies amounts planned to be settled within twelve months from the balance sheet date to current liabilities. Accordingly, the Company reclassifies and presents current balances of $233,504 and $1,375,000 respectively, in the current portion of loans payables, related parties account in the condensed consolidated balance sheets as of December 31, 2023 and December 31, 2022. Non-current amounts are classified to the loans payable, related parties, less current portion account in the condensed consolidated balance sheets and amounted to $247,055 and $0 as of December 31, 2023, and December 31, 2022 respectively. Interest expense for the year ended December 31, 2023 was $145,344, recorded to interest expense, related parties in the condensed consolidated statements of operations.

 

The Company, Fortman Insurance Services, LLC, Fortman Insurance Agency, LLC, Jonathan Fortman, and Zachary Fortman (collectively, the “Parties”) entered into a purchase agreement on or around May 1, 2019 (the “Purchase Agreement”), whereby the Company purchased the business and certain assets noted within the Purchase Agreement, as well as that certain second amendment to the Purchase Agreement on or around May 18, 2023 (the “Second Amendment”). On January 11, 2024, the Parties entered into that certain third amendment to the Purchase Agreement (the “Third Amendment”), pursuant to which the Parties agreed to a total remaining earn-out balance of $423,107 owed to both Jonathan Fortman and Zachary Fortman each under the Purchase Agreement, both employees and related parties to the Company, for a combined total earn-out amount owed of $846,214 (the “Remaining Balances”). In satisfaction of such Remaining Balances, the Company agreed to pay $11,000.00 on the first business day of each month to both Jonathan Fortman and Zachary Fortman each until the Remaining Balances are paid in full. In addition, the Parties agreed under the Third Amendment that the Remaining Balances shall accrue interest at the rate of 10% per annum until the Remaining Balances are paid in full, with an effective date of January 2, 2024, for purposes of the commencement of interest accrual. Since the Remaining Balances are final and no longer subject to contingencies, as of December 31, 2023 and the period then ended, they have been reclassified from the earn-out liability account to the loan payable, related parties, less current portion account in the amount of, $650,473 and the current portion of loans payables, related parties in the amount of, $195,741 and for the same period ended no interest has accrued.

 

XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 17. SUBSEQUENT EVENTS

 

On February 15, 2024, the Company entered into an At Market Issuance Sales Agreement (the “ATM Agreement”) with EF Hutton LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent, shares of its Common Stock (the “Shares”), having an aggregate offering price of up to $858,637. Any Shares offered and sold in the offering will be issued pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-275190), which was declared effective by the Securities and Exchange Commission on November 7, 2023, and the related prospectus supplement and accompanying base prospectus relating to the offering of the Shares. Under the Agreement, the Agent may sell Shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The offering of Shares pursuant to the Agreement will terminate upon the earlier of (i) the sale of all of the Shares subject to the Agreement, or (ii) the termination of the Agreement by the Agent or the Company, as permitted therein. The Company shall pay to the Agent in cash, upon each sale of Shares pursuant to the ATM Agreement, an amount equal to 3.5% of the gross proceeds from each sale of Shares. The Company will also reimburse the Agent for certain specified expenses in connection with entering into the Agreement. The Company has since sold 187,614 shares of Common Stock under the ATM Agreement, receiving proceeds, net of $4,634 Agent commissions, of $124,649.

XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated financial statements included herein have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounting of Reliance Global Group, Inc., and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

 

Liquidity

Liquidity

 

As of December 31, 2023, the Company’s reported cash and restricted cash aggregated balance was approximately $2,739,000, current assets were approximately $4,379,000, while current liabilities were approximately 3,190,000. As of December 31, 2023, the Company had working capital of approximately $1,189,000 and stockholders’ equity of approximately $7,147,000. For the year ended December 31, 2023, the Company reported a loss from operations of approximately $13,879,000, of which $7,594,000 was related to goodwill impairment. The Company also reported a non-cash, non-operating gain on the recognition and change in fair value of warrant liabilities of approximately $5,504,000, other expense, primarily interest expense of approximately $1,650,000, which resulted in a loss from continuing operations of $10,025,000. Additionally, the Company reported a loss from discontinued operations of approximately $1,985,000. The total net loss of the company was approximately $12,010,000. The Company completed a capital offering in March 2023, raising net proceeds of approximately $3,446,000.

 

Although there can be no assurance that debt or equity financing will be available on acceptable terms, the Company believes its financial position and its ability to raise capital to be reasonable and sufficient. Based on our assessment, we do not believe there are conditions or events that, in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one year of filing these financial statements with the Securities and Exchange Commission (“SEC”).

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

 

 

Cash and Restricted Cash

Cash and Restricted Cash

 

Cash consists of checking accounts. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Restricted cash includes cash pledged as collateral to secure obligations and/or all cash whose use is otherwise limited by contractual provisions.

 

At times, some cash balances held in banks may exceed the Federal Deposit Insurance Corporation, or FDIC, standard deposit insurance limit of $250,000.

 

The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows:

 

 

  

December 31,

2023

  

December 31,

2022

 
Cash  $1,329,016   $505,410 
Restricted cash   1,409,895    1,404,359 
Total cash and restricted cash  $2,738,911   $1,909,769 

 

Property and Equipment

Property and Equipment

 

Property and equipment is stated at cost, less accumulated depreciation. Depreciation is recognized over an asset’s estimated useful life using the straight-line method beginning on the date an asset is placed in service. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Certain capitalized software has been reclassified in the consolidated balance sheet from property and equipment, net to intangibles, net and comparative periods have been adjusted accordingly. Maintenance and repairs are charged to expense as incurred. Estimated useful lives of the Company’s Property and Equipment are as follows:

 

   Useful Life (in years) 
Computer equipment   5 
Office equipment and furniture   7 
Leasehold improvements   Shorter of the useful life or the lease term 

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance includes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels of the fair value hierarchy are as follows:

 

Level 1 — Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities;

 

Level 2 — Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and

 

Level 3 — Unobservable inputs for the asset or liability, which include management’s own assumption about the assumptions market participants would use in pricing the asset or liability, including assumptions about risk.

 

As of December 31, 2023, and 2022 respectively, the Company’s balance sheet includes certain financial instruments, including cash, notes receivables, accounts payable, and short and long-term debt. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amounts of long-term debt approximate their fair value as the variable interest rates are based on a market index.

 

 

Warrant Liabilities: The Company’s warrant liabilities (see Note 9, Warrant Liabilities) represent liability-classified derivative financial instruments recorded at fair value on a recurring basis. The fair value of the Warrant Liabilities includes significant inputs unobservable in the market and thus are considered Level 3. The Company measured the fair value of the warrant liabilities at the issuance date, December 12, 2023, and subsequently at the balance sheet date, using a binomial option pricing model. The following summarizes the significant unobservable inputs:

 

  

  

December 31,

2023

  

December 31,

2022

 
Stock price  $0.54   $8.55 
Volatility   110.0%   105.0%
Time to Expiry   4.99    4.01 
Dividend yield   0%   0%
Risk free rate   3.8%   4.1%

 

The following reconciles the warrant liabilities for the years ended December 31, 2023 and 2022:

 

  

                     
   Years ended December 31, 2023 and 2022 
   Series B Warrant Commitment   Series B warrant liabilities   Placement agent warrants   Total 
Beginning balance, December 31, 2021   37,652,808    -    -    37,652,808 
Initial recognition   -    55,061,119    1,525,924    56,587,043 
Unrealized (gain) loss   17,408,311    (48,668,869)   (1,477,024)   (32,737,582)1
Warrants exercised or transferred   (55,061,119)   (8,000)   -    (55,069,119)
Ending balance, December 31, 2022  $-   $6,384,250   $48,900   $6,433,150 
Unrealized (gain) loss        (5,534,931)   (48,575)   (5,583,506)2
Warrants exercised or exchanged   -    (580,651)   -    (580,651)
Ending balance, December 31, 2023   -   $268,668   $325   $268,993 

 

1 Recognition and change in fair value of warrant liabilities per income statement is $29,064,958. The difference of $3,672,624 is made up of the Warrant issuance costs.
2 Recognition and change in fair value of warrant liabilities per income statement is $5,503,647. The difference of $79,859 was due to a loss on a warrant exchange.

 

Earn-out liabilities: The Company generally values its Level 3 earn-out liabilities using the income valuation approach. Key valuation inputs include contingent payment arrangement terms, projected revenues and cash flows, rate of return, and probability assessments. The following table summarizes the significant unobservable inputs used in the fair value measurements:

 

   

    December 31, 2023   December 31, 2022
Valuation technique   Discounted cash flow   Discounted cash flow
Significant unobservable input   Projected revenue and probability of achievement   Projected revenue and probability of achievement

 

 

The Company values its Level 3 earn-out liability related to the Southwestern Montana Insurance Center acquisition using a Monte Carlo simulation in a risk-neutral framework (a special case of the Income Approach). The following summarizes the significant unobservable inputs:

 

 

  

December 31,

2023

 
Volatility   110%
Credit Spread   7.73%
Number of trading days   252 
Risk free rate   5.34

%

Remaining term (years)   0.2 
Stock Price  $0.54 
Dividend Yield   0%
Number of Iterations   100,000 

 

Undiscounted remaining earn out cash payments were approximately $165,000 as of December 31, 2023. The following table reconciles fair value of earn-out liabilities for the years ending December 31, 2023 and 2022:

  

 

   December 31,
2023
   December 31,
2022
 
Beginning balance – January 1  $2,709,478   $3,813,878 
           
Acquisitions and Settlements   (3,260,403)   (1,104,924)
           
Period adjustments:          
Fair value and estimate changes*   1,716,873    524 
Earn-out payable in common shares   (159,867)   - 
Earn-out transferred to loans payable, related parties   (846,214)   

-

 
           
Ending balance  $159,867   $2,709,478 
Less: Current portion   (159,867)   (2,153,478)
Ending balance, less current portion  $-   $556,000 

 

* Recorded as change in estimated acquisition earn-out payables on the consolidated statements of operations.

 

Deferred Financing Costs

Deferred Financing Costs

 

The Company has recorded deferred financing costs because of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized to interest expense using the straight-line method which approximates the interest rate method over the term of the related debt. As of December 31, 2023, and 2022, unamortized deferred financing costs were $273,864, and $313,829, respectively and are netted against the related debt.

 

Business Combinations

Business Combinations

 

The Company accounts for its business combinations using the acquisition method of accounting. Under the acquisition method, assets acquired, liabilities assumed, and consideration transferred are recorded at the date of acquisition at their respective fair values. Definite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

 

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration such as earn-outs, the Company records the contingent consideration at fair value at the acquisition date. The Company remeasures fair value as of each reporting date and changes resulting from events after the acquisition date, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings.

 

 

Identifiable Intangible Assets, net

Identifiable Intangible Assets, net

 

Finite-lived intangible assets such as customer relationships assets, trademarks and tradenames are amortized over their estimated useful lives, generally on a straight-line basis for periods ranging from 3 to 20 years. Finite-lived intangible assets are reviewed for impairment or obsolescence whenever events or circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of intangible assets is measured by a comparison of the carrying amount of the asset to the future undiscounted net cash flows expected to be generated by that asset. If the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the estimated fair value. No impairment was recognized during the periods presented.

 

Goodwill and other indefinite-lived intangibles

Goodwill and other indefinite-lived intangibles

 

The Company records goodwill when the purchase price of a business acquisition exceeds the estimated fair value of net identified tangible and intangible assets acquired. Goodwill is assigned on the acquisition date and tested for impairment at least annually, or more frequently when events or changes in circumstances indicate that the fair value of a reporting unit has more likely than not declined below its carrying value. Similarly, indefinite-lived intangible assets (if any) other than goodwill are tested annually or more frequently if indicated, for impairment. If impaired, intangible assets are written down to fair value based on the expected discounted cash flows.

 

Financial Instruments

Financial Instruments

 

The Company evaluates issued financial instruments for classification as either equity or liability based on an assessment of the financial instrument’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”) as well as in accordance with ASU 2020-06. The assessment considers whether the financial instruments issued are freestanding pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and, if applicable whether the financial instruments meet all of the requirements for equity classification under ASC 815, including whether the financial instruments are indexed to the Company’s own Common Stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance and as of each subsequent reporting period end date while the financial instruments are outstanding. Financial instruments that are determined to be liabilities under ASC 480 or ASC 815 are held at their initial fair value and remeasured to fair value at each subsequent reporting date, with changes in fair value recorded as a non-operating, non-cash loss or gain, as applicable.

 

The Company’s financial instruments consist of derivatives related to the warrants issued with the securities purchase agreement as discussed in Note 9, Warrant Liabilities. The accounting treatment of derivative financial instruments requires that we record the derivatives at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense at each balance sheet date. Upon the determination that an instrument is no longer subject to derivative accounting, the fair value of the derivative instrument at the date of such determination will be reclassified to paid in capital.

 

The adoption of Topic 326 did not significantly change our approach to the valuation of trade receivables. The Company determines whether there is an expected loss on our accounts receivable by reviewing all available data, including our customers' latest available financial statements, their credit standing, our historical collection experience, and current and future market and economic conditions. As of December 31, 2023, and December 31, 2022, it was not deemed necessary to recognize any allowance for credit losses on our trade receivables.

 

Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606 Revenue from Contracts with Customers which at its core, recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services.

 

The Company’s revenue is primarily comprised of agency commissions earned from insurance carriers (the “Customer” or “Carrier”) related to insurance plans produced through brokering, producing, and servicing agreements between insurance carriers and members. The Company defines a “Member” as an individual, family or entity currently covered or seeking insurance coverage.

 

 

The Company focuses primarily on agency services for insurance products in the “Healthcare” and property and casualty, which includes auto (collectively “P&C”) space, with nominal activity in the life insurance and bond sectors. Healthcare includes plans for individuals and families, Medicare supplements, ancillary and small businesses. The Company also earns revenue in the “Insurance Marketing” space as discussed further below.

 

Consideration for all agency services typically is based on commissions calculated by applying contractual commission rates to policy premiums. For P&C, commission rates are applied to premiums due, whereas for healthcare, commission rates, including override commissions, are applied to monthly premiums received by the Carrier.

 

The Company has two forms of billing practices, “Direct Bill” and “Agency Bill”. With Direct Bill, Carriers bill and collect policy premium payments directly from Members without any involvement from the Company. Commissions are paid to the Company by the Carrier in the following month. With Agency Bill, the Company bills Members premiums due and remits them to Carriers net of commission earned.

 

The following outlines the core principles of ASC 606:

 

Identification of the contract, or contracts, with a customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

 

Identification of the performance obligations in the contract. Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract.

 

Determination of the transaction price. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.

 

Allocation of the transaction price to the performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.

 

Recognition of revenue when, or as, the Company satisfies a performance obligation. The Company satisfies performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.

 

Healthcare revenue recognition:

 

The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.

 

There typically is one performance obligation in contracts with Carriers, to perform agency services that culminate in monthly premium cash collections by the Carrier. The performance obligation is satisfied through a combination of agency services including, marketing carrier’s insurance plans, soliciting Member applications, binding, executing and servicing insurance policies on a continuous basis throughout a policy’s life cycle which includes and culminates with the Customer’s collection of monthly premiums. No commission is earned if cash is not received by Carrier. Thus, commission revenue is earned only after a month’s cash receipts from Members’ dues is received by the Customer. Each month’s Carrier cash collections is considered a separate unit sold and transferred to the Customer i.e., the satisfaction of that month’s performance obligation.

 

 

Transaction price is typically stated in a contract and usually based on a commission rate applied to Member premiums paid and received by Carrier. The Company generally continues to receive commission payments from Carriers until a Member’s plan is cancelled or the Company terminates its agency agreement with the Carrier. Upon termination, the Company normally will no longer receive any commissions from Carriers even on business still in place. In some instances, trailing commissions could occur which would be recognized similar to other Healthcare revenue. With one performance obligation, allocation of transaction price is normally not necessary.

 

Healthcare typically utilizes the Direct Bill method.

 

The Company recognizes revenue at a point in time when it satisfies its monthly performance obligation and control of the service transfers to the Customer. Transfer occurs when Member insurance premium cash payments are received by the Customer. The Customer’s receipt of cash is the culmination and complete satisfaction of the Company’s performance obligation, and the earnings process is complete.

 

With Direct Bill, since the amount of monthly Customer cash receipts is unknown to the Company until the following month when notice is provided by Customer to Company, the Company accrues revenue at each period end. Any estimated revenue accrued and recognized at a period-end is trued up for financial reporting per actual revenue earned as provided by the Customer during the following month.

 

P&C revenue recognition:

 

The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.

 

There typically is one performance obligation in contracts with Customers, to perform agency services to solicit, receive proposals and bind insurance policies culminating with policy placement. Commission revenue is earned at the time of policy placement.

 

Transaction price is typically stated in a contract and usually based on commission rates applied to Member premiums due. With one performance obligation, allocation of transaction price is normally not necessary.

 

P&C utilizes both the Agency Bill and Direct Bill methods, depending on the Carrier.

 

The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of the service transfers to the Customer. Transfer occurs when the policy placement process is complete.

 

With both Direct Bill and Agency Bill, the Company accrues commission revenue in the period policies are placed. With Agency Bill, payment is typically received from Members in the month earned, however with Direct Bill, payment is typically received from Carriers in the month subsequent to the commissions being earned.

 

Other revenue policies: Insurance commissions earned from Carriers for life insurance products are recorded gross of amounts due to agents, with a corresponding commission expense for downstream agent commissions being recorded as commission expense within the condensed consolidated statements of operations.

 

When applicable, commission revenue is recognized net of any deductions for estimated commission adjustments due to lapses, policy cancellations, and revisions in coverage.

 

The Company could earn additional revenue from contingent commissions, profit-sharing, override and bonuses based on meeting certain revenue or profit targets established periodically by the Carriers (collectively, “Contingent Commissions”). Contingent Commissions are earned when the Company achieves targets established by Carriers. The Carriers notify the Company when it has achieved the target. The Company recognizes revenue for any Contingent Commissions at the time it is reasonably assured that a significant revenue reversal is not probable, which is generally when a Carrier notifies the Company that it is on track or has earned a Contingent Commission.

 

 

The following table disaggregates the Company’s revenue by line of business, showing commissions earned:

 

 

Year ended

December 31, 2023

  Medical   Life   Property and Casualty   Total 
                 
EBS  $883,327   $22,114   $-   $905,441 
USBA   43,193    3184    -    46,377 
CCS/UIS   -    -    289,486    289,486 
Montana   1,863,455    12,488    -    1,875,943 
Fortman   1,161,506    5,487    1,044,592    2,211,585 
Altruis   5,454,654    -    -    5,454,654 
Kush   1,209,854    -    -    1,209,854 
Reli Exchange   209,615    127,486    1,401,385    1,738,486 
Total  $10,825,064   $170,759   $2,735,463   $13,731,826 

 

Year ended

December 31, 2022

  Medical     Life     Property and Casualty     Total  
                                 
EBS   $ 781,570     $ 16,843     $ -     $ 798,413  
USBA     51,006       1462       -       52,468  
CCS/UIS     -       -              254,325       254,325  
Montana     1,860,475       7,661       -       1,868,136  
Fortman     1,267,945       6705       842,961       2,117,611  
Altruis     4,041,495       2954       -       4,044,449  
Kush     1,535,416       1040       -       1,536,456  
Reli Exchange     152,094       106,052       831,878       1,090,024  
Total   $ 9,690,001     $ 142,717     $ 1,929,164     $ 11,761,882  

 

General and Administrative

General and Administrative

 

General and administrative expenses primarily consist of personnel costs for the Company’s administrative functions, professional service fees, office rent, all employee travel expenses, and other general costs.

 

Marketing and Advertising

Marketing and Advertising

 

The Company’s direct channel expenses primarily consist of costs for e-mail marketing and newspaper advertisements. The Company’s online advertising channel expense primarily consist of social media ads. Advertising costs for both direct and online channels are expensed as incurred.

 

Equity-Based Compensation

Equity-Based Compensation

 

Equity-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, based on the terms of the awards. The fair value of the stock-based payments to nonemployees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. To the extent possible, the Company will estimate and recognize expected forfeitures.

 

 

Leases

Leases

 

The Company recognizes leases in accordance with Accounting Standards Codification Topic 842, “Leases” (“ASC 842” or “ASU 2016-12”). This standard provides enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases are recognized as a single lease expense, generally on a straight-line basis.

 

The Company is the lessee in a contract when the Company obtains the right to use an asset. We currently lease real estate and office space under non-cancelable operating lease agreements. When applicable, consideration in a contract is allocated between lease and non-lease components. Lease payments are discounted using the implicit discount rate in the lease. If the implicit discount rate for the lease cannot be readily determined, the Company uses an estimate of its incremental borrowing rate. The Company did not have any contracts accounted for as finance leases as of December 31, 2023, or 2022. Operating leases are included in the line items right-of-use assets, current portion of leases payable, and leases payable, less current portion in the consolidated balance sheets. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations. The Company determines a lease’s term by agreement with lessor and includes lease extension options and variable lease payments when option and/or variable payments are reasonably certain of being exercised or paid.

 

Income Taxes

Income Taxes

 

The Company recognizes deferred tax assets and liabilities using enacted tax rates for the effect of temporary differences between the book and tax basis of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. In evaluating its ability to recover deferred tax assets within the jurisdiction in which they arise, the Company considers all available positive and negative evidence, including the expected reversals of taxable temporary differences, projected future taxable income, taxable income available via carryback to prior years, tax planning strategies, and results of recent operations. The Company assesses the realizability of its deferred tax assets, including scheduling the reversal of its deferred tax assets and liabilities, to determine the amount of valuation allowance needed. Scheduling the reversal of deferred tax asset and liability balances requires judgment and estimation. The Company believes the deferred tax liabilities relied upon as future taxable income in its assessment will reverse in the same period and jurisdiction and are of the same character as the temporary differences giving rise to the deferred tax assets that will be realized.

 

Discontinued Operations

Discontinued Operations

 

The Company’s board of directors approved the discontinuation and abandonment of Medigap Healthcare Insurance Company, LLC (“Medigap”), a subsidiary of the Company, effective April 17, 2023, due to Medigap’s sustained recurring losses stemming from amongst other factors, greater than anticipated revenue chargebacks. The Company was unable to divest its interest in Medigap for value, and accordingly, operations were wound down in an orderly manner. In doing so, the Company transferred to its operating entity, Medigap’s customer relationships and internally developed and purchased software intangible assets, with net of amortization combined value of approximately $4,300,000, as well as, its short-term financing arrangement of $29,500, and each are respectively classified at their adjusted book values in the intangible assets and short term financing agreements accounts in the condensed consolidated balance sheets for the periods ended December 31, 2023 and December 31, 2022. These assets have continued value to the Company and have not been impaired as the fair value exceeds carrying cost. Medigap’s remaining assets were considered to have no remaining asset value and were fully impaired. Certain liabilities and estimated liabilities as outlined in the tables herein, were discharged and/or written-off in conjunction with the Settlement Agreement (as defined below) because of them having a net zero dollar estimated liability value. Accordingly, the Company recognized a net of estimated liability adjustments gain/loss of approximately $0, and an impairment loss of approximately $4,400,000, presented in income (loss) from discontinued operations in the consolidated statements of operations for the year ended December 31, 2023. As part of the abandonment, the Company cancelled third party contracts, settled outstanding vendor and other third-party obligations, ceased to enter new customer contracts via Medigap, and no further customer performance obligations existed. The Company does not expect further continuing involvement with Medigap, and in accordance with ASC 205-20-45-9, no corporate overhead has been allocated to discontinued operations.

  

Settlement Agreement

 

On June 30, 2023, the Company entered into a confidential settlement agreement and mutual release (the “Settlement Agreement”) with certain Medigap affiliated entities and persons, and the former owners of Medigap, whereby the Company would receive a settlement payment, net of costs, of $2,761,190 and was released from all past and future Medigap obligations and liabilities. The settlement payment was received in full by the Company in July 2023 and is recorded as income from discontinued operations in the condensed consolidated statements of operations for the year ended December 31, 2023.

 

The following tables present the major components of assets and liabilities included in discontinued operations on the condensed consolidated balance sheets.

 

 

   December 31, 2023   December 31, 2022 
Accounts receivable  $     -   $          73,223 
Accounts receivable, related parties   -    3,595 
Other receivables   -    5,388 
Prepaid expense and other current assets   -    3,792 
Current Assets - Discontinued Operations  $-   $85,998 
           
Condensed consolidated balance sheets - Current Assets - Discontinued Operations  $-   $85,998 
           
Property and equipment, net   -   $24,116 
Right-of-use assets   -    163,129 
Intangibles, net   -    318,000 
Goodwill   -    4,825,634 
Other Assets - Discontinued Operations  $-   $5,330,879 
           
Condensed consolidated balance sheets - Other Assets - Discontinued Operations  $-   $5,330,877 
           
Accounts payable and other accrued liabilities   -   $506,585 
Chargeback reserve   -    915,934 
Current portion of leases payable   -    178,117 
Current Liabilities - Discontinued Operations  $-   $1,600,636 
           
Condensed consolidated balance sheets - Current Liabilities - Discontinued Operations  $-   $1,600,636 

 

 

The following table rolls forward Medigap’s assets and liabilities from their carrying values pre-abandonment to their values post abandonment, and presents the impact of reclassifications, impairments, and write-offs:

 

Medigap Related Assets  Carrying Value Prior To Abandonment   Asset and Liability Transfers Retained by the Company   Asset Impairments and Liability Write-Offs   Carrying Value as of December 31, 2023 
                 
Accounts receivable  $56,398   $-   $(56,398)  $       - 
Accounts receivable, related party   3,595    -    (3,595)   - 
Other receivables   5,388    -    (5,388)   - 
Current assets – Medigap  $65,381   $-   $(65,381)  $- 
                     
Property and equipment, net  $22,378   $-   $(22,378)  $- 
Right-of-use assets   119,594    -    (119,594)   - 
Intangibles, net   4,570,536    (4,258,214 )1    (312,322)   - 
Goodwill   4,825,634    -    (4,825,634)   - 
Other assets - Medigap  $9,538,142   $(4,258,214)  $(5,279,928)  $- 
                     
Total assets - Medigap  $9,603,523   $(4,258,214)  $(5,345,309)  $- 
                     
Accounts payable and other accrued liabilities  $4,157   $-   $(4,157)  $- 
Short term financing agreements   29,500    (29,500)   -    - 
Chargeback reserve   831,725    -    (831,725 )2    - 
Current portion of leases payable   134,517    -    (134,517 )3    - 
Other liabilities   9,842    -    (9,842 )3    - 
Current liabilities - Medigap  $1,009,741   $(29,500)  $(980,241)  $- 
                     
Total liabilities - Medigap  $1,009,741   $(29,500)  $(980,241)  $- 
                     
Net assets and liabilities - Medigap  $8,593,782   $(4,228,714)  $(4,365,068)  $- 

 

  1 Includes customer relationships and internally developed and purchased software intangible assets that have continued value to the Company and have not been impaired as the fair value exceeds carrying cost.
  2 Estimated liability write-off per net zero dollar estimated liability value.
  3 Liability discharge pursuant to the Settlement Agreement.

 

The following tables disaggregate the major classes of pretax gain and loss as presented in discontinued operations in the condensed consolidated statements of operations.

 

  

Year Ended

December 31, 2023

  

Year Ended

December 31, 2022

 
Income          
Commission income  $744,030   $4,994,002 
           
Expenses          
Commission expense   110,639    604,042 
Salaries and wages   454,663    1,973,579 
General and administrative    129,363    508,342 
Marketing and advertising   426,818    2,414,583 
Depreciation and amortization   7,283    238,307 
Other expenses (income)   (3,902)   (22,454)
Total discontinued operations expenses before impairments and write-offs   1,124,864    5,716,399 
Total discontinued operations income / (loss) before impairments and write-offs  $(380,834)  $(722,397)
Gains and (losses) from recoveries and impairments / write-offs of discontinued operations assets and liabilities          
           
Settlement Recovery, net of costs  $2,761,190    - 
           
Asset impairment losses          
Accounts receivable   56,398    - 
Accounts receivable, related parties   3,595    - 
Other receivables   5,388    - 
Property and equipment, net   22,378    - 
Right-of-use assets   119,593    - 
Intangibles, net   312,322    - 
Goodwill   4,825,634    14,373,374 
Total asset impairments   5,345,308    14,373,374 
           
Liability write-off gains          
Accounts payable and other accrued liabilities   4,154    - 
Other payables   9,842    - 
Chargeback reserve   831,725    - 
Current portion of leases payable   134,517    - 
Total liability write-off gains   980,238    - 
           
Discontinued operations net asset and liability impairments / write-offs gains and (losses)   4,365,070    14,373,374 
           
Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities   (1,603,880)   (14,373,374)
           
Loss from discontinued operations before tax   (1,984,714)   (15,095,770)
           
Consolidated statement of operations - Loss from discontinued operations before tax  $(1,984,714)  $(15,095,770)

 

Seasonality

Seasonality

 

A greater number of the Company’s Medicare-related health insurance plans are sold in the fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage. The majority of the Company’s individual and family health insurance plans are sold in the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.

 

 

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In March 2024, the FASB issued ASU No. 2024-01, Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards (“ASU 2024-01”), to clarify the scope application of profits interest and similar awards by adding illustrative guidance in ASC 718, Compensation - Stock Compensation.  The ASU clarifies how to determine whether profits interest and similar awards are in the scope of ASC 718 and applies to all reporting entities that account for profits interest awards as compensation to employees or non-employees. In addition to adding the illustrative guidance, the ASU modified the language in paragraph 718-10-15-3 to improve its clarity and operability. However, this amendment does not change the intent of that guidance, nor how it should be applied. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024, including interim periods within those years. The Company is currently evaluating the effects of the adoption of ASU No. 2024-01 on its consolidated financial statements.

 

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segment’s profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures.

XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW

The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows:

 

 

  

December 31,

2023

  

December 31,

2022

 
Cash  $1,329,016   $505,410 
Restricted cash   1,409,895    1,404,359 
Total cash and restricted cash  $2,738,911   $1,909,769 
SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT

 

   Useful Life (in years) 
Computer equipment   5 
Office equipment and furniture   7 
Leasehold improvements   Shorter of the useful life or the lease term 
SCHEDULE OF WARRANT LIABILITY

  

  

December 31,

2023

  

December 31,

2022

 
Stock price  $0.54   $8.55 
Volatility   110.0%   105.0%
Time to Expiry   4.99    4.01 
Dividend yield   0%   0%
Risk free rate   3.8%   4.1%
SCHEDULE OF RECONCILES WARRANT COMMITMENT

The following reconciles the warrant liabilities for the years ended December 31, 2023 and 2022:

 

  

                     
   Years ended December 31, 2023 and 2022 
   Series B Warrant Commitment   Series B warrant liabilities   Placement agent warrants   Total 
Beginning balance, December 31, 2021   37,652,808    -    -    37,652,808 
Initial recognition   -    55,061,119    1,525,924    56,587,043 
Unrealized (gain) loss   17,408,311    (48,668,869)   (1,477,024)   (32,737,582)1
Warrants exercised or transferred   (55,061,119)   (8,000)   -    (55,069,119)
Ending balance, December 31, 2022  $-   $6,384,250   $48,900   $6,433,150 
Unrealized (gain) loss        (5,534,931)   (48,575)   (5,583,506)2
Warrants exercised or exchanged   -    (580,651)   -    (580,651)
Ending balance, December 31, 2023   -   $268,668   $325   $268,993 

 

1 Recognition and change in fair value of warrant liabilities per income statement is $29,064,958. The difference of $3,672,624 is made up of the Warrant issuance costs.
2 Recognition and change in fair value of warrant liabilities per income statement is $5,503,647. The difference of $79,859 was due to a loss on a warrant exchange.
SCHEDULE OF FAIR VALUE MEASUREMENTS

   

    December 31, 2023   December 31, 2022
Valuation technique   Discounted cash flow   Discounted cash flow
Significant unobservable input   Projected revenue and probability of achievement   Projected revenue and probability of achievement
SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS

 

  

December 31,

2023

 
Volatility   110%
Credit Spread   7.73%
Number of trading days   252 
Risk free rate   5.34

%

Remaining term (years)   0.2 
Stock Price  $0.54 
Dividend Yield   0%
Number of Iterations   100,000 
SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE

 

   December 31,
2023
   December 31,
2022
 
Beginning balance – January 1  $2,709,478   $3,813,878 
           
Acquisitions and Settlements   (3,260,403)   (1,104,924)
           
Period adjustments:          
Fair value and estimate changes*   1,716,873    524 
Earn-out payable in common shares   (159,867)   - 
Earn-out transferred to loans payable, related parties   (846,214)   

-

 
           
Ending balance  $159,867   $2,709,478 
Less: Current portion   (159,867)   (2,153,478)
Ending balance, less current portion  $-   $556,000 

 

* Recorded as change in estimated acquisition earn-out payables on the consolidated statements of operations.
SCHEDULE OF DISAGGREGATION REVENUE

The following table disaggregates the Company’s revenue by line of business, showing commissions earned:

 

 

Year ended

December 31, 2023

  Medical   Life   Property and Casualty   Total 
                 
EBS  $883,327   $22,114   $-   $905,441 
USBA   43,193    3184    -    46,377 
CCS/UIS   -    -    289,486    289,486 
Montana   1,863,455    12,488    -    1,875,943 
Fortman   1,161,506    5,487    1,044,592    2,211,585 
Altruis   5,454,654    -    -    5,454,654 
Kush   1,209,854    -    -    1,209,854 
Reli Exchange   209,615    127,486    1,401,385    1,738,486 
Total  $10,825,064   $170,759   $2,735,463   $13,731,826 

 

Year ended

December 31, 2022

  Medical     Life     Property and Casualty     Total  
                                 
EBS   $ 781,570     $ 16,843     $ -     $ 798,413  
USBA     51,006       1462       -       52,468  
CCS/UIS     -       -              254,325       254,325  
Montana     1,860,475       7,661       -       1,868,136  
Fortman     1,267,945       6705       842,961       2,117,611  
Altruis     4,041,495       2954       -       4,044,449  
Kush     1,535,416       1040       -       1,536,456  
Reli Exchange     152,094       106,052       831,878       1,090,024  
Total   $ 9,690,001     $ 142,717     $ 1,929,164     $ 11,761,882  
SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS

The following tables present the major components of assets and liabilities included in discontinued operations on the condensed consolidated balance sheets.

 

 

   December 31, 2023   December 31, 2022 
Accounts receivable  $     -   $          73,223 
Accounts receivable, related parties   -    3,595 
Other receivables   -    5,388 
Prepaid expense and other current assets   -    3,792 
Current Assets - Discontinued Operations  $-   $85,998 
           
Condensed consolidated balance sheets - Current Assets - Discontinued Operations  $-   $85,998 
           
Property and equipment, net   -   $24,116 
Right-of-use assets   -    163,129 
Intangibles, net   -    318,000 
Goodwill   -    4,825,634 
Other Assets - Discontinued Operations  $-   $5,330,879 
           
Condensed consolidated balance sheets - Other Assets - Discontinued Operations  $-   $5,330,877 
           
Accounts payable and other accrued liabilities   -   $506,585 
Chargeback reserve   -    915,934 
Current portion of leases payable   -    178,117 
Current Liabilities - Discontinued Operations  $-   $1,600,636 
           
Condensed consolidated balance sheets - Current Liabilities - Discontinued Operations  $-   $1,600,636 

 

 

The following table rolls forward Medigap’s assets and liabilities from their carrying values pre-abandonment to their values post abandonment, and presents the impact of reclassifications, impairments, and write-offs:

 

Medigap Related Assets  Carrying Value Prior To Abandonment   Asset and Liability Transfers Retained by the Company   Asset Impairments and Liability Write-Offs   Carrying Value as of December 31, 2023 
                 
Accounts receivable  $56,398   $-   $(56,398)  $       - 
Accounts receivable, related party   3,595    -    (3,595)   - 
Other receivables   5,388    -    (5,388)   - 
Current assets – Medigap  $65,381   $-   $(65,381)  $- 
                     
Property and equipment, net  $22,378   $-   $(22,378)  $- 
Right-of-use assets   119,594    -    (119,594)   - 
Intangibles, net   4,570,536    (4,258,214 )1    (312,322)   - 
Goodwill   4,825,634    -    (4,825,634)   - 
Other assets - Medigap  $9,538,142   $(4,258,214)  $(5,279,928)  $- 
                     
Total assets - Medigap  $9,603,523   $(4,258,214)  $(5,345,309)  $- 
                     
Accounts payable and other accrued liabilities  $4,157   $-   $(4,157)  $- 
Short term financing agreements   29,500    (29,500)   -    - 
Chargeback reserve   831,725    -    (831,725 )2    - 
Current portion of leases payable   134,517    -    (134,517 )3    - 
Other liabilities   9,842    -    (9,842 )3    - 
Current liabilities - Medigap  $1,009,741   $(29,500)  $(980,241)  $- 
                     
Total liabilities - Medigap  $1,009,741   $(29,500)  $(980,241)  $- 
                     
Net assets and liabilities - Medigap  $8,593,782   $(4,228,714)  $(4,365,068)  $- 

 

  1 Includes customer relationships and internally developed and purchased software intangible assets that have continued value to the Company and have not been impaired as the fair value exceeds carrying cost.
  2 Estimated liability write-off per net zero dollar estimated liability value.
  3 Liability discharge pursuant to the Settlement Agreement.

 

The following tables disaggregate the major classes of pretax gain and loss as presented in discontinued operations in the condensed consolidated statements of operations.

 

  

Year Ended

December 31, 2023

  

Year Ended

December 31, 2022

 
Income          
Commission income  $744,030   $4,994,002 
           
Expenses          
Commission expense   110,639    604,042 
Salaries and wages   454,663    1,973,579 
General and administrative    129,363    508,342 
Marketing and advertising   426,818    2,414,583 
Depreciation and amortization   7,283    238,307 
Other expenses (income)   (3,902)   (22,454)
Total discontinued operations expenses before impairments and write-offs   1,124,864    5,716,399 
Total discontinued operations income / (loss) before impairments and write-offs  $(380,834)  $(722,397)
Gains and (losses) from recoveries and impairments / write-offs of discontinued operations assets and liabilities          
           
Settlement Recovery, net of costs  $2,761,190    - 
           
Asset impairment losses          
Accounts receivable   56,398    - 
Accounts receivable, related parties   3,595    - 
Other receivables   5,388    - 
Property and equipment, net   22,378    - 
Right-of-use assets   119,593    - 
Intangibles, net   312,322    - 
Goodwill   4,825,634    14,373,374 
Total asset impairments   5,345,308    14,373,374 
           
Liability write-off gains          
Accounts payable and other accrued liabilities   4,154    - 
Other payables   9,842    - 
Chargeback reserve   831,725    - 
Current portion of leases payable   134,517    - 
Total liability write-off gains   980,238    - 
           
Discontinued operations net asset and liability impairments / write-offs gains and (losses)   4,365,070    14,373,374 
           
Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities   (1,603,880)   (14,373,374)
           
Loss from discontinued operations before tax   (1,984,714)   (15,095,770)
           
Consolidated statement of operations - Loss from discontinued operations before tax  $(1,984,714)  $(15,095,770)
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.1
STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Tables) - Barra And Associates LLC [Member]
12 Months Ended
Dec. 31, 2023
Business Acquisition [Line Items]  
SCHEDULE OF ALLOCATION OF PURCHASE PRICE

The preliminary allocation of the purchase price in connection with the acquisition of Barra was calculated as follows:

 

  

Description  Fair Value  

Weighted

Average Useful

Life (Years)

 
Acquired accounts receivable  $92,585      
Property, plant, and equipment   8,593    7 
Right-of-use asset   122,984      
Trade names   22,000    4 
Customer relationships   550,000    10 
Developed technology   230,000    5 
Agency relationships   2,585,000    10 
Lease liability   (122,984)     
Goodwill   4,236,822    Indefinite 
   $7,725,000      


SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION

  

    December 31, 
    2022 
Revenue   $12,309,504 
Net Income (Loss)   $6,700,594 
Earnings (Loss) per common share, basic   $(0.21)
Earnings (Loss) per common share, diluted   $(0.21)

 

XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.1
PROPERTY AND EQUIPMENT (Tables)
12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

 

  

December 31,

2023

  

December 31,

2022

 
Computer equipment  $110,350   $92,278 
Office equipment and furniture   47,652    40,693 
Leasehold Improvements   120,378    122,830 
Property and equipment   278,380    255,801  
Less: Accumulated depreciation   (138,381)   

(93,034

)
Property and equipment, net  $139,999   $162,767 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.1
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
SCHEDULE OF IMPAIRMENT OF GOODWILL

The following table rolls forward the Company’s goodwill balance for the periods ending December 31, 2023 and 2022 exclusive of discontinued operations.

  

   Goodwill 
December 31, 2021  $10,050,277 
Goodwill recognized in connection with Barra acquisition on April 26, 2022   4,236,822 
December 31, 2022   14,287,099 
Goodwill impairment recognized as of December 31, 2023   (7,594,000)
December 31, 2023  $6,693,099 

 

   Goodwill 
December 31, 2021  $10,050,277 
Goodwill recognized in connection with Medigap acquisition   19,199,008 
Goodwill recognized in connection with Barra acquisition   4,236,822 
Goodwill impairment (Medigap) during the year-ended December 31, 2022   (14,373,374)
December 31, 2022   19,112,733 
Goodwill impairment (Medigap) during the year ended December 31, 2023   (4,825,634)
Goodwill impairment recognized as of December 31, 2023   (7,594,000)
December 31, 2023  $6,693,099 

 
SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2023:

  

   Weighted Average Remaining Amortization period (Years)   Gross Carrying Amount   Accumulated Amortization  

Net

Carrying Amount

 
Trade name and trademarks   1.5   $1,807,189   $(1,320,939)  $486,250 
Internally developed software   3.2    1,798,922    (650,029)   1,148,893 
Customer relationships   8.0    11,922,290    (3,193,629)   8,728,661 
Purchased software   0.3    667,206    (618,418)   48,788 
Video Production Assets   -    50,000    (50,000)   - 
Non-competition agreements   0.9    3,504,810    (2,874,645)   630,165 
Trade name and trademarks       $19,750,417   $(8,707,660)  $11,042,757 

 

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2022:

 

   Weighted Average Remaining Amortization period (Years)   Gross Carrying Amount   Accumulated Amortization  

Net

Carrying Amount

 
Trade name and trademarks   4.4   $1,806,188   $(969,241)  $836,947 
Internally developed software   4.1    1,635,178    (287,990)   1,347,188 
Customer relationships   9.0    11,922,290    (2,076,086)   9,846,204 
Purchased software   0.4    665,137    (581,497)   83,640 
Video Production Assets   0.0    50,000    (50,000)   - 
Non-competition agreements   1.9    3,504,810    (2,179,420)   1,325,390 
        $19,583,603   $(6,144,234)  $13,439,369 
SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS

The following table reflects expected amortization expense as of December 31, 2023, for each of the following five years and thereafter:

 

Years ending December 31,  Amortization Expense 
2024  $2,195,191 
2025   1,801,235 
2026   1,532,267 
2027   1,196,989 
2028   1,097,825 
Thereafter   3,218,683 
Total  $11,042,757 
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.1
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Significant components of accounts payable and accrued liabilities were as follows:

 

  

December 31,

2023

  

December 31,

2022

 
         
Accounts payable,  $635,339   $747,469 
Accrued expenses   40,540    109,502 
Accrued credit card payables   54,416    58,120 
Other accrued liabilities   105,188    36,291 
Accounts payable and other accrued liabilities  $835,483   $951,382 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.1
LONG-TERM DEBT (Tables)
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
SCHEDULE OF LONG TERM DEBT

The composition of the long-term debt follows:

 

  

December 31,

2023

  

December 31,

2022

 
         
Oak Street Funding LLC Term Loan  $369,602   $426,883 
Oak Street Funding LLC Term Loan for the acquisition of EBS and USBA, variable interest of Prime Rate plus 2.5%, maturing August 2028, net of deferred financing costs of $10,069 and $12,388 as of December 31, 2023 and 2022, respectively  $369,602   $426,883 
Oak Street Funding LLC Senior Secured Amortizing Credit Facility for the acquisition of CCS, variable interest of Prime Rate plus 1.5%, maturing December 2028, net of deferred financing costs of $12,525 and $15,076 as of December 31, 2023 and 2022, respectively   604,830    693,682 
Oak Street Funding LLC Term Loan for the acquisition of SWMT, variable interest of Prime Rate plus 2.0%, maturing April 2029 net of deferred financing costs of $7,733 and $9,206 as of December 31, 2023 and 2022, respectively   695,758    788,596 
Oak Street Funding LLC Term Loan for the acquisition of FIS, variable interest of Prime Rate plus 2.0%, maturing May 2029, net of deferred financing costs of $31,026 and $36,843 as of December 31, 2023 and 2022, respectively   1,758,558    1,987,846 
Oak Street Funding LLC Term Loan for the acquisition of ABC, variable interest of Prime Rate plus 2.0%, maturing September 2029, net of deferred financing costs of $35,649 and $42,129 as of December 31, 2023 and 2022, respectively   2,899,409    3,249,575 
Oak Street Funding LLC Term Loan, variable interest of Prime Rate plus 2.5%, maturing May 2032, for the acquisition of Barra, net of deferred financing costs of $176,762 and $198,188 as of December 31, 2023 and December 31, 2022, respectively   6,089,580    6,321,812 
Long term debt gross   12,417,737    13,468,394 
Less: current portion   (1,390,766)   (1,118,721)
Long-term debt  $11,026,971   $12,349,673 
SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES

  

Fiscal year ending December 31, 

Maturities of

Long-Term Debt

 
2024  $1,390,766 
2025   1,552,772 
2026   1,729,160 
2027   1,925,603 
2028   2,107,128 
Thereafter   3,986,172 
Total   12,691,601 
Less debt issuance costs   (273,864)
Total  $12,417,737 
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.1
SIGNIFICANT CUSTOMERS (Tables)
12 Months Ended
Dec. 31, 2023
Risks and Uncertainties [Abstract]  
SCHEDULE OF CONCENTRATIONS OF REVENUES

 

Insurance Carrier 

December 31,

2023

  

December 31,

2022

 
Priority Health   35%   32%
BlueCross BlueShield   15%   14%
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.1
EQUITY (Tables)
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED

The following is a summary of the stock options granted, forfeited or expired, and exercised under the Plans for the years ended December 31, 2023 and 2022 respectively:

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years)   Aggregate Intrinsic Value 
Outstanding at December 31, 2022   10,928   $232.55    1.61   $        - 
Granted   -    -    -    - 
Forfeited or expired   -    -    -    - 
Exercised   -    -    -    - 
Outstanding at December 31, 2023   10,928   $232.55    0.61    - 

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years)   Aggregate Intrinsic Value 
Outstanding at December 31, 2021   10,928   $232.55    2.61   $                - 
Granted   -    -    -    - 
Forfeited or expired   -   $-    -    - 
Exercised   -    -    -    - 
Outstanding at December 31, 2022   10,928   $232.55    1.61    - 
SCHEDULE OF NON - VESTED STOCK OPTIONS

The following is a summary of the Company’s non-vested stock options as of December 31, 2023 and 2022 respectively:

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years) 
Non-vested at December 31, 2022   271   $236.83    2.27 
Granted   -    -    - 
Vested   (248)   239.68    0.81 
Forfeited or expired   -    -    - 
Non-vested at December 31, 2023   23   $205.70    1.59 

 

   Options   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Life (Years) 
Non-vested at December 31, 2021   3,587   $227.78    0.90 
Granted   -    -    - 
Vested   (3,315)   14.89    1.71 
Forfeited or expired   -    -    - 
Non-vested at December 31, 2022   271   $236.83    2.27 
SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL

 

   

Year Ended

December 31, 2023

   

Year Ended

December 31, 2022

 
Exercise price   $ 0.16 - $0.26     $ 0.16 - $0.26  
Expected term     3.25 to 3.75 years       3.25 to 3.75 years  
Risk-free interest rate     0.38% - 2.43 %     0.38% - 2.43 %
Estimated volatility    

293.07% - 517.13

%     293.07% - 517.13 %
Expected dividend     -       -  
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.1
EARNINGS (LOSS) PER SHARE (Tables)
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS

The following calculates basic and diluted EPS:

 

   2023   2022 
   For the Years Ended December 31, 
   2023   2022 
(Loss) income from continuing operations  $(10,025,268)  $21,561,932 
Deemed dividend   (2,539,757)   (6,930,335)
(Loss) income from continuing operations, numerator, basic   (12,565,025)   14,631,597 
(Loss) income from continuing operations, numerator, diluted  $(12,565,025)  $14,631,597 
           
Weighted average common shares, basic   2,820,275    1,094,781 
Effect of weighted average vested stock awards   -    208 
Diluted weighted average shares outstanding   2,820,275    1,094,989 
Basic (loss) income loss per common share from continuing operations:  $(4.46)  $13.36 
Diluted (loss) income per common share from continuing operations:  $(4.46)  $13.36 
SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES

Additionally, the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common share:

 

   2023   2022 
   For the years ended December 31, 
   2023   2022 
Shares subject to outstanding common stock options   10,928    10,928 
Shares subject to outstanding Series A warrants   113,000    113,000 
Shares subject to outstanding Series B Warrants and PAW   

882,970

    1,347,970 
Shares subject to outstanding Series G warrants and PA Warrants   

4,263,160

    - 
Shares subject to unvested stock awards   

3,709

    6,576 
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.1
LEASES (Tables)
12 Months Ended
Dec. 31, 2023
Leases  
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT

Future minimum lease payment under these operating leases consisted of the following:

 

Year ending December 31, 

Operating Lease

Obligations

 
2024  $320,420 
2025   153,831 
2026   113,738 
2027   117,150 
2028   120,665 
Thereafter   30,387 
Total undiscounted operating lease payments   856,191 
Less: Imputed interest   (86,685)
Present value of operating lease liabilities  $769,506 
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.1
COMMITMENTS AND CONTINGENCIES (Tables)
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
SCHEDULE OF EARN-OUT LIABILITY

The following outlines changes to the Company’s earn-out liability balances for the respective years ended December 31, 2023 and 2022:

 

    Fortman   Montana   Altruis   Kush   Barra   Total 
Ending balance December 31, 2022   $667,000   $500,001   $834,943   $147,534   $560,000   $2,709,478 
Payments    (1,433,700)   

(750,001

)   (929,168)   

(147,534

)   -    (3,260,403)

Estimate & fair value adjustments

   1,612,914    569,734    94,225    -    (560,000)   1,716,873 

Payable in Common Stock

   -     

(159,867

)   

-

    

-

    

-

    

(159,867

)

Reclass to loans payable, related parties*

   (846,214

)   -     

-

    

-

    

-

    

(846,214

)
Ending balance December 31, 2023   $-   $159,867   $-   $-   $-   $159,867 

 

   Fortman   Montana   Altruis   Kush   Barra   Total 
Ending balance December 31, 2021  $515,308   $615,969   $992,868   $1,689,733   $-   $3,813,878 
Business combinations   -    -    -    -    600,000    600,000 
Payments   (34,430)   (326,935)   (84,473)   (1,259,086)        (1,704,924)

Estimate & fair value adjustments

   186,122    210,967    (73,452)   (283,113)   (40,000)   524 
Ending balance December 31, 2022  $667,000   $500,001   $834,943   $147,534   $560,000   $2,709,478 

 

*As further described in the Note 16, Related Parties, the Company modified the Fortman contingent earn-out payable, entering into a fixed payment agreement, thus, the remaining open balance is reclassified to the loans payable, related parties account on the consolidated balance sheet as of December 31, 2023.

XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
SCHEDULE OF ACTUAL INCOME TAX RATE

The difference between the actual income tax rate versus the tax computed at the Federal Statutory rate follows:

 

  

December 31,

2023

  

December 31,

2022

 
Federal rate   21.0%   21.0%
State net of federal   

8.9

%   -7.9%
Non-taxable change in fair value of warrant commitment   9.3%   -106.3%
Goodwill impairment   11.8%   46.7%
Rate Change   -0.2%   -4.1%
Other   0.0%   2.2%
Valuation allowance   -50.9%   48.5%
Effective income tax rate   0.0%   0.0%
SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES

Deferred income tax assets and (liabilities) consist of the following:

 

  

December 31,

2023

  

December 31,

2022

 
Deferred tax assets (liabilities)          
Net operating loss carryforward  $10,399,616   $4,938,164 
Equity-based compensation   1,462,901    1,148,836 
Goodwill   (332,159)   (771,631)
Intangibles   694,358    745,227 
Fixed assets   (151,775)   (99,002)
Right of use assets   (186,905)   (300,616)
Lease liabilities   194,403    313,342 
Other   4,027    1,525 
Total deferred tax assets   

12,084,466

    5,975,846 
Valuation allowance   (12,084,466)   (5,975,846)
Net deferred tax assets  $

-

   $- 
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Cash $ 1,329,016 $ 505,410
Restricted cash 1,409,895 1,404,359
Total cash and restricted cash $ 2,738,911 $ 1,909,769
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT (Details)
Dec. 31, 2023
Computer Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life 5 years
Office Equipment and Furniture [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life 7 years
Leasehold Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Depreciation Method [Extensible Enumeration] Useful Life, Shorter of Lease Term or Asset Utility [Member]
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF WARRANT LIABILITY (Details)
Dec. 31, 2023
Dec. 31, 2022
Measurement Input, Share Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrant Liabilities 0.54 8.55
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrant Liabilities 110.0 105.0
Measurement Input, Expected Term [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Time to expiry 4 years 11 months 26 days 4 years 3 days
Measurement Input, Expected Dividend Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrant Liabilities 0 0
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrant Liabilities 3.8 4.1
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Offsetting Assets [Line Items]    
Beginning balance, December 31, 2022 $ 6,433,150 $ 37,652,808
Initial recognition   56,587,043
Unrealized (gain) loss (5,583,506) [1] (32,737,582) [2]
Warrants exercised or exchanged (580,651) (55,069,119)
Ending balance, December 31, 2023 268,993 6,433,150
Series B Warrant Commitment [Member]    
Offsetting Assets [Line Items]    
Beginning balance, December 31, 2022 37,652,808
Initial recognition  
Unrealized (gain) loss   17,408,311
Warrants exercised or exchanged (55,061,119)
Ending balance, December 31, 2023
Series B Warrant Liability [Member]    
Offsetting Assets [Line Items]    
Beginning balance, December 31, 2022 6,384,250
Initial recognition   55,061,119
Unrealized (gain) loss (5,534,931) (48,668,869)
Warrants exercised or exchanged (580,651) (8,000)
Ending balance, December 31, 2023 268,668 6,384,250
Placement Agent Warrants [Member]    
Offsetting Assets [Line Items]    
Beginning balance, December 31, 2022 48,900
Initial recognition   1,525,924
Unrealized (gain) loss (48,575) (1,477,024)
Warrants exercised or exchanged
Ending balance, December 31, 2023 $ 325 $ 48,900
[1] Recognition and change in fair value of warrant liabilities per income statement is $5,503,647. The difference of $79,859 was due to a loss on a warrant exchange.
[2] Recognition and change in fair value of warrant liabilities per income statement is $29,064,958. The difference of $3,672,624 is made up of the Warrant issuance costs.
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) (Parenthetical) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Recognition and change in fair value of warrant liability $ 5,503,647 $ 29,064,958
Warrant issuance cost $ 79,859 $ 3,672,624
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) - Fair Value, Inputs, Level 3 [Member]
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Platform Operator, Crypto-Asset [Line Items]    
Valuation technique Discounted cash flow Discounted cash flow
Significant unobservable input Projected revenue and probability of achievement Projected revenue and probability of achievement
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS (Details) - Fair Value, Inputs, Level 3 [Member]
12 Months Ended
Dec. 31, 2023
shares
Platform Operator, Crypto-Asset [Line Items]  
Number of iterations 100,000
Measurement Input, Price Volatility [Member]  
Platform Operator, Crypto-Asset [Line Items]  
Earn out liability 110
Measurement Input, Credit Spread [Member]  
Platform Operator, Crypto-Asset [Line Items]  
Earn out liability 7.73
Number of Trading Days [Member]  
Platform Operator, Crypto-Asset [Line Items]  
Earn out liability 252 days
Measurement Input, Risk Free Interest Rate [Member]  
Platform Operator, Crypto-Asset [Line Items]  
Earn out liability 5.34
Measurement Input, Expected Term [Member]  
Platform Operator, Crypto-Asset [Line Items]  
Earn out liability 2 months 12 days
Measurement Input, Share Price [Member]  
Platform Operator, Crypto-Asset [Line Items]  
Earn out liability 0.54
Measurement Input, Expected Dividend Rate [Member]  
Platform Operator, Crypto-Asset [Line Items]  
Earn out liability 0
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Beginning balance – January 1 $ 2,709,478 $ 3,813,878
Acquisitions and Settlements (3,260,403) (1,104,924)
Fair value and estimate changes [1] 1,716,873 524
Earn-out payable in common shares (159,867)
Earn-out transferred to loans payable, related parties (846,214)
Ending balance 159,867 2,709,478
Less: Current portion (159,867) (2,153,478)
Ending balance, less current portion $ 556,000
[1] Recorded as change in estimated acquisition earn-out payables on the consolidated statements of operations.
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF DISAGGREGATION REVENUE (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]    
Total $ 13,731,826 $ 11,761,882
Employee Benefits Solutions LLC [Member]    
Product Information [Line Items]    
Total 905,441 798,413
US Benefits Alliance LLC [Member]    
Product Information [Line Items]    
Total 46,377 52,468
Commercial Coverage Solutions LLC [Member]    
Product Information [Line Items]    
Total 289,486 254,325
Southwestern Montana Financial Center Inc [Member]    
Product Information [Line Items]    
Total 1,875,943 1,868,136
Fortman Insurance Services LLC [Member]    
Product Information [Line Items]    
Total 2,211,585 2,117,611
Altruis Benefits Consulting Inc [Member]    
Product Information [Line Items]    
Total 5,454,654 4,044,449
Kush [Member]    
Product Information [Line Items]    
Total 1,209,854 1,536,456
Reli Exchange [Member]    
Product Information [Line Items]    
Total 1,738,486 1,090,024
Medical [Member] | Regular [Member]    
Product Information [Line Items]    
Total 10,825,064 9,690,001
Medical [Member] | Regular [Member] | Employee Benefits Solutions LLC [Member]    
Product Information [Line Items]    
Total 883,327 781,570
Medical [Member] | Regular [Member] | US Benefits Alliance LLC [Member]    
Product Information [Line Items]    
Total 43,193 51,006
Medical [Member] | Regular [Member] | Commercial Coverage Solutions LLC [Member]    
Product Information [Line Items]    
Total
Medical [Member] | Regular [Member] | Southwestern Montana Financial Center Inc [Member]    
Product Information [Line Items]    
Total 1,863,455 1,860,475
Medical [Member] | Regular [Member] | Fortman Insurance Services LLC [Member]    
Product Information [Line Items]    
Total 1,161,506 1,267,945
Medical [Member] | Regular [Member] | Altruis Benefits Consulting Inc [Member]    
Product Information [Line Items]    
Total 5,454,654 4,041,495
Medical [Member] | Regular [Member] | Kush [Member]    
Product Information [Line Items]    
Total 1,209,854 1,535,416
Medical [Member] | Regular [Member] | Reli Exchange [Member]    
Product Information [Line Items]    
Total 209,615 152,094
Life [Member] | Regular [Member]    
Product Information [Line Items]    
Total 170,759 142,717
Life [Member] | Regular [Member] | Employee Benefits Solutions LLC [Member]    
Product Information [Line Items]    
Total 22,114 16,843
Life [Member] | Regular [Member] | US Benefits Alliance LLC [Member]    
Product Information [Line Items]    
Total 3,184 1,462
Life [Member] | Regular [Member] | Commercial Coverage Solutions LLC [Member]    
Product Information [Line Items]    
Total
Life [Member] | Regular [Member] | Southwestern Montana Financial Center Inc [Member]    
Product Information [Line Items]    
Total 12,488 7,661
Life [Member] | Regular [Member] | Fortman Insurance Services LLC [Member]    
Product Information [Line Items]    
Total 5,487 6,705
Life [Member] | Regular [Member] | Altruis Benefits Consulting Inc [Member]    
Product Information [Line Items]    
Total 2,954
Life [Member] | Regular [Member] | Kush [Member]    
Product Information [Line Items]    
Total 1,040
Life [Member] | Regular [Member] | Reli Exchange [Member]    
Product Information [Line Items]    
Total 127,486 106,052
Property and Casualty [Member] | Regular [Member]    
Product Information [Line Items]    
Total 2,735,463 1,929,164
Property and Casualty [Member] | Regular [Member] | Employee Benefits Solutions LLC [Member]    
Product Information [Line Items]    
Total
Property and Casualty [Member] | Regular [Member] | US Benefits Alliance LLC [Member]    
Product Information [Line Items]    
Total
Property and Casualty [Member] | Regular [Member] | Commercial Coverage Solutions LLC [Member]    
Product Information [Line Items]    
Total 289,486 254,325
Property and Casualty [Member] | Regular [Member] | Southwestern Montana Financial Center Inc [Member]    
Product Information [Line Items]    
Total
Property and Casualty [Member] | Regular [Member] | Fortman Insurance Services LLC [Member]    
Product Information [Line Items]    
Total 1,044,592 842,961
Property and Casualty [Member] | Regular [Member] | Altruis Benefits Consulting Inc [Member]    
Product Information [Line Items]    
Total
Property and Casualty [Member] | Regular [Member] | Kush [Member]    
Product Information [Line Items]    
Total
Property and Casualty [Member] | Regular [Member] | Reli Exchange [Member]    
Product Information [Line Items]    
Total $ 1,401,385 $ 831,878
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Other receivables $ 899 $ 11,464  
Prepaid expense and other current assets 333,756 245,535  
Current assets – Medigap 85,998  
Property and equipment, net 139,999 162,767  
Right-of-use assets 739,830 1,018,952  
Intangibles, net 11,042,757 13,439,369  
Goodwill 6,693,099 14,287,099 $ 10,050,277
Other assets - Medigap 5,330,879  
Accounts payable and other accrued liabilities 835,483 951,382  
Current portion of leases payable 285,171 339,937  
Current liabilities - Medigap 1,600,636  
Commission income 13,731,826 11,761,882  
Commission expense 3,732,939 3,140,725  
Salaries and wages 7,503,052 7,508,312  
General and administrative 4,089,989 4,959,151  
Marketing and advertising 364,974 170,311  
Depreciation and amortization 2,609,191 2,563,518  
Other expenses (income) 3,853,924 28,142,591  
Goodwill 7,594,000  
Medigap Healthcare Insurance Company [Member]      
Other receivables    
Current assets – Medigap    
Property and equipment, net    
Right-of-use assets    
Intangibles, net    
Goodwill    
Other assets - Medigap    
Accounts payable and other accrued liabilities    
Chargeback reserve    
Current portion of leases payable    
Current liabilities - Medigap    
Total assets - Medigap    
Short term financing agreements    
Other liabilities    
Total liabilities - Medigap    
Net assets and liabilities - Medigap    
Revision of Prior Period, Reclassification, Adjustment [Member]      
Commission income 744,030 4,994,002  
Commission expense 110,639 604,042  
Salaries and wages 454,663 1,973,579  
General and administrative 129,363 508,342  
Marketing and advertising 426,818 2,414,583  
Depreciation and amortization 7,283 238,307  
Other expenses (income) (3,902) (22,454)  
Total discontinued operations expenses before impairments and write-offs 1,124,864 5,716,399  
Total discontinued operations income / (loss) before impairments and write-offs (380,834) (722,397)  
Settlement Recovery, net of costs 2,761,190  
Accounts receivable, related parties 56,398  
Other receivables 5,388  
Property and equipment, net 22,378  
Right-of-use assets 119,593  
Intangibles, net 312,322  
Goodwill 4,825,634 14,373,374  
Total asset impairments 5,345,308 14,373,374  
Accounts payable and other accrued liabilities 4,154  
Other payables 9,842  
Chargeback reserve 831,725  
Current portion of leases payable 134,517  
Total liability write-off gains 980,238  
Discontinued operations net asset and liability impairments / write-offs gains and (losses) 4,365,070 14,373,374  
Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities (1,603,880) (14,373,374)  
Loss from discontinued operations before tax (1,984,714) (15,095,770)  
Consolidated statement of operations - Loss from discontinued operations before tax (1,984,714) (15,095,770)  
Asset and Liability Transfers Retained by the Company [Member] | Revision of Prior Period, Reclassification, Adjustment [Member]      
Other receivables    
Current assets – Medigap    
Property and equipment, net    
Right-of-use assets    
Intangibles, net [1] (4,258,214)    
Goodwill    
Other assets - Medigap (4,258,214)    
Accounts payable and other accrued liabilities    
Chargeback reserve    
Current portion of leases payable    
Current liabilities - Medigap (29,500)    
Total assets - Medigap (4,258,214)    
Short term financing agreements (29,500)    
Other liabilities    
Total liabilities - Medigap (29,500)    
Net assets and liabilities - Medigap (4,228,714)    
Asset Impairments and liability WriteOffs [Member] | Revision of Prior Period, Reclassification, Adjustment [Member]      
Other receivables (5,388)    
Current assets – Medigap (65,381)    
Property and equipment, net (22,378)    
Right-of-use assets (119,594)    
Intangibles, net (312,322)    
Goodwill (4,825,634)    
Other assets - Medigap (5,279,928)    
Accounts payable and other accrued liabilities (4,157)    
Chargeback reserve [2] (831,725)    
Current portion of leases payable [3] (134,517)    
Current liabilities - Medigap (980,241)    
Total assets - Medigap (5,345,309)    
Short term financing agreements    
Other liabilities [3] (9,842)    
Total liabilities - Medigap (980,241)    
Net assets and liabilities - Medigap (4,365,068)    
Nonrelated Party [Member]      
Accounts receivable 1,298,863 994,321  
Nonrelated Party [Member] | Medigap Healthcare Insurance Company [Member]      
Accounts receivable    
Nonrelated Party [Member] | Asset and Liability Transfers Retained by the Company [Member] | Revision of Prior Period, Reclassification, Adjustment [Member]      
Accounts receivable    
Nonrelated Party [Member] | Asset Impairments and liability WriteOffs [Member] | Revision of Prior Period, Reclassification, Adjustment [Member]      
Accounts receivable (56,398)    
Related Party [Member]      
Accounts receivable 6,603 18,292  
Related Party [Member] | Medigap Healthcare Insurance Company [Member]      
Accounts receivable    
Related Party [Member] | Revision of Prior Period, Reclassification, Adjustment [Member]      
Accounts receivable, related parties 3,595  
Related Party [Member] | Asset and Liability Transfers Retained by the Company [Member] | Revision of Prior Period, Reclassification, Adjustment [Member]      
Accounts receivable    
Related Party [Member] | Asset Impairments and liability WriteOffs [Member] | Revision of Prior Period, Reclassification, Adjustment [Member]      
Accounts receivable (3,595)    
Medigap Healthcare Insurance Company [Member]      
Other receivables 5,388  
Prepaid expense and other current assets 3,792  
Current Assets - Discontinued Operations 85,998  
Current assets – Medigap 85,998  
Property and equipment, net 24,116  
Right-of-use assets 163,129  
Intangibles, net 318,000  
Goodwill 4,825,634  
Other Assets - Discontinued Operations 5,330,879  
Other assets - Medigap 5,330,877  
Accounts payable and other accrued liabilities 506,585  
Chargeback reserve 915,934  
Current portion of leases payable 178,117  
Current Liabilities - Discontinued Operations 1,600,636  
Current liabilities - Medigap 1,600,636  
Medigap Healthcare Insurance Company [Member] | Carrying Value Prior to Abandonment [Member]      
Other receivables 5,388    
Current assets – Medigap 65,381    
Property and equipment, net 22,378    
Right-of-use assets 119,594    
Intangibles, net 4,570,536    
Goodwill 4,825,634    
Other assets - Medigap 9,538,142    
Accounts payable and other accrued liabilities 4,157    
Chargeback reserve 831,725    
Current portion of leases payable 134,517    
Current liabilities - Medigap 1,009,741    
Total assets - Medigap 9,603,523    
Short term financing agreements 29,500    
Other liabilities 9,842    
Total liabilities - Medigap 1,009,741    
Net assets and liabilities - Medigap 8,593,782    
Medigap Healthcare Insurance Company [Member] | Nonrelated Party [Member]      
Accounts receivable 73,223  
Medigap Healthcare Insurance Company [Member] | Nonrelated Party [Member] | Carrying Value Prior to Abandonment [Member]      
Accounts receivable 56,398    
Medigap Healthcare Insurance Company [Member] | Related Party [Member]      
Accounts receivable $ 3,595  
Medigap Healthcare Insurance Company [Member] | Related Party [Member] | Carrying Value Prior to Abandonment [Member]      
Accounts receivable $ 3,595    
[1] Includes customer relationships and internally developed and purchased software intangible assets that have continued value to the Company and have not been impaired as the fair value exceeds carrying cost.
[2] Estimated liability write-off per net zero dollar estimated liability value.
[3] Liability discharge pursuant to the Settlement Agreement.
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.24.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Dec. 31, 2021
Property, Plant and Equipment [Line Items]          
Aggregate cash balance   $ 2,739,000      
Current assets   4,379,032 $ 3,265,379    
Current liabilities   3,189,851 7,841,533    
Working capital   1,189,000      
Stockholder's equity   7,147,330 8,911,039   $ (26,066,129)
Operating income loss   13,879,192 6,580,659    
Goodwill impairment loss   7,594,000    
Fair value of warrant liabilities   5,503,647 29,064,958    
Interest expense   1,650,000      
Income loss from continuing operations   10,025,268 (21,561,932)    
Income loss from discontinued operations   1,985,000      
Net loss   12,010,000      
Raising net proceeds $ 3,446,000        
FDIC insured amount   250,000      
Earn out payments   165,000      
Unamortized deferred financing costs   273,864 $ 313,829    
Settlement payment       $ 2,761,190  
Medigap Healthcare Insurance Company, LLC [Member] | Discontinued Operations [Member]          
Property, Plant and Equipment [Line Items]          
Net of amortization combined   4,300,000      
Short term financing agreements   29,500      
Net of estimated liability adjustments gain   0      
Impairment loss on discontinued operations   $ 4,400,000      
Minimum [Member]          
Property, Plant and Equipment [Line Items]          
Estimated useful lives of intangible assets   3 years      
Maximum [Member]          
Property, Plant and Equipment [Line Items]          
Estimated useful lives of intangible assets   20 years      
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF ALLOCATION OF PURCHASE PRICE (Details) - USD ($)
Apr. 26, 2022
Dec. 31, 2023
Dec. 31, 2022
Customer Relationships [Member]      
Business Acquisition [Line Items]      
Finite lived intangible asset useful life   8 years 9 years
Barra And Associates LLC [Member]      
Business Acquisition [Line Items]      
Property, plant and equipment $ 7,725,000    
Barra And Associates LLC [Member] | Acquired Accounts Receivable [Member]      
Business Acquisition [Line Items]      
Property, plant and equipment 92,585    
Barra And Associates LLC [Member] | Property, Plant and Equipment [Member]      
Business Acquisition [Line Items]      
Property, plant and equipment $ 8,593    
Finite lived intangible asset useful life 7 years    
Barra And Associates LLC [Member] | Right of use asset [Member]      
Business Acquisition [Line Items]      
Property, plant and equipment $ 122,984    
Barra And Associates LLC [Member] | Trade Names [Member]      
Business Acquisition [Line Items]      
Property, plant and equipment $ 22,000    
Finite lived intangible asset useful life 4 years    
Barra And Associates LLC [Member] | Customer Relationships [Member]      
Business Acquisition [Line Items]      
Property, plant and equipment $ 550,000    
Finite lived intangible asset useful life 10 years    
Barra And Associates LLC [Member] | Development Technology [Member]      
Business Acquisition [Line Items]      
Property, plant and equipment $ 230,000    
Finite lived intangible asset useful life 5 years    
Barra And Associates LLC [Member] | Agency Relationship [Member]      
Business Acquisition [Line Items]      
Property, plant and equipment $ 2,585,000    
Finite lived intangible asset useful life 10 years    
Barra And Associates LLC [Member] | Lease liability [Member]      
Business Acquisition [Line Items]      
Property, plant and equipment $ (122,984)    
Barra And Associates LLC [Member] | Goodwill [Member]      
Business Acquisition [Line Items]      
Property, plant and equipment $ 4,236,822    
Finite lived intangible asset useful life Indefinite    
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION (Details) - Medigap Healthcare Insurance Company [Member]
12 Months Ended
Dec. 31, 2022
USD ($)
$ / shares
Business Acquisition [Line Items]  
Revenue | $ $ 12,309,504
Net Income (Loss) | $ $ 6,700,594
Earnings (Loss) per common share, basic | $ / shares $ (0.21)
Earnings (Loss) per common share, diluted | $ / shares $ (0.21)
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.24.1
STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Details Narrative)
8 Months Ended
Apr. 26, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2021
USD ($)
Asset Acquisition [Line Items]        
Goodwill   $ 14,287,099 $ 6,693,099 $ 10,050,277
Barra And Associates LLC [Member]        
Asset Acquisition [Line Items]        
Goodwill $ 4,236,822      
Acquisition costs $ 72,793      
Revenue from acquired entity   1,090,023    
Shares issued upon termination of employee   $ 393,708    
Measurement Input Royalty Rate [Member] | Trade Names [Member] | Barra And Associates LLC [Member]        
Asset Acquisition [Line Items]        
Business combination, measurement input 0.005      
Measurement Input, Discount Rate [Member] | Trade Names [Member] | Barra And Associates LLC [Member]        
Asset Acquisition [Line Items]        
Business combination, measurement input 19.05      
Measurement Input, Discount Rate [Member] | Customer Relationships [Member] | Barra And Associates LLC [Member]        
Asset Acquisition [Line Items]        
Business combination, measurement input 19.05      
Measurement Input Obsolescence Rate [Member] | Development Technology [Member] | Barra And Associates LLC [Member]        
Asset Acquisition [Line Items]        
Business combination, measurement input 28.06      
Barra And Associates LLC [Member] | Asset Purchase Agreement [Member]        
Asset Acquisition [Line Items]        
Asset Acquisition, Consideration Transferred $ 7,725,000      
Working capital 6,520,000      
Barra And Associates LLC [Member] | Asset Purchase Agreement [Member] | Paid At Closing [Member]        
Asset Acquisition [Line Items]        
Asset Acquisition, Consideration Transferred 6,000,000      
Barra And Associates LLC [Member] | Asset Purchase Agreement [Member] | Payable In Nine Months [Member]        
Asset Acquisition [Line Items]        
Asset Acquisition, Consideration Transferred 1,125,000      
Barra And Associates LLC [Member] | Asset Purchase Agreement [Member] | Payable Over Two Years [Member]        
Asset Acquisition [Line Items]        
Asset Acquisition, Consideration Transferred $ 600,000      
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.1
INVESTMENT IN NSURE, INC. (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Mar. 13, 2023
Oct. 08, 2020
Apr. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Mar. 31, 2021
Investments       $ 900,000  
Cash proceeds       $ 900,000 $ 450,000  
NSURE, Inc. [Member]            
Sale of stock, shares     262,684   131,345  
Cash proceeds         $ 450,000  
Proceeds from sale of stock     $ 900,000      
Remaining balance shares       0    
Securities Purchase Agreement [Member]            
Number of shares of common stock, shares 155,038          
Securities Purchase Agreement [Member] | NSURE, Inc. [Member]            
Investments   $ 5,700,000        
Securities Purchase Agreement [Member] | NSURE, Inc. [Member] | Share-Based Payment Arrangement, Tranche One [Member]            
Investments   $ 1,350,000        
Number of shares of common stock, shares   394,029        
Securities Purchase Agreement [Member] | NSURE, Inc. [Member] | Share-Based Payment Arrangement, Tranche Two [Member]            
Number of shares of common stock, shares   209,075        
Share price   $ 6.457        
Securities Purchase Agreement [Member] | NSURE, Inc. [Member] | Share-Based Payment Arrangement, Tranche Three [Member]            
Number of shares of common stock, shares   325,239        
Share price           $ 9.224
Securities Purchase Agreement [Member] | NSURE, Inc. [Member] | Common Class A [Member]            
Number of shares of common stock, shares   928,343        
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and equipment $ 278,380 $ 255,801
Less: Accumulated depreciation (138,381) (93,034)
Property and equipment, net 139,999 162,767
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment 110,350 92,278
Office Equipment and Furniture [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment 47,652 40,693
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment $ 120,378 $ 122,830
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.24.1
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 45,632 $ 37,638
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF IMPAIRMENT OF GOODWILL (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]    
Goodwill Beginning $ 14,287,099 $ 10,050,277
Goodwill impairment loss (7,594,000)
Goodwill end 6,693,099 14,287,099
Goodwill Beginning 19,112,733 10,050,277
Goodwill end 6,693,099 19,112,733
Barra & Associates, LLC [Member]    
Restructuring Cost and Reserve [Line Items]    
Goodwill acquired during period   4,236,822
Goodwill impairment loss (7,594,000)  
Medigap Healthcare Insurance Company [Member]    
Restructuring Cost and Reserve [Line Items]    
Goodwill Beginning 19,100,000  
Goodwill acquired during period   19,199,008
Goodwill impairment loss $ (4,825,634) (14,373,374)
Goodwill end   $ 19,100,000
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 19,750,417 $ 19,583,603
Accumulated Amortization (8,707,660) (6,144,234)
Net carrying amount $ 11,042,757 $ 13,439,369
Trademarks and Trade Names [Member]    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period 1 year 6 months 4 years 4 months 24 days
Gross Carrying Amount $ 1,807,189 $ 1,806,188
Accumulated Amortization (1,320,939) (969,241)
Net carrying amount $ 486,250 $ 836,947
Internally Developed Software [Member]    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period 3 years 2 months 12 days 4 years 1 month 6 days
Gross Carrying Amount $ 1,798,922 $ 1,635,178
Accumulated Amortization (650,029) (287,990)
Net carrying amount $ 1,148,893 $ 1,347,188
Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period 8 years 9 years
Gross Carrying Amount $ 11,922,290 $ 11,922,290
Accumulated Amortization (3,193,629) (2,076,086)
Net carrying amount $ 8,728,661 $ 9,846,204
Purchased Software [Member]    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period 3 months 18 days 4 months 24 days
Gross Carrying Amount $ 667,206 $ 665,137
Accumulated Amortization (618,418) (581,497)
Net carrying amount 48,788 $ 83,640
Video Production Assets [Member]    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period   0 years
Gross Carrying Amount 50,000 $ 50,000
Accumulated Amortization (50,000) (50,000)
Net carrying amount
Non-competition Agreements [Member]    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period 10 months 24 days 1 year 10 months 24 days
Gross Carrying Amount $ 3,504,810 $ 3,504,810
Accumulated Amortization (2,874,645) (2,179,420)
Net carrying amount $ 630,165 $ 1,325,390
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
2024 $ 2,195,191  
2025 1,801,235  
2026 1,532,267  
2027 1,196,989  
2028 1,097,825  
Thereafter 3,218,683  
Total $ 11,042,757 $ 13,439,369
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.24.1
GOODWILL AND OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]        
Goodwill $ 6,693,099 $ 14,287,099   $ 10,050,277
Goodwill impairment 7,594,000    
Amortization of intangible assets 2,563,559 2,525,880    
Medigap Healthcare Insurance Company [Member]        
Restructuring Cost and Reserve [Line Items]        
Goodwill   19,100,000    
Goodwill, Written off Related to Sale of Business Unit   33,400,000    
Goodwill impairment $ 4,825,634 $ 14,373,374    
Goodwill, Impaired, Accumulated Impairment Loss     $ 4,825,634  
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accounts payable, $ 635,339 $ 747,469
Accrued expenses 40,540 109,502
Accrued credit card payables 54,416 58,120
Other accrued liabilities 105,188 36,291
Accounts payable and other accrued liabilities $ 835,483 $ 951,382
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF LONG TERM DEBT (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Line of Credit Facility [Line Items]    
Long term debt gross $ 12,417,737 $ 13,468,394
Less: current portion (1,390,766) (1,118,721)
Long-term debt 11,026,971 12,349,673
SWMT [Member]    
Line of Credit Facility [Line Items]    
Long term debt gross 695,758 788,596
FIS [Member]    
Line of Credit Facility [Line Items]    
Long term debt gross 1,758,558 1,987,846
ABC [Member]    
Line of Credit Facility [Line Items]    
Long term debt gross 2,899,409 3,249,575
Barra & Associates, LLC [Member]    
Line of Credit Facility [Line Items]    
Long term debt gross 6,089,580 6,321,812
EBS and USBA [Member]    
Line of Credit Facility [Line Items]    
Long term debt gross 369,602 426,883
CCS [Member]    
Line of Credit Facility [Line Items]    
Long term debt gross $ 604,830 $ 693,682
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF LONG TERM DEBT (Details) (Parenthetical) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
SWMT [Member]    
Line of Credit Facility [Line Items]    
Variable interest of prime rate plus 2.00%  
Maturity date April 2029  
Net of deferred financing cost $ 7,733 $ 9,206
FIS [Member]    
Line of Credit Facility [Line Items]    
Variable interest of prime rate plus 2.00%  
Maturity date May 2029  
Net of deferred financing cost $ 31,026 36,843
ABC [Member]    
Line of Credit Facility [Line Items]    
Variable interest of prime rate plus 2.00%  
Maturity date September 2029  
Net of deferred financing cost $ 35,649 42,129
Barra & Associates, LLC [Member]    
Line of Credit Facility [Line Items]    
Variable interest of prime rate plus 2.50%  
Maturity date May 2032  
Net of deferred financing cost $ 176,762 198,188
EBS and USBA [Member]    
Line of Credit Facility [Line Items]    
Variable interest of prime rate plus 2.50%  
Maturity date August 2028  
Net of deferred financing cost $ 10,069 12,388
CCS [Member]    
Line of Credit Facility [Line Items]    
Variable interest of prime rate plus 1.50%  
Maturity date December 2028  
Net of deferred financing cost $ 12,525 $ 15,076
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
2024 $ 1,390,766  
2025 1,552,772  
2026 1,729,160  
2027 1,925,603  
2028 2,107,128  
Thereafter 3,986,172  
Total 12,691,601  
Less debt issuance costs (273,864)  
Total $ 12,417,737 $ 13,468,394
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.24.1
LONG-TERM DEBT (Details Narrative) - USD ($)
12 Months Ended
Apr. 26, 2022
Dec. 07, 2018
Dec. 31, 2019
Dec. 31, 2023
Dec. 31, 2022
Aug. 01, 2018
Short-Term Debt [Line Items]            
Total financed       $ 181,000 $ 482,000  
Interest rate       12.75% 0.00%  
Debt issuance costs       $ 273,864    
Short-term financings       $ 56,197 $ 154,017  
Oak Street Funding LLC [Member] | Senior Secured Amortizing Credit Facility [Member] | Prime Rate [Member]            
Short-Term Debt [Line Items]            
Interest rate     2.00%      
Oak Street Funding LLC [Member] | Term Loan [Member]            
Short-Term Debt [Line Items]            
Total financed     $ 7,912,000      
Debt issuance costs     $ 181,125      
Debt description     The borrowing rates under the Facility is a variable rate equal to Prime + 2.00% and matures 10 years from the closing date.      
Debt instrument term     10 years      
Master Credit Agreement [Member] | Oak Street Funding LLC [Member]            
Short-Term Debt [Line Items]            
Total financed $ 6,250,000          
Debt issuance costs $ 214,257          
Maturity date May 25, 2032          
Variable interest of prime rate plus 2.50%          
Employee Benefits, Solutions, LLC, and US Benefits Alliance [Member] | Credit Agreement [Member] | Oak Street Funding LLC [Member]            
Short-Term Debt [Line Items]            
Total financed           $ 750,000
Interest rate           11.00%
Debt issuance costs           $ 22,188
Commercial Coverage Solutions LLC [Member] | Oak Street Funding LLC [Member] | Senior Secured Amortizing Credit Facility [Member]            
Short-Term Debt [Line Items]            
Total financed   $ 1,025,000        
Debt issuance costs   $ 25,506        
Debt description   The borrowing rate under the Facility is a variable rate equal to Prime +1.50% and matures 10 years from the closing date.        
Debt instrument term   10 years        
Commercial Coverage Solutions LLC [Member] | Oak Street Funding LLC [Member] | Senior Secured Amortizing Credit Facility [Member] | Prime Rate [Member]            
Short-Term Debt [Line Items]            
Interest rate   1.50%        
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.24.1
WARRANT LIABILITIES (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Dec. 12, 2023
Mar. 13, 2023
Dec. 27, 2022
Jan. 04, 2022
Dec. 22, 2021
Aug. 31, 2022
Jan. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Common stock, par value               $ 0.086 $ 0.086  
Preferred stock, par value               $ 0.086 $ 0.086  
Unrealized losses                   $ 17,408,311
Number of shares issued exercised                
Cash proceeds               $ 12,500  
Net fair value gains losses               $ 5,583,506 [1] 32,737,582 [2]  
Series B Warrant Liability [Member]                    
Non-operating unrealized gains       $ 17,408,311            
Derivative Liability       $ 55,061,119            
Outstanding warrants               866,667    
Net fair value gains losses               $ 5,534,931 48,668,869  
Warrant liability               $ 268,667 6,384,250  
Series B Warrant Liability [Member] | Non Private Placement [Member]                    
Exercisable price     $ 7.50         $ 0.63    
Outstanding warrants     1,333,333              
Placement Agent Warrants [Member]                    
Issued warrant               16,303    
Exercisable price               $ 61.35    
Net fair value gains losses               $ 48,575 1,477,024  
Warrant liability               $ 325 $ 48,900  
Warrants and rights outstanding term               5 years    
Derivative liability measured at fair value               $ 1,525,923    
Series B Convertible Preferred Stock [Member]                    
Shares of common Stock             9,076      
Conversion of Stock, Shares Converted           147,939 16      
Preferred stock, par value         $ 1,000          
Securities Purchase Agreement [Member]                    
Common stock, par value   $ 0.086                
Shares of common Stock   155,038                
Aggregate purchase price         $ 20,000,000          
Securities Purchase Agreement [Member] | Series B Warrant Liability [Member]                    
Issued warrant 300,000                  
Outstanding warrants 866,667                  
Securities Purchase Agreement [Member] | Series B Convertible Preferred Stock [Member]                    
Conversion of Stock, Shares Converted         9,076          
Preferred stock, par value         $ 0.086          
Common Stock [Member]                    
Shares of common Stock               155,038 178,060  
Common Stock [Member] | Series B Warrant Liability [Member] | Non Private Placement [Member]                    
Shares of common Stock     1,667              
Number of shares issued exercised     1,667              
Cash proceeds     $ 12,500              
Common Stock [Member] | Securities Purchase Agreement [Member]                    
Common stock, par value         0.086          
Exercisable price         $ 61.35          
Shares of common Stock 300,000       178,060          
Convertible into aggregate shares         147,939          
Conversion price, per share         $ 61.35          
Common Stock [Member] | Securities Purchase Agreement [Member] | Maximum [Member]                    
Issued warrant         651,997          
[1] Recognition and change in fair value of warrant liabilities per income statement is $5,503,647. The difference of $79,859 was due to a loss on a warrant exchange.
[2] Recognition and change in fair value of warrant liabilities per income statement is $29,064,958. The difference of $3,672,624 is made up of the Warrant issuance costs.
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF CONCENTRATIONS OF REVENUES (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member]
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Priority Health [Member]    
Concentration Risk [Line Items]    
Concentration of risk percentage 35.00% 32.00%
BlueCross BlueShield [Member]    
Concentration Risk [Line Items]    
Concentration of risk percentage 15.00% 14.00%
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.24.1
SIGNIFICANT CUSTOMERS (Details Narrative)
12 Months Ended
Dec. 31, 2023
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer [Member]  
Concentration Risk [Line Items]  
Total revenue 10.00%
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Equity [Abstract]    
Number of Stock Options Outstanding, Outstanding at Beginning of Period 10,928 10,928
Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period $ 232.55 $ 232.55
Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period 1 year 7 months 9 days 2 years 7 months 9 days
Aggregate Intrinsic Value, Outstanding at Beginning of Period
Number of Stock Options Outstanding, Granted
Weighted Average Exercise Price Per Share, Granted
Aggregate Intrinsic Value, Granted
Number of Stock Options Outstanding, Forfeited or expired
Weighted Average Exercise Price Per Share, Forfeited or expired
Aggregate Intrinsic Value, Forfeited or expired
Number of Stock Options Outstanding, Exercised
Weighted Average Exercise Price Per Share, Exercised
Aggregate Intrinsic Value, Exercised
Number of Stock Options Outstanding, Outstanding at End of Period 10,928 10,928
Weighted Average Exercise Price, Outstanding at End of Period $ 232.55 $ 232.55
Weighted Average Remaining Contractual Life (years), Outstanding at End of Period 7 months 9 days 1 year 7 months 9 days
Aggregate Intrinsic Value, Outstanding at End of Period
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF NON - VESTED STOCK OPTIONS (Details) - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Equity [Abstract]    
Number of Non-vested Stock Options Outstanding, Outstanding at Beginning of Period 271 3,587
Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period $ 236.83 $ 227.78
Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period 2 years 3 months 7 days 10 months 24 days
Number of Non-vested Stock Options Outstanding, Granted
Weighted Average Exercise Price Per Share, Granted
Number of Non-vested Stock Options Outstanding, Vested (248) (3,315)
Weighted Average Exercise Price Per Share, Vested $ 239.68 $ 14.89
Weighted Average Remaining Contractual Life (years), Vested 9 months 21 days 1 year 8 months 15 days
Number of Non-vested Stock Options Outstanding, Forfeited or expired
Weighted Average Exercise Price Per Share, Forfeited or expired
Number of Stock Options Outstanding, Outstanding at End of Period 23 271
Weighted Average Exercise Price, Outstanding at End of Period $ 205.70 $ 236.83
Weighted Average Remaining Contractual Life (years), Outstanding at End of Period 1 year 7 months 2 days 2 years 3 months 7 days
XML 81 R68.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL (Details) - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Expected dividend
Minimum [Member]    
Exercise price $ 0.16 $ 0.16
Expected term 3 years 3 months 3 years 3 months
Risk-free interest rate 0.38% 0.38%
Expected volatility 293.07% 293.07%
Maximum [Member]    
Exercise price $ 0.26 $ 0.26
Expected term 3 years 9 months 3 years 9 months
Risk-free interest rate 2.43% 2.43%
Expected volatility 517.13% 517.13%
XML 82 R69.htm IDEA: XBRL DOCUMENT v3.24.1
EQUITY (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 12, 2023
Dec. 12, 2023
Mar. 16, 2023
Mar. 13, 2023
Feb. 23, 2023
Dec. 22, 2021
Nov. 30, 2023
Mar. 31, 2023
Feb. 28, 2023
Jan. 31, 2023
Dec. 31, 2022
Oct. 31, 2022
Aug. 31, 2022
Jul. 31, 2022
Mar. 31, 2022
Jan. 31, 2022
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 28, 2022
Jun. 30, 2022
May 31, 2022
Mar. 13, 2022
Dec. 31, 2021
Dec. 31, 2019
Class of Stock [Line Items]                                                            
Preferred stock, shares authorized 750,000,000                     750,000,000               750,000,000     750,000,000 750,000,000            
Preferred stock, par value $ 0.086                     $ 0.086               $ 0.086     $ 0.086 $ 0.086            
Common stock, shares authorized 2,000,000,000                     2,000,000,000               2,000,000,000     2,000,000,000 2,000,000,000            
Common stock, par value $ 0.086                     $ 0.086               $ 0.086     $ 0.086 $ 0.086            
Vested restricted stock awards                                             248 3,315            
Cash proceeds                                             $ 1,028,270 $ 2,475,000            
Common shares issued for earnout liabilities                                             $ 3,001,045              
Round up of shares due to reverse split, value                                                          
Common stock, shares outstanding 4,761,974                     1,219,573               4,761,974     4,761,974 1,219,573            
Exercise price                                                        
Warrants description         The aggregate purchase price for the Common Shares, Prefunded Warrants (Series E Warrants) and the Common Warrants (Series F Warrants) to be purchased by the Buyer shall be equal to (i) $3.80 for each Common Unit purchased by such Buyer, or (ii) $3.799 for each Prefunded Unit purchased by the Buyer, which Prefunded Warrants are exercisable into Prefunded Warrant Shares at the initial Exercise Price (as defined in the Prefunded Warrant) of $0.001 per Prefunded Warrant Share in accordance with the Prefunded Warrant.                                                  
Net Proceeds                                             $ 3,446,484 $ 17,853,351            
Additional paid in capital $ 45,739,786                     $ 35,798,139               $ 45,739,786     45,739,786 35,798,139            
Stock Issued During Period, Value, New Issues                                             $ 3,446,484 $ 20,000,051            
Dividend rate     0.00%                                                      
Volatility rate     112.00%                                                      
Risk free interest rate     4.23%                                                      
Options outstanding 10,928                     10,928               10,928     10,928 10,928         10,928  
Weighted average exercise price $ 232.55                     $ 232.55               $ 232.55     $ 232.55 $ 232.55         $ 232.55  
Weighted average remaining contractual life                                             1 year 7 months 9 days 2 years 7 months 9 days            
Number of shares option forfeitures                                             $ 0 $ 0            
Fair value $ 2,421,960                     $ 2,421,960               $ 2,421,960     2,421,960 2,421,960            
Share-Based Payment Arrangement, Noncash Expense                                             875,106 1,249,873            
Unrecognized compensation expense $ 1,542                     $ 17,166               $ 1,542     $ 1,542 $ 17,166            
Market value price per share $ 0.54                     $ 8.55               $ 0.54     $ 0.54 $ 8.55            
Shares issued commission equity award expense                                             22,221 0            
Value issued commission equity award expense                                             $ 276,400 $ 249,650            
Equity-based compensation expense                                             $ 875,000 1,250,000            
2019 Equity Incentive Plan [Member]                                                            
Class of Stock [Line Items]                                                            
Common Stock, Capital Shares Reserved for Future Issuance                                                           46,667
Options outstanding 10,928                                     10,928     10,928              
Weighted average exercise price $ 232.55                                     $ 232.55     $ 232.55              
Weighted average remaining contractual life                                             6 months 25 days              
2023 Equity Incentive Plan [Member]                                                            
Class of Stock [Line Items]                                                            
Common Stock, Capital Shares Reserved for Future Issuance 800,000                                     800,000     800,000              
Available for issuance 47,080                                     47,080     47,080              
Board of Directors [Member]                                                            
Class of Stock [Line Items]                                                            
Stockholders' equity, reverse stock split           1-for-15 reverse split                                                
Round up of shares due to reverse split           15,300                                                
Round up of shares due to reverse split, value           1,300                                                
Employees, Directors, and Consultants [Member]                                                            
Class of Stock [Line Items]                                                            
Share-Based Payment Arrangement, Noncash Expense                                             $ 15,624 $ 178,579            
Executives And Employees [Member]                                                            
Class of Stock [Line Items]                                                            
Shares restricted                                             758,026              
Shares restricted, value                                             $ 477,556              
Director [Member]                                                            
Class of Stock [Line Items]                                                            
Shares restricted                                               12,460            
Shares restricted, value                                               $ 766,250            
Employee Agreement [Member]                                                            
Class of Stock [Line Items]                                                            
Shares issued in private placement, shares                       14,275       400                            
Vested restricted stock awards                       14,275       400                            
Securities Purchase Agreement [Member]                                                            
Class of Stock [Line Items]                                                            
Shares issued in private placement, shares         155,038                                                  
Common stock, par value         $ 0.086                                                  
Warrant Agreement [Member]                                                            
Class of Stock [Line Items]                                                            
Additional paid in capital $ 0                                     $ 0     $ 0              
Series F Inducement Agreement [Member]                                                            
Class of Stock [Line Items]                                                            
Warrants exercise prices   $ 0.6562 $ 0.6562                                                      
[custom:PercentageOfBeneficialOwnership-0]   4.99% 4.99%                                                      
Shares issued price per share   $ 0.6562 $ 0.6562                                                      
Dividend rate     0.00%                                                      
Volatility rate     112.00%                                                      
Risk free interest rate     4.23%                                                      
Agreement In April 2022 [Member] | Executive [Member]                                                            
Class of Stock [Line Items]                                                            
Share based compensation, shares                                             3,908 667            
Shares restricted                         7,418                                  
Shares restricted, value                         $ 180,546                                  
Share based compensation                                             $ 83,464 $ 32,131            
Agreement In December 28, 2022 [Member] | Executive [Member]                                                            
Class of Stock [Line Items]                                                            
Share based compensation, shares                                             2,695 0            
Share based compensation                                             $ 22,404 $ 241            
Shares vested                                                 2,667          
Series A Warrant [Member]                                                            
Class of Stock [Line Items]                                                            
Shares issued in private placement, shares                                 25,000                          
Exercise of warrants, shares                                 25,000                          
Warrants exercise prices                                 $ 99.00                          
Common Stock [Member]                                                            
Class of Stock [Line Items]                                                            
Shares issued in private placement, shares                                             155,038 178,060            
Stock issued during period, shares, acquisitions                                               40,402            
Exercise of warrants, shares                                               25,000            
Vested restricted stock awards                                         3,017 22,219                
Common shares issued for earnout liabilities                     $ 109,358                       $ 54,714              
Round up of shares due to reverse split                                             15,336              
Round up of shares due to reverse split, value                                             1,300              
Shares issued service                                       147,645 400 112,557 260,602              
Settle an earn-out liability                                         174,610 352,260 636,228              
Share based compensation, shares                                       741,360                    
Number of shares converted                                               218,462            
Stock Issued During Period, Value, New Issues                                             $ 13,333 $ 15,313            
Shares issued price per share   $ 0.6562 $ 0.6562                                                      
Number of shares converted                                             897,594              
Net of cash proceeds                                             $ 898              
Common Stock [Member] | Subsequent Event [Member]                                                            
Class of Stock [Line Items]                                                            
Shares issued in private placement, shares                                     723,264                      
Common Stock [Member] | Securities Purchase Agreement [Member]                                                            
Class of Stock [Line Items]                                                            
Shares issued in private placement, shares     300,000       178,060                                              
Common stock, par value             $ 0.086                                              
Warrants exercise prices             61.35                                              
Warrants exercise price             $ 61.35                                              
Warrant conversion shares             147,939                                              
Series B Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Shares issued in private placement, shares                       1,667                                    
Exercise of warrants, shares                       1,667                 73,264                  
Warrants exercise prices                       $ 7.50                       $ 7.50            
Stock issued during period, shares, acquisitions 300,000                                     300,000     300,000              
Cash proceeds                       $ 12,500                                    
Series E Warrant [Member]                                                            
Class of Stock [Line Items]                                                            
Shares issued in private placement, shares                                       897,594                    
Series F Warrant [Member]                                                            
Class of Stock [Line Items]                                                            
Shares issued in private placement, shares                                       371,000                    
Series A Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Exercise of warrants, shares                                 375,000           113,000 113,000            
Warrants exercise prices               $ 6.60                                            
Number of shares converted                                 25,000                          
Exercise price               99.00                                            
Exercise price reduced               $ 6.13                                            
Class of Warrant or Right, Outstanding 1,695,000                     1,695,000               1,695,000     1,695,000 1,695,000            
Series F Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Exercise of warrants, shares   2,105,264                                                        
Warrants exercise prices   $ 0.6562 $ 0.6562                                                      
Cash proceeds   $ 1,029,972                                                        
Number of shares converted   1,734,264                                                        
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right 2,105,264 2,105,264 2,105,264                                 2,105,264     2,105,264              
Payments for Repurchase of Warrants   $ 1,381,474                                                        
Stock Issued During Period, Value, New Issues   $ 351,503                                                        
[custom:IssuanceOfWarrants]   371,000                                                        
[custom:PercentageOfBeneficialOwnership-0]   9.99% 9.99%                                                      
Deemed dividend $ 302,997 $ 302,997                                                        
Warrants and rights outstanding before exchange 1,103,377                                     $ 1,103,377     $ 1,103,377              
Warrants and rights outstanding after exchange $ 800,380                                     $ 800,380     $ 800,380              
Pre Exchange Warrant [Member]                                                            
Class of Stock [Line Items]                                                            
Warrants exercise prices   $ 3.55 $ 3.55                                                      
Post Exchange Warrant [Member]                                                            
Class of Stock [Line Items]                                                            
Warrants exercise prices   0.6562 0.6562                                                      
Pre And Post Exchange Warrant [Member]                                                            
Class of Stock [Line Items]                                                            
Warrants term 4 years 9 months 7 days                                     4 years 9 months 7 days     4 years 9 months 7 days              
Series G Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Class of Warrant or Right, Outstanding 4,210,528                                     4,210,528     4,210,528              
Series G Warrants [Member] | Series F Inducement Agreement [Member]                                                            
Class of Stock [Line Items]                                                            
Warrants exercise prices   $ 0.6562 $ 0.6562                                                      
Class of Warrant or Right, Outstanding   4,210,528 4,210,528                                                      
Deemed dividend     $ 2,236,760                                                      
Series E Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Exercise of warrants, shares                                             897,594              
Abeyance Shares [Member]                                                            
Class of Stock [Line Items]                                                            
Class of warrant unissued 1,734,264                                     1,734,264     1,734,264              
Abeyance Shares [Member] | Subsequent Event [Member]                                                            
Class of Stock [Line Items]                                                            
Conversion of stock shares converted                                   1,011,000 723,264                      
Common stock, shares outstanding                                     1,011,000                      
Medigap Acquisition [Member]                                                            
Class of Stock [Line Items]                                                            
Stock issued during period, shares, acquisitions                                 40,402                          
YES Americana Group LLC [Member]                                                            
Class of Stock [Line Items]                                                            
Debt conversion original debt amount                   $ 645,000                                        
Debt Conversion converted instrument shares                   66,743                                        
Warrants exercise price                   $ 9.67                                        
Private Placement [Member]                                                            
Class of Stock [Line Items]                                                            
Shares issued in private placement, shares                 155,038               178,060                          
Gross proceeds cash fee percentage       8.00%                                                    
Gross proceeds                                             $ 4,000,000              
Net Proceeds                                             3,400,000              
Financing fee                                             $ 553,000              
Series B Convertible Preferred Stock [Member]                                                            
Class of Stock [Line Items]                                                            
Preferred stock, par value             $ 1,000                                              
Shares issued in private placement, shares                                 9,076                          
Conversion of stock shares converted                           147,939     16                          
Conversion of shares                           9,076                                
Series B Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member]                                                            
Class of Stock [Line Items]                                                            
Preferred stock, par value             $ 0.086                                              
Conversion of stock shares converted             9,076                                              
Series C Prepaid Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Stock issued during period, shares, acquisitions                                 218,462                 218,462 218,462      
Warrants exercise price                                                   $ 0.015 $ 0.015      
Proceeds from issuance                                               $ 1,336            
Series C Prepaid Warrants [Member] | Common Stock [Member]                                                            
Class of Stock [Line Items]                                                            
Stock issued during period, shares, acquisitions                                 218,462                 218,462 218,462      
Series D Prepaid Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Conversion of stock shares converted                             81,472                              
Stock issued during period, shares, acquisitions                             81,423   81,500                          
Warrants exercise price                             $ 0.015                              
Proceeds from issuance                             $ 795                              
Warrant conversion shares                             81,423                              
Series D Prepaid Warrants [Member] | Common Stock [Member]                                                            
Class of Stock [Line Items]                                                            
Stock issued during period, shares, acquisitions                             81,423                              
Series A Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Warrants exercise prices $ 0.15                                     $ 0.15     $ 0.15              
Stock issued during period, shares, acquisitions 2,070,000                                     2,070,000     2,070,000              
Series C and D Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Warrants exercise prices $ 0.015                                     $ 0.015     $ 0.015              
Series E Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Stock issued during period, shares, acquisitions         897,594                                                  
Series F Warrants [Member]                                                            
Class of Stock [Line Items]                                                            
Warrants exercise prices         $ 3.55                                                  
Stock issued during period, shares, acquisitions                                                       2,105,264    
PA Warrant [Member]                                                            
Class of Stock [Line Items]                                                            
Warrants exercise prices         $ 3.91                                                  
Stock issued during period, shares, acquisitions                                                       52,632    
XML 83 R70.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]    
(Loss) income from continuing operations $ (10,025,268) $ 21,561,932
Deemed dividend (2,539,757) (6,930,335)
(Loss) income from continuing operations, numerator, basic (12,565,025) 14,631,597
(Loss) income from continuing operations, numerator, diluted $ (12,565,025) $ 14,631,597
Weighted average common shares, basic 2,820,275 1,094,781
Effect of weighted average vested stock awards 208
Diluted weighted average shares outstanding 2,820,275 1,094,989
Basic (loss) income loss per common share from continuing operations: $ (4.46) $ 13.36
Diluted (loss) income per common share from continuing operations: $ (4.46) $ 13.36
XML 84 R71.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES (Details) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares subject to unvested stock awards 10,928 10,928
Series A Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares subject to unvested stock awards 113,000 113,000
Series B Warrants And Placement Agent Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares subject to unvested stock awards 882,970 1,347,970
Series G Warrants And Placement Agent Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares subject to unvested stock awards 4,263,160
Unvested Stock Awards [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares subject to unvested stock awards 3,709 6,576
XML 85 R72.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT (Details)
Dec. 31, 2023
USD ($)
Leases  
2024 $ 320,420
2025 153,831
2026 113,738
2027 117,150
2028 120,665
Thereafter 30,387
Total undiscounted operating lease payments 856,191
Less: Imputed interest (86,685)
Present value of operating lease liabilities $ 769,506
XML 86 R73.htm IDEA: XBRL DOCUMENT v3.24.1
LEASES (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Leases    
Lease expense $ 534,404 $ 598,422
Weighted average remaining lease term 3 years 11 months 1 day 3 years 9 months 25 days
Weighted average discount rate 6.08% 5.67%
XML 87 R74.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF EARN-OUT LIABILITY (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]    
Beginning balance – January 1 $ 2,709,478 $ 3,813,878
Payments (3,260,403) (1,704,924)
Estimate & fair value adjustments 1,716,873 524
Payable in Common Stock (159,867)  
Reclass to loans payable, related parties [1] (846,214)  
Ending balance 159,867 2,709,478
Business combinations   600,000
Fortman Insurance Agency LLC [Member]    
Restructuring Cost and Reserve [Line Items]    
Beginning balance – January 1 667,000 515,308
Payments (1,433,700) (34,430)
Estimate & fair value adjustments 1,612,914 186,122
Payable in Common Stock  
Reclass to loans payable, related parties [1] (846,214)  
Ending balance 667,000
Business combinations  
Southwestern Montana Insurance Center Inc [Member]    
Restructuring Cost and Reserve [Line Items]    
Beginning balance – January 1 500,001 615,969
Payments (750,001) (326,935)
Estimate & fair value adjustments 569,734 210,967
Payable in Common Stock (159,867)  
Reclass to loans payable, related parties [1]  
Ending balance 159,867 500,001
Business combinations  
Altruis Benefits Consultants Inc [Member]    
Restructuring Cost and Reserve [Line Items]    
Beginning balance – January 1 834,943 992,868
Payments (929,168) (84,473)
Estimate & fair value adjustments 94,225 (73,452)
Payable in Common Stock  
Reclass to loans payable, related parties [1]  
Ending balance 834,943
Business combinations  
JP Kush And Associates Inc [Member]    
Restructuring Cost and Reserve [Line Items]    
Beginning balance – January 1 147,534 1,689,733
Payments (147,534) (1,259,086)
Estimate & fair value adjustments (283,113)
Payable in Common Stock  
Reclass to loans payable, related parties [1]  
Ending balance 147,534
Business combinations  
Barra & Associates, LLC [Member]    
Restructuring Cost and Reserve [Line Items]    
Beginning balance – January 1 560,000
Payments  
Estimate & fair value adjustments (560,000) (40,000)
Payable in Common Stock  
Reclass to loans payable, related parties [1]  
Ending balance 560,000
Business combinations   $ 600,000
[1] As further described in the Note 16, Related Parties, the Company modified the Fortman contingent earn-out payable, entering into a fixed payment agreement, thus, the remaining open balance is reclassified to the loans payable, related parties account on the consolidated balance sheet as of December 31, 2023.
XML 88 R75.htm IDEA: XBRL DOCUMENT v3.24.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Legal contingencies $ 0 $ 0
XML 89 R76.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF ACTUAL INCOME TAX RATE (Details)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Federal rate 21.00% 21.00%
State net of federal 8.90% (7.90%)
Non-taxable change in fair value of warrant commitment 9.30% (106.30%)
Goodwill impairment 11.80% 46.70%
Rate Change (0.20%) (4.10%)
Other 0.00% 2.20%
Valuation allowance (50.90%) 48.50%
Effective income tax rate 0.00% 0.00%
XML 90 R77.htm IDEA: XBRL DOCUMENT v3.24.1
SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Net operating loss carryforward $ 10,399,616 $ 4,938,164
Equity-based compensation 1,462,901 1,148,836
Goodwill (332,159) (771,631)
Intangibles 694,358 745,227
Fixed assets (151,775) (99,002)
Right of use assets (186,905) (300,616)
Lease liabilities 194,403 313,342
Other 4,027 1,525
Total deferred tax assets 12,084,466 5,975,846
Valuation allowance (12,084,466) (5,975,846)
Net deferred tax assets
XML 91 R78.htm IDEA: XBRL DOCUMENT v3.24.1
INCOME TAXES (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Federal net operating loss carryforwards excluding indefinite life $ 41,300,000  
Operating loss carryforward limitation Federal Net Operating Loss Carry forwards, of which $1.3 million will begin to expire beginning 2031  
Income tax description $40.0 million will not expire but are limited to use of 80% of current year taxable income  
State net operating loss carry forwards $ 34,800,000  
Change in valuation of allowance $ 6,108,620 $ 3,140,780
CARES Act [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Income tax description Internal Revenue Code Section 382 limits the ability to utilize net operating losses if a 50% change in ownership occurs over a three-year period. Such limitation of the net operating losses may have occurred, but we have not analyzed it at this time as the deferred tax asset is fully reserved.  
XML 92 R79.htm IDEA: XBRL DOCUMENT v3.24.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Jan. 11, 2024
Feb. 13, 2023
Feb. 07, 2023
Jan. 31, 2023
Jul. 31, 2019
Dec. 31, 2023
Dec. 31, 2022
Sep. 13, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]                  
Accrue interest percentage           12.75% 0.00%    
Promissory note principle           $ 181,000 $ 482,000    
Common stock par value           $ 0.086 $ 0.086    
Agreed to payment           $ 1,045,164 $ 184,252    
Other expenses           1,650,000      
Deferred purchase price       $ 1,375,000          
Accrue interest rate percentage       1.50%          
Earn out balance           159,867 2,709,478   $ 3,813,878
Employee [Member] | Purchase Agreement [Member] | Subsequent Event [Member]                  
Related Party Transaction [Line Items]                  
Accrue interest percentage 10.00%                
Agreed to payment $ 11,000.00                
Earn out balance 423,107                
Earn out owned amount 846,214                
Related Party [Member]                  
Related Party Transaction [Line Items]                  
Interest expense, related parties           150,067 6,920    
Other expenses           145,344      
Loans payables, current           233,504 1,375,000    
Loans payables, related parties           247,055 0    
Related Party [Member] | Purchase Agreement [Member] | Subsequent Event [Member]                  
Related Party Transaction [Line Items]                  
Loans payables, related parties 650,473                
Loans payables, current 195,741                
Accrued interest $ 0                
YES Americana Group LLC [Member]                  
Related Party Transaction [Line Items]                  
Promissory note principle     $ 1,845,000         $ 1,500,000  
Accruing monthly interest percentage               5.00%  
Debt instrument description   On February 13, 2023, Americana effectuated a conversion of $645,000 of the Note into 66,743 shares of the Company’s common stock, $0.086 par value per share, in accordance with the terms of the Amendment. In addition, throughout the year of 2023 the Company repaid principal to Americana of $693,145. As of December 31, 2023, and December 31, 2022 respectively, the balance owed to Americana was $0 and $1,500,000, reclassified and recorded in the convertible debt, related parties, less current portion account in the condensed consolidated balance sheets. Interest expense for the year ended December 31, 2023, was $5,334, recorded to interest expense, related parties in the condensed consolidated statements of operations. On February 7, 2023 , the Company and Americana entered into an amendment to the Note pursuant to which (i) the principal amount of the Note was increased to $1,845,000, (ii) the maturity date of the Note was amended to January 15, 2026, (iii) the interest rate under the Note shall not increase after the maturity date, and (iv) the Note can be converted at any time, at the option of Americana, into shares of the Company’s common stock, par value $0.086 per share at an agreed upon conversion price.            
Common stock par value   $ 0.086 $ 0.086            
Conversion of stock   $ 645,000              
Conversion of stock shares   66,743              
Agreed to payment           693,145      
Repayment of related party owed           0 1,500,000    
Other expenses           5,334      
YES Americana Group LLC [Member] | Employee [Member]                  
Related Party Transaction [Line Items]                  
Due to related party         $ 200,000        
Debt instrument unmortized discount         $ 27,673        
Accrue interest percentage         7.50%        
Monthly payment         $ 4,167        
Current portion of loans payables, related parties           29,167 47,249    
Non-current portion of loans payables, related parties           0 21,541    
Interest expense, related parties           6,918      
Reliance Holdings [Member]                  
Related Party Transaction [Line Items]                  
Loans payables, related parties           $ 0 $ 100,724    
Ownership percentage           0.00% 24.00%    
Common Stock [Member] | YES Americana Group LLC [Member]                  
Related Party Transaction [Line Items]                  
Ownership percentage           5.52% 0.00%    
XML 93 R80.htm IDEA: XBRL DOCUMENT v3.24.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
12 Months Ended
Dec. 15, 2024
Feb. 15, 2024
Dec. 31, 2023
Dec. 31, 2022
Subsequent Event [Line Items]        
Aggregate offering price     $ 3,446,484 $ 20,000,051
ATM Agreement [Member] | Subsequent Event [Member]        
Subsequent Event [Line Items]        
Aggregate offering price   $ 858,637    
Sold shares 187,614      
Receiving proceeds, net $ 4,634      
Agent commissions $ 124,649      
EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
H( MTL6L;/+&Y?EOYY> B>_QB-MA>VH2--H9"+(,1#W5"^A19]2#'S_OZ"E<09G2 MIEVD3Y5.!LF^GU4F2Z80/;&";NGH*"MROX2J&RO=_]I]6XPXP5&/=D2 MC;L<";S-%XX_E8];(/TUTI_CO%97UWKRZO9 M#'0HJM./GR_^%SCD'I]-%(9?#N4QNP/QS_J_TGR7@J41<_"L.P$M0P(M&E/. M:ZRFGN78OIN9NEZ+'W[2BY)A%U16CU54W.V3HGNIOK 5R8X9W?Q:!4XV15,D M;.%"0O\)JG(4#V':GAZ :+,2QUK-G//8;("[JU6*Z823> #":3A"^>UO#Q4? M;*]U 5^]Y6TW'CDC.,:X/XR2N,]C- 0_4D,F"-"C+DT%W'TFAC?&%9B6"(4:!M%*"]1"G@BRD7-Z(O MEL;X&%5+ M2AV ^V.7<^"#LA8H+\GZ]X.2ATV*AEP'3$32-!0^V"#J_LTD=CZ C8]])Y;* M7FVP\VSX(W E[+T4PJ6 .\@+%7I-A ETUZ:$TV=\SP@$I ?X*/I('@"GC6#K M#?LP#OQ-)OH=K@9S-8"^._&_FM1Q_B4%(9 0\@CN%_^(QTK(/W:=RR".U$%) M)NL^O#=R#NBA82N);%-,F2/R_ !Y8-,W"&!1:G&/?$@@,;DW5@-OC%$=3YJ!PX# (I0-*<\T>5"V1M=R7L MQ,J& _TH;E,&0%D^H9!P$UX3@&0-/* M(TZUZP^GQ]S^(68<4&@NM'%-)]0 IY;O;:;7$5'R'14GKHW-B+;S(65Z2V-' M633#V1>\B+9'%64#%^*- 3]4HJ"DI#HWC=$3!LQOH3I@5!#7UW1V6U1'B;2*J1( MF_5 .WFQ0P43%(O&<%DH M4\,\5T/QV*UDA1@F_/)6<;D,Y4O#?*$L_7XJLBG4$/&9$ P$X&L+\.\AR,MO M>+%=4S^665T#*A>86@#C+HQ=V\!N0WTOFB$!+FKH^$R?"C-](??Z/'@&)DNC MM#*,:I.N$?DS%^U0V;2-U.6%Z8H@_IP'17"BG57;)"X%07XY3,/E>ZPI?6E( MN@/S"]##N>4@UZ>GLS/='WH!-99@\T%T/RJUF0[ @?AAO]PVC"(J=4;46SX.VC,=P][0XE;>E1X^N; M;,7 ,4PY6J7,=H9*=:@X8%=6NY0K$!PZ-IC)(5]2%V%"MO4Y&#-"5@Z0 M'T!VA%%H,JQS\S$M6<.ZSZ?)#.JXS,B$BBWX2-)^TDMW$5G M[#53@"-"]8)5)+28H/;R*(#H?+$ ]>6(DHZ2F,R9#4!DC6YAF:4+(53$#A MDD L-&YSB5E7NR)%@@W/QE,*F 3WO!"-GJ0"-.>L9)(6""U!JNMPEE-3M,&# M>XOV:D"QQ4>[J-72:3@4*>@&,'O9P\_O(_I*@I%BYP U1M(CS971PMV=4# Z MWFE'J=0M?"R#R M)&K-TI$0611;NZMOBBU(SEXR!)6P( T9Q"A!-4DDA6J3)NA\5@R)8ZF0HN)JB >9*N8'@:2@) M< AK4E;_72.BT1QQ][<5U$;"B7..F]H=$-%@05G+]:4@YS3K])83G[ MN6B]X&R^4!5-P0SG.4$&%Y5M9Q>=C=+ 7N';K3)7P7;V8V[7%$LM"Y#D5%I; MXAD&?5<67X%QD+GX&GVD&@>J1"0&MUN\'YD"W -@7+,]UD;*&BWX!*C9F9\ EN%6<#*V.H[#H !2\"DIO3 M+PO8?B8D"IIW3 JIMI3HF\<58:)V1>\"]Z\F7=U2GP($W.+I MP"SIO1/J87.R0P*IZ4";)RY#HJC7^U/@Z2C$^ H=<*3(KXFF\8#2.^*&:SN\95JU29VC0%6.'MY$ M2<,\0F!'.9B5HXK%KI(@KBP$*W!2$6_.:B1-/G^:4Y0B*-BU):*"Z."\ M8F@'TA"!%P#(V9?^'?##0IV252)7,';/Y\-L:L!KB8!6NZJIDKR5*\,4.1Z; MIG1'RK-[R/C,%(R[K:N&W)9;U(+J;5I4E"RRH\_1U6L.:\4S#1]R6E:Y)6=3V<=T^']QXR8.L02YS=BP)H78HJ%6!8: M)7)(*Z;#ZE>K%*3(2C;RGAQL"(O; M+166.5W2%-XY8A_706'NO*!R9$K=\$KX *;7^[@*Y5:!K(Q8=LF-JJ:,0\[G ML3KZ(N?CBAA"H0P I7_X:''#FJ2"^&(.?HKLXO"TB56K8P+##1I&"@\SU_&X-O M(-0R3!GF'!BTVLZK5B2V$TSMHE\J#NJR<$%8$?!NOU;V6)F7#C?VG XAO^*I M96.$_IQ739ZE)9]X1.[731:ZI>SSQ=@Q9>V$N? +1!'L,U( M_/_&1K0AL.>-Q,):5Y$3Q1@F*2H;<<#EJ18#RNTD:I,!$UIOT!X$"/VX%F-D M+S]Q^/3_,]5\Z.P?U\R+'Y'LZF](=LMY3IC?%:)( R^5X[@'$AY(N3!;P^PF M"=K6",'?$?Y_0^COFVA'A#[YB'OD?D9D$H)"9%#Z])A+;P56FR&<6_<419=C M9(HPT*GNMG"!Z"#5X#VGBQH!#AF?A2YS>:17Q:/!^I+'@[B*C*R?&=G9/SRT MXJ&#[)7H@-#"N3.V&!H7=$7FB\6 7?-K_3L0(LB['G,< L$M00\.$V/,U>P/!@F*DBF>@C7"Z9;ZE@CMQ?04)TZQGI V%"S/VF+$;,!1K7>ZX(1(H!8( M:XT2IR#XAEG3K#[%LF9.T=@0G01E*?;LI ;FF'.6!=(TGQKE- M"N PJU98\$S,)<1LNM-5,ZCL8G1G'MP@\.6[U[1?5U3;QZ+4[2J_"5;<@Z@- M1.]JV'BPBVN!C;!L%A$W5!V/NI#R1QRYZ:RTB!V*^\*E]D4TE$!6,\=)NY@G M;M)$TY'P"H]">+T-- 15I<0SYM,C:^/.U%:!!T5K<6J95YN).6V70',Q)%Q) M._^*GM$J]7JK?2W[L3_N#[7(*M=6J6JU*>U*[K#53$ZJT#HY$1X6?=SW8!B, MYL&/]Q>SZ<>/U^*IRW(MZ"=7H)U$<]Z6:?H*=1?JQNIV]F^H^-OCJP13C/ESL#Z/>:*3. MSF:O;B]F=*(O&4^B_GAH_RI[!B>.QL->U!\,L(U7?XS'_^"GT2":]'OJ UB! MH(ZP9]@PIG-G,.5X!-^[_7XTF"0ZB9(8KHP':KH&8Q)H!W<,^M%PT*=IW3?U M/W;4]23!KB=RT7U3V,3--Y7"7X_MJ#+["H9$AD44VRN#-:[6111\DR&L/"1UTZ MTA*-^STARV@" ,8])LL , 58B_O#!)$!&!Z.FV0![/22@;)_0[)TH_YHH$?1 M]8D$^ EHA70$IAJ/$[T1Y83A.KI DS;#*L\ MJ08LO)0V+[D:[3"1["HW@'@@S'*SEKK893/(XKNG-0==RID-T5FNTD<,+H7' M/D!]<5^/DDI_,+=FP&PJG@P99'@DKMDIC$N11!HR/-@118*PLFR0IF +HLAI MRYMS7HKP7LJOJ&*JT81YN'A@_01^V9196[#2$M= M<0RB!,TPU5:K[(XU4'%9E=7>F&<#)FH"P'62X=Q"IT/(*BQ_DT7;^ T&@W+P MIX0_@T(P;+'QI!]LP>N"RJB ($N3L0)-JQ;D-%!W$%[@CHY4S+7+Z2 8%0ZA MB> ]18PET-E$:OWATQ-B-]")32HS;Q#.Q0I;#KKLCPP(*J2$MD8' ESJ*B/3 MI&%?H4/C#NDU%N-KG 0A>.BAHZE;SV&!N-A=:[[ZETIKN+(+);@U37DNFSEN M5*3V$_E9^>H6+CZ-AZ=QXLU7*FMTK=[\VHJ-*ZJ@6+ M'6P1(2=P*I(DMI^<1?/>.0=D5H6296U[(\E.# X0Z&,'")INCH0K><%[08X# M<[^X0P^%GR"$((*P5-3V2P+'U@2E.0P;'OHGQT 83_0)578H+L+DHD9TT[CW MJ2UWE!%\M5&''$K=="@;ITL:*\@J&QRGNGHN5)(Q10C0-X6\ (*#9B!F;,:$ M@Z)T?^PNVVPIH.6N/H'#,N.OFI2S]8U2Z=F5ZZ4HR=FL!8EV%KV3(W:/U.+?65XM$;7G?W?6L_C M?K<[')85AD!8 71]=>LJZ+B1T=YAO@,G:V]3$'=S'1$_WR X*P:WC$8-@YNH M;1X5WFG[P:[WV99M#U?U0M[T!'6H@;=SD3#2!0[> 3FBI.]WJ8X#J8QI#-5:6R&FDJE5=LIZ;W> MF_OG%(^>L&I;11L/-3IP!H>P&[&*H+Y8UNBXA0:^.TAVXFHIFK'PF7\KY6MY MZ4%AFV;!3:YY4I,8?(1)ZJFE;:N[=2_CY4(A-@B%T0&.[X7=5C"=W)'.$NHF M_7;O8:.7H7- MK/#E#N1:X#!"Q6582-\&@3\MWP"3,,(EL4B[!_EPH9A;!E2 MFMB)KS(\2G*('9NMMM*?NN10MEF.-5%UR5XW;T.1RS9YH'^('\!< _@=-%9N3L,HU'>*P.,4S<0>HP*7:EG M!OF^YC[S?:VY%31S"^WEH)M"HXJ53LQ(=$T:H?G^,=SPX( 0(6+PM2F+'58* M*!Z"4?/,T_L,&S7[L383NFULFANS0#Z:N:EU.+6B0Q\'O!C.^N1[,KL#0O8@ M4-CXPT8F#]O3'S!\* -*O&NA=EL^AM=*>&1:8GU_PHQV"Z_"&5Q5NG$Y%P2L MP?=6^%OG$>_%3JPH>TKI0J?:QP4*DM>E1D"XUT=/M@0'6#PV.%S/BUM MRIR\O04VIX+!%J0%[5&LH''RP?%<>YY TFT<:+!Q(RRN-(O@&/->7Z-^U),F M2KRXCTUH'XWO9Q^/CO7LU_/SV]FU'K: M]:.?8;=./\H/M>F_U><:C1)%&V]=34_GQ,9?!*QH-H,AF#S?T#]($'_MKH M7UJ[P3.G4K/$?A3'0W5]Z+EC/F78B^)D$O3GX%<30$<3SL#?\TJ_RE6=KDE"X+//8" M I.R"'N*31T14C9@@8==&_TO2.R=A@8/FV.N3Q,Z*75H$45R&B^(V&"_"G8J M_0L$;'V_\KTMQ#O [A4&&'Q9O59645R+N!!..K,P&]LH9=O M#/US4HS*"WHCMVSYQ@^VR;4XGN#+PA Z^Q'A.Q!R?4R38T99GV KW+%T(XQA MY3',D23TF!. 3OSAP/Z+QX\3JW[),'L/!$,?V^XV)D'R1ZR"]/OS?G>RSP8_)0#0/X\'(HI:_\$CTK@=)B/G.@/XPL5B3)_(7 M._F>MLE1S,6/$F(H^_&E3@)^.2Y6XQZ0*!X1(>7C2]US^ X7,HG&?2QE..$/ M?-M92X_V$+%8!#&)1OV8V,JN SY/QMTHZ<<-POS-03XW6\(=&VT,[ K&QM@R M3#*.1I;68,ECC]*A99@8XWO2*O_/>1[Z1ST/]I4I]^!5"[L:>[7F."+=QY$Q M+!&3?D.VH$$1AN:>+/1=@;!:O,_]COPBBT?EFZ%!OV:XAV*NK 8##1@HP]YP4!5 M<45Z\$JH8_9\]JP]?[21*-=TG1^IZ6JYZ+L_2WPX*,J6. Z8X?U^U.U1>W"P M,_%]BXFRN<_P 6L\QS$:%Q,]Q'91E(Q[.@&YW.N.1)2XNI431@#V>H\FW82:RB98*Z9?BAPX1CTWQ)U98J0Y MV[,&O(&"96M@EF.KT0$UWNU-)M\97,CR2I\@1[W\@3E 7O1 (U[(CQ&J#8G M($#51TH,X^TG'-YYR8:"+7;-DSPU7>F&&PU* MC-^LY1O!,9RMUHH803]@ -&;&-BV.6[0/&N)B.7QG-71:S,TK#G1:DS$^#+4 M'OS?#RV !OJMDA^'-U^V"$B4.]6?M0%0Z?<=3EPS8]&HSZKT/Z/#]]3H =B: M]&4/T?O^"'NYMJI[<>^CK'I_R.JB1$?=$)>HG%ON_5/;@F[^C:3<> M=ZF/MP,(=NDE:HYGQQ09@/KF!%]ZVQ=+X03^8WQ+0-VV+G&=;KFIQD$+'.IN4JQ=<<*R MP!8C^E^[E%Y,%ASP4BPOD%2&GX-0LUG[KF&L_E$LO"<.UGM!JI>+2D2&&"A7O[+0[(.0N^ M&^\\7^RD8.RZ^3I.& J#[.T-:X(6JK9(P.8 7(.R'T05=IK#8QON[4CMZ*G" M^K\GY)HUGFZ@\AG[:H861J$S?9Q^))4E\6AYG#("#QR)L&UH08+0SUS>6)YB MV5E5E&U\305FE+?">'K.FT\GGO!^253@U22YJ=Z2F6A09'@K07 Y[!P3Z&E*(=,*IHD MZ.6@I+=A(QU$K1QD$JX]I?S_@I*WH%YWSHS<[]4)2VDN'F0?OW^B\>-%[J/8 M/@7B6QBV5DZ^HZ2@72VBW^4QL@/Z^<=NMU3!&F#)/893GX)W*8:ZYD(.2Y5^ M%ZAR$;Z?$9#I[Z1XH+P NF.[@.)P]IV.[)8UBBTQPZRR**(BCLC66-,9*TS<%Z5+W5L=$#A0PC\9O4K;%012RANQL?=:7]_A5'GX MC'1-"-TR"LV%^>2]E5<^+[I?>B]GC2L\:L$OV_*O?N4.&8XE0-TIY&1L<(%O MDW3-$+/*JPMIMKHG//&T-A.\6KG283E\"E0)7Y4GYP31BJW]E<;F.)P/%O/F M5?WVS:NL@G_F\']9/,*_%#M^G];IVS<; P;=F<& +['C+R_B%\&O,-WREQ?3 M^/4T>?$*GO2WOWVS!1T'3:6U6<*CWR7NMCBD%B_5A<;^@A2 M#U00W@#7EP6H'_F"$^"[<0B\M_\74$L#!!0 ( (E$A%B\^4(^YPD /<7 M 8 >&PO=V]R:W-H965T&ULM5A9<^,V$G[GK^A2)BFK M2B/KL'S,X2I*HYG1KJ^UY*126_L D9"$#$DP .EC?_U^#9 2[;&=9&OWQ:: M1M_]=0,?[K3Y9C=2%G2?)IG]V-H41?YN?]]&&YD*V]6YS+"STB85!7Z:];[- MC12Q.Y0F^X->[W _%2IKG7YP:U?F](,NBT1E\LJ0+=-4F(>Q3/3=QU:_52]< MJ_6FX(7]TP^Y6,NY+&[R*X-?^ULNL4IE9I7.R,C5QU;8?S<^8'I'\+.2=[;Q M36S)4NMO_&,6?VSU6"&9R*A@#@+_;N5$)@DS@AJ_5SQ;6Y%\L/E=<__L;(_J+C8?&P=MRB6*U$FQ;6^^RHK>T;,+]*)=7_ISM..#EH4E;;0:748 M&J0J\__%?>6'QH'CW@L'!M6!@=/;"W):?A*%./U@]!T9I@8W_G"FNM-03F4< ME'EAL*MPKCB=+Z[#Q?3+;$*SBY^G\\7Y]&(QI_#B$XUOYK.+Z7Q.D\OS\>PB M7,PN+^8?]@L(Y:/[425@[ 4,7A#0']"YSHJ-I6D6R_@Q@WUHNU5Y4*L\'KS* M\9.,NC3L=VC0&PQ?X3?56_QDN;6&02?]ZSA%>S/!Y,5Q=[VPN(OFQA?*QTMS*UNE//_0/>^]?,>)@ M:\3!:]S_%W%\5<#SZE]<+J;!L$M_43HM=!"+0G;H3M)&W$H4)YQL9$R%S$AE MMC0BBR0MC?XF#<#!TIZ5D@JQ3+#*4-+N(CZD2^//5@'BZ!1R_4 19EDY<=H[#-0S<(:[.O9:)8 MFZ#?Z_V(1,P*HY,$&U.8 ?&H;4EG.O+)>8;8!'I%=>8&-]UYE\8RDRM56 H3 MSZQ#9V<3VKN9C\,VW-ZFIU3V*=E?D(B:3*6)E$AV3!")'06%:YE%#Y7\ MR60>:$//G6HW5R?ZUN55@RF?![3(E#7K5XI=H*W\BK9"5S^)-'\_H9]^.![T M^^]I8( M\_<[3^)\+AZV^EQNE*Z]&#"Z>I6"G4IA4A@4\BYK4 86S55DA:W]5M- A7 \ M:=,S9TRNC2^3NLR"Q[S=\#O4A<0 MIS* *TP1KMWFI8%>%LB[-E)B_"MHCT&3/3OHO0^O0O?5?]_V(/VJO=4A1U,? M"R#!ED@JQG0/X,P?X)"+[&$K/R:1)(PTK@NP:@YW7A,'2Y^X$4,SB9U)V(P8 M_IEG(%)=0@GP?$-'G:/!J-/K]>B0_[JO?J=?KU4KAYW1P'\M^'RC[6T5NQ,6 M_3!BSK# B<<"+>L1)VJ,."ISI"9VL=QUO ;?5!8;'5/38Y_#^1C].U<17>AN M<-P;=>C9"6HOG$\(V]RHG1B40X(Z8AF%+@#"6[^@65LTWJILG0U)PLV.!P+= MC$ ])W1<%:&+N?:LI U 4*:@7[K8:>=CQ8W?YM)-_@005:GCN1+8N14)QH,N M^_(YF^'2RI%" $L':EW)"EN'VL%7_6OH<]D32%X 1^LE?[Q[$M8038606U5PJ351'4OO=< MG"?R"MI4%B4E)T=3NU59E :N$(##%48NT,7R%G-?SKLBAU$H)AZ*8F5=E.J1 M[(F)$88RZV.!=:PZIP0881/^B7MHG6M5'?&A[PL6&9I5]\AG"^51 48BBG5U.W#!,^'5U]7*8QM[R;**GDY-)%4MRZF M;^ADT!D=CX(KN ^11 [F"<+C_<,AS!W@'G=&)T,Z"MP5_:U>O>6(>GCN [Q/ MC@\"P#LFY4RD""F6&)0.@HF[K_)X+!/G4+M1N:71J$*T'DQS072#?K3)=*(Q MJP^&?G\4^%[[Y+A3N69P)CDN=5D]T%ZE$+6#+UK'=PJ@?= 9# \[Q]S&<.5< MJ4P5,FB"K%,^8.5=O%+P+(VOKUU)$!>F3R).%KEZNS(Z?6OT [K@0PT3)228 M:JI'X4J?F[ALX%*TRW]LYB5B45J/:)5$UP<:$GTI2&Z&=<%P9H'A;T@^'#5P M'RXUQ)IX(-V&H<.-QLBWA;BG6D=3,>AU1S]2_X3_UB%R#?U9=^-Z(__8)2D& M,Y4G\BWR2,$/\MZ!#)(P8TS\:^X)7G8/_3?N<4C%A<])ZUMT[.M6WBOKL"&J M_%!A@]CB2% [S?MKF[!!(V'_5-*P M (!1;Y,6;76+;;_X=D<7QQJI+,YI%> M6IT 5"0W^MJ^P7'W\$>JBR9P<\BN^8@&J!>ZI#W?OG2D90-@&="?GJFAP#G]A>(RO09M18 M;ET:5R-:/1.ZH?[HO75SBDY4[(<(=(_,729A5N%"W&S&<>7F9E,N-KB,K7WW MB$IC."OJ^LEBWZY]N^ DLF6. F.^/"L937T> MTNS"_7>=#]>0<#']1(M+"B?_P%UKQLM!DU? O(+K*NL0]$%GV#OIC'H'P072 M;^9!9>\,R=?&]B'RH(?F=1!,:R"J]CC10)OR&]%&&-0%!D7,L&]HK]?%A:K] M)T[$"OVK=N@?CTN=0$T&PO=V]R:W-H965T4T"[,6FR/MQ[KD?Y/G6V&^ND-+3CZK4[F)8>%^_ M&8]=5LA*N)&II<;)RMA*>'S:]=C55HH\*%7E.(GC^;@22@\OS\/>)WMY;AI? M*BT_67)-50F[NY:EV5X,)\/]QF>U+CQOC"_/:[&6#])_J3]9?(T/5G)52>V4 MT63EZF)X-7ES/67Y(/!5R:WKK8DC61KSC3\^Y!?#F ')4F:>+0C\;>2-+$LV M!!C?.YO#@TM6[*_WUM^'V!'+4CAY8\H_5.Z+B^'9D'*Y$DWI/YOM[[*+9\;V M,E.Z\$O;5G8Z'U+6.&^J3AD(*J7;?_&CXZ&G'OW2!_NZ.[AR^?;"*N; MT?G8PSP+C;/.U'5K*GG&U"2ACT;[PM&MSF5^;& ,7 =PR1[<=?*BQ7^DAV#38FS\7K-Y(YU%2WD5T599T[PMIJ;=-?UXMG;>HE;^>(J U MGSYMGOOGC:M%)B^&:! G[48.+U^_FLSCMR^ GQ[ 3U^R_O\R]:*IIX'>W3_> M#J8C>M8/W>O!>[FT#9J7)HN0E3@B4$@WIJJ%WA$HE%;FI+0W),C)K+'**^FH M;FQ6H'M(K*V4S#4*W1<'^QJ9_O7UJ[,DB=^&O;">O/TMHFVALH*VPM&JL9RP M@8 ^*HS0U?>9-TOD\&P/1^B<(+H7J:W9J!P ?"'\$=9*[("3,T]-38P7,V(- M=&OA)9D5_4*SZ#2.HSB.:9&<1>DTI7>(1Z\';&U\+G<_X^B[6C4!"V^M ME(5#5)C&>(W@8Q*EL]9'NIA&<;* _B**3V:8X8O@V2&1J:OJ/84%*WR=!2-:Y8.#'+13^"2=G0 6ZBXS2'HIG2,%7\J&^G>*=;0AYD65NT$N$2IF MO%B6( !BM!%E(T/IBXU093@ @EZ@(PZAJ^.VJR!LY0:W%R+A!/0\ HD4Z"4K M:V,]J*9:6F5R+F P72HO^(X$%.$4(&]1[(+D,] M),JU(:/S-&7"VAVK!.D6]7\+V2S#* HN:ZLR.<#(T&O) 3G)\+U[MI8LK_$FH>%XV$"? MC<)2;V(6$A4,&=%+5P[IT>#1A,5QP6.X!A*MS,Q:!_^\_1,<0.C0H'R[*F^= MHI:>NJ;&O<=%)>TZ/*$<2KK1OGUG''8/K[2K]G'RKWC[Q/LH[)HQE'(%U7AT M.ANV(V;_X4T=GBI+X_'P"&UL ME55M;]LX#/[N7T%XAV$#C-J6\^)D28"TS; ":YOKRQT.A_N@V'0LS+8\26[: M_?JC["1+AS3 OE@B33Y\2$K49"/5-YTC&G@NBTI/W=R8>NS[.LFQY/I,UEC1 MGTRJDAL2U=K7M4*>MDYEX;,@&/@E%Y4[F[2ZI9I-9&,*4>%2@6[*DJN7["9K*3\9H6K=.H&EA 6F!B+P&EYP@LL"@M$-+YO,=U]2.MXN-^A?VYS MIUQ67..%+/X6JH97G)#9]-E-R LM:$9C=MJJTWD1.5;]NEXN[AW]@?G,)BS\?KY;7BYN'B6\(VUKXR1;GO,-A;^"$#*YE M97(-BRK%]#6 3Z3VS-B.V3D[B7B)R1E$H0!'8UITSAO"@.@/7[7AR$A*;UV)DG25,V M!3>8TBB@LB:"M\/F0QA9^Q ^PH=1Y 51#SXZQZOI085M=M'(&XU&=C=@WG P MI++\1'3PF>:P1N!:2ZNCB!MAV\KQZ>?\N9N'PDVY[+0N1VHB.-K1T=:/6V\"MKV[1A/:(?*_O#2(&$=4^ MBN'8^?&PO=V]R:W-H965T F;FJ@N6SBMGO!/C 2;7,JB2I)Q\G\^CV' MDAT[L=-VL(O=?8E%B>?^G0N9HX547_6,JK+6Q[V9,Z49P5EJ@J#WW7C0\K)NK>R9%]=ZU.CN354Q M]?B.EW)QW/-ZRQ(ESPUR8/!SST]Y62(C4.-;Q[.W M$HF$Z\]+[N^M[6#+'=/\5)9?1&%FQ[VT1PH^8?/2W,C%!][9$R&_7);:_B6+ M=F\4]$@^UT96'3%H4(FZ_64/G1_6"%)W!X'?$?A6[U:0U?*,&79RI.2"*-P- MW/#!FFJI03E18U!NC8*O NC,R?G5U=F7T<>/9'!Y1J[&'X8W9'0Y'ER>C]Y] M')+![>UP?'MT:$ 2[C_,.Z[O6J[^#JZ>3RYD;6::#.N"%YL,#D'%E9[^4L]W M_JL)X%'B>_ZP2O\@I7=@>47[[);RF(ARI*PNB"CVK!Z*NY*3@9:[; M5VP(5S:$KW'_T[%[E>MVG2^OQD,G[I,?$0GN=%B>2U6P.N> 9S.#+Z2MYI,EX$1FC"MQ;3F!3&2,*)%/84( M03U2S,"S#9WBC51V-:^%Z9,!AC3_-A=:8-9KIV(%)W>/Z[((@["*FLB:DRFO M@1U(JR'85E\H177^""\*R#[U:*6T,BT1(_<DF]SI@Q7P 'JG@!!@Z*P7H78/=*6Y_#J-?TQ<0R?@GM:9; . MMX:L_*'X/5;:'S,7-)D##+C6! J?K>SW''5!IS:-U"U6I+4,H]X^]?P32@$"C%<&P+! 3D6WV3V>*=$ MX73.N&AU&32-DBR?$2O0>TO&BJ%!W>?/K 0S+KB9R:*K;KFL^$LRK'%R7J,1 MITS/R'MHT.MT:]_!?0NF"J<3<0$M3S3E4@J%8-1Y.2]0:3-C9FMB3\!*ZU+7=9T@H&'[2+R0!DE@ M'R5 8Z)D!8 #[6NH#'->K /KCD,((,SLP18IL ^S&A6&[5J6HF!HL3;P@T&Q M4%RCG_P DOHDI*D?T3@('7"=\YW]P3;DD:W(VXTG2%:P%K3&U-X"+N<9N)!/ M\13A'!$P0014+0)6"6C!PY;@L=6\4ZV!\B!RT6 0T=<*IA=6_ YELW4<^!5] M*HK.>SY1BX@.1)A3NS"4,Z4>4?L61Z CAU)OH-P^Y)PCJ3 ;2'O:T079 M&O(@8)SC#JML^"VP$AIEH4708B;RF;/N9JA<D?JYC.FII#NMF5: MCW8"MVU> D]^#WC.SP$O:%O-!$JC7-@@,ZS&$)?2TF,.O]YTE\FV% ;BA2PT MRD-^+P3:P"'D,0(EU.9[Z_,=R=?/@Z=J_=D='$]&-U<#"_'!%;+ MR<)93F;.YC\D?.12/TE6^];#TR*N[CJ-Q>H[@ Q;'PG0ZX-&B9+X<9NN MD*U^$$/&^B]D^EA;_#2A;I8]25P+Y28VP/27+MI[PM;^"P$!&!73. M0PG\P M>MO+CBWS+TP6=1=*YY50_KOCU#71C4AAM<\R\%SZYZ/]%-MMX=OKQ.Y#!5;+ MLH@9=K"CM).]KMD$2;@EG+[5V?-I$@0_)W!7D,C>JI> O/\.!.V1"$ %#D9U M*_8[ "S'R4XJF$"7O>(Y+L73L:KM[Q9ON'-A#\N\.& P3,-D!S;@!8(=>BJ< MY]N^X+0 WF76F\UR\N(<@F>4+\/1^8?Q\.Q@\'EX,S@?DIOAQ6!T.;H\)X.+ MJYOQZ.^#\>CJDEP/;T979\Z73C$RZ!2[62DV6%.LRRRR]S>(G-XGYPKGCM-E M=QJTC660Y_,*#P3(;YWZ$CK@L\V.'>)(S:IV/#*XQ&:IB=>/,*-HZB;42S-X MWO-HX+LT"S*R#\LPC:D?N0X<8[FRPSF,$3 70[9"/Y$3L\ #3] '<-(D2VF& M,(XA/5T?&7C4"U.:9H%S:N\;P,.*EVV:ST2C2=J'$BD-O11H0%J2ILYG& PDN5:RF+<9 MW)V]#TC4CG5[W>\^.7 N97T DTC#39O6;*IXUR;=?D8"&KF0)QX0^31-0AJ' M$=#%@4N].'K%N7:D3$!0Z"7H65 -W!S'KO4L6.V&D,Q1\G^4%_Z;_TD8A_VP M@W$,,$[1V5F<43_TK*M3J-)9F'P'Q&'? Q9Q$%$O22'6T)FSS+4@#D),CW07 MB+-G(/:IF\3436,@SF@:0@JYX780AP!B$!@D@,C4HV&6(/ A T)W)XA=$/=S M,/:>P]A+,AKZG7'0 8+,=2Q<(Y3M8MG> U>&V.'"%JYP) HR&L391J <_M#P M6G,\I?]*?!K%("?*\ G8IJF[?>[@$SQ@X\U" [_87=:#O^2YHS93.X1P/#)T M6?#$?X)3(O:\%? 59Q,(^V9!WZC/P[]>#R]OAS@I#D[_\FET,SQ;J_BW7W0XHT\%G!=*/@%2MY]$/:+:N^EV861C[X/OI(%$L8\S M#FFJ< -\GTAIE@L4L/H'P$" "/!@ M&0 'AL+W=O/NWO& MG\464<)KFF2B9VRES#N6):(MID3468Z96EDSGA*I7+ZQ1,Z1Q$51FEBN;3>L ME-#,Z'>+V)SWNVPG$YKAG(/8I2GA;P-,V+YG.,8Q\$@W6ZD#5K^;DPTN4"[S M.5>>5:'$-,5,4)8!QW7/")W.P-?Y1<)7BGMQ8H.>9,78LW8F<<^P-2%,,)(: M@:C7"PXQ2320HO'K@&E4+77AJ7U$ORUF5[.LB, A2[[16&Y[1LN &-=DE\A' MMK_#PSR!QHM8(HHG[,M<7W6,=D*R]%"L_)1FY9N\'O;AI*!E7RAP#P5NP;ML M5+ <$4GZ7<[VP'6V0M-&,6I1K1JE:HZV0^'P]GRX6D!\_![.)B. M(7P8@0H^+L9J,%UU+JFZZQHH.R(,2V;V [+APSS*Y%3#.8HS_ M!K 4S8JK>^0Z<*\BCC"J@^>8X-JN=P7/JV;W"KS&!;PY>2.K! 60+(8PBOB. M) )^A"LAN3HM/\_-7")ZYQ'U#>J(G$38,]05$\ MV'&B=QQC2"A9T81*JK[$'KE:%+!FB9(+T8'%\&X\6D['M=GMAXG4U$'!=(6\ M.BSP/N+6PG>43+B!AA>8GM=65M-OFGZC70L/'/%5J:!0!'W;#'P;'+MM!K9; MK4<<8RHA(CP^ @H(?--W&A"T3,>U:S.Y5?W/#>W8@>FT6N U3+?M_,-,;U:- M7:R^@9:B[;<\9;4#Q_1:+IP[;-:)2*3(-X44"BAZE7I112NU#4N1^9->2O4] MX1N:"4APK4KM>C,P@)?R5SJ2Y87DK)A4 E:86_7'0*X3U/J:,7ET=(/J']3_ M#5!+ P04 " ")1(18">'D'*$& "V#P &0 'AL+W=OO.,6DII):#5@ROG4GJ2*$[*0*DJY 9AZV M]D$8 =ZV+5J2FV9__1[)7,(T8;OG!2SI7+YSU='U6JK/>BF$@6]E4>F;UM*8 MU8=.1V=+47+=EBM1X;.U'(]4V+MG8;+_EB:>Q&Y_9ZQ1=B+,SKZI/"56M']XP)/X[#&S+P!SN1I%# M><\-O[U6<@W*4J,T^^%,==P(+J]L4,9&X6F.?.9V^/STS]\F@Y<1W _N)M<= M@S+M22?;\M\U_.P=?LI@)"NSU#"H9F)V+*"#8/:(V [1'3LK\5YD;0@H >:S MX(R\8&]AX.1%[\J;&KC/=59(72L!_^I-M5&8#?\^96TC*S@MRU;(![WBF;AI M80EHH;Z*UNVOO]#(_W@&:7>/M'M.^@_$XBS_:71/SY.!E[3A6#A,EL++9+F2 M.G?5(>=@E@(*62U^,T*5F-GHMKDLL&KU!QCW?Q_P04$44HBG^%7ET4D28)S M3."8L"4YT#S[4N<'.P9W8^#5#%['=ST"7[G*^;00D%=HE]#&DGQ2V%C@A1L! MJZ+6P-HA].H%EIO%FP#UB1^E0!D)DN1GP(U%E2.JL<@PU6;0*Z4R^7_M:1_7 M.1+S+"]RLWD/?+\_/F#VSF&FB'GOZ08U(R$+@8;$CR.(_"Y) A^B-"!1JSM0V^E\L+B22$F<1! 2IB/:-*0Q&$"<9*0,(W^-IJ'Q_$/ MQ]2'$=\T4# 3?19A'$G2#8!:*"1$.)2D28Q[?Q]0[Z[_$X#&8F7V$4-8(8FZ M*285H;AB)$E3TO5QG[!N2L(X_+^P?B+!&V<$#&@"4J RN;\>B: M2XJ'/NJ)X,HN*$U(S"A<.=%O>LP%4!<;(R'>5"J\8U#*!<0A]BS?1V>V\9"GKRF4]>H&DF$"G#=:-Q?#3%C/K4;28)IC&V&"? M*V_;Y:+F?GL_HSCH[56P4K+,M99J Y5$+9>6YPF_KKZS6M?3_^#0:B%8(ELJ M>GM!>R.N MA;+.F><5KS*[E4EM- %N=9T8+;@2Q\-(_W7T.NQ-'O\8P*@W>7UYG#P.QK"; M4IJ!9_C<>QI#[^D>^B^#^\<)//3ZCT-'Z3W@8(C1=JDKFLH^TCHZ,MZU+F>< MG2JQK%G7MJQ=I[,;>/_BS<)('#.[C.QEPU*"(Z)=QO;&0>]'?N"Y.QOKU(\Q MJQ)O8@/(YS:Z =Y*$:$H8>(R'%,Z2BDR4==LFQZ%R52CTT3C,KAD<4"2J(L- MMF&Z>-NNQTMLRPXY6KSUM79#X"Y7ENAR6P<2;POMJ%V0;:YJ6/&-JP][!S:Q ML@F.-QG2UMG2ABNO<+IV>'#V+/.ZW'9E]+^6<[/&R,&J5AGJ$;H-#J.WE[6[ M7'=QP*T3P4=YKMSPEEL)]YPK-K!&Y7R%Y?4MQTRU.Q>N4FVN=Y.F&5#6CD/P M(8R:9=AU_Z=F]LZ;MU0IU,*]Z&7M,\ZS:[^X?I;WF+78@;UZT(ZX6Z!8H MQ!Q9?830 M6\$IN%D2OW,IM*@^\\][G$A[50E@#/YQ*]OUU8!?NG^NW_ %!+ M P04 " ")1(18\X+(M/,% #C#0 &0 'AL+W=O;7%OKB3%6V$)(O M-)FJ+)G>7_)"[<[[4;]=N!7KC74+PXNS+5OS.V[_W"XTWH8=2BY*+HU0DC1? MG??GTX/9[U0ZP1V<]Z?]BGG*U85]E;M?N>-/V.'EZG" M^/^TJ\_&89^RREA5-L*PH!2R_F6/#0\' M.7!.)&(/9VUXJ\E1^891=G6NU( MN]- 52\-XX1T0;FS&KL"S"]O/M[V.?E MDFN*8Q\!Q,%N.%VI5=I32MM*9QO4"+&UYARU:^G= MW6+^'DEM-V1W"C+&"ENYBF0%WAXX4EP;0GOQ.EJ$'I,Y&59P4BMZ)X#0V@>= MG9IJZUX9BGL-A6MF_?%T' 6SV83"03A-*8T&R9BBR30(TY!F03A)FYTH",.0 MHM$DF"6SYEP4^%7->N.OL66CPX-8L")'L'T5K^&U^9*DMAO2S> MA3$5;X^7 +O;,$0N@":^XAIRO7;%45+'BP[B!1$G?2,1 E!Z52CC+/[@K'2L M,EJ)1VC?:I%QC\$?NMG",64AE?.LR*2!D RTAZ<+OC%JI N/&"2%1-%H_M"+Q,G/B MDPG14KESQD4#X$TZJF4AD$1N6@@T,L=:$_8FE,ZE:')JB'^OA-T/>O<'8UKRC%6(C[!/N=NAS"P'*=YKQY&E7*%\I;+T MO6*%6.U]S&OS,/(R54GK:#@T5-2I4NRIY,Q4NC'XJ"F.9NA>,:'I@155G4$[ M4128XTL#1; -2)HW6+V7H'S(#G!\2T!TY!IQ$/)P2_-,K:7XV]<,<:8E7# # MFG>NN\QU;I4JYQB9H!(MI? 2(#MC1585* !OS %PDQW/3.]IXW@@R5AY.P[@\F*]QP:.2[0>P]WVU$AA:("\V3WM#Q]DH, MVM[898Y/)L>-]\]BT;"L+H26.D?.$YO'8_2_*(BB&2TJ;2H ]9KD1G&4IN4& M[3J@W.6JZU52R5^?>ZJY(S>G7!25M]57IC<+!8V.PE#-,'8^J$KJMMP\EH; ME@BDOR @Y<&5>"&3\=>'53749XH>D21YDU$^>-6Z+JGY,U\PC(R2 M9!R,DQ%&8$2C*2R:!M-T1G$Z]=:E03(=!3&(;^WMTJ W7SOR.K@;V4,SE)==K_WEAR'?=^@[>K79?,//ZXO[C>/WY\XGI MM;.PX"N(AH/)N$^Z_J2H7ZS:^FL\QAP^"OSC!E]A7+L#V%\I9=L7IZ#[KKOX M!U!+ P04 " ")1(18WU3BAJ0" "[!0 &0 'AL+W=O)_&J[J@,D2-,5:0V(0/YSWXMSU]L)^:PJ1 VO->.J[U5:;VY]7Q45 MUD1UQ0:Y.5D)61-MMG+MJXU$4KJ@FOE1$%S[-:'<&_2<;2H'/;'5C'*<2E#; MNB;R;81,[/I>Z!T,,[JNM#7X@]Z&K#%'O=A,I=GY+:6D-7)%!0>)J[XW#&]' ME];?.3Q1W*FC-=A*ED(\V\VX['N!%80,"VT)Q+Q>,$'&+,C(^+5G>FU*&WB\ M/M#O7>VFEB51F CVG9:ZZGLW'I2X(ENF9V+W@/MZKBRO$$RY)^P:W_C*@V*K MM*CWP49!37GS)J_[[W 4AV84KU44; M<93;2\FU-*?4Q.E!/OZ:C>_'R3";0[+(YY/'=);W?&W0UL$O]IA1@XG>P801 M/ JN*P4I+['\&^ ;3:VPZ"!L%)TEWF'1A3C\!%$0Q6=X<5MH['C7[_!F5#TK M(+R$!2]0:O._:HH*?@R72DOS<_P\577#C$\S;3++>66?J49HLT[XRYVDIBOO.!!.8ZL5Z:Q>%* M_[%$G:FD0E+]!@](F*X@OH(+B".XZ(S8%A,IE *[RBN*K(30'H>7YI&)CM"5 M02DCDR'0-GVQ3T^*0FRYQA+,'(-:2 1=$6Y+.G53_E%#U2C7;FPH<(RFMUIK M.YF&34/^<6_&VB.1:Z,'&*Y,:-#]; :!;$9%L]%BX]IS*;1I=K>LS'1%:1W, M^4H(?=C8!.V\'OP&4$L#!!0 ( (E$A%A0GXC2[Q HP 9 >&PO M=V]R:W-H965T">!#= R;XJ> Y ] M\L0;C^VU/,D&BWUHD2VIUQ2IL$EKO+]^J_H@JXK(IKEDE8O%RPOU^^/W"/SX('/%S4^ M./OP;D7G;,+J+ZO["N[.VE4ROF2%X&5!*C9[?S1RSR\"'"\'_,396O2N"7(R M+DPM&P&EY(5N5L((X7J)1) M7<%;#O/J#^-_?+E^_.7=60UKX9.S5,^[4/.\ _-?L*@4%+8/#:ZJ^(_M5Y^ZFZ MO7L<6ZX[(&I5<@_&S:J*9=:D+M,G\KA@UF6Y7-'BA2RH(%/&P"6:>E%6_+\L M(W5)N! -(W'HV(XC_Q-GX PC.B!N1 MCTW%B[DU:N9@NWH\S7,S((CMQ$]P]K(L?B]IGB'L=Q+GQD/;B1SR,ZTJ6M3D MAM,ISWG-F?BF^8%C!XZW.[1985B95XQ!E*K!<>L%F; *EQV1M=YL4>89JP28 M=2C)3I(!_-4WL.1G6J6+U_9VY'\Y\H70(B-_;PJF)WCNT XBK_U%$IOYDY?Y(H7):TR4L[( M1UY!$B@K@3>]O;8V7JYRR1:L0(E["AGOU TA\SP#,\P2*S 9XH:V[R [ON*C MHTW2]0OJ?@D"26E!P?)A=DYQP16M:M@O+0M8#1^\(5&@C""*[#CP23( >GK MOET<$$\(D_VA\3<<(1BLGI%?@9P:% :L'IP]J\HEX;4 >M 1B4!'!'VA?L*8 M^*%G>^ PH''/3?I[U M>_;DMXL".7&73ONVX8!X^[!7T-YF5305V]2=V&2:Q M'28!\6-7BC@.0&' $,8?$#OQ=0P9"0O-P]BXR3[2S;:?*H>I&%GCG\".(]=. MX@!, 61DA[%OXHO0'F&-NB?7!:K^/TVAL(CTFQX[W_]MZ+GQ6T%X 6&)YF#? MTYRGP#H$<1#+7MXA',8F%(*=^K$RIS:TD-ORN?5=7Z[01J>?-UV5/)?2ZH%M MNEI5, ]O" 5OR*2C@YOMG=^% N.1%@Q=+WBJ^%L; 4BA*<)MN0^DIB;%Z ZC MV%=6I5PPL@+'84JITJ)KJEUE$)G(&0U<'_2&5C$M08K?K#R(0(D2C>OZ\E>K MZ5+-Z"MK*]!#4D)/%H#T3 2YK_@S$$?NYFH 4''# MA7SXT.2,A'X4'M.3 4H&0PT.0+>H@+:,JSFKG (EO""'4@Z&/E +# $=CK^F M"UK,&1D9%0NK-5MC-K!+W_&,9<(>?0$.R'TO7./\/8OO-_&M_ :I#//'F%8% ML"[(\4TIQ FY!T5/%A0L#+&$-M(=M>)[ID!AFE,A0-P8F+=(6^]:-O@#QR)$ MP *]ZQ:\LYU8%XYK:'\ 7W.^%=8LFC0]#"R""1*0$"KVI<@+%:C9.BR;(IZ M@"1W;H(T@M47&^D&)!W!'( M!M#P5)3KG&5SMK4K^[J"#$E C3+\\AFHF18%Q\2'I&J;!U963%914C^T %_- MP F$"AQ5Z\B2)J039:6$8&WY.' &80YD]P:!G!L> #BX[;81J/$0T/WH,.") MS;@X"4W8&MODBGQ/EZNWY%-K%BH:C:;L1?(S41J[,PG8;2''04^A??V .8%I M YN=_1SC3%2'Y[R=W(].<3EYZ[X]49D 5Z04\%P4R;%Y @)TYKO3R UOA?)JF995)]VIM:6?XP-2!/45U>CJ1E2%8^U8801J(/PA# MDY"M-B%+/R,JTFTMN^9:F3UY"?X58S-V-&9EGI=K8[>9=BT3\BPT*KF"#ILS M#(@R @*1^8R\, IIH04QV_,5H_<]#/8:9XDKAZ=Y*9"@0^A#,5NF$(7&Y&KW%O&\!H*I&C4("M!$FN.D@T-\!H#0/@FM>Y*NB!WR'Y5$'VEN*$E(AI-F4L M$R81FUC;"G(_TY9$EA*U?N5+> _9X T!Z#^ :!#!E*6V$U%P'&39*56LOP)#0I\,5';XZ""W([X 6 MSS1O&"*UF6"U3KB0WCJ$['J_E>$L25X*=2N2\LDSS-XCT26@!I#'*S-Z#")<;J/G-2 M]-(.P<]9M:\&T8YFMK3Z_"!DB4)$)&U>[:X ETC\ 188(EKUX8GC)5 J>FTY MZMJQ'\C1R0!R@.]X=I+$&XNXCF_[<4R&4*GZD&3,&+VS#'GZ.AC .*QJ\!*B MP!56SY@KMJ'MJ_*SK3WXFX)GKB&1FX0/C_0BGS:2?9>UC75O@!XS10NQC1U] M B>J36\%4,8<>R>= EIH-4IE6>,FOJ]*,JQ.E1K;[4&JKF.'WK 33I)\!Y+U M_ @J=L<\-C^=U%1)N5--GH/Q)5&JMEDF@^W45+@)OVTBZW]:4B M(HC(DKBKE._;UB&'/ 7"69K6S)&89,1-U^6%19:-.-YEZL0H*AH_@V[ MUO2)"5V9 /""1""]1>_?\6)OA#U+A3U,= !KF$SJ.9^U=*NMU!P),F1AW(N4 M/;2O>@&X%%?%I5KN638O*JUT9+"$K570N;,;F[(H\_C,GD\>[R1W)W M_WA]=SLAGQY&MX_CCU"TWCUV**1+ +YX1H:US0UJ_?@7Y.<$TH.IRZYA!,0-GI*?T)ZM MNZ:6C0J<#NA@I^%F//N-\6UW$+EP=VI]TJYVJOY95WO$WKXLG-??8"X;D!,8E M@PCQR=!]Q?1_8U/8Q\<]G7 00QX>A,E?0A8N\>UP&"-E7CR(DV%C0;$:J,L:#&(#1:'4[&!S;4.Q")L4F!M%P8'Y.C]W^08#^TP3BQUOK)BA5"]681-A6#J5%DB MT;(#--;VWG5G50**!7,(KB -'@N 1:D6[/[B!\_[H?1+RWDA/\382XID11[2 MN;'M1I&"LVV+K3<=OQP@"-4QZISB5RWX/14'23]K2(4.CERMH%XJ91# T@4/ MT5K@;-[5BZILY@O2/W\/!G\-F_.^V>8\;7-#3+K]+E57@]3;98MJ%_>SZ\$Z MA>ZM%TXWZH7!JV,L.48H/51LP_S!O)90:X!46,;5L1"%N+C45H@PJ)(V/VMD M?TR1K&38KP7 1/B*8T'1"GK*%O298TF*.C U@O7"69ZU'=U]@GIMIU[QMN!8 M\'(PB_[[U@[;ZF1/>6$]OCY 2)6BJS3F4Q3Z9/9=\NQT58*!;AB=,7NI.5V! M<7T:@\\4QQT0ZTE9=3\;T37J?UOCMDINJC:4^M$UC/[2A<@O7<0F"!M-)E\^ M2]2%=QBU]U M28H1V8W@CQ?UKV&8TH$E=> /O!#^Q&%W93V8XM':+!Z=@3\$C!#XY+O^M34V MMF3UC,)+_($3D]"-\<.#[[;O.S*,E4K HGH/HS5X@%#]?EDMZJ)?2OR90B!K M9 6YE,%!5[YRCD$1!VO+7FKO8(1IT?9"/;A4VJ!OJD9[FP_4!QDF4^A>MMI; M-TTUVN)+]04!P/(! ,0.I-LD#H>V UIQ(7%%V)*)[3",2!Q%MA::ZIGJ5[;]/'A]!]2;C\XV7*7MX!:9/C-1W+7-#'4K?= P%]N! M.R3NT %4$@% 39PAP=;3T >R ^)[MNN[&Y\H4!U*I3QZA#/(&2K0=9_%#>T- M*JT_2B5*J"@0;ZM=L84G.V0@HL )B!>X^""!>G9;LDI[IU-Y7(AM68"G&#LV M\C68'FRU1/2,Q\T'ZC?13 4'=6"T8Q5. #>S\JR-C>X0?OY_X?_ 5!+ P04 M" ")1(182L5?HXX$ ,"P &0 'AL+W=OV_ MW[$34F@IV]U](7:8^?S-YYG)=+:,/XDUI1)>XB@176,MY>:R6A7^FL9$5-B& M)OC/BO&82-SRQZK8<$H"[11'5<>R&M68A(G1Z^AW"][KL%1&84(7'$0:QX2_ M#FC$MEW#-G8O;L/'M50OJKW.ACQ2C\K[S8+CKEJ@!&%,$Q&R!#A==8V^?3FH M*7MM\"ND6[&W!A7)DK$GM9D$7<-2A&A$?:D0"#Z>Z9!&D0)"&G_EF$9QI'+< M7^_0?^C8,98E$73(HH\A,FC@ 7EX*T)I_![?RDDQ]SXXUC &9Q['$[5RZ78$)]V#2P(0?DS-7K? MO]D-Z^H$V5I!MG8*_=_=S$FHXT1G\[MQR78J\.E!," B]$MTI]H&5?-9'&,Q M"2U>^?NWEN-85^.%IU?VU3F0S28*?;*,*$A6F$OF/ZU9%% N(!3J]2:5-(#E M*P3A:8<6P@D:;Q$DFQUP%, =B,A2:*. MJ<#=FI96+,)VI$[U2>2G$9%HM53A IHAITC3P\ NP1M>CT?WTS',?\"P/QW> M3_MWD_G,4_M!WYL,H3\;P6@RO;\;CY1+2:6KREFGA)U#,_T-@\OK C"KJ::) MF;UG6IXR(MP_N7S3*6JVC!NYA*5 M;41MU!4'1+5K9@-#J;>;_PUS)_;9.]RS?>2'_*IA=]4'%[PCYI@MQS*=9AUL MTVK7S&;++HU7*_P"J)S8OL=XID)M=6H!V1(>"+C VVB51CFG#RX?$^K#H>U6 MNS3(=(KVY5";CS7TN4B72I%:I=;(M' K;J/@=8C\_T"A'P2A^I-$T:M94NGZ M5AX*#8$$9A-7,B#DA;XP_):"H'[*T14%H2]^E*KLUD=_*,Q] M2O=K8;SFYOY+&M:QZKO555/_X!P*-V>7_,? MP,/.7[6I1?\!6BW';#<1QW1K3;7Z&M+/-R89TAMR#?N*:^)7#"Z.8*7)L:IQ MS:;5AH99;S;@V+>ONC>A8.$_ZCE,?0?21&;#2O&V&/7ZV83S9I[-B3>$/X8H M?T17Z&I5FG4#>#9[91O)-GK>63*)TY->KG%WU!+ M P04 " ")1(180CPPQ"\$ #:" &0 'AL+W=OT 4MNAFDI#6Y6RJWDTP0%K M'#MC.Z7LK]]K)U ZV_("_KCG^)QK7RZCK50_]892 R\5%WKL;XRI+_I]76QH M171/UE3@3BE510Q.U;JO:T7)RH$JWH_#,.M7A E_,G)K#VHRDHWA3- '!;JI M*J)V5Y3+[=B/_/W"(UMOC%WH3T8U6=,Y-8OZ0>&L?V!9L8H*S:0 1=W*[&?F@%44X+8QD(?CW3:\JY)4(9OSI._W"D M!1Z/]^PWSCMZ61)-KR7_AZW,9NSG/JQH21IN'N7V&^W\I):OD%R[3]BVL5'B M0]%H(ZL.C HJ)MIO\M+EX0B0AQ\ X@X0.]WM04[E5V+(9*3D%I2-1C8[<%8= M&L4Q82]E;A3N,L29R??IY7PZ'_4-)X\L^:A\OYPHO#*#L+8ZR@7PU#* X*N1;,%0438#84M"&&8JD9D"7(ED4* M;6<$-!)R"MQ20B&U": @O&@X8E:@)3(0XVCLIL78<1O.-!#.96%#/?E,U=&> MH:H*8$T%'L?Y#FR-HA)%;"&=V038>F.Z!T^M1+$B:O7J@R"/UA2)I/.$>P24 M \ORK,$3"&X;0!QNX#Z":BE6-C^M L[(DG%F=M 98**@M4O,L8L US%=3F2% M"XU"WQW"70;F[9GPAK[U7I.=36FG_UI6-1&[SY_R.!I^T6V,]@I,,]/'>1?K M;L\F9-DP;@5KYT*6)2LP%?8=].!6>*2PM@FJQI\-L['W#=U]!^^D ED4#BNI M#/L7/;Q>""L/XANL9\5WKSKP>3D_] 4[ 7YC)W"!.TJ4]J@M?\#BI=42V?8% M[/3B((8MT? 'I,D@&(0#2,_S8("K2>\\AJP7YCC*8TA[V1!N&H.I]?!7CE5- M]3:+K2Q[+J[]+U-=%JVEUD0I\=5M,>("YM??IE\7WZ=P?P,WBZ?%XQ1FMW>W ML\6L+1MXN/PQF]X]>3_0#U#W/M[Z.915EXC[)6?KMD*PNN(!VDOB$&V%=II" ME"9!GD1VDD$4)<$PR>UDB)-A$*4N+(<(,5F6>O@ZL)V6QIX6!DD^])ZD(=PZ M9KJ0C7"^WEH^/"[(TRR(SB.L>*TOX+:J&QO.$(0OT\"?>19D>0I_>0^_O]3? M*??5P*B]L&%V'J1A!N_]YO6/^DU%U=IU57L+J+5M/8?50^.^;/O5:WC;]6=$ MK9FPY5 B-.P-4[]]N/N)D;7K7DMIL!>ZX0;_?%!E W"_E-+L)_: P]^9R7]0 M2P,$% @ B42$6*J\Z+NA!0 -PP !D !X;"]W;W)K&ULM5=M;]LV$/[N7W%PAR(IY%AOENTT"9 7=PV6.$'BKAB&?:!E MVN8JB2Y)Q?5^_9Z39"]ITVP#M@^MC]3=<\^]\,@9"%>V3HVKOUIP< MZ=)EJI"WAFR9Y\)LSF2FU\?MH+W=N%.+I>.-[LG12BSDO70?5K<&J^X.9:9R M65BE"S)R?MP^#0[/8M:O%'Y6N63#Q_(6_5T5.V*9"BO/=?91S=SRN#UHTTS.19FY.[U^+YMX M>HR7ZLQ6_].ZUNV%;4I+ZW3>&(-!KHKZ5WQI\O#(8.!_QR!L#,**=^VH8GDA MG#@Y,GI-AK6!QD(5:F4-\X M@N0T/0BC=&DI8RM:&9U*.8-A78DT$RJW'DGEEM*0L*#BY(RTH;+8KCP"AH4- MJ8*@AZ] P#BA5)?&8CVG:0D%:>U!Z^-29;)6*UVJ\^HSEM"KO5$JBD([FDK0 M 9>4':Y!@%*XPTQS&P_'K MA2H2E J[I#DF+):<2Y&F56(6&?C_0#Z-A"DZ(-K*E)BJ#(!?56HI+/!3O2C4 M'\B!17 &SF5C1X_M:AY78'NS(?@6G./68Q%FVJ7@!;;I!J)]+!5M+ZZ6L>F)#.5]G M2(O\PAW&I>U4^#,J5P!BXZKMG# +R1XY$W.=(8$<57-Y@>!2("[+O"&R% VF."^K&R0JY6LKA[:0!]&/!@)8TWF4[3Y=K1598,0 M'M+]^?O1Q8>K$=V\H]'IW;AS\V%"5Y>G9Y=7EY-?6KB-'%JR&K3H3#K-G"F1 MFY]*],"9,$;01#L<2XQ@CJ:A](W+$(V1)'W/]WU(/=^'%$ :1+$WC"-(0=SW M>E',7Q._T0N]OC_TXOZ@=2LV]1C="[PXBK#OTS[M]7LU$,1A./2"9,#B%FJ? M.K07>2'P8C^B_=;(.L6'@EZ+?/66YD(9S(FLQ&&9_8[[KW81>$D0>L,@!I.A MUP?0,/;"L,=H6V[[T.H'B3?H1\Q-3''TT6T\\%'S>Z?33ZP>](;>(.E73#I/ M-EIW$E/!5N7.M$#7KFH8/GF9X-&P$H9/P!O:&\2)%P;Q#J;S:.OO,L^Y[7!^ M&\_UJO-T]S^K,]>T%_2\R!]PQ2$-DR&DX3"$']Y#=@>T0A8DWC'HL#K#9CZIN\$($Z0^2>M'WT7%A_,^[ M89!X ?HW#'S$TD?/15[<"QDL'$1>$%1.XFU;],+X_SX+;^@41[XTU'9B4N\;*7AA7P?:[! MO%FP@]W?"B=_ E!+ P04 " ")1(18%F/E0R@& [#0 &0 'AL+W=O M='=-2'_]G5D[(?3DT"M!;*]GGGGF===G:Z7_-$M$ M"Z]569OSWM+:U:?!P.1+K(3IJQ76]&:A="4L/>KG@5EI%(53JLI!% 3IH!*R M[EV/BO#<)/UTF+.\$?I.X-GOWP)[,E?J3'VZ+\U[ A+#$ MW#*"H,L+7F%9,A#1^*O#[.U,LN+^_1;]QOE.OLR%P2M5_BX+NSSO93TH<"&: MTCZJ]:_8^3-DO%R5QOW"NI6-XQ[DC;&JZI2)027K]BI>NSCL*63!=Q2B3B%R MO%M#CN6UL.+B3*LU:)8F-+YQKCIM(B=K3LK,:GHK2<]>W-Y?/7R>PM/DC^GL M;& )D=<'>:=]V6I'W]$.(_BL:KLT,*T++-X##(C*CD^TY7,9?8AXC7D?XM"' M*(CB#_#BG7^QPTN_YU^=JPKA2;S"M31YJ4RC$?XSF1NKJ2+^>\CG%C$^C,A= M\LFL1([G/6H#@_H%>Q<__1"FP<\?\$UV?)./T/\U'Q]J'^9V__ T]<)A'_:Q MX6F)7B$7"]18YPASM&O$&NP2N5,:48)L0VPPU,KIZ^3N[V",'CA$A2 M\K&:H]X5 /QS)?*V9AQX%/8#^+&[>&P9H:9)IA:PZ.2R_I@D3D=\\>Y5?4K< MQ;Q$R)>B?D;R$A9":G@198.LN!9:B]JR?Y6T-'\LC/LQ8X1!RC?>+TH5:UE2 MA*H5J3J1,.QG)).D_1%)/#*1J]; :="/6#OIA_3F@4*E(6AI\POO-S(LV@G% MD1*W^2D!6I_.:-7E!11;Z"0!=3*PE*0$B_0_$(M M*1X-X6M+T]J!K)21;-OT61TZ]9]^R*)P]+.AUZ7,-R IZXI&<*Z>:_DWLR P M-):0"Z#M0916HJ&ZR76#A:>Q%%P8I-/4.ZV":JS&A;0D2'^N?E3-L=MS"E\) MSB <=[(G[WCMW'JCPJL[.DJ_L?&]FAY90>Z%X:#HECCSH@+XM@K932Z^/KVC MAM'DXQYG80RR4R1T7$HQEZ5DU!/RD/8NXZJ1&Z3M!%D_O^^%Z^G-]/%Q>KW? M#9/9;/HT@\G]-=S=3BYO[VZ?;J>S_ZL_M@SWJ;VCY=US@ZRH.2QQ 9J(!G*J M^0WM\%3[!1Q!&/CQ>.RG84H/B3^.,S],$V_Z5R/MYI0WP<*ECU+55F[H)VGD MCX.0[L(D\[,X?>N2XSB._' XAA,X'HU"/XU#./%N:TOM(:D3#:3CQ(^'&8R2 MH1]%(^]&OKILM.3#8>B/1D-6)U)!$)&V.SQP8!LJEIU@EA(')Q@'@:-_XMTA MT86] $!(UI(@II#%?IQ$74LF?A"-B/XP&GI/RE*G% $^2^.R$H8W_(>PC.'7_^WV\Y%99K;1ZE=S!Y883$M(4VHY!!GO8 M)?..DWG%R80NF\9W,VTI\R4,% 64I:.$ M)\L[#>Z^5ACF#0T S;&E.=FUNW$C- M^Y$O>D(O4WQL4&K9CMVN MWG*W4I-ZC_B"=<-SH$"8=0>Z.(M:V^V>U"9XXVA8NOV[VPK>53JE7RYH^ R) MX=L&H-8U[6U+N0*5$VF: K37D91=:L131Y]0I"KZWJRA0#JK;<:[WCYHJ1*; M=O(X5,JV[V*VQG:50RG(NPW/1AI2;A_E44N'7AY%C/MMG= P]A9-24'J-OB" MIE*CR:S'"HXL\F'L@SGF.^R7 V5+V='H^OL(4C\,,C^- HBIJ0-_E 4N;6[? M<.$P;(D=_J>IP/W2_=:B*Q3^DN"ZI (2=)1UMOMPZ- TV#O05JB?W;&=QI1J M:MN>;7>KNR^#27L@?A-O/RL^"TTU;:#$!:D&_=&P![H]JKV2OFY0LP"]7RAEMP]L8/>]=/$_4$L#!!0 ( (E$A%@/6='T$@8 *\- M 9 >&PO=V]R:W-H965T'W M#><@C]=2_:U7G!OZF:6Y/FFOC"D^=+LZ6?&,Z8XL>(Z5A509,QBJ95<7BK.Y M4\K2;NC[_6[&1-X^/79S8W5Z+$N3BIR/%>DRRYAZ/..I7)^T@_9FXEXL5\9. M=$^/"[;D$VZ^%F.%4;>Q,A<9S[60.2F^.&F/@@]GL95W K\+OM9;WV29S*3\ MVPZNYB=MWP+B*4^,M<#P]\#/>9I:0X#QH[;9;K:TBMO?&^L?'7=PF3'-SV7Z M3E-C*KE8$@$WGUSW[6 M?MA2&/HO*(2U0NAP5QLYE!?,L--C)=>DK#2LV0]'U6D#G,CMH4R,PJJ GCF] MO[P>32\O:#RZGWZGZ?WH=C(ZGU[=W4Z.NP;VK50WJ6V=5;;"%VP%(=W(W*PT M7>9S/M\UT 6P!EVX07<6OFKQ@B<=B@*/0C^,7K$7-6PC9Z__$EN>,L/G-&;* M/-)4L5PS%QV:_AS-M%$8_?4<\32];0;]#+^]$TQ6G+7K B.%BQ/>.M3*FA*9<$3!D!D '2%)!@ M(P=&0S/.E&Y!0CC*XPGI4:+M2:$J97M$ - MTVY;*I1,.)]K6BB9.;4'IH0LM=M'1^CI_)MYLIC9Z$/$+],9EE-$J-PG1%[>O5I$,C9P)YPK,9 M'+3)E4K"[H91Z#[VG-W:];"%C<]'-DLY"EWJ9-=PP5OR*?!];Q#&^,+/=BR( M/"F5#09&,#\#79@"HK?8V/=\'PH#KS^(:-#I4>P%_0&%A^XO'GAA?&@M!EXO M#JCO'09#NLMIP@M3L0DBQR;T=HY%:%VZ#7$$&092/>)T#;=._GXYH5'&E4A8 MSNB3DF6Q&W+-XB;4]B(-46$YS'C.%R(1+$U!:)UC??:XC<,:" 9'FLY7@B_H M\B=/2MMA6G<+Z''E$5JF4R@4O"0*I %:7^4<4*[=T[.4/_*9*M$3:5 ='^TR MMF?YQ&HW_=#8$,AS%\QU]-]:9Q2ETB6K)M])>3MOB6Z5*X*3- GL.O& M"_L"HR7/D\=Z^8O,F5EAO2E;UJ]_,.!'Q&R4#W!S<5>S!Y[63JCYV.8L>-,+ M6K^TFV?.TL:6(H9LQT8W<)RK@L'ACIO&&[VF53UUF[7M([OIW>Q3E=%-'VA9 M+LAN@_MN%5RV^=A0MWU/5/&TOY5G>\L:=\^JQS#3V- <&3+?C^-]&SLT6X[F ML"X7VSPGE<'1QN"&9<65WE;]8FXA3)W6 M'A+OF>*T#>,I"1A^#.JFXO9]@:9%Z.7Y;WA<-!W*17R,"A3X QK&?2\,8DL/ M@6ZK1H!*T_.]&!TH..RAY 3VKO#(Z/J M$OXD7CUE;IA:"C3WE"^@ZG<&O3:IZGE0#8PLW)5\)@TN^.YSA1<55U8 ZPN) MD*H'=H/FC7;Z+U!+ P04 " ")1(18"ZI)WN4$ "_"@ &0 'AL+W=O MX2>PD3;NV =(N MQ09LW6YI=Q\.]T&Q:5M7V?(DN6G__4C9>>O:XH# L23RT<.'%*VSE39W-D=T M\%"HTIYW<^>J]_V^C7,LA.WI"DM:2;4IA*.AR?JV,B@2[U2H?C08'/4+(9Y8XG^M.S2F2X0'=;?3,T MZF]0$EE@::4NP6!ZWIV%[R]&;.\-?DA/EZ@4 Q&-GRUF=[,E.^Z^K]&O?.P4RU)8O-3J;YFX_+Q[W(4$4U$K]UVO M/F(;SYCQ8JVL?\*JL8U.NA#7UNFB=28&A2R;?_'0ZK#C<#QXP2%J'2+/N]G( ML_P@G)B>&;T"P]:$QB\^5.]-Y&3)25DX0ZN2_-QT<7NQF/]U.[^^@?D/>B[. M^HY@>;$?MQ 7#43T D08P1==NMS"O$PPV0?H$Y\-J6A-ZB)Z%?$#QCT8A@%$ M@VCX"MYP$^30XQV]%&2]M/BSQM+!_)Z>%OZ9+:TS5!+_/A=O@S9\'HV/R7M; MB1C/NW0.+)I[[$[?O@F/!J>O0_]_"7D=XOKKS;P33GKP&Q9\+>$* MEZ:F\P?AV L\"CHN1[C4127*1R!YT& "LG0:1 DS!U^$N:/V\,G:6I0QPD(H MM##+#&+!FAZP_]LWQU$T.)W=?-FN^+GP]!W5M,MA?@4?:^?H*'[^?+GOE.T8 M!YVJ-KR3 V*PRF6%T?+='9N'-MFQR<2_+C*40&066"8?-_CQ;&1GS$.J* MM_X#CL?'P=%P KW.C+@NUENF7E-/6"L6UQ/;P*RD4K!$D"0QV>T*L!,ZY!=T,J[$I8Z6:P$D]R"+Q_][@N,:R.=I$ X@/E#G(LR\ZP*(LQ[TN]:WV.Q MI*Q,FF,;>&/V-ZB(4=*IC+850=>6/@%5I1J2;"7BN(F0M> >"SNVWIT76C$V MHI'JGI[7N >WU'Q,F^^V_H)M^GW9<+%TVIQ0<+Z:T.6:%$=32$5Z)E:>5 M,$K"^U)J*/]M@0AW2+"'A3\5;9UL67DI4SJ1/LO?:U)]%(XYH*)67#P)U,RT M\T3:6>PXHO!DR-*1U!0 ==/]TMPS7Y=H#VZ>R-*&^+2,MB?6UYOCF$MBU*DK MW10D"J,DJ4@8!_*=G[)TV'DLR&-/<4KB\C]*T6_H 6A#[JW_>A=?)ND3'FV% M^0QUM-DM=B_"-BVT8E"63:SK5D GFEA5E-D-!T8EW6-A\P!\7"BHPM=1O*3, M;M<*.GS6"UW3.GTUA&*K86_\YYI_1L5I.:,Q8F*;YO/,+OM1"64T%+8LE M$< =RG2[@AB-HUL4<.'+5-*)P0>Z>UGBRQ'ILFQO,KZ;^C[-^?:->D_6_8US MTM%*[MN^]83'D^ H',&(VM0(0FK_1Z.3Y[Y;_9U+18$F\U@#DLG2@L*47 >]R;@+IKDN-0.G*W]%66KZ/A3^-:<;)AHV MH/54:[<>\ :;.^OT%U!+ P04 " ")1(18$!T;/NLP #7EP &0 'AL M+W=OWC?R!"03X.WN M=@0MRV[-R,>*5G>\W=@/$%F4T"8!/@"4K/?K)Z\Z (*TVV_WRT9'6R2!NK*R M\LZL7QZ+\DMU;TRMOV[6>?7KL_NZWKY\\:):W)M-6IT56Y/#DU51;M(:OI9W M+ZIM:=(E-=JL7R2]WNC%)LWR9Z]^H=\^E:]^*7;U.LO-IU)7N\TF+9]>FW7Q M^.NS^)G]X3J[NZ_QAQ>O?MFF=V9NZIOMIQ*^O7"]++.-R:NLR'5I5K\^F\4O M7R=];$!O_)Z9QRKXK'$IMT7Q!;]<+G]]UL,9F;59U-A%"G\>S+E9K[$GF,<_ MI--G;DQL&'ZVO;^EQ<-B;M/*G!?K/[)E??_KL\DSO32K=+>NKXO'WXPL:(C] M+8IU1?_J1WYW.'BF%[NJ+C;2&&:PR7+^FWX50 0-)KT##1)ID-"\>2":Y9NT M3E_]4A:/NL2WH3?\0$NEUC"Y+,==F=SZ[_KC6SV_?/?A M\NWE^>S#9ST[/_]X\^'SY8=W^M/'J\OSRXNY/OE4K+-%9JKGO[RH86CLX,5" MAGG-PR0'AHD3_;[(Z_M*7^1+LVQV\ +F[":>V(F_3H[V^,8LSG0_CG322_I' M^NL[0/2IO]&!_F:+1;'+ZRR_TW:=^G_/;JNZ!,3Y/UTKYO[ZW?WA:7I9;=.% M^?49')?*E _FV:N__5L\ZOU\9+8#-]O!L=Y?O4ZKK-+%2G_"OO,Z913/E_!# MEB^R[=K0X_,BKV U2WK>M8BCPW0O@L96?W%L_?G>J!1@O-FF^1-">>$>FZ5> M97D*3=.UKJ _ \>^KC1TMMX!MNA[4YHLU_?I@]&WQN0:)K--2WAR^Z3K>P-# M4;?00N,8Y1(Z,W"2ZGOZ+ONZ==-3=R8W9;I>/^%SL\4I0%OLZB;/\-L_G=[/9)_H8__S\#)>E?VQ9.)H*9@=#79MU1C-_MRYN MH=&[LMAM(WV9+\XB G &S1_O"YQW\9C# -7NMLJ665H"NI[IV7H-O=>FE/EH M0-Z\2HG^5=0!](H#5 $L84R@*SA=!2!8A)MVIH^@ZM"AZO HJEYE_]C!%.NG M+O0[VK0;_5Q_>D98"(3 ;&Y-Z8A!%*($[E0\_KD"#K(M2MR315K=$RR@QQIV MUO]V=U>:.]HW 9-^3 %LVVU9?,V 1@ ^T\ZB<;]:=3K]?0@ZH_Y4S^*ISWZ M%$?QA'\;1_%@S+_UH\G8_CB<#NC3,!KV!M)D-)3&\"<9RH_3B7Q*HE[%3JMJ5]+\P 5Z!)^I!FZ_1V;32Q2#P+] V0:%,U( EOKS/S +B#6.@Q>UM4&2*+L@B: MWF9K'*PN=)EF%&0B_6CTLH#EU782FM>=XMJ+?)DQAA>E@F=XQG#QD3W2;F,CF1">FCJ% M8P>36A8[ %%Z"Q)+)]X$JX&1X*3NH$/X6=\5=FL2MA$89/Z<77Q7V:W]%D-EE%$I E/_.+HZ/'\P8F!Y.]J&I"\:KKE![MH?N40K010 >([5^[Q:B4*[D<^67 C"ZST#^0^:SIBD D<>#C?WA80V6*:=B MN7_$=B!NE32W158N=AO$^P7QBD6]@WYA\B"_5@#SW7JIEAF JM0X@3(C]K@J MBPTT+ZH RD?Q;NSP;GP4[\XM&;[V9!A_Z\*_HSUUXQ]VI3JZIW\4*](M:#N/V0K@V-[F>LZ*'("Q6_"N++\LX@ MEL/4UHB))9/6"FD(G.7;=7:7.H[_ D;#B5/;1]K''?R/PB.2T$0X:T![&E5K#Y> *J8B.3]K*$69/X=)OF7_!\/@&V+@QB(\#Q MK5G2#-\88A0@S%@&=5Z4V;R_,(#TZ^3$LX7M(@7X!^!L_IQ[=7'_]05@)25@+2[5\21;C_$X@5 M_00DD7@$GX>]832(>^JZ!:0X&O2FT60ZI$\@Y RGZC,M^2!<62J:1-,XID&F MT,%X-#U&)R:.3DR.THE/90&4#XX1,48X)UL$8Q>5.-I/-Y6PG:M&Y[KQLW$_ MPV;1/L+AJ^&D5"!AX$%&1-EM=L(4#/2^R$1\?A-\P^:(JG=Y]D^4=71NTJ$20TJJ-H9SC%Y>F- P<$)&7'BV,$T:!](13+\$PF: "NV(_6 _?C:E00L/#*'J2 MF;;AGGGXP?%9&A0L<>Z/]P8)D!:!#4=L7XF,@N0$&,:N!.WXS(E? 3H=V;;NHT8# M=1$I)$) HR[?SY!&W9H>)4]O82_T[W!H2(I^ MZ^0_8'-UN:,Y==&JHYUVTRH<21T?2=,[#_0.G/JE 7F4105<^+;,K%KXB-(> M2XH+DXG@6!F0$QS5 &@!GM$#LB*@7)@Z&9E-+2CM '=?-PP-T&W]".BL-FGY M!3H"A*]!P0-,0UF8Q? -[ %L(VTL'C!O1Q%CR!V(5X3Q3OA)]0I!S8N[ST"F M*!?W3[P<6%F!ZM,_A6YE.2!4A5-G/MD7&$3%6LZ46O0'QM' MU"J2-MT*34:#+$%)6]3K)X7]Y/8;=1NHW6NVV\'97/-1%# [W'.(]C,-SNOJ MNW7=Y,4>;%=RP/?[B(#;9 LG20H M6E;=-0V> "D;0;<\6)E57\X.V[00"BC)H>RU-;1GZZ=N4U>367GU05BA5U(S M3SK"N:%(%RG24H5 I,S&G$2\39_P)YY5A2274:3([TYI.]'NQ(=I V"Y8$UBG#1.;C!0)47"Q1HG=% M1;/: AMH EC0A'A Y*H+%H!0>&"A0AU:5W/]X?SUWOR%*#^DH&@S$D-#$+AT MR8:,TI"WB55]P3P\4.;KF?Z#!2)UY8'UTOZH@Q\;K/J/V?4UNG:N+F>O+Z\N M/_]=[6'9'MXE:EX7BR_".G[2O;/A /Y,SH9#]7N!$"=>$,>]LY[^'SKN#?&O M^HP0!P)[\76;E4]Z<#:=PC^]6+W)'I"V+/53ACHCML'WKP'U0:@"HHN+U_VS M"3P8G,7PJ&.IX7-2 )G^XEY855#X@!4<0Z2R5(*$#VW0&[5_W-QI:ZMDYQ\_ MG%]>7L:^:?4(AG6>@. M_Y5W*DW*F7KMM Y_]'>+&+='T>C81)->A-]"O_YK^H2)*N,#$*DHM#A.-7# M8=0;Q5$<3T&K&R;#:)H,]' 4#2?CJ#?HJYN<#P8L^>0.B,MS. .@$<5CT!PG M41_4P9/!)!J-)M$$U,'G^@14RC$TA5[@2Q^UQC%TEL"WV.XUP/"K*1<9(7_I MI ]T]YP$\X'V$[(!/(=Y\H,I/U 7^?(H'!+ X5/X?Q3U)X,H&?;@,TQSVNO1 MCX-^/XJ'O>^!Z'?V= !,)\-HV!]$TWZ,JX%VP_$0/\'/DWXT[(W@2W( +$9L MQ$M:_:0'&QD+*.R7;\*A3W-/1K1#\*F?#.7[=-H'.>8ZP 4BTC0BNHD"0@9T MKPM;@?XB2T%KD3=^@% *_4]AJV#5PXGN1Z-Q$HV2 8@LW8/I?W$P=+/ *(.Q M'D^CR7"J+](R/P5^J]8A\0Q/^=O9Y;7^?79U7MPLD'$42#NIG?Q(W4F*=)C@!C[FU M0CE:LQ?W: JV=HR_U@"IJ34*$,#9*$W2E^YK([ +U !K#!>%? Y/[Q^!C:%/ M!#W^(&F%)C\TBH$>L0"UCKU&FFT;*;T,+Z3E&C21C,PI9#1![H>BT6EN=C4: M$E=ENC$8ZJ%.4HVB4,:6*2<*7#(BS)#[PN+$2>N9! >@.&6A.@!T$2N;N'%U M\?O%%4#B6SCB3EB+30)'.P="E@&IIR :/3X;]^''#SMJA2LH4SJTR_2ITLDP M:3/'X5E_@"S363Y(WCAA71H8M&79GP*6[?GNWRW?#4:\1!,R2Z)QC\VJ-_G2 MX:?R1A;"BRTW"I!&S);(W!2Y#!"V:D/-UHF8>Y5B^ MFYNZ7HO1X*0?):,>L*P^LZBX-R!&]UQ]8BF2%3-Z^:4*E&PR_8B-Q=FO_@-8 MY3@>P;!]/0329BF.E9K9Q;79 '97]REZCT[B(1"GT1CIMW\]9'QPO-8%?/62 MMSUXI(Q@'Y/!*$KB ??1(/RX&S) !YU92K [G,1O-$P3GY&/Y>3!)A7GT"Y MSTO(\KEH-69F.!R2DUK]!]'T"D?/O5DQ) 2F!:;*6C,;AKC KP:HB_8J M1MVC/JFXYZ.A>D?-.6^, /RM\Y2?%U6W#>=X5]U&'-N_:O7?H+QHEBPMY)9V M1MYWOZ 6@0*T,L9;_3IB8@""?^YRMLZ0GPJ).JDHOE,R Q W)/T&W?8T#-DX M-KB__V0\=(J*M3A^PSK-JG= 'JR-)M!W[+MD%"<7"Q U%:IV! G4*6>T\4<4 MY BHN)_P0? 1T8+C, ;Z,!I /_ W.>JQB(.8NOAX=!:"!,\'[,&M:)K=*'2T MGP/A5]*Y"CMOX(]3T\F6@ZABY[,(F_A]"X^AW8E58(X[0X8@.[/_;N3T^ 6Y MZ)>1:FCQ:.DPRT@,X.Q-%1DIH'"(9P[IQ4Q(?@R:B1^3'X% Z.T@@8!8H<\% MMCJKS2G:NC&FR=KAW30;&.U0SJGZ;"P.[%& =#G[-"MG#]SN2B!HE;6J^EX< M;0LF93&9W !-6%FOD*62=T6QQ-B<,_U./@'_%7>B.&5X'H,CW":*CZOB< ]CXPBZ\9#B(TIC>UDV71B7 MO(BNIHH\U$M1ZCDZAS3C)I95.Z0_E6,PK; FAGYE64UW'X!UH>VF;A\%Y:W8 MOE^Q+U(&'@ $-84;Q8],U6&))5FE-9Z=(%*:*I%_K V);*"5KD[5Y8M0?W M3-SP=C3X)?F!R::AB96:>D^B![V2.)S24"^>NP4(F[$8 L-^0Z!(/"M(CK*" M2S*EK]C&=^E/W$R"CN!,=C*&H[UV,X9P*-4]%(HUQTBC/2H<>&Y*,:L"^.^S M;>4BI5!',6B2%%,I?@6>:P[15C2D=GHB(^T"<179.9L2Q"U%.2.B6&=IB1.V MQZ(/_/[H+OG8[_AHL/8K2VLYMHK\&&AJ#1E)Z-#MW+$?" =W)/[[AFTP>4NV M+,- AWK>R9I6(2UO2-P4I=-V]3<9"")-)HB%\I_,11UG()Y[<80+ZMALRNZB M7HQ$IK)4(=N@AYLMG37Y:]&] !K>>LU$ A#,H$I,! 90AY;^'8$$Z(]:L#5> M2'ASL6E DW>P!R2)TV#K[(LAGU6:$\U;FL6:?*NWF->")$\YAX!X$N?9)J.@ MBNC8IEK(G0#5@VU]'KKJW-;BJ1+X6#AT@ $(I[(K!'&K"4EBI/P5'W9+18]E M5M< RB5ZPT#4#]TMUA?1$)6632L6!S4=IYP^PR$^GN+PW;[TX_T<<*;;SE7H M/@_/EX^$R4" ;<3RAZXBDCR$&RU$5JBL+U2BKD,?8.#4R8,09Y'55-<@SJ]' MQBX8AH.S66[RP6OI#H1QV$".+@D#22]"HR/B-AR^>T34T*="!/6" MYJMLJ+&TL^'&-"#^-HF':)DILP<:BV?RFUD290X;PXN^,:I26 /&A^!:6.&#D'*[57*!\-0,"&%!^W*:I=R#)(#QP;=HZ1G\.D4 M?V 8Y=#9#OJ,\+ %P ]F=@!1:#",Q'1:+9%*CT6"+"UDXOA=!W7OI)41U>$1 M$0CD,/3FV;:G&,_Y.9NBR&H8(?/&.#):3!!9?W"":"Q@$N^#]4GA=_':$H:# MZP9Y?64HG!VF^N=N><<-4*"#H7:+VJM^Y+2%)KBA+O0I$)X# =/3;/'YHJ&3 M^ K,9&V.[ E%,(!"(%AR%D35A*^Y: <7O2:!U@T]U^\4( F>>=DT:DDALDYU MS<37%NH%%-GEY.@F\86&K45[1J58_J=3U"GW-M3+%+@7*$%L-LOO(OI*I)L< M4C!K=$]%FO->!+O/0L+H<*<;I!)9S8%XGD*TW 3.=2GGU25"5#X1PHDQZ1V< M9)8&*H4<9U=5+*M_*&"3IU&GZYN(R++8VE/]N=@"Y>PG(V!:2^+A@>$?F*>8 M)RGS1#P'&%;'/GKKU!'[O G#(II:GT.1!K4J*1XKS0,C X%;,EVLO<;WBD8\ M#'8TY+%(441TB3JPX6E("; +*[!7_ZX1T"@PN?>[DA(BP<0%.R/L"8BHLR#M M $/,)7_69R!$*HS8X, \BLJ3* 6RB@,B%!N N"&8#8.T!U[=TQ4\1EN\?$4MVOQK@4N MS$Y!Y0>RW:1K%7I'VVH P:"R*2N=[-5'ULTEOAZ-DTO/9TZ 6CW7H]Y(V\60 M1' N^0"2WW!NT:R3(K@)8 1PACXV/%?P4LE.ZQ4%+BSH-TEK8JL,2E'; G2/X,:5(E)@L +;5$ KI>(]TAQ-B@(&=U MZC8+@#X+0NO&D0R@Z/SAZCT13-A#"TY:.B*$YW.K74ELA#3-,\JJ=K8PM9+T MGO9NUD];I-^H%%9>Y0C/'3Q=2,X"\!ID]C9]V24 ^=K7 M\$)X$*SJPYL1/#W3?R R!\TB.X>*AF&.RF>C!6/O9_?!M$@LF88P84:W*?OZ M'HJUQ')(YI[#R[,@FY0WQL5W^Y=4$T NK]$%3Q!H93G!.EN9PO!+Y288;KJ5 MVSNS50.JJ%@E0GS+7S62/4'X@S+ @V&H=A\FR=F\&B M%M]X1[;H>T<.1 7LT](@-)+1DM.6 Z2"?JH5N>H.C!$04Q=)%,0)OFP<(V#A8D?O-<6B MH$=;,H6L^)(H7^PJ,>'+0C#L+A7RYJ1&XN2+IP5948(H?1L7+H .LN5#.9"Z M"+04 $Z;^I^!GACRE*P2NH*>)LZPM8XLSR6"O=I539;DI5SIILBQC@@YYU(> MW<^,LTZAWVU=->BVO**6%&37P:)DD6?Z E719K>6/%/W(:9EE3.7H<+O/+!L MSJXP74H\-F%H$=K3['@Z.S-G?/X8$5,'6,+\YD2ZL1B@YHF88B*6A4*)I%%F M>4@B<&*[BJW;0>A[2QH(Q0G!6L=@B*$QA]G?217*:+[^BRWJ0)1$VH5C.N[+ M^I#E5:A-K3%LT4GR#(]UR@Y*A ALR])FG5G^:IF"1%;*06[1P0:QN-E2-*GC M)4WBG2/T<1WD*,@+RD$@QQVOA%/8/=_'52BW"D1EA+)S#U4U^6QRSA@]TY@I5VGK7B9CO"U$WZ)3ZF+@MG)!8"[\YK91-?/77X;)/S"/@5#RT'(]3G M/&OR*"W>[P-TYW,7J15:I@I/.DGX$#+MU[$!::SNHB$=Z<*'-IK3<)Q+'F4 MBGTA*L<#,+ZHAF0-N+Q@LR_GYH1,P9&Y)F7.\$1_R<7O%1XP/N@=0C!#&A!, M<$X$E"6*T&X4%&^YH^:QQ3B$71.'R,+K+=@2=!1D8,N;U-*1.7NT& FI]2FT M5K@O]-YN2_J5-P(VS.4ZM65 N'?A:*E?3ALO0(HO;=S8GEH@BF"7D/C_C8QH M36#'A<3"2E>1(\5H)BDJ:W' Y:D. Y0'B0:N">XT4- X?TST27L3S2]\6CP>BBQSV[BO2LC_3LY!_N6G'7@7=- M>$ HX=P:FP&!"_I(XHN%@%WS2_T';$3@%SZD. 2$6XP>;"9&FZOWMSK:'W02 M9"*0/043 ](MU::2O1?14Y0XQ7Q""ODP/>NR$;, 1PD>Z9(=-@%;(*@U O(" MXQMZ=;/Z%',9V(5D371BE"7;LZ,:Z Y4^4-PSQ7PNJ;H50UK M#W9V+9 15LV@_ :KXUZ7$JR+/3>5E0ZR0W9?>-2]B 83R&K&."D)]L0E FDX M(EYA_I/GV["'P*J4:,:<,K8V+I&^"C0H6HMCR[S:3,1INP0:BV?"<=^++Z@9 MW:>>;W6OI6W[X^J$RZQR1?VJ3IG2KN06BW7EQ JMDA-AAOAC6X/A:32SO=Y< MSF?OWEU?O)M]OOSX05]?_'[QX>:"$GT/YOFR_T"JG#0JJIR+9T3R=2]>SS&5 M>M*/^@DEYB11' \DA6:*M9D&L;J9OY[I 9:7[,,0DP$\'(RB_GBLSL_G+VXN MYY3&FTRFT6 RLG^53;R+H\FH'PV&0RPB.9A@SB_\-!Y&TT%?O04I$-@15JP< MQ91L"D-.QO"]-QA$PVFBDRB)XL,15'_0E6F\(24CA_KC;U$];#G& ]S!&" M)1[WHO%P*K6F8.Q1'W_MPQ=85#*B;5'-;7&)F=W;H@YNRW@""Q_W*(\MF@SZ MLBWC*4PP[O.V# %2 +5X,$H0& #AT:2Y+0"=?C)4]F^X+;UH,![J<30:Q;PK MHTD4]T?!KB2C,>S34(_&O:&>#))H"J\BCD"C.'9;,H#M AA.ASJ9$N@'M'^# MP=3NRA"!%<-$>X,>C37LCV#G1K0QRFU,#"OH30?PVBCJ#1,]0;".)X@/6-LT M&;AM@0VD:J=4ZPLF-H['7/4KF0(NT5[!7@)232;)40>[KU$9'R]2^8Z)#8LH M2Y"/,PP41H+?Z6?_@7J5,H+:'T&'C]+F(Y?X$/J[70 ,X!C0W-RL)=A\U;0% M^1*CS4Y7DJHEK-4%3(EY483',6W9.H"M++ M-T"A4FB-<3)A%VZ*)+#+\K@&*(TG8U2-'!K5R*$YML^^#E]\O! ?!X>> M7#L,=+"L^/&^NO?YX 2EWK*,N0B?(+00:'")Z"PY'-'\6 4!-B(7-[/CDH? ML=@DA;,WY/+4Q6OAQJ'DK;J2$US>%<4[5EGM]3>66:/F!#AT-QQ;L&E_9A5& M9,JBK$7XIE0ZG0&P?0?$0YZ%3BR7ND1%2DS'S**VELG#,/=V3BM7L& !42 M=UZCSK@M@"22--H0J5&'=;JDTU:L3D&%5&&Q MJ*+$[,^"+392F)K*MAC-><$M4]N>TEG8P59 M95TTE!_#X7+2I] E^J80%X"6T0B$C$W/1)!/X >*W@)E2BFHO M(=3&'5/!3RDMS99EU"AP%C,F0;TYTQ^;NV>C_^4"#1JM\Z%(3=',W&[1L;SKS*+:,12>,&ZAI'A6_:RO/K-MJRT.9BK^AYQ*(; MUB[B6@A-PM*0#^P$&I* #:\&+6&SVZC6H(YOANNKG0$3([:#0IO"8<27$C2! ML>*D5:,<^T%GFA1%+(V-DZ"$ M55H*-50[N=VWTPR[-K%5TXU*BD'=3_:%C, M@BA\6:/#%NKX=L_ECJLEF]K2QY]8*E_+)52%K=<(+[FZ?\!(R41>SFUEZ5%.3!=,V *D?L3Y.VBB/&$6N"9!"?<)"MQ+;9SA7%(IHL M15,4A:.K99@)M@\=&\QAV1)5CJ-@#,E*I."KUE4KA@S[7;!60;7[/W= HI;9 MPM)HIDCPY(F(5TNF;EY^X%-*^,Z7!V'H:(8E:P@5F<+0;1^O6P?IHLJ:E5D! M2K_*33,=VTFFCS]%9F?J9]_G.F]1ZWLPN0=0HRD9]Q:MS.06S@#B5"&+FE$< M.-61(IN+NC/>H0M-!5.$JS2C7-) MXL0:>&^YDE6T\5TLI8ZTIY3*K*J;S-QE#R3=X;T9XB7LVBJNLBUW+/D3?(R* M^^I"R?'J0E0ZD(/6EE;N.U!?Z'A/!TI4=7??9?("0HMJ'^(-F:6*4HKVBC>+ MLO6X+^_M3F_AWR*W+!P-\W?I-LS7"*\(D=B9JZMS)R!*"RLD1BA0V&O0GEHQ M1I'P#2!/:@9T8(VE245V%O=IT!UG6>\JY,84"M=\51S4!(0U*W@3)JY@=MI-H*Y8:P^2VKBFXC"C.[A4Q MT6) NEK1I3=FR3MA;P]CMX.X_CE,J\3=P!L#RRHX_X1;SF]N7BC\5UYYUI/Z*J[$?)4F_ZX7] MVH^GNA\-I\/.WNPSBE@)"63832=3D O^([]@08_UONGSBMG&%.IR/$@BN.1NMXW>Z!+=-2/XF0: M%$VJ;,M^3$6FE:MG@PY6=$J/^@.!Z7=.%( -E&0RGGXW)'ZH^['' EMOU&^H M#1X-CQ@U[HW(SW_N6),6>0 >3V, ,:RV72ETSSJ$D!Q/T$/MWKUJ#'1\!7$T M G(\ZH_^,JK\T"A==$J7!6:N <$DKU"+L:D#1,I:>S"?OE$$B,C>:2CPL,CH M"@.B(E6'$E$D";6!N0N+]K#BZV\ILBDZRA?X$0T&2_@80/!5]5)91G$MY$(P MZ=S.D2^3^43:T>="SX)YSISH?^5$_\\N'O':B(348AWOO'LCU$QBA#JC]VRY1LW[*)K<3S%VV9Q=O8C MSF^/R TPT@6#0O0)EK"?2!7A&%8>PQA)0LT< 73D#SOV7SQ\'%GU2X;1^T 8 M!E@NOS$(;E^4C*?1-+%+X2B3SDY&/=B+I-_927\ __>F;33X/AJ(XF$\'%O0 M\A?NB2Z4$@>G+Y;KZP&(-'DB?[$"_VD7'<5PFG%""&4_/M=)@"^'R6KS$/R?/947G^8 %P#LN\.!"6V?'0 MW]H@-NP@KT)L32"&#P91KT_7>H" .1#RAR 0AN%MK6 P$$L!W?L@H4V Q"6J&6T5QAH- MDE$TB2>@B WB 5X@HAJW3]+KHZ^+6K- :GK6D 2^@8.0IB.58?7M(!?/[T^DW.I=M>:%/ M$*.>?\<80"_Z0( F?2$>8V2;4R"@ZAUYU?'U$S;O/&=!3@SI=L_"OE^$/9/5 MJWN:W01.!4?LF@=Y:JK2#34:F!A?W^FK8?(\.Z45$8*^0P"B&Y18MCDLT!R5 M1$3R."9U]+L$#2M.= H3@+-]. []\2"4 !K@MTQ^$KY\U4$@D>Y4?U4&0*8_ M<#!QEQ (1SW*TO\*#V^QT;UI:^*7?03OFP/HY>IXMVSS!U'U;A_5A8F.>R$L MD3EWO/N7C@6]_-<.!EZY@:+=9-*C^S?$$ MU-;>%"@+K!$O&?VV#QDDD.\=3N%P/S4'_*DYY%%COZ\?G1RO'SUG-S'N;Z>! M_P?J1 ==ZIFRYNKBW59%NU[-778L*)Q5K%W&R*K!ZD?['+J5; M68/<45=GB2O:*I.C[LUF1G;;2":S#&S6&4MDC=)-)3EY-EBVE@S4$LO..K8; M8K9\ $G'YCRQN.)N9M\/]/ C^-I03]^[8EX.8@P(!7MK2OVMK#MWI<)*KDC_ M!"AF^-JFF@LZ<,3S:H6Q?KCV3X[7'K\F1S- [9)K80:AG( (.7SF^)UN!]_W]:V^ MU3=Z@-[CI;8H$ _8T_%V-G]M"W1B\.>'XHR>GO9 ;@[CL^525JH@JQJ!VR<< M=3J.)\]?ZOD"=AVOY;(E9G"S/E'.'XXO+BY$(RF=K6<4'QV$IM[8"7CG'QYZ M%+$EP:ZB08(Z-DKJSC;\:%3&1@;A(&P*[EB29Q[DDIV3O]MUE&$IS<4#T^ + MMQH_7N;>_.]]1[Z\;&>\[FORIMK5(OB= RC;VS_?[&9+H=P!E%PS'/H4U'(5 M1OZX71GT8%'VV*U2;59Z?22'L%G7'2A6\X=6]BZ&7Q'O8E?!N8,F11O&_]D\:AV-_ MO"!&V<<4!V%'@4E:JNAC,J@])234D_VCX#"-98A#<"H^(*ZU3D6+SC"LQY&> MFSM1EFS%"L'<9-*%N?P:L2C;\@ &CQ5HJ8!7E13#H#:5M&DB;1"?[A^T\->9 ME[*-Q65,ZPGR:FW?3CE&T"F.+;O;T2T!ON"&33Z_S\PJ\+8O@?V1J0$#3TMW MW,\_OGG?J-#N7*;VAJX@IDX44+$8\2%/67"$I02MG"VMZ:(ICPE[JRM$G]$&UBU);;I*A6NB-2 M#6*TIMA%#"[D(#T[XX:AL&Z4^_<&P/_G!*M+OGM!WL(PX"XP\ !HM 9 >&PO=V]R:W-H965T[94?5Y*3RF[M!UJ")$XH4D-2 M=CR__IX&2(JR*46>J5LI1P0)-(#NQNG337YX2K/O^4*(@OU8QDG^\6A1%*OW MY^?Y9"&687Z6KD2")[,T6X8%FMG\/%]E(IS*090F+!.SCT<=_OZ"FS1 ]O@2B:>\<G'(X-6)&(Q M*4A$B)]'T15Q3)*PCM]+H4?UG#2P>5U)_RPWC\T\A+GHIO'7:%HL/A[Y1VPJ M9N$Z+H;ITZ^BW)!#\B9IG,O_V5/9USABDW5>I,MR,%:PC!+U&_XH%7'( +,< M(!5QKB:2J[P,B_#3ARQ]8AGUAC2ZD%N5H[&X*"&KC(H,3R.,*SZ-[J^O.\-O M[/8S&_6O;OJ?^]W.S9AUNMW;^YMQ_^:*W=T.^MU^;\2.Q^%#+/*3#^<%)J;A MYY-RD@LUB;EC$FZRZS0I%CGK)5,QW19PCA77RS:K95^8>R5>BLD9L[C.3,.T M]LBS:C584IZ[0UYG,DG721$EWRZ"R] MSU?A1'P\PF')1?8HCC[]XV_<-7[9LUJ[7JV]3_JG4??7WN7]H$=6&_9&XV&_ M.^Y=LFYG]"OKW[#1N#/N7?=@1CR7-S\/;K^V;6+O-.V;&"^$EHE)FDRB. KE MR4IG;!+F"Q8F4QQ4Z"R:%&*J[F5BE6;4>HJ*192P8B%8N%I!Q>1,.%!QF$P$ M4P@4*BODZ!46!!2L2.6((BW">,<\FKPG%YC01.4D>1$6 O!1U,-F0*"<13D+ MH4H/[B>6#R+3*!=G+.Z;6I3G?,:Y;9J ;W,6U8SBZS0UM M^$))7+>-0/<#1U[9NN4$VEAN>:=>WS%3]RQ?#SB7DP00X+D!V^-=3NU=SL'> M!8WTKSNDD?M1[_/]@ WZ7WKL;GA[UQN.O['.S27K_>]]_XY4U.9@>V=J=S#V M9^?7[G,Q6\=L$,T$.X8;/(LPRT^T;KI- MM/>.&6>.C1__S'&T+VD,/(BCXIEQ;IP9[.^,&P[]:F,$+Y'Y5ZMGV!PA_E;JZM]?7_?$NA]\OFL!300]%F@I& M12X=YTGM#,ZTV=FL="KIRDQ0]'QE$TOZ+AGG)9SM6;OV[2")VDADM(X+5NJ= MX30MHT(>F?I9V\KO8IQK=;+F]'_9)V<2V+0+,8^2A+10A@#]U2HXLSS==4S= M-WQVBG^;IM;'.8V CZ3".5TC#)TRQ]$-E^N,>4-?7+4#IL>WKKNOK/J#TA!T#CCT,A10T+$)< M#\),M'CEB-#A#Y%-HAQ"R5BXE\]$EM$,0C1XH:8>:CAW=L6P]L#CM!N,PW@M"+?;O'6%::)DDBZ;Q %4 ?(1O%WLVO&9I;N> MJ;NFK9D[)F-_<3*HTL LML<\\ $GV(-F?HUF_L%H]KG3'[(OG<%]CUWW.J/[ MH:0VHS8?Y6F<"JIQ'2H=T D:B*.*2%1];NND:B**6BIH<20S%WA/M#APAG;)P M^MLZEZPA?Z]]!D)J"B%)$#*;:$EF5QB:LW\B>GOC,4@GW&*9B5#!W6 T^+)*LPD*A_[ MMJN;W%8RMF(195CE! WU($7(D4%VUY@ .$%Y+F%68RW')N*I)57Y.KR!]N5L M\F*PBL\.. M<5/NG##,9433DK)L04VD,MS=68>*%FG*6JE08+#-/XV@J1]01 M)Z=SD:ZJ6Y]'12JIAN$^OVC4E&O9-07P,0)V&9G"*D0.] 2W+_;IBOPQ@-18Q[%R-* MJ,"H+%.Z&WR(VZ5C!%1 L+EV/[KH,!ML+; PA6_C(9S7\CRMVQV=W_='DB^; M/OS4=ZM?C6IP81+B=/DNO-)Q&#?Q@,@U;GF@R^#(G^&)RS#!'0[J2JP.4_H> MVH9MZTY@X@ ,L#Y'*T3%QGM6]K_K&5QPZ3B1OFP;@'=XP@) M8>G5=-?EM")/KID*(1PTE4HB5.>@]:N2",ZBH?LF,6A2"_<,W7."LB""N5V+ M[EIH8%.F*\VB;9NEIAKM9M%VFL7SL7&/V#+!DVV59O$"+)!;RBP.- 6M<=LU M21G0L.MOFP7: 7?5JM^F68"A(-7(X3#?-O4 M7UGVT%E%8>4Q;%0PS;D7(Z%%,!QI6&TVC < M.S "&]V 28[)?%(K V[# Q*C6JSP(!TQY %*2S,XYXJ38%"@#=+=<1\G\9)1>4@>SA'# <7]R][-B,IZN',[Z%_*BM)%9]"Y MZ?;8Z-=>;SR2M:2ZW#Q=Q>C2."3*"TRMBON=ZO9ETS*W&\NHG?B UP! M<(A],.#/2=\*+'5M4V>)*%3R; ,H<,+I5=5I.CM=TT:K&3B" C<#K4]P-(]( M.]5(Q!A)2*[2=/H4Q;'$$\)@U[)+G1ZX4"C; GQ[P<&:^%/BO8T75*1Q8]!P M,LEH=/.(R<&&*\-:%Z1R+AY"9!@EW<#C@$/%V.U+NH=3*RN^FXF@2<\G0*[[ M#K8FVK\#KKM(4%Q@_EM=Y4_-PEIPBF5HR]KC4YA-98R-Q$ MOLO!X8VQ!)GBRRWI&CV,,DEJU="G+"H$''R&;*-U=7N-H1)!93%/7E"G M[C9H5GEF98QWS*6^O%I]V5*KWX=BDA!;7KWMLJ4&MN$:YP%63@SHN+JD];T" M.9N('7$@=DRE4;],!3EV#I9LF:8<5@-@#7\D>-/8Z*>&UI5K54)+D:R]5 MAIE%"?"'G#9$JE6FDJ!XCF' '.J7*KNG;3A*[-$SI4-5ER?,;/C+;ECE%DP$ M2DF&+"]/F%7KN[D1)!@VD>]C=:&Z53-LH_Y&L43; ]VSN72K:A^X#GQ#-VV^ M99B_*.1&%+NX7E.:#W<%V? KAS%]D.K2UL@=7,J!*H?AK*]88EY^-B+/:*P@ MOH) DBC[)6G!'H1(F()H5,D).<:58#@8E#2]^D;2/-JT-2HZC% M.I5WG[7%R'RKV- D]!2;LGM?OI+0NG7UHWI) 1J.U-&PY.LB\$Q<&R8R1$F4\^: BCQS M3N0B8*Y!::>IC2'(/D.".&52+"-6/8)I\LHB>CS M&_IHBX&6PMTM,#0?$&=JUV'V7V;2(QYSXR8IO;]&(*"0CT M/2D_59'=EX0Q?Z@;GF[Z%C.!RY;AE5!2[B*GCPA( ?3N3P\,4U;T3*INL),2 M!W99KQ;Q($"C!(M>L($-0:%""VBYCP39D55/*PA^(KPTRSD[)H\Z.6 .X(4% M /*M$CP\"IL! %2[@G.J[E*8@#A)Y.C%ZJ.H;=:4?=Z4#._;MD93EQ2< M6_J^Z5C(SF\[&/3>A*B=[QOR)4J]()S2 46.O3)+#*!X SF!;Y=,X1AIJQ$ M6;!'^A2J+89LAQ PD$.GTVBZ=]L3OMN>LJW.=][X7!4T92X_RD7\)S]57Z[6 M=^L/?SOJ<]=-=_75, +!G"P5BQF&&F>><\0R]2&N:A3I2G[\^I 6X$3R&PO=V]R:W-H965T6$&NTI\XDN;W5=N*K#$ M%2N%G:K-$^[\\013)8S_A&<0>][; MBSS+!V99NZ75!K0[36ANX%WUUD2.2Q>4F=6TR\G.MF?S:3+O?>QWH3]Z[LWF MP]YH/H-D] "=Q:P_ZLUFT!T/._U1,N^/1S,XF[,7@>8<+J##M&:0R"4DQJB4 M,XL&!H,N?!YB_H+Z[U;5$D-W3S7=L>ELV<0_8%.+8:BDS0STY!*7WP-4R;6# M?_'>OTY\$O$!TTNHUT*(H[A^ J]^>*^ZQ[OZ 5ZG-+1B#"3IUY(;[J7U>4!K MT+>8FZ-.;R'KQR%=VMV9@J5X7Z&\,JA?L=+^_;?:5?3'"<*- ^'&*?3VK/O4 M>U@,>C!^A&0P&'=](-ULLIAVGY)9#R;3?K=WC/=)Y..\YQD&-!.,MQJ;<,,I$RDI2"M M+8%F*T7X&W,'>S>#G[@9/*!)-2\\\"/C&IZ9*!$^^?0ET.05-54C6!AUN$Z\/7O0JTN2GH+9@P5X%H3:*Q79@OA93#.IA%J_05S?[C>#9(TR M??N/N:>\!QB@BXO@[(4+;M_@;$<(SH./2BTW7 AHA'']*KR)8^A3BJZXY!:# M#W =7L=;G!.:;1XTV_QES4ZF8W@<3X<)%2C_]7&=]@94MAY@/H:D^^>B/^N[ MY6,:/GG3<0U_)Z;_G4?; Y&J;JNSY"2EO[;DDIY[2^;2F'U4-#3K9]Z-_CVVX^9'K- MI0&!*S*-+J\I#GK;(;<3JPK?E5Z4)5G[849_*E"[ [2_4LKN)^Z"P]^4]C]0 M2P,$% @ B42$6!O9&UL?55M;],P$/Z>7W$*"&U2M"1.WVDK=5L1DQ@K>P$AQ MH[]KKI9W2X_/L+9(U\7J,^GOJ$@UM2/ M=X"7+2![ 3!D<"N%R30L18+)OP ^L>LHLCW%2W82\1KC"XA"#UC HA-X49=R MU. -7DI9T9-6YK<'JX(+ UPDL/Q9YQ6]-0/?%FMM%#V6[\=R;Y&CX\BV@2:Z MXC'.7.H0C>H9W?F;5^$@>'N"=Z_CW3N%/G^X>K^\?OJPA+MW&XZAP1"OS1E'@[%.&?U.F<%XT"H#U^]XH" E- MZXFSB..ZK MN,*$!0'6+<]Z,F+,PLO8AG,/9./*"J ?GSO%J>B"PR2X:>^/Q MV$H#Y@T'0SCV4OR#!B]1;9HQINE&:F':7N]VNTFY: ?$7_-VS-YRME36@\U1*LU=L@.[_,?\#4$L#!!0 M ( (E$A%AS(]H?< 8 %,1 9 >&PO=V]R:W-H965TSN=3F2J]>B MV8]O]"4RU]7_L&K6TA8D2UW*>2.,'LRSHG[RSTTN\';]Y /.S!U?AU?P2# MX3@>7@S.WO0AOKGICV^@/>:WN= 'Q]T231K!;M*H/ZO5.T^HMQVXE$4YT] O M4I$^5-!%7S<..VN'SYR]&GLBZ8!K$W"HX^[1YVX"X%;ZV%,!D#)=97D.O$AA M4)2\F&:X68BU%J6&7J:37.JE$O!'?*M+A3#ZG;L]'L^$-9$Y9G)63*$TJ "%8PU(#RNN4BAG L[E?,&+NQ?/0L<.7FJ8 MKD-\RW->),(LKA8NA,IDJD$4J=&'1ROFMT)MCKC(.U/F[K:V,V/ >;$NI3X@3!9AT23R*G1?8% M364%H-VBX9-55L[@C"O%D5H^+C.=5=/X+UZH+ >'D=IWCS@N(Z'C/++I@(T? MPX#0*+JWF&'T,H7$5VX;Y]IL_7&(V@'Q(X]02N'@D0$7-\4(B]P'%G[2WB]% MFDWYXL'N[8C8483>A#\>P?MX[0I)NS%[ .E252A$(-T)K@Z%89A'$7*@C4%V M Q?_O!TAT;\I M#>_[@XO7XW[O,'[7'\47?1CU+^/!<#"\@/CR:C0>_!Z/!U=#N.Z/!E>]772S MUX-OIYN*E9% $#KF(.;\+R23A)=B*E4FJFCNXJ#LGMEYS>R&6\S*556X17K( M/R&33)'0A&EFC$4^1SO9EXI>K)JLGCJPHX?D\Q-B:+UO'(.X<6RT<2S>9:F0<*UDNJRYJ2G_AV!-=;Q**(5B%W/I$?X%(BCKT#L$!HP0D.&PA$)/4PAZNT&L8<@1H-N M@(@,;>)%@0$^9H!'GP0Q17/?!V/[:QC;040\I]DU@U.]ML>]-0[^[ MZM%>@]_1_HJ)N6%B$_MY@4]3TK=Q:68++9XJ&Z3JA05/9NL$O=<_,>VN:30V M.8FW[@DB\F&M^8%P6%6.[6R['R15OW;>0D]-OB ,(L1>9)L)OTH?&\_;-T.& M0]]%/+/ # /#Y!%F41B988A#&@6F+;+&FWT@Q!PD8A:ZUEB6/']($M.]OO-N9C>_&,3U1?E^>?USPR57TZS0D(L)BM).@/V)JJ_P M]:"4B^K:?"M+S.'J=2:00919@-\G4I;K@3&P^1WE]&]02P,$% @ B42$ M6%O74]+E @ &ULE55M M;]HP$/[.KSAEU;1)4?-. P.D\%(5J2^HE$W3M \F.8BU),YL4]I_/SN!C'6 MMB_)^7SWW/-<[$MOR_@/D2)*>,FS0O2-5,JR:UDB3C$GXI*56*B=%>,YD6K) MUY8H.9*D2LHSR[7MMI436AB#7N6;\4&/;61&"YQQ$)L\)_QUB!G;]@W'V#L> MZ3J5VF$->B59XQSEHIQQM;(:E(3F6 C*"N"XZAN1TQWZ.KX*^$QQ*PYLT$J6 MC/W0BVG2-VQ-"#.,I48@ZO6,(\PR#:1H_-QA&DU)G7AH[]&O*^U*RY(('+'L M"TUDVC=" Q)7X%:\ZT(5RS&19-#C; M<1RLT;512JVQ%CA;ZH\PE5[M4Y%.U;(5,"D2##Y$\!2?!O2[I[TT#V+.,;X$CS'!-=VO3-X M7M,$K\)KG\";D==*') B@2B.^89D KY%2R&Y.C;?CVFN$;WCB/HJ=45)8NP; MZJX(Y,]H#-Z_<]KVIS-\_8:O?PY],!_=3,8+];$>KN%?/^ Q#6>K'-S+R!4M/W04U8G<$PO=.'8.;(.!D&.?%V-.P%5 MK7HF--YFHD;U(/D=7H_C.\+7M!"0X4JEVI=7@0&\'G'U0K*R&BM+)M60JLQ4 M_160ZP"UOV),[A>Z0/.?&?P"4$L#!!0 ( (E$A%A/*2UCJ00 %L+ 9 M >&PO=V]R:W-H965T)NCM=V7VP=R7OXD/?< M\2X>I;K7&R$,?"V+2E]V-\9LSWL]G6U$R?69W(H*9U92E=R@J=8]O56"+VNG MLN@QQPEZ)<^K;O^B'KM1_0NY,T5>B1L%>E>67#T-1"$?+[NT^S)PFZ\WQ@[T M^A=;OA:I,'?;&X56KT59YJ6H="XK4&)UV4WH^<"WZ^L%GW+QJ/>^P9YD(>6] M-2;+RZYC"8E"9,8B\7]*OZ['B6!==B*(O/ M^=)L+KM1%Y9BQ7>%N96/'\3S>6J"F2QT_0N/S=HPZ$*VTT:6S\[(H,RKYI]_ M?;Z'/8?(><.!/3NPFG>S466#DAJ%LSGZ MF?[T^N/O[^?CVQF,QH,YG,SYHA#Z]*)G$-PNZ67/0(,&B+T!1!G,9&4V&L;5 M4BR_!>@AJY8:>Z$V8$<11R([ Y<28 YSC^"Y[5'=&B]X$V]A8)3KK)!ZIP3\ MD2RT42B+/P^=ML%R#V/95#G76YZ)RR[F@A;J073[O_Y" ^>W(TR]EJEW#+V? M#C^,1W?3,5Q?@0T0M $ZQ/0HUF&F\XWH9++<2IW7N2%78#8""EFMWQNA2M0U MWM5*%IBS^AQ>^'3^Q:>#01+E0J@V4/#/$=:YYO> E&R)N=I5R[Q:PW0ZA#EN MU)E*7L$[<(.8! [#+X\%)(K<8TY0.V%!JDGS[,LN?SW'>) "KY9PEPX2 @]< MY5;1D%=X+J&-77*CL*S +3<"ML5. SOS(=FM,=DLWPBH0YP@!LJ(&T4_0BX5 M58ZL4I&AOI:0E%*9_"\[.T0[Q\4\RXO9?I[-O^\:.^S,@62K\L+RB2$DH>M"3)B# M;&*?A'X$8101/PY^FLW5)/WNF#HPXT\-%52BPP*,(XD\%ZBE0GRD0TD@^.$>3'Q0_\_:?V P)O+(%$7%C MKS,5&BL$"EZ)RL#6*AZOYH3BI(/[!'!J#4HC$C(*IS7T7HUY![0.#HE#:@W, M.3Q[$+IPI([Z;1WUO[N.#N]F=]-D/ODTAEDRO[N=S"?CM"VPS1,XO4X^II!\ M','P=CR:S.$J&4ZF]*B.QNG=OM8.Z:"WU_"40JWKMDXCW*XR3>_3CK:=8](T3*_+ MF[9SQM4ZKS048H6NSEF(455-*]<81F[K]FDA#39C]><&NU^A[ *<7TEI7@R[ M0=M/]_\&4$L#!!0 ( (E$A%@2*DSR? ( & % 9 >&PO=V]R:W-H M965T=^66A'(GZC>QF8SZHM:, M M.$/_9M2S^4W"-XI;=6"#[60EQ*-UQOG \:P@9)AIRT#,[PEC9,P2&1F_=IQ. M5]("#^T]^UW3N^EE113&@GVGN2X&SK4#.:Y)S?1<;.]QU\^EY(O9!83^!PB\(#S! M%W8=APW?U2M\%1">PY)G*+6YN)JB@A_#E=+2W)*?Q[IN.WR:P+3.XBGDSB9+.;#Q7@Z M26UDGGQ+)LLD/:;Z).]QU?!_U<[&7-62F!V$F$A)48(Y*"Q7QM@?UC^1X&PF MJ9!4O\ ]$J8+""_A',( SL]&K,98"J7 6FE!D>7@VV6_!^?'=M$]N/4ERDTS MVPHR47/=#D 7[9Z/83LU?]+;M^>!R WE"ABN#=2[^'CI@&SGN76TJ)H96@EM M)K(Q"_,$HK0)9GTMA-X[MD#WJ$:_ 5!+ P04 " ")1(189YSAZ#@0&L)C%K&]K^^QTGD+978'N[TFF%%#SV MS#,O?L9Q:@]"WJLYHH;'*(Q5/3?7>G%:**CQ'".F;+' F%:F0D9,DRAG!;60 MR":)4106/,/X>/#]+T4_P2KM2_+;D^@G^;HZ4EL2"?[8EF4+X MVR%,9YRJ!1MC/4?45RA7F&M\_."6G$][ CS) CS9A]X8M"Z#]NU5 -US&%X& M,!AV6Y^AVQMVNC<#N.@W;X9!^QC.N_WSH$-#Z/8A^*O7Z0?M;:GL=;8]E>$< MK:D(J4-Y/ .N@&VZ%,04]!R!B#B^![$PK:1@)EFL<7(,="I,D=,0A 1\7'!I M9ED\(0'EF"M:61(O9 +2"QD9DTTB/2&3"M"P!FC/,1JAM#;[GF#0P*/.5PM, M>C=\.H5?J)7574?_)6E5\MIDO'61UAORZ<\ZWU+V;#'(*K^9^8%C_XUCQSC. M_^X%<]_$[?W'@AW\;,EV[%4>]AP'Q>PX*+[[.+CIWA#H73 P5'[%]6V=OQ?W M9SN_):(%BY\^?JAX;OF3@EC$^14J4\O7AP)3QN0MN=[1R;O3_'\X:-T\)[5U MM[VRFVQUR:[XQ#*O_)IAUEUJ>^B=5."(]*IVJ4)=5''WM.H/G)(?W_ATBG;9 M(7H5J[]%+5SPCXN5LHG,*]MEDV75V5$-_]AWBU0/]\2N5"F%\B^48\L>[&NV M4M9LI7DLZMFZW.>UKM7P6!-1^CU.ZW.S05<=]O!U;86W.MM M>PO"K\1@F4VS@ATOT3V+7G;H68N$- >TDVZ)'E[IY9C43-/BQ-(H(_!MKTB/ MGPI:+)*[]4AHNJDGPSE]&J$T M"K0^%4)O!.,@^]AJ? =02P,$% @ B42$6(_C)#95! [0H !D !X M;"]W;W)K&ULI59;;^I&$'[G5XSU7F?-EAB@>EC/ M!$FU/4H4IYC)F&<@<-$U?/NJ[VG]0N%'C!MY< ;MR9SS)RV,HZYA:4*88*@T M J/',PXP2300T?ASBVGLK]2&A^<=^K?"=_)ESB0.>/(81VK5-5H&1+A@>:+N M^.8:M_X4!$.>R.(7-J6N9QD0YE+Q=&M,#-(X*Y_L91N' X/69P;.UL I>)<7 M%2R'3+%>1_ -"*U-:/I0N%I8$[DXTTD)E*!_8[)3O9%_-QU/OP=0G=P&P3G, M1G<07/MW(ZC>LWF"\KQ34W2/UJZ%6\Q^B>E\@FD[<,,SM9(PRB*,W@/4B."> MI;-CV7=.(@XQO 37-L&Q'/<$GKOWVBWP&I]YS4069TL),Q00K)A ^,V?2R6H M2'X_YG )YQZ'TXUS)=)O[]^'8::+GO!^,!^-,A#,>3A_O1$$:SX)@#)Z\X[L#]"BL+ MGE#;4J@@9$F8)TRAU%T0A\"R"*(XR15&^M(K^-<\*SJ;.J5.A3H,U KA5V1B M6S9 2<=T3@FBQ!^H5B=I#!%3U X\QQ&2)U7']-RVV?2:I%EMD(YENJX'YU^^ MSX0L3[7 A;D-4=4FU(:G.1"J73<;Y(K7;OXWS%VPSS[@GATB/Q9CB+38,]DM MD7#3E*:?U$4N=\0U[OD?\?*)SH96_?R]Z7>[GHA/&/$4Q']Z"G;S%\![23%QSO9#^*8NT52Y)7LZ+[[*VO=1@H I+:0.C\42PNBDJCCR5( M#'-!II1)? F37+=E$;-=OB\^Y#N7I*'XV[385VU&"\:'S%8*H_>#XPM!.3(V M7HNQ@:?&1E 2E/G\#UWFQ/&P-G=5450X7Y<#A*9'VVEM'_\ $*#04?*!ND-0 M$,G:=DW+LG;/K]GWX7%GK^?KS'^$5LLQVTW",=UZ4Y^^AO3]C4F)](9-]4#M806AB+8M%2U)<\TR5V\C^[7Z7\\L5 MYDV]7 1OF%C&%/X$%V1J73:IXD6Y7)6"XNMBH9ES1>M1<5S1/HI"*]#_"\[5 M3M 7[#?&ULC55=C]HZ$'WG5XQRJZJ5HLT7"2D%I/U@U966 M+EK@5GTTR4"L.G%J.TO[[^\X@=SM%8ON"_'8 M.H4Q]=CS=%9@R?25K+&BDYU4)3-DJKVG:X4L;T&E\$+?3[R2\%L1O>;%*S/:[0;.JE(LOK67)>8J6Y MK$#A;NI-"OUF CV4KYPQH/^=3QK2 4F!G+P.CS@K>FV+JI [DN&.-,,_R\ 6/\<26+Y-" MM[]PZ'R'=&/6:"/+(YCLDE?=E_TZYN$5(/7? (1'0-CJ[BYJ5=XQPV83)0^@ MK#>QV44;:HLF<;RR15D91:><<&;V.+]>S5?P8(U!YYV9'@IB,( MWR (0EC(RA0:YE6.^9\$'JGI)84G23?A1<8[S*X@"EP(_3"ZP!?U(48M7_)6 MB$A5T^9QMA[&N6893A]Z[1O6"SNS]7T'B?[Z@:MBK&EYBGZUNO\SO M-H]S>+J'^\UZ\SR'Q=WWC6D4#N@%\;(I M0=B<0,U^4W\9:*AR"DQ!SD#MKICAU;[ST9!)ZD!M, >YLSZPDX):F3S&\'^# M&'Q'I@"KW/)2?;'YKM1.AJLI6'"1LQU M)INJC>O/D$]IT9#&B1M\"@:/J/48'LJZL>Z<0)17 Q_2Q$W2&#X.EC;/E,@7 M)AJT>?HOI>!LRP4WG!+Z#D;))S?V$SCWC+Q7O5RBVK<3RU:!M'9MW>_V0_&Z MFP7_NG<3=<'4GE>:).P(ZE^-8@=4-Z4ZP\BZG0Q;:6C.M,N"!CLJZT#G.RG- MR; 7]'\5LW\ 4$L#!!0 ( (E$A%AY"A1C0 0 #P) 9 >&PO=V]R M:W-H965T)Y/+?=V4;FDP3VH?V ;Q:[_[V6^ONLU2/>L.Y@>]% M7NJ>LS%F>]'IZ&S#"Z;/Y9:7^&8E5<$,'M6ZH[>*LV6E5.0=ZKI1IV"B=/K= MBG>G^EVY,[DH^9T"O2L*IEZ&/)?//<=S]HQ[L=X8R^CTNUNVYC-N'K9W"D^= M \I2%+S40I:@^*KG#+R+86#E*X&?!7_6KVBPD2RD?+2'R;+GN-8AGO/,6 2& MCR<^XGEN@="-;PVF_0O5>P8RX)I/I+Y+V)I-CTG<6#)5VR7FWOY M_)4W\806+Y.YKO[AN98-J0/93AM9-,KH02'*^LF^-WEXI9"X'RC01H%6?M>& M*B^OF&']KI+/H*PTHEFB"K721N=$:8LR,PK?"M0S_='MSSFX'H4;69J-AG&YY,NW M !UT\N IW7LZI$<1KWAV#KY'@+K4/X+G'R+W*[SHH\AE40B#_64TL'()(W17 ME&M>9H)KN!(ZRZ7>*0Z_#1;:*&R?W]]+0VW$?]^(':D+O649[SDX,YJK)^[T M3SYYD7MY)(3@$$)P#+T_&WT=7SU#X>1Z,O_U/6^/ MX\TWO+62.0XJ)@*:$=:0;1CF18.18#8<$U5L6?ER\BFA7GRI@3-5ME$8'NE:50()>P/'@6CB3 MIF!EU66L9##(C=H)#3_M] :&3"D&@']FWD-G*4Q&Y*@CAIW;&7NH=./1+X/O)=.(/3.*R! MD$QI2KPHL>0>Z@S:<.H3BGB!Z\-9:ZR-P"N&PPDKMI>P8D+!$\MW'-CR#[P% M:A,>B3Q*4B] 3U(2(U :$$I#B[;W[0RE8B\B2>Q;W^S\@BAMT0J\!&=&9H]6 MW M3DD1QY4G[#:-US[.9C>Q6=W[ MY9/$PQ_6>+C3=A!P$F2Q$"6S^T0?(H[<.O/-\U5'8 L%?M4./HU(ZH>63) 9 M^U4W$(I!NDE4'V(7.XX&_[X;DHAXV+_4 5.)$6%GPGW31G=U&[UW$79>;;2" MJW6UMVW^=Z6IE]N!>_@T&-0;\2_Q^KOBAJFUP'+E?(6J[GD<.J#J75T?C-Q6 M^W$A#6[;BMS@YPU75@#?KR0ZWARL@<,'4_]/4$L#!!0 ( (E$A%A&S31. M500 )L) 9 >&PO=V]R:W-H965TGW1;JOY"@NF6F*-)>TLA"R8IJE>9/]25#KG)3Y)4%51,/EVC;G87#7\QFYAS)(&EXJ($B8NKQL"_N(Z-O!7XQG&C#L9@+)D) M\=U,1ME5PS.$,,>Y-@B,/B]X@WEN@(C&CRUF8W^D43P<[]!OK>UDRXPIO!'Y MGSS3JZM&MP$9+EB5Z['8?,6M/9;@7.3*_L.FEHWC!LPKI46Q528&!2_K+WO= M^N% H>M]HA!L%0++NS[(LAPRS?J74FQ &FE",P-KJM4F)_"=/!7.H&S*9OEJ,XOVYJ@C4![OH6YKF&"3V#\ .Y%J5<*TC+#["- MFSCMB04[8M?!2<0ASEL0^BX$7A">P OWAH86+_G,T'(N"H0I>X4A5_-%\@4;_=]^\1/O]Q-\HSW?Z!1Z M?W+S-1T^WZ7P> N#F^GSX [>8P7CP30]QO@TYG2%3L87"Y18SA%FJ#>()>@5 MFNJH6 Z\]I(F+TFF$5Y0JDI9";-&F^M*8P9,V[5;S%"2VD0S76DAWVJMA?#K]N.8DQ%*NKW$ A9;N6ZK M1Q+-CODX#Z)L$G>3V3!?L7*)9"4L&)?PPO(*C>*&2PKN*8[1T.O%1H, MWTO,P/E#B&S#<_)0L295*^+[K2[)1$FK0Q)C0^2F/J#IM0*C';5\VGDD5TGP M:MIFP_E&![/Z5C*>8B8:S=BSM*-N*R:1E,)D;ZS_Q:0&LO\G\BS>YUG\TWDV M3&_3\3@='@9I,)FDTPD,'H9P-QISTW\1.:1&XO[+I^$CGICXKKMZ;I M*9FM+&IU=5+X;I0$;L_S:>1'7;<;)N\)>!:&@>O'/3B'LT['=Y/0AW-G5&K* M/&ZN;TAZD1O&7>A$L1L$'>>6OYJ2W9+W8]_M=&*C3J0\+R!MVXN-8RN%[X+= MA#A8P=#S+/USYPZ)+APX 'PZ+?)"E]23!&*WUXG=;I0<+8ZS TGBLQ>&VO_'L+] T_Z.U4C[H&$6*)?V64!Q M$U6IZ]ZY7]V_/ 9UPWT7KY\M]TPN>:D@QP6I>JT.E8&LGP+U1(NU;;\SH:F9 MV^&*7D\HC0#M+X30NXDY8/\>Z_\+4$L#!!0 ( (E$A%BEH%R4A@( %H& M 9 >&PO=V]R:W-H965T04I*JE?H1A71]F/;@P$VP:G!F.TGW[V<;BM*6='W8"_:U[SD^YX(O MT8[Q1U$ 2/14TDH,K4+*]9EMBZR $HL3MH9*[2P9+[%4(5_98LT!YP944MMS MG+Y=8E)9<636ICR.V$924L&4([$I2\S_G -ENZ'E6L\+,[(JI%ZPXVB-5Y"" MO%]/N8KLEB4G)52"L IQ6 ZMD7N6!#K?)/P@L!-[2R&%JG%LIAB3=4 MSMCN$AH_1F#&J#!/M*MS!ST+91LA6=F E8*25/6(GYHZ[ '<0P"O 7@?!?@- MP#=&:V7&UAA+'$><[1#7V8I-3TQM#%JY(95^BZGD:IH+L+ M-)ND\]E5,I^,43)*+]'5+4KGH_GD9G([U_MF\>+Z[@$=C4%B0L4Q^H;NTS$Z M^GP?!SNO83;J@AM);RV$I[A MZQ_@&V49VU225"LT991D! 3Z.5H(R=6G]JO+7LWG=_/IZWNJAFHVI-,0HZR P)K@F!?8,\)3\/@E<#.O)X?A-T* M@U9A\*[".9.8&G$(5[EJ:O\4'+RIE#?P3T/7?27X;9X;.N&@_UJPO7?S==>] MP7Q%*H$H+!72.1DH(EYWLCJ0;&V:P8))U5K,M%#-'[A.4/M+QN1SH/M+^SN) M_P)02P,$% @ B42$6& I5E_L @ 8 D !D !X;"]W;W)K&ULM99M;]HP$,>_RBF3IDU"30@%V@Z0* 0-"5K&0Z>IV@N3 M7(A5)TYMIY1O/SNA&9,@E:KQ!NS8][_?7IW\V4ST.CQ3C"8X M$R"S."9B=XN,;[M6W7I[,*>;2)D'=J^3D@TN4*W2F= SNU0):(R)I#P!@6'7 MZM=O;NN.,2]J ME3Z-X>'X37V4!Z^#61.) \Y^TD!%7>O*@@!#DC$UY]OON ^H:?1\SF3^"]MB M;[ME@9])Q>.]L2:(:5+\D]=](@X,6O43!N[>P,VY"TIME.]Q>"[-UQ-/+@?@;=8CJ?]I3>$U<(;K28P&3]X M,)O?S[SY\A?T[X;@_5B-9U/O;@E?AJ@(9?)KQU::PZC9_M[G;>'3/>%SB/X% M-.HUA=C68,:(Y21(< M4D_T=A@KC.51\L89R"]+\LO*)'M247T(,(!,8I@Q8#3$8Y#5,DW8(1&R JA9 M C4KE>[#D/IXD#V3RU$F$JHR@9454"G\P3RV2NS6&2N@=0;R=DG>_C\54"W3 M?K<"KDJ@JTJE">K/<<19 .,X%?P%30IEY9NO%/Q@_JY+W.LSOOGK,Y#7G;]= MPJE,=25[#8:HO?J4Y(UVBBKB 3QZK\IT[S73AS3)8A3Y\M'@WO&^*NIMHNNM M!HN("_.QYR'D!0!+%#%P 7TI]2UFI2BC:G>B"HKP[8-^:>X>4R(V-)' ,-3^ MG8NV_D"(HIT7$\73O(6NN=(-.1]&^@J$PFS0ZR'GZFUBNG)YJ>K] 5!+ P04 M " ")1(18F*?P08B(Z M+(5$W5DP'A.INOS)%"D'$F2@.#)MR_+,F-#$&/:S:S=\V&=+&=$$;C@2RS@F M?',!$5L/#&R\7IC1IU#J"^:PGY(GN 5YG]YPU3,+EH#&D C*$L1A,3#.\=D( M>QJ013Q06(M2&^E4YHP]Z\XD&!B6GA%$X$M-0=3/"D8019I)S>//EM0HQM3 M>S2&3?:)W'>BK8 M7PK)XBU8S2"F2?Y+7K9"E "V]P; W@+L/8 :N![@; %.EF@^LRRM,9%DV.=L MC;B.5FRZD6F3H54V--'+>"NYNDL53@YO1]\NQ_?32_3C"CV>SV;GW^_0=')^ M,9E.[GZB3V.0A$;B<]^4:C -,?TM\45.;+]!/ :_@QS\!=F6[=3 1X?#[2K< M5"D6>=I%GG;&Y[S!=PU$+#DH THT2=*E_()N0\(!W7#J _IU#?$<^.^Z/!N) M]38[$RGQ86"H?22 K\ 8?OR />MK7=8MD54T< H-G(S=>T.#*T(Y>B#1$M _ M<@A$DB"[2;+M=0=^F- _2Q#HUU3QH(F$6-3JX[2I3TMD%7VZA3[=1H\\$LZ) M$F1*R9Q&5%(0=?GF)-C*6/0QN1I:';?;-U?E1&JB>AW7M4H?7$ JTW6+Z;K' M6CHW\P.+U"*J!#:-OFYD/W;=6B*K".$50GCOX6NO37U:(JOH)QHX<;J8]=HY;(*BJ<%BJ< MOH>'3]O4IR6RBC[8VA4J5J-/[E3UB"1#\))2OJDM2)H)NF@#A N$,8I9(D.! M; \%9%.W&48'9!C5[PMMJHDNYH- MV^^Q*7"K%5U;;%6-=C4=;BR)#CWU0HD$)8D\P-6-HQR]8BVQ5379E6W8?1=7MUK/M<56U6A7T>'&@NA@5^IV]JMOL_00K=]@7!/^1!.!(E@HE-4Y48KP_*5 WI$LS9ZK MYTRJI_2L&0()@.L =7_!F'SMZ$?UXM7,\"]02P,$% @ B42$6!2EDV:> M!0 W!P !D !X;"]W;W)K&ULM5G;;MLX$/T5 MPELL6L"M1.KN=0SX5C1 T@1)LWD(\L#(M"U4$KTB$[?]^J4ND2R)YD:N]L66 M*,[AG"$Y#@ MM>$FV&QYVJ!-QCN\(;>$W^VN$W&GE2BK("(Q"V@,$K(^&TSA:&ED!EF/OP.R M9P?7(*7R1.GW].9\=3;04X](2'R>0F#Q]T+F) Q3).''/P7HH!PS-3R\?D7_ MG)$79)XP(W,:W@0ONIS?+0LU[!TNQ[VN7K !RA;U L)NH$E2L3*>,BJ-$N<=)@F.Q%\D/DO@!$]&AB;CQMSC>-+-0'AY'$AY7 MMRW86)2R?B*&'H2>?";=TF=7Z;/(C\JM),MU,[?E#;)=SS,:3K>[-7=\#U7E76@>JQ4&KWEP$^"D( _Y366[4J)W7:T]H]1A4R@8Z M?1<!())#AFJCUTJ$>_X3578DIJ%93;ZTWO:JG M JWV8J+,4JB21DBI/3H4E *HD2L-TS.:ZEO6TW1MVW7M8_Y66@:IM/8FC2J(@M41Y8Q)7HW2>S/;7%V@ART/FD8U:J0VD_I#2 M(8=+/HR8KN58S:F1](.FX^A'G:VT 5)K@U,2^.]7^X)6S[(!5;(!J67#:27 M:W];1:VI:G>J;[;Z!_-4&-1;JM)KJ$OO WR\J38,P/$*Y),&@ABL<9" %QP^ M$T#78%](_["0_ND+P4ZP#6*?1@0PCGE>60(&W@%K:.G&T#8=X'A#U_( \H:Z M;0X]RP6BW4%#.UUW[6G0#DY8(I)LLJ,M!GSZ'//\ZVS96AZ?3;-#HT;[#(Z6 M4-:.1G-9_P4:+67M4T,?+46,94_*DSNM9 RCT6E FNTZNU/+*=6620X'E!5\"TR<++@JL M]%9DKEP*P*D%%=3U/2]R"TR8$W=L;"+B#E\I2AA,!)*KHL#BK0^4;[I.P]D& MIB3+E0FX<6>),YB!>EI.A-ZY-4M*"F"2<(8$++I.KW$U"$V^3?A!8"-WUL@X MF7/^8C:W:=?QC""@D"C#@/5C#0.@U!!I&;\K3J=>Y=% *"[RB:LHW-U#YL0(33J7]19LRMZ63DY54O*C 6D%!6/G$KU4? M=@"-Z C KP#^/J!Y!!!4@, :+9596T.L<-P1?(.$R=9L9F%[8]':#6'F7YPI MH4^)QJEX-K@9#9_N1NCA&DU'@X?[P>W=:(:>>]-I[_X1#1[&X]O'\4@OSX:@ M,*'R')U-L "F<9669(C=I"K?+\O[1\HW?#3FFDJB M$4LA?4_@:B^U(7]KJ.^?9!Q"WYP0-#@W^'^"3E!W=_ \D5'^'I) MPE=,$9:A":8I]G@*"<\8*6\K2U&28Y8!(@PM,!%HC>D*$%^@#18" M,X4HP7-"B7H[U)6R5,N6,I-I'8>A%T3-5L==[QK^F.>WO:C9#B_KQ'=FPMI, M>-+,_&^GK7E:/Q+4P[J,18981)16&A*[Z*EM8ER^)4;Q9=V M?LRYTM/(+G/]O0!A$O3Y@G.UW9@"]1&ULM55=;]HP%'W? MK[C*I&F3: -)Z:8.(O&I(L&*8'0/U1Z?N%!=UDVB[X M4:<@&URB7A5S:69^S9+2'+FB@H/$==?KM:X&;1OO FXI;M7!&*R36(A[.YFD M7:]I!2'#1%L&8EZ/.$#&+)&1\;#C].HC+?!PO&=GDX +3#5P#! M#A"\%1#N *$S6BESMH9$DZ@CQ1:DC39L=N!RX]#&#>7V*RZU-+O4X'2T'%R/ MAJOI"&[&,.Y-%G#;FZY&,!OUEJO%:#;Z]GT)'X>H"67J$YS!F% )MX25V( ) M+TJM&C#%1V00PMT,\QCESXZOC3++[R<[%?U*1?"*BE8 ,\%UIF#$4TQ?$OC& M4NTKV/OJ!R<9AYB<0]AJ0- ,PB."!F^'!R?DA'6:0\=W^0K?G!%M2PYN"I1$ M"]F @7PNM#CK*65J]6YJ ##1F*NCZ:O8P^/LMM*O5$$2['JFE!7*1_2B#^]; ME\VOQZS_([(7B;BH$W%QBCVR?QWB"EACDG'Z4.(QOZ=)AE0EHN0:4TB(RMZ! M>=:F'QTS^R^87CAMUT[;)ZF7=,/IFB:$:RBYB&TF2I M%;AD5U5?S;.9-6UJXD6 MA6M\L="FC;IA9BXZE#; [*^%T/N)/:"^.J/?4$L#!!0 ( (E$A%@+:=#A M_ , -P2 9 >&PO=V]R:W-H965T(-%"M95@%T';>UC=@TL&L)K$.=M ^^_73M*D>P4OAS8\ M$#OQ?/-Y9NPO<7^*C8YX@E,):A/'3+Y>8R1V/8]X;S=F M?+76]H;?[Z9LA7/4#^E4FIY?HH0\QD1QD8#$9<\;D*MKVK(&V8A'CCOUK@UV M*D]"/-O.7=CS LL((UQH"\',98LW&$46R?#XMP#U2I_6\'W[#?TVF[R9S!-3 M>".BOWFHUSWOPH,0EVP3Z9G8?<9B0AG!A8A4]@^[8FS@P6*CM(@+8\,@YDE^ M92]%(-X94'+ @!8&-..=.\I8#IEF_:X4.Y!VM$&SC6RJF;4AQQ.;E;F6YBDW M=KH_O_D\&CZ,1_#U%L:CQ]$8FG [N)O!XV#\,(+):#!_F(TFHR_W<_ACB)KQ M2/T)G^"6<0F/+-K@&=PEZ4:K,QCC%B-C_VV"\1/*?[J^-@RM'W]1L+G.V= # M; B%B4CT6L$H"3'\$< W4ROG1]_F=TV=B$-<-*!)SH &M EJS20J!VRS#%LS M@VT?@)U&3-LE 5]3E$P+>08W\C75XM- *;.6OHV- =QIC-7>,.3HS?WH=B5> MJ90ML.>9I:90;M'K__X;:0=_.;B?E]S/7>C]+QN;'1!+X-J2-XM#[>.8H[0R M%+NXMWT2V%_7W^[QWBJ]MYS>)\C41J)9V#HOG#.82KY >!0FICSB^M590$[T M$R/7+KFW:\UZNP;NG9)[QQGW$9,)F&T9(LZ>LC#O8]CYF'-R(.$7I>.+_YOP M&XDAUS#/=,29;2?TB1&[+(E?UIKMRQJXDZ#:UX-?D.\"Q%[*C'<:G>;^E)-W MJD*.W&/N)0MYLH(A>U5N97 BGAHO6C&FM6:[@/_%]"L](D[).#;=;A#:HA": M/+D852I#W#*S9]W/N'J&6XDFCHF1'E0:9DRCNRR<7DZ-:Z56I%5O6=2A5Z02 M+.+4E&/+HOUQ%V@UFN<'=H%*_C&,(]FJ Z$^_$/C5RE6J1 MBWH37X=TD4J[B%->CDV\&X1"G+^-DY_N"[02)NH6ICU%,;>OY<5KH*LDW,@G MQI16HD9)K25!ZU X6BD<=4K0D251@/RP%P2-UH&]@%8"1=W:XMH+AGS+0TS" MGZN!V\FI(:PTC9[76P%UB!FMQ(RZO[V.K(#6AX^ _WX"^.\.'&*4J^Q81<%" M;!*=GSV4=\NCFT%^8%$-S\]])DRN>*(@PJ4Q#1H=XU?F1REY1XLT.[YX$EJ+ M.&NNS6<#2CO /%\*H=\ZUD%YH-7_#E!+ P04 " ")1(18-=2XY @$ !J M# &0 'AL+W=O?9E9NANA?RNEHQI^%GD7/6/X92YD034.Y<)5*\EH M6@85N>M[7N06-.-.OUO:'F6_*]8ZSSA[E*#614'EKQN6BVW/(<[>,,D62VT, M;K^[H@LV9?II]2AQY-8H:58PKC+!0;)YSQF0ZQ$)3$#I\35C6W7P#D;*3(CO M9G"7]AS/,&(Y2[2!H/C8L"'+".:>2D7 MLXQ&^1DW^S[5$K]F&*?[T^&G\>CI?@P/M_!Q+N%I.H)W?[SONAJ9&#PWJ68=[F;US\Q* M?/@LN%XJ&/.4I2\!7)10Z_#W.H9^(^*()5<0D OP/3^P$!J]/MQOH!/4RQJ4 M>-$9O$&2B#77&5_ H\BS)&,*O@UF2DL\Z/_8%FR'%]CQS.V_5BN:L)Z#UULQ MN6%._^T;$GD?;&+_)[ 7TL-:>MB$WK]ABXQSHWQ&<\H3!F_?Q#XA'^!/RM>8 M6X#8].] VR6H25:;OM_V.F$[[KJ;0VFG?D%,@OC [P7K5LVZUBZC$_ZD3:*X?:SSU*]U3F*[EMAN M9#2FDE]BK8(5_45G.8.,0R** LN%6E)I%3EL6]:[U8FC]A'?QJGM5P0:;D=< M:XI?IPDS 5=S)B5+00O(!0[W0B^PHN:XF2D:I,[L0N-3H7$8^20\$MK(Y_>% M=FJAG6:A/#W( 38!G=.39=NH4[?CQ/""'_&>*Y_7R/">*74-PS5N <&ULM9U=;]LX M%H;_BN!=+&: W9H4/T3-)@'2).T4V\X4R73V8K 7JLTDQLA25I*;%M@?OY+M MFJ)$G9CR42^:V"$/R<-7\F.^$G7VG!=_EH]:5\'7=9J5Y[/'JGKZ:3XO%X]Z MG92O\B>=U7^YSXMU4M4OBX=Y^53H9+FMM$[G(2%RODY6V>SB;/O>Q^+B+-]4 MZ2K3'XN@W*S72?'MM4[SY_,9G7U_XW;U\%@U;\POSIZ2!WVGJT]/'XOZU?P0 M9;E:ZZQ MSV=J%BSU?;))J]O\^6>]'Y%HXBWRM-S^'SSORY)9L-B45;[>5ZY[L%YENY_) MUWTF6A6H'*@0[BN$W0I\H +;5V#;@>YZMAW6=5(E%V=%_AP43>DZ6O/+-C?; MVO5H5EDSCW=54?]U5=>K+NZN?KZY_O3^)OCU37#][N[R[=O;F[>7O[W[]9?@ M]N;WFU\^W00_7.LJ6:7EC\$_@D]WU\$/?_WQ;%[5;3<1YHM].Z]W[80#[= P M^)!GU6,9W&1+O;0#S.M.'WH>?N_YZQ",>*T7KP)&_QZ$)&2.#ET=7ST$NL,. MB63;>'(@WL%\7"MY5>EW^QY6R743FCM@1EFJZ2;*%?%"08TG=.D()9 MHX\/HX_1!1EC#AXIF#5X2LQG+ADGR7V]MMBX9%'4D:2CF BY5&Y)TA8+4+!? M5_EZK8O%*DF#J_R++FJ0\SA=PL%]9P@KFIV*T*0B1%?H/B16 I"BV0DP.$-! M8 TRGKB"U7,5?<3W55.GW59Z2+;0F62)<&;55:? M0K?*U5G]EWKB%K!:P4:\)PLIFIT2 SE4X*L5%6^PHMD),(!#080 U"I[*J0J M$C%G7;FZ"DI%F1S0J^$/"@-(_76S6B=9/3GEIMA^SM_5XU\M]!&G5#"R]QPA M1;/S8(B'*GR1HB(/5C0[ 09Z*(@5@$CC_JDRI%0HT16IH^#V>Q)UBS0T2!+" M2'*95L5F51HHO:H_\C=IM7CR5PJ%])PDKFIT(PT A15=IB$H^6-'L!!CR M"4&P&%;IOIY%G5QP*7A'I8Z"G/#Z7SR@4@,E(0PE_]J4C[ 449=4L*+9HS6@ M$W)\*:)B#58T.P$&:T)X\698BJ+_81V26/6EZ"@HF.1BX%,]-,01PL1QJ]-5 MQA&Y@)(WQ-HE(,5C0[ 89B0GCA9EB3JB^UB*G^ M%R-701(3$O(!31K "&' ^*"7JT7]%>B[&H/_!;?Z89,F!2Q0U*45K&CV*KP! M&4;PU^%1 08KFIT S ,7L09%.B^GJT[%0HBNV=-1\E8U@HE YC)#%PP&"Z. M4&C]UBF+]G 'O.=RBD48UO*4)C"5<%VE*1"(&01B(XVE?;VV1)5B+.PNE3K* M18J*B PHV; )@]GD."6/6N:'6_:>P2E69ICA)(;O/3%48L**9B? $!,;Z3^Q MOK/$&8V["U..8H(2,@"PS( ,@T'F. &?9@G 7?">R"F6;YBA*X9O6C%4M,** M9GO\!JWX2-L*KN?N5^ :($(@>VR&FCA,3<<=#3C6 ]P57U%@1;,39XB.XQME M')71L*+9"3",QD<:9;QO@%$E&1?=55UW0<*C :N,MR[+@?'I.%6?8%# [7O/ MY!3+3=P@'<=WT3@JJV%%LQ-@6(V/=-&XPQRCD@K2NXS+43"44-]#<]L8CH*<<,KC M 2T+ U("!JGCM/RBV0&WXGV!XA3+5L( F,#WW00J2&%%LQ-@0$J,]-U$WTYS MFQVN@H()3@>^*PK#. )FG.,$>[PE C?G/7%3K%$) UD"WZ83J-R$%B[;[5P:V[H"M?ETM4E!PP188!&P$#S?G6O?=T0.*3WU$RQ^"0,-0E\ MNTZ@!6_>> MQ2E6GJ0!)HEOZDE4.L**9B? T)$<:>K)OE777#K610-',2H5'[B)01IHD3"T M'"'B418(W*SWY$VQ0B0-/4E\%T^B$A)6-#L!AI#D2!=/]MTY1E5/O/U2E,N! M&\.DP18)8\L1VCW-_8#;]Y[#2>X@:]U"-L$]9+@WD4V!4M*@E!SIX\'U/-P/ MA$#VV PE29B2CC@4<*P/N!_>BIABB4D:@I/XAJ!$Q3*L:/:-E0;+HI&&8-2_ M08V&7*G.B=U1+))RX"*CR,!2!,/2$6H^P?* &_>=0:QH=JH,OT7X[EV$RF98 MT>P$&#:+1KIW4=^4$UQU+R]RE)(1&5@@C@PP13 P':'@4YP.N'7O&9QB]2DR M&!?ANW81*IEA1;,38,@L&NG:P?4\P"3JNWIA+ 96YZ+6C?DP41VA\A<]$+@) M[YF<8K$J,A@6X9MV$2I1846S$V"(*AIIVL'U?*3<-_4HX0-7@RI#0@HFH2.D M?+P[ K?EO<_#%"M7RL"8PO?U%"IB846S$V 02XWT]93+UXOZ]XNXRA%)Q, " MB#+LHV#VJ:?F21?5MR#)EL%54FZ2M'[A:9? ;7C/U10+5[FRHR"-PYC* 5Q0AG,4S#G> M*<-:"M\(5*ALA17-3D!KOZ611B!_0-WS'N"IU@UBPU-QOA^9HQ*A%C1[ 08(HQ'^IEP/9^S/[*?&1O8BV'8&W., MG& )P;WQUL4D.W.VMN:<8&].W,TYI]F=L[T]Y^C].1W&)N%G4JQPG22T]BHE8STGM7 "67]W4H=)16C*NIN5#YO/;]DK8N' M[6-=RF"1;[)J]T"0P[N'9\=<;A^8TGG_=?-,F>US44R8W0-I/B3%PRHK@U3? MUR')J^::C6+WB)?=BRI_VCXEY7->5?EZ^^NC3I:Z: K4?[_/\^K[BZ:!PY-V M+OX/4$L#!!0 ( (E$A%C&V9B//14 ,[ 9 >&PO=V]R:W-H965T MA MF ?%9A)M;G5]/;MT3EZDZ'([X[HB_RKH$^- M\+?7M>6FJKYU']XOWA[YW2G1)9VW78R<_?=(+^ARV85B)_+[-NK12Z7=@>+? MN^C_Z%O/6G.3-_2B6OZ[6+3W;X^2(V]!;_.'9?NY>OJ%;EL4=O'FU;+I__6> MMF7](V_^T+35:GLP.X-546[^S[]OD1 .0.3 7A[ !X>$!TX@&P/(,,#@@,' M!-L#@K$'A-L#^J:?;-K> S?+V_SLM*Z>O+HKS:)U?_3H]TIZOL\_F7]Y\NK[U/EQ[[ M?I9=7K/OV5_7GSZ\GYU_81_>G7\XO[S(O.M?LNS+M7=^.?.NO[!?/F:7[",+ M*43Y:4;;O%@V/WO'WJ_7,^^GO_Y\>M*R)G0GU] MXV7E@B[V YRPMK\ @'< 7& PXHS.7WL$O?*PCXGBA&;C#\>*P[/QAR.@->3E M@J<%+4P.PJ5?%PJ/? MV:C94"\O%U[5-W_^4->T;+V\:6BK1& 3.11:1PB)PV@ @EP,!V%(P@$*X'E. M1"%\02$$4;C8:ZOWM[\D&*&_>Q_IHKC+UZJV@_'49^NI[HM0 B<)TS098#.A M-BTVT0LVD::'L =JW3[W78/^_E"LV2.N?>65M%4!$TD-0B1-I3M#42S"<10/ M&@Z>VL2&QR\-C\&&]\_[X^KV^*&[+P[>!;'4DIBD"?$'#9:+(1\E:8@'+0;/ M:6*+DY<6)V"+WY=M7MX5W8AW\/HFY%1W7I+RD3""T)*#+#\$$]"%*,A!G(YPH9_,AS7X7.< MB@'G=P@F>#L,A"NON6TF<#3U;4,4#SZF1TDT1,@%*T2<%B*8%UY4JU71]$JV M*.?52MTK9&J'2$Q0@H<<4%42Q1%*Y+O#!0]$G @B#1/D[=Y28F7#9=K&VHU3 M,GPVJ JBP(_QD/W"IS6UV9SC(9CD7>?+O.[N@FYT?,KO#HR$,FN+0Y_X0Q(S M4Q=,")*NM@N"ASC#0S#%^R=%OIEHZYJ_ZAZ(_^V_4+9?YGDX\E.42L] M1<$P(B$:JCKX#"S_/:^J]+YN'.B_GU&-/Q'5>/GM?/]+5#:U_4R)FB(N>"HF-.T3%,T4&>,H%!JQ&S1,6WB+D@]I@3>PP3^_%SH7 @$_PL M$?DM?BYD >&R@,"RX,/*%0>!%3:A,#:Y$O5=O.&(YXR<" 3_*QJ$EO1]O'CFH3 FN3ZGMW*7DOKE7=; ME'DY[V/Q#:$BA3 @$@NA HA L4 @N42_HR0=,1Q?%HVA(O4P(!:+H0 M+X2+%P*+E\_TL6BV#.>J+JK:NZ+LO\4K[S.=+QG.Q6TQ[Y!+"5Z*+M>M['4[D!-5 M8BREN"E*89(0?YC>!9_=U-9S3AR,X<2C5K8#.5/EF*3#,7NF*H8Q&QR?! M: /.:(,QC'91-/.J9%V_FZOKEG[ZJ]YP0&[H;553KUBM\Z+N]=9F7*R+EAY7 MM[?JP5&1P8QPD RW,\P4!<,8L4>'-#JZ8*X!9ZX!S%QAL#9]QCOQ?EI63?/S M1,SD7)ACDG2#Y1 S1<$88Y)*=Y8+?AIP?AK _/2:MNVRE^@=(:W8F/K<+^AT M?'5>-0?VB2@28N((H52B4)8FY+,I@?2;23BO#$=.H?-E_U?L[V7>LCZVSNM# M,CU4Y%2S^V;X$()K-X!I2B ]3)R)AC 3'94:$S6-W"Y8:#YF-ILE0W\_@ M:DSP<,%I0\YI0YC3CEN8#V42FQ D;>28P969H.*"PT:S^"M(S5X/>75Z4RGLK4NP23'Q,AL,O7+,) M1"X8;<09;00SVMD!?5WNUHWVEHV>]P3VB2"O-XCVA7M%3AOE?$ZDF,(E4>C' M0ZVI*'C@\08W<"J G/1&,.GM%MCDMGNW=;7JM%.GP7<3VP>QZPL?FNE0K]XI MP96)]3%K)Y-C$KJJD@?@=4&>(TZ>(Y@\?V!XPOAL9W[:_+L2$YE8'R/VM(S1 MD#\H2X9^&L;#SIG!YSP5$TZ>(]TFR+*IEL6BGZ]H6O9?/^/#'@$"+,?>#T,G MT^M#T*E*'H#.R;LRA)=EP$S\_&5(^_ RI'VI\[*YI77C?>Y>WE,RC&Z>/<;" MI+TUWA^>@Q5@^)1-5X"M1LML1=N_7%P[1+!V%!<E3 AT&SU:T??"XBHEA%3-B_O"=)L17I'SRQ++8.0YPR$:*X1,>CF\, MJ O-$W/-$\.:!YI\A \UZ8)6L])M1=M'C(N<&!8YXS?MQ IE<:!+61(66X!< MR)28RY08EBD_/LD)5V#2\:SFH=N*MH\KESJQ1NJ,FOR#@YA@9S7UW%:T?>RX MUHEAK3-IBA".:0*E51UB*]H^E,*K!F$=8KPK)Y:7+(YQ&DJOJ(#K-4;)A>2( MN>2(QV3LC'I**/)I#CPEK&H)6]'V >):(M:DYYCOJHGE=0UU1[(J%VQ%VW_- M)9<+R9A7WV@>F' ,@Y%J2J##T-F*M@\=%PN)R9*'=IQ*% I U;W@6HTQW MD/&I6\=P.T\*GZ;I/*G5:)FM:/N7B,N/!)8?H^9)$\4"AR)7#Z[*&!@7^B'A M^B&Q_>;P1+&6$3&8AJ^1@RLVALF%5$BX5$BLOD0\4:;;RXF-<*W&&+G0 G7 M (F5]XTG"N;?IS=*SPBKU-]6M'UPA#>36W@UN2K;7I7D"-=EC(P+SI]PSI], M?X5YHB#WZE1'N!)C2%S0^Y33^]36Z]!3.6'I.,1QFN+A4 -7:0J0K6C[ '$2 MG[I^*7JJFME'D@D ?![&J+F@]2FG]:GF+31CY@K?:8)\Q4KNF2JHOS*_$ YO MC*@+YI]RYI_"S'_*#.([3]0G.T!$T5 M'+[+3PR&]!2NV!@F%RP^Y2P^A5G\^(G%5,'>-_GSDBV(5?YN*]H^0)R_IYKW MPYM/+,(1#:;/I@0"@'1!\E-.\M,Q"4?PP_6=)L:A$4XA#!1I^W!P8SA=R(*4 MRX)TS(K ^-%-H1#4HYM5A6 KVCY(@L<1K!"F3D>F*O70)5-'$CFVJAYL11N8 M*8EN2K!^N*S*W6[=J[R;M8!F#37!3*<-[8;+K(4;@"GX+_DCM0:?/53#J'CC M#$Z31'K_B*IDF@8$2PX3\)E-;CL6VJY9"#C4D;P_O!]^Z;ZF/(URPIC.]X$BG[ $LVJ=+ 6;H"@X 'EP^H!ZKY_QD1W37O,[PBK&L=: MN,'U%+RM?%CFC+XC;*4[38H$(>C$)T6[6@U?K3J'F2%]-JRD]U" M:C5<9BW< 'G1[=:.VIIB0JM^Q-NRL]TAZ$2SB?:X&G_<@WW7Q:/:E@_N[EK8 ME7!N7'I%FUZ-3^_4%ZDAAH.7+$R*- (J0:MI#'L/=ML_I5"S MY?*[NXYVA9H;#V+1A%CC0CQZ%+?=_.-,VJYVLQHNLQ9N M +"@W30&T:-2GC5!C$9@6=S)R=/9I KUN BNT4AC&WU54S9V+G9ODQ92Q^9[ MN=!*N*:X/JOA4EE2Q[(4=F(SC02?::0QFMYEX)SODDOV7HCUZ>5=.6JXK*DT MA:=U$J;#N:QL4HTC\!+DE\:+VCRA7A/1""4Y"T^-DA-A))A*(XVKM&$^O2:< M$42RLL(!HPL21$X$D6 >C33NT2/3Z35AC*"1<^=01! >OO=^4I4CL!'TA<81 M>DPVO2:&$3!RTAQ!B3_:&HPPDW!N?TH3$()-B>L6S!E1AI7YG'O*=%$ M,8&&R/PZ16$JCU!.;)61X*N,=,;*4UY#H@EJA)0B<2U.T'!C03:IRA%("=QZ MI(WRA[T,4),AW9JG\B[2/EGR_8A(3-*)83(2').1;!161NKMBSKZG+'!PG1%]P348:V^0)TPQ$)NVJ??N:FLVA M8 M.:'^@K9P.2'=@N\RTA@OFVM%A:3,2W)N1 MQKYYZGYYI/!O3L*425^I<]ER7MY"YL3(&0E.SDACY6PZ]V>VP]Z6*?,.?+OD MWXEE-!(\HY'&-'ILJJ0M&^@94OA.QP0/'\;9I!I'0".P>XUCM+5^:6.^VI9- M].XBV%4:3DRLD>!BC30VUJ.[L:PME-LR;3E0[_!Q(BT$1VNDL;0V[3*AR!C*!.--[;=OJD ME<'5II:9V0V760LWN%""--*8?H_NPLF(CC?3U&8.CQ-QU%N [W\E^%\CC0'V M5_3;^W*^?%@PVC]_:-IJU:^F+C?9$??%>NNY6S)M7N;+Y;.WH(]T6:U9]^Y^ M6#_4\_N\Z1Q4J]OVJ;LUBI<%D)V^:._SUKO/'ZG'4S >^SN ]7UQ/UX7L2]7 M5JUW0VFY-?OM*FOZDK?LT_98^GU.Z8*=]NZFFE=-^_HK_BUKVF+5WX JS^HU M:V!GR_Q?6E?>HEHN\]JCBB/Z2EY_);_Q#86= 6P_D=HUNWG(V=VZ;< U;=OE MQC_V?#=K\5IUU4Z:>TK;6=[F9Z<,ZCMZ09=+UH:NV[X]ZFC$R[?L,MQV5_#- M.WQT(GU_@=[,D.)[=H^D[!?6*U2_13[[C74)]ML)K_[L=)W?T8^L99T!\Y+> MLE/Q7W>^2W6WVK?[T%9KUKF.O)NJ9?VD__.>Y@M:=P78[[=5U>X^=!4\5?6W MOKEG_P-02P,$% @ B42$6#674"6]!P 8CH !D !X;"]W;W)K&ULM9OO<^(V&L?_%0V]N6MG=A=+_@'L)-@9!LEOGOV38*-GH^$OM8CZ6O[XE'(+]F6 M]_O9Y6ZJ/^D;**$IYFD4B1Y.O+WA5^3UV2!Q0E_A/QQ^SD,\I_RKT07_*# MV>JRY^0MXC%?JAS!]+\'/N%QG)-T._XHH;UCG7G@Z>=G.BU^O/XQ]RSC$Q'_ M$JW4]K(W[*$57[-]K#Z+QQ]Y^8/\G+<4<5;\18]E6:>'EOM,B:0,UBU(HO3P MGWTM.^(D0'/: T@90.H!P9D MPQPZP'>F0"O#/!>&^"7 ?YK X(R("CZ_M!9 M14]/F6+C"RD>D?_XMN*%K, M/E[/Z&QR=?TSNII,;NZN?YY=?T2W-Y]FDUFX0-]/N6)1G*%K)B7++X@?T%MT MMYBB[__QPT5?Z=;DS/ZRK/G#H69RIF:,YB)5VPR%Z8JO6N(G+\03"Z"ON^'8 M%^2Y+SX0*W'.Y#ODXC>(.,1M:Y ]?,J7UO#IZ\-)2WAH#_]IG^IPYVSM]/6U M8TM?NL?KRBUXP1G>K=3)3ZJG-^@V9JE"+%VA\(]]M--92:%?/^GB:*9XDOW6 M=N4!T?I1N>Q7:18W":$%=!5B$&C M@[$6HIG"("L-(6$4"&:H-3RJ-;2JM5!B^64KXA67_\H0U^L+]=0FF9725;)A M'C>SYE@1.$&!256MT]>C8U2-K5]_HY9Q> M].NA$:5+D7 4BZPU3UDQ7?MZU!P>[G PPJ/ZK-$L&/A#)_#KG0W9.@H$,_3 M3K5SX[$&CWFN^F7IW\[L[."N*&@[SMNX WJ"C8+DI$3 M>"-_6!M9H VD4#13(E))1*P2S5+%-5HXU#2#"T= MA_@D&-;%;)9\2[ ?X%%]7Q2"-I%"T4RE*K\ VPV#AE*K*"O%XJN7M +U$$J: MH97>"+6,.U 7 91&H6BFFI61@.U.PC6WK#Q 303<=!$P<7!;FH2L-P2E42B: M*5?E-V"[X?"915F>$E,MVTZ*)>>K=NF"IA7C>4&CKR?V^KI:K*"T$)1&H6BF MWN!)W.)GK_E>VESI(L$?M4M0H':E'@ID=!6A;NPIWZ>U#S=0EP(W[8?#>K*N&F2M(2B-0M%,U2K' ]LMC[M4 M#S&IHC_U8%OQ-9?YJ%M'*4N7A44HLC-"@EH@N&EMD($[#+RZD*-FML;ND-0= M$-#642B:><.V\D"(W0-9<*5B7E@?Y=!J$\0.Z2H(*&T*2@M+FGE++,!X5!OV M%*I:4[?* B%V"V3.5]&&[="/G,5JNV22HUD^K>6W#=%$)#N6/KU!GSY-T*]S MGMQS^1OZ"TU/]P@WQSW"L4BK]*"V"2AM"DH+06D4BF9>'Y7_0L@W?'R @#HS MH+0I*"T$I5$HFBEZ9=\0NWV3;R/%&I63;C&X]22;W.MB;<\'?;#C.LOGFD)'? ME!#4RP&E42B:*6'EY9"7O1P]"'FFHH0I/=$^WY=X0FSU^SY3A9)HPZ*T54Y0 MNX!76. M0&E34%H(2J-0-%/TRE\B=G\I/,ZQ^XRO][&>:A]XEL^^4:I8NHGN8VYY.M-. M[ZRZO:TN>N),MK5C"MJ.$)1&H6CF,_"5/>7:[:DY^_IBQK8C.C_L#FI.@=)" M4!J%HIG25@Z6B[]AQG9!;2E0VA24%H+2*!3-%+VRI5S[8T'_9\:VTSNK;F\K M<34NX7)3O,28H65^Z_3P9MCQ[/%%R:OB]<#:^0E^ M/SV\[EAA#F]?SIG<1&F&8K[62.?=0._ZY.&%QL.!$KOB!;Q[H91(BH];SE9< MY@7T]VLAU/-!7L'QM=+QWU!+ P04 " ")1(18V?),SQ\& #Q-0 &0 M 'AL+W=O;(I@R6,FSM(53]21>9K%3*K-;-$4JXRS M61X41TW::G6:,0N3QG"0[YMFPT&ZEE&8\&E&Q#J.6?9XR:-T<]%P&D\[;L+% M4NH=S>%@Q1;\ELN[U3136\V",@MCGH@P34C&YQ>-D7/NMULZ(#_C[Y!OQ-YW MHF_E/DV_ZXWKV46CI:^(1SR0&L'4QP,?\RC2)'4=/W;01M&F#MS__D3_D-^\ MNIE[)O@XC?X)9W)YT>@UR(S/V3J2-^GF(]_=D*=Y01J)_"_9;,_M>@T2K(5, MXUVPNH(X3+:?[.=.B+T I_U" -T%T&,#W%V >VQ >Q?0SI79WDJN@\\D&PZR M=$,R?;:BZ2^YF'FTNOTPT?_W6YFIHZ&*D\/;\<]-;V[&7\DO?D[M8G;WY_.VA*=06:TPQVK5UN M6Z,OM#9:96>$=MX1VJ*T)'P,A_L\.".NDX>[)>'^\>'/6F\JV0KM:*$=S7GN M"[QQ_N_A&;GA$=.]6"S#E2#?/O'XGF?_ELD# G6.GXL5"_A%0R6QX-D#;PS_ M^,WIM/XL$PL3YB/!+"'=0D@WIW=>$/)R+=0>(<@H^+$.19A7A&\3M8]<2QZ+ M4BE=3"DQ83X2S)*R74C9!OODAS ))2>1*J8S$B:2)8OP/N*$":%^1-:"S]>1 M.CKG99*"Z*J2PM?9(X^<9:),/CBP7Q9H2>454GD@Z9)E&2.C9$9&0J1!R"07 M9#(9@PD,(JM*A GSD6"6E)U"R@Y^ GDO^V_3!3)7 4!.DZD4+]1@<\?&"Z%D+Y#39=M5-BPGPDF"5YOY"\ MCY_??4PI,6$^$LR2TFF9$7<+-\-W/&\OQ?O4ZWG/$AQNMJI&6#1;I#U;XIR< MY$;(:2'DU9.08);#C5?MFZ@T'XMF"V\\C4/Q4]U!]36H-!^+9NMIK(T##O=_ M(=O=@Q_TGM=WGR<[JF/!HMD:&<_BU&A:7F%W7S0:8SBRLH9(-%M#8V:<$]V, M*ICY4SV2SK6D.W'!*HEJ=E!I/A;-5MOX':<&P^.@.AY4FH]%L_4TIL=!=CW. MH>UQ*.WWVL_K)*KMP:+9*AGCXYSN?+YF;,;)9Q9S^$DDW%3ESHAJ=;!HMLS& M[#@UN!T'U>Z@TGPLFOV4W!@>BFQX=KS]Y*;T\(D&W&SE!^!U&!YJ# ^%#<]) M8Z!7V.V7QT!P9&4-Z_ N=&\^!IZ0.:8^_LJD#>ZL#>ZT31WNAAIW0VN8N:&H M4S>H-!^+9NMIG!"%W4KU4MD^*)6>?OA[4"M1O0X6S5;)>!T*>YW3:B7,=EI ML42U,%@T6T1C82@XI#^J6/K\@4?I]GG:5QXLDS1*%X]PL40U.:@T'XMF*VY, M#NW64"PQ#9CT6P]C1VBL!VJ7BQ[A^-*MZQ8HKH9+)JMDG$S%!S=GU@L M8;8'U$I4!X-%LY>G& ?CP@[FJ"G'!4^"1VM8"19*N,G*"UA0O1 6S9;;>"'7 MJ6$]$.J<#BK-QZ+9>AI?Y,*^J'*AW/&L0NGU2A85P U7EJF616A[J]#@J9J3 M*N4K;&A8"8=6%K$.!^,:!^/"#N:84CGA3&B=V7T8A1(>3\+-54YK5!N$1;.E M-C;(]6HHDZB3.J@T'XMFZVD6J0X;XQH;X\)S M-<=D^%]I.MN$402G-JJU0:7Y6#1;8V-MW%X-J8TZI8-*\[%HMI[&!+FP4:F> MVOV#U&Y3M]/3+P[8J8WJ<[!H]MIQXW/:L,\Y;?4XS+Y.9GR>\\MZ&QQ<548L MVE;&YM[K-?IEJ$\L6X2)(!&?*WSK3+\]E&W?+]INR'25OW%SGTJ9QOG7)6&PO=V]R:W-H965T?[4#&-&"3]B:VS[[[_\X/E]:& MBQ<9(RIX2Q,FVTZL5';KNC*,,26RPC-D>F;)14J4'HJ5*S.!)+).:>+ZGM=P M4T*9TVE9VU1T6CQ7"64X%2#S-"7BO8<)W[2=JK,SS.@J5L;@=EH96>$:)F M?'./VWSJ)E[($VF_L-FN]1P(MONPYU"K'7'PMPZ^Y2Z$ M+.6 *-)I";X!85;K:*9C4[7>&HXR+T1 F=S"=3>!N M,AMW(7BP[6,P>8#9<-1]' [@<0+=_I=%, ^L^7R BM!$7L 5C#&B*Y+!/9)$ MQ2$1" &3N2 L1.CS-"/L'9[&F#ZC^-YRE>8VZFZX9>P5C/X1QJH/8\Y4+&'( M(HQ^#^#JA,NL_5W6/?]DQ &&%:A5+\'W?!\6\P&+K5%2NB&KSF5U-[!IY&V0: PE0?WH0A9.QS2O,];F9$0VXY^@!+% M&IW.QP_5AO?Y!/!U"7Q]*GIGAFMD.<(/.#N$5C@WK;-YZ6M]+#7OINY=M]SU M =EZ*5L_*?N@"T_ 0IXBG(^XU/?I"$#]#X!&T_/J-T?T&Z5^XZ3^D A&V4KN MU#,4H&E2?5KV+ER:1T]#0W7D>A1XAN=)%SG9C_5=!81;H^27G:C

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�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end XML 95 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 96 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 98 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 427 522 1 true 147 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://relianceglobalgroup.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://relianceglobalgroup.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://relianceglobalgroup.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://relianceglobalgroup.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://relianceglobalgroup.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://relianceglobalgroup.com/role/OrganizationAndDescriptionOfBusiness ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS Sheet http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinations STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS Notes 9 false false R10.htm 00000010 - Disclosure - INVESTMENT IN NSURE, INC. Sheet http://relianceglobalgroup.com/role/InvestmentInNsureInc. INVESTMENT IN NSURE, INC. Notes 10 false false R11.htm 00000011 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://relianceglobalgroup.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 00000012 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssets GOODWILL AND OTHER INTANGIBLE ASSETS Notes 12 false false R13.htm 00000013 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://relianceglobalgroup.com/role/AccountsPayableAndAccruedLiabilities ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 13 false false R14.htm 00000014 - Disclosure - LONG-TERM DEBT Sheet http://relianceglobalgroup.com/role/Long-termDebt LONG-TERM DEBT Notes 14 false false R15.htm 00000015 - Disclosure - WARRANT LIABILITIES Sheet http://relianceglobalgroup.com/role/WarrantLiabilities WARRANT LIABILITIES Notes 15 false false R16.htm 00000016 - Disclosure - SIGNIFICANT CUSTOMERS Sheet http://relianceglobalgroup.com/role/SignificantCustomers SIGNIFICANT CUSTOMERS Notes 16 false false R17.htm 00000017 - Disclosure - EQUITY Sheet http://relianceglobalgroup.com/role/Equity EQUITY Notes 17 false false R18.htm 00000018 - Disclosure - EARNINGS (LOSS) PER SHARE Sheet http://relianceglobalgroup.com/role/EarningsLossPerShare EARNINGS (LOSS) PER SHARE Notes 18 false false R19.htm 00000019 - Disclosure - LEASES Sheet http://relianceglobalgroup.com/role/Leases LEASES Notes 19 false false R20.htm 00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://relianceglobalgroup.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 00000021 - Disclosure - INCOME TAXES Sheet http://relianceglobalgroup.com/role/IncomeTaxes INCOME TAXES Notes 21 false false R22.htm 00000022 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://relianceglobalgroup.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 22 false false R23.htm 00000023 - Disclosure - SUBSEQUENT EVENTS Sheet http://relianceglobalgroup.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 23 false false R24.htm 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 24 false false R25.htm 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPolicies 25 false false R26.htm 00000026 - Disclosure - STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Tables) Sheet http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsTables STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Tables) Tables http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinations 26 false false R27.htm 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://relianceglobalgroup.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://relianceglobalgroup.com/role/PropertyAndEquipment 27 false false R28.htm 00000028 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssets 28 false false R29.htm 00000029 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://relianceglobalgroup.com/role/AccountsPayableAndAccruedLiabilitiesTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://relianceglobalgroup.com/role/AccountsPayableAndAccruedLiabilities 29 false false R30.htm 00000030 - Disclosure - LONG-TERM DEBT (Tables) Sheet http://relianceglobalgroup.com/role/Long-termDebtTables LONG-TERM DEBT (Tables) Tables http://relianceglobalgroup.com/role/Long-termDebt 30 false false R31.htm 00000031 - Disclosure - SIGNIFICANT CUSTOMERS (Tables) Sheet http://relianceglobalgroup.com/role/SignificantCustomersTables SIGNIFICANT CUSTOMERS (Tables) Tables http://relianceglobalgroup.com/role/SignificantCustomers 31 false false R32.htm 00000032 - Disclosure - EQUITY (Tables) Sheet http://relianceglobalgroup.com/role/EquityTables EQUITY (Tables) Tables http://relianceglobalgroup.com/role/Equity 32 false false R33.htm 00000033 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables) Sheet http://relianceglobalgroup.com/role/EarningsLossPerShareTables EARNINGS (LOSS) PER SHARE (Tables) Tables http://relianceglobalgroup.com/role/EarningsLossPerShare 33 false false R34.htm 00000034 - Disclosure - LEASES (Tables) Sheet http://relianceglobalgroup.com/role/LeasesTables LEASES (Tables) Tables http://relianceglobalgroup.com/role/Leases 34 false false R35.htm 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://relianceglobalgroup.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://relianceglobalgroup.com/role/CommitmentsAndContingencies 35 false false R36.htm 00000036 - Disclosure - INCOME TAXES (Tables) Sheet http://relianceglobalgroup.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://relianceglobalgroup.com/role/IncomeTaxes 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfRestrictedCashInStatementOfCashFlowDetails SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW (Details) Details 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT (Details) Details 38 false false R39.htm 00000039 - Disclosure - SCHEDULE OF WARRANT LIABILITY (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails SCHEDULE OF WARRANT LIABILITY (Details) Details 39 false false R40.htm 00000040 - Disclosure - SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) Details 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) (Parenthetical) Sheet http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetailsParenthetical SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) (Parenthetical) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfFairValueMeasurementsDetails SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS (Details) Details 43 false false R44.htm 00000044 - Disclosure - SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfGainOrLossesRecognizedFairValueDetails SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE (Details) Details 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF DISAGGREGATION REVENUE (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails SCHEDULE OF DISAGGREGATION REVENUE (Details) Details 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS (Details) Details 46 false false R47.htm 00000047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables 47 false false R48.htm 00000048 - Disclosure - SCHEDULE OF ALLOCATION OF PURCHASE PRICE (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails SCHEDULE OF ALLOCATION OF PURCHASE PRICE (Details) Details 48 false false R49.htm 00000049 - Disclosure - SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION (Details) Details 49 false false R50.htm 00000050 - Disclosure - STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Details Narrative) Sheet http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Details Narrative) Details http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsTables 50 false false R51.htm 00000051 - Disclosure - INVESTMENT IN NSURE, INC. (Details Narrative) Sheet http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative INVESTMENT IN NSURE, INC. (Details Narrative) Details http://relianceglobalgroup.com/role/InvestmentInNsureInc. 51 false false R52.htm 00000052 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 52 false false R53.htm 00000053 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://relianceglobalgroup.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://relianceglobalgroup.com/role/PropertyAndEquipmentTables 53 false false R54.htm 00000054 - Disclosure - SCHEDULE OF IMPAIRMENT OF GOODWILL (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails SCHEDULE OF IMPAIRMENT OF GOODWILL (Details) Details 54 false false R55.htm 00000055 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD (Details) Details 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS (Details) Details 56 false false R57.htm 00000057 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details Narrative) Sheet http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative GOODWILL AND OTHER INTANGIBLE ASSETS (Details Narrative) Details http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsTables 57 false false R58.htm 00000058 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Details 58 false false R59.htm 00000059 - Disclosure - SCHEDULE OF LONG TERM DEBT (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails SCHEDULE OF LONG TERM DEBT (Details) Details 59 false false R60.htm 00000060 - Disclosure - SCHEDULE OF LONG TERM DEBT (Details) (Parenthetical) Sheet http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical SCHEDULE OF LONG TERM DEBT (Details) (Parenthetical) Details 60 false false R61.htm 00000061 - Disclosure - SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES (Details) Details 61 false false R62.htm 00000062 - Disclosure - LONG-TERM DEBT (Details Narrative) Sheet http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative LONG-TERM DEBT (Details Narrative) Details http://relianceglobalgroup.com/role/Long-termDebtTables 62 false false R63.htm 00000063 - Disclosure - WARRANT LIABILITIES (Details Narrative) Sheet http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative WARRANT LIABILITIES (Details Narrative) Details http://relianceglobalgroup.com/role/WarrantLiabilities 63 false false R64.htm 00000064 - Disclosure - SCHEDULE OF CONCENTRATIONS OF REVENUES (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails SCHEDULE OF CONCENTRATIONS OF REVENUES (Details) Details 64 false false R65.htm 00000065 - Disclosure - SIGNIFICANT CUSTOMERS (Details Narrative) Sheet http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative SIGNIFICANT CUSTOMERS (Details Narrative) Details http://relianceglobalgroup.com/role/SignificantCustomersTables 65 false false R66.htm 00000066 - Disclosure - SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED (Details) Details 66 false false R67.htm 00000067 - Disclosure - SCHEDULE OF NON - VESTED STOCK OPTIONS (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails SCHEDULE OF NON - VESTED STOCK OPTIONS (Details) Details 67 false false R68.htm 00000068 - Disclosure - SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL (Details) Details 68 false false R69.htm 00000069 - Disclosure - EQUITY (Details Narrative) Sheet http://relianceglobalgroup.com/role/EquityDetailsNarrative EQUITY (Details Narrative) Details http://relianceglobalgroup.com/role/EquityTables 69 false false R70.htm 00000070 - Disclosure - SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS (Details) Details 70 false false R71.htm 00000071 - Disclosure - SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES (Details) Details 71 false false R72.htm 00000072 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT (Details) Details 72 false false R73.htm 00000073 - Disclosure - LEASES (Details Narrative) Sheet http://relianceglobalgroup.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://relianceglobalgroup.com/role/LeasesTables 73 false false R74.htm 00000074 - Disclosure - SCHEDULE OF EARN-OUT LIABILITY (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails SCHEDULE OF EARN-OUT LIABILITY (Details) Details 74 false false R75.htm 00000075 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://relianceglobalgroup.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://relianceglobalgroup.com/role/CommitmentsAndContingenciesTables 75 false false R76.htm 00000076 - Disclosure - SCHEDULE OF ACTUAL INCOME TAX RATE (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails SCHEDULE OF ACTUAL INCOME TAX RATE (Details) Details 76 false false R77.htm 00000077 - Disclosure - SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES (Details) Sheet http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES (Details) Details 77 false false R78.htm 00000078 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://relianceglobalgroup.com/role/IncomeTaxesTables 78 false false R79.htm 00000079 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://relianceglobalgroup.com/role/RelatedPartyTransactions 79 false false R80.htm 00000080 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://relianceglobalgroup.com/role/SubsequentEvents 80 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. form10-k.htm 17776, 17788 [dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. form10-k.htm 17777, 17789 [dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. form10-k.htm 17777, 17789 [EXG.rendering.tooManyDimensions] Presentation group http://relianceglobalgroup.com/role/EquityDetailsNarrative with 8 axes could have more than 2 billion cells. Split up this presentation group and see EXG, Rendering, to see how to reduce the number of combinations by selecting fewer members for each axis. - form10-k.htm - form10-k.htm form10-k.htm reli-20231231.xsd reli-20231231_cal.xml reli-20231231_def.xml reli-20231231_lab.xml reli-20231231_pre.xml image_001.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 101 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "RELI", "nsuri": "http://relianceglobalgroup.com/20231231", "dts": { "inline": { "local": [ "form10-k.htm" ] }, "schema": { "local": [ "reli-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "reli-20231231_cal.xml" ] }, "definitionLink": { "local": [ "reli-20231231_def.xml" ] }, "labelLink": { "local": [ "reli-20231231_lab.xml" ] }, "presentationLink": { "local": [ "reli-20231231_pre.xml" ] } }, "keyStandard": 403, "keyCustom": 119, "axisStandard": 34, "axisCustom": 0, "memberStandard": 35, "memberCustom": 102, "hidden": { "total": 246, "http://relianceglobalgroup.com/20231231": 80, "http://fasb.org/us-gaap/2023": 163, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 427, "entityCount": 1, "segmentCount": 147, "elementCount": 828, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1240, "http://xbrl.sec.gov/dei/2023": 42 }, "report": { "R1": { "role": "http://relianceglobalgroup.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://relianceglobalgroup.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OtherAssetsNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R3": { "role": "http://relianceglobalgroup.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R4": { "role": "http://relianceglobalgroup.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:CommissionIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R5": { "role": "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity", "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://relianceglobalgroup.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R7": { "role": "http://relianceglobalgroup.com/role/OrganizationAndDescriptionOfBusiness", "longName": "00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS", "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R8": { "role": "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinations", "longName": "00000009 - Disclosure - STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS", "shortName": "STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://relianceglobalgroup.com/role/InvestmentInNsureInc.", "longName": "00000010 - Disclosure - INVESTMENT IN NSURE, INC.", "shortName": "INVESTMENT IN NSURE, INC.", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://relianceglobalgroup.com/role/PropertyAndEquipment", "longName": "00000011 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssets", "longName": "00000012 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://relianceglobalgroup.com/role/AccountsPayableAndAccruedLiabilities", "longName": "00000013 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://relianceglobalgroup.com/role/Long-termDebt", "longName": "00000014 - Disclosure - LONG-TERM DEBT", "shortName": "LONG-TERM DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://relianceglobalgroup.com/role/WarrantLiabilities", "longName": "00000015 - Disclosure - WARRANT LIABILITIES", "shortName": "WARRANT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:WarrantLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:WarrantLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://relianceglobalgroup.com/role/SignificantCustomers", "longName": "00000016 - Disclosure - SIGNIFICANT CUSTOMERS", "shortName": "SIGNIFICANT CUSTOMERS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://relianceglobalgroup.com/role/Equity", "longName": "00000017 - Disclosure - EQUITY", "shortName": "EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://relianceglobalgroup.com/role/EarningsLossPerShare", "longName": "00000018 - Disclosure - EARNINGS (LOSS) PER SHARE", "shortName": "EARNINGS (LOSS) PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://relianceglobalgroup.com/role/Leases", "longName": "00000019 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://relianceglobalgroup.com/role/CommitmentsAndContingencies", "longName": "00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://relianceglobalgroup.com/role/IncomeTaxes", "longName": "00000021 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://relianceglobalgroup.com/role/RelatedPartyTransactions", "longName": "00000022 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://relianceglobalgroup.com/role/SubsequentEvents", "longName": "00000023 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R25": { "role": "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsTables", "longName": "00000026 - Disclosure - STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Tables)", "shortName": "STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_BarraAndAssociatesLLCMember", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_BarraAndAssociatesLLCMember", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R27": { "role": "http://relianceglobalgroup.com/role/PropertyAndEquipmentTables", "longName": "00000027 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R28": { "role": "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsTables", "longName": "00000028 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R29": { "role": "http://relianceglobalgroup.com/role/AccountsPayableAndAccruedLiabilitiesTables", "longName": "00000029 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R30": { "role": "http://relianceglobalgroup.com/role/Long-termDebtTables", "longName": "00000030 - Disclosure - LONG-TERM DEBT (Tables)", "shortName": "LONG-TERM DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R31": { "role": "http://relianceglobalgroup.com/role/SignificantCustomersTables", "longName": "00000031 - Disclosure - SIGNIFICANT CUSTOMERS (Tables)", "shortName": "SIGNIFICANT CUSTOMERS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R32": { "role": "http://relianceglobalgroup.com/role/EquityTables", "longName": "00000032 - Disclosure - EQUITY (Tables)", "shortName": "EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R33": { "role": "http://relianceglobalgroup.com/role/EarningsLossPerShareTables", "longName": "00000033 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)", "shortName": "EARNINGS (LOSS) PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R34": { "role": "http://relianceglobalgroup.com/role/LeasesTables", "longName": "00000034 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R35": { "role": "http://relianceglobalgroup.com/role/CommitmentsAndContingenciesTables", "longName": "00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:EarnOutLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:EarnOutLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R36": { "role": "http://relianceglobalgroup.com/role/IncomeTaxesTables", "longName": "00000036 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:ScheduleOfActualIncometaxRateTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:ScheduleOfActualIncometaxRateTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R37": { "role": "http://relianceglobalgroup.com/role/ScheduleOfRestrictedCashInStatementOfCashFlowDetails", "longName": "00000037 - Disclosure - SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW (Details)", "shortName": "SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R38": { "role": "http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails", "longName": "00000038 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT (Details)", "shortName": "SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_ComputerEquipmentMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "RELI:ScheduleOfEstimatedUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_ComputerEquipmentMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "RELI:ScheduleOfEstimatedUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R39": { "role": "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails", "longName": "00000039 - Disclosure - SCHEDULE OF WARRANT LIABILITY (Details)", "shortName": "SCHEDULE OF WARRANT LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "RELI:ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "RELI:ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R40": { "role": "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails", "longName": "00000040 - Disclosure - SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details)", "shortName": "SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "RELI:WarrantLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "RELI:WarrantLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "RELI:ScheduleOfReconcilesWarrantCommitmentTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R41": { "role": "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetailsParenthetical", "longName": "00000041 - Disclosure - SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) (Parenthetical)", "shortName": "SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:RecognitionAndChangeInFairValueOfWarrantLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:WarrantIssuanceCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "link:footnote", "td", "tr", "table", "RELI:ScheduleOfReconcilesWarrantCommitmentTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R42": { "role": "http://relianceglobalgroup.com/role/ScheduleOfFairValueMeasurementsDetails", "longName": "00000042 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS (Details)", "shortName": "SCHEDULE OF FAIR VALUE MEASUREMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member", "name": "RELI:ValuationTechnique", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member", "name": "RELI:ValuationTechnique", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R43": { "role": "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails", "longName": "00000043 - Disclosure - SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS (Details)", "shortName": "SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member", "name": "RELI:NumberOfIterations", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member", "name": "RELI:NumberOfIterations", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R44": { "role": "http://relianceglobalgroup.com/role/ScheduleOfGainOrLossesRecognizedFairValueDetails", "longName": "00000044 - Disclosure - SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE (Details)", "shortName": "SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:AcquisitionsAndSettlements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R45": { "role": "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails", "longName": "00000045 - Disclosure - SCHEDULE OF DISAGGREGATION REVENUE (Details)", "shortName": "SCHEDULE OF DISAGGREGATION REVENUE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R46": { "role": "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "longName": "00000046 - Disclosure - SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS (Details)", "shortName": "SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OtherReceivablesNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember", "name": "RELI:CommissionIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DiscontinuedOperationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R47": { "role": "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "RELI:LiquidityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "RELI:LiquidityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R48": { "role": "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "longName": "00000048 - Disclosure - SCHEDULE OF ALLOCATION OF PURCHASE PRICE (Details)", "shortName": "SCHEDULE OF ALLOCATION OF PURCHASE PRICE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_CustomerRelationshipsMember", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-04-26_custom_BarraAndAssociatesLLCMember", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R49": { "role": "http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails", "longName": "00000049 - Disclosure - SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION (Details)", "shortName": "SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "From2022-01-012022-12-31_custom_MedigapHealthcareInsuranceCompanyMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31_custom_MedigapHealthcareInsuranceCompanyMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R50": { "role": "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative", "longName": "00000050 - Disclosure - STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Details Narrative)", "shortName": "STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-04-26_custom_BarraAndAssociatesLLCMember", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R51": { "role": "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "longName": "00000051 - Disclosure - INVESTMENT IN NSURE, INC. (Details Narrative)", "shortName": "INVESTMENT IN NSURE, INC. (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:Investments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-04-012023-04-30_custom_NSUREIncMember", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R52": { "role": "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "00000052 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R53": { "role": "http://relianceglobalgroup.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "00000053 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R54": { "role": "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails", "longName": "00000054 - Disclosure - SCHEDULE OF IMPAIRMENT OF GOODWILL (Details)", "shortName": "SCHEDULE OF IMPAIRMENT OF GOODWILL (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R55": { "role": "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails", "longName": "00000055 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD (Details)", "shortName": "SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R56": { "role": "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails", "longName": "00000056 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS (Details)", "shortName": "SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R57": { "role": "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "longName": "00000057 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Details Narrative)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R58": { "role": "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "longName": "00000058 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R59": { "role": "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "longName": "00000059 - Disclosure - SCHEDULE OF LONG TERM DEBT (Details)", "shortName": "SCHEDULE OF LONG TERM DEBT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "RELI:LongTermDebtNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R60": { "role": "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical", "longName": "00000060 - Disclosure - SCHEDULE OF LONG TERM DEBT (Details) (Parenthetical)", "shortName": "SCHEDULE OF LONG TERM DEBT (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_SWMTMember", "name": "us-gaap:LongTermDebtPercentageBearingVariableInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_SWMTMember", "name": "us-gaap:LongTermDebtPercentageBearingVariableInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R61": { "role": "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails", "longName": "00000061 - Disclosure - SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES (Details)", "shortName": "SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R62": { "role": "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "longName": "00000062 - Disclosure - LONG-TERM DEBT (Details Narrative)", "shortName": "LONG-TERM DEBT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2019-12-31_custom_SeniorSecuredAmortizingCreditFacilityMember_custom_OakStreetFundingLLCMember_us-gaap_PrimeRateMember", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "us-gaap:DebtInstrumentDescription", "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R63": { "role": "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative", "longName": "00000063 - Disclosure - WARRANT LIABILITIES (Details Narrative)", "shortName": "WARRANT LIABILITIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2021-01-012021-12-31", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "RELI:WarrantLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R64": { "role": "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails", "longName": "00000064 - Disclosure - SCHEDULE OF CONCENTRATIONS OF REVENUES (Details)", "shortName": "SCHEDULE OF CONCENTRATIONS OF REVENUES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_PriorityHealthMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_PriorityHealthMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R65": { "role": "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative", "longName": "00000065 - Disclosure - SIGNIFICANT CUSTOMERS (Details Narrative)", "shortName": "SIGNIFICANT CUSTOMERS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R66": { "role": "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails", "longName": "00000066 - Disclosure - SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED (Details)", "shortName": "SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R67": { "role": "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails", "longName": "00000067 - Disclosure - SCHEDULE OF NON - VESTED STOCK OPTIONS (Details)", "shortName": "SCHEDULE OF NON - VESTED STOCK OPTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R68": { "role": "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails", "longName": "00000068 - Disclosure - SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL (Details)", "shortName": "SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "AsOf2023-12-31_srt_MinimumMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_srt_MinimumMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R69": { "role": "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "longName": "00000069 - Disclosure - EQUITY (Details Narrative)", "shortName": "EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-03-132023-03-13", "name": "us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R70": { "role": "http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails", "longName": "00000070 - Disclosure - SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS (Details)", "shortName": "SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:DeemedDividends", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R71": { "role": "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails", "longName": "00000071 - Disclosure - SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES (Details)", "shortName": "SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_StockOptionsMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_StockOptionsMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R72": { "role": "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails", "longName": "00000072 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT (Details)", "shortName": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R73": { "role": "http://relianceglobalgroup.com/role/LeasesDetailsNarrative", "longName": "00000073 - Disclosure - LEASES (Details Narrative)", "shortName": "LEASES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R74": { "role": "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails", "longName": "00000074 - Disclosure - SCHEDULE OF EARN-OUT LIABILITY (Details)", "shortName": "SCHEDULE OF EARN-OUT LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "RELI:ChangesDueToPayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "RELI:EarnOutLiabilitiesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R75": { "role": "http://relianceglobalgroup.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000075 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommitmentsAndContingencies", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:CommitmentsAndContingencies", "span", "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommitmentsAndContingencies", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:CommitmentsAndContingencies", "span", "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R76": { "role": "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails", "longName": "00000076 - Disclosure - SCHEDULE OF ACTUAL INCOME TAX RATE (Details)", "shortName": "SCHEDULE OF ACTUAL INCOME TAX RATE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "RELI:ScheduleOfActualIncometaxRateTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "RELI:ScheduleOfActualIncometaxRateTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R77": { "role": "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails", "longName": "00000077 - Disclosure - SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES (Details)", "shortName": "SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R78": { "role": "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative", "longName": "00000078 - Disclosure - INCOME TAXES (Details Narrative)", "shortName": "INCOME TAXES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R79": { "role": "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000079 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-312023-01-31", "name": "RELI:DeferredPurchasePrice", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R80": { "role": "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative", "longName": "00000080 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-02-142024-02-15_custom_ATMAgreementMember_us-gaap_SubsequentEventMember", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } } }, "tag": { "RELI_ABCMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ABCMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "ABC [Member]", "documentation": "ABC [Member]" } } }, "auth_ref": [] }, "RELI_APAMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "APAMember", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Asset Purchase Agreement [Member]", "documentation": "Asset Purchase Agreement [Member]" } } }, "auth_ref": [] }, "RELI_ATMAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ATMAgreementMember", "presentation": [ "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "ATM Agreement [Member]", "documentation": "ATM Agreement [Member]" } } }, "auth_ref": [] }, "RELI_AbeyanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AbeyanceSharesMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Abeyance Shares [Member]", "documentation": "Abeyance Shares [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts payable and other accrued liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r34" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/AccountsPayableAndAccruedLiabilities" ], "lang": { "en-us": { "role": { "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r31" ] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Accounts payable and other accrued liabilities", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "RELI_AccountsPayableAndOtherAccruedLiabilitiesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AccountsPayableAndOtherAccruedLiabilitiesWriteOffs", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and other accrued liabilities", "documentation": "Accounts payable and other accrued liabilities write offs.", "label": "AccountsPayableAndOtherAccruedLiabilitiesWriteOffs" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts payable,", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30", "r732" ] }, "us-gaap_AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other payables", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r30" ] }, "RELI_AccountsReceivableImpairements": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AccountsReceivableImpairements", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, related parties", "documentation": "Accounts receivable impairements.", "label": "AccountsReceivableImpairements" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r322", "r323" ] }, "RELI_AccrueInterestRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AccrueInterestRatePercentage", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrue interest rate percentage", "documentation": "Accrue interest rate percentage" } } }, "auth_ref": [] }, "RELI_AccruedCreditCardPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AccruedCreditCardPayables", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued credit card payables", "documentation": "Accrued credit card payables." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36" ] }, "RELI_AccruingMonthlyInterestPercentage": { "xbrltype": "percentItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AccruingMonthlyInterestPercentage", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accruing monthly interest percentage", "documentation": "Accruing monthly interest percentage" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r75", "r235", "r557" ] }, "RELI_AcquiredAccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AcquiredAccountsReceivableMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails" ], "lang": { "en-us": { "role": { "label": "Acquired Accounts Receivable [Member]", "documentation": "Acquired Accounts Receivable [Member]" } } }, "auth_ref": [] }, "us-gaap_AcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquisitionCosts", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Acquisition costs", "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties." } } }, "auth_ref": [ "r200", "r201" ] }, "RELI_AcquisitionOfBusinessDeferredPurchasePriceLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AcquisitionOfBusinessDeferredPurchasePriceLiability", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Acquisition of business deferred purchase price liability", "documentation": "Acquisition of business deferred purchase price liability." } } }, "auth_ref": [] }, "RELI_AcquisitionsAndSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AcquisitionsAndSettlements", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfGainOrLossesRecognizedFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Acquisitions and Settlements", "documentation": "Acquisitions and settlements." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "verboseLabel": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r151", "r732", "r892" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r435", "r436", "r437", "r597", "r795", "r796", "r797", "r864", "r894" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Share based compensation", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustment to reconcile net income to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Marketing and Advertising", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r215" ] }, "RELI_AgencyRelationshipMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AgencyRelationshipMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails" ], "lang": { "en-us": { "role": { "label": "Agency Relationship [Member]", "documentation": "Agency Relationship [Member]" } } }, "auth_ref": [] }, "RELI_AggregatePurchasePriceOfCommonSharesPreferredSharesAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AggregatePurchasePriceOfCommonSharesPreferredSharesAndWarrants", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate purchase price", "documentation": "Aggregate purchase price of common shares, preferred shares and warrants." } } }, "auth_ref": [] }, "RELI_AgreementInAprilTwoThousandTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AgreementInAprilTwoThousandTwentyTwoMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agreement In April 2022 [Member]", "documentation": "Agreement In April 2022 [Member]" } } }, "auth_ref": [] }, "RELI_AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agreement In December 28, 2022 [Member]", "documentation": "Agreement In December 28, 2022 [Member]" } } }, "auth_ref": [] }, "RELI_AltruisBenefitsConsultantsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AltruisBenefitsConsultantsIncMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Altruis Benefits Consultants Inc [Member]", "documentation": "Altruis Benefits Consultants Inc [Member]" } } }, "auth_ref": [] }, "RELI_AltruisBenefitsConsultingIncMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AltruisBenefitsConsultingIncMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Altruis Benefits Consulting Inc [Member]", "documentation": "Altruis Benefits Consulting Inc [Member]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of debt issuance costs and accretion of debt discount", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r383", "r496", "r716", "r717", "r787" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r10", "r68", "r72" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r760" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails" ], "lang": { "en-us": { "role": { "label": "Shares subject to unvested stock awards", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r299" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r58" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative", "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative", "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r464" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r860" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r728", "r861", "r862", "r863" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition." } } }, "auth_ref": [ "r860" ] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r860" ] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTable", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r860" ] }, "RELI_AssetAndLiabilityTransfersRetainedByTheCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AssetAndLiabilityTransfersRetainedByTheCompanyMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Asset and Liability Transfers Retained by the Company [Member]", "documentation": "Asset and Liability Transfers Retained by the Company [Member]" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total asset impairments", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r10", "r73" ] }, "RELI_AssetImpairmentsAndLiabilityWriteOffsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AssetImpairmentsAndLiabilityWriteOffsMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Impairments and liability WriteOffs [Member]", "documentation": "Asset Impairments and liability WriteOffs [Member]" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets [Default Label]", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r203", "r239", "r265", "r306", "r313", "r317", "r328", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r466", "r470", "r487", "r549", "r640", "r732", "r745", "r821", "r822", "r873" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "RELI_AssetsAndLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "AssetsAndLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Net assets and liabilities - Medigap", "documentation": "Assets and liabilities of disposal group including discontinued operation current." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r231", "r245", "r265", "r328", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r466", "r470", "r487", "r732", "r821", "r822", "r873" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Total assets - Medigap", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r4", "r124", "r141", "r180", "r229", "r230" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Current assets - discontinued operations", "verboseLabel": "Current assets \u2013 Medigap", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r124", "r141", "r177", "r180", "r229", "r230" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r760" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r757", "r759", "r760" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r757", "r759", "r760" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r757", "r759", "r760" ] }, "RELI_BarraAndAssociatesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "BarraAndAssociatesLLCMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "Barra And Associates LLC [Member]", "documentation": "Barra And Associates LLC [Member]" } } }, "auth_ref": [] }, "RELI_BarraMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "BarraMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails", "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Barra & Associates, LLC [Member]", "documentation": "Barra & Associates, LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Principles of Consolidation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "RELI_BlueCrossBlueShieldMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "BlueCrossBlueShieldMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "BlueCross BlueShield [Member]", "documentation": "BlueCross BlueShield [Member]" } } }, "auth_ref": [] }, "RELI_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "BoardOfDirectorsMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board of Directors [Member]", "documentation": "Board of Directors [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails", "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical", "http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsTables" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r460", "r725", "r726" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails", "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical", "http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r95", "r96", "r460", "r725", "r726" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r460" ] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Earnings (Loss) per common share, basic", "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r772", "r773" ] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Earnings (Loss) per common share, diluted", "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r772", "r773" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r772", "r773" ] }, "us-gaap_BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue from acquired entity", "documentation": "Total revenue reported by the acquired entity for its previous full fiscal year before the business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r458", "r459" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r458", "r459" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfGainOrLossesRecognizedFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair value and estimate changes", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r463", "r786" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails", "http://relianceglobalgroup.com/role/ScheduleOfGainOrLossesRecognizedFairValueDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance \u2013 January 1", "periodEndLabel": "Ending balance", "label": "Earn out balance", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r1", "r101", "r462" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfGainOrLossesRecognizedFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Earn-out liability, current portion", "negatedLabel": "Less: Current portion", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r101" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business combination, measurement input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r485" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfGainOrLossesRecognizedFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Earn-out liability, less current portion", "verboseLabel": "Ending balance, less current portion", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r101" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinations" ], "lang": { "en-us": { "role": { "label": "STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r194", "r461" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r97", "r98" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business Combinations", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r94" ] }, "RELI_CARESActMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CARESActMember", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CARES Act [Member]", "documentation": "CARES Act [Member]" } } }, "auth_ref": [] }, "RELI_CCSMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CCSMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "CCS [Member]", "documentation": "CCS [Member]" } } }, "auth_ref": [] }, "RELI_CarryingValuePriorToAbandonmentMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CarryingValuePriorToAbandonmentMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Carrying Value Prior to Abandonment [Member]", "documentation": "Carrying Value Prior to Abandonment [Member]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://relianceglobalgroup.com/role/ScheduleOfRestrictedCashInStatementOfCashFlowDetails": { "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfRestrictedCashInStatementOfCashFlowDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r214", "r551", "r608", "r635", "r732", "r745", "r778" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r54", "r202" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and restricted cash at beginning of year", "periodEndLabel": "Cash and restricted cash at end of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r53", "r166", "r262" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase and decrease in cash and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r166" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "FDIC insured amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash used and provided from discontinued financing activities", "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r166" ] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash used in discontinued investing activities", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r140", "r166" ] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash provided by discontinued operating activities", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r140", "r166" ] }, "RELI_ChangeInEstimatedAcquisitionEarnoutPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ChangeInEstimatedAcquisitionEarnoutPayables", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 }, "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Change in estimated acquisition earn-out payables", "documentation": "Change in estimated acquisition earnout payables." } } }, "auth_ref": [] }, "RELI_ChangesDueToAmountPayableInCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ChangesDueToAmountPayableInCommonShares", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Payable in Common Stock", "documentation": "Changes due to amount payable in common shares." } } }, "auth_ref": [] }, "RELI_ChangesDueToBusinessCombinations": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ChangesDueToBusinessCombinations", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Business combinations", "documentation": "Changes due to business combinations." } } }, "auth_ref": [] }, "RELI_ChangesDueToFairValueAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ChangesDueToFairValueAdjustments", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Estimate & fair value adjustments", "documentation": "Changes due to fair value adjustments." } } }, "auth_ref": [] }, "RELI_ChangesDueToPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ChangesDueToPayments", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Payments", "documentation": "Changes due to payments." } } }, "auth_ref": [] }, "RELI_ChargebackReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ChargebackReserveCurrent", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Chargeback reserve", "documentation": "Chargeback reserve current." } } }, "auth_ref": [] }, "RELI_ChargebackReserveWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ChargebackReserveWriteOffs", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Chargeback reserve", "documentation": "Chargeback reserve write offs.", "label": "ChargebackReserveWriteOffs" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://relianceglobalgroup.com/role/Cover", "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r225", "r242", "r243", "r244", "r265", "r290", "r291", "r296", "r298", "r304", "r305", "r328", "r359", "r361", "r362", "r363", "r366", "r367", "r387", "r388", "r391", "r394", "r402", "r487", "r587", "r588", "r589", "r590", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r609", "r627", "r649", "r672", "r693", "r694", "r695", "r696", "r697", "r767", "r789", "r799" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r242", "r243", "r244", "r304", "r387", "r388", "r389", "r391", "r394", "r400", "r402", "r587", "r588", "r589", "r590", "r718", "r767", "r789" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercisable price", "verboseLabel": "Warrants exercise prices", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r403" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issued warrant", "verboseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock issued during period, shares, acquisitions", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r403" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Outstanding warrants", "verboseLabel": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants description", "documentation": "Description of reason for issuing warrant or right." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightUnissued", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of warrant unissued", "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r464" ] }, "RELI_CommercialCoverageSolutionsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommercialCoverageSolutionsLLCMember", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Commercial Coverage Solutions LLC [Member]", "documentation": "Commercial Coverage Solutions LLC [Member]" } } }, "auth_ref": [] }, "RELI_CommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommissionExpense", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Commission expense", "documentation": "Commission expense." } } }, "auth_ref": [] }, "RELI_CommissionIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommissionIncome", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Commission income", "documentation": "Commission income." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r42", "r119", "r550", "r626" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r182", "r353", "r354", "r700", "r817" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r894" ] }, "RELI_CommonSharesIssuedForEarnoutLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonSharesIssuedForEarnoutLiabilities", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Common shares issued for earnout liabilities", "documentation": "Common shares issued for earnout liabilities.", "label": "CommonSharesIssuedForEarnoutLiabilities" } } }, "auth_ref": [] }, "RELI_CommonSharesIssuedForSeriesBWarrantInShares": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonSharesIssuedForSeriesBWarrantInShares", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common shares issued for series B warrant in shares", "documentation": "Common shares issued for series b warrant shares." } } }, "auth_ref": [] }, "RELI_CommonSharesIssuedForSeriesBWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonSharesIssuedForSeriesBWarrants", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Common shares issued for Series B warrants", "documentation": "Common shares issued for Series B Warrants.", "label": "CommonSharesIssuedForSeriesBWarrants" } } }, "auth_ref": [] }, "RELI_CommonSharesIssuedForSeriesBWarrantsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonSharesIssuedForSeriesBWarrantsValue", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common shares issued for Series B warrants", "documentation": "Common shares issued for series warrants, value." } } }, "auth_ref": [] }, "RELI_CommonSharesIssuedForSeriesDWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonSharesIssuedForSeriesDWarrants", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common shares issued for Series D Warrants", "documentation": "Common shares issued for Series D Warrants." } } }, "auth_ref": [] }, "RELI_CommonSharesIssuedForSeriesEWarrantShares": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonSharesIssuedForSeriesEWarrantShares", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common shares issued for Series E warrants, shares", "verboseLabel": "Number of shares converted", "documentation": "Common shares issued for eries e warrant." } } }, "auth_ref": [] }, "RELI_CommonSharesIssuedForSeriesEWarrantsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonSharesIssuedForSeriesEWarrantsValue", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common shares issued for Series E warrants", "documentation": "Common shares issued for series warrants, value." } } }, "auth_ref": [] }, "RELI_CommonSharesIssuedForSeriesFWarrantShares": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonSharesIssuedForSeriesFWarrantShares", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common shares issued for Series F warrants, shares", "documentation": "Common shares issued for series f warrant." } } }, "auth_ref": [] }, "RELI_CommonSharesIssuedForSeriesFWarrantsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonSharesIssuedForSeriesFWarrantsValue", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common shares issued for Series F warrants", "documentation": "Common shares issued for series warrants, value." } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r43" ] }, "RELI_CommonStockIssuedForPrepaidAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonStockIssuedForPrepaidAssets", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common stock issued for pre-paid assets", "documentation": "Common stock issued for pre-paid assets." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://relianceglobalgroup.com/role/Cover", "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r795", "r796", "r864", "r889", "r894" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheetsParenthetical", "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "verboseLabel": "Common stock par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r150" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheetsParenthetical", "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r150", "r627" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r150" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheetsParenthetical", "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r17", "r150", "r627", "r646", "r894", "r895" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.086 par value; 2,000,000,000 shares authorized and 4,761,974 and 1,219,573 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r150", "r553", "r732" ] }, "RELI_CommonStocksMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CommonStocksMember", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock [Member]", "documentation": "Common Stock [Member]", "label": "Common Stock [Member] [Default Label]" } } }, "auth_ref": [] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Equity-Based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r88" ] }, "RELI_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Computer Equipment [Member]", "documentation": "Computer Equipment [Member]", "label": "Computer Equipment [Member] [Default Label]" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails", "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r60", "r62", "r110", "r111", "r321", "r699" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails", "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r60", "r62", "r110", "r111", "r321", "r581", "r699" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails", "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r60", "r62", "r110", "r111", "r321", "r699", "r771" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SignificantCustomers" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT CUSTOMERS", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r170" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails", "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r699" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails", "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration of risk percentage", "verboseLabel": "Total revenue", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r60", "r62", "r110", "r111", "r321" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails", "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r59", "r60", "r62", "r63", "r110", "r199", "r699" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails", "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r60", "r62", "r110", "r111", "r321", "r699" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r269", "r466", "r467", "r470", "r471", "r516", "r701", "r820", "r823", "r824" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "auth_ref": [ "r269", "r466", "r467", "r470", "r471", "r516", "r701", "r820", "r823", "r824" ] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common shares issued for preferred stock", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r55", "r56", "r57" ] }, "us-gaap_ConversionOfStockAmountIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockAmountIssued1", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of stock", "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r55", "r56", "r57" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Converted", "verboseLabel": "Conversion of stock shares converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r55", "r56", "r57" ] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible into aggregate shares", "verboseLabel": "Warrant conversion shares", "terseLabel": "Conversion of stock shares", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r55", "r56", "r57" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of shares", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r27", "r79", "r149", "r187", "r397" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "RELI_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CreditAgreementMember", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Credit Agreement [Member]", "documentation": "Credit Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "RELI_CurrentPortionOfLeasesPayableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CurrentPortionOfLeasesPayableWriteOffs", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of leases payable", "documentation": "Current portion of leases payable write offs.", "label": "CurrentPortionOfLeasesPayableWriteOffs" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails", "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r61", "r321" ] }, "RELI_CustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "CustomerMember", "presentation": [ "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Member]", "documentation": "Customer [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r100" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Conversion converted instrument shares", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r55", "r57" ] }, "us-gaap_DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt conversion original debt amount", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r55", "r57" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r26", "r147", "r148", "r204", "r205", "r269", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r497", "r713", "r714", "r715", "r716", "r717", "r790" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r26", "r205", "r384" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price, per share", "verboseLabel": "Warrants exercise price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r184", "r370" ] }, "us-gaap_DebtInstrumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDescription", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt description", "verboseLabel": "Debt instrument description", "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total." } } }, "auth_ref": [ "r26", "r79", "r121", "r147", "r204", "r205" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total financed", "verboseLabel": "Promissory note principle", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r113", "r115", "r368", "r497", "r714", "r715" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "verboseLabel": "Accrue interest percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r38", "r369" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Maturity date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r223", "r713", "r866" ] }, "us-gaap_DebtInstrumentMaturityDateDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDateDescription", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Maturity date", "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities." } } }, "auth_ref": [ "r39" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r40", "r269", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r497", "r713", "r714", "r715", "r716", "r717", "r790" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Monthly payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r40", "r122" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument unmortized discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r112", "r115", "r826" ] }, "RELI_DeemedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "DeemedDividend", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deemed dividend", "documentation": "Deemed dividend." } } }, "auth_ref": [] }, "RELI_DeemedDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "DeemedDividends", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deemed dividend", "documentation": "Deemed dividends.", "label": "DeemedDividends" } } }, "auth_ref": [] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred Financing Costs", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r238" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less debt issuance costs", "label": "Debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r114", "r826" ] }, "RELI_DeferredPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "DeferredPurchasePrice", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred purchase price", "documentation": "Deferred purchase price." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Intangibles", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r445" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r857" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforward", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r93", "r858" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Federal net operating loss carryforwards excluding indefinite life", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": [ "r93", "r858" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "State net operating loss carry forwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": [ "r93", "r858" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r93", "r858" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Equity-based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r93", "r858" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r446" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Goodwill", "label": "Deferred Tax Liabilities, Goodwill", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill." } } }, "auth_ref": [ "r93", "r102", "r103", "r858" ] }, "RELI_DeferredTaxLiabilitiesLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "DeferredTaxLiabilitiesLeaseLiabilities", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "documentation": "Deferred tax liabilities lease liabilities." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Right of use assets", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r93", "r858" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Fixed assets", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r93", "r858" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r10", "r74" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r10", "r74" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r10", "r310" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r616", "r618", "r632", "r633", "r634", "r636", "r637", "r638", "r639", "r641", "r642", "r643", "r644", "r660", "r661", "r662", "r663", "r666", "r667", "r668", "r669", "r684", "r685", "r688", "r690", "r735", "r737" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r105", "r106", "r107", "r108", "r616", "r618", "r632", "r633", "r634", "r636", "r637", "r638", "r639", "r641", "r642", "r643", "r644", "r660", "r661", "r662", "r663", "r666", "r667", "r668", "r669", "r684", "r685", "r688", "r690", "r706", "r735", "r737" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r246", "r247", "r486", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r641", "r643", "r644", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r706", "r890" ] }, "RELI_DerivativeLiabilityMeasuredAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "DerivativeLiabilityMeasuredAtFairValue", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative liability measured at fair value", "documentation": "Derivative liability measured at fair value." } } }, "auth_ref": [] }, "RELI_DevelopmentTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "DevelopmentTechnologyMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Development Technology [Member]", "documentation": "Development Technology [Member]" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r801", "r891" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DISAGGREGATION REVENUE", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r828" ] }, "RELI_DisclosureLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "DisclosureLeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases", "verboseLabel": "Schedule Of Future Minimum Lease Payment" } } }, "auth_ref": [] }, "RELI_DisclosureWarrantLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "DisclosureWarrantLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Warrant Liabilities" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss from discontinued operations before tax", "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax", "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": [ "r128", "r130", "r132" ] }, "RELI_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfAmortizationCombined": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfAmortizationCombined", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net of amortization combined", "documentation": "Discontinued operation gain loss on disposal of discontinued operation net of amortization combined." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated statement of operations - Loss from discontinued operations before tax", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r128", "r129", "r130", "r131", "r132", "r138", "r159", "r885" ] }, "RELI_DiscontinuedOperationsNetAssetAndLiabilityIumpairmentsWriteoffs": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "DiscontinuedOperationsNetAssetAndLiabilityIumpairmentsWriteoffs", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued operations net asset and liability impairments / write-offs gains and (losses)", "documentation": "Discontinued operations net asset and liability umpairments writeoffs." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": [ "r14", "r29" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r229" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Other assets - discontinued operations", "verboseLabel": "Other assets - Medigap", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r5", "r124", "r141", "r180", "r229", "r230" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Goodwill Beginning", "periodEndLabel": "Goodwill end", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r4", "r124", "r141", "r180" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Total discontinued operations expenses before impairments and write-offs", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r139" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Total discontinued operations income / (loss) before impairments and write-offs", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r139" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Current Assets - Discontinued Operations", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r124", "r141", "r177", "r180" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Current Liabilities - Discontinued Operations", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r124", "r141", "r177", "r180" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Other Assets - Discontinued Operations", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r5", "r124", "r141", "r180" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group." } } }, "auth_ref": [ "r725", "r726" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r759" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r757", "r759", "r760" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r757", "r759", "r760", "r762" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r758" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r746" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r759" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r759" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r761" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r749" ] }, "RELI_EBSandUSBAMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EBSandUSBAMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "EBS and USBA [Member]", "documentation": "EBS and USBA [Member]" } } }, "auth_ref": [] }, "RELI_EarnOutLiabilitiesMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EarnOutLiabilitiesMeasurementInput", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Earn out liability", "documentation": "Earn-out liabilities measurement input." } } }, "auth_ref": [] }, "RELI_EarnOutLiabilitiesMeasurementInputTerm": { "xbrltype": "durationItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EarnOutLiabilitiesMeasurementInputTerm", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Earn out liability", "documentation": "Earn-out liabilities measurement input term.", "label": "EarnOutLiabilitiesMeasurementInputTerm" } } }, "auth_ref": [] }, "RELI_EarnOutLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EarnOutLiabilitiesTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF EARN-OUT LIABILITY", "documentation": "Tabular disclosure of earn out liabilities." } } }, "auth_ref": [] }, "RELI_EarnOutPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EarnOutPayments", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Earn out payments", "documentation": "Earn out payments." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic loss per share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r256", "r275", "r276", "r278", "r279", "r281", "r287", "r290", "r296", "r297", "r298", "r302", "r481", "r482", "r544", "r563", "r708" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic (loss) earnings per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted loss per share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r256", "r275", "r276", "r278", "r279", "r281", "r290", "r296", "r297", "r298", "r302", "r481", "r482", "r544", "r563", "r708" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted (loss) earnings per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/EarningsLossPerShare" ], "lang": { "en-us": { "role": { "label": "EARNINGS (LOSS) PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r286", "r299", "r300", "r301" ] }, "RELI_EarnoutPayableInCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EarnoutPayableInCommonShares", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfGainOrLossesRecognizedFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Earn-out payable in common shares", "documentation": "Earn-out payable in common shares." } } }, "auth_ref": [] }, "RELI_EarnoutTransferredToLoansPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EarnoutTransferredToLoansPayableRelatedParties", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfGainOrLossesRecognizedFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Earn-out transferred to loans payable, related parties" } } }, "auth_ref": [] }, "RELI_EffectOfWeightedAverageVestedStockAwards": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EffectOfWeightedAverageVestedStockAwards", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails" ], "lang": { "en-us": { "role": { "label": "Effect of weighted average vested stock awards", "documentation": "Effect of weighted averagevested stock awards." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective income tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r441" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Federal rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r266", "r441", "r453" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r856", "r859" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Rate Change", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r453", "r856" ] }, "RELI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantCommitment": { "xbrltype": "percentItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantCommitment", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Non-taxable change in fair value of warrant commitment", "documentation": "Effective income tax rate reconciliation change in fair value of warrant commitment." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill impairment", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r856", "r859" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "State net of federal", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r856", "r859" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfActualIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits." } } }, "auth_ref": [ "r856", "r859" ] }, "RELI_EmployeeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EmployeeAgreementMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee Agreement [Member]", "documentation": "Employee Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity-based compensation expense", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "RELI_EmployeeBenefitsSolutionsLLCAndUSBenefitsAllianceMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EmployeeBenefitsSolutionsLLCAndUSBenefitsAllianceMember", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee Benefits, Solutions, LLC, and US Benefits Alliance [Member]", "documentation": "Employee Benefits, Solutions, LLC, and US Benefits Alliance [Member]" } } }, "auth_ref": [] }, "RELI_EmployeeBenefitsSolutionsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EmployeeBenefitsSolutionsLLCMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Employee Benefits Solutions LLC [Member]", "documentation": "Employee Benefits Solutions LLC [Member]" } } }, "auth_ref": [] }, "RELI_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EmployeeMember", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee [Member]", "documentation": "Employee [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r855" ] }, "RELI_EmployeesDirectorsAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "EmployeesDirectorsAndConsultantsMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employees, Directors, and Consultants [Member]", "documentation": "Employees, Directors, and Consultants [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r752" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r748" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r748" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r766" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r748" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r763" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r760" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r748" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r748" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r748" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r748" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r764" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r226", "r251", "r252", "r253", "r270", "r271", "r272", "r274", "r282", "r284", "r303", "r329", "r332", "r404", "r435", "r436", "r437", "r450", "r451", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r488", "r489", "r490", "r491", "r492", "r493", "r507", "r571", "r572", "r573", "r597", "r672" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "auth_ref": [ "r325", "r326", "r327" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ownership percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r325" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGain", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-operating unrealized gains", "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r324" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedLoss", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrealized losses", "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r324" ] }, "RELI_ExecutiveMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ExecutiveMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive [Member]", "documentation": "Executive [Member]" } } }, "auth_ref": [] }, "RELI_ExecutivesAndEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ExecutivesAndEmployeesMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executives And Employees [Member]", "documentation": "Executives And Employees [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "RELI_FISMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "FISMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "FIS [Member]", "documentation": "FIS [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Recognition and change in fair value of warrant liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r10" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r18" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r18" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r376", "r416", "r417", "r418", "r419", "r420", "r421", "r483", "r520", "r521", "r522", "r714", "r715", "r722", "r723", "r724" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r376", "r416", "r417", "r418", "r419", "r420", "r421", "r483", "r522", "r714", "r715", "r722", "r723", "r724" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FAIR VALUE MEASUREMENTS", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r19", "r109" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r376", "r416", "r417", "r418", "r419", "r420", "r421", "r520", "r521", "r522", "r714", "r715", "r722", "r723", "r724" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r19", "r23" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r13", "r25" ] }, "RELI_FinancialInstrumentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "FinancialInstrumentPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Financial Instruments", "documentation": "Financial Instrument Policy Text Block." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated useful lives of intangible assets", "verboseLabel": "Finite lived intangible asset useful life", "terseLabel": "Weighted Average Remaining Amortization Period", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r237", "r343" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r174" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r174" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r174" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r174" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r174" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r529", "r530" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Gross Carrying Amount", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r173", "r530" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r529" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r69", "r71" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAmortizationExpenseOfAcquiredIntangiblesAssetsDetails", "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Net carrying amount", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r173", "r529" ] }, "RELI_FinitelivedIntangibleAssetUsefulLives": { "xbrltype": "stringItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "FinitelivedIntangibleAssetUsefulLives", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails" ], "lang": { "en-us": { "role": { "label": "Finite lived intangible asset useful life", "documentation": "Finite-lived intangible asset, useful lives." } } }, "auth_ref": [] }, "RELI_FortmanInsuranceAgencyLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "FortmanInsuranceAgencyLLCMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Fortman Insurance Agency LLC [Member]", "documentation": "Fortman Insurance Agency LLC [Member]" } } }, "auth_ref": [] }, "RELI_FortmanInsuranceServicesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "FortmanInsuranceServicesLLCMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Fortman Insurance Services LLC [Member]", "documentation": "Fortman Insurance Services LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r162", "r651" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Goodwill", "periodStartLabel": "Goodwill Beginning", "periodEndLabel": "Goodwill end", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r236", "r333", "r543", "r712", "r732", "r805", "r812" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill acquired during period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r336", "r712" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "GOODWILL AND OTHER INTANGIBLE ASSETS", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r172" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and other indefinite-lived intangibles", "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r175" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r335", "r339", "r712" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 }, "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails", "http://relianceglobalgroup.com/role/StatementsOfCashFlows", "http://relianceglobalgroup.com/role/StatementsOfOperations", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Goodwill impairment", "verboseLabel": "Goodwill", "terseLabel": "Goodwill impairment loss", "negatedLabel": "Goodwill impairment loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r10", "r334", "r338", "r340", "r712" ] }, "us-gaap_GoodwillMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill [Member]", "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [] }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Goodwill, Written off Related to Sale of Business Unit", "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r337", "r712" ] }, "RELI_GrossProceedsCashFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "GrossProceedsCashFeePercentage", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds cash fee percentage", "documentation": "Gross proceeds cash fee percentage." } } }, "auth_ref": [] }, "RELI_GrossProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "GrossProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds", "documentation": "Proceeds from private placement, gross." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r757", "r759", "r760" ] }, "RELI_ImpairmentLossOnDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ImpairmentLossOnDiscontinuedOperations", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Impairment loss on discontinued operations", "documentation": "Impairment loss on discontinued operations." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Income loss from continuing operations", "label": "(Loss) income from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r104", "r161", "r168", "r275", "r276", "r278", "r279", "r295", "r298" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss (income) from continuing operations before tax", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r197", "r265", "r273", "r306", "r312", "r316", "r318", "r328", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r482", "r487", "r559", "r710", "r821" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Continuing operations", "verboseLabel": "Basic (loss) income loss per common share from continuing operations:", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r158", "r207", "r208", "r256", "r273", "r275", "r276", "r278", "r279", "r290", "r296", "r297", "r482", "r544", "r886" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Continuing operations", "label": "Diluted (loss) income per common share from continuing operations:", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r158", "r256", "r273", "r275", "r276", "r278", "r279", "r290", "r296", "r297", "r298", "r482", "r544", "r886" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss from discontinued operations before tax", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r128", "r129", "r130", "r131", "r132", "r143", "r230", "r455", "r560" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Income loss from discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r128", "r129", "r130", "r131", "r132", "r138", "r143", "r197" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Discontinued operations", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r159", "r256", "r291", "r296", "r297", "r881", "r886" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Discontinued operations", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r198", "r291", "r296", "r297" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r725", "r726" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r266", "r438", "r442", "r443", "r448", "r452", "r454", "r456", "r457", "r592" ] }, "us-gaap_IncomeTaxExaminationDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationDescription", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax description", "label": "Income Tax Examination, Description", "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings." } } }, "auth_ref": [ "r92" ] }, "RELI_IncomeTaxExpirationDateDescription": { "xbrltype": "stringItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "IncomeTaxExpirationDateDescription", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income tax description", "documentation": "Income tax expiration date description." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r250", "r439", "r440", "r443", "r444", "r447", "r449", "r586" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Change in valuation of allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r856" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, related parties", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayable", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Other payables", "label": "Increase (Decrease) in Other Accounts Payable", "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payables and other accrued liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-current assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r786" ] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other receivables", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expense and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r9" ] }, "RELI_InitialRecognitionOfWarrantCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "InitialRecognitionOfWarrantCommitment", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails" ], "lang": { "en-us": { "role": { "label": "Initial recognition", "documentation": "Initial recognition of warrant commitment" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Identifiable Intangible Assets, net", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r71", "r525", "r526", "r527", "r529", "r707" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Intangibles, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r67", "r70" ] }, "RELI_IntangiblesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "IntangiblesNet", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangibles, net", "documentation": "Intangibles, net.", "label": "IntangiblesNet" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest expense, related parties", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r114", "r210", "r254", "r309", "r495", "r657", "r743", "r893" ] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseOther", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest expense", "verboseLabel": "Other expenses", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r257", "r260", "r261" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36" ] }, "RELI_InternallyDevelopedSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "InternallyDevelopedSoftwareMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Internally Developed Software [Member]", "documentation": "Internally Developed Software [Member]" } } }, "auth_ref": [] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc." ], "lang": { "en-us": { "role": { "label": "INVESTMENT IN NSURE, INC.", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r775", "r776", "r802" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment in NSURE, Inc.", "verboseLabel": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r548" ] }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAllOtherInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "auth_ref": [] }, "RELI_IssuanceOfPlacementAgentWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "IssuanceOfPlacementAgentWarrants", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of placement agent warrants", "documentation": "Issuance of placement agent warrants" } } }, "auth_ref": [] }, "RELI_IssuanceOfSeriesDWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "IssuanceOfSeriesDWarrants", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of Series D Warrants", "documentation": "Issuance of Series D Warrants." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share based payments to service providers", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r10" ] }, "RELI_IssuanceOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "IssuanceOfWarrants", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "[custom:IssuanceOfWarrants]", "documentation": "Issuance of warrants." } } }, "auth_ref": [] }, "RELI_IsusanceOfCommonSharesInExchangeForSeriesBWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "IsusanceOfCommonSharesInExchangeForSeriesBWarrants", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares in exchange for Series B warrants", "verboseLabel": "Cash proceeds", "documentation": "Isusance of common shares in exchange for warrants." } } }, "auth_ref": [] }, "RELI_IsusanceOfCommonSharesInExchangeForSeriesCWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "IsusanceOfCommonSharesInExchangeForSeriesCWarrants", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares in exchange for Series C warrants", "documentation": "Isusance of common shares in exchange for series C warrants." } } }, "auth_ref": [] }, "RELI_JPKushAndAssociatesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "JPKushAndAssociatesIncMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "JP Kush And Associates Inc [Member]", "documentation": "JP Kush And Associates Inc [Member]" } } }, "auth_ref": [] }, "RELI_KushMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "KushMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Kush [Member]", "documentation": "Kush [Member]" } } }, "auth_ref": [] }, "RELI_LeaseAssetsAcquiredInExchangeForLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "LeaseAssetsAcquiredInExchangeForLeaseLiabilities", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Lease assets acquired in exchange for lease liabilities", "documentation": "Lease assets acquired in exchange for lease liabilities." } } }, "auth_ref": [] }, "RELI_LeaseLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "LeaseLiabilityMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails" ], "lang": { "en-us": { "role": { "label": "Lease liability [Member]", "documentation": "Lease liability [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails", "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r178" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r502" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r870" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted operating lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/Leases" ], "lang": { "en-us": { "role": { "label": "LEASES", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r499" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r35", "r265", "r328", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r467", "r470", "r471", "r487", "r625", "r709", "r745", "r821", "r873", "r874" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r155", "r206", "r555", "r732", "r791", "r803", "r867" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r37", "r232", "r265", "r328", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r467", "r470", "r471", "r487", "r732", "r821", "r873", "r874" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Total liabilities - Medigap", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r4", "r124", "r141", "r180", "r229", "r230" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Current liabilities - discontinued operations", "verboseLabel": "Current liabilities - Medigap", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r124", "r141", "r177", "r180", "r229", "r230" ] }, "RELI_LifeMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "LifeMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Life [Member]", "documentation": "Life [Member]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r790" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r32", "r790" ] }, "RELI_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "LiquidityPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Liquidity", "documentation": "Liquidity [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_LoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayable", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loans payables, related parties", "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r26", "r205", "r883" ] }, "us-gaap_LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableCurrent", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loans payables, current", "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r36" ] }, "RELI_LoansPayableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "LoansPayableNonCurrent", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Loans payables, related parties", "documentation": "Loans payable non current.", "label": "LoansPayableNonCurrent" } } }, "auth_ref": [] }, "RELI_LoansPayableRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "LoansPayableRelatedPartiesCurrent", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of loans payables, related parties", "documentation": "Loans payable-related parties, current.", "label": "LoansPayableRelatedPartiesCurrent" } } }, "auth_ref": [] }, "RELI_LoansPayableRelatedPartiesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "LoansPayableRelatedPartiesNonCurrent", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-current portion of loans payables, related parties", "documentation": "Loans payable-related parties, non-current." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long term debt gross", "verboseLabel": "Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r26", "r205", "r375", "r385", "r714", "r715", "r883" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Current portion of long-term debt", "negatedLabel": "Less: current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r240" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r269", "r827" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r269", "r379" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r269", "r379" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r269", "r379" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r269", "r379" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCumulativeMaturitiesOfLong-termLoansAndCreditFacilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r269", "r379" ] }, "RELI_LongTermDebtNet": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "LongTermDebtNet", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-term debt", "documentation": "Long term debt, net." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long term debt, less current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r241" ] }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtPercentageBearingVariableInterestRate", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Variable interest of prime rate plus", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time." } } }, "auth_ref": [ "r38" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebt" ], "lang": { "en-us": { "role": { "label": "LONG-TERM DEBT", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r183" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible debt, related parties, less current portion", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r40" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r321", "r720", "r828", "r887", "r888" ] }, "RELI_MarketValueOfShare": { "xbrltype": "perShareItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "MarketValueOfShare", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Market value price per share", "documentation": "Market value of share." } } }, "auth_ref": [] }, "us-gaap_MarketingAndAdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketingAndAdvertisingExpense", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Marketing and advertising", "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising." } } }, "auth_ref": [ "r162" ] }, "RELI_MasterCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "MasterCreditAgreementMember", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Master Credit Agreement [Member]", "documentation": "Master Credit Agreement [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r355", "r356", "r357", "r358", "r423", "r524", "r570", "r617", "r618", "r680", "r681", "r682", "r683", "r692", "r702", "r703", "r711", "r718", "r727", "r734", "r825", "r875", "r876", "r877", "r878", "r879", "r880" ] }, "us-gaap_MeasurementInputCreditSpreadMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputCreditSpreadMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Credit Spread [Member]", "documentation": "Measurement input using amount above (below) yield between two debt instruments similar in maturity, but different in credit quality." } } }, "auth_ref": [ "r865" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r865" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r865" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r865" ] }, "RELI_MeasurementInputObsolescenceRateMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "MeasurementInputObsolescenceRateMember", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Measurement Input Obsolescence Rate [Member]", "documentation": "Measurement Input Obsolescence Rate [Member]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r865" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r865" ] }, "RELI_MeasurementInputRoyaltyRateMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "MeasurementInputRoyaltyRateMember", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Measurement Input Royalty Rate [Member]", "documentation": "Measurement Input Royalty Rate [Member]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r865" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r484" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "RELI_MedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "MedicalMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Medical [Member]", "documentation": "Medical [Member]" } } }, "auth_ref": [] }, "RELI_MedigapAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "MedigapAcquisitionMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Medigap Acquisition [Member]", "documentation": "Medigap Acquisition [Member]" } } }, "auth_ref": [] }, "RELI_MedigapHealthcareInsuranceCompanyLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "MedigapHealthcareInsuranceCompanyLLCMember", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Medigap Healthcare Insurance Company, LLC [Member]", "documentation": "Medigap Healthcare Insurance Company, LLC [Member]" } } }, "auth_ref": [] }, "RELI_MedigapHealthcareInsuranceCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "MedigapHealthcareInsuranceCompanyMember", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails", "http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Medigap Healthcare Insurance Company [Member]", "documentation": "Medigap Healthcare Insurance Company [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r355", "r356", "r357", "r358", "r423", "r524", "r570", "r617", "r618", "r680", "r681", "r682", "r683", "r692", "r702", "r703", "r711", "r718", "r727", "r734", "r825", "r875", "r876", "r877", "r878", "r879", "r880" ] }, "RELI_NSUREIncMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "NSUREIncMember", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "NSURE, Inc. [Member]", "documentation": "NSURE, Inc. [Member]" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "auth_ref": [ "r321", "r720", "r828", "r887", "r888" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided from continuing and discontinued financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r259" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided from continuing financing activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r785" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided and used in continuing and discontinued investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r259" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided and used in continuing investing activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r785" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in continuing and discontinued operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r166", "r167", "r168" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in continuing operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r166", "r167", "r168" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 }, "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows", "http://relianceglobalgroup.com/role/StatementsOfOperations", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "label": "Net Income (loss)", "verboseLabel": "Net (Loss) income", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r160", "r168", "r209", "r230", "r248", "r249", "r253", "r265", "r273", "r275", "r276", "r278", "r279", "r283", "r284", "r295", "r306", "r312", "r316", "r318", "r328", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r482", "r487", "r562", "r648", "r670", "r671", "r710", "r743", "r821" ] }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails" ], "lang": { "en-us": { "role": { "label": "(Loss) income from continuing operations, numerator, basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": [ "r288", "r298" ] }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails" ], "lang": { "en-us": { "role": { "label": "(Loss) income from continuing operations, numerator, diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": [ "r289", "r292", "r293", "r294", "r298" ] }, "RELI_NetOfEstimatedLiabilityAdjustmentsGain": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "NetOfEstimatedLiabilityAdjustmentsGain", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net of estimated liability adjustments gain", "documentation": "Net of estimated liability adjustments gain." } } }, "auth_ref": [] }, "RELI_NetRecoveriesAndImpairmentsWriteoffsFromDiscontinuedAssetsAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "NetRecoveriesAndImpairmentsWriteoffsFromDiscontinuedAssetsAndLiabilities", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities", "documentation": "Net recoveries and impairments writeoffs from discontinued assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "RELI_NonPrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "NonPrivatePlacementMember", "presentation": [ "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non Private Placement [Member]", "documentation": "Non Private Placement [Member]" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash investing and financing transactions:" } } }, "auth_ref": [] }, "RELI_NoncashInvestingAndFinancingTransactionsDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "NoncashInvestingAndFinancingTransactionsDiscontinuedOperations", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash investing and financing transactions, discontinued operations", "documentation": "Noncash investing and financing transactions, discontinued operations." } } }, "auth_ref": [] }, "RELI_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "NoncashLeaseExpense", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash lease expense", "documentation": "Non cash lease expense" } } }, "auth_ref": [] }, "RELI_NoncompetitionAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "NoncompetitionAgreementsMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Non-competition Agreements [Member]", "documentation": "Non-competition Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Other expenses (income)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r163" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r792", "r793" ] }, "RELI_NumberOfIterations": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "NumberOfIterations", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Number of iterations", "documentation": "Number of Iterations" } } }, "auth_ref": [] }, "RELI_NumberOfTradingDaysMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "NumberOfTradingDaysMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Number of Trading Days [Member]", "documentation": "Number of Trading Days [Member]" } } }, "auth_ref": [] }, "RELI_OakStreetFundingLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "OakStreetFundingLLCMember", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Oak Street Funding LLC [Member]", "documentation": "Oak Street Funding LLC [Member]" } } }, "auth_ref": [] }, "RELI_OfficeEquipmentAndFurnitureMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "OfficeEquipmentAndFurnitureMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails", "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office Equipment and Furniture [Member]", "documentation": "Office Equipment and Furniture [Member]" } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsLineItems", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails" ], "lang": { "en-us": { "role": { "label": "Offsetting Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsTable", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails" ], "lang": { "en-us": { "role": { "label": "Offsetting Assets [Table]", "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements." } } }, "auth_ref": [ "r156", "r157" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "negatedLabel": "Operating income loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r306", "r312", "r316", "r318", "r710" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r869" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Right-of-use assets", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r868" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFutureMinimumLeasePaymentDetails" ], "lang": { "en-us": { "role": { "label": "Present value of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r501" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Current portion of leases payable", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r501" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Leases payable, less current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r501" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r500" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://relianceglobalgroup.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r504", "r731" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://relianceglobalgroup.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r503", "r731" ] }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLimitationsOnUse", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforward limitation", "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/OrganizationAndDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r123", "r196", "r582", "r583" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r36" ] }, "us-gaap_OtherAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other receivables", "label": "Other Asset Impairment Charges", "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value." } } }, "auth_ref": [ "r787", "r815" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other non-current assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r238" ] }, "us-gaap_OtherDeferredCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDeferredCostsNet", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Net of deferred financing cost", "documentation": "Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies." } } }, "auth_ref": [ "r779" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Other liabilities", "verboseLabel": "Due to related party", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r118", "r547", "r621", "r622", "r745", "r891" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of loans payables, related parties", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r36", "r732" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Loans payable, related parties, less current portion", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r41" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r164" ] }, "RELI_OtherPayablesWriteoffs": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "OtherPayablesWriteoffs", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other payables", "documentation": "Other payables writeoffs.", "label": "OtherPayablesWriteoffs" } } }, "auth_ref": [] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Other receivables", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r759" ] }, "RELI_PAWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PAWarrantMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "PA Warrant [Member]", "documentation": "PA Warrant [Member]" } } }, "auth_ref": [] }, "RELI_PaidAtClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PaidAtClosingMember", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Paid At Closing [Member]", "documentation": "Paid At Closing [Member]" } } }, "auth_ref": [] }, "RELI_PayableInNineMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PayableInNineMonthsMember", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payable In Nine Months [Member]", "documentation": "Payable In Nine Months [Member]" } } }, "auth_ref": [] }, "RELI_PayableOverTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PayableOverTwoYearsMember", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payable Over Two Years [Member]", "documentation": "Payable Over Two Years [Member]" } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForCommissions", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agent commissions", "documentation": "The amount of cash paid for commissions during the current period." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfWarrants", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Warrants", "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt." } } }, "auth_ref": [ "r50" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r52" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financing fee", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r49" ] }, "RELI_PaymentsOnEarnoutLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PaymentsOnEarnoutLiabilities", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash payments on earn-out liability", "documentation": "Payments on earnout liabilities.", "label": "PaymentsOnEarnoutLiabilities" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Business acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r47" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r165" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r165" ] }, "RELI_PercentageOfBeneficialOwnership": { "xbrltype": "percentItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PercentageOfBeneficialOwnership", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "[custom:PercentageOfBeneficialOwnership-0]", "documentation": "Percentage of beneficial ownership." } } }, "auth_ref": [] }, "RELI_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants [Member]", "documentation": "Placement Agent Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854" ] }, "srt_PlatformOperatorCryptoAssetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PlatformOperatorCryptoAssetLineItems", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto-Asset [Line Items]" } } }, "auth_ref": [] }, "srt_PlatformOperatorCryptoAssetTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PlatformOperatorCryptoAssetTable", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFairValueMeasurementsDetails", "http://relianceglobalgroup.com/role/ScheduleOfLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto-Asset [Table]" } } }, "auth_ref": [] }, "RELI_PostExchangeWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PostExchangeWarrantMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Post Exchange Warrant [Member]", "documentation": "Post Exchange Warrant [Member]" } } }, "auth_ref": [] }, "RELI_PreAndPostExchangeWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PreAndPostExchangeWarrantMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pre And Post Exchange Warrant [Member]", "documentation": "Pre And Post Exchange Warrant [Member]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r753" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r754" ] }, "RELI_PreExchangeWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PreExchangeWarrantMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pre Exchange Warrant [Member]", "documentation": "Pre Exchange Warrant [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r735", "r736", "r739", "r740", "r741", "r742", "r889", "r894" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheetsParenthetical", "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r149", "r387" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheetsParenthetical", "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r149", "r627" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r149", "r387" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r149", "r627", "r646", "r894", "r895" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.086 par value; 750,000,000 shares authorized and 0 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r149", "r552", "r732" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid expense and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r780" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "RELI_PriorityHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PriorityHealthMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Priority Health [Member]", "documentation": "Priority Health [Member]" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Raising net proceeds", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net of cash proceeds", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Private Placement of shares and warrants", "verboseLabel": "Net Proceeds", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r6" ] }, "RELI_ProceedsFromLoanAcquiredThroughAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ProceedsFromLoanAcquiredThroughAcquisition", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Loans acquired through acquisitions", "documentation": "Proceeds from loan acquired through acquisition." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash payments and proceeds of convertible debt, related parties", "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfInvestmentProjects": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfInvestmentProjects", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of investment in NSURE", "verboseLabel": "Cash proceeds", "documentation": "The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from short term financing", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants into common stock", "verboseLabel": "Cash proceeds", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r783" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r319", "r528", "r564", "r565", "r566", "r567", "r568", "r569", "r705", "r719", "r733", "r774", "r818", "r819", "r828", "r887" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "auth_ref": [ "r319", "r528", "r564", "r565", "r566", "r567", "r568", "r569", "r705", "r719", "r733", "r774", "r818", "r819", "r828", "r887" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r230", "r248", "r249", "r258", "r265", "r273", "r283", "r284", "r306", "r312", "r316", "r318", "r328", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r465", "r468", "r469", "r482", "r487", "r545", "r561", "r596", "r648", "r670", "r671", "r710", "r729", "r730", "r744", "r781", "r821" ] }, "RELI_PropertyAndCasualtyMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PropertyAndCasualtyMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Property and Casualty [Member]", "documentation": "Property and Casualty [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails", "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Depreciation Method [Extensible Enumeration]", "documentation": "Indicates method of allocating cost over useful life in systematic and rational manner for property, plant, and equipment." } } }, "auth_ref": [ "r345" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r176", "r218", "r221", "r222" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r178", "r234", "r558" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails", "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Member]", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r11", "r546", "r558", "r732" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r11", "r218", "r221", "r556" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PROPERTY AND EQUIPMENT", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails", "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r178" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Estimated useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "RELI_PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PurchaseAgreementMember", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase Agreement [Member]", "documentation": "Purchase Agreement [Member]" } } }, "auth_ref": [] }, "RELI_PurchasedSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "PurchasedSoftwareMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Purchased Software [Member]", "documentation": "Purchased Software [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r355", "r356", "r357", "r358", "r415", "r423", "r432", "r433", "r434", "r523", "r524", "r570", "r617", "r618", "r680", "r681", "r682", "r683", "r692", "r702", "r703", "r711", "r718", "r727", "r734", "r737", "r816", "r825", "r876", "r877", "r878", "r879", "r880" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "auth_ref": [ "r355", "r356", "r357", "r358", "r415", "r423", "r432", "r433", "r434", "r523", "r524", "r570", "r617", "r618", "r680", "r681", "r682", "r683", "r692", "r702", "r703", "r711", "r718", "r727", "r734", "r737", "r816", "r825", "r876", "r877", "r878", "r879", "r880" ] }, "RELI_ReclassToLoansPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ReclassToLoansPayableRelatedParties", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Reclass to loans payable, related parties", "documentation": "Reclass to loans payable related parties." } } }, "auth_ref": [] }, "us-gaap_ReclassificationTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationTypeAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Reclassification, Type [Axis]", "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r777" ] }, "us-gaap_ReclassificationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationTypeDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r777" ] }, "RELI_RecognitionAndChangeInFairValueOfWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "RecognitionAndChangeInFairValueOfWarrantLiability", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetailsParenthetical", "http://relianceglobalgroup.com/role/StatementsOfOperations", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recognition and change in fair value of warrant liabilities", "verboseLabel": "Recognition and change in fair value of warrant liability", "terseLabel": "Fair value of warrant liabilities", "documentation": "Recognition and change in fair value of warrant liability." } } }, "auth_ref": [] }, "RELI_RegularMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "RegularMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Regular [Member]", "documentation": "Regular [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r422", "r511", "r512", "r620", "r621", "r622", "r623", "r624", "r645", "r647", "r679" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r267", "r268", "r511", "r512", "r513", "r514", "r620", "r621", "r622", "r623", "r624", "r645", "r647", "r679" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Earn out owned amount", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r117", "r511" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r652", "r653", "r656" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r422", "r511", "r512", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r620", "r621", "r622", "r623", "r624", "r645", "r647", "r679", "r872" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r508", "r509", "r510", "r512", "r515", "r593", "r594", "r595", "r654", "r655", "r656", "r676", "r678" ] }, "RELI_ReliExchangeMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ReliExchangeMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Reli Exchange [Member]", "documentation": "Reli Exchange [Member]" } } }, "auth_ref": [] }, "RELI_RelianceHoldingsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "RelianceHoldingsMember", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reliance Holdings [Member]", "documentation": "Reliance Holdings [Member]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal repayments of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r784" ] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments of loans payable, related parties", "label": "Agreed to payment", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r51" ] }, "RELI_RepaymentsOfRelatedPartysOwed": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "RepaymentsOfRelatedPartysOwed", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repayment of related party owed", "documentation": "Repayments of related partys owed." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal repayments of short-term financings", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r51" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r227", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r285", "r302", "r330", "r331", "r451", "r479", "r480", "r481", "r482", "r498", "r506", "r507", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r584" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "auth_ref": [ "r227", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r285", "r302", "r330", "r331", "r451", "r479", "r480", "r481", "r482", "r498", "r506", "r507", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r584" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate cash balance", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r53", "r202", "r233", "r262", "r551" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/ScheduleOfRestrictedCashInStatementOfCashFlowDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfRestrictedCashInStatementOfCashFlowDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash and restricted cash", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r53", "r233", "r262" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://relianceglobalgroup.com/role/ScheduleOfRestrictedCashInStatementOfCashFlowDetails": { "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfRestrictedCashInStatementOfCashFlowDetails" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r778", "r788" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails", "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r346", "r347", "r348", "r349", "r350", "r351", "r352" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r152", "r189", "r554", "r575", "r580", "r591", "r628", "r732" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r226", "r270", "r271", "r272", "r274", "r282", "r284", "r329", "r332", "r435", "r436", "r437", "r450", "r451", "r472", "r474", "r475", "r477", "r480", "r571", "r573", "r597", "r894" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r307", "r308", "r311", "r314", "r315", "r319", "r320", "r321", "r413", "r414", "r528" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r224", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r704" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r255", "r265", "r307", "r308", "r311", "r314", "r315", "r319", "r320", "r321", "r328", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r487", "r545", "r821" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "auth_ref": [] }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Reclassification, Adjustment [Member]" } } }, "auth_ref": [ "r228" ] }, "RELI_RightOfUseAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "RightOfUseAssetMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails" ], "lang": { "en-us": { "role": { "label": "Right of use asset [Member]", "documentation": "Right of use asset [Member]" } } }, "auth_ref": [] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "RELI_SWMTMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SWMTMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetails", "http://relianceglobalgroup.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "SWMT [Member]", "documentation": "SWMT [Member]" } } }, "auth_ref": [] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesAndWages", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Salaries and wages", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r782" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of stock", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedPerTransaction", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Receiving proceeds, net", "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, shares", "verboseLabel": "Sold shares", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfConcentrationsOfRevenuesDetails", "http://relianceglobalgroup.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r321", "r770" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "auth_ref": [ "r285", "r424", "r768", "r798" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/AccountsPayableAndAccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "RELI_ScheduleOfActualIncometaxRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ScheduleOfActualIncometaxRateTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ACTUAL INCOME TAX RATE", "documentation": "Tabular disclosure of actual income tax rate." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/EarningsLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/ScheduleOfProFormaInformationRelatedToAcquisitionDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r95", "r96", "r460" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r464" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF LONG TERM DEBT", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r40", "r79", "r82", "r112", "r113", "r115", "r120", "r186", "r188", "r714", "r716", "r794" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r193" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r15", "r83", "r84", "r85", "r86" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r14", "r22", "r28", "r124", "r133", "r134", "r135", "r136", "r137", "r142", "r144", "r145", "r181" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/EarningsLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r800" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r325", "r326", "r327" ] }, "RELI_ScheduleOfEstimatedUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ScheduleOfEstimatedUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT", "documentation": "Schedule of Estimated Useful Life of Property Plant and Equipment [Table Text Block]" } } }, "auth_ref": [] }, "RELI_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF WARRANT LIABILITY", "documentation": "Schedule of Warrant Liability [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r69", "r71", "r529" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF IMPAIRMENT OF GOODWILL", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r712", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF NON - VESTED STOCK OPTIONS", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": [ "r90" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEstimatedUsefulLivePropertyAndEquipmentDetails", "http://relianceglobalgroup.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ALLOCATION OF PURCHASE PRICE", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r195" ] }, "RELI_ScheduleOfReconcilesWarrantCommitmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ScheduleOfReconcilesWarrantCommitmentTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF RECONCILES WARRANT COMMITMENT", "documentation": "Schedule of Reconciles Warrant Commitment [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r116", "r117", "r652", "r653", "r656" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r24", "r202", "r884" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails", "http://relianceglobalgroup.com/role/ScheduleOfImpairmentOfGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r346", "r347", "r348", "r349", "r350", "r351", "r352" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r20", "r21", "r89" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r192" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r76", "r77", "r78", "r79", "r80", "r81", "r82", "r186", "r188", "r189", "r242", "r243", "r244", "r304", "r387", "r388", "r389", "r391", "r394", "r400", "r402", "r587", "r588", "r589", "r590", "r718", "r767", "r789" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r71" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SignificantCustomersTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CONCENTRATIONS OF REVENUES", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r59", "r60", "r62", "r63", "r110", "r199" ] }, "RELI_SeasonalityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeasonalityPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Seasonality", "documentation": "Seasonality [Policy Text Block]" } } }, "auth_ref": [] }, "RELI_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r747" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r751" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r750" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r755" ] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]", "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale." } } }, "auth_ref": [ "r7", "r125", "r126", "r127" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "General and Administrative", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r16" ] }, "RELI_SeniorSecuredAmortizingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeniorSecuredAmortizingCreditFacilityMember", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Senior Secured Amortizing Credit Facility [Member]", "documentation": "Senior Secured Amortizing Credit Facility [Member]" } } }, "auth_ref": [] }, "RELI_SeriesAWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesAWarrantMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Warrant [Member]", "documentation": "Series A Warrant [Member]" } } }, "auth_ref": [] }, "RELI_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesAWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/Cover", "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails" ], "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]", "documentation": "Series A Warrants [Member]" } } }, "auth_ref": [] }, "RELI_SeriesBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesBConvertiblePreferredStockMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock [Member]", "documentation": "Series B Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "RELI_SeriesBWarrantCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesBWarrantCommitmentMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails" ], "lang": { "en-us": { "role": { "label": "Series B Warrant Commitment [Member]", "documentation": "Series B Warrant Commitment [Member]" } } }, "auth_ref": [] }, "RELI_SeriesBWarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesBWarrantLiabilityMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Warrant Liability [Member]", "documentation": "Series B Warrant Liability [Member]" } } }, "auth_ref": [] }, "RELI_SeriesBWarrantsAndPlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesBWarrantsAndPlacementAgentWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails" ], "lang": { "en-us": { "role": { "label": "Series B Warrants And Placement Agent Warrants [Member]", "documentation": "Series B Warrants And Placement Agent Warrants [Member]" } } }, "auth_ref": [] }, "RELI_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesBWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Warrants [Member]", "documentation": "Series B Warrants [Member]" } } }, "auth_ref": [] }, "RELI_SeriesCPrepaidWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesCPrepaidWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series C Prepaid Warrants [Member]", "documentation": "Series C Prepaid Warrants [Member]" } } }, "auth_ref": [] }, "RELI_SeriesCandDWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesCandDWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series C and D Warrants [Member]", "documentation": "Series C and D Warrants [Member]" } } }, "auth_ref": [] }, "RELI_SeriesDPrepaidWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesDPrepaidWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series D Prepaid Warrants [Member]", "documentation": "Series D Prepaid Warrants [Member]" } } }, "auth_ref": [] }, "RELI_SeriesEWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesEWarrantMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series E Warrant [Member]", "documentation": "Series E Warrant [Member]" } } }, "auth_ref": [] }, "RELI_SeriesEWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesEWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series E Warrants [Member]", "documentation": "Series E Warrants [Member]" } } }, "auth_ref": [] }, "RELI_SeriesFInducementAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesFInducementAgreementMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series F Inducement Agreement [Member]", "documentation": "Series F Inducement Agreement [Member]" } } }, "auth_ref": [] }, "RELI_SeriesFWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesFWarrantMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series F Warrant [Member]", "documentation": "Series F Warrant [Member]" } } }, "auth_ref": [] }, "RELI_SeriesFWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesFWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series F Warrants [Member]", "documentation": "Series F Warrants [Member]" } } }, "auth_ref": [] }, "RELI_SeriesGWarrantsAndPlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesGWarrantsAndPlacementAgentWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails" ], "lang": { "en-us": { "role": { "label": "Series G Warrants And Placement Agent Warrants [Member]", "documentation": "Series G Warrants And Placement Agent Warrants [Member]" } } }, "auth_ref": [] }, "RELI_SeriesGWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SeriesGWarrantsMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series G Warrants [Member]", "documentation": "Series G Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_SettlementLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SettlementLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Settlement payment", "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers." } } }, "auth_ref": [] }, "RELI_SettlementRecoveryNetOfCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SettlementRecoveryNetOfCosts", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Settlement Recovery, net of costs", "documentation": "Settlement recovery net of costs." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://relianceglobalgroup.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share based compensation expense", "verboseLabel": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "RELI_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisedGrantedIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisedGrantedIntrinsicValue", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Exercised", "documentation": "Share-based compensation arrangement by share-based payment award exercised outstanding intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Expected dividend", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r432" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r434" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Available for issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r87" ] }, "RELI_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedOrExpiredIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedOrExpiredIntrinsicValue", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Forfeited or expired", "documentation": "Share-based compensation arrangement by share-based payment award forfeited or expired outstanding intrinsic value." } } }, "auth_ref": [] }, "RELI_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares option forfeitures", "documentation": "Share based compensation arrangement by share based payment award options forfeitures." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Stock Options Outstanding, Forfeited or expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r835" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Per Share, Forfeited or expired", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r835" ] }, "RELI_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Granted", "documentation": "Share-based compensation arrangement by share-based payment award granted outstanding intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails", "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "label": "Number of Stock Options Outstanding, Granted", "verboseLabel": "Number of Non-vested Stock Options Outstanding, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r427" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price Per Share, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r429" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value, Outstanding at Beginning of Period", "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at End of Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r87" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Stock Options Outstanding, Outstanding at Beginning of Period", "periodEndLabel": "Number of Stock Options Outstanding, Outstanding at End of Period", "label": "Options outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r425", "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period", "periodEndLabel": "Weighted Average Exercise Price, Outstanding at End of Period", "label": "Weighted average exercise price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r425", "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares vested", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r430" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Per Share, Exercised", "verboseLabel": "Exercise price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Per Share, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r427" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividend rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee." } } }, "auth_ref": [ "r212" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Volatility rate", "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee." } } }, "auth_ref": [ "r211" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee." } } }, "auth_ref": [ "r213" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r431" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Non-vested Stock Options Outstanding, Outstanding at Beginning of Period", "periodEndLabel": "Number of Stock Options Outstanding, Outstanding at End of Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Number of Non-vested Stock Options Outstanding, Forfeited or expired", "documentation": "Number of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price Per Share, Forfeited or expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "documentation": "Weighted average grant-date fair value of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period", "periodEndLabel": "Weighted Average Exercise Price, Outstanding at End of Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "RELI_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life (years), Outstanding at End of Period", "documentation": "share-based compensation arrangement by share-based payment award options outstanding weighted average remaining contractual term." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period", "verboseLabel": "Weighted average remaining contractual life", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r191" ] }, "RELI_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermNonVested": { "xbrltype": "durationItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermNonVested", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period", "documentation": "Share-based compensation arrangement by share-based payment award options outstanding weighted average remaining contractual term non-vested.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermNonVested" } } }, "auth_ref": [] }, "RELI_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermsNonVested": { "xbrltype": "durationItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermsNonVested", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Remaining Contractual Life (years), Outstanding at End of Period", "documentation": "Share-based compensation arrangement by share-based payment award options outstanding weighted average remaining contractual term non-vested.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermsNonVested" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Non-vested Stock Options Outstanding, Vested", "label": "Vested restricted stock awards", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Per Share, Vested", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "RELI_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm2", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfNon-VestedStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life (years), Vested", "documentation": "Share-based compensation arrangement by share-based payment award, options, vested weighted average remaining contractual term" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "verboseLabel": "Shares issued price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "RELI_SharesIssuedUponTerminationOfEmployee": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SharesIssuedUponTerminationOfEmployee", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued upon termination of employee", "documentation": "Shares issued upon termination of employee." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Remaining balance shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short term financing agreements", "verboseLabel": "Short-term financings", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r146", "r204", "r732", "r882" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "RELI_ShortTermFinancingAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ShortTermFinancingAgreements", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Short term financing agreements", "documentation": "Short term financing agreements.", "label": "ShortTermFinancingAgreements" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r169", "r263" ] }, "RELI_SignificantUnobservableInput": { "xbrltype": "stringItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SignificantUnobservableInput", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Significant unobservable input", "documentation": "Significant unobservable input." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r756" ] }, "RELI_SouthwesternMontanaFinancialCenterIncMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SouthwesternMontanaFinancialCenterIncMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Southwestern Montana Financial Center Inc [Member]", "documentation": "Southwestern Montana Financial Center Inc [Member]" } } }, "auth_ref": [] }, "RELI_SouthwesternMontanaInsuranceCenterIncMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SouthwesternMontanaInsuranceCenterIncMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfEarn-outLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Southwestern Montana Insurance Center Inc [Member]", "documentation": "Southwestern Montana Insurance Center Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://relianceglobalgroup.com/role/Cover", "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r225", "r242", "r243", "r244", "r265", "r290", "r291", "r296", "r298", "r304", "r305", "r328", "r359", "r361", "r362", "r363", "r366", "r367", "r387", "r388", "r391", "r394", "r402", "r487", "r587", "r588", "r589", "r590", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r609", "r627", "r649", "r672", "r693", "r694", "r695", "r696", "r697", "r767", "r789", "r799" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r17", "r45", "r226", "r251", "r252", "r253", "r270", "r271", "r272", "r274", "r282", "r284", "r303", "r329", "r332", "r404", "r435", "r436", "r437", "r450", "r451", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r488", "r489", "r490", "r491", "r492", "r493", "r507", "r571", "r572", "r573", "r597", "r672" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://relianceglobalgroup.com/role/Cover", "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r270", "r271", "r272", "r303", "r528", "r585", "r609", "r619", "r620", "r621", "r622", "r623", "r624", "r627", "r630", "r631", "r632", "r633", "r634", "r636", "r637", "r638", "r639", "r641", "r642", "r643", "r644", "r645", "r647", "r650", "r651", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r672", "r738" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r285", "r424", "r768", "r769", "r798" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://relianceglobalgroup.com/role/Cover", "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails", "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r270", "r271", "r272", "r303", "r528", "r585", "r609", "r619", "r620", "r621", "r622", "r623", "r624", "r627", "r630", "r631", "r632", "r633", "r634", "r636", "r637", "r638", "r639", "r641", "r642", "r643", "r644", "r645", "r647", "r650", "r651", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r672", "r738" ] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common shares issued to settle convertible debt, related parties", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r55", "r56", "r57" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued pursuant to acquisition of Medigap, shares", "verboseLabel": "Stock issued during period, shares, acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r149", "r150", "r189" ] }, "RELI_StockIssuedDuringPeriodSharesCommissionEquityAwardExpense": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodSharesCommissionEquityAwardExpense", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued commission equity award expense", "documentation": "Shares issued commission equity award expense." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued due to conversion of preferred stock, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r17", "r44", "r79", "r189", "r378" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for conversion of Series C warrants, shares", "verboseLabel": "Number of shares converted", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r17", "r79", "r149", "r150", "r189" ] }, "RELI_StockIssuedDuringPeriodSharesConversionOfUnitsSeriesD": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodSharesConversionOfUnitsSeriesD", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for conversion of Series D warrants, shares", "documentation": "Stock issued during period shares conversion of units series D." } } }, "auth_ref": [] }, "RELI_StockIssuedDuringPeriodSharesForVestedStockAwards": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodSharesForVestedStockAwards", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for vested stock awards, shares", "documentation": "Shares issued for vested stock awards, shares." } } }, "auth_ref": [] }, "RELI_StockIssuedDuringPeriodSharesIssuanceOfSeriesCWarrantsInExchangeForCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSeriesCWarrantsInExchangeForCommonShares", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of Series C warrants in exchange for common shares, shares", "documentation": "Stock issued during period shares issuance of series c warrants in exchange for common shares." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common shares issued for services, shares", "verboseLabel": "Shares issued service", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued in private placement, shares", "verboseLabel": "Number of shares of common stock, shares", "terseLabel": "Shares of common Stock", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r17", "r149", "r150", "r189", "r587", "r672", "r694" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common shares issued for earnout liabilities, shares", "verboseLabel": "Settle an earn-out liability", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares restricted", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r17", "r189" ] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Round up of shares due to reverse split, shares", "verboseLabel": "Round up of shares due to reverse split", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r17" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Share based compensation, shares", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r17", "r149", "r150", "r189" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share based compensation, shares", "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfStockOptionsGrantedForfeitedOrExpiredDetails", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares issued exercised", "verboseLabel": "Number of Stock Options Outstanding, Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r17", "r149", "r150", "r189", "r428" ] }, "RELI_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Series A warrants, shares", "verboseLabel": "Exercise of warrants, shares", "documentation": "Shares issued for exercise of warrants, shares." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued pursuant to acquisition", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r17", "r45", "r189" ] }, "RELI_StockIssuedDuringPeriodValueCommissionEquityAwardExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodValueCommissionEquityAwardExpense", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Value issued commission equity award expense", "documentation": "Value issued commission equity award expense." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued due to conversion of preferred stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r17", "r45", "r189" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for conversion of Series C warrants", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r17", "r45", "r189" ] }, "RELI_StockIssuedDuringPeriodValueConversionOfUnitsSeriesB": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodValueConversionOfUnitsSeriesB", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for conversion of Series B warrants", "documentation": "Stock issued during period value conversion of units series B." } } }, "auth_ref": [] }, "RELI_StockIssuedDuringPeriodValueConversionOfUnitsSeriesBShares": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodValueConversionOfUnitsSeriesBShares", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for conversion of Series B warrants, shares", "documentation": "Stock issued during period value conversion of units series B shares." } } }, "auth_ref": [] }, "RELI_StockIssuedDuringPeriodValueConversionOfUnitsSeriesD": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodValueConversionOfUnitsSeriesD", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for conversion of Series D warrants", "documentation": "Stock issued during period value conversion of units series D." } } }, "auth_ref": [] }, "RELI_StockIssuedDuringPeriodValueForVestedStockAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodValueForVestedStockAwards", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for vested stock awards", "documentation": "Shares issued for vested stock awards." } } }, "auth_ref": [] }, "RELI_StockIssuedDuringPeriodValueIssuanceOfSeriesCWarrantsInExchangeForCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodValueIssuanceOfSeriesCWarrantsInExchangeForCommonShares", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of Series C warrants in exchange for common shares", "documentation": "Stock issued during period value issuance on series warrants in exchange for common shares." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common shares issued for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity", "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued in private placement", "verboseLabel": "Stock Issued During Period, Value, New Issues", "terseLabel": "Aggregate offering price", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r17", "r149", "r150", "r189", "r597", "r672", "r694", "r744" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common shares issued for earnout liabilities", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares restricted, value", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r17", "r149", "r150", "r189" ] }, "RELI_StockIssuedDuringPeriodValueReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Round up of shares due to reverse split", "verboseLabel": "Round up of shares due to reverse split, value", "documentation": "Reduction in the number of value during the period as a result of a reverse stock split." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Share based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r91", "r149", "r150", "r189" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share based compensation", "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [] }, "RELI_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Series A warrants", "documentation": "Shares issued for exercise of warrants." } } }, "auth_ref": [] }, "RELI_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "StockOptionsMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails" ], "lang": { "en-us": { "role": { "label": "Stock Options [Member]", "documentation": "Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity", "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Stockholder's equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r150", "r153", "r154", "r171", "r629", "r646", "r673", "r674", "r732", "r745", "r791", "r803", "r867", "r894" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/Equity" ], "lang": { "en-us": { "role": { "label": "EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r185", "r264", "r386", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r401", "r404", "r478", "r675", "r677", "r698" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stockholders' equity, reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r190" ] }, "RELI_SubscriptionReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "SubscriptionReceivableMember", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Subscription Receivable [Member]", "documentation": "Subscription Receivable [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r494", "r518" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r494", "r518" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r494", "r518" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r494", "r518" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r494", "r518" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r517", "r519" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH AND NON-CASH TRANSACTIONS:" } } }, "auth_ref": [] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, net", "label": "Tangible Asset Impairment Charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r132", "r179" ] }, "RELI_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "TermLoanMember", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Term Loan [Member]", "documentation": "Term Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r721", "r828" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r721", "r828" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r801", "r871" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "auth_ref": [] }, "RELI_TotalLiabilityWriteoffs": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "TotalLiabilityWriteoffs", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDiscontinuedOperationsOnCondensedConsolidatedBalanceSheetsAndStatementsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Total liability write-off gains", "documentation": "Total liability writeoffs." } } }, "auth_ref": [] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfAllocationOfPurchasePriceDetails", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r99" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r99" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "RELI_TwoThousandNineteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "TwoThousandNineteenEquityIncentivePlanMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2019 Equity Incentive Plan [Member]", "documentation": "2019 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "RELI_TwoThousandTwentyThreeEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "TwoThousandTwentyThreeEquityIncentivePlanMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2023 Equity Incentive Plan [Member]", "documentation": "2023 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/IncomeTaxesDetailsNarrative", "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative", "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative", "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative", "http://relianceglobalgroup.com/role/SubsequentEventsDetailsNarrative", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r464" ] }, "RELI_USBenefitsAllianceLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "USBenefitsAllianceLLCMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDisaggregationRevenueDetails" ], "lang": { "en-us": { "role": { "label": "US Benefits Alliance LLC [Member]", "documentation": "US Benefits Alliance LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unamortized deferred financing costs", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "RELI_UnvestedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "UnvestedStockAwardsMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfDilutiveNetLossPerCommonSharesDetails" ], "lang": { "en-us": { "role": { "label": "Unvested Stock Awards [Member]", "documentation": "Unvested Stock Awards [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r64", "r65", "r66", "r216", "r217", "r219", "r220" ] }, "RELI_ValuationTechnique": { "xbrltype": "stringItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "ValuationTechnique", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Valuation technique", "documentation": "Valuation technique." } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://relianceglobalgroup.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://relianceglobalgroup.com/role/InvestmentInNsureInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854" ] }, "RELI_VideoProductionAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "VideoProductionAssetsMember", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfIntangibleAssetsAndWeighted-averageRemainingAmortizationPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Video Production Assets [Member]", "documentation": "Video Production Assets [Member]" } } }, "auth_ref": [] }, "RELI_WarrantAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WarrantAgreementMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant Agreement [Member]", "documentation": "Warrant Agreement [Member]" } } }, "auth_ref": [] }, "RELI_WarrantCommitmentUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WarrantCommitmentUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrealized (gain) loss", "negatedLabel": "Net fair value gains losses", "documentation": "Unrealized (gain) loss." } } }, "auth_ref": [] }, "us-gaap_WarrantExercisePriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantExercisePriceDecrease", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price reduced", "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r403" ] }, "RELI_WarrantIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WarrantIssuanceCost", "crdr": "debit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Warrant issuance cost", "documentation": "Warrant issuance cost." } } }, "auth_ref": [] }, "RELI_WarrantLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WarrantLiabilities", "crdr": "credit", "calculation": { "http://relianceglobalgroup.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://relianceglobalgroup.com/role/BalanceSheets", "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails" ], "lang": { "en-us": { "role": { "label": "Warrant liabilities", "periodStartLabel": "Beginning balance, December 31, 2022", "periodEndLabel": "Ending balance, December 31, 2023", "documentation": "Warrant liabilities." } } }, "auth_ref": [] }, "RELI_WarrantLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WarrantLiabilitiesTextBlock", "presentation": [ "http://relianceglobalgroup.com/role/WarrantLiabilities" ], "lang": { "en-us": { "role": { "label": "WARRANT LIABILITIES", "documentation": "Warrant Liabilities [Text Block]" } } }, "auth_ref": [] }, "RELI_WarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WarrantLiability", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant liability", "documentation": "Warrant liability." } } }, "auth_ref": [] }, "RELI_WarrantLiabilityReclassifiedToEquityUponExerciseOfSeriesBWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WarrantLiabilityReclassifiedToEquityUponExerciseOfSeriesBWarrants", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Warrant liability reclassified to equity upon exercise of Series B Warrants", "documentation": "Warrant liability reclassified to equity upon exercise of series B warrants." } } }, "auth_ref": [] }, "RELI_WarrantsAndRightsOutstandingAfterExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WarrantsAndRightsOutstandingAfterExchange", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants and rights outstanding after exchange", "documentation": "Warrants and rights outstanding after exchange." } } }, "auth_ref": [] }, "RELI_WarrantsAndRightsOutstandingBeforeExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WarrantsAndRightsOutstandingBeforeExchange", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants and rights outstanding before exchange", "documentation": "Warrants and rights outstanding before exchange." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant Liabilities", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r485" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/ScheduleOfWarrantLiabilityDetails", "http://relianceglobalgroup.com/role/WarrantLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Time to expiry", "verboseLabel": "Warrants and rights outstanding term", "terseLabel": "Warrants term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r866" ] }, "RELI_WarrantsExercisedOrTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WarrantsExercisedOrTransferred", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfReconcilesWarrantCommitmentDetails" ], "lang": { "en-us": { "role": { "label": "Warrants exercised or exchanged", "documentation": "Warrants exercised or transferred." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding \u2013 Diluted", "verboseLabel": "Diluted weighted average shares outstanding", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r289", "r298" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://relianceglobalgroup.com/role/ScheduleOfCalculationsOfBasicAndDilutedEpsDetails", "http://relianceglobalgroup.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding \u2013 Basic", "verboseLabel": "Weighted average common shares, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r287", "r298" ] }, "RELI_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WorkingCapital", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/StrategicInvestmentsAndBusinessCombinationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital", "documentation": "Working capital." } } }, "auth_ref": [] }, "RELI_WorkingCapitalDeficiency": { "xbrltype": "monetaryItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "WorkingCapitalDeficiency", "crdr": "credit", "presentation": [ "http://relianceglobalgroup.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Working capital", "documentation": "Working capital deficiency.", "label": "Working capital deficiency" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://relianceglobalgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r765" ] }, "RELI_YESAmericanaGroupLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://relianceglobalgroup.com/20231231", "localname": "YESAmericanaGroupLLCMember", "presentation": [ "http://relianceglobalgroup.com/role/EquityDetailsNarrative", "http://relianceglobalgroup.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "YES Americana Group LLC [Member]", "documentation": "YES Americana Group LLC [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-11" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "740", "Section": "25", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479692/805-740-25-8" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "740", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479692/805-740-25-9" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r767": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r768": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r769": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//321/tableOfContent" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org//325/tableOfContent" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 102 0001493152-24-013118-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-013118-xbrl.zip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Ď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end XML 104 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001812727 2023-01-01 2023-12-31 0001812727 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2023-01-01 2023-12-31 0001812727 2023-06-30 0001812727 2024-04-04 0001812727 2023-12-31 0001812727 2022-12-31 0001812727 us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 us-gaap:NonrelatedPartyMember 2022-12-31 0001812727 us-gaap:RelatedPartyMember 2023-12-31 0001812727 us-gaap:RelatedPartyMember 2022-12-31 0001812727 2022-01-01 2022-12-31 0001812727 us-gaap:NonrelatedPartyMember 2023-01-01 2023-12-31 0001812727 us-gaap:NonrelatedPartyMember 2022-01-01 2022-12-31 0001812727 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001812727 us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001812727 us-gaap:PreferredStockMember 2022-12-31 0001812727 us-gaap:CommonStockMember 2022-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001812727 RELI:SubscriptionReceivableMember 2022-12-31 0001812727 us-gaap:RetainedEarningsMember 2022-12-31 0001812727 us-gaap:PreferredStockMember 2021-12-31 0001812727 us-gaap:CommonStockMember 2021-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001812727 RELI:SubscriptionReceivableMember 2021-12-31 0001812727 us-gaap:RetainedEarningsMember 2021-12-31 0001812727 2021-12-31 0001812727 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001812727 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001812727 RELI:SubscriptionReceivableMember 2023-01-01 2023-12-31 0001812727 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001812727 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001812727 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001812727 RELI:SubscriptionReceivableMember 2022-01-01 2022-12-31 0001812727 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001812727 us-gaap:PreferredStockMember 2023-12-31 0001812727 us-gaap:CommonStockMember 2023-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001812727 RELI:SubscriptionReceivableMember 2023-12-31 0001812727 us-gaap:RetainedEarningsMember 2023-12-31 0001812727 2023-03-01 2023-03-31 0001812727 srt:MinimumMember 2023-12-31 0001812727 srt:MaximumMember 2023-12-31 0001812727 us-gaap:SegmentDiscontinuedOperationsMember RELI:MedigapHealthcareInsuranceCompanyLLCMember 2023-01-01 2023-12-31 0001812727 us-gaap:SegmentDiscontinuedOperationsMember RELI:MedigapHealthcareInsuranceCompanyLLCMember 2023-12-31 0001812727 us-gaap:ComputerEquipmentMember 2023-12-31 0001812727 RELI:OfficeEquipmentAndFurnitureMember 2023-12-31 0001812727 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001812727 us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001812727 us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001812727 us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001812727 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001812727 us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001812727 us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001812727 us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001812727 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001812727 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001812727 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2021-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2021-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2021-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-01-01 2022-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2022-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2023-01-01 2023-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2023-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2023-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputCreditSpreadMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member RELI:NumberOfTradingDaysMember 2023-01-01 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember RELI:MedicalMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember RELI:LifeMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember 2023-01-01 2023-12-31 0001812727 RELI:USBenefitsAllianceLLCMember RELI:MedicalMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:USBenefitsAllianceLLCMember RELI:LifeMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:USBenefitsAllianceLLCMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:USBenefitsAllianceLLCMember 2023-01-01 2023-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:MedicalMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:LifeMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember 2023-01-01 2023-12-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember RELI:MedicalMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember RELI:LifeMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember 2023-01-01 2023-12-31 0001812727 RELI:FortmanInsuranceServicesLLCMember RELI:MedicalMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:FortmanInsuranceServicesLLCMember RELI:LifeMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:FortmanInsuranceServicesLLCMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:FortmanInsuranceServicesLLCMember 2023-01-01 2023-12-31 0001812727 RELI:AltruisBenefitsConsultingIncMember RELI:MedicalMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:AltruisBenefitsConsultingIncMember RELI:LifeMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:AltruisBenefitsConsultingIncMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:AltruisBenefitsConsultingIncMember 2023-01-01 2023-12-31 0001812727 RELI:KushMember RELI:MedicalMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:KushMember RELI:LifeMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:KushMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:KushMember 2023-01-01 2023-12-31 0001812727 RELI:ReliExchangeMember RELI:MedicalMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:ReliExchangeMember RELI:LifeMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:ReliExchangeMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:ReliExchangeMember 2023-01-01 2023-12-31 0001812727 RELI:MedicalMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:LifeMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember 2023-01-01 2023-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember RELI:MedicalMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember RELI:LifeMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-12-31 0001812727 RELI:USBenefitsAllianceLLCMember RELI:MedicalMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:USBenefitsAllianceLLCMember RELI:LifeMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:USBenefitsAllianceLLCMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:MedicalMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:LifeMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-12-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember RELI:MedicalMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember RELI:LifeMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-12-31 0001812727 RELI:FortmanInsuranceServicesLLCMember RELI:MedicalMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:FortmanInsuranceServicesLLCMember RELI:LifeMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:FortmanInsuranceServicesLLCMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-12-31 0001812727 RELI:AltruisBenefitsConsultingIncMember RELI:MedicalMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:AltruisBenefitsConsultingIncMember RELI:LifeMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:AltruisBenefitsConsultingIncMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-12-31 0001812727 RELI:KushMember RELI:MedicalMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:KushMember RELI:LifeMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:KushMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:KushMember 2022-01-01 2022-12-31 0001812727 RELI:ReliExchangeMember RELI:MedicalMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:ReliExchangeMember RELI:LifeMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:ReliExchangeMember RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:ReliExchangeMember 2022-01-01 2022-12-31 0001812727 RELI:MedicalMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:LifeMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember 2022-01-01 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:NonrelatedPartyMember 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:RelatedPartyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:RelatedPartyMember 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-12-31 0001812727 RELI:CarryingValuePriorToAbandonmentMember RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetAndLiabilityTransfersRetainedByTheCompanyMember us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetImpairmentsAndLiabilityWriteOffsMember us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:NonrelatedPartyMember 2023-12-31 0001812727 RELI:CarryingValuePriorToAbandonmentMember RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:RelatedPartyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetAndLiabilityTransfersRetainedByTheCompanyMember us-gaap:RelatedPartyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetImpairmentsAndLiabilityWriteOffsMember us-gaap:RelatedPartyMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:RelatedPartyMember 2023-12-31 0001812727 RELI:CarryingValuePriorToAbandonmentMember RELI:MedigapHealthcareInsuranceCompanyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetAndLiabilityTransfersRetainedByTheCompanyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember RELI:AssetImpairmentsAndLiabilityWriteOffsMember 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2023-01-01 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2022-01-01 2022-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001812727 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001812727 RELI:BarraAndAssociatesLLCMember RELI:APAMember 2022-04-26 2022-04-26 0001812727 RELI:PaidAtClosingMember RELI:BarraAndAssociatesLLCMember RELI:APAMember 2022-04-26 2022-04-26 0001812727 RELI:PayableInNineMonthsMember RELI:BarraAndAssociatesLLCMember RELI:APAMember 2022-04-26 2022-04-26 0001812727 RELI:PayableOverTwoYearsMember RELI:BarraAndAssociatesLLCMember RELI:APAMember 2022-04-26 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:TradeNamesMember RELI:MeasurementInputRoyaltyRateMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:TradeNamesMember us-gaap:MeasurementInputDiscountRateMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:CustomerRelationshipsMember us-gaap:MeasurementInputDiscountRateMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:DevelopmentTechnologyMember RELI:MeasurementInputObsolescenceRateMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember 2022-04-26 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember 2022-04-26 2022-12-31 0001812727 RELI:BarraAndAssociatesLLCMember 2023-01-01 2023-12-31 0001812727 RELI:BarraAndAssociatesLLCMember RELI:AcquiredAccountsReceivableMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:PropertyPlantAndEquipmentMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:RightOfUseAssetMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:TradeNamesMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:CustomerRelationshipsMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:DevelopmentTechnologyMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:AgencyRelationshipMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember RELI:LeaseLiabilityMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:GoodwillMember 2022-04-26 0001812727 RELI:BarraAndAssociatesLLCMember us-gaap:GoodwillMember 2022-04-26 2022-04-26 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-01-01 2022-12-31 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember 2020-10-08 0001812727 us-gaap:CommonClassAMember RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember 2020-10-07 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember RELI:NSUREIncMember 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember RELI:NSUREIncMember 2020-10-07 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember RELI:NSUREIncMember 2020-10-07 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember RELI:NSUREIncMember 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember RELI:NSUREIncMember 2020-10-07 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember RELI:NSUREIncMember 2021-03-31 0001812727 RELI:NSUREIncMember 2022-01-01 2022-12-31 0001812727 RELI:NSUREIncMember 2023-04-01 2023-04-30 0001812727 RELI:NSUREIncMember 2023-12-31 0001812727 RELI:ComputerEquipmentAndSoftwareMember 2023-12-31 0001812727 RELI:ComputerEquipmentAndSoftwareMember 2022-12-31 0001812727 RELI:OfficeEquipmentAndFurnitureMember 2022-12-31 0001812727 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2023-06-30 0001812727 RELI:BarraMember 2022-01-01 2022-12-31 0001812727 RELI:BarraMember 2023-01-01 2023-12-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2023-01-01 2023-12-31 0001812727 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001812727 RELI:InternallyDevelopedSoftwareMember 2023-12-31 0001812727 us-gaap:CustomerRelationshipsMember 2023-12-31 0001812727 RELI:PurchasedSoftwareMember 2023-12-31 0001812727 RELI:VideoProductionAssetsMember 2023-12-31 0001812727 RELI:NoncompetitionAgreementsMember 2023-12-31 0001812727 us-gaap:TrademarksAndTradeNamesMember 2022-12-31 0001812727 RELI:InternallyDevelopedSoftwareMember 2022-12-31 0001812727 us-gaap:CustomerRelationshipsMember 2022-12-31 0001812727 RELI:PurchasedSoftwareMember 2022-12-31 0001812727 RELI:VideoProductionAssetsMember 2022-12-31 0001812727 RELI:NoncompetitionAgreementsMember 2022-12-31 0001812727 RELI:EBSandUSBAMember 2023-12-31 0001812727 RELI:EBSandUSBAMember 2022-12-31 0001812727 RELI:CCSMember 2023-12-31 0001812727 RELI:CCSMember 2022-12-31 0001812727 RELI:SWMTMember 2023-12-31 0001812727 RELI:SWMTMember 2022-12-31 0001812727 RELI:FISMember 2023-12-31 0001812727 RELI:FISMember 2022-12-31 0001812727 RELI:ABCMember 2023-12-31 0001812727 RELI:ABCMember 2022-12-31 0001812727 RELI:BarraMember 2023-12-31 0001812727 RELI:BarraMember 2022-12-31 0001812727 RELI:EBSandUSBAMember 2023-01-01 2023-12-31 0001812727 RELI:CCSMember 2023-01-01 2023-12-31 0001812727 RELI:SWMTMember 2023-01-01 2023-12-31 0001812727 RELI:FISMember 2023-01-01 2023-12-31 0001812727 RELI:ABCMember 2023-01-01 2023-12-31 0001812727 RELI:EmployeeBenefitsSolutionsLLCAndUSBenefitsAllianceMember RELI:CreditAgreementMember RELI:OakStreetFundingLLCMember 2018-08-01 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember 2018-12-07 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember RELI:OakStreetFundingLLCMember 2018-12-06 2018-12-07 0001812727 RELI:CommercialCoverageSolutionsLLCMember RELI:SeniorSecuredAmortizingCreditFacilityMember us-gaap:PrimeRateMember RELI:OakStreetFundingLLCMember 2018-12-07 0001812727 RELI:TermLoanMember RELI:OakStreetFundingLLCMember 2019-12-31 0001812727 RELI:TermLoanMember RELI:OakStreetFundingLLCMember 2019-01-01 2019-12-31 0001812727 RELI:SeniorSecuredAmortizingCreditFacilityMember us-gaap:PrimeRateMember RELI:OakStreetFundingLLCMember 2019-12-31 0001812727 RELI:MasterCreditAgreementMember RELI:OakStreetFundingLLCMember 2022-04-26 0001812727 RELI:MasterCreditAgreementMember RELI:OakStreetFundingLLCMember 2022-04-26 2022-04-26 0001812727 srt:MaximumMember us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-22 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-22 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-21 2021-12-22 0001812727 RELI:SeriesBConvertiblePreferredStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-21 2021-12-22 0001812727 RELI:SeriesBConvertiblePreferredStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-22 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2021-12-22 0001812727 RELI:SecuritiesPurchaseAgreementMember 2021-12-21 2021-12-22 0001812727 2021-01-01 2021-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-01-04 2022-01-04 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-01-04 0001812727 RELI:SeriesBWarrantLiabilityMember RELI:NonPrivatePlacementMember 2022-12-27 0001812727 RELI:SeriesBWarrantLiabilityMember us-gaap:CommonStockMember RELI:NonPrivatePlacementMember 2022-12-27 2022-12-27 0001812727 RELI:SeriesBWarrantLiabilityMember RELI:NonPrivatePlacementMember 2023-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember RELI:SecuritiesPurchaseAgreementMember 2023-12-12 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember 2023-12-12 2023-12-12 0001812727 RELI:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001812727 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember RELI:PriorityHealthMember 2023-01-01 2023-12-31 0001812727 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember RELI:PriorityHealthMember 2022-01-01 2022-12-31 0001812727 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember RELI:BlueCrossBlueShieldMember 2023-01-01 2023-12-31 0001812727 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember RELI:BlueCrossBlueShieldMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2022-08-31 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2022-08-01 2022-08-31 0001812727 us-gaap:PrivatePlacementMember 2022-01-01 2022-01-31 0001812727 RELI:MedigapAcquisitionMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantMember 2022-01-31 0001812727 RELI:EmployeeAgreementMember 2022-03-01 2022-03-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-05-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-06-30 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-05-31 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-06-30 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-07-31 0001812727 RELI:SeriesDPrepaidWarrantsMember us-gaap:CommonStockMember 2022-07-31 0001812727 RELI:EmployeeAgreementMember 2022-12-01 2022-12-31 0001812727 RELI:SeriesBWarrantsMember 2022-12-01 2022-12-31 0001812727 RELI:SeriesBWarrantsMember 2022-12-31 0001812727 us-gaap:CommonStockMember 2023-01-01 2023-01-31 0001812727 RELI:BoardOfDirectorsMember 2023-02-22 2023-02-23 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-01 2023-02-28 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-28 0001812727 us-gaap:PrivatePlacementMember 2023-03-01 2023-03-31 0001812727 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001812727 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001812727 RELI:SeriesBWarrantsMember 2023-07-01 2023-09-30 0001812727 RELI:SeriesEWarrantMember 2023-10-01 2023-12-31 0001812727 RELI:SeriesFWarrantMember 2023-10-01 2023-12-31 0001812727 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001812727 RELI:SeriesBWarrantsMember 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantsMember 2023-11-30 0001812727 RELI:SeriesAWarrantsMember 2023-11-01 2023-11-30 0001812727 RELI:SeriesAWarrantsMember 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2022-12-31 0001812727 RELI:SeriesAWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-01-31 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-01-31 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-01-31 0001812727 RELI:SeriesCandDWarrantsMember 2023-12-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-07-01 2022-07-31 0001812727 RELI:SecuritiesPurchaseAgreementMember 2023-03-13 2023-03-13 0001812727 RELI:SecuritiesPurchaseAgreementMember 2023-03-13 0001812727 RELI:SeriesEWarrantsMember 2023-03-13 0001812727 RELI:SeriesFWarrantsMember 2022-03-13 0001812727 RELI:PAWarrantMember 2022-03-13 0001812727 2023-03-13 2023-03-13 0001812727 RELI:SeriesFWarrantsMember 2023-03-13 0001812727 RELI:PAWarrantMember 2023-03-13 0001812727 us-gaap:PrivatePlacementMember 2023-03-16 2023-03-16 0001812727 us-gaap:PrivatePlacementMember 2023-01-01 2023-12-31 0001812727 RELI:WarrantAgreementMember 2023-12-31 0001812727 RELI:SeriesFWarrantsMember 2023-12-12 0001812727 RELI:SeriesFWarrantsMember 2023-12-11 2023-12-12 0001812727 RELI:SeriesFWarrantsMember 2023-12-31 0001812727 RELI:SeriesFWarrantsMember 2023-12-31 2023-12-31 0001812727 us-gaap:CommonStockMember 2023-12-12 0001812727 RELI:PreExchangeWarrantMember 2023-12-12 0001812727 RELI:PostExchangeWarrantMember 2023-12-12 0001812727 RELI:PreAndPostExchangeWarrantMember 2023-12-31 0001812727 2023-12-12 2023-12-12 0001812727 RELI:SeriesGWarrantsMember RELI:SeriesFInducementAgreementMember 2023-12-12 0001812727 RELI:SeriesFInducementAgreementMember 2023-12-12 0001812727 RELI:SeriesGWarrantsMember RELI:SeriesFInducementAgreementMember 2023-12-12 2023-12-12 0001812727 RELI:SeriesFInducementAgreementMember 2023-12-12 2023-12-12 0001812727 RELI:SeriesEWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesGWarrantsMember 2023-12-31 0001812727 RELI:AbeyanceSharesMember 2023-12-31 0001812727 RELI:AbeyanceSharesMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-31 0001812727 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-31 0001812727 RELI:AbeyanceSharesMember us-gaap:SubsequentEventMember 2024-03-31 0001812727 RELI:AbeyanceSharesMember us-gaap:SubsequentEventMember 2024-04-01 2024-06-30 0001812727 RELI:TwoThousandNineteenEquityIncentivePlanMember 2019-12-31 0001812727 RELI:TwoThousandNineteenEquityIncentivePlanMember 2023-12-31 0001812727 RELI:TwoThousandNineteenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001812727 RELI:TwoThousandTwentyThreeEquityIncentivePlanMember 2023-12-31 0001812727 RELI:EmployeesDirectorsAndConsultantsMember 2023-01-01 2023-12-31 0001812727 RELI:EmployeesDirectorsAndConsultantsMember 2022-01-01 2022-12-31 0001812727 RELI:ExecutivesAndEmployeesMember 2023-01-01 2023-12-31 0001812727 srt:DirectorMember 2022-01-01 2022-12-31 0001812727 RELI:ExecutiveMember RELI:AgreementInAprilTwoThousandTwentyTwoMember 2022-10-01 2022-10-31 0001812727 RELI:ExecutiveMember RELI:AgreementInAprilTwoThousandTwentyTwoMember 2023-01-01 2023-12-31 0001812727 RELI:ExecutiveMember RELI:AgreementInAprilTwoThousandTwentyTwoMember 2022-01-01 2022-12-31 0001812727 RELI:ExecutiveMember RELI:AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember 2022-12-28 0001812727 RELI:ExecutiveMember RELI:AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember 2023-01-01 2023-12-31 0001812727 RELI:ExecutiveMember RELI:AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember 2022-01-01 2022-12-31 0001812727 srt:MinimumMember 2022-12-31 0001812727 srt:MaximumMember 2022-12-31 0001812727 srt:MinimumMember 2023-01-01 2023-12-31 0001812727 srt:MaximumMember 2023-01-01 2023-12-31 0001812727 srt:MinimumMember 2022-01-01 2022-12-31 0001812727 srt:MaximumMember 2022-01-01 2022-12-31 0001812727 RELI:StockOptionsMember 2023-01-01 2023-12-31 0001812727 RELI:StockOptionsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesAWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesAWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesBWarrantsAndPlacementAgentWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesBWarrantsAndPlacementAgentWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:SeriesGWarrantsAndPlacementAgentWarrantsMember 2023-01-01 2023-12-31 0001812727 RELI:SeriesGWarrantsAndPlacementAgentWarrantsMember 2022-01-01 2022-12-31 0001812727 RELI:UnvestedStockAwardsMember 2023-01-01 2023-12-31 0001812727 RELI:UnvestedStockAwardsMember 2022-01-01 2022-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2022-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2022-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2022-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2022-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2023-01-01 2023-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2023-01-01 2023-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2023-01-01 2023-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2023-01-01 2023-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2023-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2023-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2023-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2023-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2021-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2021-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2021-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2021-12-31 0001812727 RELI:BarraMember 2021-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2022-01-01 2022-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2022-01-01 2022-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2022-01-01 2022-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2022-01-01 2022-12-31 0001812727 RELI:CARESActMember 2023-01-01 2023-12-31 0001812727 RELI:RelianceHoldingsMember 2023-12-31 0001812727 RELI:RelianceHoldingsMember 2022-12-31 0001812727 RELI:EmployeeMember RELI:YESAmericanaGroupLLCMember 2019-07-31 0001812727 RELI:EmployeeMember RELI:YESAmericanaGroupLLCMember 2019-07-01 2019-07-31 0001812727 RELI:EmployeeMember RELI:YESAmericanaGroupLLCMember 2023-12-31 0001812727 RELI:EmployeeMember RELI:YESAmericanaGroupLLCMember 2022-12-31 0001812727 RELI:EmployeeMember RELI:YESAmericanaGroupLLCMember 2023-01-01 2023-12-31 0001812727 RELI:YESAmericanaGroupLLCMember 2022-09-13 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-07 2023-02-07 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-07 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-13 2023-02-13 0001812727 RELI:YESAmericanaGroupLLCMember 2023-02-13 0001812727 RELI:YESAmericanaGroupLLCMember 2023-01-01 2023-12-31 0001812727 RELI:YESAmericanaGroupLLCMember 2022-01-01 2022-12-31 0001812727 RELI:CommonStocksMember RELI:YESAmericanaGroupLLCMember 2023-12-31 0001812727 RELI:CommonStocksMember RELI:YESAmericanaGroupLLCMember 2022-12-31 0001812727 2023-01-31 2023-01-31 0001812727 2023-01-31 0001812727 RELI:EmployeeMember us-gaap:SubsequentEventMember RELI:PurchaseAgreementMember 2024-01-11 0001812727 RELI:EmployeeMember us-gaap:SubsequentEventMember RELI:PurchaseAgreementMember 2024-01-10 2024-01-11 0001812727 us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember RELI:PurchaseAgreementMember 2024-01-11 0001812727 us-gaap:SubsequentEventMember RELI:ATMAgreementMember 2024-02-14 2024-02-15 0001812727 us-gaap:SubsequentEventMember RELI:ATMAgreementMember 2024-12-14 2024-12-15 iso4217:USD shares iso4217:USD shares pure false FY 0001812727 http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember 10-K true 2023-12-31 --12-31 2023 false 001-40020 RELIANCE GLOBAL GROUP, INC. FL 46-3390293 300 Blvd. of the Americas Suite 105 Lakewood NJ 08701 (732) 380-4600 Common Stock RELI NASDAQ Series A Warrants RELIW NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 7800000 5692387 None 339 Mazars USA LLP Washington, Pennsylvania 1329016 505410 1409895 1404359 1298863 994321 6603 18292 6603 18292 899 11464 333756 245535 85998 4379032 3265379 139999 162767 739830 1018952 900000 11042757 13439369 6693099 14287099 20292 23284 5330879 23015009 38427729 835483 951382 56197 154017 454953 1422249 7414 101113 1390766 1118721 285171 339937 159867 2153478 1600636 3189851 7841533 897529 122266 1500000 11026971 12349673 484335 714068 556000 268993 6433150 15867679 29516690 0.086 0.086 750000000 750000000 0 0 0 0 0.086 0.086 2000000000 2000000000 4761974 4761974 1219573 1219573 409509 104883 45739786 35798139 -39001965 -26991983 7147330 8911039 23015009 38427729 13731826 11761882 13731826 11761882 3732939 3140725 7503052 7508312 4089989 4959151 364974 170311 1716873 524 2609191 2563518 7594000 27611018 18342541 -13879192 -6580659 1506186 911106 150067 6920 150067 6920 6530 -4341 5503647 29064958 3853924 28142591 -10025268 21561932 -1984714 -15095770 -12009982 6466162 -4.46 13.36 -0.70 -13.78 -5.16 -0.42 -4.46 13.36 -0.70 -13.78 -5.16 -0.42 2820275 1094781 2820275 1094989 1219573 104883 35798139 -26991983 8911039 766596 65928 809178 875106 636228 54714 2946331 3001045 66743 5740 639260 645000 15336 1300 -1300 155038 13333 3433151 3446484 260602 22412 567448 589860 373264 32100 628410 660510 897594 77193 -78897 -1704 371000 31906 998066 1029972 -12009982 -12009982 4761974 409509 45739786 -39001965 7147330 730407 62815 27329201 -20000000 -33458145 -26066129 730407 62815 27329201 -20000000 -33458145 -26066129 1249873 1249873 9076 781 178060 15313 -16043 20000000 20000051 40402 3475 4759976 4763451 25000 2150 2472850 2475000 -218462 -18788 18788 14675 1262 -1262 218462 18788 -17452 1336 81423 7002 -6207 795 1667 143 12357 12500 8000 8000 -9076 -781 147939 12723 -11942 6466162 6466162 6466162 6466162 1219573 104883 35798139 -26991983 8911039 1219573 104883 35798139 -26991983 8911039 -12009982 6466162 2609191 2563518 7594000 46883 41875 -5377 21452 875106 1249873 397049 -5503647 -29064958 1716873 524 304542 -123096 -11689 11161 -10565 11464 -104590 -2501023 -2992 6492 -48266 -1811237 -93699 269613 -4596575 -17668176 3748605 14478179 -847970 -3189997 22864 61454 166947 740922 900000 450000 6000000 710189 -6352376 -18289936 710189 -24642312 1090622 875010 214257 6520000 12500 2131 241975 322095 310383 1045164 184252 -855000 1500000 419225 1704924 1028270 2475000 3446484 17853351 984623 25074156 -17700 47200 966923 25121356 829142 -2710953 1909769 4620722 2738911 1909769 1612829 863936 645000 3001045 660510 8000 36761 190069 192811 6930335 1525923 1125000 156542 310146 5081309 <p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zwSnnanA0Yx1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1. <span id="xdx_82A_zGOidBT1Z6R7">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliance Global Group, Inc. (formerly known as Ethos Media Network, Inc.) (“RELI”, “Reliance”, or the “Company”) was incorporated in Florida on August 2, 2013.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 26, 2022, the Company acquired the assets of Barra &amp; Associates, LLC., an unaffiliated full-service insurance agency headquartered in Illinois (see Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z3d5H9vY2to4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2. <span id="xdx_826_z4oTeB8eTf3c">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zlwlUshENHYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z0eaWlJVdrE7">Basis of Presentation and Principles of Consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements included herein have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounting of Reliance Global Group, Inc., and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--LiquidityPolicyTextBlock_zqM00e41XfGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zw4M79Oeu6be">Liquidity</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company’s reported cash and restricted cash aggregated balance was approximately $<span id="xdx_904_eus-gaap--RestrictedCashAndCashEquivalents_iI_c20231231_zEl3wC2ZYNIl" title="Aggregate cash balance">2,739,000</span>, current assets were approximately $<span id="xdx_905_eus-gaap--AssetsCurrent_iI_pn3d_c20231231_z7u54gdoTkK" title="Current assets">4,379,000</span>, while current liabilities were approximately <span id="xdx_906_eus-gaap--LiabilitiesCurrent_iI_pn3d_c20231231_z4ianLuf3oJi" title="Current liabilities">3,190,000</span>. As of December 31, 2023, the Company had working capital of approximately $<span id="xdx_907_ecustom--WorkingCapitalDeficiency_iNI_di_c20231231_zLXnHQa0fRo1" title="Working capital">1,189,000</span> and stockholders’ equity of approximately $<span id="xdx_900_eus-gaap--StockholdersEquity_iI_pn3d_c20231231_zIQn2PE7nyP9" title="Stockholder's equity">7,147,000</span>. For the year ended December 31, 2023, the Company reported a loss from operations of approximately $<span id="xdx_902_eus-gaap--OperatingIncomeLoss_iN_pn3d_di_c20230101__20231231_zO7tPQvkFvRe" title="Operating income loss">13,879,000</span>, of which $<span id="xdx_900_eus-gaap--GoodwillImpairmentLoss_c20230101__20231231_zotbxcIpQLk8" title="Goodwill impairment loss">7,594,000</span> was related to goodwill impairment. The Company also reported a non-cash, non-operating gain on the recognition and change in fair value of warrant liabilities of approximately $<span id="xdx_90A_ecustom--RecognitionAndChangeInFairValueOfWarrantLiability_pn3d_c20230101__20231231_z6Lvwd08Slu7" title="Fair value of warrant liabilities">5,504,000</span>, other expense, primarily interest expense of approximately $<span id="xdx_906_eus-gaap--InterestExpenseOther_c20230101__20231231_ztoDDhfgGBdc" title="Interest expense">1,650,000</span>, which resulted in a loss from continuing operations of $<span id="xdx_90F_eus-gaap--IncomeLossFromContinuingOperations_iN_pn3d_di_c20230101__20231231_z4a0e9izU5hc" title="Income loss from continuing operations">10,025,000</span>. Additionally, the Company reported a loss from discontinued operations of approximately $<span id="xdx_90D_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_iN_di_c20230101__20231231_zggF1T94WYvl" title="Income loss from discontinued operations">1,985,000</span>. The total net loss of the company was approximately $<span id="xdx_906_eus-gaap--ProfitLoss_iN_di_c20230101__20231231_znZSGF2aTydh" title="Net loss">12,010,000</span>. The Company completed a capital offering in March 2023, raising net proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230301__20230331_zNNB7w3fITh8" title="Raising net proceeds">3,446,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although there can be no assurance that debt or equity financing will be available on acceptable terms, the Company believes its financial position and its ability to raise capital to be reasonable and sufficient. Based on our assessment, we do not believe there are conditions or events that, in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one year of filing these financial statements with the Securities and Exchange Commission (“SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--UseOfEstimates_zkLNCy4qCfn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z1c1VMBVR4ta">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zZQv4POCG4hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zAfDfVh7hox7">Cash and Restricted Cash</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash consists of checking accounts. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash includes cash pledged as collateral to secure obligations and/or all cash whose use is otherwise limited by contractual provisions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At times, some cash balances held in banks may exceed the Federal Deposit Insurance Corporation, or FDIC, standard deposit insurance limit of $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zkD1sDzX8RSk" title="FDIC insured amount">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_z2vesGLRd3j6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zD1MYCljuFD7" style="display: none">SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_z6bd1BX2El5e" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zgLTgufzZwG8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--Cash_iI_maRCACEzxqQ_z7fu8305Pvae" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,329,016</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">505,410</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RestrictedCashCurrent_iI_maRCACEzxqQ_z5C2bnDiARx2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,409,895</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,404,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iTI_mtRCACEzxqQ_zovywO0jSIDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash and restricted cash</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,738,911</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,909,769</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zWoPYN9u3Fmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zep7ko41h59a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z9qRSc5Rkhdb">Property and Equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is stated at cost, less accumulated depreciation. Depreciation is recognized over an asset’s estimated useful life using the straight-line method beginning on the date an asset is placed in service. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Certain capitalized software has been reclassified in the consolidated balance sheet from property and equipment, net to intangibles, net and comparative periods have been adjusted accordingly. Maintenance and repairs are charged to expense as incurred. Estimated useful lives of the Company’s Property and Equipment are as follows:</span></p> <p id="xdx_892_ecustom--ScheduleOfEstimatedUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock_zmUf3k0d8m66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zTwjzSeXPo5a" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computer equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 36%; text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGZTz4PnrzS3" title="Estimated useful life">5</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Office equipment and furniture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zDkmYWmOv8W5" title="Estimated useful life">7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zjHXnc6sSPzc" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0828">Shorter of the useful life or the lease term</span></span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_z5lDG3TOXdpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zT0gtvN6g535" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span><span id="xdx_86D_z8k42G3jk4pb">Fair Value of Financial Instruments</span></span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance includes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels of the fair value hierarchy are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 — Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 — Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 — Unobservable inputs for the asset or liability, which include management’s own assumption about the assumptions market participants would use in pricing the asset or liability, including assumptions about risk.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, and 2022 respectively, the Company’s balance sheet includes certain financial instruments, including cash, notes receivables, accounts payable, and short and long-term debt. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amounts of long-term debt approximate their fair value as the variable interest rates are based on a market index.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant Liabilities:</b> The Company’s warrant liabilities (see Note 9, <i>Warrant Liabilities</i>) represent liability-classified derivative financial instruments recorded at fair value on a recurring basis. The fair value of the Warrant Liabilities includes significant inputs unobservable in the market and thus are considered Level 3. The Company measured the fair value of the warrant liabilities at the issuance date, December 12, 2023, and subsequently at the balance sheet date, using a binomial option pricing model. The following summarizes the significant unobservable inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_ecustom--ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock_z5QsIV6YX9If" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B3_zfM5aRE7OWCg" style="display: none">SCHEDULE OF WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231_zmSyaBLK8nce" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20221231_zyPc6bNKp1s9" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXHaY2TZ5xk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.54</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8.55</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7sJOLAGR4p4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">105.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Time to Expiry</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zxg2Pu8OqsR2" title="Time to expiry">4.99</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zP9PSUs4rf6l" title="Time to expiry">4.01</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zssL2RpSyfZh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zc4RuPXCYp3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zGBNPRParhOe" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrant Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.1</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A0_zGdKZ190pzNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--ScheduleOfReconcilesWarrantCommitmentTableTextBlock_zocEww4cTGFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following reconciles the warrant liabilities for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B4_zpDjNAGYJTZ4" style="display: none">SCHEDULE OF RECONCILES WARRANT COMMITMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4B8_us-gaap--DerivativeInstrumentRiskAxis_custom--SeriesBWarrantCommitmentMember_zwJQrc0aVO" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4B2_us-gaap--DerivativeInstrumentRiskAxis_custom--SeriesBWarrantLiabilityMember_z529ZXvERTdl" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4BD_us-gaap--DerivativeInstrumentRiskAxis_custom--PlacementAgentWarrantsMember_znGFElrGk1w3" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4BD_zAD8r7UahoM8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31, 2023 and 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B Warrant Commitment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B warrant liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Placement agent warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_43A_c20220101__20221231_ecustom--WarrantLiabilities_iS_zeoPh8UlEJdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Beginning balance, December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">37,652,808</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">37,652,808</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--InitialRecognitionOfWarrantCommitment_zBjMv1HpFYg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Initial recognition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,061,119</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,525,924</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,587,043</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantCommitmentUnrealizedGainLoss_zG2wBlg2b83j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized (gain) loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,408,311</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(48,668,869</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,477,024</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32,737,582</td><td style="text-align: left">)<sup id="xdx_F2B_zAoISOx5E1xe">1</sup></td></tr> <tr id="xdx_40E_ecustom--WarrantsExercisedOrTransferred_zCC76Q13bcri" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised or transferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55,061,119</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55,069,119</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_436_c20230101__20231231_ecustom--WarrantLiabilities_iS_zIZgJ5vixI84" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Ending balance, December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,384,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">48,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,433,150</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20230101__20231231_ecustom--WarrantLiabilities_iS_zj6w8Y4O2FS6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance, December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,384,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">48,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,433,150</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantCommitmentUnrealizedGainLoss_zG8THwVQndp4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unrealized (gain) loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,534,931</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(48,575</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,583,506</td><td style="text-align: left">)<sup id="xdx_F23_zsjBk77LyBH1">2</sup></td></tr> <tr id="xdx_40E_ecustom--WarrantsExercisedOrTransferred_zEzNjQ3dFYAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised or exchanged</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(580,651</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(580,651</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_431_c20230101__20231231_ecustom--WarrantLiabilities_iE_znbi3sHpzwRk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268,993</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F02_ziC101SDV46">1</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zM4sIOKj2mB1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition and change in fair value of warrant liabilities per income statement is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_ecustom--RecognitionAndChangeInFairValueOfWarrantLiability_c20220101__20221231_zPhBj3xDv9bb" title="Recognition and change in fair value of warrant liability">29,064,958</span>. The difference of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--WarrantIssuanceCost_c20220101__20221231_zaVWsnsfSsug" title="Warrant issuance cost">3,672,624</span> is made up of the Warrant issuance costs.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><sup id="xdx_F06_zrpBgBacXio5">2</sup></td> <td id="xdx_F19_zWOeK1YtrsZ6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition and change in fair value of warrant liabilities per income statement is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--RecognitionAndChangeInFairValueOfWarrantLiability_c20230101__20231231_zyilvmYaBgHh" title="Recognition and change in fair value of warrant liability">5,503,647</span>. The difference of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_ecustom--WarrantIssuanceCost_c20230101__20231231_zABBiwTHoSph" title="Warrant issuance cost">79,859</span> was due to a loss on a warrant exchange.</td></tr> </table> <p id="xdx_8AB_zbtDowQ1QQ7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Earn-out liabilities:</b> The Company generally values its Level 3 earn-out liabilities using the income valuation approach. Key valuation inputs include contingent payment arrangement terms, projected revenues and cash flows, rate of return, and probability assessments. The following table summarizes the significant unobservable inputs used in the fair value measurements:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zPbdBOexTxLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zfGHH3n0MD87" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENTS</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation technique</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_ecustom--ValuationTechnique_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zo0rWqLbW1pe" style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center" title="Valuation technique"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounted cash flow</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_ecustom--ValuationTechnique_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqYdUQ13wkF4" style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center" title="Valuation technique"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounted cash flow</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant unobservable input</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_ecustom--SignificantUnobservableInput_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZDx6rBYyNK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center" title="Significant unobservable input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projected revenue and probability of achievement</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_ecustom--SignificantUnobservableInput_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ijikQu9EEa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center" title="Significant unobservable input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projected revenue and probability of achievement</span></td></tr> </table> <p id="xdx_8AF_zUD70IclrwOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company values its Level 3 earn-out liability related to the Southwestern Montana Insurance Center acquisition using a Monte Carlo simulation in a risk-neutral framework (a special case of the Income Approach). The following summarizes the significant unobservable inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zw9jP7qYItL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B4_zf9fTt7Yutf" style="display: none">SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Volatility</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"><span id="xdx_90F_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zTMUv8llStch" title="Earn out liability">110</span></td><td style="text-align: left; width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit Spread</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zynhPifUVmAf" title="Earn out liability">7.73</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Number of trading days</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--EarnOutLiabilitiesMeasurementInputTerm_iI_dtD_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--NumberOfTradingDaysMember_z5cgHY1HRPhb" title="Number of trading days">252</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zrMytMVwfbAd" title="Earn out liability">5.34</span></span></td><td style="text-align: left"><p style="margin: 0">%</p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--EarnOutLiabilitiesMeasurementInputTerm_iI_dtY_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zB8CYd4tU2Of" title="Earn out liability">0.2</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zxcgnr18F2bb" title="Earn out liability">0.54</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--EarnOutLiabilitiesMeasurementInput_iI_pid_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGlb0m4fKwMj" title="Earn out liability">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Number of Iterations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--NumberOfIterations_iI_pid_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztlQWix0FhIj" title="Number of iterations">100,000</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zhOVGHr4quZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undiscounted remaining earn out cash payments were approximately $<span id="xdx_904_ecustom--EarnOutPayments_iI_c20231231_zHw2qRKTeWwg" title="Earn out payments">165,000</span> as of December 31, 2023. The following table reconciles fair value of earn-out liabilities for the years ending December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">  </p> <p id="xdx_892_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zZCSyItCSItg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zQ7X3GGysGyk" style="display: none">SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_ziHnPWiI9XQe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zfdV8ZCsZFOa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zTyzs2xI0Mje" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Beginning balance – January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,709,478</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,813,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AcquisitionsAndSettlements_zyZh9WA398v5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Acquisitions and Settlements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,260,403</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,104,924</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Period adjustments:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_zdHnG3Ycskul" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value and estimate changes<sup id="xdx_F46_zilI5q6lSLA5">*</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,716,873</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">524</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EarnoutPayableInCommonShares_zmFlY1VvjDX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Earn-out payable in common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(159,867</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--EarnoutTransferredToLoansPayableRelatedParties_zTZJlmjAyzQ7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Earn-out transferred to loans payable, related parties</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(846,214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zjzOiuIZYgN3" style="vertical-align: bottom; background-color: White"> <td>Ending balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">159,867</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,709,478</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iNI_di_c20231231_zvX5urrfEka9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Current portion">(159,867</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iNI_di_c20221231_zIh4FoCAJrwb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Current portion">(2,153,478</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Ending balance, less current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iI_c20231231_zdU43Tu11qrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, less current portion"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iI_c20221231_zbqbqnDYqZ2d" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, less current portion">556,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_zS4hSLVff6s4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F17_zCt26CiQwPE3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recorded as change in estimated acquisition earn-out payables on the consolidated statements of operations.</span></td></tr> </table> <p id="xdx_8AD_z1FzhNbcHYC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--DeferredChargesPolicyTextBlock_zXQv8OaHKHw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zwKCcLMtEevl">Deferred Financing Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has recorded deferred financing costs because of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized to interest expense using the straight-line method which approximates the interest rate method over the term of the related debt. As of December 31, 2023, and 2022, unamortized deferred financing costs were $<span id="xdx_90E_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20231231_zU6iKRvvYNCb" title="Unamortized deferred financing costs">273,864</span>, and $<span id="xdx_908_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20221231_zGop3OLVmcb5" title="Unamortized deferred financing costs">313,829</span>, respectively and are netted against the related debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--BusinessCombinationsPolicy_zEOuqOuCUdN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z2MS9N818RS3">Business Combinations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its business combinations using the acquisition method of accounting. Under the acquisition method, assets acquired, liabilities assumed, and consideration transferred are recorded at the date of acquisition at their respective fair values. Definite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration such as earn-outs, the Company records the contingent consideration at fair value at the acquisition date. The Company remeasures fair value as of each reporting date and changes resulting from events after the acquisition date, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziXaIpHLxHB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zpc6QOuGwHOc">Identifiable Intangible Assets, net</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finite-lived intangible assets such as customer relationships assets, trademarks and tradenames are amortized over their estimated useful lives, generally on a straight-line basis for periods ranging from <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zZZpyFfyg417" title="Estimated useful lives of intangible assets">3</span> to <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zCP8ENtsrxn7" title="Estimated useful lives of intangible assets">20</span> years. Finite-lived intangible assets are reviewed for impairment or obsolescence whenever events or circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of intangible assets is measured by a comparison of the carrying amount of the asset to the future undiscounted net cash flows expected to be generated by that asset. If the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the estimated fair value. No impairment was recognized during the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_zBirntzQsJFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zjRvnxGCPg46">Goodwill and other indefinite-lived intangibles</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records goodwill when the purchase price of a business acquisition exceeds the estimated fair value of net identified tangible and intangible assets acquired. Goodwill is assigned on the acquisition date and tested for impairment at least annually, or more frequently when events or changes in circumstances indicate that the fair value of a reporting unit has more likely than not declined below its carrying value. Similarly, indefinite-lived intangible assets (if any) other than goodwill are tested annually or more frequently if indicated, for impairment. If impaired, intangible assets are written down to fair value based on the expected discounted cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--FinancialInstrumentPolicyTextBlock_zts08lSNoBD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zvvIVdYzBGS">Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates issued financial instruments for classification as either equity or liability based on an assessment of the financial instrument’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”) as well as in accordance with ASU 2020-06. The assessment considers whether the financial instruments issued are freestanding pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and, if applicable whether the financial instruments meet all of the requirements for equity classification under ASC 815, including whether the financial instruments are indexed to the Company’s own Common Stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance and as of each subsequent reporting period end date while the financial instruments are outstanding. Financial instruments that are determined to be liabilities under ASC 480 or ASC 815 are held at their initial fair value and remeasured to fair value at each subsequent reporting date, with changes in fair value recorded as a non-operating, non-cash loss or gain, as applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments consist of derivatives related to the warrants issued with the securities purchase agreement as discussed in Note 9, <i>Warrant Liabilities</i>. The accounting treatment of derivative financial instruments requires that we record the derivatives at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense at each balance sheet date. Upon the determination that an instrument is no longer subject to derivative accounting, the fair value of the derivative instrument at the date of such determination will be reclassified to paid in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The adoption of Topic 326 did not significantly change our approach to the valuation of trade receivables. The Company determines whether there is an expected loss on our accounts receivable by reviewing all available data, including our customers' latest available financial statements, their credit standing, our historical collection experience, and current and future market and economic conditions. As of December 31, 2023, and December 31, 2022, it was not deemed necessary to recognize any allowance for credit losses on our trade receivables.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zEkaIGe34p9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zj3JQimjJKD8">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606 <i>Revenue from Contracts with Customers</i> which at its core, recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenue is primarily comprised of agency commissions earned from insurance carriers (the “Customer” or “Carrier”) related to insurance plans produced through brokering, producing, and servicing agreements between insurance carriers and members. The Company defines a “Member” as an individual, family or entity currently covered or seeking insurance coverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company focuses primarily on agency services for insurance products in the “Healthcare” and property and casualty, which includes auto (collectively “P&amp;C”) space, with nominal activity in the life insurance and bond sectors. Healthcare includes plans for individuals and families, Medicare supplements, ancillary and small businesses. The Company also earns revenue in the “Insurance Marketing” space as discussed further below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration for all agency services typically is based on commissions calculated by applying contractual commission rates to policy premiums. For P&amp;C, commission rates are applied to premiums due, whereas for healthcare, commission rates, including override commissions, are applied to monthly premiums received by the Carrier.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has two forms of billing practices, “Direct Bill” and “Agency Bill”. With Direct Bill, Carriers bill and collect policy premium payments directly from Members without any involvement from the Company. Commissions are paid to the Company by the Carrier in the following month. With Agency Bill, the Company bills Members premiums due and remits them to Carriers net of commission earned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following outlines the core principles of ASC 606:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identification of the contract, or contracts, with a customer</i>. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identification of the performance obligations in the contract</i>. Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Determination of the transaction price</i>. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocation of the transaction price to the performance obligations in the contract</i>. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognition of revenue when, or as, the Company satisfies a performance obligation</i>. The Company satisfies performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Healthcare revenue recognition:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There typically is one performance obligation in contracts with Carriers, to perform agency services that culminate in monthly premium cash collections by the Carrier. The performance obligation is satisfied through a combination of agency services including, marketing carrier’s insurance plans, soliciting Member applications, binding, executing and servicing insurance policies on a continuous basis throughout a policy’s life cycle which includes and culminates with the Customer’s collection of monthly premiums. No commission is earned if cash is not received by Carrier. Thus, commission revenue is earned only after a month’s cash receipts from Members’ dues is received by the Customer. Each month’s Carrier cash collections is considered a separate unit sold and transferred to the Customer i.e., the satisfaction of that month’s performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction price is typically stated in a contract and usually based on a commission rate applied to Member premiums paid and received by Carrier. The Company generally continues to receive commission payments from Carriers until a Member’s plan is cancelled or the Company terminates its agency agreement with the Carrier. Upon termination, the Company normally will no longer receive any commissions from Carriers even on business still in place. In some instances, trailing commissions could occur which would be recognized similar to other Healthcare revenue. With one performance obligation, allocation of transaction price is normally not necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare typically utilizes the Direct Bill method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue at a point in time when it satisfies its monthly performance obligation and control of the service transfers to the Customer. Transfer occurs when Member insurance premium cash payments are received by the Customer. The Customer’s receipt of cash is the culmination and complete satisfaction of the Company’s performance obligation, and the earnings process is complete.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With Direct Bill, since the amount of monthly Customer cash receipts is unknown to the Company until the following month when notice is provided by Customer to Company, the Company accrues revenue at each period end. Any estimated revenue accrued and recognized at a period-end is trued up for financial reporting per actual revenue earned as provided by the Customer during the following month.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">P&amp;C revenue recognition</span>:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There typically is one performance obligation in contracts with Customers, to perform agency services to solicit, receive proposals and bind insurance policies culminating with policy placement. Commission revenue is earned at the time of policy placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction price is typically stated in a contract and usually based on commission rates applied to Member premiums due. With one performance obligation, allocation of transaction price is normally not necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P&amp;C utilizes both the Agency Bill and Direct Bill methods, depending on the Carrier.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of the service transfers to the Customer. Transfer occurs when the policy placement process is complete.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With both Direct Bill and Agency Bill, the Company accrues commission revenue in the period policies are placed. With Agency Bill, payment is typically received from Members in the month earned, however with Direct Bill, payment is typically received from Carriers in the month subsequent to the commissions being earned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other revenue policies:</span> Insurance commissions earned from Carriers for life insurance products are recorded gross of amounts due to agents, with a corresponding commission expense for downstream agent commissions being recorded as commission expense within the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When applicable, commission revenue is recognized net of any deductions for estimated commission adjustments due to lapses, policy cancellations, and revisions in coverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company could earn additional revenue from contingent commissions, profit-sharing, override and bonuses based on meeting certain revenue or profit targets established periodically by the Carriers (collectively, “Contingent Commissions”). Contingent Commissions are earned when the Company achieves targets established by Carriers. The Carriers notify the Company when it has achieved the target. The Company recognizes revenue for any Contingent Commissions at the time it is reasonably assured that a significant revenue reversal is not probable, which is generally when a Carrier notifies the Company that it is on track or has earned a Contingent Commission.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--DisaggregationOfRevenueTableTextBlock_ziX78NrLjgtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates the Company’s revenue by line of business, showing commissions earned:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zmADIobqu1kc" style="display: none">SCHEDULE OF DISAGGREGATION REVENUE</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231__srt--ProductOrServiceAxis__custom--MedicalMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_z93RNs5k0Ffg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231__srt--ProductOrServiceAxis__custom--LifeMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_z9yJDKAVivC" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20230101__20231231__srt--ProductOrServiceAxis__custom--PropertyAndCasualtyMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_zScHjB7Bl1Lg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Property and Casualty</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_zGOH39I0hKq7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--EmployeeBenefitsSolutionsLLCMember_zxTiXVgpUR52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">EBS</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">883,327</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">22,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0993">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">905,441</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--USBenefitsAllianceLLCMember_zgqUrlaGIjAe" style="vertical-align: bottom; background-color: White"> <td>USBA</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,377</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--CommercialCoverageSolutionsLLCMember_z5HMKCkLrd83" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>CCS/UIS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,486</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,486</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--SouthwesternMontanaFinancialCenterIncMember_zLziKGUQNQ9" style="vertical-align: bottom; background-color: White"> <td>Montana</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,863,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,875,943</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--FortmanInsuranceServicesLLCMember_zKxWEmAEYA5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fortman</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,161,506</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,044,592</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,211,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--AltruisBenefitsConsultingIncMember_zO4W17IoWixe" style="vertical-align: bottom; background-color: White"> <td>Altruis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,454,654</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,454,654</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--KushMember_zy5BIst57EBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kush</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,209,854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1022">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,209,854</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--ReliExchangeMember_zcEk4IbTLXWg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Reli Exchange</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">209,615</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">127,486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,401,385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,738,486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z796i0hPzlv6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,825,064</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">170,759</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,735,463</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,731,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220101__20221231__srt--ProductOrServiceAxis__custom--MedicalMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_zmOCQ1KQ3P1e" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20220101__20221231__srt--ProductOrServiceAxis__custom--LifeMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_zulBdXu9TiRd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20220101__20221231__srt--ProductOrServiceAxis__custom--PropertyAndCasualtyMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_z3pdDatnbXni" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property and Casualty</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_zYbwadMJyVT7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--EmployeeBenefitsSolutionsLLCMember_z7KFzeNtXjXk" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EBS</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">781,570</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,843</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">798,413</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--USBenefitsAllianceLLCMember_zNNk3iJrOBO9" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USBA</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,006</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1462</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1043">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,468</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--CommercialCoverageSolutionsLLCMember_zAzqWxWc8L7k" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCS/UIS</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       254,325 </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">254,325</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--SouthwesternMontanaFinancialCenterIncMember_ziG5ojwBJVy5" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Montana</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,860,475</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,661</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1053">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,868,136</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--FortmanInsuranceServicesLLCMember_zXG2acoiKyxg" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fortman</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,267,945</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6705</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">842,961</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,117,611</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--AltruisBenefitsConsultingIncMember_z8aN3QYm7cLk" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Altruis</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,041,495</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2954</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,044,449</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--KushMember_ze75GTMw155l" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kush</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,535,416</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1040</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,536,456</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--ReliExchangeMember_zSfpBMf43wEh" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reli Exchange</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,094</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,052</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">831,878</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,090,024</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zwSOfHjLYny3" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,690,001</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">142,717</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,929,164</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,761,882</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zP2iQfLvXRNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_840_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXDt9XjsVvX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z5i4m1cDLcXa">General and Administrative</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses primarily consist of personnel costs for the Company’s administrative functions, professional service fees, office rent, all employee travel expenses, and other general costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_zwVqyreMiOz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zPqYrFr4sdvf">Marketing and Advertising</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s direct channel expenses primarily consist of costs for e-mail marketing and newspaper advertisements. The Company’s online advertising channel expense primarily consist of social media ads. Advertising costs for both direct and online channels are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zcqPw5yPJUce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z3Uqi4DUglph">Equity-Based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, based on the terms of the awards. The fair value of the stock-based payments to nonemployees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. To the extent possible, the Company will estimate and recognize expected forfeitures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zMuztgBjbXnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z46qaqMwMz2k">Leases</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes leases in accordance with Accounting Standards Codification Topic 842, “Leases” (“ASC 842” or “ASU 2016-12”). This standard provides enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases are recognized as a single lease expense, generally on a straight-line basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is the lessee in a contract when the Company obtains the right to use an asset. We currently lease real estate and office space under non-cancelable operating lease agreements. When applicable, consideration in a contract is allocated between lease and non-lease components. Lease payments are discounted using the implicit discount rate in the lease. If the implicit discount rate for the lease cannot be readily determined, the Company uses an estimate of its incremental borrowing rate. The Company did not have any contracts accounted for as finance leases as of December 31, 2023, or 2022. Operating leases are included in the line items right-of-use assets, current portion of leases payable, and leases payable, less current portion in the consolidated balance sheets. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations. The Company determines a lease’s term by agreement with lessor and includes lease extension options and variable lease payments when option and/or variable payments are reasonably certain of being exercised or paid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zlUzNetwQ0Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zCmkXmh4xXW">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes deferred tax assets and liabilities using enacted tax rates for the effect of temporary differences between the book and tax basis of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. In evaluating its ability to recover deferred tax assets within the jurisdiction in which they arise, the Company considers all available positive and negative evidence, including the expected reversals of taxable temporary differences, projected future taxable income, taxable income available via carryback to prior years, tax planning strategies, and results of recent operations. The Company assesses the realizability of its deferred tax assets, including scheduling the reversal of its deferred tax assets and liabilities, to determine the amount of valuation allowance needed. Scheduling the reversal of deferred tax asset and liability balances requires judgment and estimation. The Company believes the deferred tax liabilities relied upon as future taxable income in its assessment will reverse in the same period and jurisdiction and are of the same character as the temporary differences giving rise to the deferred tax assets that will be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_847_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zcMxCelEMs0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zNWsHEojELn4">Discontinued Operations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s board of directors approved the discontinuation and abandonment of Medigap Healthcare Insurance Company, LLC (“Medigap”), a subsidiary of the Company, effective April 17, 2023, due to Medigap’s sustained recurring losses stemming from amongst other factors, greater than anticipated revenue chargebacks. The Company was unable to divest its interest in Medigap for value, and accordingly, operations were wound down in an orderly manner. In doing so, the Company transferred to its operating entity, Medigap’s customer relationships and internally developed and purchased software intangible assets, with net of amortization combined value of approximately $<span id="xdx_909_ecustom--DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfAmortizationCombined_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyLLCMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zBgQLKabniJ9" title="Net of amortization combined">4,300,000</span>, as well as, its short-term financing arrangement of $<span id="xdx_90E_ecustom--ShortTermFinancingAgreements_iI_c20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyLLCMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zspBUTNvwo47" title="Short term financing agreements">29,500</span>, and each are respectively classified at their adjusted book values in the intangible assets and short term financing agreements accounts in the condensed consolidated balance sheets for the periods ended December 31, 2023 and December 31, 2022. These assets have continued value to the Company and have not been impaired as the fair value exceeds carrying cost. Medigap’s remaining assets were considered to have no remaining asset value and were fully impaired. Certain liabilities and estimated liabilities as outlined in the tables herein, were discharged and/or written-off in conjunction with the Settlement Agreement (as defined below) because of them having a net zero dollar estimated liability value. Accordingly, the Company recognized a net of estimated liability adjustments gain/loss of approximately $<span id="xdx_908_ecustom--NetOfEstimatedLiabilityAdjustmentsGain_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyLLCMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zRESSPnn9ivf" title="Net of estimated liability adjustments gain">0</span>, and an impairment loss of approximately $<span id="xdx_908_ecustom--ImpairmentLossOnDiscontinuedOperations_pp0p0_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyLLCMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zPWvcXDbAQFf" title="Impairment loss on discontinued operations">4,400,000</span>, presented in income (loss) from discontinued operations in the consolidated statements of operations for the year ended December 31, 2023. As part of the abandonment, the Company cancelled third party contracts, settled outstanding vendor and other third-party obligations, ceased to enter new customer contracts via Medigap, and no further customer performance obligations existed. The Company does not expect further continuing involvement with Medigap, and in accordance with ASC 205-20-45-9, no corporate overhead has been allocated to discontinued operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Settlement Agreement</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 30, 2023, the Company entered into a confidential settlement agreement and mutual release (the “Settlement Agreement”) with certain Medigap affiliated entities and persons, and the former owners of Medigap, whereby the Company would receive a settlement payment, net of costs, of $<span id="xdx_90C_eus-gaap--SettlementLiabilitiesCurrent_iI_c20230630_z9QrBGYfyWc3" title="Settlement payment">2,761,190</span> and was released from all past and future Medigap obligations and liabilities. The settlement payment was received in full by the Company in July 2023 and is recorded as income from discontinued operations in the condensed consolidated statements of operations for the year ended December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_898_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zGJAIbRlQ2xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables present the major components of assets and liabilities included in discontinued operations on the condensed consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zQZIe8DmeGX1" style="display: none">SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyMember_zzTGGrygEY1j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyMember_z8faDvposYQb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zVL6r1fnlER" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">          73,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWwpiVfxxv7h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable, related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVRI6SihbG8i" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_iI_z2qMuEjsNsS9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,388</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_zH5lYlJjsaJ9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expense and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,792</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_iI_zwp3peIQYCEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Current Assets - Discontinued Operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">85,998</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zsEQCOTiFZFf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed consolidated balance sheets - Current Assets - Discontinued Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">85,998</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zPliumkuDplj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">24,116</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zXb4MaTa75l6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">163,129</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zOveFB86Lh42" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1132">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">318,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Goodwill_iI_zbrwnTJzDlW2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_iI_zWWNubiAsZ78" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Other Assets - Discontinued Operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,330,879</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_zFK2RpmaeLPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed consolidated balance sheets - Other Assets - Discontinued Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,330,877</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_z1kyaEoeAXNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable and other accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1144">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">506,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ChargebackReserveCurrent_iI_z8nFBpWtlM2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Chargeback reserve</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">915,934</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zcxSoyLov7Aj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Current portion of leases payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iI_z1873RPuMWHb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current Liabilities - Discontinued Operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zinN2lSwd433" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Condensed consolidated balance sheets - Current Liabilities - Discontinued Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,600,636</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table rolls forward Medigap’s assets and liabilities from their carrying values pre-abandonment to their values post abandonment, and presents the impact of reclassifications, impairments, and write-offs:</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Medigap Related Assets</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyMember__srt--StatementScenarioAxis__custom--CarryingValuePriorToAbandonmentMember_zo0WEWDu9z0h" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value Prior To Abandonment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember__srt--StatementScenarioAxis__custom--AssetAndLiabilityTransfersRetainedByTheCompanyMember_zLUlHgde3Rj8" style="border-bottom: Black 1.5pt solid; text-align: center">Asset and Liability Transfers Retained by the Company</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember__srt--StatementScenarioAxis__custom--AssetImpairmentsAndLiabilityWriteOffsMember_zWZzUALwisf9" style="border-bottom: Black 1.5pt solid; text-align: center">Asset Impairments and Liability Write-Offs</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20231231__us-gaap--ReclassificationTypeAxis__custom--MedigapHealthcareInsuranceCompanyMember_z3U4Vae1SsNj" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value as of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z6O1rEnl6oMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">56,398</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(56,398</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">       <span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zBB3ViixTaVj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable, related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1165">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,595</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zvKnMtNq0Q24" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,595</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_iI_zohEBgGWyb28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1175">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,388</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_znfFylNZOsKd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Current assets – Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65,381</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,381</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zoRAmJCafFKl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22,378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(22,378</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zb8sHtm9Ry19" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,594</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(119,594</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1192">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_z7VyD4AH04T5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,570,536</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">(4,258,214 )<sup id="xdx_F2D_zeNA6B6z5oce">1</sup></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(312,322</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1197">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Goodwill_iI_zMnoAd4gwht2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1200">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_i01I_zGoWHkFnaXff" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other assets - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,538,142</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,258,214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,279,928</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iI_zoxfT5lSvv2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total assets - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,603,523</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,258,214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,345,309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zKkqfjjv10U6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts payable and other accrued liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,157</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ShortTermFinancingAgreements_iI_zXRMY0z1jbBl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term financing agreements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1222">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ChargebackReserveCurrent_iI_zF6UuY9xMZg2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Chargeback reserve</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">831,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">(831,725 )<sup id="xdx_F29_zmkoE66QGabh">2</sup></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zK1ZwFFSZsK7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current portion of leases payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">(134,517 )<sup id="xdx_F25_zyz1V69fRv4d">3</sup></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherLiabilities_iI_zkhlhuvfI9E7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,842</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(9,842 )<sup id="xdx_F23_zO90gwviGEp3">3</sup></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i01I_zRNCCpgkaE3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,009,741</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(980,241</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_iI_zLd6PxTO45yd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,009,741</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(980,241</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AssetsAndLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zQNKo5gtsrn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net assets and liabilities - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,593,782</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,228,714</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,365,068</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"> </span></td> <td style="width: 0.25in"><span id="xdx_F05_zpiu8zGTXMRc" style="font-size: 10pt">1</span></td> <td style="text-align: justify"><span id="xdx_F16_zVOljeGGMMZb" style="font-size: 10pt">Includes customer relationships and internally developed and purchased software intangible assets that have continued value to the Company and have not been impaired as the fair value exceeds carrying cost.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span id="xdx_F0F_zp409ah5EP97" style="font-size: 10pt">2</span></td> <td style="text-align: justify"><span id="xdx_F1D_zBo9UO2Ls7Gg" style="font-size: 10pt">Estimated liability write-off per net zero dollar estimated liability value.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span id="xdx_F06_zli9A4bgOJQ8" style="font-size: 10pt">3</span></td> <td style="text-align: justify"><span id="xdx_F1A_zjaez4DXYPW4" style="font-size: 10pt">Liability discharge pursuant to the Settlement Agreement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables disaggregate the major classes of pretax gain and loss as presented in discontinued operations in the condensed consolidated statements of operations.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zcbrpTZLFOT2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zuTiWaq03jB5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, 2022</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--CommissionIncome_zrtJ9z9RR527" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-left: 10pt">Commission income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">744,030</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,994,002</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--CommissionExpense_zDrBjgcwyXef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Commission expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,639</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">604,042</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--SalariesAndWages_z1v17QR7MiKk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Salaries and wages</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">454,663</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,973,579</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_zC1txXtGpi4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">General and administrative </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">129,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">508,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--MarketingAndAdvertisingExpense_znjrNqwuWtY5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Marketing and advertising</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">426,818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,414,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DepreciationAndAmortization_zQZaqDwamQ12" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238,307</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_z8lhPgxSqSEe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,902</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,454</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_zeV4MMEa4RS1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total discontinued operations expenses before impairments and write-offs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,124,864</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,716,399</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_zmKowf9chE8h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Total discontinued operations income / (loss) before impairments and write-offs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(380,834</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(722,397</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gains and (losses) from recoveries and impairments / write-offs of discontinued operations assets and liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--SettlementRecoveryNetOfCosts_zzZyD53KwZ7e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Settlement Recovery, net of costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,761,190</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Asset impairment losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccountsReceivableImpairements_iN_di_zBOmjFTAz7Mf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccountsReceivableImpairements_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHXd85nx3sxa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Accounts receivable, related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssetImpairmentCharges_z3o8sxwXGn96" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,388</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--TangibleAssetImpairmentCharges_zpmpOKsSAJKg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseImpairmentLoss_iN_di_zL5cM6mbXPrl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,593</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--IntangiblesNet_zFfaopY1p4ha" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312,322</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GoodwillImpairmentLoss_zJk2bJj7GQlb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetImpairmentCharges_iNT_di_zov9e4oGffk1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total asset impairments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,345,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,373,374</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Liability write-off gains</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccountsPayableAndOtherAccruedLiabilitiesWriteOffs_zvRpG4c33a12" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Accounts payable and other accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--OtherPayablesWriteoffs_zKGUwqQHtTd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Other payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,842</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ChargebackReserveWriteOffs_zpp9HPHkDLml" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Chargeback reserve</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">831,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CurrentPortionOfLeasesPayableWriteOffs_zNINvwB21qC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Current portion of leases payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">134,517</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--TotalLiabilityWriteoffs_z6km2qGiEzPj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Total liability write-off gains</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">980,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DiscontinuedOperationsNetAssetAndLiabilityIumpairmentsWriteoffs_zk8Zful4FcMh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Discontinued operations net asset and liability impairments / write-offs gains and (losses)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,365,070</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--NetRecoveriesAndImpairmentsWriteoffsFromDiscontinuedAssetsAndLiabilities_zU88q31cKXxi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,603,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_zQYsOkxVKYhc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from discontinued operations before tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,984,714</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,095,770</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zAmOF7TvePo5" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">Consolidated statement of operations - Loss from discontinued operations before tax</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,984,714</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(15,095,770</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8A0_zymB96dvEpR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84C_ecustom--SeasonalityPolicyTextBlock_zDaKbTP9jtHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zP7VTcy1Mlc3">Seasonality</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A greater number of the Company’s Medicare-related health insurance plans are sold in the fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage. The majority of the Company’s individual and family health insurance plans are sold in the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBwJzDMQbWQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zvuo3bjRzT3b">Recently Issued Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2024, the FASB issued ASU No. 2024-01, Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards (“ASU 2024-01”), to clarify the scope application of profits interest and similar awards by adding illustrative guidance in ASC 718, <i>Compensation - Stock Compensation</i>.  The ASU clarifies how to determine whether profits interest and similar awards are in the scope of ASC 718 and applies to all reporting entities that account for profits interest awards as compensation to employees or non-employees. In addition to adding the illustrative guidance, the ASU modified the language in paragraph 718-10-15-3 to improve its clarity and operability. However, this amendment does not change the intent of that guidance, nor how it should be applied. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024, including interim periods within those years. The Company is currently evaluating the effects of the adoption of ASU No. 2024-01 on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segment’s profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_858_zoMz5TrUE6Of" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zlwlUshENHYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z0eaWlJVdrE7">Basis of Presentation and Principles of Consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements included herein have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounting of Reliance Global Group, Inc., and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--LiquidityPolicyTextBlock_zqM00e41XfGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zw4M79Oeu6be">Liquidity</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company’s reported cash and restricted cash aggregated balance was approximately $<span id="xdx_904_eus-gaap--RestrictedCashAndCashEquivalents_iI_c20231231_zEl3wC2ZYNIl" title="Aggregate cash balance">2,739,000</span>, current assets were approximately $<span id="xdx_905_eus-gaap--AssetsCurrent_iI_pn3d_c20231231_z7u54gdoTkK" title="Current assets">4,379,000</span>, while current liabilities were approximately <span id="xdx_906_eus-gaap--LiabilitiesCurrent_iI_pn3d_c20231231_z4ianLuf3oJi" title="Current liabilities">3,190,000</span>. As of December 31, 2023, the Company had working capital of approximately $<span id="xdx_907_ecustom--WorkingCapitalDeficiency_iNI_di_c20231231_zLXnHQa0fRo1" title="Working capital">1,189,000</span> and stockholders’ equity of approximately $<span id="xdx_900_eus-gaap--StockholdersEquity_iI_pn3d_c20231231_zIQn2PE7nyP9" title="Stockholder's equity">7,147,000</span>. For the year ended December 31, 2023, the Company reported a loss from operations of approximately $<span id="xdx_902_eus-gaap--OperatingIncomeLoss_iN_pn3d_di_c20230101__20231231_zO7tPQvkFvRe" title="Operating income loss">13,879,000</span>, of which $<span id="xdx_900_eus-gaap--GoodwillImpairmentLoss_c20230101__20231231_zotbxcIpQLk8" title="Goodwill impairment loss">7,594,000</span> was related to goodwill impairment. The Company also reported a non-cash, non-operating gain on the recognition and change in fair value of warrant liabilities of approximately $<span id="xdx_90A_ecustom--RecognitionAndChangeInFairValueOfWarrantLiability_pn3d_c20230101__20231231_z6Lvwd08Slu7" title="Fair value of warrant liabilities">5,504,000</span>, other expense, primarily interest expense of approximately $<span id="xdx_906_eus-gaap--InterestExpenseOther_c20230101__20231231_ztoDDhfgGBdc" title="Interest expense">1,650,000</span>, which resulted in a loss from continuing operations of $<span id="xdx_90F_eus-gaap--IncomeLossFromContinuingOperations_iN_pn3d_di_c20230101__20231231_z4a0e9izU5hc" title="Income loss from continuing operations">10,025,000</span>. Additionally, the Company reported a loss from discontinued operations of approximately $<span id="xdx_90D_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_iN_di_c20230101__20231231_zggF1T94WYvl" title="Income loss from discontinued operations">1,985,000</span>. The total net loss of the company was approximately $<span id="xdx_906_eus-gaap--ProfitLoss_iN_di_c20230101__20231231_znZSGF2aTydh" title="Net loss">12,010,000</span>. The Company completed a capital offering in March 2023, raising net proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230301__20230331_zNNB7w3fITh8" title="Raising net proceeds">3,446,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although there can be no assurance that debt or equity financing will be available on acceptable terms, the Company believes its financial position and its ability to raise capital to be reasonable and sufficient. Based on our assessment, we do not believe there are conditions or events that, in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one year of filing these financial statements with the Securities and Exchange Commission (“SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2739000 4379000 3190000 -1189000 7147000 -13879000 7594000 5504000 1650000 -10025000 -1985000 -12010000 3446000 <p id="xdx_84A_eus-gaap--UseOfEstimates_zkLNCy4qCfn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z1c1VMBVR4ta">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zZQv4POCG4hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zAfDfVh7hox7">Cash and Restricted Cash</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash consists of checking accounts. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash includes cash pledged as collateral to secure obligations and/or all cash whose use is otherwise limited by contractual provisions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At times, some cash balances held in banks may exceed the Federal Deposit Insurance Corporation, or FDIC, standard deposit insurance limit of $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zkD1sDzX8RSk" title="FDIC insured amount">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_z2vesGLRd3j6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zD1MYCljuFD7" style="display: none">SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_z6bd1BX2El5e" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zgLTgufzZwG8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--Cash_iI_maRCACEzxqQ_z7fu8305Pvae" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,329,016</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">505,410</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RestrictedCashCurrent_iI_maRCACEzxqQ_z5C2bnDiARx2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,409,895</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,404,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iTI_mtRCACEzxqQ_zovywO0jSIDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash and restricted cash</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,738,911</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,909,769</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zWoPYN9u3Fmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 250000 <p id="xdx_890_eus-gaap--ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_z2vesGLRd3j6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zD1MYCljuFD7" style="display: none">SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_z6bd1BX2El5e" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zgLTgufzZwG8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--Cash_iI_maRCACEzxqQ_z7fu8305Pvae" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,329,016</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">505,410</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RestrictedCashCurrent_iI_maRCACEzxqQ_z5C2bnDiARx2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,409,895</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,404,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iTI_mtRCACEzxqQ_zovywO0jSIDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash and restricted cash</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,738,911</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,909,769</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1329016 505410 1409895 1404359 2738911 1909769 <p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zep7ko41h59a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z9qRSc5Rkhdb">Property and Equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is stated at cost, less accumulated depreciation. Depreciation is recognized over an asset’s estimated useful life using the straight-line method beginning on the date an asset is placed in service. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Certain capitalized software has been reclassified in the consolidated balance sheet from property and equipment, net to intangibles, net and comparative periods have been adjusted accordingly. Maintenance and repairs are charged to expense as incurred. Estimated useful lives of the Company’s Property and Equipment are as follows:</span></p> <p id="xdx_892_ecustom--ScheduleOfEstimatedUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock_zmUf3k0d8m66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zTwjzSeXPo5a" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computer equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 36%; text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGZTz4PnrzS3" title="Estimated useful life">5</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Office equipment and furniture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zDkmYWmOv8W5" title="Estimated useful life">7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zjHXnc6sSPzc" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0828">Shorter of the useful life or the lease term</span></span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_z5lDG3TOXdpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_ecustom--ScheduleOfEstimatedUsefulLifeOfPropertyPlantAndEquipmentTableTextBlock_zmUf3k0d8m66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zTwjzSeXPo5a" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVE PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computer equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 36%; text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGZTz4PnrzS3" title="Estimated useful life">5</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Office equipment and furniture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zDkmYWmOv8W5" title="Estimated useful life">7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zjHXnc6sSPzc" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0828">Shorter of the useful life or the lease term</span></span></span></td><td style="text-align: left"> </td></tr> </table> P5Y P7Y <p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zT0gtvN6g535" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span><span id="xdx_86D_z8k42G3jk4pb">Fair Value of Financial Instruments</span></span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance includes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels of the fair value hierarchy are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 — Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 — Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 — Unobservable inputs for the asset or liability, which include management’s own assumption about the assumptions market participants would use in pricing the asset or liability, including assumptions about risk.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, and 2022 respectively, the Company’s balance sheet includes certain financial instruments, including cash, notes receivables, accounts payable, and short and long-term debt. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amounts of long-term debt approximate their fair value as the variable interest rates are based on a market index.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant Liabilities:</b> The Company’s warrant liabilities (see Note 9, <i>Warrant Liabilities</i>) represent liability-classified derivative financial instruments recorded at fair value on a recurring basis. The fair value of the Warrant Liabilities includes significant inputs unobservable in the market and thus are considered Level 3. The Company measured the fair value of the warrant liabilities at the issuance date, December 12, 2023, and subsequently at the balance sheet date, using a binomial option pricing model. The following summarizes the significant unobservable inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_ecustom--ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock_z5QsIV6YX9If" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B3_zfM5aRE7OWCg" style="display: none">SCHEDULE OF WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231_zmSyaBLK8nce" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20221231_zyPc6bNKp1s9" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXHaY2TZ5xk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.54</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8.55</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7sJOLAGR4p4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">105.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Time to Expiry</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zxg2Pu8OqsR2" title="Time to expiry">4.99</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zP9PSUs4rf6l" title="Time to expiry">4.01</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zssL2RpSyfZh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zc4RuPXCYp3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zGBNPRParhOe" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrant Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.1</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A0_zGdKZ190pzNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--ScheduleOfReconcilesWarrantCommitmentTableTextBlock_zocEww4cTGFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following reconciles the warrant liabilities for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B4_zpDjNAGYJTZ4" style="display: none">SCHEDULE OF RECONCILES WARRANT COMMITMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4B8_us-gaap--DerivativeInstrumentRiskAxis_custom--SeriesBWarrantCommitmentMember_zwJQrc0aVO" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4B2_us-gaap--DerivativeInstrumentRiskAxis_custom--SeriesBWarrantLiabilityMember_z529ZXvERTdl" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4BD_us-gaap--DerivativeInstrumentRiskAxis_custom--PlacementAgentWarrantsMember_znGFElrGk1w3" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4BD_zAD8r7UahoM8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31, 2023 and 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B Warrant Commitment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B warrant liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Placement agent warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_43A_c20220101__20221231_ecustom--WarrantLiabilities_iS_zeoPh8UlEJdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Beginning balance, December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">37,652,808</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">37,652,808</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--InitialRecognitionOfWarrantCommitment_zBjMv1HpFYg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Initial recognition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,061,119</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,525,924</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,587,043</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantCommitmentUnrealizedGainLoss_zG2wBlg2b83j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized (gain) loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,408,311</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(48,668,869</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,477,024</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32,737,582</td><td style="text-align: left">)<sup id="xdx_F2B_zAoISOx5E1xe">1</sup></td></tr> <tr id="xdx_40E_ecustom--WarrantsExercisedOrTransferred_zCC76Q13bcri" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised or transferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55,061,119</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55,069,119</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_436_c20230101__20231231_ecustom--WarrantLiabilities_iS_zIZgJ5vixI84" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Ending balance, December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,384,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">48,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,433,150</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20230101__20231231_ecustom--WarrantLiabilities_iS_zj6w8Y4O2FS6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance, December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,384,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">48,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,433,150</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantCommitmentUnrealizedGainLoss_zG8THwVQndp4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unrealized (gain) loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,534,931</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(48,575</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,583,506</td><td style="text-align: left">)<sup id="xdx_F23_zsjBk77LyBH1">2</sup></td></tr> <tr id="xdx_40E_ecustom--WarrantsExercisedOrTransferred_zEzNjQ3dFYAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised or exchanged</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(580,651</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(580,651</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_431_c20230101__20231231_ecustom--WarrantLiabilities_iE_znbi3sHpzwRk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268,993</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F02_ziC101SDV46">1</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zM4sIOKj2mB1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition and change in fair value of warrant liabilities per income statement is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_ecustom--RecognitionAndChangeInFairValueOfWarrantLiability_c20220101__20221231_zPhBj3xDv9bb" title="Recognition and change in fair value of warrant liability">29,064,958</span>. The difference of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--WarrantIssuanceCost_c20220101__20221231_zaVWsnsfSsug" title="Warrant issuance cost">3,672,624</span> is made up of the Warrant issuance costs.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><sup id="xdx_F06_zrpBgBacXio5">2</sup></td> <td id="xdx_F19_zWOeK1YtrsZ6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition and change in fair value of warrant liabilities per income statement is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--RecognitionAndChangeInFairValueOfWarrantLiability_c20230101__20231231_zyilvmYaBgHh" title="Recognition and change in fair value of warrant liability">5,503,647</span>. The difference of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_ecustom--WarrantIssuanceCost_c20230101__20231231_zABBiwTHoSph" title="Warrant issuance cost">79,859</span> was due to a loss on a warrant exchange.</td></tr> </table> <p id="xdx_8AB_zbtDowQ1QQ7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Earn-out liabilities:</b> The Company generally values its Level 3 earn-out liabilities using the income valuation approach. Key valuation inputs include contingent payment arrangement terms, projected revenues and cash flows, rate of return, and probability assessments. The following table summarizes the significant unobservable inputs used in the fair value measurements:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zPbdBOexTxLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zfGHH3n0MD87" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENTS</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation technique</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_ecustom--ValuationTechnique_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zo0rWqLbW1pe" style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center" title="Valuation technique"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounted cash flow</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_ecustom--ValuationTechnique_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqYdUQ13wkF4" style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center" title="Valuation technique"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounted cash flow</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant unobservable input</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_ecustom--SignificantUnobservableInput_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZDx6rBYyNK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center" title="Significant unobservable input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projected revenue and probability of achievement</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_ecustom--SignificantUnobservableInput_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ijikQu9EEa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center" title="Significant unobservable input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projected revenue and probability of achievement</span></td></tr> </table> <p id="xdx_8AF_zUD70IclrwOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company values its Level 3 earn-out liability related to the Southwestern Montana Insurance Center acquisition using a Monte Carlo simulation in a risk-neutral framework (a special case of the Income Approach). The following summarizes the significant unobservable inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zw9jP7qYItL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B4_zf9fTt7Yutf" style="display: none">SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Volatility</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"><span id="xdx_90F_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zTMUv8llStch" title="Earn out liability">110</span></td><td style="text-align: left; width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit Spread</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zynhPifUVmAf" title="Earn out liability">7.73</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Number of trading days</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--EarnOutLiabilitiesMeasurementInputTerm_iI_dtD_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--NumberOfTradingDaysMember_z5cgHY1HRPhb" title="Number of trading days">252</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zrMytMVwfbAd" title="Earn out liability">5.34</span></span></td><td style="text-align: left"><p style="margin: 0">%</p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--EarnOutLiabilitiesMeasurementInputTerm_iI_dtY_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zB8CYd4tU2Of" title="Earn out liability">0.2</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zxcgnr18F2bb" title="Earn out liability">0.54</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--EarnOutLiabilitiesMeasurementInput_iI_pid_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGlb0m4fKwMj" title="Earn out liability">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Number of Iterations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--NumberOfIterations_iI_pid_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztlQWix0FhIj" title="Number of iterations">100,000</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zhOVGHr4quZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undiscounted remaining earn out cash payments were approximately $<span id="xdx_904_ecustom--EarnOutPayments_iI_c20231231_zHw2qRKTeWwg" title="Earn out payments">165,000</span> as of December 31, 2023. The following table reconciles fair value of earn-out liabilities for the years ending December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">  </p> <p id="xdx_892_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zZCSyItCSItg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zQ7X3GGysGyk" style="display: none">SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_ziHnPWiI9XQe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zfdV8ZCsZFOa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zTyzs2xI0Mje" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Beginning balance – January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,709,478</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,813,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AcquisitionsAndSettlements_zyZh9WA398v5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Acquisitions and Settlements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,260,403</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,104,924</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Period adjustments:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_zdHnG3Ycskul" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value and estimate changes<sup id="xdx_F46_zilI5q6lSLA5">*</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,716,873</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">524</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EarnoutPayableInCommonShares_zmFlY1VvjDX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Earn-out payable in common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(159,867</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--EarnoutTransferredToLoansPayableRelatedParties_zTZJlmjAyzQ7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Earn-out transferred to loans payable, related parties</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(846,214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zjzOiuIZYgN3" style="vertical-align: bottom; background-color: White"> <td>Ending balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">159,867</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,709,478</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iNI_di_c20231231_zvX5urrfEka9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Current portion">(159,867</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iNI_di_c20221231_zIh4FoCAJrwb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Current portion">(2,153,478</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Ending balance, less current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iI_c20231231_zdU43Tu11qrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, less current portion"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iI_c20221231_zbqbqnDYqZ2d" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, less current portion">556,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_zS4hSLVff6s4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F17_zCt26CiQwPE3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recorded as change in estimated acquisition earn-out payables on the consolidated statements of operations.</span></td></tr> </table> <p id="xdx_8AD_z1FzhNbcHYC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_ecustom--ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock_z5QsIV6YX9If" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B3_zfM5aRE7OWCg" style="display: none">SCHEDULE OF WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231_zmSyaBLK8nce" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20221231_zyPc6bNKp1s9" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXHaY2TZ5xk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.54</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8.55</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7sJOLAGR4p4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">105.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Time to Expiry</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zxg2Pu8OqsR2" title="Time to expiry">4.99</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zP9PSUs4rf6l" title="Time to expiry">4.01</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zssL2RpSyfZh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zc4RuPXCYp3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zGBNPRParhOe" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrant Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.1</td><td style="text-align: left">%</td></tr> </table> 0.54 8.55 110.0 105.0 P4Y11M26D P4Y3D 0 0 3.8 4.1 3.8 4.1 <p id="xdx_89F_ecustom--ScheduleOfReconcilesWarrantCommitmentTableTextBlock_zocEww4cTGFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following reconciles the warrant liabilities for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B4_zpDjNAGYJTZ4" style="display: none">SCHEDULE OF RECONCILES WARRANT COMMITMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4B8_us-gaap--DerivativeInstrumentRiskAxis_custom--SeriesBWarrantCommitmentMember_zwJQrc0aVO" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4B2_us-gaap--DerivativeInstrumentRiskAxis_custom--SeriesBWarrantLiabilityMember_z529ZXvERTdl" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4BD_us-gaap--DerivativeInstrumentRiskAxis_custom--PlacementAgentWarrantsMember_znGFElrGk1w3" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4BD_zAD8r7UahoM8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31, 2023 and 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B Warrant Commitment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B warrant liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Placement agent warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_43A_c20220101__20221231_ecustom--WarrantLiabilities_iS_zeoPh8UlEJdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Beginning balance, December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">37,652,808</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">37,652,808</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--InitialRecognitionOfWarrantCommitment_zBjMv1HpFYg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Initial recognition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,061,119</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,525,924</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,587,043</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantCommitmentUnrealizedGainLoss_zG2wBlg2b83j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized (gain) loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,408,311</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(48,668,869</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,477,024</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32,737,582</td><td style="text-align: left">)<sup id="xdx_F2B_zAoISOx5E1xe">1</sup></td></tr> <tr id="xdx_40E_ecustom--WarrantsExercisedOrTransferred_zCC76Q13bcri" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised or transferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55,061,119</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55,069,119</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_436_c20230101__20231231_ecustom--WarrantLiabilities_iS_zIZgJ5vixI84" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Ending balance, December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,384,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">48,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,433,150</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20230101__20231231_ecustom--WarrantLiabilities_iS_zj6w8Y4O2FS6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance, December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,384,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">48,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,433,150</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantCommitmentUnrealizedGainLoss_zG8THwVQndp4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unrealized (gain) loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,534,931</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(48,575</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,583,506</td><td style="text-align: left">)<sup id="xdx_F23_zsjBk77LyBH1">2</sup></td></tr> <tr id="xdx_40E_ecustom--WarrantsExercisedOrTransferred_zEzNjQ3dFYAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised or exchanged</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(580,651</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(580,651</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_431_c20230101__20231231_ecustom--WarrantLiabilities_iE_znbi3sHpzwRk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268,993</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F02_ziC101SDV46">1</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zM4sIOKj2mB1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition and change in fair value of warrant liabilities per income statement is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_ecustom--RecognitionAndChangeInFairValueOfWarrantLiability_c20220101__20221231_zPhBj3xDv9bb" title="Recognition and change in fair value of warrant liability">29,064,958</span>. The difference of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--WarrantIssuanceCost_c20220101__20221231_zaVWsnsfSsug" title="Warrant issuance cost">3,672,624</span> is made up of the Warrant issuance costs.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><sup id="xdx_F06_zrpBgBacXio5">2</sup></td> <td id="xdx_F19_zWOeK1YtrsZ6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition and change in fair value of warrant liabilities per income statement is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--RecognitionAndChangeInFairValueOfWarrantLiability_c20230101__20231231_zyilvmYaBgHh" title="Recognition and change in fair value of warrant liability">5,503,647</span>. The difference of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMRVMgV0FSUkFOVCBDT01NSVRNRU5UIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_ecustom--WarrantIssuanceCost_c20230101__20231231_zABBiwTHoSph" title="Warrant issuance cost">79,859</span> was due to a loss on a warrant exchange.</td></tr> </table> 37652808 37652808 55061119 1525924 56587043 17408311 -48668869 -1477024 -32737582 -55061119 -8000 -55069119 6384250 48900 6433150 6384250 48900 6433150 -5534931 -48575 -5583506 -580651 -580651 268668 325 268993 29064958 3672624 5503647 79859 <p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zPbdBOexTxLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zfGHH3n0MD87" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENTS</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation technique</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_ecustom--ValuationTechnique_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zo0rWqLbW1pe" style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center" title="Valuation technique"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounted cash flow</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_ecustom--ValuationTechnique_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqYdUQ13wkF4" style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center" title="Valuation technique"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounted cash flow</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant unobservable input</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_ecustom--SignificantUnobservableInput_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZDx6rBYyNK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center" title="Significant unobservable input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projected revenue and probability of achievement</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_ecustom--SignificantUnobservableInput_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ijikQu9EEa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center" title="Significant unobservable input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projected revenue and probability of achievement</span></td></tr> </table> Discounted cash flow Discounted cash flow Projected revenue and probability of achievement Projected revenue and probability of achievement <p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zw9jP7qYItL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B4_zf9fTt7Yutf" style="display: none">SCHEDULE OF LEVEL 3 FAIR VALUE MEASUREMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Volatility</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"><span id="xdx_90F_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zTMUv8llStch" title="Earn out liability">110</span></td><td style="text-align: left; width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit Spread</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zynhPifUVmAf" title="Earn out liability">7.73</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Number of trading days</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--EarnOutLiabilitiesMeasurementInputTerm_iI_dtD_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--NumberOfTradingDaysMember_z5cgHY1HRPhb" title="Number of trading days">252</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zrMytMVwfbAd" title="Earn out liability">5.34</span></span></td><td style="text-align: left"><p style="margin: 0">%</p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--EarnOutLiabilitiesMeasurementInputTerm_iI_dtY_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zB8CYd4tU2Of" title="Earn out liability">0.2</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--EarnOutLiabilitiesMeasurementInput_iI_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zxcgnr18F2bb" title="Earn out liability">0.54</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--EarnOutLiabilitiesMeasurementInput_iI_pid_uPure_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGlb0m4fKwMj" title="Earn out liability">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Number of Iterations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--NumberOfIterations_iI_pid_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztlQWix0FhIj" title="Number of iterations">100,000</span></span></td><td style="text-align: left"> </td></tr> </table> 110 7.73 P252D 5.34 P0Y2M12D 0.54 0 100000 165000 <p id="xdx_892_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zZCSyItCSItg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zQ7X3GGysGyk" style="display: none">SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_ziHnPWiI9XQe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zfdV8ZCsZFOa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zTyzs2xI0Mje" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Beginning balance – January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,709,478</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,813,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AcquisitionsAndSettlements_zyZh9WA398v5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Acquisitions and Settlements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,260,403</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,104,924</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Period adjustments:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_zdHnG3Ycskul" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value and estimate changes<sup id="xdx_F46_zilI5q6lSLA5">*</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,716,873</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">524</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EarnoutPayableInCommonShares_zmFlY1VvjDX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Earn-out payable in common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(159,867</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--EarnoutTransferredToLoansPayableRelatedParties_zTZJlmjAyzQ7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Earn-out transferred to loans payable, related parties</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(846,214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zjzOiuIZYgN3" style="vertical-align: bottom; background-color: White"> <td>Ending balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">159,867</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,709,478</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iNI_di_c20231231_zvX5urrfEka9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Current portion">(159,867</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iNI_di_c20221231_zIh4FoCAJrwb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Current portion">(2,153,478</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Ending balance, less current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iI_c20231231_zdU43Tu11qrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, less current portion"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iI_c20221231_zbqbqnDYqZ2d" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, less current portion">556,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_zS4hSLVff6s4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F17_zCt26CiQwPE3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recorded as change in estimated acquisition earn-out payables on the consolidated statements of operations.</span></td></tr> </table> 2709478 3813878 -3260403 -1104924 1716873 524 -159867 -846214 159867 2709478 159867 2153478 556000 <p id="xdx_841_eus-gaap--DeferredChargesPolicyTextBlock_zXQv8OaHKHw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zwKCcLMtEevl">Deferred Financing Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has recorded deferred financing costs because of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized to interest expense using the straight-line method which approximates the interest rate method over the term of the related debt. As of December 31, 2023, and 2022, unamortized deferred financing costs were $<span id="xdx_90E_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20231231_zU6iKRvvYNCb" title="Unamortized deferred financing costs">273,864</span>, and $<span id="xdx_908_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20221231_zGop3OLVmcb5" title="Unamortized deferred financing costs">313,829</span>, respectively and are netted against the related debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 273864 313829 <p id="xdx_844_eus-gaap--BusinessCombinationsPolicy_zEOuqOuCUdN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z2MS9N818RS3">Business Combinations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its business combinations using the acquisition method of accounting. Under the acquisition method, assets acquired, liabilities assumed, and consideration transferred are recorded at the date of acquisition at their respective fair values. Definite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration such as earn-outs, the Company records the contingent consideration at fair value at the acquisition date. The Company remeasures fair value as of each reporting date and changes resulting from events after the acquisition date, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziXaIpHLxHB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zpc6QOuGwHOc">Identifiable Intangible Assets, net</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finite-lived intangible assets such as customer relationships assets, trademarks and tradenames are amortized over their estimated useful lives, generally on a straight-line basis for periods ranging from <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zZZpyFfyg417" title="Estimated useful lives of intangible assets">3</span> to <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zCP8ENtsrxn7" title="Estimated useful lives of intangible assets">20</span> years. Finite-lived intangible assets are reviewed for impairment or obsolescence whenever events or circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of intangible assets is measured by a comparison of the carrying amount of the asset to the future undiscounted net cash flows expected to be generated by that asset. If the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the estimated fair value. No impairment was recognized during the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P3Y P20Y <p id="xdx_84A_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_zBirntzQsJFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zjRvnxGCPg46">Goodwill and other indefinite-lived intangibles</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records goodwill when the purchase price of a business acquisition exceeds the estimated fair value of net identified tangible and intangible assets acquired. Goodwill is assigned on the acquisition date and tested for impairment at least annually, or more frequently when events or changes in circumstances indicate that the fair value of a reporting unit has more likely than not declined below its carrying value. Similarly, indefinite-lived intangible assets (if any) other than goodwill are tested annually or more frequently if indicated, for impairment. If impaired, intangible assets are written down to fair value based on the expected discounted cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--FinancialInstrumentPolicyTextBlock_zts08lSNoBD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zvvIVdYzBGS">Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates issued financial instruments for classification as either equity or liability based on an assessment of the financial instrument’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”) as well as in accordance with ASU 2020-06. The assessment considers whether the financial instruments issued are freestanding pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and, if applicable whether the financial instruments meet all of the requirements for equity classification under ASC 815, including whether the financial instruments are indexed to the Company’s own Common Stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance and as of each subsequent reporting period end date while the financial instruments are outstanding. Financial instruments that are determined to be liabilities under ASC 480 or ASC 815 are held at their initial fair value and remeasured to fair value at each subsequent reporting date, with changes in fair value recorded as a non-operating, non-cash loss or gain, as applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments consist of derivatives related to the warrants issued with the securities purchase agreement as discussed in Note 9, <i>Warrant Liabilities</i>. The accounting treatment of derivative financial instruments requires that we record the derivatives at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense at each balance sheet date. Upon the determination that an instrument is no longer subject to derivative accounting, the fair value of the derivative instrument at the date of such determination will be reclassified to paid in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The adoption of Topic 326 did not significantly change our approach to the valuation of trade receivables. The Company determines whether there is an expected loss on our accounts receivable by reviewing all available data, including our customers' latest available financial statements, their credit standing, our historical collection experience, and current and future market and economic conditions. As of December 31, 2023, and December 31, 2022, it was not deemed necessary to recognize any allowance for credit losses on our trade receivables.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zEkaIGe34p9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zj3JQimjJKD8">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606 <i>Revenue from Contracts with Customers</i> which at its core, recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenue is primarily comprised of agency commissions earned from insurance carriers (the “Customer” or “Carrier”) related to insurance plans produced through brokering, producing, and servicing agreements between insurance carriers and members. The Company defines a “Member” as an individual, family or entity currently covered or seeking insurance coverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company focuses primarily on agency services for insurance products in the “Healthcare” and property and casualty, which includes auto (collectively “P&amp;C”) space, with nominal activity in the life insurance and bond sectors. Healthcare includes plans for individuals and families, Medicare supplements, ancillary and small businesses. The Company also earns revenue in the “Insurance Marketing” space as discussed further below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration for all agency services typically is based on commissions calculated by applying contractual commission rates to policy premiums. For P&amp;C, commission rates are applied to premiums due, whereas for healthcare, commission rates, including override commissions, are applied to monthly premiums received by the Carrier.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has two forms of billing practices, “Direct Bill” and “Agency Bill”. With Direct Bill, Carriers bill and collect policy premium payments directly from Members without any involvement from the Company. Commissions are paid to the Company by the Carrier in the following month. With Agency Bill, the Company bills Members premiums due and remits them to Carriers net of commission earned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following outlines the core principles of ASC 606:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identification of the contract, or contracts, with a customer</i>. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identification of the performance obligations in the contract</i>. Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Determination of the transaction price</i>. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocation of the transaction price to the performance obligations in the contract</i>. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognition of revenue when, or as, the Company satisfies a performance obligation</i>. The Company satisfies performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Healthcare revenue recognition:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There typically is one performance obligation in contracts with Carriers, to perform agency services that culminate in monthly premium cash collections by the Carrier. The performance obligation is satisfied through a combination of agency services including, marketing carrier’s insurance plans, soliciting Member applications, binding, executing and servicing insurance policies on a continuous basis throughout a policy’s life cycle which includes and culminates with the Customer’s collection of monthly premiums. No commission is earned if cash is not received by Carrier. Thus, commission revenue is earned only after a month’s cash receipts from Members’ dues is received by the Customer. Each month’s Carrier cash collections is considered a separate unit sold and transferred to the Customer i.e., the satisfaction of that month’s performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction price is typically stated in a contract and usually based on a commission rate applied to Member premiums paid and received by Carrier. The Company generally continues to receive commission payments from Carriers until a Member’s plan is cancelled or the Company terminates its agency agreement with the Carrier. Upon termination, the Company normally will no longer receive any commissions from Carriers even on business still in place. In some instances, trailing commissions could occur which would be recognized similar to other Healthcare revenue. With one performance obligation, allocation of transaction price is normally not necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare typically utilizes the Direct Bill method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue at a point in time when it satisfies its monthly performance obligation and control of the service transfers to the Customer. Transfer occurs when Member insurance premium cash payments are received by the Customer. The Customer’s receipt of cash is the culmination and complete satisfaction of the Company’s performance obligation, and the earnings process is complete.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With Direct Bill, since the amount of monthly Customer cash receipts is unknown to the Company until the following month when notice is provided by Customer to Company, the Company accrues revenue at each period end. Any estimated revenue accrued and recognized at a period-end is trued up for financial reporting per actual revenue earned as provided by the Customer during the following month.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">P&amp;C revenue recognition</span>:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There typically is one performance obligation in contracts with Customers, to perform agency services to solicit, receive proposals and bind insurance policies culminating with policy placement. Commission revenue is earned at the time of policy placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction price is typically stated in a contract and usually based on commission rates applied to Member premiums due. With one performance obligation, allocation of transaction price is normally not necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P&amp;C utilizes both the Agency Bill and Direct Bill methods, depending on the Carrier.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of the service transfers to the Customer. Transfer occurs when the policy placement process is complete.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With both Direct Bill and Agency Bill, the Company accrues commission revenue in the period policies are placed. With Agency Bill, payment is typically received from Members in the month earned, however with Direct Bill, payment is typically received from Carriers in the month subsequent to the commissions being earned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other revenue policies:</span> Insurance commissions earned from Carriers for life insurance products are recorded gross of amounts due to agents, with a corresponding commission expense for downstream agent commissions being recorded as commission expense within the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When applicable, commission revenue is recognized net of any deductions for estimated commission adjustments due to lapses, policy cancellations, and revisions in coverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company could earn additional revenue from contingent commissions, profit-sharing, override and bonuses based on meeting certain revenue or profit targets established periodically by the Carriers (collectively, “Contingent Commissions”). Contingent Commissions are earned when the Company achieves targets established by Carriers. The Carriers notify the Company when it has achieved the target. The Company recognizes revenue for any Contingent Commissions at the time it is reasonably assured that a significant revenue reversal is not probable, which is generally when a Carrier notifies the Company that it is on track or has earned a Contingent Commission.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--DisaggregationOfRevenueTableTextBlock_ziX78NrLjgtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates the Company’s revenue by line of business, showing commissions earned:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zmADIobqu1kc" style="display: none">SCHEDULE OF DISAGGREGATION REVENUE</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231__srt--ProductOrServiceAxis__custom--MedicalMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_z93RNs5k0Ffg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231__srt--ProductOrServiceAxis__custom--LifeMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_z9yJDKAVivC" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20230101__20231231__srt--ProductOrServiceAxis__custom--PropertyAndCasualtyMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_zScHjB7Bl1Lg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Property and Casualty</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_zGOH39I0hKq7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--EmployeeBenefitsSolutionsLLCMember_zxTiXVgpUR52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">EBS</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">883,327</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">22,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0993">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">905,441</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--USBenefitsAllianceLLCMember_zgqUrlaGIjAe" style="vertical-align: bottom; background-color: White"> <td>USBA</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,377</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--CommercialCoverageSolutionsLLCMember_z5HMKCkLrd83" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>CCS/UIS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,486</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,486</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--SouthwesternMontanaFinancialCenterIncMember_zLziKGUQNQ9" style="vertical-align: bottom; background-color: White"> <td>Montana</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,863,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,875,943</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--FortmanInsuranceServicesLLCMember_zKxWEmAEYA5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fortman</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,161,506</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,044,592</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,211,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--AltruisBenefitsConsultingIncMember_zO4W17IoWixe" style="vertical-align: bottom; background-color: White"> <td>Altruis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,454,654</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,454,654</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--KushMember_zy5BIst57EBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kush</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,209,854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1022">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,209,854</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--ReliExchangeMember_zcEk4IbTLXWg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Reli Exchange</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">209,615</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">127,486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,401,385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,738,486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z796i0hPzlv6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,825,064</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">170,759</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,735,463</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,731,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220101__20221231__srt--ProductOrServiceAxis__custom--MedicalMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_zmOCQ1KQ3P1e" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20220101__20221231__srt--ProductOrServiceAxis__custom--LifeMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_zulBdXu9TiRd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20220101__20221231__srt--ProductOrServiceAxis__custom--PropertyAndCasualtyMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_z3pdDatnbXni" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property and Casualty</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_zYbwadMJyVT7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--EmployeeBenefitsSolutionsLLCMember_z7KFzeNtXjXk" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EBS</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">781,570</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,843</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">798,413</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--USBenefitsAllianceLLCMember_zNNk3iJrOBO9" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USBA</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,006</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1462</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1043">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,468</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--CommercialCoverageSolutionsLLCMember_zAzqWxWc8L7k" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCS/UIS</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       254,325 </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">254,325</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--SouthwesternMontanaFinancialCenterIncMember_ziG5ojwBJVy5" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Montana</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,860,475</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,661</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1053">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,868,136</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--FortmanInsuranceServicesLLCMember_zXG2acoiKyxg" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fortman</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,267,945</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6705</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">842,961</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,117,611</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--AltruisBenefitsConsultingIncMember_z8aN3QYm7cLk" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Altruis</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,041,495</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2954</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,044,449</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--KushMember_ze75GTMw155l" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kush</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,535,416</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1040</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,536,456</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--ReliExchangeMember_zSfpBMf43wEh" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reli Exchange</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,094</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,052</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">831,878</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,090,024</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zwSOfHjLYny3" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,690,001</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">142,717</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,929,164</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,761,882</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zP2iQfLvXRNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_898_eus-gaap--DisaggregationOfRevenueTableTextBlock_ziX78NrLjgtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates the Company’s revenue by line of business, showing commissions earned:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zmADIobqu1kc" style="display: none">SCHEDULE OF DISAGGREGATION REVENUE</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231__srt--ProductOrServiceAxis__custom--MedicalMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_z93RNs5k0Ffg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231__srt--ProductOrServiceAxis__custom--LifeMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_z9yJDKAVivC" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20230101__20231231__srt--ProductOrServiceAxis__custom--PropertyAndCasualtyMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_zScHjB7Bl1Lg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Property and Casualty</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_zGOH39I0hKq7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--EmployeeBenefitsSolutionsLLCMember_zxTiXVgpUR52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">EBS</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">883,327</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">22,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0993">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">905,441</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--USBenefitsAllianceLLCMember_zgqUrlaGIjAe" style="vertical-align: bottom; background-color: White"> <td>USBA</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,377</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--CommercialCoverageSolutionsLLCMember_z5HMKCkLrd83" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>CCS/UIS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,486</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,486</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--SouthwesternMontanaFinancialCenterIncMember_zLziKGUQNQ9" style="vertical-align: bottom; background-color: White"> <td>Montana</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,863,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,875,943</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--FortmanInsuranceServicesLLCMember_zKxWEmAEYA5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fortman</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,161,506</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,044,592</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,211,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--AltruisBenefitsConsultingIncMember_zO4W17IoWixe" style="vertical-align: bottom; background-color: White"> <td>Altruis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,454,654</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,454,654</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--KushMember_zy5BIst57EBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kush</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,209,854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1022">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,209,854</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--ReliExchangeMember_zcEk4IbTLXWg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Reli Exchange</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">209,615</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">127,486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,401,385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,738,486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z796i0hPzlv6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,825,064</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">170,759</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,735,463</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,731,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220101__20221231__srt--ProductOrServiceAxis__custom--MedicalMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_zmOCQ1KQ3P1e" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20220101__20221231__srt--ProductOrServiceAxis__custom--LifeMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_zulBdXu9TiRd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20220101__20221231__srt--ProductOrServiceAxis__custom--PropertyAndCasualtyMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__custom--RegularMember_z3pdDatnbXni" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property and Casualty</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_zYbwadMJyVT7" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--EmployeeBenefitsSolutionsLLCMember_z7KFzeNtXjXk" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EBS</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">781,570</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,843</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">798,413</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--USBenefitsAllianceLLCMember_zNNk3iJrOBO9" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USBA</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,006</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1462</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1043">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,468</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--CommercialCoverageSolutionsLLCMember_zAzqWxWc8L7k" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCS/UIS</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       254,325 </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">254,325</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--SouthwesternMontanaFinancialCenterIncMember_ziG5ojwBJVy5" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Montana</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,860,475</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,661</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1053">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,868,136</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--FortmanInsuranceServicesLLCMember_zXG2acoiKyxg" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fortman</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,267,945</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6705</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">842,961</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,117,611</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--AltruisBenefitsConsultingIncMember_z8aN3QYm7cLk" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Altruis</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,041,495</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2954</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,044,449</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--KushMember_ze75GTMw155l" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kush</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,535,416</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1040</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,536,456</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidatedEntitiesAxis__custom--ReliExchangeMember_zSfpBMf43wEh" style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reli Exchange</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,094</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,052</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">831,878</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,090,024</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zwSOfHjLYny3" style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,690,001</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">142,717</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,929,164</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,761,882</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 883327 22114 905441 43193 3184 46377 289486 289486 1863455 12488 1875943 1161506 5487 1044592 2211585 5454654 5454654 1209854 1209854 209615 127486 1401385 1738486 10825064 170759 2735463 13731826 781570 16843 798413 51006 1462 52468 254325 254325 1860475 7661 1868136 1267945 6705 842961 2117611 4041495 2954 4044449 1535416 1040 1536456 152094 106052 831878 1090024 9690001 142717 1929164 11761882 <p id="xdx_840_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zXDt9XjsVvX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z5i4m1cDLcXa">General and Administrative</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses primarily consist of personnel costs for the Company’s administrative functions, professional service fees, office rent, all employee travel expenses, and other general costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_zwVqyreMiOz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zPqYrFr4sdvf">Marketing and Advertising</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s direct channel expenses primarily consist of costs for e-mail marketing and newspaper advertisements. The Company’s online advertising channel expense primarily consist of social media ads. Advertising costs for both direct and online channels are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zcqPw5yPJUce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z3Uqi4DUglph">Equity-Based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, based on the terms of the awards. The fair value of the stock-based payments to nonemployees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. To the extent possible, the Company will estimate and recognize expected forfeitures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zMuztgBjbXnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z46qaqMwMz2k">Leases</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes leases in accordance with Accounting Standards Codification Topic 842, “Leases” (“ASC 842” or “ASU 2016-12”). This standard provides enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases are recognized as a single lease expense, generally on a straight-line basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is the lessee in a contract when the Company obtains the right to use an asset. We currently lease real estate and office space under non-cancelable operating lease agreements. When applicable, consideration in a contract is allocated between lease and non-lease components. Lease payments are discounted using the implicit discount rate in the lease. If the implicit discount rate for the lease cannot be readily determined, the Company uses an estimate of its incremental borrowing rate. The Company did not have any contracts accounted for as finance leases as of December 31, 2023, or 2022. Operating leases are included in the line items right-of-use assets, current portion of leases payable, and leases payable, less current portion in the consolidated balance sheets. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations. The Company determines a lease’s term by agreement with lessor and includes lease extension options and variable lease payments when option and/or variable payments are reasonably certain of being exercised or paid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zlUzNetwQ0Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zCmkXmh4xXW">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes deferred tax assets and liabilities using enacted tax rates for the effect of temporary differences between the book and tax basis of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. In evaluating its ability to recover deferred tax assets within the jurisdiction in which they arise, the Company considers all available positive and negative evidence, including the expected reversals of taxable temporary differences, projected future taxable income, taxable income available via carryback to prior years, tax planning strategies, and results of recent operations. The Company assesses the realizability of its deferred tax assets, including scheduling the reversal of its deferred tax assets and liabilities, to determine the amount of valuation allowance needed. Scheduling the reversal of deferred tax asset and liability balances requires judgment and estimation. The Company believes the deferred tax liabilities relied upon as future taxable income in its assessment will reverse in the same period and jurisdiction and are of the same character as the temporary differences giving rise to the deferred tax assets that will be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_847_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zcMxCelEMs0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zNWsHEojELn4">Discontinued Operations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s board of directors approved the discontinuation and abandonment of Medigap Healthcare Insurance Company, LLC (“Medigap”), a subsidiary of the Company, effective April 17, 2023, due to Medigap’s sustained recurring losses stemming from amongst other factors, greater than anticipated revenue chargebacks. The Company was unable to divest its interest in Medigap for value, and accordingly, operations were wound down in an orderly manner. In doing so, the Company transferred to its operating entity, Medigap’s customer relationships and internally developed and purchased software intangible assets, with net of amortization combined value of approximately $<span id="xdx_909_ecustom--DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfAmortizationCombined_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyLLCMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zBgQLKabniJ9" title="Net of amortization combined">4,300,000</span>, as well as, its short-term financing arrangement of $<span id="xdx_90E_ecustom--ShortTermFinancingAgreements_iI_c20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyLLCMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zspBUTNvwo47" title="Short term financing agreements">29,500</span>, and each are respectively classified at their adjusted book values in the intangible assets and short term financing agreements accounts in the condensed consolidated balance sheets for the periods ended December 31, 2023 and December 31, 2022. These assets have continued value to the Company and have not been impaired as the fair value exceeds carrying cost. Medigap’s remaining assets were considered to have no remaining asset value and were fully impaired. Certain liabilities and estimated liabilities as outlined in the tables herein, were discharged and/or written-off in conjunction with the Settlement Agreement (as defined below) because of them having a net zero dollar estimated liability value. Accordingly, the Company recognized a net of estimated liability adjustments gain/loss of approximately $<span id="xdx_908_ecustom--NetOfEstimatedLiabilityAdjustmentsGain_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyLLCMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zRESSPnn9ivf" title="Net of estimated liability adjustments gain">0</span>, and an impairment loss of approximately $<span id="xdx_908_ecustom--ImpairmentLossOnDiscontinuedOperations_pp0p0_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyLLCMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zPWvcXDbAQFf" title="Impairment loss on discontinued operations">4,400,000</span>, presented in income (loss) from discontinued operations in the consolidated statements of operations for the year ended December 31, 2023. As part of the abandonment, the Company cancelled third party contracts, settled outstanding vendor and other third-party obligations, ceased to enter new customer contracts via Medigap, and no further customer performance obligations existed. The Company does not expect further continuing involvement with Medigap, and in accordance with ASC 205-20-45-9, no corporate overhead has been allocated to discontinued operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Settlement Agreement</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 30, 2023, the Company entered into a confidential settlement agreement and mutual release (the “Settlement Agreement”) with certain Medigap affiliated entities and persons, and the former owners of Medigap, whereby the Company would receive a settlement payment, net of costs, of $<span id="xdx_90C_eus-gaap--SettlementLiabilitiesCurrent_iI_c20230630_z9QrBGYfyWc3" title="Settlement payment">2,761,190</span> and was released from all past and future Medigap obligations and liabilities. The settlement payment was received in full by the Company in July 2023 and is recorded as income from discontinued operations in the condensed consolidated statements of operations for the year ended December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_898_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zGJAIbRlQ2xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables present the major components of assets and liabilities included in discontinued operations on the condensed consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zQZIe8DmeGX1" style="display: none">SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyMember_zzTGGrygEY1j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyMember_z8faDvposYQb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zVL6r1fnlER" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">          73,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWwpiVfxxv7h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable, related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVRI6SihbG8i" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_iI_z2qMuEjsNsS9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,388</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_zH5lYlJjsaJ9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expense and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,792</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_iI_zwp3peIQYCEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Current Assets - Discontinued Operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">85,998</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zsEQCOTiFZFf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed consolidated balance sheets - Current Assets - Discontinued Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">85,998</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zPliumkuDplj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">24,116</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zXb4MaTa75l6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">163,129</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zOveFB86Lh42" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1132">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">318,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Goodwill_iI_zbrwnTJzDlW2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_iI_zWWNubiAsZ78" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Other Assets - Discontinued Operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,330,879</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_zFK2RpmaeLPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed consolidated balance sheets - Other Assets - Discontinued Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,330,877</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_z1kyaEoeAXNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable and other accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1144">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">506,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ChargebackReserveCurrent_iI_z8nFBpWtlM2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Chargeback reserve</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">915,934</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zcxSoyLov7Aj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Current portion of leases payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iI_z1873RPuMWHb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current Liabilities - Discontinued Operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zinN2lSwd433" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Condensed consolidated balance sheets - Current Liabilities - Discontinued Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,600,636</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table rolls forward Medigap’s assets and liabilities from their carrying values pre-abandonment to their values post abandonment, and presents the impact of reclassifications, impairments, and write-offs:</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Medigap Related Assets</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyMember__srt--StatementScenarioAxis__custom--CarryingValuePriorToAbandonmentMember_zo0WEWDu9z0h" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value Prior To Abandonment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember__srt--StatementScenarioAxis__custom--AssetAndLiabilityTransfersRetainedByTheCompanyMember_zLUlHgde3Rj8" style="border-bottom: Black 1.5pt solid; text-align: center">Asset and Liability Transfers Retained by the Company</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember__srt--StatementScenarioAxis__custom--AssetImpairmentsAndLiabilityWriteOffsMember_zWZzUALwisf9" style="border-bottom: Black 1.5pt solid; text-align: center">Asset Impairments and Liability Write-Offs</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20231231__us-gaap--ReclassificationTypeAxis__custom--MedigapHealthcareInsuranceCompanyMember_z3U4Vae1SsNj" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value as of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z6O1rEnl6oMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">56,398</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(56,398</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">       <span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zBB3ViixTaVj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable, related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1165">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,595</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zvKnMtNq0Q24" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,595</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_iI_zohEBgGWyb28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1175">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,388</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_znfFylNZOsKd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Current assets – Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65,381</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,381</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zoRAmJCafFKl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22,378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(22,378</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zb8sHtm9Ry19" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,594</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(119,594</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1192">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_z7VyD4AH04T5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,570,536</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">(4,258,214 )<sup id="xdx_F2D_zeNA6B6z5oce">1</sup></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(312,322</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1197">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Goodwill_iI_zMnoAd4gwht2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1200">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_i01I_zGoWHkFnaXff" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other assets - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,538,142</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,258,214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,279,928</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iI_zoxfT5lSvv2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total assets - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,603,523</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,258,214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,345,309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zKkqfjjv10U6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts payable and other accrued liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,157</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ShortTermFinancingAgreements_iI_zXRMY0z1jbBl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term financing agreements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1222">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ChargebackReserveCurrent_iI_zF6UuY9xMZg2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Chargeback reserve</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">831,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">(831,725 )<sup id="xdx_F29_zmkoE66QGabh">2</sup></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zK1ZwFFSZsK7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current portion of leases payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">(134,517 )<sup id="xdx_F25_zyz1V69fRv4d">3</sup></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherLiabilities_iI_zkhlhuvfI9E7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,842</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(9,842 )<sup id="xdx_F23_zO90gwviGEp3">3</sup></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i01I_zRNCCpgkaE3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,009,741</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(980,241</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_iI_zLd6PxTO45yd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,009,741</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(980,241</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AssetsAndLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zQNKo5gtsrn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net assets and liabilities - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,593,782</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,228,714</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,365,068</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"> </span></td> <td style="width: 0.25in"><span id="xdx_F05_zpiu8zGTXMRc" style="font-size: 10pt">1</span></td> <td style="text-align: justify"><span id="xdx_F16_zVOljeGGMMZb" style="font-size: 10pt">Includes customer relationships and internally developed and purchased software intangible assets that have continued value to the Company and have not been impaired as the fair value exceeds carrying cost.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span id="xdx_F0F_zp409ah5EP97" style="font-size: 10pt">2</span></td> <td style="text-align: justify"><span id="xdx_F1D_zBo9UO2Ls7Gg" style="font-size: 10pt">Estimated liability write-off per net zero dollar estimated liability value.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span id="xdx_F06_zli9A4bgOJQ8" style="font-size: 10pt">3</span></td> <td style="text-align: justify"><span id="xdx_F1A_zjaez4DXYPW4" style="font-size: 10pt">Liability discharge pursuant to the Settlement Agreement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables disaggregate the major classes of pretax gain and loss as presented in discontinued operations in the condensed consolidated statements of operations.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zcbrpTZLFOT2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zuTiWaq03jB5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, 2022</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--CommissionIncome_zrtJ9z9RR527" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-left: 10pt">Commission income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">744,030</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,994,002</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--CommissionExpense_zDrBjgcwyXef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Commission expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,639</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">604,042</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--SalariesAndWages_z1v17QR7MiKk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Salaries and wages</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">454,663</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,973,579</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_zC1txXtGpi4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">General and administrative </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">129,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">508,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--MarketingAndAdvertisingExpense_znjrNqwuWtY5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Marketing and advertising</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">426,818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,414,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DepreciationAndAmortization_zQZaqDwamQ12" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238,307</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_z8lhPgxSqSEe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,902</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,454</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_zeV4MMEa4RS1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total discontinued operations expenses before impairments and write-offs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,124,864</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,716,399</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_zmKowf9chE8h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Total discontinued operations income / (loss) before impairments and write-offs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(380,834</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(722,397</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gains and (losses) from recoveries and impairments / write-offs of discontinued operations assets and liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--SettlementRecoveryNetOfCosts_zzZyD53KwZ7e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Settlement Recovery, net of costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,761,190</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Asset impairment losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccountsReceivableImpairements_iN_di_zBOmjFTAz7Mf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccountsReceivableImpairements_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHXd85nx3sxa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Accounts receivable, related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssetImpairmentCharges_z3o8sxwXGn96" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,388</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--TangibleAssetImpairmentCharges_zpmpOKsSAJKg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseImpairmentLoss_iN_di_zL5cM6mbXPrl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,593</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--IntangiblesNet_zFfaopY1p4ha" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312,322</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GoodwillImpairmentLoss_zJk2bJj7GQlb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetImpairmentCharges_iNT_di_zov9e4oGffk1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total asset impairments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,345,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,373,374</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Liability write-off gains</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccountsPayableAndOtherAccruedLiabilitiesWriteOffs_zvRpG4c33a12" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Accounts payable and other accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--OtherPayablesWriteoffs_zKGUwqQHtTd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Other payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,842</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ChargebackReserveWriteOffs_zpp9HPHkDLml" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Chargeback reserve</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">831,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CurrentPortionOfLeasesPayableWriteOffs_zNINvwB21qC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Current portion of leases payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">134,517</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--TotalLiabilityWriteoffs_z6km2qGiEzPj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Total liability write-off gains</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">980,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DiscontinuedOperationsNetAssetAndLiabilityIumpairmentsWriteoffs_zk8Zful4FcMh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Discontinued operations net asset and liability impairments / write-offs gains and (losses)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,365,070</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--NetRecoveriesAndImpairmentsWriteoffsFromDiscontinuedAssetsAndLiabilities_zU88q31cKXxi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,603,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_zQYsOkxVKYhc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from discontinued operations before tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,984,714</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,095,770</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zAmOF7TvePo5" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">Consolidated statement of operations - Loss from discontinued operations before tax</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,984,714</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(15,095,770</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8A0_zymB96dvEpR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 4300000 29500 0 4400000 2761190 <p id="xdx_898_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zGJAIbRlQ2xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables present the major components of assets and liabilities included in discontinued operations on the condensed consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zQZIe8DmeGX1" style="display: none">SCHEDULE OF DISCONTINUED OPERATIONS ON CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyMember_zzTGGrygEY1j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyMember_z8faDvposYQb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zVL6r1fnlER" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">          73,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWwpiVfxxv7h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable, related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVRI6SihbG8i" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_iI_z2qMuEjsNsS9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,388</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_zH5lYlJjsaJ9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expense and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,792</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_iI_zwp3peIQYCEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Current Assets - Discontinued Operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">85,998</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zsEQCOTiFZFf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed consolidated balance sheets - Current Assets - Discontinued Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">85,998</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zPliumkuDplj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">24,116</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zXb4MaTa75l6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">163,129</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zOveFB86Lh42" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1132">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">318,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Goodwill_iI_zbrwnTJzDlW2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_iI_zWWNubiAsZ78" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Other Assets - Discontinued Operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,330,879</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_zFK2RpmaeLPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed consolidated balance sheets - Other Assets - Discontinued Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,330,877</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_z1kyaEoeAXNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable and other accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1144">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">506,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ChargebackReserveCurrent_iI_z8nFBpWtlM2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Chargeback reserve</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">915,934</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zcxSoyLov7Aj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Current portion of leases payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iI_z1873RPuMWHb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current Liabilities - Discontinued Operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zinN2lSwd433" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Condensed consolidated balance sheets - Current Liabilities - Discontinued Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,600,636</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table rolls forward Medigap’s assets and liabilities from their carrying values pre-abandonment to their values post abandonment, and presents the impact of reclassifications, impairments, and write-offs:</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Medigap Related Assets</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--MedigapHealthcareInsuranceCompanyMember__srt--StatementScenarioAxis__custom--CarryingValuePriorToAbandonmentMember_zo0WEWDu9z0h" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value Prior To Abandonment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember__srt--StatementScenarioAxis__custom--AssetAndLiabilityTransfersRetainedByTheCompanyMember_zLUlHgde3Rj8" style="border-bottom: Black 1.5pt solid; text-align: center">Asset and Liability Transfers Retained by the Company</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember__srt--StatementScenarioAxis__custom--AssetImpairmentsAndLiabilityWriteOffsMember_zWZzUALwisf9" style="border-bottom: Black 1.5pt solid; text-align: center">Asset Impairments and Liability Write-Offs</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20231231__us-gaap--ReclassificationTypeAxis__custom--MedigapHealthcareInsuranceCompanyMember_z3U4Vae1SsNj" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value as of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z6O1rEnl6oMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">56,398</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(56,398</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">       <span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zBB3ViixTaVj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable, related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1165">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,595</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zvKnMtNq0Q24" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,595</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_iI_zohEBgGWyb28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1175">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,388</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_znfFylNZOsKd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Current assets – Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65,381</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,381</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zoRAmJCafFKl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22,378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(22,378</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zb8sHtm9Ry19" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,594</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(119,594</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1192">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_z7VyD4AH04T5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,570,536</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">(4,258,214 )<sup id="xdx_F2D_zeNA6B6z5oce">1</sup></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(312,322</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1197">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Goodwill_iI_zMnoAd4gwht2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1200">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_i01I_zGoWHkFnaXff" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other assets - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,538,142</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,258,214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,279,928</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iI_zoxfT5lSvv2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total assets - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,603,523</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,258,214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,345,309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zKkqfjjv10U6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts payable and other accrued liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,157</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ShortTermFinancingAgreements_iI_zXRMY0z1jbBl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term financing agreements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(29,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1222">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ChargebackReserveCurrent_iI_zF6UuY9xMZg2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Chargeback reserve</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">831,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">(831,725 )<sup id="xdx_F29_zmkoE66QGabh">2</sup></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zK1ZwFFSZsK7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current portion of leases payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">(134,517 )<sup id="xdx_F25_zyz1V69fRv4d">3</sup></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherLiabilities_iI_zkhlhuvfI9E7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,842</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(9,842 )<sup id="xdx_F23_zO90gwviGEp3">3</sup></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i01I_zRNCCpgkaE3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,009,741</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(980,241</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_iI_zLd6PxTO45yd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,009,741</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(980,241</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AssetsAndLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zQNKo5gtsrn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net assets and liabilities - Medigap</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,593,782</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,228,714</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,365,068</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"> </span></td> <td style="width: 0.25in"><span id="xdx_F05_zpiu8zGTXMRc" style="font-size: 10pt">1</span></td> <td style="text-align: justify"><span id="xdx_F16_zVOljeGGMMZb" style="font-size: 10pt">Includes customer relationships and internally developed and purchased software intangible assets that have continued value to the Company and have not been impaired as the fair value exceeds carrying cost.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span id="xdx_F0F_zp409ah5EP97" style="font-size: 10pt">2</span></td> <td style="text-align: justify"><span id="xdx_F1D_zBo9UO2Ls7Gg" style="font-size: 10pt">Estimated liability write-off per net zero dollar estimated liability value.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span id="xdx_F06_zli9A4bgOJQ8" style="font-size: 10pt">3</span></td> <td style="text-align: justify"><span id="xdx_F1A_zjaez4DXYPW4" style="font-size: 10pt">Liability discharge pursuant to the Settlement Agreement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables disaggregate the major classes of pretax gain and loss as presented in discontinued operations in the condensed consolidated statements of operations.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zcbrpTZLFOT2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zuTiWaq03jB5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, 2022</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--CommissionIncome_zrtJ9z9RR527" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-left: 10pt">Commission income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">744,030</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,994,002</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--CommissionExpense_zDrBjgcwyXef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Commission expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,639</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">604,042</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--SalariesAndWages_z1v17QR7MiKk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Salaries and wages</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">454,663</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,973,579</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_zC1txXtGpi4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">General and administrative </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">129,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">508,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--MarketingAndAdvertisingExpense_znjrNqwuWtY5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Marketing and advertising</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">426,818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,414,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DepreciationAndAmortization_zQZaqDwamQ12" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238,307</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_z8lhPgxSqSEe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,902</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,454</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_zeV4MMEa4RS1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total discontinued operations expenses before impairments and write-offs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,124,864</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,716,399</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_zmKowf9chE8h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Total discontinued operations income / (loss) before impairments and write-offs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(380,834</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(722,397</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gains and (losses) from recoveries and impairments / write-offs of discontinued operations assets and liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--SettlementRecoveryNetOfCosts_zzZyD53KwZ7e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Settlement Recovery, net of costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,761,190</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Asset impairment losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccountsReceivableImpairements_iN_di_zBOmjFTAz7Mf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccountsReceivableImpairements_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHXd85nx3sxa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Accounts receivable, related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssetImpairmentCharges_z3o8sxwXGn96" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,388</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--TangibleAssetImpairmentCharges_zpmpOKsSAJKg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseImpairmentLoss_iN_di_zL5cM6mbXPrl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,593</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--IntangiblesNet_zFfaopY1p4ha" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312,322</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GoodwillImpairmentLoss_zJk2bJj7GQlb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetImpairmentCharges_iNT_di_zov9e4oGffk1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total asset impairments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,345,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,373,374</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Liability write-off gains</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccountsPayableAndOtherAccruedLiabilitiesWriteOffs_zvRpG4c33a12" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Accounts payable and other accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--OtherPayablesWriteoffs_zKGUwqQHtTd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Other payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,842</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ChargebackReserveWriteOffs_zpp9HPHkDLml" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Chargeback reserve</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">831,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CurrentPortionOfLeasesPayableWriteOffs_zNINvwB21qC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Current portion of leases payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">134,517</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--TotalLiabilityWriteoffs_z6km2qGiEzPj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Total liability write-off gains</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">980,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DiscontinuedOperationsNetAssetAndLiabilityIumpairmentsWriteoffs_zk8Zful4FcMh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Discontinued operations net asset and liability impairments / write-offs gains and (losses)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,365,070</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--NetRecoveriesAndImpairmentsWriteoffsFromDiscontinuedAssetsAndLiabilities_zU88q31cKXxi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Net gains and (losses) from recoveries and impairments / write-offs from discontinued operations assets and liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,603,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_zQYsOkxVKYhc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from discontinued operations before tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,984,714</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,095,770</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zAmOF7TvePo5" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">Consolidated statement of operations - Loss from discontinued operations before tax</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,984,714</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(15,095,770</td><td style="text-align: left">)</td></tr> </table> 73223 3595 3595 5388 3792 85998 85998 24116 163129 318000 4825634 5330879 5330877 506585 915934 178117 1600636 1600636 56398 -56398 3595 -3595 3595 -3595 5388 -5388 65381 -65381 22378 -22378 119594 -119594 4570536 -4258214 -312322 4825634 -4825634 9538142 -4258214 -5279928 9603523 -4258214 -5345309 4157 -4157 29500 -29500 831725 -831725 134517 -134517 9842 -9842 1009741 -29500 -980241 1009741 -29500 -980241 8593782 -4228714 -4365068 744030 4994002 110639 604042 454663 1973579 129363 508342 426818 2414583 7283 238307 -3902 -22454 1124864 5716399 -380834 -722397 2761190 -56398 -3595 5388 22378 -119593 312322 4825634 14373374 -5345308 -14373374 4154 9842 831725 134517 980238 4365070 14373374 -1603880 -14373374 -1984714 -15095770 -1984714 -15095770 <p id="xdx_84C_ecustom--SeasonalityPolicyTextBlock_zDaKbTP9jtHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zP7VTcy1Mlc3">Seasonality</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A greater number of the Company’s Medicare-related health insurance plans are sold in the fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage. The majority of the Company’s individual and family health insurance plans are sold in the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBwJzDMQbWQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zvuo3bjRzT3b">Recently Issued Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2024, the FASB issued ASU No. 2024-01, Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards (“ASU 2024-01”), to clarify the scope application of profits interest and similar awards by adding illustrative guidance in ASC 718, <i>Compensation - Stock Compensation</i>.  The ASU clarifies how to determine whether profits interest and similar awards are in the scope of ASC 718 and applies to all reporting entities that account for profits interest awards as compensation to employees or non-employees. In addition to adding the illustrative guidance, the ASU modified the language in paragraph 718-10-15-3 to improve its clarity and operability. However, this amendment does not change the intent of that guidance, nor how it should be applied. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024, including interim periods within those years. The Company is currently evaluating the effects of the adoption of ASU No. 2024-01 on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segment’s profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_806_eus-gaap--BusinessCombinationDisclosureTextBlock_zk58BQuysWh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3. <span id="xdx_826_zUlwL5E1kI13">STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, we have acquired ten insurance brokerages (see table below). As our acquisition strategy continues, our reach within the insurance arena can provide us with the ability to offer lower rates, which could boost our competitive position within the industry.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquired</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reliance 100% Controlled Entity</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Location</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Line of Business</b></span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Benefits Alliance, LLC (USBA)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Benefits Alliance, LLC</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 24, 2018</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michigan</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Insurance</span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Benefit Solutions, LLC (EBS)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Benefits Solutions, LLC</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 24, 2018</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michigan</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Insurance</span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial Solutions of Insurance Agency, LLC (CCS or Commercial Solutions)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial Coverage Solutions LLC</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 1, 2018</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P&amp;C – Trucking Industry</span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Southwestern Montana Insurance Center, Inc. (Southwestern Montana or Montana or SWMT)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Southwestern Montana Insurance Center, LLC</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2019</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Montana</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group Health Insurance</span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fortman Insurance Agency, LLC (Fortman or Fortman Insurance or FIS)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fortman Insurance Solutions, LLC</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 1, 2019</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ohio</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P&amp;C and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Insurance</span></p></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Altruis Benefits Consultants, Inc. (Altruis or ABC)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Altruis Benefits Corporation</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 1, 2019</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michigan</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Insurance</span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UIS Agency, LLC (UIS)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UIS Agency, LLC</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 17, 2020</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P&amp;C – Trucking Industry</span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.P. Kush and Associates, Inc. (Kush)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kush Benefit Solutions, LLC</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 1, 2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michigan</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Insurance</span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barra &amp; Associates, LLC (Barra)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RELI Exchange, LLC</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 26, 2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Illinois</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P&amp;C and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Insurance</span></p></td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Barra &amp; Associates, LLC Transaction</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 26, 2022, we entered into an asset purchase agreement (the “APA”) with Barra &amp; Associates, LLC (“Barra”) pursuant to which the Company purchased all of the assets of Barra &amp; Associates, LLC on April 26, 2022 for a purchase price in the amount of $<span id="xdx_909_eus-gaap--AssetAcquisitionConsiderationTransferred_c20220426__20220426__us-gaap--AssetAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--TypeOfArrangementAxis__custom--APAMember_zWtH7BoVWQie" title="Asset Acquisition, Consideration Transferred">7,725,000</span> in cash, with $<span id="xdx_903_eus-gaap--AssetAcquisitionConsiderationTransferred_c20220426__20220426__us-gaap--AssetAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--TypeOfArrangementAxis__custom--APAMember__srt--StatementScenarioAxis__custom--PaidAtClosingMember_zAeDDm8PD18b" title="Asset Acquisition, Consideration Transferred">6,000,000</span> paid to Barra at closing, $<span id="xdx_906_eus-gaap--AssetAcquisitionConsiderationTransferred_c20220426__20220426__us-gaap--AssetAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--TypeOfArrangementAxis__custom--APAMember__srt--StatementScenarioAxis__custom--PayableInNineMonthsMember_zpftyQ4Fktai" title="Asset Acquisition, Consideration Transferred">1,125,000</span> payable in nine months from closing, and a final earnout of $<span id="xdx_901_eus-gaap--AssetAcquisitionConsiderationTransferred_c20220426__20220426__us-gaap--AssetAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--TypeOfArrangementAxis__custom--APAMember__srt--StatementScenarioAxis__custom--PayableOverTwoYearsMember_zX17CQEJ50e7" title="Asset Acquisition, Consideration Transferred">600,000</span> payable over two years from closing based upon meeting stated milestones. The APA contains standard, commercial representations and warranties and covenants. The source of the cash payment was $<span id="xdx_907_ecustom--WorkingCapital_c20220426__20220426__us-gaap--AssetAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--TypeOfArrangementAxis__custom--APAMember_zT6CXHjK4sd5" title="Working capital">6,520,000</span> in funds borrowed from Oak Street Lending (“Loan”), our existing lender pursuant to a Fifth Amendment to Credit Agreement and Promissory Note, of even date. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The acquisition of Barra was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zoGXj3n0AQC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preliminary allocation of the purchase price in connection with the acquisition of Barra was calculated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zqaSqMFyicE" style="display: none">SCHEDULE OF ALLOCATION OF PURCHASE PRICE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Useful</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Acquired accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredAccountsReceivableMember_zyVIqhFtdAo8" style="width: 14%; text-align: right" title="Property, plant and equipment">92,585</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 14%; text-align: center"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property, plant, and equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zFFCCKUWudMg" style="text-align: right" title="Property, plant and equipment">8,593</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zkstiRaQy2yd" title="Finite lived intangible asset useful life">7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right-of-use asset</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--RightOfUseAssetMember_z4OcjUxaJ9Q2" style="text-align: right" title="Property, plant and equipment">122,984</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade names</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zCvXruUf2Swb" style="text-align: right" title="Property, plant and equipment">22,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zsUzahbitgf7" title="Finite lived intangible asset useful life">4</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zWxcHCezxIV3" style="text-align: right" title="Property, plant and equipment">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zRhkj6rRpn89" title="Finite lived intangible asset useful life">10</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Developed technology</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopmentTechnologyMember_z4GPt7fRlBa8" style="text-align: right" title="Property, plant and equipment">230,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopmentTechnologyMember_znjjg5oY5O0a" title="Finite lived intangible asset useful life">5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Agency relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AgencyRelationshipMember_zLuGlq7bxAaa" style="text-align: right" title="Property, plant and equipment">2,585,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AgencyRelationshipMember_zgAjrnqk6Tf8" title="Finite lived intangible asset useful life">10</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LeaseLiabilityMember_zWTcZH4C9oAa" style="text-align: right" title="Property, plant and equipment">(122,984</td><td style="text-align: left">)</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zj6nNoabj3w7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plant and equipment">4,236,822</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--FinitelivedIntangibleAssetUsefulLives_c20220426__20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zhXwF4lCkPt9" title="Finite lived intangible asset useful life">Indefinite</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zfNtkT8t1h43" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plant and equipment">7,725,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></p> <p id="xdx_8AD_z4oHRQ6yCm15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade name was measured at fair value using the relief-from-royalty method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue from the trade name, a pre-tax royalty rate of <span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_dp_uPure_c20220426__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRoyaltyRateMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zeV6Q8TWNNXd" title="Business combination, measurement input">0.5%</span> and a discount rate of <span id="xdx_90A_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_c20220426__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zlfLYgK3QX86" title="Business combination, measurement input">19.5%</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer and Agency relationships were measured at fair value using the multiple-period excess earnings method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue and costs associated with existing customers, and a discount rate of <span id="xdx_90B_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_c20220426__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zGWUB34zoRt7" title="Business combination, measurement input">19.5%</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developed technology was measured at fair value using the cost replacement method of the cost approach. Significant inputs used to measure the fair value include an estimate of cost to replace, an obsolescence rate of <span id="xdx_901_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_c20220426__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputObsolescenceRateMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopmentTechnologyMember__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_ziKGW3TMKXTg" title="Business combination, measurement input">28.6%</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill of $<span id="xdx_902_eus-gaap--Goodwill_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zifByeu4gbV7" title="Goodwill">4,236,822</span> arising from the acquisition of Barra consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the acquisition of Barra is currently expected to be deductible for income tax purposes. Total acquisition costs incurred for the acquisition of Barra were $<span id="xdx_90C_eus-gaap--AcquisitionCosts_c20220426__20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zw3U7VQchKKg" title="Acquisition costs">72,793</span> recorded as a component of General and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from April 26, 2022 to December 31, 2022 was $<span id="xdx_90F_eus-gaap--BusinessAcquisitionRevenueReportedByAcquiredEntityForLastAnnualPeriod_c20220426__20221231__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zZBDd8jm6kUg" title="Revenue from acquired entity">1,090,023</span> and a loss of $<span id="xdx_904_ecustom--SharesIssuedUponTerminationOfEmployee_c20220426__20221231__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zNTYmk80QwAc" title="Shares issued upon termination of employee">393,708</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Pro Forma Information</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results of operations of Barra will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental pro forma financial information approximate combined financial information assumes that the acquisition had occurred at the beginning of the nine months ended December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_z4yKMH2AS7X" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zeVJulLmzwpl" style="display: none">SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zASAqyPKD34e" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessAcquisitionsProFormaRevenue_znHNGzHdTOdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Revenue</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">12,309,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zpc61Ows82kj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net Income (Loss)</td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,700,594</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareBasic_zSEvCS6NObAj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Earnings (Loss) per common share, basic</td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.21</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareDiluted_znmuUAw2ljni" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Earnings (Loss) per common share, diluted</td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.21</td><td style="text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 7725000 6000000 1125000 600000 6520000 <p id="xdx_895_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zoGXj3n0AQC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preliminary allocation of the purchase price in connection with the acquisition of Barra was calculated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zqaSqMFyicE" style="display: none">SCHEDULE OF ALLOCATION OF PURCHASE PRICE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Useful</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Acquired accounts receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredAccountsReceivableMember_zyVIqhFtdAo8" style="width: 14%; text-align: right" title="Property, plant and equipment">92,585</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 14%; text-align: center"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property, plant, and equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zFFCCKUWudMg" style="text-align: right" title="Property, plant and equipment">8,593</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zkstiRaQy2yd" title="Finite lived intangible asset useful life">7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right-of-use asset</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--RightOfUseAssetMember_z4OcjUxaJ9Q2" style="text-align: right" title="Property, plant and equipment">122,984</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade names</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zCvXruUf2Swb" style="text-align: right" title="Property, plant and equipment">22,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zsUzahbitgf7" title="Finite lived intangible asset useful life">4</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zWxcHCezxIV3" style="text-align: right" title="Property, plant and equipment">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zRhkj6rRpn89" title="Finite lived intangible asset useful life">10</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Developed technology</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopmentTechnologyMember_z4GPt7fRlBa8" style="text-align: right" title="Property, plant and equipment">230,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopmentTechnologyMember_znjjg5oY5O0a" title="Finite lived intangible asset useful life">5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Agency relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AgencyRelationshipMember_zLuGlq7bxAaa" style="text-align: right" title="Property, plant and equipment">2,585,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AgencyRelationshipMember_zgAjrnqk6Tf8" title="Finite lived intangible asset useful life">10</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LeaseLiabilityMember_zWTcZH4C9oAa" style="text-align: right" title="Property, plant and equipment">(122,984</td><td style="text-align: left">)</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zj6nNoabj3w7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plant and equipment">4,236,822</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--FinitelivedIntangibleAssetUsefulLives_c20220426__20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zhXwF4lCkPt9" title="Finite lived intangible asset useful life">Indefinite</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20220426__us-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_zfNtkT8t1h43" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plant and equipment">7,725,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></p> 92585 8593 P7Y 122984 22000 P4Y 550000 P10Y 230000 P5Y 2585000 P10Y -122984 4236822 Indefinite 7725000 0.005 19.05 19.05 28.06 4236822 72793 1090023 393708 <p id="xdx_89E_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--BarraAndAssociatesLLCMember_z4yKMH2AS7X" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zeVJulLmzwpl" style="display: none">SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zASAqyPKD34e" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessAcquisitionsProFormaRevenue_znHNGzHdTOdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Revenue</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">12,309,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_zpc61Ows82kj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net Income (Loss)</td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,700,594</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareBasic_zSEvCS6NObAj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Earnings (Loss) per common share, basic</td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.21</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareDiluted_znmuUAw2ljni" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Earnings (Loss) per common share, diluted</td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.21</td><td style="text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 12309504 6700594 -0.21 -0.21 <p id="xdx_803_eus-gaap--InvestmentTextBlock_z0UeG4Dwzy31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4. <span id="xdx_82E_zBxxoDKXBks1">INVESTMENT IN NSURE, INC.</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 19, 2020, the Company entered into a securities purchase agreement with NSURE, Inc. (“NSURE”), which was further amended on October 8, 2020, and as amended provides that the Company may invest up to an aggregate of $<span id="xdx_900_eus-gaap--Investments_iI_pp0p0_c20201008__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--NSUREIncMember_zwaVFk7gWSh3" title="Investments">5,700,000</span> in NSURE to be funded in three tranches. In exchange, the Company will receive a total of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20201007__20201008__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--NSUREIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zXR5FIVgYGh5" title="Number of shares of common stock, shares">928,343</span> shares of NSURE’s Class A Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year 2020, by October 8, 2020, the Company funded the first tranche, $<span id="xdx_908_eus-gaap--Investments_iI_pp0p0_c20201008__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--NSUREIncMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zjRIhJ8Fafal" title="Investments">1,350,000</span> in exchange for <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20201007__20201008__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--NSUREIncMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zoQoQHnUjIS9" title="Number of shares of common stock, shares">394,029</span> shares. The second tranche allowed the Company to acquire an additional <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20201007__20201008__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--NSUREIncMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zGPqhn32jfTb" title="Number of shares of common stock, shares">209,075</span> shares at a price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pp3p0_c20201008__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--NSUREIncMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z3EycRVU2fDg" title="Share price">6.457</span> per share by no later than December 30, 2020. The third full tranche allowed the Company to purchase an additional <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20201007__20201008__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--NSUREIncMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z9n6ZMFELM8g" title="Number of shares of common stock, shares">325,239</span> shares at a purchase price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pp3p0_c20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--NSUREIncMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zYQGjhmD5Va9" title="Share price">9.224</span> after December 20, 2020, but no later than March 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did not fund tranches two and three in the required timeframes, thus, the Company relinquished its rights under the contract to any additional NSURE shares aside for the ones already acquired with tranche one.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fourth quarter of the year ended December 31, 2022, the Company sold <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20221231__dei--LegalEntityAxis__custom--NSUREIncMember_zZRAcZqbvuff" title="Sale of shares">131,345</span> of its NSURE shares to unaffiliated third parties, receiving cash proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromSaleOfInvestmentProjects_c20220101__20221231__dei--LegalEntityAxis__custom--NSUREIncMember_z1BA0lPi19s7" title="Cash proceeds">450,000</span>. During April 2023, the Company sold its remaining <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230401__20230430__dei--LegalEntityAxis__custom--NSUREIncMember_zzISF4HAwWhc" title="Sale of stock, shares">262,684</span> of NSURE shares to unaffiliated third parties, receiving the shares’ cost basis and cash proceeds of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230401__20230430__dei--LegalEntityAxis__custom--NSUREIncMember_zS4KrEr0sTQd" title="Proceeds from sale of stock">900,000</span>. The Company’s remaining NSURE share balance as of December 31, 2023, was $<span id="xdx_90D_eus-gaap--SharesOutstanding_iI_c20231231__dei--LegalEntityAxis__custom--NSUREIncMember_zXosN3cPtiv7" title="Remaining balance shares">0</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measured the NSURE shares subsequent to acquisition in accordance with ASC 321-10-35-2, at cost less impairment since no readily determinable fair value was available to the Company. The investment was reviewed for impairment at each reporting period by qualitatively assessing any indicators demonstrating fair value of the investment is less than carrying value. The Company did not observe any price changes resulting from orderly transactions for identical or similar assets for the years ended December 31, 2023, or 2022. ASC 321-10-50-4 further requires an entity to disclose unrealized gains and losses for periods that relate to equity securities held at a reporting date. To date, the Company has not recognized any unrealized gains or losses on NSURE security.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5700000 928343 1350000 394029 209075 6.457 325239 9.224 131345 450000 262684 900000 0 <p id="xdx_800_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zZ7uuCViwym6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5. <span id="xdx_826_zXGTfU7u8Pt5">PROPERTY AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zSnvVI4Js2ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zrHGpXUBc3xg" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20231231_zFkBvXCp5LSk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20221231_zJLKLT2eMKm3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_zZpTqtPLN51d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,350</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,278</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zxSYVKmG3esg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment and furniture</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,652</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,693</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zPbYhuXLcq24" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,378</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,830</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzrfx_zNH8iCXBZ8bh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278,380</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">255,801 </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzrfx_zy6gDFxA8Rk8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(138,381</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(93,034</span></p> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzrfx_zG4mqhz3XpGf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,999</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162,767</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A2_zECw1noM4p45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense associated with property and equipment, is included within depreciation and amortization in the Company’s consolidated statements of operations and is, $<span id="xdx_901_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zfVBnt4XgM2c" title="Depreciation expense">45,632</span> and $<span id="xdx_90C_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zXKXDtyc5D25" title="Depreciation expense">37,638</span> for the years ended December 31, 2023, and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zSnvVI4Js2ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zrHGpXUBc3xg" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20231231_zFkBvXCp5LSk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20221231_zJLKLT2eMKm3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndSoftwareMember_zZpTqtPLN51d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,350</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,278</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember_zxSYVKmG3esg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment and furniture</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,652</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,693</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zPbYhuXLcq24" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,378</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,830</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzrfx_zNH8iCXBZ8bh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278,380</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">255,801 </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzrfx_zy6gDFxA8Rk8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(138,381</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(93,034</span></p> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzrfx_zG4mqhz3XpGf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,999</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162,767</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 110350 92278 47652 40693 120378 122830 278380 255801 138381 93034 139999 162767 45632 37638 <p id="xdx_80D_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zfDKCzt29OSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6. <span id="xdx_821_zH6beWD70qKc">GOODWILL AND OTHER INTANGIBLE ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 350-20-35-45, all the Company’s goodwill is assigned to a single operating and reporting unit. All acquisitions made by the Company are in one general insurance agency industry and operate in a very similar economic and regulatory environment. The Company has one executive who is responsible for the operations of the insurance agencies. This executive reports directly to the Chief Executive Officer (“CEO”) on a quarterly basis. Additionally, the CEO who is responsible for the strategic direction of the Company reviews the operations of the insurance agency business collectively, as opposed to office by office.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December 31, 2022, due to a declining market capitalization attributed to Medigap’s performance, the Company performed a goodwill impairment test utilizing a hybrid of the Market Approach – Traded Market Value Method and Income Approach – Discounted Cash Flow Method and Discounted Forward Market Multiple Method, concluding that the Company’s fair value and resultant net assets, implied a goodwill balance of $<span id="xdx_90A_eus-gaap--Goodwill_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zbXHNKIEDHtc">19,100,000 </span>versus our goodwill balance prior to write-down of $<span id="xdx_907_eus-gaap--GoodwillWrittenOffRelatedToSaleOfBusinessUnit_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zLK0GugIbHY6">33,400,000</span>. Thus, the Company recognized an approximate impairment charge of $<span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_pn3d_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zF08vWkd1rBk">14,373,000</span> presented in the l<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">oss from discontinued operations before tax account in the consolidated statements of operations for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></span>As of June 30, 2023, the Company recognized an additional goodwill impairment of $<span id="xdx_908_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iI_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_fLg_____zbNwtD2rh0be">4,825,634 </span>upon the abandonment of Medigap, presented in the loss from discontinued operations before tax account in the consolidated statements of operations for the year ended December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023, due to a declining market capitalization, the Company performed a quantitative goodwill impairment test utilizing the discounted cash flow method of the income approach with market participant control adjustments in consideration of market capitalization, and concluded that the Company’s carrying value of equity exceeded its fair value of equity in the approximate amount of $<span id="xdx_904_eus-gaap--GoodwillImpairmentLoss_c20230101__20231231_z02s230y4ky4">7,594,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which the Company recognized as a goodwill impairment charge, presented in the goodwill impairment account on the consolidated statements of operations for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfGoodwillTextBlock_gL3SOGTB-HGO_z7VBYEWn6V1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table rolls forward the Company’s goodwill balance for the periods ending December 31, 2023 and 2022 exclusive of discontinued operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B5_zoYSstTv7sL" style="display: none">SCHEDULE OF IMPAIRMENT OF GOODWILL</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Goodwill_iS_pp0p0_c20220101__20221231_znCeOLRYKqVe" style="width: 14%; text-align: right" title="Goodwill Beginning">10,050,277</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Goodwill recognized in connection with Barra acquisition on April 26, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--GoodwillAcquiredDuringPeriod_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zFXNHf0PBkbd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill acquired during period">4,236,822</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_980_eus-gaap--Goodwill_iS_pp0p0_c20230101__20231231_zZkoHgALDobf" style="padding-bottom: 1.5pt; text-align: right" title="Goodwill Beginning">14,287,099</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Goodwill impairment recognized as of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--GoodwillImpairmentLoss_iN_di_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zW4pFawcqIJk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill impairment loss">(7,594,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--Goodwill_iE_pp0p0_c20230101__20231231_zHJvgE8toabd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill end">6,693,099</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zoVacgwsyMFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table rolls forward the Company’s goodwill balance for the periods ended December 31, 2023, and December 31, 2022 inclusive of discontinued operations.</span></p> <div id="xdx_C0E_gL3SOGTB-HGO_z9ei8qmifxaa"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" id="xdx_307_134_zBAMbXAruNDg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF IMPAIRMENT OF GOODWILL (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_iS_pp0p0_c20220101__20221231_zxu2oj8kqPFh" style="width: 14%; text-align: right" title="Goodwill Beginning">10,050,277</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Goodwill recognized in connection with Medigap acquisition</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--GoodwillAcquiredDuringPeriod_pp0p0_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zCMOSKvTj2ni" style="text-align: right" title="Goodwill acquired during period">19,199,008</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Goodwill recognized in connection with Barra acquisition</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--GoodwillAcquiredDuringPeriod_pp0p0_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_z2vl9kHLaJH" style="text-align: right" title="Goodwill acquired during period">4,236,822</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Goodwill impairment (Medigap) during the year-ended December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--GoodwillImpairmentLoss_iN_pp0p0_di_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zZ6tUHieF1u5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill impairment loss">(14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_iS_pp0p0_c20230101__20231231_zJOumvMVNq4h" style="text-align: right" title="Goodwill Beginning">19,112,733</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Goodwill impairment (Medigap) during the year ended December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--GoodwillImpairmentLoss_iN_pp0p0_di_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zDpUdfRPv1Ch" style="padding-bottom: 1.5pt; text-align: right" title="Goodwill impairment loss">(4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Goodwill impairment recognized as of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--GoodwillImpairmentLoss_iN_di_c20230101__20231231_zhByUBMIGoUj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill impairment loss">(7,594,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_iE_pp0p0_c20230101__20231231_zt9Q2NAl1JY1" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill end">6,693,099</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C03_gL3SOGTB-HGO_zh8RC9vrqAtb"> </span></span></p> <p id="xdx_896_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zAntIhcpic16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_zdMaPMdmV0q1" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Amortization period (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Carrying Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying Amount</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Trade name and trademarks</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 11%; text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zC8f7i4WBmyf" title="Weighted Average Remaining Amortization Period">1.5</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z3yhAIsXIFR5" style="width: 11%; text-align: right" title="Gross Carrying Amount">1,807,189</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXLpm8RY12Ne" style="width: 11%; text-align: right" title="Accumulated Amortization">(1,320,939</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zi8B4OUorkbj" style="width: 11%; text-align: right" title="Net Carrying Amount">486,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Internally developed software</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_z7tfDDjypQj5" title="Weighted Average Remaining Amortization Period">3.2</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zsbs8Pc2lbDb" style="text-align: right" title="Gross Carrying Amount">1,798,922</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_z72YoVDPCMJb" style="text-align: right" title="Accumulated Amortization">(650,029</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zuAaP6yedLs8" style="text-align: right" title="Net Carrying Amount">1,148,893</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zNrmzYK1I9z" title="Weighted Average Remaining Amortization Period">8.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4UJZbQ5X058" style="text-align: right" title="Gross Carrying Amount">11,922,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zybggwilHKUi" style="text-align: right" title="Accumulated Amortization">(3,193,629</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zQJX3ZUZPmSc" style="text-align: right" title="Net Carrying Amount">8,728,661</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Purchased software</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zNlCsZYK1yf9" title="Weighted Average Remaining Amortization Period">0.3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zkQykRxaMgek" style="text-align: right" title="Gross Carrying Amount">667,206</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zxep7N36aJd6" style="text-align: right" title="Accumulated Amortization">(618,418</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zuda9s2pk4f2" style="text-align: right" title="Net Carrying Amount">48,788</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Video Production Assets</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zjClewsPALU7" style="text-align: right" title="Gross Carrying Amount">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zu9vdNYaZqK6" style="text-align: right" title="Accumulated Amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zjz0ERxoPgYe" style="text-align: right" title="Net Carrying Amount"><span style="-sec-ix-hidden: xdx2ixbrl1543">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zNPORQ83Fmad" title="Weighted Average Remaining Amortization Period">0.9</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zr7pIeDNSPI4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount">3,504,810</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zbUuz1MWIH9d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization">(2,874,645</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zaNArpGVj1Vc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Amount">630,165</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Trade name and trademarks</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zI6TWH8U5X79" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount">19,750,417</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231_zpqG5k85otq8" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">(8,707,660</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231_zEhdxHyEqfwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount">11,042,757</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Amortization period (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Carrying Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying Amount</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Trade name and trademarks</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 11%; text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zF9RmSDqQhYg" title="Weighted Average Remaining Amortization Period">4.4</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQIPQXadfWCe" style="width: 11%; text-align: right" title="Gross Carrying Amount">1,806,188</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zLDsV2AShPx4" style="width: 11%; text-align: right" title="Accumulated Amortization">(969,241</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zPiCUrt8KD63" style="width: 11%; text-align: right" title="Net Carrying Amount">836,947</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Internally developed software</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zwgeRqBjV28h" title="Weighted Average Remaining Amortization Period">4.1</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_znWVfgr3cTOh" style="text-align: right" title="Gross Carrying Amount">1,635,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zv7uB8FmWCC1" style="text-align: right" title="Accumulated Amortization">(287,990</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_ztCWnh4wubk5" style="text-align: right" title="Net Carrying Amount">1,347,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zIaTiOdsYhhe" title="Weighted Average Remaining Amortization Period">9.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zLLhFNzTF8za" style="text-align: right" title="Gross Carrying Amount">11,922,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zikOrtLIMtKc" style="text-align: right" title="Accumulated Amortization">(2,076,086</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zQ6D8ttXKp01" style="text-align: right" title="Net Carrying Amount">9,846,204</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Purchased software</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zABu5yNO0vTj" title="Weighted Average Remaining Amortization Period">0.4</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zNGJnnLouo8h" style="text-align: right" title="Gross Carrying Amount">665,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zv7dyn6pwhc5" style="text-align: right" title="Accumulated Amortization">(581,497</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zByI8TrnxCbh" style="text-align: right" title="Net Carrying Amount">83,640</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Video Production Assets</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zqRqjMdENwN5" title="Weighted Average Remaining Amortization Period">0.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zD8sZFX4rlrh" style="text-align: right" title="Gross Carrying Amount">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zFBWjcD6oMKk" style="text-align: right" title="Accumulated Amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zEvwy9XENye7" style="text-align: right" title="Net Carrying Amount"><span style="-sec-ix-hidden: xdx2ixbrl1597">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_znRpGf9Jtkk" title="Weighted Average Remaining Amortization Period">1.9</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zvRp7OumBoN9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount">3,504,810</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zxCfjexn0qf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization">(2,179,420</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_z9dQbFT0zxCj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Amount">1,325,390</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231_zekiuSjMSmH6" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount">19,583,603</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231_zt6JC6anpeG9" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">(6,144,234</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231_zHraDwhJzZLe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount">13,439,369</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zbCZEVDZwOsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense is $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230101__20231231_zwgCP32nVU56" title="Amortization of intangible assets">2,563,559</span> and $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220101__20221231_z1IyghZmhGGh" title="Amortization of intangible assets">2,525,880</span> for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zZu6Ui4FQL46" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reflects expected amortization expense as of December 31, 2023, for each of the following five years and thereafter:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z74tEVGwqGz5" style="display: none">SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Years ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231_ztrbH8ItiFmh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANziEa_zjFZM29tQ8Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,195,191</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANziEa_zmvMQ9shDmd2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,801,235</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANziEa_z7hCjU41Oxig" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,532,267</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANziEa_zLdJTlTDcawi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,196,989</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANziEa_zYxWmpcpG1z5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097,825</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANziEa_zmV5yotfjCy9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,218,683</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANziEa_zpFv7rB19hkh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,042,757</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zF8n2AbeCy5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 19100000 33400000 14373000 4825634 7594000 <p id="xdx_89E_eus-gaap--ScheduleOfGoodwillTextBlock_gL3SOGTB-HGO_z7VBYEWn6V1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table rolls forward the Company’s goodwill balance for the periods ending December 31, 2023 and 2022 exclusive of discontinued operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B5_zoYSstTv7sL" style="display: none">SCHEDULE OF IMPAIRMENT OF GOODWILL</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Goodwill_iS_pp0p0_c20220101__20221231_znCeOLRYKqVe" style="width: 14%; text-align: right" title="Goodwill Beginning">10,050,277</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Goodwill recognized in connection with Barra acquisition on April 26, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--GoodwillAcquiredDuringPeriod_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zFXNHf0PBkbd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill acquired during period">4,236,822</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_980_eus-gaap--Goodwill_iS_pp0p0_c20230101__20231231_zZkoHgALDobf" style="padding-bottom: 1.5pt; text-align: right" title="Goodwill Beginning">14,287,099</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Goodwill impairment recognized as of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--GoodwillImpairmentLoss_iN_di_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zW4pFawcqIJk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill impairment loss">(7,594,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--Goodwill_iE_pp0p0_c20230101__20231231_zHJvgE8toabd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill end">6,693,099</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" id="xdx_307_134_zBAMbXAruNDg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF IMPAIRMENT OF GOODWILL (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_iS_pp0p0_c20220101__20221231_zxu2oj8kqPFh" style="width: 14%; text-align: right" title="Goodwill Beginning">10,050,277</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Goodwill recognized in connection with Medigap acquisition</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--GoodwillAcquiredDuringPeriod_pp0p0_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zCMOSKvTj2ni" style="text-align: right" title="Goodwill acquired during period">19,199,008</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Goodwill recognized in connection with Barra acquisition</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--GoodwillAcquiredDuringPeriod_pp0p0_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_z2vl9kHLaJH" style="text-align: right" title="Goodwill acquired during period">4,236,822</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Goodwill impairment (Medigap) during the year-ended December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--GoodwillImpairmentLoss_iN_pp0p0_di_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zZ6tUHieF1u5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill impairment loss">(14,373,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_iS_pp0p0_c20230101__20231231_zJOumvMVNq4h" style="text-align: right" title="Goodwill Beginning">19,112,733</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Goodwill impairment (Medigap) during the year ended December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--GoodwillImpairmentLoss_iN_pp0p0_di_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--MedigapHealthcareInsuranceCompanyMember_zDpUdfRPv1Ch" style="padding-bottom: 1.5pt; text-align: right" title="Goodwill impairment loss">(4,825,634</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Goodwill impairment recognized as of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--GoodwillImpairmentLoss_iN_di_c20230101__20231231_zhByUBMIGoUj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill impairment loss">(7,594,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_iE_pp0p0_c20230101__20231231_zt9Q2NAl1JY1" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill end">6,693,099</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>   10050277 4236822 14287099 7594000 6693099 10050277 19199008 4236822 14373374 19112733 4825634 7594000 6693099 <p id="xdx_896_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zAntIhcpic16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_zdMaPMdmV0q1" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Amortization period (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Carrying Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying Amount</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Trade name and trademarks</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 11%; text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zC8f7i4WBmyf" title="Weighted Average Remaining Amortization Period">1.5</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z3yhAIsXIFR5" style="width: 11%; text-align: right" title="Gross Carrying Amount">1,807,189</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zXLpm8RY12Ne" style="width: 11%; text-align: right" title="Accumulated Amortization">(1,320,939</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zi8B4OUorkbj" style="width: 11%; text-align: right" title="Net Carrying Amount">486,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Internally developed software</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_z7tfDDjypQj5" title="Weighted Average Remaining Amortization Period">3.2</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zsbs8Pc2lbDb" style="text-align: right" title="Gross Carrying Amount">1,798,922</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_z72YoVDPCMJb" style="text-align: right" title="Accumulated Amortization">(650,029</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zuAaP6yedLs8" style="text-align: right" title="Net Carrying Amount">1,148,893</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zNrmzYK1I9z" title="Weighted Average Remaining Amortization Period">8.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4UJZbQ5X058" style="text-align: right" title="Gross Carrying Amount">11,922,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zybggwilHKUi" style="text-align: right" title="Accumulated Amortization">(3,193,629</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zQJX3ZUZPmSc" style="text-align: right" title="Net Carrying Amount">8,728,661</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Purchased software</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zNlCsZYK1yf9" title="Weighted Average Remaining Amortization Period">0.3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zkQykRxaMgek" style="text-align: right" title="Gross Carrying Amount">667,206</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zxep7N36aJd6" style="text-align: right" title="Accumulated Amortization">(618,418</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zuda9s2pk4f2" style="text-align: right" title="Net Carrying Amount">48,788</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Video Production Assets</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zjClewsPALU7" style="text-align: right" title="Gross Carrying Amount">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zu9vdNYaZqK6" style="text-align: right" title="Accumulated Amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zjz0ERxoPgYe" style="text-align: right" title="Net Carrying Amount"><span style="-sec-ix-hidden: xdx2ixbrl1543">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zNPORQ83Fmad" title="Weighted Average Remaining Amortization Period">0.9</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zr7pIeDNSPI4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount">3,504,810</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zbUuz1MWIH9d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization">(2,874,645</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zaNArpGVj1Vc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Amount">630,165</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Trade name and trademarks</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zI6TWH8U5X79" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount">19,750,417</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231_zpqG5k85otq8" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">(8,707,660</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20231231_zEhdxHyEqfwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount">11,042,757</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Amortization period (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Carrying Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying Amount</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Trade name and trademarks</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 11%; text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zF9RmSDqQhYg" title="Weighted Average Remaining Amortization Period">4.4</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQIPQXadfWCe" style="width: 11%; text-align: right" title="Gross Carrying Amount">1,806,188</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zLDsV2AShPx4" style="width: 11%; text-align: right" title="Accumulated Amortization">(969,241</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zPiCUrt8KD63" style="width: 11%; text-align: right" title="Net Carrying Amount">836,947</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Internally developed software</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zwgeRqBjV28h" title="Weighted Average Remaining Amortization Period">4.1</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_znWVfgr3cTOh" style="text-align: right" title="Gross Carrying Amount">1,635,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_zv7uB8FmWCC1" style="text-align: right" title="Accumulated Amortization">(287,990</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--InternallyDevelopedSoftwareMember_ztCWnh4wubk5" style="text-align: right" title="Net Carrying Amount">1,347,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zIaTiOdsYhhe" title="Weighted Average Remaining Amortization Period">9.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zLLhFNzTF8za" style="text-align: right" title="Gross Carrying Amount">11,922,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zikOrtLIMtKc" style="text-align: right" title="Accumulated Amortization">(2,076,086</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zQ6D8ttXKp01" style="text-align: right" title="Net Carrying Amount">9,846,204</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Purchased software</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zABu5yNO0vTj" title="Weighted Average Remaining Amortization Period">0.4</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zNGJnnLouo8h" style="text-align: right" title="Gross Carrying Amount">665,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zv7dyn6pwhc5" style="text-align: right" title="Accumulated Amortization">(581,497</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedSoftwareMember_zByI8TrnxCbh" style="text-align: right" title="Net Carrying Amount">83,640</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Video Production Assets</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zqRqjMdENwN5" title="Weighted Average Remaining Amortization Period">0.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zD8sZFX4rlrh" style="text-align: right" title="Gross Carrying Amount">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zFBWjcD6oMKk" style="text-align: right" title="Accumulated Amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VideoProductionAssetsMember_zEvwy9XENye7" style="text-align: right" title="Net Carrying Amount"><span style="-sec-ix-hidden: xdx2ixbrl1597">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_znRpGf9Jtkk" title="Weighted Average Remaining Amortization Period">1.9</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zvRp7OumBoN9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount">3,504,810</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_zxCfjexn0qf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization">(2,179,420</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NoncompetitionAgreementsMember_z9dQbFT0zxCj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Amount">1,325,390</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231_zekiuSjMSmH6" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount">19,583,603</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231_zt6JC6anpeG9" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">(6,144,234</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231_zHraDwhJzZLe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount">13,439,369</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> P1Y6M 1807189 -1320939 486250 P3Y2M12D 1798922 -650029 1148893 P8Y 11922290 -3193629 8728661 P0Y3M18D 667206 -618418 48788 50000 -50000 P0Y10M24D 3504810 -2874645 630165 19750417 -8707660 11042757 P4Y4M24D 1806188 -969241 836947 P4Y1M6D 1635178 -287990 1347188 P9Y 11922290 -2076086 9846204 P0Y4M24D 665137 -581497 83640 P0Y 50000 -50000 P1Y10M24D 3504810 -2179420 1325390 19583603 -6144234 13439369 2563559 2525880 <p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zZu6Ui4FQL46" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reflects expected amortization expense as of December 31, 2023, for each of the following five years and thereafter:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z74tEVGwqGz5" style="display: none">SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Years ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231_ztrbH8ItiFmh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANziEa_zjFZM29tQ8Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,195,191</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANziEa_zmvMQ9shDmd2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,801,235</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANziEa_z7hCjU41Oxig" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,532,267</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANziEa_zLdJTlTDcawi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,196,989</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANziEa_zYxWmpcpG1z5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097,825</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANziEa_zmV5yotfjCy9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,218,683</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANziEa_zpFv7rB19hkh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,042,757</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2195191 1801235 1532267 1196989 1097825 3218683 11042757 <p id="xdx_80D_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zeWjmBDKAdC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7. <span id="xdx_827_zHoTO4NLPFlb">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z66kMoAjHR2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant components of accounts payable and accrued liabilities were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zYgXZDZeMFn" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20231231_zKDHsDaZnpa9" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20221231_zRxl9zSrGLcf" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_iI_maAPAALzkmq_zGeJU1uoR6ej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable,</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">635,339</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">747,469</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzkmq_z5Sy9FPmrBg5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109,502</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedCreditCardPayables_iI_maAPAALzkmq_zlyO1mGp5OE9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued credit card payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,416</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,120</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maAPAALzkmq_zMXSg8zsyyk1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,188</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,291</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzkmq_z4CxwCSXEZb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and other accrued liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">835,483</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">951,382</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zlt4CKnO2Ol6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z66kMoAjHR2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant components of accounts payable and accrued liabilities were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zYgXZDZeMFn" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20231231_zKDHsDaZnpa9" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20221231_zRxl9zSrGLcf" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_iI_maAPAALzkmq_zGeJU1uoR6ej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable,</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">635,339</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">747,469</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzkmq_z5Sy9FPmrBg5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109,502</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedCreditCardPayables_iI_maAPAALzkmq_zlyO1mGp5OE9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued credit card payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,416</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,120</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maAPAALzkmq_zMXSg8zsyyk1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,188</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,291</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzkmq_z4CxwCSXEZb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and other accrued liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">835,483</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">951,382</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 635339 747469 40540 109502 54416 58120 105188 36291 835483 951382 <p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zU3aDx5efyVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8. <span id="xdx_826_zptTq2gBp8Mg">LONG-TERM DEBT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zoZ4FwpiGhE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The composition of the long-term debt follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zc5Ico8SBYdh" style="display: none">SCHEDULE OF LONG TERM DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20231231_zwP0cFoBAxb6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zfh24Amod592" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oak Street Funding LLC Term Loan</span></td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_zBH4xIoIPcV9" style="text-align: right" title="Long term debt current">369,602</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_zdIEUuWUdUha" style="text-align: right" title="Long term debt current">426,883</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Oak Street Funding LLC Term Loan for the acquisition of EBS and USBA, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_zqYLrBNBoqx5" title="Variable interest of prime rate plus">2.5</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_znsSUQ93O6Ye" title="Maturity date">August 2028</span>, net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_z9iOL30nyQZ2" title="Net of deferred financing cost">10,069</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_zFCB5vVvE5Ab" title="Net of deferred financing cost">12,388</span> as of December 31, 2023 and 2022, respectively</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_zHLjXhhw9h34" style="width: 16%; text-align: right" title="Long term debt current">369,602</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_z3jn1Qvwjx26" style="width: 16%; text-align: right" title="Long term debt current">426,883</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Oak Street Funding LLC Senior Secured Amortizing Credit Facility for the acquisition of CCS, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--CreditFacilityAxis__custom--CCSMember_zObxeB1b0qjl" title="Variable interest of prime rate plus">1.5</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--CCSMember_zlz1IfNH304d" title="Maturity date">December 2028</span>, net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--CreditFacilityAxis__custom--CCSMember_zW4GX4HB2HP7" title="Net of deferred financing cost">12,525</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--CreditFacilityAxis__custom--CCSMember_z5BxBjA0OqEi" title="Net of deferred financing cost">15,076</span> as of December 31, 2023 and 2022, respectively</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--CreditFacilityAxis__custom--CCSMember_z71udHx0c0ua" style="text-align: right" title="Long term debt current">604,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--CreditFacilityAxis__custom--CCSMember_zaHZSvIFnYOj" style="text-align: right" title="Long term debt current">693,682</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Oak Street Funding LLC Term Loan for the acquisition of SWMT, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_zk416y91cP1f" title="Variable interest of prime rate plus">2.0</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_ztkXRHnCwSb1" title="Maturity date">April 2029</span> net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_z9yLcy0V0gd6" title="Net of deferred financing cost">7,733</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_zlwg7kcNYwJ9" title="Net of deferred financing cost">9,206</span> as of December 31, 2023 and 2022, respectively</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_zzkbmRxxhPQl" style="text-align: right" title="Long term debt current">695,758</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_zJNdp5X5JAIj" style="text-align: right" title="Long term debt current">788,596</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Oak Street Funding LLC Term Loan for the acquisition of FIS, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_zTad3u9MBvpj" title="Variable interest of prime rate plus">2.0</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_zNbvJBT46w" title="Maturity date">May 2029</span>, net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_z0XT0TeymdU2" title="Net of deferred financing cost">31,026</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_zgVdabHNA7of" title="Net of deferred financing cost">36,843</span> as of December 31, 2023 and 2022, respectively</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_z1cw8aPLADoh" style="text-align: right" title="Long term debt current">1,758,558</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_zB4btWiLZ2qe" style="text-align: right" title="Long term debt current">1,987,846</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Oak Street Funding LLC Term Loan for the acquisition of ABC, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_zFARsWhlXdgc" title="Variable interest of prime rate plus">2.0</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_zEk2JHyVqqCl" title="Maturity date">September 2029</span>, net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_zmMCcdYGQXk9" title="Net of deferred financing cost">35,649</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_z1Qlp0sFsMNl" title="Net of deferred financing cost">42,129</span> as of December 31, 2023 and 2022, respectively</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_zWSBq9gfmzt5" style="text-align: right" title="Long term debt current">2,899,409</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_zLuHdgdtDKV5" style="text-align: right" title="Long term debt current">3,249,575</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Oak Street Funding LLC Term Loan, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zs6ciHpJBt6g" title="Variable interest of prime rate plus">2.5</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_z4XHHR8HEjR4" title="Maturity date">May 2032</span>, for the acquisition of Barra, net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zeWcCCufYsHl" title="Net of deferred financing cost">176,762</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zM4Drj9BBKTk" title="Net of deferred financing cost">198,188</span> as of December 31, 2023 and December 31, 2022, respectively</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zi9aARZzddT5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long term debt current">6,089,580</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zDkMXhSaUSsi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long term debt current">6,321,812</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebt_iI_zsdIEUtrlkI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Long term debt gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,417,737</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,468,394</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_di_zm3Mu5lJBePl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,390,766</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,118,721</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--LongTermDebtNet_iI_zc9CAa4tJAJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,026,971</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,349,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zQqQgSCud8J7" style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Oak Street Funding LLC – Term Loans and Credit Facilities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year of 2018 the Company entered into two debt agreements with Oak Street Funding LLC (“Oak Street”). On August 1, 2018, EBS and USBA entered into a Credit Agreement with Oak Street whereby EBS and USBA borrowed $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20180801__us-gaap--BusinessAcquisitionAxis__custom--EmployeeBenefitsSolutionsLLCAndUSBenefitsAllianceMember__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_zsb2d1G8Ku92" title="Borrowings">750,000</span> from Oak Street under a Term Loan. The Term Loan is secured by certain assets of the Company. Interest accrues at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20180801__us-gaap--BusinessAcquisitionAxis__custom--EmployeeBenefitsSolutionsLLCAndUSBenefitsAllianceMember__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_zBqclQViq97f" title="Debt instrument, interest rate">11.00</span>% on the basis of a 360-day year, maturing 120 months from the Amortization Date (September 25, 2018). The Company incurred debt issuance costs associated with the Term Loan in the amount of $<span id="xdx_90E_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20180801__us-gaap--BusinessAcquisitionAxis__custom--EmployeeBenefitsSolutionsLLCAndUSBenefitsAllianceMember__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_zOv54Y7fsWW2" title="Debt issuance costs">22,188</span>. On December 7, 2018, CCS entered into a Facility with Oak Street whereby CCS borrowed $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20181207__us-gaap--BusinessAcquisitionAxis__custom--CommercialCoverageSolutionsLLCMember__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredAmortizingCreditFacilityMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_zz4DapMVgXHl" title="Borrowings">1,025,000</span> from Oak Street under a senior secured amortizing credit facility. <span id="xdx_904_eus-gaap--DebtInstrumentDescription_c20181206__20181207__us-gaap--BusinessAcquisitionAxis__custom--CommercialCoverageSolutionsLLCMember__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredAmortizingCreditFacilityMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_ziqLyuuVxi83" title="Debt description">The borrowing rate under the Facility is a variable rate equal to Prime +<span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181207__us-gaap--BusinessAcquisitionAxis__custom--CommercialCoverageSolutionsLLCMember__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredAmortizingCreditFacilityMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zQtFT0bOrvK7" title="Debt instrument, interest rate">1.50</span>% and matures <span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20181206__20181207__us-gaap--BusinessAcquisitionAxis__custom--CommercialCoverageSolutionsLLCMember__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredAmortizingCreditFacilityMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_zmbAXlDWbBJ2" title="Debt instrument term">10</span> years from the closing date.</span> The Company incurred debt issuance costs associated with the Facility in the amount of $<span id="xdx_90F_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20181207__us-gaap--BusinessAcquisitionAxis__custom--CommercialCoverageSolutionsLLCMember__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredAmortizingCreditFacilityMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_zLr7sO7GCYe5" title="Debt issuance costs">25,506</span>, which were deferred and are amortized over the length of the Facility.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year of 2019 the Company entered in a number of Credit Agreements with Oak Street whereby the Company borrowed a total amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191231__us-gaap--DebtInstrumentAxis__custom--TermLoanMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_zTalkFEwUMN7" title="Borrowings">7,912,000</span> under the Term Loans. The Term Loans are secured by certain assets of the Company. <span id="xdx_902_eus-gaap--DebtInstrumentDescription_c20190101__20191231__us-gaap--DebtInstrumentAxis__custom--TermLoanMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_zDUQew8pfukf" title="Debt description">The borrowing rates under the Facility is a variable rate equal to Prime + <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredAmortizingCreditFacilityMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zh3OFT4LaHyh" title="Debt instrument, interest rate">2.00</span>% and matures <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--DebtInstrumentAxis__custom--TermLoanMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_zJqC79LUrwE2" title="Debt instrument term">10</span> years from the closing date.</span> The Company recorded debt issuance costs associated with the loans in total of $<span id="xdx_900_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20191231__us-gaap--DebtInstrumentAxis__custom--TermLoanMember__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember_zwvSysrQmjb2" title="Debt issuance costs">181,125</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 26, 2022 the Company entered into a secured promissory note (the Note) with Oak Street subject to the terms of the Master Credit Agreement, whereby the Company borrowed $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20220426__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember__us-gaap--TypeOfArrangementAxis__custom--MasterCreditAgreementMember_z8bVd8YOiwj9" title="Borrowings">6,250,000</span> with a maturity date of <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20220426__20220426__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember__us-gaap--TypeOfArrangementAxis__custom--MasterCreditAgreementMember_zNCLzPWTSKMh" title="Maturity date">May 25, 2032</span>. The Note is secured by certain assets of the Company and subject to certain financial covenants. Interest accrues at the Prime Rate plus an Applicable Margin of <span id="xdx_900_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20220426__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember__us-gaap--TypeOfArrangementAxis__custom--MasterCreditAgreementMember_zvLN5jIWCnGg" title="Variable interest of prime rate plus">2.500</span>% on the basis of a 360-day year. The Company incurred debt issuance costs associated with the Note of $<span id="xdx_90B_eus-gaap--DeferredFinanceCostsNet_iI_c20220426__dei--LegalEntityAxis__custom--OakStreetFundingLLCMember__us-gaap--TypeOfArrangementAxis__custom--MasterCreditAgreementMember_ztBTt13p18Z3" title="Debt issuance costs">214,257</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregated cumulative maturities of long-term obligations (including the Term Loan and the Facility), excluding deferred financing costs, as of December 31, 2023 are:</span></p> <p id="xdx_891_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zj6RrhJWmwag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_zWOxMCrEnUdh" style="display: none">SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Fiscal year ending December 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zhotJ8fb3HR7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturities of </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Long-Term Debt</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzUlL_zPGtXDKkaaK1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%; font-weight: bold"> </td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">1,390,766</span></td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzUlL_zxchZCdOHsOh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">1,552,772</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzUlL_zAdiMdpXXlp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">1,729,160</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maDICAzUlL_zDYUKdyOADG5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">1,925,603</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maDICAzUlL_zsvisQQXhzD2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">2,107,128</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_maDICAzUlL_zT7vGdeRvGx3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">3,986,172</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzUlL_zj7KuidDWZHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">12,691,601</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredFinanceCostsNet_iNI_di_zIQJBgiUQEzj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less debt issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">(273,864</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--LongTermDebt_iI_z2RXEJzHTOej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">12,417,737</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zUepNXIjrVj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Short-Term Financings</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has various short-term notes payable for financed items such as insurance premiums and CRM software purchases. Total financed for the year ended December 31, 2023 and 2022 respectively was approximately $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231_z0Hor1lWGHKl" title="Borrowings">181,000</span> and $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231_zxkTRI7yBsXe" title="Total financed">482,000</span>. These are normally paid in equal installments over a period of twelve months or less and carry interest rates ranging between <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20231231_zrrfrYCHt3ub" title="Interest rate">12.75</span>% and <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20221231_zOZYBKLTMpEc" title="Interest rate">0</span>% per annum. As of December 31, 2023 and 2022, approximately $<span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_pn3d_c20231231_zdiYKNmz2yJ" title="Short-term financings">56,000</span> and $<span id="xdx_90A_eus-gaap--ShortTermBorrowings_iI_pn3d_c20221231_zrNgW7Nob9H5" title="Short-term financings">154,000</span> remains outstanding on short-term financings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zoZ4FwpiGhE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The composition of the long-term debt follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zc5Ico8SBYdh" style="display: none">SCHEDULE OF LONG TERM DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20231231_zwP0cFoBAxb6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zfh24Amod592" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oak Street Funding LLC Term Loan</span></td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_zBH4xIoIPcV9" style="text-align: right" title="Long term debt current">369,602</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_zdIEUuWUdUha" style="text-align: right" title="Long term debt current">426,883</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Oak Street Funding LLC Term Loan for the acquisition of EBS and USBA, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_zqYLrBNBoqx5" title="Variable interest of prime rate plus">2.5</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_znsSUQ93O6Ye" title="Maturity date">August 2028</span>, net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_z9iOL30nyQZ2" title="Net of deferred financing cost">10,069</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_zFCB5vVvE5Ab" title="Net of deferred financing cost">12,388</span> as of December 31, 2023 and 2022, respectively</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_zHLjXhhw9h34" style="width: 16%; text-align: right" title="Long term debt current">369,602</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--CreditFacilityAxis__custom--EBSandUSBAMember_z3jn1Qvwjx26" style="width: 16%; text-align: right" title="Long term debt current">426,883</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Oak Street Funding LLC Senior Secured Amortizing Credit Facility for the acquisition of CCS, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--CreditFacilityAxis__custom--CCSMember_zObxeB1b0qjl" title="Variable interest of prime rate plus">1.5</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--CCSMember_zlz1IfNH304d" title="Maturity date">December 2028</span>, net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--CreditFacilityAxis__custom--CCSMember_zW4GX4HB2HP7" title="Net of deferred financing cost">12,525</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--CreditFacilityAxis__custom--CCSMember_z5BxBjA0OqEi" title="Net of deferred financing cost">15,076</span> as of December 31, 2023 and 2022, respectively</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--CreditFacilityAxis__custom--CCSMember_z71udHx0c0ua" style="text-align: right" title="Long term debt current">604,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--CreditFacilityAxis__custom--CCSMember_zaHZSvIFnYOj" style="text-align: right" title="Long term debt current">693,682</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Oak Street Funding LLC Term Loan for the acquisition of SWMT, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_zk416y91cP1f" title="Variable interest of prime rate plus">2.0</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_ztkXRHnCwSb1" title="Maturity date">April 2029</span> net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_z9yLcy0V0gd6" title="Net of deferred financing cost">7,733</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_zlwg7kcNYwJ9" title="Net of deferred financing cost">9,206</span> as of December 31, 2023 and 2022, respectively</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_zzkbmRxxhPQl" style="text-align: right" title="Long term debt current">695,758</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--SWMTMember_zJNdp5X5JAIj" style="text-align: right" title="Long term debt current">788,596</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Oak Street Funding LLC Term Loan for the acquisition of FIS, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_zTad3u9MBvpj" title="Variable interest of prime rate plus">2.0</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_zNbvJBT46w" title="Maturity date">May 2029</span>, net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_z0XT0TeymdU2" title="Net of deferred financing cost">31,026</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_zgVdabHNA7of" title="Net of deferred financing cost">36,843</span> as of December 31, 2023 and 2022, respectively</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_z1cw8aPLADoh" style="text-align: right" title="Long term debt current">1,758,558</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--FISMember_zB4btWiLZ2qe" style="text-align: right" title="Long term debt current">1,987,846</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Oak Street Funding LLC Term Loan for the acquisition of ABC, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_zFARsWhlXdgc" title="Variable interest of prime rate plus">2.0</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_zEk2JHyVqqCl" title="Maturity date">September 2029</span>, net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_zmMCcdYGQXk9" title="Net of deferred financing cost">35,649</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_z1Qlp0sFsMNl" title="Net of deferred financing cost">42,129</span> as of December 31, 2023 and 2022, respectively</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_zWSBq9gfmzt5" style="text-align: right" title="Long term debt current">2,899,409</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--ABCMember_zLuHdgdtDKV5" style="text-align: right" title="Long term debt current">3,249,575</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Oak Street Funding LLC Term Loan, variable interest of Prime Rate plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zs6ciHpJBt6g" title="Variable interest of prime rate plus">2.5</span>%, maturing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_dd_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_z4XHHR8HEjR4" title="Maturity date">May 2032</span>, for the acquisition of Barra, net of deferred financing costs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--OtherDeferredCostsNet_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zeWcCCufYsHl" title="Net of deferred financing cost">176,762</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--OtherDeferredCostsNet_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zM4Drj9BBKTk" title="Net of deferred financing cost">198,188</span> as of December 31, 2023 and December 31, 2022, respectively</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zi9aARZzddT5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long term debt current">6,089,580</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--LongTermDebt_iI_c20221231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_zDkMXhSaUSsi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long term debt current">6,321,812</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebt_iI_zsdIEUtrlkI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Long term debt gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,417,737</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,468,394</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_di_zm3Mu5lJBePl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,390,766</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,118,721</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--LongTermDebtNet_iI_zc9CAa4tJAJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,026,971</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,349,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 369602 426883 0.025 August 2028 10069 12388 369602 426883 0.015 December 2028 12525 15076 604830 693682 0.020 April 2029 7733 9206 695758 788596 0.020 May 2029 31026 36843 1758558 1987846 0.020 September 2029 35649 42129 2899409 3249575 0.025 May 2032 176762 198188 6089580 6321812 12417737 13468394 1390766 1118721 11026971 12349673 750000 0.1100 22188 1025000 The borrowing rate under the Facility is a variable rate equal to Prime +1.50% and matures 10 years from the closing date. 0.0150 P10Y 25506 7912000 The borrowing rates under the Facility is a variable rate equal to Prime + 2.00% and matures 10 years from the closing date. 0.0200 P10Y 181125 6250000 2032-05-25 0.02500 214257 <p id="xdx_891_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zj6RrhJWmwag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_zWOxMCrEnUdh" style="display: none">SCHEDULE OF CUMULATIVE MATURITIES OF LONG -TERM LOANS AND CREDIT FACILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Fiscal year ending December 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zhotJ8fb3HR7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturities of </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Long-Term Debt</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzUlL_zPGtXDKkaaK1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%; font-weight: bold"> </td> <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">$</span></td><td style="font: normal 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">1,390,766</span></td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzUlL_zxchZCdOHsOh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">1,552,772</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzUlL_zAdiMdpXXlp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">1,729,160</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maDICAzUlL_zDYUKdyOADG5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">1,925,603</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maDICAzUlL_zsvisQQXhzD2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">2,107,128</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_maDICAzUlL_zT7vGdeRvGx3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">3,986,172</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzUlL_zj7KuidDWZHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">12,691,601</span></td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredFinanceCostsNet_iNI_di_zIQJBgiUQEzj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less debt issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">(273,864</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--LongTermDebt_iI_z2RXEJzHTOej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: normal 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">12,417,737</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1390766 1552772 1729160 1925603 2107128 3986172 12691601 273864 12417737 181000 482000 0.1275 0 56000 154000 <p id="xdx_808_ecustom--WarrantLiabilitiesTextBlock_zbFfIvVwlOzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9. <span id="xdx_82A_z4JtoCfjgaQj">WARRANT LIABILITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series B Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 22, 2021, the Company entered into a securities purchase agreement (SPA) with two institutional investors for the purchase and sale of (i) warrants to purchase up to an aggregate of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211222__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zd2QTW8MOBzk">651,997</span> shares of the Company’s common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211222__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmK0sXVZxlta" title="Common stock, par value">0.086</span> per share at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211222__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zwBHggdHKQd4">61.35</span> per share, (ii) an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20211221__20211222__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zr6n208ssoch" title="Shares of common Stock">178,060</span> shares of Common Stock, and (iii) <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20211221__20211222__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zlneGnWADNI9">9,076</span> shares of the Company’s newly-designated Series B convertible preferred stock, par value $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211222__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zMwcWYiTtPYj" title="Preferred stock, par value">0.086</span> per share, with a stated value of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211222__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zJS2VzkeP147">1,000</span> per share, initially convertible into an aggregate of <span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20211221__20211222__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zyDx8be8gb1h" title="Convertible into aggregate shares">147,939</span> shares of Common Stock at a conversion price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211222__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zd6RdAeVzba7" title="Conversion price, per share">61.35</span> per share, each a freestanding financial instrument, (the “Private Placement”). The aggregate purchase price for the Common Shares, the Preferred Shares and the Warrants was approximately $<span id="xdx_900_ecustom--AggregatePurchasePriceOfCommonSharesPreferredSharesAndWarrants_c20211221__20211222__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zepkGsgJK9g4" title="Aggregate purchase price">20,000,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By entering into the Private Placement on December 22, 2021, the Company entered into a commitment to issue the Common Shares, Preferred Shares, and Series B Warrants on the Initial Closing Date for a fixed price and exercise price, as applicable. The commitment to issue Series B Warrants (the “Warrant Commitment”) represents a derivative financial instrument, other than an outstanding share, that, at inception, has both of the following characteristics: (i) embodies a conditional obligation indexed to the Company’s equity. The Company classified the commitment to issue the warrants as a derivative liability because it represents a written option that does not qualify for equity accounting The Company initially measured the derivative liability at its fair value and will subsequently remeasure the derivative liability, at fair value with changes in fair value recognized in earnings. An option pricing model was utilized to calculate the fair value of the Warrant Commitment. The Company initially recorded $<span id="xdx_909_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20210101__20211231_znUB1LzNbO0l" title="Unrealized losses">17,408,311</span> of non-operating unrealized losses within the recognition and change in fair value of warrant liabilities account for the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Private Placement closed on January 4, 2022, at which time the Company remeasured the derivative liability for the warrants issued in the transaction, recognizing $<span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20220104__20220104__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_zf1ddjph33ff" title="Non-operating unrealized gains">17,408,311</span> of non-operating unrealized losses and a derivative liability of $<span id="xdx_908_eus-gaap--DerivativeLiabilities_iI_c20220104__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_zpHr9KiT8rM5" title="Derivative Liability">55,061,119</span>. The closing of the Private Placement settled the subscription receivable reported on the Company’s balance sheet as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the SPA, due to a non-Private Placement related dilutive share issuance, effective December 27, 2022, the Series B Warrants outstanding increased to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221227__us-gaap--SubsidiarySaleOfStockAxis__custom--NonPrivatePlacementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_zj1i190PTyn7">1,333,333</span> and the exercise price reset to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221227__us-gaap--SubsidiarySaleOfStockAxis__custom--NonPrivatePlacementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_zVmOdkUjRik5">7.50</span>. On December 27, 2022, <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20221227__20221227__us-gaap--SubsidiarySaleOfStockAxis__custom--NonPrivatePlacementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXeoZYYLqn49" title="Number of shares issued exercised">1,667</span> Series B Warrants were exercised into <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221227__20221227__us-gaap--SubsidiarySaleOfStockAxis__custom--NonPrivatePlacementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcGHCpo9j4Sj">1,667</span> shares of common stock with cash proceeds to the Company of $<span id="xdx_90B_ecustom--IsusanceOfCommonSharesInExchangeForSeriesBWarrants_c20221227__20221227__us-gaap--SubsidiarySaleOfStockAxis__custom--NonPrivatePlacementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLLEIlZNXZad" title="Cash proceeds">12,500</span>. Pursuant to a number of dilutive issuances throughout fiscal year 2023, as of December 31, 2023, the exercise price in effect was $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--NonPrivatePlacementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_zPC89c5s8I38">0.63</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 12, 2023, the Company entered into an agreement with one of the SPA institutional investors, pursuant to which (i) the Company extended the expiration date of their <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231212__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_zCMNXBFzuHej" title="Outstanding warrants">866,667</span> remaining outstanding Series B Warrants to December 28, 2028 and (ii) institutional investor waived a restriction in the SPA such that the Company will be permitted to consummate an “at-the-market offering” with a registered broker-dealer, whereby such registered broker-dealer is acting as principal or agent in the purchase of shares (the “ATM”) of the Company’s common stock from the Company after sixty (60) days following December 14, 2023. Further, on December 12, 2023, the Company entered into an exchange offer with the other SPA institutional investor, pursuant to which the investor exchanged its remaining Series B Warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231212__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5qoqttwpHRg">300,000</span> shares of Common Stock for <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231212__20231212__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zb6Sn3RVx86d">300,000</span> shares of Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2023 and 2022, net fair value gains recognized for the Series B Warrants were $<span id="xdx_906_ecustom--WarrantCommitmentUnrealizedGainLoss_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_z1EZ86HunzV3" title="Net fair value gains losses">5,534,931</span> and $<span id="xdx_90A_ecustom--WarrantCommitmentUnrealizedGainLoss_iN_di_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_zElZcfJ7ravc" title="Net fair value gains losses">48,668,869</span> respectively, presented in the recognition and change in fair value of warrant liabilities account in the consolidated statements of operations. The Series B Warrant liability outstanding as of December 31, 2023 and 2022 is $<span id="xdx_905_ecustom--WarrantLiability_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_zJ10CWRmd902" title="Warrant liability">268,667</span> and $<span id="xdx_909_ecustom--WarrantLiability_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_ztX1pP5oYzNk" title="Warrant liability">6,384,250</span> respectively, presented in the warrant liability account on the consolidated balance sheets and there remain <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--SeriesBWarrantLiabilityMember_zAnB60LzTefd" title="Outstanding warrants">866,667</span> of Series B Warrants outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Placement Agent Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Private Placement, the Company issued <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--PlacementAgentWarrantsMember_z9ezeQrKgqHi" title="Issued warrant">16,303</span> warrants to the placement agent for the Private Placement. The warrants were issued as compensation for the Placement Agent’s services. The Placement Agent Warrants (PAW) are: (i) exercisable on any day after the six (6) month anniversary of the issue date, (ii) expire <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--PlacementAgentWarrantsMember_zETfCnY6VSP9" title="Warrants and rights outstanding term">five years</span> after the closing of the Private Placement, and (iii) exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--PlacementAgentWarrantsMember_zqBiOrFraMzl" title="Exercisable price">61.35</span> per share. The Placement Agent Warrants contain terms that may require the Company to transfer assets to settle the warrants. Therefore, the Placement Agent Warrants are classified as a derivative liability, initially measured at fair value of $<span id="xdx_902_ecustom--DerivativeLiabilityMeasuredAtFairValue_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--PlacementAgentWarrantsMember_zFLGa9tKCD1f" title="Derivative liability measured at fair value">1,525,923</span> on the date of issuance and will be remeasured each accounting period with the changes in fair value reported in earnings. The Placement Agent Warrants are considered financing expense fees paid to the Placement Agent in relation to a derivative liability measured at fair value, thus, are included along with non-operating unrealized gains and losses in the recognition and change in fair value of warrant liabilities account in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2023 and 2022, net fair value gains recognized for the PAW were, $<span id="xdx_90E_ecustom--WarrantCommitmentUnrealizedGainLoss_iN_di_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--PlacementAgentWarrantsMember_zDJQjEOwwDt6" title="Net fair value gains losses">48,575</span> and $<span id="xdx_90D_ecustom--WarrantCommitmentUnrealizedGainLoss_iN_di_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--PlacementAgentWarrantsMember_zH5m1eZ8ACA7" title="Net fair value gains losses">1,477,024</span> respectively, presented in the recognition and change in fair value of warrant liabilities account in the consolidated statements of operations. The PAW liability outstanding as of December 31, 2023 and 2022 is $<span id="xdx_908_ecustom--WarrantLiability_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--PlacementAgentWarrantsMember_zwTr2Cf7hbE3" title="Warrant liability">325</span> and $<span id="xdx_903_ecustom--WarrantLiability_iI_c20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--PlacementAgentWarrantsMember_zUTZRZeWzW9i" title="Warrant liability">48,900</span> respectively, presented in the warrant liability account on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 651997 0.086 61.35 178060 9076 0.086 1000 147939 61.35 20000000 17408311 17408311 55061119 1333333 7.50 1667 1667 12500 0.63 866667 300000 300000 -5534931 -48668869 268667 6384250 866667 16303 P5Y 61.35 1525923 -48575 -1477024 325 48900 <p id="xdx_802_eus-gaap--ConcentrationRiskDisclosureTextBlock_zjMK7jzgZYnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10. <span id="xdx_825_zEySG0Rqijm2">SIGNIFICANT CUSTOMERS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carriers representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerMember_zjeF8e4ziPjh" title="Total revenue">10</span>% or more of total revenue are presented in the table below:</span></p> <p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zTIaYACQ2wPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zInueqFDvTP2" style="display: none">SCHEDULE OF CONCENTRATIONS OF REVENUES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Insurance Carrier</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Priority Health</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__dei--LegalEntityAxis__custom--PriorityHealthMember_z4RxTL6ApRv8" style="width: 12%; text-align: right" title="Concentration of risk percentage">35</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__dei--LegalEntityAxis__custom--PriorityHealthMember_zactWWvcN7z4" style="width: 12%; text-align: right" title="Concentration of risk percentage">32</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BlueCross BlueShield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__dei--LegalEntityAxis__custom--BlueCrossBlueShieldMember_zWJr8B3O75Jk" style="text-align: right" title="Concentration of risk percentage">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__dei--LegalEntityAxis__custom--BlueCrossBlueShieldMember_zTDsQ4BoGYqf" style="text-align: right" title="Concentration of risk percentage">14</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AD_zGb1YbgcCpXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No other single insurance carrier accounted for more than <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerMember_zEZIqg5pV0Dc" title="Total revenue">10</span>% of the Company’s commission revenues. The loss of any significant customer could have a material adverse effect on the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.10 <p id="xdx_899_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zTIaYACQ2wPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zInueqFDvTP2" style="display: none">SCHEDULE OF CONCENTRATIONS OF REVENUES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Insurance Carrier</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Priority Health</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__dei--LegalEntityAxis__custom--PriorityHealthMember_z4RxTL6ApRv8" style="width: 12%; text-align: right" title="Concentration of risk percentage">35</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__dei--LegalEntityAxis__custom--PriorityHealthMember_zactWWvcN7z4" style="width: 12%; text-align: right" title="Concentration of risk percentage">32</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BlueCross BlueShield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__dei--LegalEntityAxis__custom--BlueCrossBlueShieldMember_zWJr8B3O75Jk" style="text-align: right" title="Concentration of risk percentage">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__dei--LegalEntityAxis__custom--BlueCrossBlueShieldMember_zTDsQ4BoGYqf" style="text-align: right" title="Concentration of risk percentage">14</td><td style="text-align: left">%</td></tr> </table> 0.35 0.32 0.15 0.14 0.10 <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zXl2khhfrKy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11. <span id="xdx_821_zPcqx9ltmqe3">EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been authorized to issue <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zA0qMMIwoGNe" title="Preferred stock, shares authorized">750,000,000</span> shares of $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zFX3sZ0F7dac" title="Preferred stock, par value">0.086</span> par value Preferred Stock. The Board of Directors is expressly vested with the authority to divide any or all of the Preferred Stock into series and to fix and determine the relative rights and preferences of the shares of each series so established, within certain guidelines established in the Articles of Incorporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220131__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zZdebyVPDlmg" title="Number of shares issued">9,076</span> shares of its newly designated Series B convertible preferred stock through the Private Placement for the purpose of raising capital. The Series B convertible preferred stock have no voting rights and initially each share may be converted into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20220131__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zN8G7yxmTzRa" title="Shares converted">16</span> shares of the Company’s common stock. The holders of the Series B convertible preferred stock are not entitled to receive any dividends other than any dividends paid on account of the common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder) to common stock which amounts shall be paid pari-passu with all holders of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br/> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During August 2022, all <span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20220831__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zTTLo83OASf3" title="Conversion of shares">9,076</span> Series B Convertible Preferred Stock were converted by third parties into <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20220801__20220831__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zq8PwKOgqXdh" title="Shares converted">147,939</span> shares of common stock and as of December 31, 2023 and 2022 none remain outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been authorized to issue <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zpLkotuavms1" title="Common stock, shares authorized">2,000,000,000</span> shares of common stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zAxGgUWsrNxc" title="Common stock, par value">0.086</span> par value. Each share of issued and outstanding common stock shall entitle the holder thereof to fully participate in all shareholder meetings, to cast one vote on each matter with respect to which shareholders have the right to vote, and to share ratably in all dividends and other distributions declared and paid with respect to common stock, as well as in the net assets of the corporation upon liquidation or dissolution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zTohwqwRJN8a" title="Number of shares issued">178,060</span> shares of common stock through the Private Placement for the purpose of raising capital. See Note 9 - <i>Warrant Liabilities </i>for proceeds received by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20220101__20220131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MedigapAcquisitionMember_zUu53gHwckPb" title="Stock issued during period, shares, acquisitions">40,402</span> shares of common stock pursuant to the Medigap Acquisition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, upon agreement with Series A warrant holders, <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20220101__20220131__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantMember_zEHfVCsFJZm5" title="Exercise of Series A warrants, shares">25,000</span> warrants were exercised at a price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220131__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantMember_zWN3GucmJmk1" title="Warrants exercise price">99.00</span> into <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantMember_zGpLed0rG3I6" title="Number of shares">25,000</span> shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220301__20220331__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zZ7L9ZhatH8j" title="Number of shares issued">400</span> shares of the Company’s common stock due to the vesting of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220301__20220331__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zIP0Ie4LVeZ2" title="Vesting of stock award">400</span> stock awards pursuant to an employee agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May and June 2022, <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220531__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember_z8CiHCC2KvP" title="Class of common stock warrant"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220630__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember_zB6cLLlqAoae" title="Class of common stock warrant">218,462</span></span> Series C prepaid warrants were exchanged for <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7cpxT1d7YId" title="Prepaid warrants"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb8u89gUntYe" title="Prepaid warrants">218,462</span></span> shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2022, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220731__us-gaap--StatementClassOfStockAxis__custom--SeriesDPrepaidWarrantsMember_zpG6nyNU4BS7" title="Class of common stock warrant">81,423</span> Series D prepaid warrants were exchanged for <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220731__us-gaap--StatementClassOfStockAxis__custom--SeriesDPrepaidWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUEMG6KWBxmf" title="Prepaid warrants">81,423</span> shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2022, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221201__20221231__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zL0Yl4dR2Cqh" title="Number of shares issued">14,275</span> shares of the Company’s common stock due to the vesting of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20221201__20221231__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zp1t7JbI9nDj" title="Vesting of stock award">14,275</span> stock awards pursuant to several employee agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2022, upon agreement with Series B warrant holders, <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesBWarrantsMember_zhmAidNpOwR9" title="Number of shares issued exercised">1,667</span> warrants were exercised at a price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesBWarrantsMember_zB4m7knSlzu9" title="Exercise price">7.50</span> into <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesBWarrantsMember_zrnranlw2Wq3" title="Number of shares issued">1,667</span> shares of the Company’s common stock with cash proceeds to the Company of $<span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesBWarrantsMember_ztzPv7zn1sl6" title="Cash proceeds">12,500</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueOther_c20230101__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUiYHI7BQjw5" title="Common shares issued for earnout liabilities">109,358</span> shares of the Company’s common stock to settle two earn-out liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 23, 2023, pursuant to authority granted by the Board of Directors of the Company, the Company implemented a <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230222__20230223__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zfuBVfwWBPe3" title="Stockholders' equity, reverse stock split">1-for-15 reverse split</span> of the Company’s authorized and issued and outstanding common stock (the “Reverse Split-2023”). The par value remains unchanged. All share and per share information as well as common stock and additional paid-in capital have been retroactively adjusted to reflect the Reverse Split-2023 for all periods presented, unless otherwise indicated. The split resulted in a rounding addition of approximately <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230222__20230223__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zomxWcmJsh47" title="Round up of shares due to reverse split">15,300</span> shares valued at par, totaling $<span id="xdx_90A_ecustom--StockIssuedDuringPeriodValueReverseStockSplits_c20230222__20230223__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zDVYA5Gogde2" title="Round up of shares due to reverse split, value">1,300</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, Yes Americana, a related party, converted $<span id="xdx_906_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20230201__20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--YESAmericanaGroupLLCMember_zzTwqLD5VmFi" title="Debt conversion original debt amount">645,000</span> of its outstanding convertible debt into <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230201__20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--YESAmericanaGroupLLCMember_zXFQv11r2SUh" title="Debt conversion converted instrument shares">66,743</span> shares of the Company’s common stock. The conversion considered the fair market value of the stock on the day of conversion of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--YESAmericanaGroupLLCMember_zjLHi59Ltdq7" title="Debt instrument convertible conversion price">9.67</span> for the total of <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230201__20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--YESAmericanaGroupLLCMember_zLFUVFl8Icc3" title="Debt Conversion converted instrument shares">66,743</span> shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2023, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230301__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zeoLvN1CZMck">155,038</span> shares of the Company’s common stock in conjunction with the Private Placement-2023 as defined and discussed further below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the second quarter of 2023, the Company issued from its common stock, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqJ5MP3IGuzb" title="Shares issued service">112,557</span> shares in lieu of services provided, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSj1Qm9WAgQi" title="Settle an earn-out liability">352,260</span> shares to settle an earn-out liability and <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zixMslSsJ6P8" title="Vested restricted stock awards">22,219</span> shares pursuant to vested restricted stock awards earned by agents through an equity-based compensation program at one of the Company’s subsidiaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the third quarter of 2023, the Company issued from its common stock, <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zceIphSDu5h8">174,610</span> shares to settle an earn-out liability, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyT3VorstbQg">400</span> shares in lieu of services provided, <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2J4ea5OTMFj">3,017</span> shares to employees for vested stock awards, and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--SeriesBWarrantsMember_zr1cs3Q4zTw5" title="Warrants exercised">73,264</span> for Series B </span>Warrants exercised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fourth quarter of 2023, the Company issued from its common stock, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesEWarrantMember_zVnFjAg9SBP1">897,594</span> and <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantMember_zaRcKxMObv77">371,000</span> shares for Series E and Series F warrant exercises, respectively, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMsRDKvWV8Md" title="Share-based compensation">741,360</span> for share based compensation, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT1OrPSbPXNl">147,645</span> shares in lieu of services, and <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesBWarrantsMember_zXtvqXwT27v4" title="Prepaid warrants">300,000</span> shares for Series B Warrants exchanged.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and December 31, 2022, there were <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zs9Pmw1axWri" title="Common stock, shares outstanding">4,761,974</span> and <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zMv5l4lPBXy2" title="Common stock, shares outstanding">1,219,573</span> shares of Common Stock outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series A Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In conjunction with the Company’s initial public offering, the Company issued <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zMYJR5iDvdd6">2,070,000</span> Series A Warrants which were classified as equity warrants because of provisions, pursuant to the warrant agreement, that permit the holder obtain a fixed number of shares for a fixed monetary amount. The warrants are standalone equity securities that are transferable without the Company’s consent or knowledge. The warrants were recorded at a value per the offering of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_ziVj6Ug0GNJj">0.15</span>. The warrants may be exercised at any point from the effective date until the 5-year anniversary of issuance, on or around February 8, 2026, and are not subject to antidilution provisions. In January 2022, <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20220101__20220131__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantsMember_zZXKiJ6OhXil" title="Exercise of Series A warrants, shares">375,000</span> Series A Warrants were exercised into <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20220101__20220131__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantsMember_zNOhJSTAB182" title="Number of shares converted">25,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023 the Series A Warrant holders voted and approved an amendment to the Series A Warrant agreement pursuant to which the warrants were issued, and reduced the exercise price from the stated $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20231130__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantsMember_zXWgNm5tw0o2" title="Exercise price">6.60</span> (post-Reverse Split-2023 effective exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20231101__20231130__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantsMember_zEi4ythIeuvj" title="Exercise price">99.00</span>) per share to $<span id="xdx_90D_eus-gaap--WarrantExercisePriceDecrease_pid_c20231101__20231130__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantsMember_z0YgkZpsWiNc" title="Exercise price reduced">6.13</span> per share, subject to adjustment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of both December 31, 2023 and December 31, 2022, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantsMember_zZSijzvdqZ38"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantsMember_z9HtTksboAOh">1,695,000</span></span> Series A Warrants remain outstanding, exercisable into <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantsMember_z7PUfywqTeCi" title="Shares exercisable"><span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAWarrantsMember_zAXNk6mWEKVf" title="Shares exercisable">113,000</span></span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series C and D Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, as a result of the Private Placement and the Medigap Acquisition, the Company received a deficiency notification from Nasdaq indicating violation of Listing Rule 5365(a). As part of its remediation plan, in March 2022, the Company entered into Exchange Agreements with the holders of common stock issued in January 2022. Pursuant to the Exchange Agreements, the Company issued <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220131__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember_zaufj2xiN5bj" title="Class of common stock warrant">218,462</span> Series C prepaid warrants in exchange for <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220131__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9fvJqUmjd6i" title="Class of common stock warrant">218,462</span> shares of the Company’s common stock. Additionally, as compensation for entering into the Exchange Agreements, the Company issued <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220131__us-gaap--StatementClassOfStockAxis__custom--SeriesDPrepaidWarrantsMember_z8kIMuXzJxL1" title="Class of common stock warrant">81,500</span> Series D prepaid warrants to the Private Placement investors for no additional consideration. The fair value of the Series D prepaid warrants was treated as a deemed dividend and accordingly treated as a reduction from income available to common stockholders in the calculation of earnings per share. Refer to Note 12, <i>Earnings (Loss) Per Share</i> for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series C and D Warrants are equity classified pursuant to the warrant agreement provisions that permit holders to obtain a fixed number of shares for a fixed monetary amount. The warrants are standalone equity securities that are transferable without the Company’s consent or knowledge. The warrants expire on the fifth anniversary of the respective issuance dates and are exercisable at a per share exercise price equal to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCandDWarrantsMember_zcr7CQy89dn5" title="Warrents exercise price">0.015</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May and June 2022, the <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220531__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember_zktiYMBpkSA8" title="Warrant conversion shares"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220630__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember_z2mQC8i7jWL7" title="Warrant conversion shares">218,462</span></span> Series C prepaid warrants were converted for <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220531__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5i1HIMWdnVd" title="Warrant conversion shares"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220630__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0Xg3yBoRv3b" title="Warrant conversion shares">218,462</span></span> shares of the Company’s common stock for a conversion price of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220531__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember_zFPECKSGCRlk" title="Warrants exercise price"><span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220630__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember_zhV4KJHJDWvk" title="Warrants exercise price">0.015</span></span>. Through December 31, 2022, the Company has received payments of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCPrepaidWarrantsMember_zW2vxnEQZC4d" title="Proceeds from issuance">1,336</span> for these issuances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2022, <span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220701__20220731__us-gaap--StatementClassOfStockAxis__custom--SeriesDPrepaidWarrantsMember_zgFgJDeYdOIl" title="Warrant conversion shares">81,423</span> Series D prepaid warrants were converted into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_pid_c20220701__20220731__us-gaap--StatementClassOfStockAxis__custom--SeriesDPrepaidWarrantsMember_z8jhbF5LYaPi" title="Warrant conversion shares">81,472</span> shares of the Company’s common stock for a conversion price of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220731__us-gaap--StatementClassOfStockAxis__custom--SeriesDPrepaidWarrantsMember_zrAXsHP9lOr6" title="Warrants exercise price">0.015</span> through both cash and cashless exercises. Proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220701__20220731__us-gaap--StatementClassOfStockAxis__custom--SeriesDPrepaidWarrantsMember_zBVs5kazhJ1a" title="Proceeds from issuance">795</span> were received in conjunction with the cash exercise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Series E, F &amp; G Warrants, and</i></b></p> <p style="margin: 0"><b><i>Abeyance Shares</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, the Company entered into a securities purchase agreement (the “SPA-2023”) with one institutional buyer for the purchase and sale of, (i) an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230313__20230313__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zzZy7mV6vbxc" title="Number of shares issued">155,038</span> shares (the “Common Shares”) of the Company’s common stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230313__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPK6dbgUjDH7" title="Common stock, par value">0.086</span> per share (the “Common Stock”) along with accompanying common warrants (the “Common Units”), (ii) prefunded warrants (the “Prefunded Warrants” or “Series E Warrants”) that are exercisable into <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230313__us-gaap--StatementClassOfStockAxis__custom--SeriesEWarrantsMember_zeWkL7FocRJ1" title="Class of common stock warrant">897,594</span> shares of Common Stock (the “Prefunded Warrant Shares”) along with accompanying common warrants (the “Pre-Funded Units”), and (iii) common warrants (the “Common Warrants” or “Series F Warrants”) to initially acquire up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220313__us-gaap--StatementClassOfStockAxis__custom--SeriesFWarrantsMember_zzlrUyP2Zlek" title="Stock issued during period, shares, acquisitions">2,105,264</span> shares of Common Stock (the “Common Warrant Shares”) (representing 200% of the Common Shares and Prefunded Warrant Shares) in a private placement offering (the “Private Placement-2023”). Additionally, the Company agreed to issue a warrant to the Placement Agent (defined below), to initially acquire <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220313__us-gaap--StatementClassOfStockAxis__custom--PAWarrantMember_zSKAyaAHj5qe" title="Stock issued during period, shares, acquisitions">52,632</span> shares of common stock (the “PA Warrant”) and <span style="background-color: white">entered into a registration rights agreement with the buyer to register for resale the common shares underlying the Series E and F Warrants.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20230313__20230313_zDJbOkrDMbx3" title="Warrants description">The aggregate purchase price for the Common Shares, Prefunded Warrants (Series E Warrants) and the Common Warrants (Series F Warrants) to be purchased by the Buyer shall be equal to (i) $3.80 for each Common Unit purchased by such Buyer, or (ii) $3.799 for each Prefunded Unit purchased by the Buyer, which Prefunded Warrants are exercisable into Prefunded Warrant Shares at the initial Exercise Price (as defined in the Prefunded Warrant) of $0.001 per Prefunded Warrant Share in accordance with the Prefunded Warrant.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Common Warrant (Series F) has an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230313__us-gaap--StatementClassOfStockAxis__custom--SeriesFWarrantsMember_zAZpX5Cge2k5" title="Warrants exercise price">3.55</span> per share, subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the date of the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private Placement-2023<span style="background-color: white">. The Common Warrant will be exercisable six months following the date of issuance and will expire five and a half years from the date of issuance.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The PA Warrant has an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230313__us-gaap--StatementClassOfStockAxis__custom--PAWarrantMember_zlj23U0QZlI4" title="Warrants exercise price">3.91</span> per share, subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the date of the SPA-2023. The PA Warrant will be exercisable six months following the date of issuance and will expire five years from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The closing of the Private Placement-2023 occurred on March 16, 2023. EF Hutton, a division of Benchmark Investments, LLC (the “Placement Agent”) acted as the sole placement agent and was entitled to an <span id="xdx_90B_ecustom--GrossProceedsCashFeePercentage_pid_dp_uPure_c20230316__20230316__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zC8tOYmwDsS3" title=" Gross proceeds cash fee percentage">8</span>% of gross proceeds cash fee and the reimbursement of certain Placement Agent fees and customary expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Gross and net proceeds to the Company from the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private Placement-2023 <span style="background-color: white">were approximately $<span id="xdx_90F_ecustom--GrossProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQvb0c2Hmib2" title="Gross proceeds">4</span> million and $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ziHCq9mVyIM1" title="Net Proceeds">3.4</span> million respectively, to be utilized primarily for general working capital and administrative purposes. Direct financing fees approximated $<span id="xdx_90B_eus-gaap--PaymentsOfFinancingCosts_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zr3uTM0hW5G5" title="Financing fee">553,000</span>.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined the Series E Warrants, Series F Warrants, and PA Warrants are equity in nature because of provisions, pursuant to the warrant agreements, that permit the holder to obtain a fixed number of shares for a fixed monetary amount. The values offset to $<span id="xdx_909_eus-gaap--AdditionalPaidInCapital_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--WarrantAgreementMember_z2DFJMjAzNxg" title="Additional paid in capital">0</span> in additional paid-in capital in the Company’s condensed consolidated statements of stockholders’ equity (deficit).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 12, 2023, the Company entered into that certain Inducement Offer to Exercise Series F Warrants to Subscribe for Common Shares with the institutional investor (the “Series F Inducement Agreement”), pursuant to which (i) the Company agreed to lower the exercise price of the Series F Warrants to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zMb0rRq5i3i4">0.6562 </span>per share (which is equal to the Nasdaq minimum price) (the “Nasdaq Minimum Price”) and (ii) the institutional buyer agreed to exercise the Series F Warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zIrX5yTolDUi">2,105,264 </span>shares of Common Stock into <span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20231211__20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_z3goF9tinKJb">2,105,264 </span>shares of Common Stock (the “Exercise Shares”) by payment of the aggregate exercise price of approximately $<span id="xdx_901_eus-gaap--PaymentsForRepurchaseOfWarrants_c20231211__20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zCTkUo2L8cOb">1,381,474</span>, gross of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231211__20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zofD00RZFtPj">351,503 </span>of expenses, including but not limited to EF Hutton LLC, who acted as placement agent in connection therewith, resulting in $<span id="xdx_90D_eus-gaap--ProceedsFromWarrantExercises_c20231211__20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zGZUxPcUdhJj">1,029,972 </span>in net proceeds to the Company. The closing occurred on December 14, 2023 (the “Closing Date”). The Exercise Shares were all exercised, resulting in the issuance of <span id="xdx_901_ecustom--IssuanceOfWarrants_c20231211__20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zDULDPnHJPl2">371,000 </span>shares, and <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20231211__20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_z6i3c8aHcHZ5">1,734,264 </span>shares held in abeyance (the “Abeyance Shares”) due to the <span id="xdx_90E_ecustom--PercentageOfBeneficialOwnership_iI_pid_dp_uPure_c20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zycmz6I9WGB2">9.99</span>% beneficial ownership limitation stipulated in the Series F Inducement Agreement. The Company accounted for the exercise price decrease inducement as a modification which resulted in a deemed dividend of $<span id="xdx_907_ecustom--DeemedDividend_c20231211__20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zoQrbXV6NX6e" title="Deemed dividend">302,997</span> recorded as an increase and decrease to the additional paid-in capital account, in the consolidated balance sheets and statements of stockholders’ equity (deficit) as of December 31, 2023. The Company valued (a) the fair value of the <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zAlQ4dbKDsgg">2,105,264</span> warrants immediately before exchange in the amount of $<span id="xdx_909_ecustom--WarrantsAndRightsOutstandingBeforeExchange_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zB7vcrtieqWk" title="Warrants and rights outstanding before exchange">1,103,377</span>, (b) the fair value of the warrants immediately after the exchange in the amount of $<span id="xdx_908_ecustom--WarrantsAndRightsOutstandingAfterExchange_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zv4231AIhWP9" title="Warrants and rights outstanding after exchange">800,380</span>, and (c) recorded the difference as a deemed dividend in the amount of $<span id="xdx_907_ecustom--DeemedDividend_c20231231__20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_zZ3CHUreUHzl" title="Deemed dividend">302,997</span>. The warrants were valued using the Black-Scholes option pricing model using the following assumptions: a) fair value of common stock of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231212__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlZr5WbC1yaa" title="Shares issued price per share">0.6562</span>, b) exercise prices of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231212__us-gaap--StatementEquityComponentsAxis__custom--PreExchangeWarrantMember_zxnGPqylX0Uj" title="Warrants exercise prices">3.55</span> pre-exchange and $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231212__us-gaap--StatementEquityComponentsAxis__custom--PostExchangeWarrantMember_zyGiH7F7kE4j" title="Warrants exercise prices">0.6562</span> post-exchange, c) term of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PreAndPostExchangeWarrantMember_z0NXJQCRzaPg" title="Warrants term">4.77</span> years pre-exchange and post-exchange, d) dividend rate of <span id="xdx_907_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_pid_dp_uPure_c20231212__20231212_zesGVggQvQSb" title="Dividend rate">0</span>%, e) volatility of <span id="xdx_90F_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_pid_dp_uPure_c20231212__20231212_zfyv33UTRChh" title="Volatility rate">112</span>% pre-exchange and post-exchange, and f) risk free interest rate of <span id="xdx_901_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_pid_dp_uPure_c20231212__20231212_zCwfSqmXwlGb" title="Risk free interest rate">4.23</span>% pre-exchange and post-exchange.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, pursuant to the Series F Inducement Agreement, the Company issued a new unregistered Series G common share purchase warrant (the “Series G Warrant”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesGWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SeriesFInducementAgreementMember_zchm24huKKr8">4,210,528</span> shares of Common Stock at an initial exercise price equal to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesGWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SeriesFInducementAgreementMember_zzvjMCLLg1Ce" title="Exercise price">0.6562</span>, but subject to a <span id="xdx_902_ecustom--PercentageOfBeneficialOwnership_iI_pid_dp_uPure_c20231212__us-gaap--TypeOfArrangementAxis__custom--SeriesFInducementAgreementMember_zQ2JAkORFXx8">4.99%</span> beneficial ownership limitation. The Series G Warrant termination date is December 12, 2028. The Company’s accounting for the Series G Warrant resulted in a deemed dividend of $<span id="xdx_90E_ecustom--DeemedDividend_c20231212__20231212__us-gaap--StatementEquityComponentsAxis__custom--SeriesGWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SeriesFInducementAgreementMember_zhAHjSCADXYc" title="Deemed dividend">2,236,760</span> recorded as an increase and decrease to the additional paid-in capital account, in the consolidated balance sheets and statements of stockholders’ equity (deficit) as of December 31, 2023. The warrants were valued using the Black-Scholes option pricing model with the following assumptions: a) fair value of common stock of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20231212__us-gaap--TypeOfArrangementAxis__custom--SeriesFInducementAgreementMember_zFObYferSl6" title="Shares issued price per share">0.6562</span>, b) exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231212__us-gaap--TypeOfArrangementAxis__custom--SeriesFInducementAgreementMember_zN6FahNwvwhc" title="Warrants exercise prices">0.6562</span>, c) term of 5 years, d) dividend rate of <span id="xdx_90B_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_pid_dp_uPure_c20231212__20231212__us-gaap--TypeOfArrangementAxis__custom--SeriesFInducementAgreementMember_zigNKDBIioDc" title="Dividend rate">0</span>%, e) volatility of <span id="xdx_900_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_pid_dp_uPure_c20231212__20231212__us-gaap--TypeOfArrangementAxis__custom--SeriesFInducementAgreementMember_zpoIiVIl5aAb" title="Volatility rate">112</span>%, and f) risk free interest rate of <span id="xdx_90F_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_pid_dp_uPure_c20231212__20231212__us-gaap--TypeOfArrangementAxis__custom--SeriesFInducementAgreementMember_zxjb3zUyMHPe" title="Risk free interest rate">4.23</span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify"><b>Series E:</b> There remains no Series E Warrants outstanding pursuant to exercises occurring throughout the fiscal year of <span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesEWarrantsMember_zAbloSjxVo75" title="Exercise of warrants, shares">897,594</span> warrants exercised into <span id="xdx_90E_ecustom--CommonSharesIssuedForSeriesEWarrantShares_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziFRaOVddqw8" title="Number of shares converted">897,594</span> shares of the Company’s common stock for a net of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoOwCtsRUJO5" title="Net of cash proceeds">898</span> in cash proceeds.</td></tr> <tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify"><b>Series F: </b>There remain <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesFWarrantsMember_zVVaHKeqOb4j">no</span> Series F Warrants outstanding pursuant to the Series F Inducement Agreement.</td></tr> <tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify"><b>Series G:</b> There remain <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesGWarrantsMember_zkjG5Pn35nPh">4,210,528</span> Series G Warrants outstanding.</td></tr> <tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify"><b>Abeyance Shares:</b> There remain <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AbeyanceSharesMember_zMvQsM9yveYe" title="Class of warrant unissued">1,734,264</span> unissued Abeyance Shares outstanding.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to December 31, 2023, during the first quarter of 2024, upon request from the institutional investor, the Company converted <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__custom--AbeyanceSharesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWhyM6bCuzx" title="Converted shares">723,264</span> Abeyance Shares into Common Stock, thereby issuing <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zj18MoIryCga" title="Shares issued">723,264</span> of Common Stock, resulting in a remaining <span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20240331__us-gaap--StatementEquityComponentsAxis__custom--AbeyanceSharesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zeK1ZK5D3MN2" title="Common stock, shares outstanding">1,011,000</span> outstanding Abeyance Shares. During the second quarter of 2024, the institutional investor requested the Company convert the remaining <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__custom--AbeyanceSharesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNhf2w52fvjc" title="Conversion of stock shares converted">1,011,000</span> Abeyance Shares into Common Stock. The Company has yet to issue any shares in reference to this request but does intend to issue them during the remaining period of the second quarter of 2024. Upon and post issuance of these shares, there will be no remaining Abeyance Shares outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity Incentive Plans</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2019 Equity Incentive Plan</i></b>. During the year ended December 31, 2019, the Company adopted the Reliance Global Group, Inc. 2019 Equity Incentive Plan (the “2019 Plan”) under which various forms of equity awards can be granted to employees, directors, consultants, and service providers. Awards include but are not limited to, restricted stock, restricted stock units, performance shares and stock options. A total of <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20191231__us-gaap--PlanNameAxis__custom--TwoThousandNineteenEquityIncentivePlanMember_zXP2YXkmC88i">46,667</span> shares of common stock were reserved for issuance under the 2019 Plan. As of December 31, 2023, after considering 2019 Plan shares held for outstanding options, there remains no additional capacity for further awards. As of the same date, there are <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandNineteenEquityIncentivePlanMember_zQq0v0z2CyMj" title="Options outstanding">10,928</span> options outstanding with a weighted average exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandNineteenEquityIncentivePlanMember_z4xHBMXtUSo2" title="Weighted average exercise price">232.55</span> and weighted average remaining contractual life of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandNineteenEquityIncentivePlanMember_zoQwNL6Dzegl" title="Weighted average remaining contractual life">0.57</span> years. The Company issues new shares of common stock for any option exercises, from its shares available under either its 2019 Plan or 2023 Plan (as defined below).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023 Equity Incentive Plan</i></b><span style="background-color: white">. </span>On August 10, 2023, the Company adopted, the Reliance Global Group, Inc. 2023 Equity Incentive Plan (the “2023 Plan”, and together with the 2019 Plan, the “Plans”). The purpose of the 2023 Plan is to provide a means through which the Company and its subsidiaries may attract and retain key personnel, and to provide a means whereby directors, officer, employees, consultants, and advisors of the Company and its subsidiaries can acquire and maintain an equity interest in the Company, or be paid incentive compensation, thereby strengthening their commitment to the welfare of the Company and its subsidiaries and aligning their interests with those of the Company’s stockholders. The 2023 Plan provides for various stock-based incentive awards, including incentive and nonqualified stock options, stock appreciation rights (“SARs”), restricted stock and restricted stock units (“RSUs”), and other equity-based or cash-based awards. It became effective on August 10, 2023 and will terminate on August 10, 2033, unless the Compensation Committee terminates it earlier. A total of <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zjWVsZybCJkj">800,000</span> shares of Common Stock were reserved for issuance under the 2023 Plan, and as of December 31, 2023 there were no new options granted, and there remain <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zwVWWdPKMk81" title="Available for issuance">47,080</span> shares available for issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Administration of the Plans</i></b>. The Plans are administered by the Compensation Committee of the Board. The Compensation Committee is authorized to select from among eligible employees, directors, and service providers those individuals to whom shares and options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Compensation Committee is also authorized to prescribe, amend, and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any shares and options granted hereunder is within the discretion of the Compensation Committee.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Options:</i></b> The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees, non-employee directors, consultants, and service providers are eligible to receive options which are not ISOs, i.e. “Non-Statutory Stock Options.” The options granted by the Compensation Committee in connection with its adoption of the Plans were Non-Statutory Stock Options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zImy0grxHdFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the stock options granted, forfeited or expired, and exercised under the Plans for the years ended December 31, 2023 and 2022 respectively:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zc6ZkLL5xa92" style="display: none">SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zwstRAVk4cr5" style="width: 11%; text-align: right" title="Number of Stock Options Outstanding, Outstanding at Beginning of Period">10,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zsj57WbDd5W8" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">232.55</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_ziPWnstDBLa2" title="Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period">1.61</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231_zTNFZ9hC28L3" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning of Period">        <span style="-sec-ix-hidden: xdx2ixbrl2138">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zBc1zkniDyv7" style="text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2140">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zNZxsQm6a2ja" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2142">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_pp0p0_c20230101__20231231_z5OxqEdN5s87" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2144">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Forfeited or expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zCnipqFbmwlf" style="text-align: right" title="Number of Stock Options Outstanding, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2146">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zHHB4PISD7ol" style="text-align: right" title="Weighted Average Exercise Price Per Share, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2148">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedOrExpiredIntrinsicValue_pp0p0_c20230101__20231231_zq7Lhw7wvd9d" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2150">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231_zindlhP2kTI8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2152">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zwtx6orEoHtk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2154">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisedGrantedIntrinsicValue_pp0p0_c20230101__20231231_zCoolKMufgn8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2156">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zKLfH4SD8DA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">10,928</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zRscZr55h8n8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">232.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231_zU6APC46wnc9" title="Weighted Average Remaining Contractual Life (years), Outstanding at End of Period">0.61</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231_zI7NfzWXdMYc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl2164">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zrYujBl6rsti" style="width: 11%; text-align: right" title="Number of Stock Options Outstanding, Outstanding at Beginning of Period">10,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z5NlDwUuofxj" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">232.55</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zjI5gdZSiwbc" title="Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period">2.61</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_za39IXx3NTA4" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning of Period">                <span style="-sec-ix-hidden: xdx2ixbrl2172">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_z1umazVuWFM6" style="text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2174">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zYzEoqL4vsa6" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2176">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_pp0p0_c20220101__20221231_zSkzQFvaudai" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2178">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Forfeited or expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_zbUQyODsll6c" style="text-align: right" title="Number of Stock Options Outstanding, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2180">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zs0AHr2RErp8" style="text-align: right" title="Weighted Average Exercise Price Per Share, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2182">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedOrExpiredIntrinsicValue_pp0p0_c20220101__20221231_zMsprxdNMK7d" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2184">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231_zwhgotET8tHe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2186">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z3VfhfjLH5g3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2188">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisedGrantedIntrinsicValue_pp0p0_c20220101__20221231_zs4BqN8py8Ef" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2190">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zvXw1ycWnUv1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">10,928</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_ziV5I04k4mk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">232.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_zkUWBJTFmHAd" title="Weighted Average Remaining Contractual Life (years), Outstanding at End of Period">1.61</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220101__20221231_zRaqbvLK1zuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl2198">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z6rhnuuMXroa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_z8KXfSCs0nCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the Company’s non-vested stock options as of December 31, 2023 and 2022 respectively:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_z4XbMEAHTO34" style="display: none">SCHEDULE OF NON - VESTED STOCK OPTIONS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Non-vested at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231_zVkBq4zJJVIb" style="width: 14%; text-align: right" title="Number of Non-vested Stock Options Outstanding, Outstanding at Beginning of Period">271</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_z0Zetuplfq02" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">236.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermNonVested_dtY_c20230101__20231231_zDxPYAwHrgV1" title="Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period">2.27</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zaUvJCmlqhja" style="text-align: right" title="Number of Non-vested Stock Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2208">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zHSOuHzy3vdf" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2210">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231_zY0qIvDXGXvb" style="text-align: right" title="Number of Non-vested Stock Options Outstanding, Vested">(248</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231_z4tSmGA4wzSj" style="text-align: right" title="Weighted Average Exercise Price Per Share, Vested">239.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_z04RMqk3OgVi" title="Weighted Average Remaining Contractual Life (years), Vested">0.81</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20230101__20231231_zGeix4mJs3Z5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Non-vested Stock Options Outstanding, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2218">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zqkacXPEKcGk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2220">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231_zayIdFYfoQSk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zCDBp96bSOJk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">205.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermsNonVested_dtY_c20230101__20231231_zAUEmOdCc8c3" title="Weighted Average Remaining Contractual Life (years), Outstanding at End of Period">1.59</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Non-vested at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231_zqA3td3jauRh" style="width: 14%; text-align: right" title="Number of Non-vested Stock Options Outstanding, Outstanding at Beginning of Period">3,587</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_zylqTcqXbiYk" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">227.78</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermNonVested_dtY_c20220101__20221231_zAmokqtThVvk" title="Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period">0.90</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zyY5XcoOIi86" style="text-align: right" title="Number of Non-vested Stock Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2234">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zZ0oEhY0Mh15" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2236">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231_zvEluwEIYVBe" style="text-align: right" title="Number of Non-vested Stock Options Outstanding, Vested">(3,315</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_z9nLm3c0HMAj" style="text-align: right" title="Weighted Average Exercise Price Per Share, Vested">14.89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zj0uhx1nIQg" title="Weighted Average Remaining Contractual Life (years), Vested">1.71</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20220101__20221231_zgSn7pho6MU9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Non-vested Stock Options Outstanding, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2244">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zJmcIj9k0545" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2246">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20220101__20221231_zHlquYKLFFO9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">271</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20221231_zO8dkmYmv5pk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">236.83</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermsNonVested_dtY_c20220101__20221231_zoiKWpHdTWB4" title="Weighted Average Remaining Contractual Life (years), Outstanding at End of Period">2.27</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zTkwDLcHvjWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2023 and 2022, the Board did not approve any options to be issued pursuant to the Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2023 and 2022, no employee terminations occurred resulting in option forfeitures of $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_c20230101__20231231_z7j2X7BKCTQa" title="Number of shares option forfeitures"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_c20220101__20221231_zvq15nELcaU4" title="Number of shares option forfeitures">0</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of December 31, 2023, the Company determined that the options granted and outstanding had a total fair value of $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20231231_zosSZkDdoCMa" title="Fair value">2,421,960</span>. The options will be amortized in future periods through February 2024. During the year ended December 31, 2023, the Company recognized $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember_zYMqjNIsfH5e">15,624</span> of compensation expense relating to the stock options granted to employees, directors, and consultants. As of December 31, 2023, unrecognized compensation expense totaled $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20231231_zF4QZRq2qCP8" title="Unrecognized compensation expense">1,542</span> which will be recognized on a straight-line basis over the vesting period or requisite service period through February 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on December 31, 2023. The market value as of December 31, 2023 was $<span id="xdx_90B_ecustom--MarketValueOfShare_iI_pid_c20231231_zA2mzAt4ndcc" title="Market value price per share">0.54</span> based on the closing bid price for December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of December 31, 2022, the Company determined that the options granted and outstanding had a total fair value of $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20221231_zxmwtjOPWGC7">2,421,960</span>. The options will be amortized in future periods through February 2024. During the year ended December 31, 2022, the Company recognized $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesDirectorsAndConsultantsMember_zgAQeUa2FE5c">178,579 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of compensation expense relating to the stock options granted to employees, directors, and consultants. As of December 31, 2022, unrecognized compensation expense totaled $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20221231_zH08dQxLvVW7">17,166 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which will be recognized on a straight-line basis over the vesting period or requisite service period through February 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on December 31, 2022. The market value as of December 31, 2022 was $<span id="xdx_908_ecustom--MarketValueOfShare_iI_pid_c20221231_zTY2VnsXyTE7" title="Market value price per share">8.55</span> based on the closing bid price for December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes option-pricing models require the Company to make predictive assumptions regarding future stock price volatility, recipient exercise behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the expected term of the option. The expected term of the options was computed by taking the mid-point between the vesting date and expiration date. The following assumptions were used in the Black-Scholes option-pricing model, not accounting for the reverse splits:</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMqYcxvrWVu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zfvBYbTD8Wd9" style="display: none">SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember_zVORBKF1d2k6" title="Exercise price">0.16</span> - $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember_zIQ7GV2CUzzh" title="Exercise price">0.26</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_zlrrPJmDGkQk" title="Exercise price">0.16</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zEbpIkbYlg08" title="Exercise price">0.26</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zXDK2rZuOMg5" title="Expected term">3.25</span> to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ze75teqZbGRk" title="Expected term">3.75</span> years</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zOrOWW7gyxZc" title="Expected term">3.25</span> to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zCTOQmgbfzXi" title="Expected term">3.75</span> years</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zforqsqQ8Zxj" title="Risk-free interest rate">0.38</span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z1tiWarTYR8a" title="Risk-free interest rate">2.43</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z0cQOrYAo8Ti" title="Risk-free interest rate">0.38</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zyUapGU3SNp3" title="Risk-free interest rate">2.43</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated volatility</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zfgl5oXR0dx3" title="Estimated volatility">293.07</span>% - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zwEF3NRIZf9i" title="Expected volatility">517.13</span></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zexVftztGzO8" title="Estimated volatility">293.07</span>% - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zI5o0mlgnwB3" title="Expected volatility">517.13</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230101__20231231_z48CQiQL4hZ6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2304">-</span> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231_z9z863vNzOik" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2306">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_zeIijBgVNvsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Awards</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Plans provide for various forms of stock awards. During the years ended December 31, 2023, and 2022, certain directors, executives and employees were granted equity awards which vested immediately. Respectively, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ExecutivesAndEmployeesMember_z2mK0U8YS9eb" title="Shares were awarded and issued">758,026</span> and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__srt--TitleOfIndividualAxis__srt--DirectorMember_zAGMPLRXfdwc" title="Shares were awarded and issued">12,460</span> shares were awarded and issued, valued at $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ExecutivesAndEmployeesMember_zNb9JeRzVqc5" title="Value were awarded and issued">477,556</span> and $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20220101__20221231__srt--TitleOfIndividualAxis__srt--DirectorMember_zbvN8yyi6n2f" title="Value were awarded and issued">766,250</span>, presented in the salaries and wages (for executives and employees) and general and administrative (for directors) accounts in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Pursuant to an agreement in April 2022, further amended in October 2022 between the Company and an executive, the executive was granted <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221001__20221031__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInAprilTwoThousandTwentyTwoMember_zucRaQcj7vK7" title="Shares restricted">7,418</span> restricted shares of the Company’s common stock which vest quarterly over a three-year period. The shares granted were valued at $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20221001__20221031__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInAprilTwoThousandTwentyTwoMember_z1dzfnrGQjhf" title="Shares restricted, value">180,546</span> at the date of the grant. For the years ended December 31, 2023, and 2022 respectively, <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInAprilTwoThousandTwentyTwoMember_zmSGX4e7Udc9" title="Share based compensation, shares">3,908</span> and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInAprilTwoThousandTwentyTwoMember_zlCSazMdnnm9" title="Share based compensation, shares">667</span> shares have been issued under the agreement, and compensation expense was $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInAprilTwoThousandTwentyTwoMember_zvhuGLU1gcbj" title="Share based compensation">83,464</span> and $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInAprilTwoThousandTwentyTwoMember_zIIn7HPqxNXd" title="Share based compensation">32,131</span>, presented in the salaries and wages account in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Pursuant to a grant award agreement effective December 28, 2022 between the Company and an executive, the executive was granted an annual award of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20221228__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember_z7n1Ms9DCcMe" title="Shares vested">2,667</span> shares of the Company’s common stock to vest monthly each year throughout the duration of employment. The grant value for the years ended December 2023 and 2022 respectively was, $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember_zGSBCa72pzGf" title="Share based compensation">22,404</span> and $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember_z6JVaWejEmYf" title="Share based compensation">241</span> and recorded as compensation expense, presented in the salaries and wages account in the consolidated statements of operations. For the years ended December 31, 2023, and 2022 respectively, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember_z01Am8KA2xFa" title="Share based compensation, shares">2,695</span> and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--TypeOfArrangementAxis__custom--AgreementInDecemberTwentyEightTwoThousandTwentyTwoMember_zyjy2TC2SeA5" title="Share based compensation, shares">0</span> shares have been issued under the agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to an equity-based commission compensation program at one of the Company’s subsidiaries which provides down-line agents the ability to earn and receive restricted stock awards upon completion of agreed upon service requirements, the Company grants annual</span> restricted stock awards which have vesting or other restrictions of up to twelve months. For the years ended December 31, 2023 and 2022 respectively, <span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesCommissionEquityAwardExpense_c20230101__20231231_zyScUyb5T3ra" title="Shares issued commission equity award expense">22,221</span> and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesCommissionEquityAwardExpense_c20220101__20221231_zFRiKuunIUE1" title="Shares issued commission equity award expense">0</span> shares were issued under the program, and commission equity award expense was, $<span id="xdx_902_ecustom--StockIssuedDuringPeriodValueCommissionEquityAwardExpense_c20230101__20231231_zJbzkgFTYnMe" title="Value issued commission equity award expense">276,400</span> and <span id="xdx_909_ecustom--StockIssuedDuringPeriodValueCommissionEquityAwardExpense_c20220101__20221231_z1moYiszfj44" title="Value issued commission equity award expense">249,650</span>, presented in the commission expense account in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total equity-based compensation for the years ended December 31, 2023 and 2022 was approximately $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231_z3d9WsgQCnTa" title="Equity-based compensation expense">875,000</span> and $<span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231_zv1luHFJTHu6" title="Equity-based compensation expense">1,250,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 750000000 0.086 9076 16 9076 147939 2000000000 0.086 178060 40402 25000 99.00 25000 400 400 218462 218462 218462 218462 81423 81423 14275 14275 1667 7.50 1667 12500 109358 1-for-15 reverse split 15300 1300 645000 66743 9.67 66743 155038 112557 352260 22219 174610 400 3017 73264 897594 371000 741360 147645 300000 4761974 1219573 2070000 0.15 375000 25000 6.60 99.00 6.13 1695000 1695000 113000 113000 218462 218462 81500 0.015 218462 218462 218462 218462 0.015 0.015 1336 81423 81472 0.015 795 155038 0.086 897594 2105264 52632 The aggregate purchase price for the Common Shares, Prefunded Warrants (Series E Warrants) and the Common Warrants (Series F Warrants) to be purchased by the Buyer shall be equal to (i) $3.80 for each Common Unit purchased by such Buyer, or (ii) $3.799 for each Prefunded Unit purchased by the Buyer, which Prefunded Warrants are exercisable into Prefunded Warrant Shares at the initial Exercise Price (as defined in the Prefunded Warrant) of $0.001 per Prefunded Warrant Share in accordance with the Prefunded Warrant. 3.55 3.91 0.08 4000000 3400000 553000 0 0.6562 2105264 2105264 1381474 351503 1029972 371000 1734264 0.0999 302997 2105264 1103377 800380 302997 0.6562 3.55 0.6562 P4Y9M7D 0 1.12 0.0423 4210528 0.6562 0.0499 2236760 0.6562 0.6562 0 1.12 0.0423 897594 897594 898 4210528 1734264 723264 723264 1011000 1011000 46667 10928 232.55 P0Y6M25D 800000 47080 <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zImy0grxHdFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the stock options granted, forfeited or expired, and exercised under the Plans for the years ended December 31, 2023 and 2022 respectively:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zc6ZkLL5xa92" style="display: none">SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zwstRAVk4cr5" style="width: 11%; text-align: right" title="Number of Stock Options Outstanding, Outstanding at Beginning of Period">10,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zsj57WbDd5W8" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">232.55</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_ziPWnstDBLa2" title="Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period">1.61</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231_zTNFZ9hC28L3" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning of Period">        <span style="-sec-ix-hidden: xdx2ixbrl2138">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zBc1zkniDyv7" style="text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2140">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zNZxsQm6a2ja" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2142">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_pp0p0_c20230101__20231231_z5OxqEdN5s87" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2144">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Forfeited or expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zCnipqFbmwlf" style="text-align: right" title="Number of Stock Options Outstanding, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2146">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zHHB4PISD7ol" style="text-align: right" title="Weighted Average Exercise Price Per Share, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2148">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedOrExpiredIntrinsicValue_pp0p0_c20230101__20231231_zq7Lhw7wvd9d" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2150">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231_zindlhP2kTI8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2152">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zwtx6orEoHtk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2154">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisedGrantedIntrinsicValue_pp0p0_c20230101__20231231_zCoolKMufgn8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2156">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zKLfH4SD8DA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">10,928</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zRscZr55h8n8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">232.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231_zU6APC46wnc9" title="Weighted Average Remaining Contractual Life (years), Outstanding at End of Period">0.61</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231_zI7NfzWXdMYc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl2164">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zrYujBl6rsti" style="width: 11%; text-align: right" title="Number of Stock Options Outstanding, Outstanding at Beginning of Period">10,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z5NlDwUuofxj" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">232.55</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zjI5gdZSiwbc" title="Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period">2.61</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_za39IXx3NTA4" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning of Period">                <span style="-sec-ix-hidden: xdx2ixbrl2172">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_z1umazVuWFM6" style="text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2174">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zYzEoqL4vsa6" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2176">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_pp0p0_c20220101__20221231_zSkzQFvaudai" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2178">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Forfeited or expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_zbUQyODsll6c" style="text-align: right" title="Number of Stock Options Outstanding, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2180">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zs0AHr2RErp8" style="text-align: right" title="Weighted Average Exercise Price Per Share, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2182">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedOrExpiredIntrinsicValue_pp0p0_c20220101__20221231_zMsprxdNMK7d" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2184">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231_zwhgotET8tHe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2186">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z3VfhfjLH5g3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2188">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisedGrantedIntrinsicValue_pp0p0_c20220101__20221231_zs4BqN8py8Ef" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2190">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zvXw1ycWnUv1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">10,928</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_ziV5I04k4mk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">232.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_zkUWBJTFmHAd" title="Weighted Average Remaining Contractual Life (years), Outstanding at End of Period">1.61</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220101__20221231_zRaqbvLK1zuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl2198">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10928 232.55 P1Y7M9D 10928 232.55 P0Y7M9D 10928 232.55 P2Y7M9D 10928 232.55 P1Y7M9D <p id="xdx_89E_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_z8KXfSCs0nCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the Company’s non-vested stock options as of December 31, 2023 and 2022 respectively:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_z4XbMEAHTO34" style="display: none">SCHEDULE OF NON - VESTED STOCK OPTIONS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Non-vested at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231_zVkBq4zJJVIb" style="width: 14%; text-align: right" title="Number of Non-vested Stock Options Outstanding, Outstanding at Beginning of Period">271</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_z0Zetuplfq02" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">236.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermNonVested_dtY_c20230101__20231231_zDxPYAwHrgV1" title="Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period">2.27</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zaUvJCmlqhja" style="text-align: right" title="Number of Non-vested Stock Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2208">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zHSOuHzy3vdf" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2210">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231_zY0qIvDXGXvb" style="text-align: right" title="Number of Non-vested Stock Options Outstanding, Vested">(248</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231_z4tSmGA4wzSj" style="text-align: right" title="Weighted Average Exercise Price Per Share, Vested">239.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_z04RMqk3OgVi" title="Weighted Average Remaining Contractual Life (years), Vested">0.81</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20230101__20231231_zGeix4mJs3Z5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Non-vested Stock Options Outstanding, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2218">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zqkacXPEKcGk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2220">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231_zayIdFYfoQSk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zCDBp96bSOJk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">205.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermsNonVested_dtY_c20230101__20231231_zAUEmOdCc8c3" title="Weighted Average Remaining Contractual Life (years), Outstanding at End of Period">1.59</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Non-vested at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231_zqA3td3jauRh" style="width: 14%; text-align: right" title="Number of Non-vested Stock Options Outstanding, Outstanding at Beginning of Period">3,587</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_zylqTcqXbiYk" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">227.78</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermNonVested_dtY_c20220101__20221231_zAmokqtThVvk" title="Weighted Average Remaining Contractual Life (years), Outstanding at Beginning of Period">0.90</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zyY5XcoOIi86" style="text-align: right" title="Number of Non-vested Stock Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2234">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zZ0oEhY0Mh15" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl2236">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231_zvEluwEIYVBe" style="text-align: right" title="Number of Non-vested Stock Options Outstanding, Vested">(3,315</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_z9nLm3c0HMAj" style="text-align: right" title="Weighted Average Exercise Price Per Share, Vested">14.89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zj0uhx1nIQg" title="Weighted Average Remaining Contractual Life (years), Vested">1.71</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20220101__20221231_zgSn7pho6MU9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Non-vested Stock Options Outstanding, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2244">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zJmcIj9k0545" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share, Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl2246">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20220101__20221231_zHlquYKLFFO9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">271</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20221231_zO8dkmYmv5pk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">236.83</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermsNonVested_dtY_c20220101__20221231_zoiKWpHdTWB4" title="Weighted Average Remaining Contractual Life (years), Outstanding at End of Period">2.27</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 271 236.83 P2Y3M7D 248 239.68 P0Y9M21D 23 205.70 P1Y7M2D 3587 227.78 P0Y10M24D 3315 14.89 P1Y8M15D 271 236.83 P2Y3M7D 0 0 2421960 15624 1542 0.54 2421960 178579 17166 8.55 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMqYcxvrWVu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zfvBYbTD8Wd9" style="display: none">SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember_zVORBKF1d2k6" title="Exercise price">0.16</span> - $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember_zIQ7GV2CUzzh" title="Exercise price">0.26</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_zlrrPJmDGkQk" title="Exercise price">0.16</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zEbpIkbYlg08" title="Exercise price">0.26</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zXDK2rZuOMg5" title="Expected term">3.25</span> to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ze75teqZbGRk" title="Expected term">3.75</span> years</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zOrOWW7gyxZc" title="Expected term">3.25</span> to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zCTOQmgbfzXi" title="Expected term">3.75</span> years</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zforqsqQ8Zxj" title="Risk-free interest rate">0.38</span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z1tiWarTYR8a" title="Risk-free interest rate">2.43</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z0cQOrYAo8Ti" title="Risk-free interest rate">0.38</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zyUapGU3SNp3" title="Risk-free interest rate">2.43</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated volatility</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zfgl5oXR0dx3" title="Estimated volatility">293.07</span>% - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zwEF3NRIZf9i" title="Expected volatility">517.13</span></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zexVftztGzO8" title="Estimated volatility">293.07</span>% - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zI5o0mlgnwB3" title="Expected volatility">517.13</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230101__20231231_z48CQiQL4hZ6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2304">-</span> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231_z9z863vNzOik" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2306">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 0.16 0.26 0.16 0.26 P3Y3M P3Y9M P3Y3M P3Y9M 0.0038 0.0243 0.0038 0.0243 2.9307 5.1713 2.9307 5.1713 758026 12460 477556 766250 7418 180546 3908 667 83464 32131 2667 22404 241 2695 0 22221 0 276400 249650 875000 1250000 <p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_z7dH5xHuBT8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12. <span id="xdx_82B_zl8AiaFSLdVl">EARNINGS (LOSS) PER SHARE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings per common share (“EPS”) applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted-average number of common shares outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zYbK5MOlEUM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following calculates basic and diluted EPS:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zdak8jz1nv" style="display: none">SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20230101__20231231_zE0c7pYRMgp4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zqK2ovg6BzM6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperations_zRmVWIq3Etg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">(Loss) income from continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,025,268</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">21,561,932</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeemedDividends_zgC6jihTckcb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deemed dividend</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,539,757</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,930,335</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_zbWG2wbfKgvh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">(Loss) income from continuing operations, numerator, basic</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,565,025</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,631,597</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_zRoChUxZe5Ka" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(Loss) income from continuing operations, numerator, diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,565,025</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,631,597</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_z3QSqPhsHpAa" style="vertical-align: bottom; background-color: White"> <td>Weighted average common shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,820,275</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,094,781</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--EffectOfWeightedAverageVestedStockAwards_zFQmosGqFpB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Effect of weighted average vested stock awards</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2369">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zo4JeM1EYx2d" style="vertical-align: bottom; background-color: White"> <td>Diluted weighted average shares outstanding</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,820,275</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,094,989</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_zIV8GcT4qmR5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Basic (loss) income loss per common share from continuing operations:</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.46</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13.36</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_zuw4V0qJ8uG1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diluted (loss) income per common share from continuing operations:</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4.46</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13.36</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zv1DOwc7lhZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDgKRrujBal6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common share:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zKOxGkYY1qV1" style="display: none">SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zBZIkXn8HaDh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zPNmIY1uqjlk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_z66zboTWiFMj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Shares subject to outstanding common stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,928</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">10,928</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsMember_zt9f0XLkcj73" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares subject to outstanding Series A warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsAndPlacementAgentWarrantsMember_zXCrv7sb28Ob" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares subject to outstanding Series B Warrants and PAW</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.25in">882,970</p> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,347,970</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesGWarrantsAndPlacementAgentWarrantsMember_z7nu3rb7PIw" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares subject to outstanding Series G warrants and PA Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">4,263,160</p> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2393">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedStockAwardsMember_zh36d4Z8Asti" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares subject to unvested stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">3,709</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,576</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zooIxV0WqT0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zYbK5MOlEUM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following calculates basic and diluted EPS:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zdak8jz1nv" style="display: none">SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20230101__20231231_zE0c7pYRMgp4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zqK2ovg6BzM6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperations_zRmVWIq3Etg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">(Loss) income from continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,025,268</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">21,561,932</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeemedDividends_zgC6jihTckcb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deemed dividend</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,539,757</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,930,335</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_zbWG2wbfKgvh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">(Loss) income from continuing operations, numerator, basic</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,565,025</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,631,597</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_zRoChUxZe5Ka" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(Loss) income from continuing operations, numerator, diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,565,025</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,631,597</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_z3QSqPhsHpAa" style="vertical-align: bottom; background-color: White"> <td>Weighted average common shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,820,275</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,094,781</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--EffectOfWeightedAverageVestedStockAwards_zFQmosGqFpB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Effect of weighted average vested stock awards</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2369">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zo4JeM1EYx2d" style="vertical-align: bottom; background-color: White"> <td>Diluted weighted average shares outstanding</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,820,275</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,094,989</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_zIV8GcT4qmR5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Basic (loss) income loss per common share from continuing operations:</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.46</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13.36</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_zuw4V0qJ8uG1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diluted (loss) income per common share from continuing operations:</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4.46</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13.36</td><td style="text-align: left"> </td></tr> </table> -10025268 21561932 -2539757 -6930335 -12565025 14631597 -12565025 14631597 2820275 1094781 208 2820275 1094989 -4.46 13.36 -4.46 13.36 <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDgKRrujBal6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common share:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zKOxGkYY1qV1" style="display: none">SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zBZIkXn8HaDh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zPNmIY1uqjlk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_z66zboTWiFMj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Shares subject to outstanding common stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,928</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">10,928</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsMember_zt9f0XLkcj73" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares subject to outstanding Series A warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsAndPlacementAgentWarrantsMember_zXCrv7sb28Ob" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares subject to outstanding Series B Warrants and PAW</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.25in">882,970</p> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,347,970</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesGWarrantsAndPlacementAgentWarrantsMember_z7nu3rb7PIw" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares subject to outstanding Series G warrants and PA Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">4,263,160</p> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2393">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedStockAwardsMember_zh36d4Z8Asti" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares subject to unvested stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">3,709</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,576</td><td style="text-align: left"> </td></tr> </table> 10928 10928 113000 113000 882970 1347970 4263160 3709 6576 <p id="xdx_80F_eus-gaap--LesseeOperatingLeasesTextBlock_zoVII4tiQLB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13. <span id="xdx_824_z5mlmRdzjgB3">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. The standard requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease, initially measured at the present value of the lease payments. The Company’s leases consist of operating leases on buildings and office space.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASU 2016-02, right-of-use assets are amortized over the life of the underlying leases. Lease expense for the years ended December 31, 2023 and 2022 was $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zhSfp9oMjj8j" title="Lease expense">534,404</span> and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20220101__20221231_zKXwgl412Nfl" title="Lease expense">598,422</span>, respectively. As of December 31, 2023 and 2022, the weighted average remaining lease term and weighted average discount rates for the operating leases were <span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zJ5k2PGKEdCe" title="Weighted average remaining lease term">3.92</span> years and <span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_z8xjvR5Jkypk" title="Weighted average discount rate">6.08</span>% and <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zNwp4Eydwex7" title="Weighted average remaining lease term">3.82</span> years and <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zNGb7GqclVhh" title="Weighted average discount rate">5.67</span>% respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zksf86BMBqB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease payment under these operating leases consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zmjkP6CFbb93" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Year ending December 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231_zGoMZ9iLAW63" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Lease</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Obligations</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzuGy_zLMpagytp8wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">320,420</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzuGy_zeSBrofZW31f" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">153,831</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzuGy_zEi7tdF7L6Oa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,738</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzuGy_zpo6ta6O5EV9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117,150</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzuGy_zJbTzFB3K8Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">120,665</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzuGy_zyf2CJ9X3klj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,387</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzuGy_zFEa0429qtEk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total undiscounted operating lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">856,191</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zyE04KM6ZI2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(86,685</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zKoNgf0uFa5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">769,506</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_z9JVuJtvyrPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 534404 598422 P3Y11M1D 0.0608 P3Y9M25D 0.0567 <p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zksf86BMBqB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease payment under these operating leases consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zmjkP6CFbb93" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Year ending December 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231_zGoMZ9iLAW63" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Lease</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Obligations</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzuGy_zLMpagytp8wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">320,420</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzuGy_zeSBrofZW31f" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">153,831</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzuGy_zEi7tdF7L6Oa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,738</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzuGy_zpo6ta6O5EV9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117,150</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzuGy_zJbTzFB3K8Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">120,665</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzuGy_zyf2CJ9X3klj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,387</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzuGy_zFEa0429qtEk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total undiscounted operating lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">856,191</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zyE04KM6ZI2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(86,685</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zKoNgf0uFa5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">769,506</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 320420 153831 113738 117150 120665 30387 856191 86685 769506 <p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zjpJxeVN4e6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14. <span id="xdx_822_zciyQo9Nx048">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal Contingencies</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly, $<span id="xdx_907_eus-gaap--CommitmentsAndContingencies_iI_c20221231_zUgMi15yjHf9" title="Legal contingencies"><span id="xdx_903_eus-gaap--CommitmentsAndContingencies_iI_c20231231_zkX3oOCf4uL8" title="Legal contingencies">0</span></span> legal contingencies are accrued as of December 31, 2023 and 2022. Litigation relating to the insurance brokerage industry is not uncommon. As such the Company, from time to time have been, subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earn-out liabilities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has recognized several earn-out liabilities resulting from contingent consideration provisions included in business combination agreements. Earn-out consideration is normally earned by acquirees when they meet or exceed pre-agreed upon earnings targets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--EarnOutLiabilitiesTableTextBlock_zZqLAViS2tD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following outlines changes to the Company’s earn-out liability balances for the respective years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zHwI8nAiZvQh" style="display: none">SCHEDULE OF EARN-OUT LIABILITY</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--BusinessAcquisitionAxis_custom--FortmanInsuranceAgencyLLCMember_zyhYyKempGUl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fortman</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BA_us-gaap--BusinessAcquisitionAxis_custom--SouthwesternMontanaInsuranceCenterIncMember_zeVwe3QXn1qk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Montana</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B8_us-gaap--BusinessAcquisitionAxis_custom--AltruisBenefitsConsultantsIncMember_zkW01iaM2QYg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Altruis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B6_us-gaap--BusinessAcquisitionAxis_custom--JPKushAndAssociatesIncMember_zCqrPb75ilri" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Kush</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--BusinessAcquisitionAxis_custom--BarraMember_zrNrqYAbKYHh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Barra</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B7_z2czDw0DQ7X9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_431_c20230101__20231231_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zwVa8h9zkd5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Ending balance December 31, 2022</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">667,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">500,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">834,943</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">147,534</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">560,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">2,709,478</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ChangesDueToPayments_zTdJPNXOCkyc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Payments</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,433,700</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">(750,001</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(929,168</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">(147,534</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2451">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,260,403</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--ChangesDueToFairValueAdjustments_zofm3RNx3352" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Estimate &amp; fair value adjustments</p></td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,612,914</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">569,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2457">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(560,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,716,873</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--ChangesDueToAmountPayableInCommonShares_zd9a5EzlfR6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Payable in Common Stock</p></td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2461">-</span> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">(159,867</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2463">-</span></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2464">-</span></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2465">-</span></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">(159,867</p></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">Reclass to loans payable, related parties*</p> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--FortmanInsuranceAgencyLLCMember_fKg_____zj9PMDQdTpKe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclass to loans payable, related parties">(846,214<p style="margin: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--SouthwesternMontanaInsuranceCenterIncMember_fKg_____zewDzmsrQsPg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclass to loans payable, related parties"><span style="-sec-ix-hidden: xdx2ixbrl2470">-</span> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_988_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--AltruisBenefitsConsultantsIncMember_fKg_____zAiQlh7PYqq9" style="margin: 0" title="Reclass to loans payable, related parties"><span style="-sec-ix-hidden: xdx2ixbrl2472">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_98B_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--JPKushAndAssociatesIncMember_fKg_____z2Q9lSd11qA3" style="margin: 0" title="Reclass to loans payable, related parties"><span style="-sec-ix-hidden: xdx2ixbrl2474">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_98D_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_fKg_____z71zUE2sFy1b" style="margin: 0" title="Reclass to loans payable, related parties"><span style="-sec-ix-hidden: xdx2ixbrl2476">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_981_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231_fKg_____zdAy8BJo0Ypj" style="margin: 0" title="Reclass to loans payable, related parties">(846,214</p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_438_c20230101__20231231_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zRDDRljh0ci7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance December 31, 2023</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2480">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">159,867</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2482">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2483">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2484">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">159,867</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--BusinessAcquisitionAxis_custom--FortmanInsuranceAgencyLLCMember_z7xWMzK99TZ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fortman</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--BusinessAcquisitionAxis_custom--SouthwesternMontanaInsuranceCenterIncMember_zEsL1tLrIqC5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Montana</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B8_us-gaap--BusinessAcquisitionAxis_custom--AltruisBenefitsConsultantsIncMember_zCWB6hzEmceg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Altruis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B6_us-gaap--BusinessAcquisitionAxis_custom--JPKushAndAssociatesIncMember_zH224zoXxrHc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Kush</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--BusinessAcquisitionAxis_custom--BarraMember_zDPRjahQT7b9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Barra</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B7_zTchg5FcNjO7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_43C_c20220101__20221231_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zaKtdPiAkLLh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Ending balance December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">515,308</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">615,969</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">992,868</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,689,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2491">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">3,813,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ChangesDueToBusinessCombinations_z7rcUQoOqNGb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Business combinations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2494">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2495">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2496">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2497">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ChangesDueToPayments_zuL3XHoHwkB3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(34,430</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(326,935</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(84,473</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,259,086</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,704,924</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--ChangesDueToFairValueAdjustments_zh0BS8ShsXw8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Estimate &amp; fair value adjustments</p></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">186,122</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">210,967</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,452</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(283,113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">524</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_432_c20220101__20221231_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zV1vUVAIXLH1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">667,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">500,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">834,943</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">147,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">560,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,709,478</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F0D_zDmJARm1Liwa" style="width: 35pt; text-align: right">*</td><td id="xdx_F10_zldCMHKyZAq" style="text-align: justify">As further described in the Note 16, <i>Related Parties</i>, the Company modified the Fortman contingent earn-out payable, entering into a fixed payment agreement, thus, the remaining open balance is reclassified to the loans payable, related parties account on the consolidated balance sheet as of December 31, 2023.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_8AE_zHYimOjpf8vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br/></span></p> 0 0 <p id="xdx_89E_ecustom--EarnOutLiabilitiesTableTextBlock_zZqLAViS2tD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following outlines changes to the Company’s earn-out liability balances for the respective years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zHwI8nAiZvQh" style="display: none">SCHEDULE OF EARN-OUT LIABILITY</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--BusinessAcquisitionAxis_custom--FortmanInsuranceAgencyLLCMember_zyhYyKempGUl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fortman</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BA_us-gaap--BusinessAcquisitionAxis_custom--SouthwesternMontanaInsuranceCenterIncMember_zeVwe3QXn1qk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Montana</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B8_us-gaap--BusinessAcquisitionAxis_custom--AltruisBenefitsConsultantsIncMember_zkW01iaM2QYg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Altruis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B6_us-gaap--BusinessAcquisitionAxis_custom--JPKushAndAssociatesIncMember_zCqrPb75ilri" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Kush</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--BusinessAcquisitionAxis_custom--BarraMember_zrNrqYAbKYHh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Barra</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B7_z2czDw0DQ7X9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_431_c20230101__20231231_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zwVa8h9zkd5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Ending balance December 31, 2022</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">667,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">500,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">834,943</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">147,534</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">560,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">2,709,478</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ChangesDueToPayments_zTdJPNXOCkyc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Payments</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,433,700</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">(750,001</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(929,168</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">(147,534</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2451">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,260,403</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--ChangesDueToFairValueAdjustments_zofm3RNx3352" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Estimate &amp; fair value adjustments</p></td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,612,914</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">569,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2457">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(560,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,716,873</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--ChangesDueToAmountPayableInCommonShares_zd9a5EzlfR6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Payable in Common Stock</p></td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2461">-</span> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">(159,867</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2463">-</span></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2464">-</span></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2465">-</span></p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">(159,867</p></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">Reclass to loans payable, related parties*</p> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--FortmanInsuranceAgencyLLCMember_fKg_____zj9PMDQdTpKe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclass to loans payable, related parties">(846,214<p style="margin: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--SouthwesternMontanaInsuranceCenterIncMember_fKg_____zewDzmsrQsPg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclass to loans payable, related parties"><span style="-sec-ix-hidden: xdx2ixbrl2470">-</span> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_988_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--AltruisBenefitsConsultantsIncMember_fKg_____zAiQlh7PYqq9" style="margin: 0" title="Reclass to loans payable, related parties"><span style="-sec-ix-hidden: xdx2ixbrl2472">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_98B_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--JPKushAndAssociatesIncMember_fKg_____z2Q9lSd11qA3" style="margin: 0" title="Reclass to loans payable, related parties"><span style="-sec-ix-hidden: xdx2ixbrl2474">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_98D_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--BarraMember_fKg_____z71zUE2sFy1b" style="margin: 0" title="Reclass to loans payable, related parties"><span style="-sec-ix-hidden: xdx2ixbrl2476">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_981_ecustom--ReclassToLoansPayableRelatedParties_c20230101__20231231_fKg_____zdAy8BJo0Ypj" style="margin: 0" title="Reclass to loans payable, related parties">(846,214</p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_438_c20230101__20231231_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zRDDRljh0ci7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance December 31, 2023</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2480">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">159,867</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2482">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2483">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2484">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">159,867</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--BusinessAcquisitionAxis_custom--FortmanInsuranceAgencyLLCMember_z7xWMzK99TZ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fortman</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--BusinessAcquisitionAxis_custom--SouthwesternMontanaInsuranceCenterIncMember_zEsL1tLrIqC5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Montana</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B8_us-gaap--BusinessAcquisitionAxis_custom--AltruisBenefitsConsultantsIncMember_zCWB6hzEmceg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Altruis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B6_us-gaap--BusinessAcquisitionAxis_custom--JPKushAndAssociatesIncMember_zH224zoXxrHc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Kush</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--BusinessAcquisitionAxis_custom--BarraMember_zDPRjahQT7b9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Barra</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B7_zTchg5FcNjO7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_43C_c20220101__20221231_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zaKtdPiAkLLh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Ending balance December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">515,308</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">615,969</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">992,868</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,689,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2491">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">3,813,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ChangesDueToBusinessCombinations_z7rcUQoOqNGb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Business combinations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2494">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2495">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2496">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2497">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ChangesDueToPayments_zuL3XHoHwkB3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(34,430</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(326,935</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(84,473</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,259,086</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,704,924</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--ChangesDueToFairValueAdjustments_zh0BS8ShsXw8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Estimate &amp; fair value adjustments</p></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">186,122</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">210,967</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,452</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(283,113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">524</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_432_c20220101__20221231_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zV1vUVAIXLH1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">667,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">500,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">834,943</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">147,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">560,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,709,478</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F0D_zDmJARm1Liwa" style="width: 35pt; text-align: right">*</td><td id="xdx_F10_zldCMHKyZAq" style="text-align: justify">As further described in the Note 16, <i>Related Parties</i>, the Company modified the Fortman contingent earn-out payable, entering into a fixed payment agreement, thus, the remaining open balance is reclassified to the loans payable, related parties account on the consolidated balance sheet as of December 31, 2023.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 667000 500001 834943 147534 560000 2709478 -1433700 -750001 -929168 -147534 -3260403 1612914 569734 94225 -560000 1716873 -159867 -159867 -846214 -846214 159867 159867 515308 615969 992868 1689733 3813878 600000 600000 -34430 -326935 -84473 -1259086 -1704924 186122 210967 -73452 -283113 -40000 524 667000 500001 834943 147534 560000 2709478 <p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_z0vzUPz7AE83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15. <span id="xdx_827_zye6XbwvGwWf">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_ecustom--ScheduleOfActualIncometaxRateTableTextBlock_zThujIkaWFbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The difference between the actual income tax rate versus the tax computed at the Federal Statutory rate follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zHHPfw2o0UUk" style="display: none">SCHEDULE OF ACTUAL INCOME TAX RATE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_zlxKIMo5fyTi" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zPctNEDumZOj" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEITR_zedQW7NGWmx8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Federal rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maEITR_zq9nURdasav1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State net of federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">8.9</p></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-7.9</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantCommitment_pid_dp_maEITR_zkc18OqWpcW7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Non-taxable change in fair value of warrant commitment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-106.3</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maEITR_z0JQSepHSIve" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46.7</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maEITR_zMHcj7Bfp6jf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Rate Change</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-4.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_pid_dpi_uPure_msEITR_zKuE0S6leQV6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.2</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEITR_zfzEiZa95scf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-50.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">48.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_mtEITR_zqOL0sZn6Opf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A6_zFufn1rBrFd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did not have any material uncertain tax positions. The Company’s policy is to recognize interest and penalties accrued related to unrecognized benefits as a component income tax expense (benefit). The Company did not recognize any interest or penalties, nor did it have any interest or penalties accrued as of December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z5ikNav8LIil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax assets and (liabilities) consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zPIVDahdr0dd" style="display: none">SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231_zHTHvD7dSKpb" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zoT2NoaZjNo4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets (liabilities)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzVPl_zdmezeUjh8x6" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Net operating loss carryforward</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">10,399,616</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,938,164</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzVPl_zHyyTRMYzztf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Equity-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,462,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,148,836</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_iNI_di_msDTAGzVPl_zmKO7Vmpme46" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(332,159</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(771,631</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzVPl_ztChVFkTv4S" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">694,358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">745,227</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_msDTAGzVPl_zPMp9VHgjRw9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(151,775</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(99,002</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_msDTAGzVPl_zYKjwS0JnfTc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Right of use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(186,905</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(300,616</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesLeaseLiabilities_iI_maDTAGzVPl_ziZResRZcqSj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">194,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzVPl_zZQHpXQetEE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,027</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,525</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzVPl_maDTANzYkJ_zzzUlWqRIMOf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">12,084,466</p> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,975,846</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzYkJ_zDWAmYW0xxfk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,084,466</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,975,846</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzYkJ_zBfL1F2NZvBb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2583">-</span></p></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2584">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zFnc6Hd5VjE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20231231_ztu7M62SQLZ4" title="Federal net operating loss carryforwards excluding indefinite life">41.3 </span>million of <span id="xdx_901_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_pn5n6_c20230101__20231231_zMXYbm5xXMEb" title="Operating loss carryforward limitation">Federal Net Operating Loss Carry forwards, of which $1.3 million will begin to expire beginning 2031</span> and <span id="xdx_908_ecustom--IncomeTaxExpirationDateDescription_pn5n6_c20230101__20231231_zRvhiYkt9rt6" title="Income tax description">$40.0 million will not expire but are limited to use of 80% of current year taxable income</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20231231_zwUSglsGG032" title="State net operating loss carry forwards">34.8</span> million of state net operation loss carry forward to offset future taxable income in the states in which it currently operates. These carryforwards start expiring in 2029.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--IncomeTaxExaminationDescription_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESActMember_z5A3LJaX8eKi" title="Income tax description">Internal Revenue Code Section 382 limits the ability to utilize net operating losses if a 50% change in ownership occurs over a three-year period. Such limitation of the net operating losses may have occurred, but we have not analyzed it at this time as the deferred tax asset is fully reserved.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023 and 2022, the valuation allowance increased $<span id="xdx_903_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_zeMGb9uO5Er5" title="Change in valuation of allowance">6,108,620</span> and $<span id="xdx_90C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20220101__20221231_zYvfH99KYh03" title="Change in valuation of allowance">3,140,780</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax periods ending December 31, 2020, 2021, and 2022 are open for examination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_ecustom--ScheduleOfActualIncometaxRateTableTextBlock_zThujIkaWFbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The difference between the actual income tax rate versus the tax computed at the Federal Statutory rate follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zHHPfw2o0UUk" style="display: none">SCHEDULE OF ACTUAL INCOME TAX RATE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_zlxKIMo5fyTi" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zPctNEDumZOj" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEITR_zedQW7NGWmx8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Federal rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maEITR_zq9nURdasav1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State net of federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">8.9</p></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-7.9</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantCommitment_pid_dp_maEITR_zkc18OqWpcW7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Non-taxable change in fair value of warrant commitment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-106.3</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maEITR_z0JQSepHSIve" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46.7</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maEITR_zMHcj7Bfp6jf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Rate Change</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-4.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_pid_dpi_uPure_msEITR_zKuE0S6leQV6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.2</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEITR_zfzEiZa95scf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-50.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">48.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_mtEITR_zqOL0sZn6Opf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.210 0.210 0.089 -0.079 0.093 -1.063 0.118 0.467 -0.002 -0.041 -0.000 -0.022 -0.509 0.485 0.000 0.000 <p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z5ikNav8LIil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax assets and (liabilities) consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zPIVDahdr0dd" style="display: none">SCHEDULE OF DEFERRED INCOME TAX ASSETS AND LIABILITIES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231_zHTHvD7dSKpb" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zoT2NoaZjNo4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets (liabilities)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzVPl_zdmezeUjh8x6" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Net operating loss carryforward</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">10,399,616</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,938,164</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzVPl_zHyyTRMYzztf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Equity-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,462,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,148,836</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_iNI_di_msDTAGzVPl_zmKO7Vmpme46" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(332,159</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(771,631</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzVPl_ztChVFkTv4S" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">694,358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">745,227</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_msDTAGzVPl_zPMp9VHgjRw9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(151,775</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(99,002</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_msDTAGzVPl_zYKjwS0JnfTc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Right of use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(186,905</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(300,616</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesLeaseLiabilities_iI_maDTAGzVPl_ziZResRZcqSj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">194,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzVPl_zZQHpXQetEE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,027</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,525</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzVPl_maDTANzYkJ_zzzUlWqRIMOf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">12,084,466</p> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,975,846</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzYkJ_zDWAmYW0xxfk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,084,466</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,975,846</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzYkJ_zBfL1F2NZvBb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2583">-</span></p></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2584">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10399616 4938164 1462901 1148836 332159 771631 694358 745227 151775 99002 186905 300616 194403 313342 4027 1525 12084466 5975846 12084466 5975846 41300000 Federal Net Operating Loss Carry forwards, of which $1.3 million will begin to expire beginning 2031 $40.0 million will not expire but are limited to use of 80% of current year taxable income 34800000 Internal Revenue Code Section 382 limits the ability to utilize net operating losses if a 50% change in ownership occurs over a three-year period. Such limitation of the net operating losses may have occurred, but we have not analyzed it at this time as the deferred tax asset is fully reserved. 6108620 3140780 <p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zjvzSAuiCHB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16. <span id="xdx_824_zeJx998Igle7">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Loan Agreement with Reliance Global Holdings, LLC (“Reliance Holdings”), a related party under common control. There is no term to the loan, and it bears no interest. Repayment will be made as the Company has business cash flows. The proceeds from the various loans were utilized to fund the acquisitions of USBA, EBS, CCS, SWMT Acquisition, Fortman, Altruis, and UIS. As of December 31, 2023, and the 2022 the Reliance Holdings related party loan payable balance was $<span id="xdx_903_eus-gaap--LoansPayable_iI_pp0p0_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RelianceHoldingsMember_z9qlmx6EAiOc" title="Related party loan payable">0</span> and $<span id="xdx_909_eus-gaap--LoansPayable_iI_pp0p0_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RelianceHoldingsMember_z7I2O7pQoL3g" title="Related party loan payable">100,724</span> respectively, and Reliance Holdings owned approximately <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RelianceHoldingsMember_zeS2HdQZIJo6" title="Ownership percentage">0</span>% and <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RelianceHoldingsMember_zDk7qUbLKmVl" title="Ownership percentage">24</span>% respectively, of the Company’s Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company incurred a liability of $<span id="xdx_900_eus-gaap--OtherLiabilities_iI_c20190731__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember_zGYpiP2i1hhg" title="Due to related party">200,000</span> to an employee for a software purchased in July of 2019. The payable was issued with a $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20190731__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember_zLDJVVlIL2Qf" title="Debt instrument unmortized discount">27,673</span> discount, utilizing a <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20190731__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember_zLA2DXZBpntl" title="Debt interest rate">7.5</span>% discount rate. There are monthly payment terms of $<span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPayment_c20190701__20190731__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember_zGNVfblVCRR7" title="Monthly payment">4,167</span> through June 2024, the date of final settlement. The balance is carried at present value on the condensed consolidated balance sheets. The Company classifies amounts planned to be settled within twelve months from the balance sheet date to current liabilities. Accordingly, the Company presents current balances of $ <span id="xdx_90E_ecustom--LoansPayableRelatedPartiesCurrent_iI_c20231231__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember_zxUWuN6tGA92" title="Current portion of loans payables, related parties">29,167</span> and $<span id="xdx_903_ecustom--LoansPayableRelatedPartiesCurrent_iI_c20221231__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember_z7BuOXy6b3Ed" title="Current portion of loans payables, related parties">47,249</span> in the current portion of loans payables, related parties account in the condensed consolidated balance sheets as of December 31, 2023, and December 31, 2022. Non-current amounts are classified to the loans payable, related parties, less current portion account in the condensed consolidated balance sheets and amounted to $<span id="xdx_90D_ecustom--LoansPayableRelatedPartiesNonCurrent_iI_c20231231__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember_zYkSjKhdnuN7" title="Non-current portion of loans payables, related parties">0</span> and $<span id="xdx_907_ecustom--LoansPayableRelatedPartiesNonCurrent_iI_c20221231__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember_zPjoh5cCWnK1" title="Non-current portion of loans payables, related parties">21,541</span> as of December 31, 2023, and December 31, 2022, respectively. Amortization expense to bring the payable to present value for the year ended December 31, 2023, was $<span id="xdx_908_eus-gaap--InterestExpense_c20230101__20231231__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember_z3Qz065v5Zed" title="Interest expense, related parties">6,918</span>, and is classified to the interest expense, related parties account in the condensed consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 13, 2022, the Company issued a promissory note to YES Americana Group, LLC (“Americana”) a related party entity beneficially owned by the Company’s Chief Executive Officer, for the principal sum of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20220913__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zxtZZxAvb1Nk" title="Promissory note principle">1,500,000</span> (the “Note”), accruing monthly interest of <span id="xdx_905_ecustom--AccruingMonthlyInterestPercentage_iI_pid_dp_uPure_c20220913__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zTr9ipi7N5x" title="Accruing monthly interest percentage">5</span>% per annum beginning nine months after Note issuance. <span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20230207__20230207__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zZBj4z0UnYY5" title="Debt instrument description">On February 7, 2023 , the Company and Americana entered into an amendment to the Note pursuant to which (i) the principal amount of the Note was increased to $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20230207__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zDEQVoHtcp59" title="Promissory note principle">1,845,000</span>, (ii) the maturity date of the Note was amended to January 15, 2026, (iii) the interest rate under the Note shall not increase after the maturity date, and (iv) the Note can be converted at any time, at the option of Americana, into shares of the Company’s common stock, par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230207__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_z595hRQR9ic3" title="Common stock par value">0.086</span> per share at an agreed upon conversion price.</span> <span id="xdx_90C_eus-gaap--DebtInstrumentDescription_c20230213__20230213__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zsm2DwE91xAd" title="Debt instrument description">On February 13, 2023, Americana effectuated a conversion of $<span id="xdx_901_eus-gaap--ConversionOfStockAmountIssued1_c20230213__20230213__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zuuEnp2UAzth" title="Conversion of stock">645,000</span> of the Note into <span id="xdx_908_eus-gaap--ConversionOfStockSharesIssued1_pid_c20230213__20230213__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zZVcU4JZJLje" title="Conversion of stock shares">66,743</span> shares of the Company’s common stock, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230213__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zzqwXf1Utdq1" title="Common stock par value">0.086</span> par value per share, in accordance with the terms of the Amendment. In addition, throughout the year of 2023 the Company repaid principal to Americana of $<span id="xdx_904_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230101__20231231__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zxW9zmZ9TNX" title="Repayment of related party debt">693,145</span>. As of December 31, 2023, and December 31, 2022 respectively, the balance owed to Americana was $<span id="xdx_90B_ecustom--RepaymentsOfRelatedPartysOwed_c20230101__20231231__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zwq45yhUE3lb" title="Repayment of related party owed">0</span> and $<span id="xdx_906_ecustom--RepaymentsOfRelatedPartysOwed_c20220101__20221231__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zJAiWLnaW4X2" title="Repayment of related party owed">1,500,000</span>, reclassified and recorded in the convertible debt, related parties, less current portion account in the condensed consolidated balance sheets. Interest expense for the year ended December 31, 2023, was $<span id="xdx_906_eus-gaap--InterestExpenseOther_c20230101__20231231__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zFGUdm3reyv1" title="Interest expense, related parties">5,334</span>, recorded to interest expense, related parties in the condensed consolidated statements of operations.</span> Americana owned approximately <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CommonStocksMember__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_zPrTycBqqOzg" title="Ownership percentage">5.52</span>% and <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CommonStocksMember__dei--LegalEntityAxis__custom--YESAmericanaGroupLLCMember_z9ZG1R6ISLa5" title="Ownership percentage">0.00</span>% respectively, of the Company’s Common Stock as of December 31, 2023, and 2022 respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the first amendment to the April 26, 2022 asset purchase agreement between the Company and Barra &amp; Associates, LLC, a related party entity beneficially owned by a senior vice president of the Company, the Company agreed to pay a deferred purchase price (the “DPP”) of $<span id="xdx_901_ecustom--DeferredPurchasePrice_c20230131__20230131_zHKoFlnpXZy8" title="Deferred purchase price">1,375,000</span> by January 31, 2023, and all amounts unpaid thereafter will accrue interest at a rate of <span id="xdx_90A_ecustom--AccrueInterestRatePercentage_iI_pid_dp_uPure_c20230131_zEVIEjhxWq35" title="Accrue interest rate percentage">1.5</span>% per month until paid. The Company intends to fully repay all unpaid amounts inclusive of interest over the next two years. The Company classifies amounts planned to be settled within twelve months from the balance sheet date to current liabilities. Accordingly, the Company reclassifies and presents current balances of $<span id="xdx_909_eus-gaap--LoansPayableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zrkSbgkURpXl" title="Current portion of loans payables, related parties">233,504</span> and $<span id="xdx_90A_eus-gaap--LoansPayableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zLmqcOQlRwFl" title="Current portion of loans payables, related parties">1,375,000</span> respectively, in the current portion of loans payables, related parties account in the condensed consolidated balance sheets as of December 31, 2023 and December 31, 2022. Non-current amounts are classified to the loans payable, related parties, less current portion account in the condensed consolidated balance sheets and amounted to $<span style="background-color: #FDFFFF"><span id="xdx_90A_ecustom--LoansPayableNonCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zt8bBsgWaT82" title="Loans payables, related parties">247,055</span> </span>and $<span id="xdx_905_ecustom--LoansPayableNonCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwQq46ZUD7I9" title="Loans payables, related parties">0</span> as of December 31, 2023, and December 31, 2022 respectively. Interest expense for the year ended December 31, 2023 was $<span id="xdx_906_eus-gaap--InterestExpenseOther_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zI1qJVR66KP6" title="Other expenses">145,344</span>, recorded to interest expense, related parties in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company, Fortman Insurance Services, LLC, Fortman Insurance Agency, LLC, Jonathan Fortman, and Zachary Fortman (collectively, the “Parties”) entered into a purchase agreement on or around May 1, 2019 (the “Purchase Agreement”), whereby the Company purchased the business and certain assets noted within the Purchase Agreement, as well as that certain second amendment to the Purchase Agreement on or around May 18, 2023 (the “Second Amendment”). On January 11, 2024, the Parties entered into that certain third amendment to the Purchase Agreement (the “Third Amendment”), pursuant to which the Parties agreed to a total remaining earn-out balance of $<span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20240111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzaGnGw9uVc5" title="Earn out balance">423,107</span> owed to both Jonathan Fortman and Zachary Fortman each under the Purchase Agreement, both employees and related parties to the Company, for a combined total earn-out amount owed of $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240110__20240111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLeqEgqUFxi2" title="Earn out owned amount">846,214</span> (the “Remaining Balances”). In satisfaction of such Remaining Balances, the Company agreed to pay $<span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_pp2d_c20240110__20240111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z3S2rfU03Wof" title="Agreed to payment">11,000.00</span> on the first business day of each month to both Jonathan Fortman and Zachary Fortman each until the Remaining Balances are paid in full. In addition, the Parties agreed under the Third Amendment that the Remaining Balances shall accrue interest at the rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zKoIteJA94J3" title="Accrue interest percentage">10</span>% per annum until the Remaining Balances are paid in full, with an effective date of January 2, 2024, for purposes of the commencement of interest accrual. Since the Remaining Balances are final and no longer subject to contingencies, as of December 31, 2023 and the period then ended, they have been reclassified from the earn-out liability account to the loan payable, related parties, less current portion account in the amount of, $<span id="xdx_906_eus-gaap--LoansPayable_iI_c20240111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKpVuqtTkuWi" title="Loans payables, related parties">650,473</span> and the current portion of loans payables, related parties in the amount of, $<span id="xdx_90F_eus-gaap--LoansPayableCurrent_iI_c20240111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdFUe9hIp9ig" title="Loans payables, current">195,741</span> and for the same period ended <span id="xdx_901_eus-gaap--InterestPayableCurrent_iI_do_c20240111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSFu4AOvVd08" title="Accrued interest">no</span> interest has accrued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0 100724 0 0.24 200000 27673 0.075 4167 29167 47249 0 21541 6918 1500000 0.05 On February 7, 2023 , the Company and Americana entered into an amendment to the Note pursuant to which (i) the principal amount of the Note was increased to $1,845,000, (ii) the maturity date of the Note was amended to January 15, 2026, (iii) the interest rate under the Note shall not increase after the maturity date, and (iv) the Note can be converted at any time, at the option of Americana, into shares of the Company’s common stock, par value $0.086 per share at an agreed upon conversion price. 1845000 0.086 On February 13, 2023, Americana effectuated a conversion of $645,000 of the Note into 66,743 shares of the Company’s common stock, $0.086 par value per share, in accordance with the terms of the Amendment. In addition, throughout the year of 2023 the Company repaid principal to Americana of $693,145. As of December 31, 2023, and December 31, 2022 respectively, the balance owed to Americana was $0 and $1,500,000, reclassified and recorded in the convertible debt, related parties, less current portion account in the condensed consolidated balance sheets. Interest expense for the year ended December 31, 2023, was $5,334, recorded to interest expense, related parties in the condensed consolidated statements of operations. 645000 66743 0.086 693145 0 1500000 5334 0.0552 0.0000 1375000 0.015 233504 1375000 247055 0 145344 423107 846214 11000.00 0.10 650473 195741 0 <p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zdRMAZ8ZZIWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17. <span id="xdx_829_zsWIL7moBLE7">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On February 15, 2024, the Company entered into an At Market Issuance Sales Agreement (the “ATM Agreement”) with EF Hutton LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent, shares of its Common Stock (the “Shares”), having an aggregate offering price of up to $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240214__20240215__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5X88k1rXng1" title="Aggregate offering price">858,637</span></span><span style="font-size: 10pt">. Any Shares offered and sold in the offering will be issued pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-275190), which was declared effective by the Securities and Exchange Commission on November 7, 2023, and the related prospectus supplement and accompanying base prospectus relating to the offering of the Shares. Under the Agreement, the Agent may sell Shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The offering of Shares pursuant to the Agreement will terminate upon the earlier of (i) the sale of all of the Shares subject to the Agreement, or (ii) the termination of the Agreement by the Agent or the Company, as permitted therein. The Company shall pay to the Agent in cash, upon each sale of Shares pursuant to the ATM Agreement, an amount equal to 3.5% of the gross proceeds from each sale of Shares. The Company will also reimburse the Agent for certain specified expenses in connection with entering into the Agreement. The Company has since sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241214__20241215__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMy1f14I5Ze4" title="Sold shares">187,614</span> shares of Common Stock under the ATM Agreement, receiving proceeds, net of $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20241214__20241215__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5ba4ppuk0vd" title="Receiving proceeds, net">4,634</span> Agent commissions, of $<span id="xdx_903_eus-gaap--PaymentsForCommissions_c20241214__20241215__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIpguMyxBaTl" title="Agent commissions">124,649</span>.</span></p> 858637 187614 4634 124649 Recognition and change in fair value of warrant liabilities per income statement is $29,064,958. The difference of $3,672,624 is made up of the Warrant issuance costs. Recognition and change in fair value of warrant liabilities per income statement is $5,503,647. The difference of $79,859 was due to a loss on a warrant exchange. Recorded as change in estimated acquisition earn-out payables on the consolidated statements of operations. Includes customer relationships and internally developed and purchased software intangible assets that have continued value to the Company and have not been impaired as the fair value exceeds carrying cost. Estimated liability write-off per net zero dollar estimated liability value. Liability discharge pursuant to the Settlement Agreement. As further described in the Note 16, Related Parties, the Company modified the Fortman contingent earn-out payable, entering into a fixed payment agreement, thus, the remaining open balance is reclassified to the loans payable, related parties account on the consolidated balance sheet as of December 31, 2023.

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�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